<SEC-DOCUMENT>0001213900-26-036629.txt : 20260331
<SEC-HEADER>0001213900-26-036629.hdr.sgml : 20260331
<ACCEPTANCE-DATETIME>20260330200741
ACCESSION NUMBER:		0001213900-26-036629
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260331
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42195
		FILM NUMBER:		26816200

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0283146-10k_ostherap.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:osti="http://www.ostherapies.com/20251231" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-14838">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-34"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-14839"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-14840">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-14841">2025</ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-45"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from _______ to _______.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-56"><b>001-42195</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-62"><b>OS THERAPIES INCORPORATED</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-72"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-77"><span style="font-size: 10pt"><b>82-5118368</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-14842">115 Pullman Crossing Road</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-14843">Suite 103</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-14844">Grasonville</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-14845">Maryland</ix:nonNumeric></b></span></td> <td style="width: 2%; padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-103"><span style="font-size: 10pt"><b>21638</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-14846">(410)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-14847">297-7793</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-142"><span style="font-size: 10pt">Common Stock, par value $0.001 per share</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-146"><span style="font-size: 10pt">OSTX</span></ix:nonNumeric></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName" id="ixv-14848">NYSE</ix:nonNumeric> American</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(g)
of the Act: <b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by checkmark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-14849">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by checkmark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-14850">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-14851">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-14852">Yes</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 25%; text-align: justify"><span style="font-size: 10pt">Large accelerated filer </span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%; text-align: justify"><span style="font-size: 10pt">Accelerated filer </span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-14853">Non-accelerated filer</ix:nonNumeric> </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-205"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td colspan="2" style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-size: 10pt">Emerging growth Company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-212"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-218"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-224"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-230"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-242"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the registrant&#8217;s
common stock held by non-affiliates, computed by reference to the price at which the common stock was last sold as of June 30, 2025, the
last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction contextRef="c1" decimals="-5" name="dei:EntityPublicFloat" scale="6" unitRef="usd" id="ixv-14854">49.6</ix:nonFraction> million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of the registrant&#8217;s Common Stock outstanding
as of March 26, 2026 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14855">39,533,227</ix:nonFraction> shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-14856">None</ix:nonNumeric>.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS THERAPIES INCORPORATED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 10%">&#160;</td>
    <td style="vertical-align: top; width: 81%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><b><a href="#J_001">PART I.</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_002">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">2</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_003">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">19</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1B.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_004">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 1C.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_005">Cybersecurity</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_006">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_007">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_008">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><b><a href="#J_009">PART II.</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_011">Reserved</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 7.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 7A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">68</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 8.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_014">Financial Statement and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 9.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">104</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 9A.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_016">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">104</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 9B.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_017">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center">104</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 9C.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="vertical-align: bottom; text-align: center">104</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><b><a href="#J_019">PART III.</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">105</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 10.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">105</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 11.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_021">Executive Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">109</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 12.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">114</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 13.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">116</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 14.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_024">Principal Accounting Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">118</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><b><a href="#J_025">PART IV.</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">119</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 15.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_026">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">119</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Item 16.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="#J_027">Form 10-K Summary</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">120</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cautionary Note Regarding Forward-Looking Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report contains &#8220;forward-looking
statements&#8221; (within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and
Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), which may include information concerning
our beliefs, plans, objectives, goals, expectations, strategies, anticipations, assumptions, estimates, intentions, future events, future
revenues or performance, capital expenditures and other information that is not historical information. Forward-looking statements involve
known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance
or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking
statements. When used in this report, the words &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;project,&#8221; &#8220;plan,&#8221; &#8220;contemplate,&#8221; &#8220;plan,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221;
&#8220;believe&#8221; and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking
statements are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations
and beliefs, but there can be no assurance that we will realize our expectations or that our beliefs will prove to be correct.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number of risks
and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this report.
Examples of risks and uncertainties that could cause actual results to differ materially from historical performance and any forward-looking
statements include, but are not limited to, the risks described under the section below titled &#8220;Risk Factors&#8221; of this Form
10-K, as well as any of our subsequent filings with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There may be other factors
of which we are currently unaware or which we currently deem immaterial that may cause our actual results to differ materially from the
forward-looking statements. All forward-looking statements attributable to us or persons acting on our behalf apply only as of the date
they are made and are expressly qualified in their entirety by the cautionary statements included in this report. Except as may be required
by law, we undertake no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances occurring
after the date they were made or to reflect the occurrence of unanticipated events, or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We make available through
our Internet website, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and
amendments to such reports and other filings made by us with the Securities and Exchange Commission (&#8220;SEC&#8221;), as soon as practicable
after we electronically file such reports and filings with the SEC. Our website address is www.ostherapies.com. The information contained
on our website is not incorporated by reference into this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note Regarding Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SiLinkers&#8482;, CAPs&#8482;
and other common law trade names, trademarks or service marks of our company appearing in this report are the property of OS Therapies
Incorporated. This report contains additional trade names, trademarks and service marks owned by their respective owners. Solely for convenience,
trademarks and trade names referred to in this annual report may appear without the &#8482; or &#174; symbols, but such an omission is
not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owners
will not assert their rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade
names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship by us of, these other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1. Business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview and Mission</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies Incorporated
(&#8220;OS Therapies,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a clinical stage biopharmaceutical
company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our
mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an
extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and
high metastases rates. We are currently seeking to answer the call for new treatments that will prevent metastasis and the recurrence
of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate that produces
a cellular immune response against the cancer antigen HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we opened a clinical
study to produce data for the U.S. Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after
resection of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October 2023. In the first quarter of 2025, we announced
that our Phase IIb clinical trial achieved its primary endpoint with statistical significance. In October 2025, we announced final two-year
overall survival data from the Phase IIb trial, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients achieved two-year
overall survival from the most recent pulmonary resection, compared with 40% in historical control patients (p &lt; 0.0001). OST-HER2
was observed to be well-tolerated in the study. In January 2026, we announced positive immune biomarker data from the Phase IIb trial
indicating that activation of immune blood biomarkers in the interferon gamma pathway correlated with, and was predictive of, overall
survival, distinguishing long-term survivors (&#8805; two years) from short-term survivors (&lt; one year). These biomarker findings are
based on exploratory analyses and have not been validated as surrogate endpoints for clinical benefit. Based on the totality of the data
generated to date, including the observed survival outcomes, safety profile and the significant unmet medical need in this patient population,
we intend to engage with the FDA regarding potential regulatory pathways for OST-HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged in ongoing
regulatory interactions with the FDA, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and the European
Medicines Agency (EMA) regarding the clinical and biomarker data for OST-HER2 in recurrent, fully resected pulmonary metastatic Osteosarcoma.
Following submission of the Non-Clinical and Chemistry, Manufacturing &amp; Controls (CMC) modules of our Biologics License Application
(BLA) to the FDA at the end of January 2026, we anticipate submitting the clinical BLA module following an expected Type B meeting with
the FDA in the second quarter of 2026 and completing conditional Marketing Authorization Application (MAA) submissions to both the MHRA
and the EMA in the second quarter of 2026. We also anticipate releasing additional biomarker data in the second quarter of 2026 to further
characterize immune pathway activation and its relationship to clinical outcomes. We expect to initiate confirmatory clinical studies
in the third quarter of 2026 in support of conditional approval pathways. If OST-HER2 receives approval under the FDA&#8217;s Accelerated
Approval Program prior to September 30, 2029, we would become eligible to receive a Priority Review Voucher under the Rare Pediatric Disease
Designation Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon success in gaining regulatory
approval from the FDA with OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&#8217;s potential use, both alone and in combination
with HER2 targeting antibodies such as Herceptin&#174;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has
potential uses in both the prevention of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated
with HER targeting antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to an OST-Tunable
Drug Conjugate (OST-tADC) platform, a next generation antibody-drug conjugate (ADC) silicone dioxide linker technology. &#8220;Tunable&#8221;
is a term used in drug development that refers to the properties that can be influenced by chemical modifications, and &#8220;antibody-drug
conjugate&#8221; or ADC is a term used to describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly
active and toxic pharmaceutical molecule, through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to
deploy the cytotoxic payload or toxic agent against the tumor. Furthering our founding mission, we intend to investigate clinical indications
for OST-tADC in Osteosarcoma and other solid tumors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Pipeline of Our Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have built a pipeline of
product candidates targeting multiple indications for solid cancers. Our pipeline includes two drug technologies: (i)&#160;OST-HER2, an
off-the-shelf immunotherapy, which is a type of cancer treatment that helps one&#8217;s immune system fight cancer, comprised of a genetically
weakened and modified strain of <i>Listeria monocytogenes</i>, a species of bacteria that causes the infection listeriosis, that expresses
HER2 peptides, and (ii)&#160;OST-tADC,&#160;a next generation tunable ADC with a plug-and-play platform that features tunable pH sensitive
silicone linkers (SiLinkers&#8482;). The payloads may include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments
directly into and in the vicinity of solid tumors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OST-HER2 (OST31-164).&#160;&#160;&#160;&#160;</i></b>Our
most advanced product candidate, OST-HER2, is a genetically engineered strain of <i>Listeria monocytogenes</i>, attenuated for reduced
virulence, increased antibiotic susceptibility and the expression of three HER2 protein epitopes fused to immune-enhancing peptides on
the membrane of the bacteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OST-HER2 has received an orphan
drug designation in the United&#160;States. The FDA may designate a biologic product as an orphan product if it is intended to treat a
rare disease or condition, which generally is defined as having a patient population of fewer than 200,000 individuals in the United&#160;States.
Osteosarcoma has an incidence rate of approximately 1,000 individuals affected per year in the United&#160;States. Orphan product designation,
subject to limited exceptions, can provide a period of market exclusivity for a product that is the first to receive marketing approval
for the designated indication. Other potential indications may include breast, esophageal, lung and other solid tumors. In August&#160;2021,
OST-HER2 was awarded rare pediatric disease designation and previously received fast track designation by the FDA.&#160;Such designations
by the FDA do not convey any advantages in, or shorten the duration of, the regulatory review or approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OST-tADC. </i></b>Our
tunable drug conjugate (tADC) platform is currently in preclinical development. Each tADC contains four main components: ligand, payload
cassette adaptor, linker and payload. In addition, tADCs contain units to optimize physicochemical properties. The ligands are selected
to bind to receptors overexpressed on cancer cells. Upon binding, the tADC construct gets internalized into the cancer cell, where the
payload is released, to cause cell death. The payload cassette adapters enable the stoichiometrical attachments of linkers and payloads.
The SiLinkers represent a novel and pH-sensitive linker system. The SiLinker release profile can be tuned with proximal functional groups,
resulting in payload release in the endosome, lysosome or the slightly acidic tumor microenvironment. The SiLinker system is compatible
with a variety of payloads and not limited to the employment of cytotoxic drug delivery. The first set of internal programs focus on the
use of SiLinker and conditionally active payloads (CAPs&#8482;) drug products. CAPs are cytotoxic drugs which on their own, due to their
functional groups, cannot readily permeate cells at physiological pH; however, at the slightly acidic pH of the tumor-microenvironment,
after some linker cleavage, these payloads readily permeate into cancer cells, resulting in an enhanced bystander effect. Our lead program
targets folate receptor alpha, a protein expressed on the surface of cells that participates in cell signaling, as well as cellular replication
and division, and is overexpressed in multiple cancers such as ovarian and endometrial cancers. The lead compound employs folic acid,
a small molecule, as the targeting ligands and contains six exatecan-silanols, which is a type of silanol-based cytotoxic payload. This
discovery work is being carried out at Syngene International Limited, an integrated contract research organization (CRO) based in Bangalore,
India.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
evaluate collaboration opportunities for our product candidates. We expect to work opportunistically with pharmaceutical and biotechnology
companies, as we have done with BlinkBio, Inc. by in-licensing the OST-tADC technology, seeking to utilize our technology and know-how
for developing additional oncologic drug products. The following table summarizes information regarding our product candidates and development
programs.</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="ea028314601_img1.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="ea028314601_img2.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our development
of OST-HER2 for multiple indications of solid cancers in humans, OST-HER2 is a product candidate for veterinary use in canines. As part
of our growth strategies, we intend to consider potentially out-licensing OST-HER2 to animal health companies for such use. See &#8220;<i>OS-Focused
Clinical Trials and Studies&#160;&#8212;&#160;Preclinical Animal Study</i>&#8221; for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Acquisition of HER2 and <i>Lm</i>-Related
Assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#8220;HER2 Purchase Agreement&#8221;), between us and
Ayala Pharmaceuticals, Inc. (formerly known as Advaxis, Inc. (&#8220;Ayala&#8221;)), we completed the acquisition of the <i>Lm</i>-based
immune-oncology programs and related intellectual property assets (the &#8220;HER2 Assets&#8221;) from Ayala. The HER2 Assets include
two investigational new drug applications (&#8220;IND&#8221;) with the FDA: (i) ADXS-503 for non-small cell lung cancer; and (ii) ADXS-504
for prostate cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our OS-Focused Clinical Trials and Studies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our former licensors
have conducted a number of clinical trials and studies in the field of Osteosarcoma and Tunable Drug Conjugates to date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Phase&#160;IIb Clinical
Trial. </i></b>In July 2021, we initiated a Phase IIb clinical trial to evaluate the safety and efficacy of our OST-HER2 product candidate
in patients following complete surgical resection of recurrent pulmonary metastatic Osteosarcoma. The study was sponsored by us and conducted
by George Clinical, Inc. A total of 41 eligible patients between the ages of 12 and 39 were enrolled, with full enrollment completed in
October 2023. Patients received a total of 16 intravenous infusions of OST-HER2 administered over a 48-week treatment period. The trial
was conducted at major hospitals across 21 clinical sites in 18 U.S. states. The treatment phase has been completed, and patients continue
to be followed prospectively for long-term survival.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint of the
study was 12-month event-free survival (&#8220;EFS&#8221;), defined as the proportion of patients who remained recurrence-free at 12 months
following surgical resection. EFS outcomes were compared to a best available historical control derived from published U.S. literature
(the &#8220;Published Control&#8221;), with recurrence assessments conducted every three months in accordance with standard of care. In
the first quarter of 2025, we announced that the study met its primary endpoint with statistical significance. Specifically, 33% of OST-HER2-treated
patients (n=41) were event-free at 12 months compared to 20% in the Published Control population, representing a 13-percentage point absolute
improvement over historical outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Secondary endpoints included
overall survival and safety. In October 2025, we announced final two-year overall survival data. Among 36 evaluable patients, 75% (27
of 36) were alive two years following their most recent pulmonary resection compared to 40% in the Published Control population (p &lt;
0.0001). Earlier interim analyses demonstrated 12-month overall survival of 91% for OST-HER2-treated patients compared to 80% in the Published
Control, and 24-month overall survival of 61% compared to 40%, respectively. Survival assessments were conducted at three-month intervals.
The study was not powered as a randomized controlled trial, and comparisons were made against published historical data rather than a
contemporaneous control arm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Safety was assessed throughout
the treatment period and follow-up using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). OST-HER2
was generally well tolerated. No treatment-emergent adverse events classified as CTCAE Grade 5 (death) were reported. Adverse events were
monitored during the 48-week treatment period, with ongoing follow-up for survival and long-term safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2026, we announced
results from exploratory biomarker analyses evaluating immune activation markers in peripheral blood. Activation of biomarkers within
the interferon gamma pathway was observed to correlate with overall survival outcomes and distinguished long-term survivors (&#8805; two
years) from short-term survivors (&lt; one year). These biomarker analyses were exploratory in nature, were not pre-specified as primary
or secondary endpoints, and have not been validated as surrogate endpoints for clinical benefit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Phase IIb trial
met its primary endpoint and demonstrated favorable overall survival outcomes relative to historical controls, the study was conducted
as an open-label trial and did not include a randomized, contemporaneous control arm. Comparisons to historical controls are subject to
inherent limitations, including potential differences in patient populations, standards of care, supportive therapies and assessment methodologies,
and such comparisons may not be predictive of results in a randomized controlled trial. We intend to continue engaging with the FDA regarding
potential regulatory pathways for OST-HER2. However, there can be no assurance that the FDA will determine that the results of the Phase
IIb trial are sufficient to support submission or approval of a BLA. The FDA may require additional clinical data, including data from
a randomized Phase III clinical trial, prior to approval. The necessity, scope and design of any additional trials will depend on future
regulatory interactions and formal FDA determinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Phase&#160;Ib Clinical
Trial. </i></b>From September 2015 through May 2017, Advaxis, Inc. (&#8220;Advaxis&#8221;) sponsored and conducted a Phase Ib clinical
trial evaluating ADXS-HER2 (also known as ADXS31-164), the intellectual property rights to which we subsequently acquired from Ayala for
further development and commercialization as our OST-HER2 product candidate. The Phase Ib study was a multicenter, open-label, dose-escalation
trial designed to evaluate safety and tolerability, determine the maximum tolerated dose (&#8220;MTD&#8221;), and establish a recommended
Phase II dose. The study enrolled 12 adult patients with advanced, HER2-expressing solid tumors. Patients received escalating intravenous
doses of ADXS-HER2 administered every three weeks during a 12-week treatment cycle. Clinical sites were located at hospitals in Colorado,
Michigan, North Carolina, Pennsylvania and Texas. Following completion of study treatment, all 12 patients entered a three-year surveillance
period to monitor for potential <i>Listeria monocytogenes</i>-related complications.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoints were
safety and tolerability, including the incidence of dose-limiting toxicities (&#8220;DLTs&#8221;) during the first four months of treatment
and the frequency and severity of adverse events, assessed using the CTCAE, including Grade 4 events (life-threatening consequences).
Secondary endpoints included (i) objective tumor response rate (complete or partial response) as assessed by Response Evaluation Criteria
in Solid Tumors (RECIST) v1.1 and immune-related RECIST (ir-RECIST), and (ii) immunologic response parameters measured through serial
peripheral blood collection and analysis of peripheral blood mononuclear cells and serum biomarkers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No dose-limiting toxicities
were observed at the highest dose level evaluated (1 &#215; 10<sup>9</sup> colony-forming units (&#8220;CFU&#8221;)), and no maximum
tolerated dose was reached. ADXS-HER2 administered intravenously at 1 &#215; 10<sup>9</sup> CFU appeared to be generally well tolerated
in the 12 treated and evaluable subjects. No objective tumor responses (complete or partial responses) were observed in this late-stage,
heavily pre-treated patient population. Based on the observed safety and tolerability profile, 1 &#215; 10<sup>9</sup> CFU was selected
as the recommended Phase II dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase Ib study was primarily
designed to assess safety and dose selection and was not powered or intended to evaluate clinical efficacy. Accordingly, the absence of
objective tumor responses in this small, heterogeneous patient population should be interpreted in the context of the study&#8217;s dose-escalation
design and safety-focused objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Preclinical Animal Study.
</i></b>From July 2012 through September 2015, a prior licensee of Advaxis sponsored and conducted a preclinical study evaluating ADXS-HER2
in 18 companion canines with HER2-positive appendicular Osteosarcoma following standard-of-care treatment (amputation and chemotherapy).
This study is sometimes referred to as a Phase I veterinary clinical study. We subsequently acquired the intellectual property rights
to ADXS-HER2 constructs for further development and commercialization as OST-HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Canine appendicular Osteosarcoma
is recognized in scientific literature as a spontaneous large-animal model with biological and clinical similarities to pediatric Osteosarcoma.
In this study, ADXS-HER2 was administered in the setting of minimal residual disease following definitive surgical and chemotherapeutic
management. Outcomes were compared to a historical control cohort treated with amputation and chemotherapy alone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Results published in 2016
in Clinical Cancer Research (Mason, N. et al., &#8220;Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and
Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma&#8221;) reported improvements in overall survival
and metastatic disease progression relative to the historical control group. Reported overall survival rates at one, two and three years
were 77.8%, 67% and 56%, respectively, for ADXS-HER2-treated dogs, compared to 55%, 28% and 22%, respectively, for historical controls.
Median survival time was 956 days in the ADXS-HER2-treated group compared to 423 days in the historical control group (hazard ratio 0.33;
95% confidence interval 0.136&#8211;0.802; p = 0.014). A reduction in the incidence of metastatic disease was also reported relative to
historical controls. The study also noted the important translational relevance of the findings for children with Osteosarcoma. This study
for canine Osteosarcoma indications constituted preclinical work as it relates to our development of OST-HER2 to treat Osteosarcoma in
humans. These findings were generated in a small, non-randomized veterinary study using historical controls. Animal study results are
not necessarily predictive of clinical outcomes in humans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following completion of the
study, an application for conditional licensure of ADXS-HER2 for the treatment of canine Osteosarcoma was submitted to the United States
Department of Agriculture (&#8220;USDA&#8221;). In December 2017, ADXS-HER2 was granted a conditional license for veterinary use in dogs
one year of age and older diagnosed with Osteosarcoma. As the current owner of the ADXS-HER2 constructs, we held the conditional license
for OST-HER2. The conditional license permitted limited commercial distribution while additional data was to be generated to support full
licensure. We subsequently allowed the conditional license to lapse in connection with manufacturing process improvements and a strategic
reassessment of our development priorities. We may seek a new conditional license in the future following engagement with a USDA-licensed
contract manufacturer. Full USDA licensure would require submission of additional data, including studies addressing safety, purity, potency,
effectiveness, metabolism and shedding in canines. We are currently evaluating potential future development strategies with respect to
the veterinary indication. There can be no assurance that we will seek or obtain future USDA licensure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Preclinical Development.
</i></b>Our OST-HER2 product candidate is also being evaluated for potential development in additional HER2-expressing solid tumor indications,
including breast, esophageal and lung cancers. These programs are currently in the preclinical stage. The scope of additional preclinical
development required, if any, will depend on multiple factors, including the totality of available clinical and nonclinical data, the
specific tumor indication pursued, the design of any subsequent clinical protocol (including whether additional cohorts are incorporated
into a follow-on or master protocol) and feedback from the FDA and other regulatory authorities. While OST-HER2 has been evaluated clinically
in Osteosarcoma, regulatory authorities may require additional preclinical pharmacology, toxicology, biodistribution or other nonclinical
studies to support initiation of clinical trials in different tumor types. The extent of any such requirements will depend on regulatory
determinations regarding the sufficiency and applicability of existing data to the proposed indications. There can be no assurance that
additional preclinical studies will not be required prior to initiating clinical trials in breast, esophageal, lung or other solid tumor
indications, or that existing clinical data will be deemed sufficient to support expansion into those indications.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our OST-tADC product candidate
for all indications is also currently in preclinical development. We will need to conduct further preclinical trials for OST-tADC prior
to the submission of an IND in order to pursue clinical trials with these candidates. Such preclinical trials are expected to include
pharmacokinetics and pharmacodynamics, two-week dose finding toxicology studies in vivo (on living cell lines or in living animals), as
well as good laboratory practice (GLP) trials ensuring stability, potency and purity of the IND product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Technology Platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in the process of building
a fully integrated platform technology to accelerate the development of a range of product candidates across multiple therapeutic areas.
Our platform technology is intended to leverage our management&#8217;s in-depth experience in immunotherapy research, development and
manufacturing to enable us to pursue multiple therapeutic targets. Our scientists and scientific advisors have accumulated decades of
collective experience in the field of immunotherapy, oncology and small-molecule drug production, contributing key insights and significant
achievement in our clinical development process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Growth Strategies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to enrich and
lengthen the lives of patients by being a leading, fully integrated biotechnology company. We are seeking to develop, manufacture and
commercialize multiple product candidates targeting orphan and non-orphan oncologic diseases across multiple tissue types and therapeutic
areas. To achieve our goal, we are pursuing the following growth strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may consider out-licensing OST-HER2 to animal health companies for veterinary use in dogs diagnosed with Osteosarcoma, one year of age or older, consistent with prior conditional licensure and preclinical data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Obtain marketing approval for OST-HER2 in Osteosarcoma, then quickly pivot to a master protocol within breast, esophageal, lung and other solid tumors where metastases express HER2 that could be targeted by immune cells.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Complete pre-clinical and toxicology trials with the lead drug candidate for OST-tADC (OST-tADC-A, Exatecan-silanol-FRa) and submit an IND to initiate a Phase&#160;I trial in ovarian cancer and other folate receptor alpha-overexpressing tumors, including endometrial cancer and certain Osteosarcomas. We believe that positive results from preclinical and GLP toxicology studies may also facilitate potential out-licensing opportunities for SiLinker and CAPs drug products, without limiting therapeutic development.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Establish global commercial, clinical and medical affairs infrastructure to support the potential launch and commercialization of OST-HER2-based therapies and related product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through these strategies,
we aim to leverage our OST-HER2 and OST-tADC platforms to develop a diversified oncology pipeline across multiple tumor types, while maintaining
flexibility to pursue both human and veterinary indications, and to capture value through partnerships, out-licensing and clinical expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expansion Opportunities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek to expand our
business through acquisitions, in-licensing of complementary products or technologies, or the acquisition of companies with complementary
capabilities. While we have current collaborative agreements in place, we believe in an opportunistic approach to collaboration and licensing;
thus, we expect to operate in a manner that is customary in the pharmaceutical industry, including potential acquisitions and partnerships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe there is continued
interest from larger pharmaceutical companies in biotechnology firms developing next-generation therapies, including ADCs, due in part
to the potential of these therapies to address unmet medical needs in oncology. Advances in ADC technology, including combinations with
immunotherapies and other targeted agents, have broadened the potential applications for these modalities, which we may consider as part
of our expansion strategy.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Scientific Collaborations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Scientific Collaborators.
</i></b>We collaborate with experts and physicians to help advance our programs and, together, we are focused on translational strategies
to support the clinical study of our new therapy candidates. These collaborations support our goals to translate deep expertise in structure-based
drug design into a novel portfolio of precisely targeted therapies. We strive to address medical needs for patients with cancer harboring
resistance mutations in driver kinases using technology originally developed at the University of Pennsylvania under the guidance of Dr.&#160;Robert
G.&#160;Petit, our Chief Medical and Scientific Officer. Our partnering approach with physician-scientists allows us to understand the
limitations of existing therapies, which we believe will lead to product candidates that address the dual needs of treatment resistance
and kinase selectivity. OST-HER2&#8217;s compositions and methods of use are covered by two granted U.S.&#160;utility patents and one
granted Japanese patent. These patents were originally developed at the University of Pennsylvania and were owned either solely by the
University or jointly with Advaxis. We acquired all rights, title and interest in these patents from Advaxis pursuant to an assignment,
which enables us to develop, manufacture and commercialize OST-HER2 without reliance on in-licensing from Advaxis. See &#8220;<i>Our Licensing
Obligations&#160;&#8212;&#160;Advaxis</i>&#8221; and &#8220;<i>Our Intellectual Property</i>&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also established collaborations
through service agreements with global CROs to provide scale and expertise in research chemistry, chemical manufacturing, biology, pharmacology
and toxicology, and clinical studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Scientific Advisory
Board. </i></b>We have established a scientific advisory board comprised of six members with extensive experience in the field of oncology.
Our scientific advisors include researchers who publish widely cited research on topics relevant to the study and treatment of cancer,
lead clinical units at experienced precision medicine cancer centers in the United&#160;States and are actively involved in our drug development
process and programs. Our scientific advisory board meets periodically with our board of directors and management to discuss matters relating
to our business activities and to establish commercial business alliances. Members of our scientific advisory board are reimbursed by
us for out-of-pocket expenses incurred in connection with serving on our advisory board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our scientific advisory board
currently includes the following physicians and their professional affiliations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Nabil M.&#160;Ahmed, MD&#160;&#8212;&#160;Texas
Children&#8217;s Hospital</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Peter M.&#160;Anderson, MD&#160;&#8212;&#160;Cleveland Clinic</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Meenakshi Hedge, MD&#160;&#8212;&#160;Texas Children&#8217;s Hospital</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alejandro Sweet-Cordero, MD&#160;&#8212;&#160;University of California San Francisco</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Brenda Weigel, MD&#160;&#8212;&#160;Masonic Cancer Center&#160;&#8212;&#160;University of Minnesota</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Felasfa M.&#160;Wodajo, MD&#160;&#8212;&#160;Inova Fairfax Hospital, Virginia</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Patient Advocacy Advisory
Board. </i></b>We have established a patient advocacy advisory board comprised of four members with experience dealing with the effects
of Osteosarcoma. This board is responsible for reviewing and establishing our patient advocacy philosophy and policy. This board also
develops procedures for patient care evaluation while adhering to regulatory standards. This board identifies gaps in patient care and
represents patient interests at FDA meetings, ensuring that patient voices are heard in regulatory discussions. Members of our patient
advocacy advisory board are reimbursed by us for out-of-pocket expenses incurred in connection with serving on such board and sign customary
non-disclosure agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patient advocacy advisory
board currently includes the following individuals and their affiliations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Miriam Cohen&#160;&#8212;&#160;Founding Member, Chairperson and President of Osteosarcoma Collaborative</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Olivia Egge&#160;&#8212;&#160;Founding Member, Counsel and Patient Advocate of Osteosarcoma Collaborative; MD candidate at David Geffen School of Medicine at UCLA; Osteosarcoma Survivor</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Mac Tichenor&#160;&#8212;&#160;President of Osteosarcoma Institute</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tony Trent&#160;&#8212;&#160;President of The Tyler Trent Foundation</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Serena Subada&#160;&#8212;&#160;OST-HER2 Trial Participant</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>ADC Advisory Board.
</i></b>We have established an ADC advisory board comprised of two members with extensive experience with ADC technologies. This board
is responsible for reviewing and establishing our strategy and policies related to ADCs and helps to design and implement procedures for
evaluating the efficacy and safety of our ADC technologies, ensuring compliance with regulatory standards. This board identifies opportunities
to enhance ADC technology and address challenges in development, contributing to the advancement of innovative therapies in the field.
Members of our ADC advisory board are reimbursed by us for out-of-pocket expenses incurred in connection with serving on such board and
sign customary non-disclosure agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADC advisory board currently
includes the following professionals and their affiliations:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Borys Shor, Ph.D. &#8212;&#160;President
and Chief Executive Officer of Manhattan BioSolutions, Inc.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Jutta Wanner, Ph.D. &#8212;&#160;Senior
Vice President of Drug Discovery at Alpha-9 Oncology, Inc.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Colin Goddard, Ph.D. &#8212;&#160;Chairman
at BlinkBio, Inc.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the members of our
advisory boards may serve as consultants under consulting agreements for which they will receive compensation. To date, however, none
of our advisory board members has served as consultants to us, and we have not entered into any consulting agreements with any of them.&#160;
To our knowledge, none of our advisory board members has any conflict of interest between their obligations to us and their obligations
to others. Hospitals, medical centers and companies with which advisory board members are involved may in the future have commercial relationships
with us.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Licensing Obligations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Advaxis. </i></b>In
November&#160;2020, we entered into an amended and restated development, license and supply agreement with Advaxis, pursuant to which
Advaxis granted a license to us that allowed us to utilize Advaxis&#8217; ADXS-HER2 construct patents to develop and commercialize ADXS-HER2,
our lead product candidate (OST-HER2). On April 9, 2025, we acquired from Ayala (formerly Advaxis) the HER2 Assets. In connection with
such acquisition, the amended and restated development, license and supply agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>BlinkBio. </i></b>In
August&#160;2020, we entered into a licensing agreement with BlinkBio, Inc., pursuant to which BlinkBio granted a license to us that allows
us to utilize BlinkBio&#8217;s proprietary technology to develop, manufacture and commercialize certain of our products. BlinkBio granted
us an exclusive license for tADC&#8217;s that are directed towards, binds to or modifies the folate receptor alpha and a co-exclusive
license for tADC&#8217;s that are directed towards, binds to or modifies any target other than the folate receptor alpha, such as HER2.
In connection with the license agreement, we also agreed to issue a convertible note to BlinkBio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>Biolacuna
Ltd.</i></b> We have contracted with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements
to register OST-HER2 and gain approval of its use in the respective regions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">European Medicines Agency (EMA, Europe);</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines Evaluation Board (MEB, Netherlands);</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines and Healthcare products Regulatory Agency (MHRA,
United Kingdom); and</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">U.S. Food and Drug Administration (FDA, United States).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>University of Pennsylvania.</i></b>
On April 9, 2025, we acquired from Ayala the HER2 Assets. Pursuant to the terms of the HER2 Purchase Agreement, the amended and restated
development, license and supply agreement with Advaxis terminated. In connection with the acquisition of the HER2 Assets, we were assigned
by Ayala a license agreement with the Trustees of the University of Pennsylvania covering the use of HER2 construct patents. Under the
terms of the license agreement, we are required to pay an annual license fee to the Trustees of the University of Pennsylvania. We are
obligated to pay a royalty equal to 1.5% of net sales related to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">OST-HER2-related sales;</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">ADXS-503-related sales;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">ADXS-504-related sales; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Sales related to any new immunotherapy drug candidates created from the <i>Lm</i> platform during the
term of such licensing agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for more information on our licensing obligations
and the BlinkBio convertible note.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our ability and the ability of those third parties from whom we in-license patents to obtain and maintain intellectual property
protection in the United&#160;States and other countries for our current or future product candidates, including our lead core product
candidate OST-HER2, our other core product candidate OST-tADC, our non-core product candidates, our proprietary compound library and other
know-how. We seek to protect our proprietary and intellectual property position by, among other methods, in-licensing, owning, co-owning
and filing patents and patent applications in the United&#160;States and abroad related to our proprietary technology, inventions and
improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing
technological innovation to develop and maintain our proprietary and intellectual property position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following our acquisition
of the HER2 Assets from Ayala, we now own or co-own certain patents covering our lead product candidates. We also in-license patents
and patent applications for our other core candidate, OST-tADC, from BlinkBio, Inc. We co-own with the University of Pennsylvania the
intellectual property related to OST-HER2, which includes two granted U.S. utility patents, one granted Japanese patent, and two additional
foreign patents and pending applications, with expected expiration between 2029 and 2035, excluding any potential patent term extensions.
We hold exclusive rights to patents and patent applications covering the commercial manufacturing of OST-HER2 and our broader <i>Listeria</i>-based
immunotherapy platform, including two granted U.S. utility patents, one pending U.S. patent application, 11 granted foreign patents and
12 pending foreign applications. These patents are expected to expire in 2038, with one U.S. patent expiring in 2040 after patent term
adjustment. The intellectual property licensed from BlinkBio, Inc. includes six granted U.S. utility patents and multiple foreign patents
and pending applications covering methods of use for silicon-based drug conjugates and silanol-based therapeutic payloads, with expected
expiration between 2036 and 2037, excluding any potential patent term extensions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets
and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain
our proprietary position in the field of oncology. Our future plans also include reliance on data exclusivity, market exclusivity and
patent term extensions when available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of patent protection
we require to successfully commercialize our current or future product candidates may be unavailable or severely limited in some cases
and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that
any of the patents that we own, co-own or in-license have, or that any of such pending patent applications that mature into issued patents
will include, claims with a scope sufficient to protect&#160;OST-HER2 and OST-tADC&#160;or our other current or future product candidates.
In addition, if the breadth or strength of protection provided by such patent applications or any patents we may own, co-own or in-license&#160;is
threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to stop third
parties from making, using, selling, offering to sell or importing products identical or similar to ours will depend on the extent to
which we have rights under valid and enforceable patents, trade secrets or other intellectual property rights that cover these activities.
The patent rights of biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific
and factual issues. Our and any future licensor&#8217;s current and future patent applications may not result in the issuance of any patent
in any particular jurisdiction, and the claims of any current or future issued patents, even if those claims are valid and enforceable,
may not provide sufficient protection from competitors. Any owned or in-licensed patent rights we may obtain may not enable us to prevent
others from replicating, manufacturing, using or administering our product candidates for any indication. Moreover, the coverage initially
claimed in a patent application may be significantly reduced before a patent is issued, and a patent&#8217;s scope can be reinterpreted
after issuance. In addition, any patent we may own, co-own or in-license may be challenged, circumvented or invalidated by third parties.
As a result, we cannot ensure that any of our product candidates will be protected by valid and enforceable patents. See &#8220;<i>Risk
Factors&#160;&#8212;&#160;Risks Related to Our Intellectual Property</i>&#8221; for a more comprehensive description of risks related
to our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Commercialization Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to retain significant
development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates
on our own, or potentially with a partner, in the United&#160;States and other regions. We currently have no sales, marketing or commercial
product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United&#160;States,
and potentially other regions, following further advancement of our product candidates. We believe that such a focused sales and marketing
organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for
which our product candidates are being developed. Clinical data, the size of the addressable patient population and the size of the commercial
infrastructure and manufacturing needs may all influence or alter our commercialization plans. The responsibilities of the marketing organization
would include developing educational initiatives with respect to approved products and establishing relationships with researchers and
practitioners in relevant fields of medicine.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Future Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own or operate,
and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for
the manufacture of our product candidates for pre-clinical and clinical testing, as well as for commercial manufacturing if any of our
product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to package, label, store
and distribute our investigational product candidates, as well as our commercial products if marketing approval is obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that this strategy
allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment,
and personnel while also enabling us to focus our expertise and resources on the development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our product candidates
are biopharmaceuticals and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to
scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates
that can be produced cost-effectively at contract manufacturing facilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, the OST-HER2 active
pharmaceutical ingredients (API) (e.g., clinical drug substance) are manufactured in accordance with GMPs. The drug product formulation
is being developed with the goal of producing lyophilized therapeutics with consistent and immediate release dissolution profiles that
can be reproducibly manufactured using automated equipment. All manufacturing activities for the OST-HER2 drug product are performed in
accordance with GMPs. We currently rely on these vendors as single-source contract manufacturing organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in the process of developing
our supply chain for each of our product candidates and intend to put in place framework agreements under which third party ReciBioPharma,
a chemical manufacturer, will generally provide us with necessary quantities of API and drug product on a project-by-project basis based
on our development needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we advance our product
candidates through development, we will explore adding backup suppliers for the OST-tADC and drug product for each of our product candidates
to protect against any potential supply disruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally expect to rely
on third parties for the manufacture of any companion diagnostics that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current or future product
candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety,
efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive
regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable authorities in other countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Preclinical Studies and IND</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before initiating clinical
trials in humans, a sponsor must complete preclinical development activities, which generally include laboratory evaluations of product
chemistry, manufacturing, formulation and stability, as well as <i>in vitro</i> and animal studies designed to assess pharmacology, toxicology
and potential safety risks. Nonclinical safety studies intended to support an IND application are required to comply with applicable GLP
regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To initiate human clinical trials in
the United States, a sponsor must submit an IND to the FDA. An IND contains, among other things, results of preclinical studies, manufacturing
and analytical data, any available clinical data or relevant literature, and a proposed clinical trial protocol. The IND submission process
is intended to allow the FDA to assess whether the investigational product is reasonably safe to evaluate in humans and whether the proposed
clinical trial protocol is appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An IND becomes effective 30
days after receipt by the FDA unless the FDA, within that 30-day period, places the proposed clinical trial on full or partial clinical
hold due to safety concerns or deficiencies in the submission. If a clinical hold is imposed, the sponsor must address the FDA&#8217;s
concerns to the agency&#8217;s satisfaction before the clinical trial may proceed. Accordingly, submission of an IND does not guarantee
that the FDA will permit a clinical trial to begin. Certain long-term nonclinical studies, such as reproductive toxicity or carcinogenicity
studies, may continue after an IND becomes effective.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials must be conducted
in accordance with applicable federal statutes and regulations governing drug development and human subject research, as well as in compliance
with Good Clinical Practice (&#8220;GCP&#8221;) requirements, which are international ethical and scientific quality standards intended
to protect the rights, safety and welfare of human subjects and to ensure the integrity and reliability of clinical trial data. Clinical
trials must also be conducted pursuant to protocols that detail, among other things, the study objectives, inclusion and exclusion criteria,
dosing regimen, safety monitoring procedures, and statistical analysis plans designed to evaluate efficacy and safety endpoints.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are typically
conducted at multiple geographically dispersed sites to support generalizability of the data and to enable the FDA to evaluate the overall
benefit-risk profile of the investigational product and determine whether it satisfies the applicable statutory standard for approval.
Clinical data generated in these trials form the basis for the product labeling, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, each
clinical trial must be reviewed and approved by an Institutional Review Board (&#8220;IRB&#8221;) prior to initiation. An IRB is a duly
constituted body established to review and monitor biomedical research involving human subjects and has authority to approve, require
modifications to, or disapprove research in order to protect the rights and welfare of trial participants. In foreign jurisdictions, clinical
trials are subject to review and approval by independent ethics committees or similar regulatory authorities in accordance with applicable
local laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may impose a clinical
hold at any time before or during a clinical trial if it identifies safety concerns or determines that the investigation is not being
conducted in accordance with applicable statutory or regulatory requirements. A clinical hold may delay or suspend a trial until the identified
deficiencies are satisfactorily addressed. Similarly, an IRB may suspend or terminate a trial at its institution for non-compliance with
applicable legal or regulatory requirements or IRB determinations, or if it determines that the research presents an unexpected serious
risk to subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investigational products used
in clinical trials must be manufactured in accordance with applicable current good manufacturing practice (&#8220;cGMP&#8221;) requirements
under federal law and related regulations. While full commercial-scale validation is not required during early development, manufacturing
controls must be sufficient to ensure product identity, strength, quality and purity appropriate for the stage of development. As clinical
development progresses, regulatory expectations for manufacturing controls and validation generally increase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Marketing Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before we can commercialize
any of our current or future product candidates, we must obtain marketing approval from the applicable regulatory authorities. We have
not received approval to market any of our current product candidates. We expect to rely on third-party contract research organizations
and regulatory consultants to assist us in preparing and submitting marketing applications and navigating the regulatory review process.
Securing regulatory approval requires the submission of extensive preclinical and clinical data, as well as supporting information, to
the relevant regulatory authorities for each therapeutic indication and line of treatment to establish the product candidate&#8217;s safety,
efficacy, and, in the case of biologics, purity and potency. Securing regulatory approval also requires the submission of detailed information
regarding the drug manufacturing process and, in most cases, inspection of manufacturing facilities by the applicable regulatory authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process required by the FDA before
a drug or biologic product may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">completion of nonclinical laboratory studies and, as applicable, animal studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product for its intended use or uses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pre-approval inspection of manufacturing facilities and, in certain cases, clinical trial sites; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FDA review and approval of a marketing application, such as an NDA or BLA, which must occur before a drug or biologic product may be commercially marketed or sold.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not permitted to market
our current or future product candidates in the United States until we receive approval of an NDA or BLA from the FDA, as applicable.
In the European Economic Area, we must receive a marketing authorization from the European Commission following review by the European
Medicines Agency, and in other foreign jurisdictions, we must obtain approval from comparable regulatory authorities prior to commercialization.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Post-Market Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or comparable foreign
regulatory authorities approve any of our current or future product candidates, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion, and recordkeeping for the drug will be subject to extensive and ongoing regulatory
requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, continued
compliance with cGMPs, and compliance with GCPs for any clinical trials conducted post-approval. Regulatory approvals may also be subject
to limitations on the approved indications, conditions of approval, or requirements for additional post-marketing studies, including Phase
IV clinical trials and ongoing safety surveillance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Later discovery of previously
unknown problems with a product, including adverse events of unanticipated severity or frequency, or issues with our manufacturing processes
or third-party manufacturers, or failure to comply with regulatory requirements, may result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">restrictions on the marketing or manufacturing of the drug, withdrawal from the market, or product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fines, warning or other letters or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refusal by regulatory authorities to approve pending applications or supplements, or suspension or revocation of marketing approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seizure or detention of drugs, or refusal to permit the import or export of products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To produce our product candidates
for clinical trials and any products for commercial purposes, either at our own facilities or at third-party facilities, we and our third-party
vendors must comply with applicable cGMP requirements. As part of our ongoing quality and process improvement efforts, we routinely assess
our quality systems and implement enhancements as necessary to maintain compliance with applicable regulations. Regulatory authorities,
including the FDA and comparable foreign authorities, may inspect our facilities to confirm compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Animal Health Products</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. federal agencies
oversee the regulation of animal health products, including the FDA, the USDA and,
as applicable, the U.S.&#160;Environmental Protection Agency (&#8220;EPA&#8221;). The FDA Center for Veterinary Medicine regulates animal
pharmaceuticals under the Federal Food, Drug, and Cosmetic Act. The EPA regulates certain pesticidal products intended for use in or on
animals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USDA, through the Animal
and Plant Health Inspection Service (&#8220;APHIS&#8221;) and the Center for Veterinary Biologics (&#8220;CVB&#8221;), regulates veterinary
biologics, including vaccines, diagnostics and immunomodulators, under the Virus-Serum-Toxin Act. APHIS oversees the importation, interstate
movement and environmental release of veterinary biologics, while the CVB evaluates the safety, purity, potency and efficacy of these
products prior to licensure.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CVB&#8217;s licensure
process for veterinary biologics generally includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-License Evaluation. Review of the manufacturer&#8217;s application and supporting data on safety, efficacy, and quality, which may include laboratory and field studies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Licensing Decision. Granting a license if regulatory requirements are met, or requesting additional data if necessary.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Labeling Review. Approval of product labeling, including indications, dosage, administration, contraindications, and warnings.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Manufacturing Standards. Establishment and enforcement of requirements for facilities, equipment, and procedures, with inspections to ensure compliance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-Licensure Surveillance. Ongoing monitoring for safety or efficacy concerns, and requirements for reporting adverse events or conducting post-marketing studies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conditional licenses may be
granted for veterinary biologics in special circumstances, such as limited markets or unmet needs, if the product demonstrates a reasonable
expectation of safety and efficacy. Products with conditional licensure may be marketed under specific restrictions and are subject to
follow-up studies to support full licensure. The CVB continues to monitor licensed products, enforce manufacturing standards, and may
require additional data, inspections, or post-marketing studies as needed to ensure ongoing safety and efficacy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Other Healthcare Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we begin commercializing
any of our current or future product candidates, our operations will be subject to a variety of U.S. federal, state and foreign healthcare
laws and regulations. These laws govern, among other things, the recommendation, prescribing, marketing, distribution and reimbursement
of biopharmaceutical products. Healthcare providers, including physicians, play a central role in prescribing and recommending drugs for
which we obtain marketing approval. Our arrangements with healthcare providers, payors and other customers are subject to requirements
designed to ensure the integrity of these interactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. federal laws include,
among others, the Anti-Kickback Statute, which prohibits offering or receiving remuneration to induce or reward the referral or recommendation
of products reimbursable under federal healthcare programs, and the False Claims Act, which imposes penalties for submitting, or causing
the submission of, false or fraudulent claims to the federal government. Analogous state laws may impose similar requirements, including
reporting obligations for payments or other transfers of value to healthcare providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare reform legislation
also influences coverage, pricing and reimbursement for biopharmaceutical products. In the United States, statutes such as the Affordable
Care Act and the Inflation Reduction Act, as well as other federal and state programs, establish requirements for Medicaid and Medicare
drug rebates, coverage determinations, pricing transparency and other programmatic matters. States may also adopt regulations affecting
pricing, reimbursement and product access, including measures that encourage importation, bulk purchasing or competitive bidding. Similar
legislative and regulatory frameworks exist in other countries, where foreign authorities regulate drug approval, reimbursement and healthcare
coverage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance with these laws
and regulations informs our commercial programs, interactions with healthcare providers and payors, product labeling and pricing strategies.
Government authorities may update, amend or reinterpret these laws, which can affect operational requirements for biopharmaceutical companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Privacy and Data Protection Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations may involve
the collection, use, storage and transmission of personal information, including health-related data obtained in connection with clinical
trials, research activities and other business operations. As a result, we are subject to a variety of federal, state, and foreign privacy
and data protection laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>HIPAA and HITECH. </i></b>In
the United States, the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), establishes standards for the privacy and security of
protected health information maintained by healthcare providers, health plans and healthcare clearinghouses, as well as their business
associates. These laws impose requirements relating to the use, disclosure and safeguarding of individually identifiable health information,
including administrative, physical, and technical safeguards and breach notification obligations. HIPAA and HITECH also provide for civil
and criminal penalties for violations and authorize enforcement by the U.S. Department of Health and Human Services and, in certain circumstances,
state attorneys general.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>International Data Protection
Laws. </i></b>Outside the United States, privacy and data protection laws regulate the processing of personal information, including health-related
data. For example, the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;) establishes requirements governing
the collection, processing, storage and transfer of personal data and imposes obligations on organizations that process such data. The
GDPR includes restrictions on cross-border data transfers and provides individuals with certain rights regarding their personal data.
The United Kingdom has adopted a similar regulatory framework under the UK GDPR and the Data Protection Act 2018. Compliance with these
frameworks may affect how we collect, process, and transfer personal data in connection with our operations in Europe and other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>U.S. State Privacy Laws.
</i></b>Several U.S. states have enacted comprehensive privacy laws that regulate the collection and use of personal information. For
example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act (&#8220;CPRA&#8221;),
provides California residents with rights regarding their personal information and imposes obligations on covered businesses relating
to disclosures, consumer rights requests, and limitations on certain uses or sharing of personal data. These laws are enforced by state
authorities and may provide private rights of action in certain circumstances. Additional states have adopted or are considering similar
privacy legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance with these privacy
and data protection requirements may affect how we design our clinical trial activities, information systems, data processing practices
and contractual arrangements with third parties that process personal information on our behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Environmental Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations, facilities
and product development activities are subject to a variety of U.S. federal, state, local and foreign environmental, health and safety
laws and regulations. These requirements govern, among other things, air emissions, wastewater discharges, the use and storage of hazardous
substances, the generation and disposal of hazardous and non-hazardous waste, and the remediation of environmental contamination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
and manufacturing-related activities involve the use of hazardous and flammable materials, including chemicals and biological and radioactive
materials, and may generate hazardous waste. We typically rely on third-party contractors for the transport, treatment and disposal of
these materials and wastes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Environmental regulatory authorities,
including the EPA and comparable state and foreign agencies, administer laws and regulations relating to pollution control, environmental
protection and workplace health and safety. These requirements address, among other matters, emissions to air, discharges to land or water,
and the handling, storage, transportation and disposal of regulated materials. Compliance with these laws and regulations is an ongoing
component of our operations and facility management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Pricing Regulations and Third-Party
Coverage and Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements governing
regulatory approval, pricing and reimbursement for pharmaceutical and biologic products vary significantly among countries. In some jurisdictions,
governmental authorities regulate or approve the price of a drug before it can be marketed, while in others pricing reviews occur after
marketing authorization. In many foreign markets, prescription drug pricing remains subject to ongoing governmental oversight even after
initial approval. As a result, the timing of commercial launch and the price at which products may be marketed can be influenced by regulatory
review and reimbursement determinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
any of our current or future product candidates will depend, in part, on the availability of coverage and reimbursement from government
healthcare programs, private health insurers and other third-party payors. These payors determine whether a product will be covered under
a particular health plan and establish reimbursement levels. In making these determinations, payors typically consider factors such as
the product&#8217;s safety and efficacy, clinical value, medical necessity and cost-effectiveness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare systems in the
United States and other countries increasingly emphasize cost containment. Government authorities and third-party payors employ a range
of mechanisms to manage pharmaceutical expenditures, including coverage limitations, formulary controls, negotiated discounts and rebates,
and utilization management tools. These policies may influence product pricing, prescribing practices and reimbursement levels.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, coverage
and reimbursement decisions for many medicines under the Medicare program are administered by the Centers for Medicare &amp; Medicaid
Services (&#8220;CMS&#8221;), a component of the U.S. Department of Health and Human Services. CMS policies often inform reimbursement
approaches adopted by private payors and other healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Trade Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our global operations are
subject to various U.S. and foreign laws and regulations relating to anti-corruption, anti-money laundering, export controls, economic
sanctions and other international trade matters (collectively, &#8220;Trade Laws&#8221;). These laws generally prohibit companies and
their employees, agents and other representatives from offering, authorizing or providing improper payments or other benefits to government
officials or private parties in order to obtain or retain business or secure an improper advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of our business,
we may interact with government agencies, government-affiliated hospitals, universities and other public institutions, including in connection
with clinical trials, regulatory approvals and research collaborations. We may also engage third parties, such as contract research organizations,
consultants and other service providers, to support these activities. Trade Laws may apply to our activities and to those conducted on
our behalf by such third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance with applicable
Trade Laws informs our internal policies, procedures and contractual arrangements with third parties engaged in our operations in the
United States and internationally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and pharmaceutical
industries are highly competitive and characterized by rapid technological advancement, evolving regulatory requirements, and significant
research and development efforts. We face competition from large pharmaceutical companies, biotechnology companies, academic institutions,
government agencies and other research organizations that are developing or commercializing therapies for cancer and rare diseases, including
Osteosarcoma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are not currently
aware of any adjuvant therapy for Osteosarcoma intended for use in pediatric patients that is further advanced in development than OST-HER2,
a number of organizations are developing therapies that may compete with our product candidates. These include product candidates under
development by companies such as AstraZeneca and Y-mAbs Therapeutics, as well as programs being pursued by academic and research institutions,
including MD Anderson Cancer Center.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition in this industry
is based on a number of factors, including the ability to successfully develop product candidates, demonstrate safety and efficacy in
clinical trials, obtain regulatory approvals, secure intellectual property protection, establish manufacturing capabilities, obtain reimbursement
from third-party payors and successfully commercialize approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Human Capital and Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2026, we had
four full-time employees and one part-time employee.&#160; We also utilize the services of a limited number of consultants as needed to
perform specialized regulatory and medical-related services. Our employees are not represented by labor unions or covered by collective
bargaining agreements. We consider our relationship with our employees to be good. All of our employees have entered into agreements with
our company requiring them not to disclose our proprietary information and assigning to us all rights to inventions made during their
employment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate address is 115
Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638. This space is the accounting office of our Chief Financial Officer and
provided to us rent free. We believe that suitable additional or alternative space would be available in the future on commercially reasonable
terms, if necessary. As of the date of this annual report, all our operations are conducted remotely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>PIPE Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, we entered
into a Securities Purchase Agreement (the &#8220;PIPE Purchase Agreement&#8221;) with certain institutional and accredited investors,
substantially all of whom were existing stockholders, to issue immediately separable units (the &#8220;Units&#8221;), each consisting
of one share of Series A senior convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) and one warrant to purchase one share
of common stock (each, a &#8220;Series A Warrant&#8221;). The Units were sold at $4.00 per Unit (the &#8220;PIPE Financing&#8221;). At
two closings on December 31, 2024 and January 14, 2025, we issued an aggregate of 1,775,750 shares of Series A Preferred Stock and Series
A Warrants exercisable into 1,775,750 shares of common stock, generating gross proceeds of approximately $7.1 million before fees and
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Brookline Capital Markets,
a division of Arcadia Securities, LLC, acted as exclusive placement agent for the issuance and sale of the securities in the PIPE Financing.
Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as exclusive placement agent. In connection with the PIPE Financing,
we paid Brookline cash fees totaling $159,685 and $79,723 to Brookline and Brookline&#8217;s selected dealer, respectively, plus warrants
to purchase an aggregate of 59,848 shares of common stock (the &#8220;Agent Warrants&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PIPE Purchase Agreement
required stockholder approval under NYSE American rules for issuances that could exceed 20% of common stock outstanding as of December
24, 2024. On April 9, 2025, we held a Special Meeting of Stockholders, at which the issuance of shares upon (i) conversion of the Series
A Preferred Stock, (ii) exercise of the Series A Warrants, and (iii) exercise of the Agent Warrants, in each case without regard to any
limits on conversion or exercise therein and in amounts collectively equal to or exceeding 20% of our common stock outstanding as of December
24, 2024 (including upon the operation of applicable price reset and anti-dilution provisions and/or the reduction of conversion prices
and exercise prices), was approved by our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Acquisition of HER2
Assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, we completed
the acquisition of the HER2 Assets from Ayala. The HER2 Assets include two INDs with the FDA: (i) ADXS-503 for non-small cell lung cancer;
and (ii) ADXS-504 for prostate cancer. In consideration for the purchase of the HER2 Assets, we agreed to assume certain specified liabilities
and to pay an aggregate purchase price of $8,000,000, which was paid as follows: (i) $400,000 to Ayala ($150,000 of which was transferred
upon signing of the HER2 Purchase Agreement and the remainder on the closing date); (ii) $100,000 to a third party on behalf of Ayala
on the closing date; and (iii) $7,500,000 worth of shares of our common stock, or 4,774,637 shares based on the volume-weighted average
price of our common stock over the 30 trading days immediately preceding the closing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>ATM Equity Offering
Program and Sales</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2025, we entered
into an at market issuance sales agreement (the &#8220;Sales Agreement&#8221;) with B. Riley Securities, Inc. and JonesTrading Institutional
Services LLC (each, a &#8220;Sales Agent&#8221; and, together, the &#8220;Sales Agents&#8221;) relating to shares of our common stock.
Pursuant to the Sales Agreement, we may offer and sell shares of our common stock from time to time having an aggregate offering price
of up to $18,000,000 through or to the Sales Agents. We will pay each of the Sales Agents a total commission for its services in acting
as agent in the sale of common stock up to 3.0% of the gross sales price per share of all shares sold through it as agent under the Sales
Agreement. The amount of proceeds we will receive will depend upon the actual number of shares of our common stock sold and the market
price at which such shares are sold. Because there is no minimum offering amount required as a condition to close a sale, the actual total
public offering amount, commissions and proceeds to us are not determinable at this time. Sales of our common stock under the Sales Agreement
are being made pursuant to a prospectus supplement filed with the SEC on August 25, 2025. As of March 26, 2026, we have sold an aggregate
of 282,679 shares of our common stock for aggregate gross proceeds of $530,162 pursuant to the Sales Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Warrant Exercise Inducement
and Exchange Offers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 11, 2025, we completed
a final closing of a warrant exercise inducement and exchange offer (the &#8220;First Inducement Offering&#8221;). On September 2, 2025,
we closed on a second warrant exercise inducement and exchange offer (the &#8220;Second Inducement Offering&#8221;). On January 14, 2026,
we closed on a third warrant exercise inducement and exchange offer (the &#8220;Third Inducement Offering&#8221; and, collectively with
the First Inducement Offering and Second Inducement Offering, the &#8220;Inducement Offerings&#8221;). The First Inducement Offering and
Second Inducement Offering were made to holders of certain of our Series A Warrants to purchase shares of our common stock having a then
current exercise price of $1.12 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to certain inducement
offer letter agreements, holders of Series A Warrants exercised for cash their Series A Warrants to purchase an aggregate of 7,154,338
shares of our common stock at the then current exercise price of $1.12 per share and in exchange we issued to such holders new warrants
(the &#8220;New Warrants&#8221;) to purchase up to an aggregate of 7,154,338 shares of our common stock at an exercise price of $3.00
per share, subject to adjustment as provided therein. The New Warrants are immediately exercisable from the date of issuance and have
a term of exercise of five years from such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Third Inducement Offering
was made to less than 10 accredited investors that held New Warrants to purchase up to an aggregate of 5,382,148 shares of our common
stock having a then current exercise price of $3.00 or $2.10 per share. Pursuant to certain inducement offer letter agreements, such holders
of New Warrants exercised for cash their New Warrants to purchase 2,499,558 shares of our common stock at a reduced exercise price of
$1.40 per share and in exchange we issued to such holders new warrants (the &#8220;2026 Warrants&#8221;) to purchase up to an aggregate
of 2,499,558 shares of our common stock at an exercise price of $1.40 per share, subject to adjustment as provided therein. The 2026 Warrants
are immediately exercisable from the date of issuance and have a term of exercise of five years from such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered
broker dealer and FINRA member (the &#8220;Solicitation Agent&#8221;) to act as our exclusive warrant solicitation agent in connection
with the Inducement Offerings and paid the Solicitation Agent a cash fee equal to 5.0%, 1.5% and 8.0% of the total gross cash proceeds
received from the exercise by the holders of their respective warrants in connection with the First Inducement Offering, Second Inducement
Offering and Third Inducement Offering, respectively. We also paid the Solicitation Agent $15,000 and $25,000 for its reasonable legal
and other expenses in connection with the First Inducement Offering and Third Inducement Offering, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds to us from
the Inducement Offerings, before deducting transaction fees and other offering expenses, were approximately $11.5 million. We are using
the net proceeds from the Inducement Offerings to support U.S. and international regulatory and pre-commercial efforts aimed at securing
marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic Osteosarcoma, provide
funding for our wholly owned subsidiary OS Animal Health&#8217;s proposed spin-off transaction preparations, and for general corporate
purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock
underlying the New Warrants have been registered for resale under the Securities Act. We agreed to file a registration statement on Form
S-3 (or other appropriate form, including on Form S-1, if we are not then eligible to register securities on Form S-3) providing for the
resale of the shares of common stock issued or issuable upon exercise of the 2026 Warrants within 30 calendar days of March 2, 2026, and
to use commercially reasonable efforts to have such registration statement declared effective by the SEC within 60 calendar days (or within
90 calendar days in case of &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement
effective at all times until the earlier of (i) the time no holder owns any 2026 Warrants or shares of common stock issuable upon exercise
thereof and (ii) the Delegend Date (as defined in the inducement offer letter agreements entered into in connection with the Third Inducement
Offering).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Privately Negotiated
Warrant Exercise Inducement and Exchange Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 10, 2026 through February 2026, we entered into privately
negotiated inducement offer letters, pursuant to which certain remaining holders of our New Warrants exercised for cash their New Warrants
to purchase an aggregate of 123,216 shares of our common stock at a reduced exercise price of $1.40 per share and in exchange we issued
new warrants to purchase up to an aggregate of 123,216 shares of our common stock at an exercise price of $1.40 per share, subject to
adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance and have a term of exercise of
five years from such date. We received gross proceeds of approximately $172,502 from the exercise of these New Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or other appropriate form, including on Form S-1, if we are not then eligible to register securities on Form S-3)
providing for the resale of the shares of common stock issued or issuable upon exercise of these warrants on or before March 30, 2026,
and to use commercially reasonable efforts to have such registration statement declared effective by the SEC within 60 calendar days (or
within 90 calendar days in case of &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement
effective at all times until the earlier of (i) the time no holder of these warrants owns any such warrants or shares of common stock
issuable upon exercise thereof and (ii) the Delegend Date (as defined in the privately negotiated inducement offer letters).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>2026 Bridge Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, pursuant
to a securities purchase agreement (the &#8220;Bridge SPA&#8221;), we issued to certain accredited investors in a private placement transaction
(i) 10.0% original issue discount unsecured convertible promissory notes in an aggregate principal amount of $2,200,000 (the &#8220;Bridge
Notes&#8221;) and (ii) warrants to purchase up to an aggregate of 1,666,667 shares of our common stock (the &#8220;Bridge Warrants&#8221;
and such private placement transaction, the &#8220;Bridge Financing&#8221;), for aggregate gross proceeds of $2,000,000, before deducting
placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March 4, 2027 and accrue interest at a rate of 4.0%
per annum. The Bridge Warrants were immediately exercisable upon issuance, expire five years from the date of issuance and have an exercise
price of $1.40 per share, subject to adjustment as provided therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes were sold
at a 10% original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $110,000. The Bridge Notes are convertible into shares of our common stock under certain circumstances. If we complete a &#8220;Qualified
Offering,&#8221; defined as a registered public offering or registered direct offering resulting in at least $2.5 million in gross proceeds
from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically convert into
the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment of the Bridge
Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of our common stock at a conversion price equal
to 90% of the average daily volume-weighted average price of our common stock during the 10 trading days immediately preceding the holder&#8217;s
conversion notice, subject to adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
of the Bridge Financing to fund clinical development activities, including ongoing and planned clinical trials, and advance our research
and development programs, as well as for working capital and general corporate purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered
broker dealer and FINRA member to act as the exclusive placement agent for the Bridge Financing. In connection with the Bridge Financing,
we paid to the placement agent (a) a cash fee equal to 7.0% of the aggregate gross cash proceeds received by us in connection with the
Bridge Financing and (b) a one-time expense reimbursement of $25,000 for its legal and other expenses incurred in connection with the
Bridge Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to file a registration
statement on Form S-3 (or Form S-1 if we are not then eligible to register securities for Form S-3) by April 3, 2026 to register for resale
the shares of our common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed as a Delaware
limited liability company on April&#160;12, 2018 under the name OS Therapies, LLC.&#160;On June&#160;24, 2019, we converted from a limited
liability company to a Delaware corporation and changed our name to OS Therapies Incorporated. We completed our initial public offering
in August 2024 and our common stock is currently listed on NYSE American under the symbol &#8220;OSTX.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We presently conduct all of
our operations remotely. Our registered corporate address is 115 Pullman Crossing Road, Suite #103, Grasonville, Maryland 21638, and our
telephone number is (410)&#160;297-7793. Our website address is www.ostherapies.com. We make available on this website, free of charge,
our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports pursuant
to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish
such information to, the SEC. Reports and other information we file with the SEC may also be viewed at the SEC&#8217;s website at www.sec.gov.
The information contained on, or that can be accessed through, our website is not incorporated by reference into this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1A. Risk Factors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>In addition to the other
information contained in this Form 10-K, the following risk factors should be considered carefully in evaluating our company&#8217;s business.
Our business, financial condition or results of operations could be materially and adversely affected by any of these risks. Additional
risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition or results
of operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factor Summary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
certain risks. The risks described under the heading &#8220;Risk Factors&#8221; immediately following this summary may have an adverse
effect on our business, cash flows, financial condition and results of operations or may cause us to be unable to successfully execute
all or part of our strategy. Below are the principal factors that make our business speculative or risky:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Risks Related to Our Financial
Position and Need for Additional Capital</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We are a clinical stage biopharmaceutical
company and have not generated any revenue to date from drug sales, and may never become profitable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We have incurred significant
operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are unable to raise capital
when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development
programs or commercialization efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our independent registered public
accounting firm has expressed substantial doubt about our ability to continue as a going concern.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our ability to utilize our net
operating loss carryforwards and certain other tax attributes may be limited.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Risks Related to Drug Development
and Regulatory Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We depend heavily on the success
of our core product candidates, OST-HER2 and OST-tADC.&#160;We may not be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Delays or difficulties in enrolling patients in clinical trials could delay regulatory approval and increase
development costs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are not able to obtain,
or if there are delays in obtaining, required regulatory approvals for both our current or future product candidates, we will not be
able to commercialize, or will be delayed in commercializing, our current or future product candidates, and our ability to generate revenue
will be materially impaired.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our current or future product
candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences
following marketing approval, if any.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to obtain
or maintain orphan drug designation or exclusivity for any product candidates and, even if we do, that exclusivity may not prevent the
FDA, EMA or other regulatory authorities from approving other competing products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Even if we receive regulatory
approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our current or future product candidates, if approved, could be subject
to labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements
or experience unanticipated problems with our drugs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Manufacturing our current or
future product candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability
to provide supply of our current or future product candidates for preclinical studies and clinical trials or for commercial purposes
could be delayed or stopped.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our future growth may depend,
in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and
uncertainties that could materially adversely affect our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Risks Related to Intellectual
Property</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we or those from whom we
in-license patents are unable to obtain and maintain patent and other intellectual property protection for our technology and product
candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop
and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and
drugs may be impaired.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If our trademarks and trade
names for our products or company name are not adequately protected in one or more countries where we intend to market our products,
we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially
adverse consequences to building our product brand recognition.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we are unable to adequately
protect and enforce our trade secrets, our business and competitive position would be harmed.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may initiate, become a defendant
in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming
and unsuccessful.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We may not obtain or grant licenses
or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">If we fail to comply with our
obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions
to our business relationships with our licensors, we could lose license rights that are important to our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any owned, co-owned or in-licensed patent covering our current or
                                                                                                                           future product candidates or other valuable technology could be narrowed or found invalid or unenforceable if challenged in court or
                                                                                                                           before administrative bodies in the U.S.&#160;or abroad, including the USPTO and the EPO.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Risks Related to Management and
Our Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">In our industry in particular,
our future success depends on our ability to retain key scientific employees and to attract, retain and motivate qualified personnel.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Our internal computer systems,
or those of our third-party CROs or other contractors or consultants, may fail or suffer security
breaches, which could result in a material disruption of our current or future product candidates&#8217; development programs.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">We will incur increased costs
as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Position and
Need for Additional Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical stage biopharmaceutical
company and have not generated any revenue to date from drug sales, and may never become profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to achieve profitability
depends on our ability to generate revenue from product sales. To date, while we have generated interest in potential research collaborations,
we have not generated any commercial revenue from our product candidates, including our lead product candidate OST-HER2 and our OST-tADC
platform. We do not expect to generate revenue from drug sales in the near future. We will not generate revenue unless and until we successfully
complete the development of, obtain regulatory approval for, and commercialize one or more of our product candidates. Our lead product
candidate, OST-HER2, has completed a Phase IIb clinical trial in patients with recurrent, fully resected pulmonary metastatic Osteosarcoma
and we are currently pursuing regulatory interactions with the FDA and regulatory authorities in the United Kingdom and European Union
regarding potential approval pathways. These pathways may include the FDA&#8217;s Accelerated Approval Program and conditional approval
pathways in other jurisdictions. However, there can be no assurance that any such approvals will be granted, that confirmatory trials
will be successful or that we will ultimately be able to commercialize OST-HER2. Our OST-tADC platform remains in the preclinical stage
of development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we pursue these regulatory
pathways, we face significant risks and uncertainties that may prevent us from generating revenue, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to attract and retain
qualified scientific, clinical and management personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully
develop our product candidates, including completing preclinical studies and clinical trials, generating positive safety and efficacy
data, and conducting any confirmatory trials that may be required to support accelerated or conditional approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain regulatory
approval for our product candidates from the FDA and other regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the costs, timing and uncertainties
associated with advancing additional development programs we may identify internally or through collaborations or other strategic arrangements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to identify, develop
and utilize biomarkers that support regulatory submissions or demonstrate clinical benefit;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to establish and
maintain relationships with third-party manufacturers and suppliers for clinical and potential commercial supply, and to accurately forecast
and meet supply requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to enter into and
maintain collaboration, licensing, manufacturing, distribution and other strategic arrangements on favorable terms;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to establish commercialization
capabilities, obtain adequate reimbursement and coverage from third-party payors, and achieve market acceptance among physicians, patients
and payors if our products are approved;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to compete effectively
with existing or future therapies; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain, maintain
and enforce intellectual property protection and regulatory exclusivity for our product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while OST-HER2
has received Rare Pediatric Disease Designation and we may become eligible to receive a Priority Review Voucher if certain regulatory
approvals are obtained within specified timeframes, there can be no assurance that we will meet the requirements to receive such a voucher
or that it will provide any financial or strategic benefit to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the numerous risks
and uncertainties associated with drug development and commercialization, we may never generate significant revenue from product sales
or achieve profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred significant operating losses
in recent periods and anticipate that we will incur continued losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
devoted substantially all of our resources to the research and development of our product candidates, including OST-HER2 and our OST-tADC
platform. As a result, we have incurred significant operating losses and negative cash flows from operations. For each of the years ended
December 31, 2025 and 2024, we incurred operating losses and negative cash flows from operations. Since July 2018, we have financed our
operations primarily through public and private offerings of our securities, from which we have raised aggregate gross proceeds of approximately
$41.1 million. We have not generated any revenue from product sales and do not expect to do so unless and until one or more of our
product candidates receives regulatory approval and is successfully commercialized. We expect to continue to incur significant expenses
and operating losses for the foreseeable future. Our historical losses, together with expected future losses, have had and will continue
to have an adverse effect on our stockholders&#8217; equity and working capital. Our expenses are expected to increase substantially as
we:</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">advance the development of our
product candidates, including completing preclinical studies and conducting clinical trials, including any confirmatory trials that may
be required to support potential regulatory approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">prepare regulatory submissions
and continue interactions with regulatory authorities in the United States and internationally;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">manufacture clinical trial materials
and establish or expand relationships with third-party manufacturers to support clinical development and potential commercialization;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">continue research and development
activities to expand and advance our product pipeline, including our OST-tADC platform;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">seek regulatory approval for
our product candidates and prepare for potential commercialization;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expand our internal capabilities,
including hiring additional scientific, clinical, regulatory and management personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">maintain, expand, and protect
our intellectual property portfolio; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">incur additional legal, accounting,
insurance, investor relations and other expenses associated with operating as a public company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we will need
to generate significant revenue to achieve profitability, and we may never achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to raise capital when needed
or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or commercialization
efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of biopharmaceutical
product candidates is capital intensive and subject to significant uncertainty. We are currently advancing our lead product candidate,
OST-HER2, toward potential regulatory submission and approval, and our OST-tADC platform remains in preclinical development. We expect
our expenses to increase substantially as we continue to support regulatory interactions, prepare for potential BLA submissions, conduct
additional analyses, initiate any required confirmatory clinical trials, and expand our research and development activities. If OST-HER2
receives regulatory approval, we also expect to incur significant costs related to commercialization, including manufacturing scale-up,
sales, marketing, distribution and medical affairs, whether independently or with collaborators.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital requirements will
depend on many factors, including regulatory outcomes, the scope and timing of any additional clinical trials that may be required by
regulatory authorities, the costs of manufacturing and process development for our product candidates, the pace of expansion into additional
indications or geographies, and our ability to establish collaborations or strategic partnerships. In particular, despite the positive
results from our Phase IIb clinical trial, regulatory authorities may require additional clinical data, including from randomized controlled
trials, which would significantly increase our funding needs and extend development timelines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require substantial
additional capital to support our ongoing operations and execute our business strategy. However, we may be unable to obtain financing
on acceptable terms, or at all. Market conditions, including volatility in the biotechnology sector, and our clinical, regulatory and
commercial progress may adversely impact our ability to raise capital. If we are unable to secure adequate funding when needed, we may
be required to delay, reduce or terminate development programs, including for OST-HER2 or our OST-tADC platform, limit our ability to
pursue additional indications or regulatory approvals in other jurisdictions, delay or forgo commercialization efforts, or curtail our
operations, any of which could materially harm our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause dilution
to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional
capital through a combination of public and private securities offerings, including our at-the-market offering program, as well as
other debt financings, strategic collaborations and alliances and licensing arrangements. The terms of any financing may adversely
affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or
the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible
securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could
adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with
collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some
of our technologies or current or future product candidates or otherwise agree to terms unfavorable to us, any of which may have a
material adverse effect on our business, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our independent registered public accounting
firm has expressed substantial doubt about our ability to continue as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant
operating losses and negative cash flows from operations since our inception and expect to continue to incur substantial losses for the
foreseeable future as we advance the development of our product candidates, including OST-HER2, and continue preclinical development of
our OST-tADC platform. To date, we have financed our operations primarily through the issuance of equity and equity-linked securities,
including common stock, preferred stock, convertible promissory notes and warrants in public and private offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently generate
product revenue and do not expect to generate any product revenue in the near term. In addition, we do not expect our existing collaboration
or licensing arrangements, if any, to provide significant cash inflows sufficient to fund our operations. Our ability to generate revenue,
if any, will depend on the successful development, regulatory approval and commercialization of our product candidates, which is subject
to significant uncertainty and may not occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of our recurring losses from operations, negative cash
flows, and net capital deficiency, our independent registered public accounting firm has included an explanatory paragraph in its report
on our consolidated financial statements expressing substantial doubt about our ability to continue as a going concern for at least 12
months from the date of issuance of the consolidated financial statements. Our consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to raise substantial
additional capital to fund our operations and remain a going concern. However, we cannot guarantee that we will be able to obtain sufficient
additional funding or that such funding, if available, will be obtainable on acceptable terms. If we are unable to raise additional capital
or otherwise address our liquidity needs, we may be required to significantly delay, scale back or discontinue the development of our
product candidates, including OST-HER2, or otherwise curtail our operations. In such case, there can be no assurance that we will be able
to continue as a going concern. In addition, the inclusion of a going concern explanatory paragraph in our auditor&#8217;s report may
adversely affect our ability to obtain financing on acceptable terms, or at all, and could negatively impact the market price of our common
stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes in the future may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as
amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage
points (by value) in the ownership of its equity over a three-year period), the corporation&#8217;s ability to use its&#160;pre-change&#160;tax
attributes to offset its post-change income may be limited. We have experienced such ownership changes in the past, and we may experience
ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside our
control. As of December&#160;31, 2025 and 2024, we had federal and state NOLs of approximately $33,561,091 and $22,236,580, respectively,
federal and state research and development tax credits of $268,568 and $268,568, respectively, and general business credit carryforwards
of approximately $3,492,199 and $1,672,876, respectively. Our ability to utilize these NOLs and tax credit carryforwards may be limited
by an &#8220;ownership change.&#8221;&#160; If we undergo future ownership changes, many of which may be outside of our control, our ability
to utilize our NOLs and tax credit carryforwards could be further limited by Sections 382 and 383 of the Code. There is also a risk that
due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise
become unavailable to offset future income tax liabilities. Additionally, our NOLs and tax credit carryforwards could be limited under
state law. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Drug Development and Regulatory
Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend heavily on the success of our
lead product candidates, OST-HER2 and OST-tADC.&#160;We may not be able to obtain regulatory approval for, or successfully commercialize,
any of our current or future product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no products
approved for sale and may never successfully develop marketable product candidates. Our business depends heavily on the successful development,
regulatory approval, and commercialization of our current and future immunotherapy product candidates for Osteosarcoma, of which our lead
candidate, OST-HER2, is in Phase IIb clinical development. OST-tADC remains in preclinical development and will require substantial additional
preclinical and clinical testing, as well as regulatory approvals, before we may commercialize it. The preclinical studies and clinical
trials of our product candidates, as well as the manufacturing and marketing of any approved product, are subject to extensive and rigorous
regulation by government authorities in the United States, the European Economic Area (EEA), and other jurisdictions in which we intend
to test or market our product candidates. Before obtaining regulatory approvals, we must demonstrate through preclinical studies and clinical
trials that each product candidate is safe and effective for its intended indication. Drug development is a lengthy, expensive, and uncertain
process, and delay or failure can occur at any stage. Even with sufficient funding, there can be no assurance that any of our product
candidates will be successfully developed, approved, or commercialized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot market our product
candidates in the United States without approval of a BLA from the FDA, in the EEA without approval of a MAA from the EMA, or in other
foreign jurisdictions without the requisite approvals. Obtaining regulatory approval is complex, time-consuming, costly, and uncertain,
and the FDA, EMA, or other foreign authorities may delay, limit, or deny approval for many reasons, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">inability to demonstrate that
our product candidates are safe and effective for their target indications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">preclinical or clinical trial
results that fail to meet required statistical or clinical significance;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">disagreement with the number,
design, size, conduct, or implementation of our studies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">requests to conduct additional
preclinical studies or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">non-approval of formulation,
labeling, or specifications;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">actions by CROs that materially adversely affect study results;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities&#8217;
determination that our data are insufficient to demonstrate that clinical benefits outweigh safety risks;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">disagreement with our interpretation
of study data;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">non-acceptance of data generated
at certain study sites;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">advisory committee recommendations
that are negative or impose conditions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">requirements to implement a
Risk Evaluation and Mitigation Strategy (REMS);</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">determinations that manufacturing
processes or facilities do not comply with regulatory requirements, including cGMPs; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">changes in regulatory policies,
requirements, or procedures.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of these factors are
beyond our control and could prevent or delay regulatory approval, limit the indications for which a product may be approved, or impose
significant post-approval obligations. Any such setback could materially and adversely affect our business, prospects, and ability to
generate revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Delays or difficulties in enrolling patients
in clinical trials could prevent or delay regulatory approval and increase development costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to initiate
or continue clinical trials for our current or future product candidates if we are unable to locate and enroll a sufficient number of
eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United&#160;States.&#160;This
challenge is particularly significant because we are focused on patients with rare Osteosarcoma, which has a relatively low prevalence,
with an incident rate of approximately 1,000 individuals affected per year in the United&#160;States. Identifying patients who meet our
eligibility criteria, including those with specific molecular or driver gene profiles, may be difficult and could lead to slower-than-expected
enrollment. Some of our competitors have ongoing clinical trials for current or future product candidates that treat the same patient
populations as our current or future product candidates, and patients who would otherwise be eligible for our clinical trials may instead
enroll in clinical trials of our competitors&#8217; current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we successfully enrolled
41 patients in our Phase IIb clinical trial of OST-HER2, patient enrollment in future trials may be slower or more limited due to the
rarity of the disease, competition for patients from other clinical trials, or other factors outside our control, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the willingness of participants
to enroll in our clinical trials and available support in our countries of interest;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the obtaining of informed consent
from parents or guardians of pediatric patients which meet evolving regulatory requirements in the United&#160;States and other countries;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the severity of the disease
under investigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the eligibility criteria for
the clinical trial in question;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the availability of an appropriate
screening test;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the perceived risks and benefits
of the product candidate under study;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the efforts to facilitate timely
enrollment in clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the patient referral practices
of physicians;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the ability to monitor patients
adequately during and after treatment; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the proximity and availability
of clinical trial sites for prospective patients.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure to enroll a sufficient number of patients in future trials
could result in significant delays, increased development costs, or the need to suspend or abandon one or more clinical trials. Such delays
may also impair our ability to seek participation in expedited regulatory programs, such as the FDA&#8217;s priority review or fast track
designations, and could materially impact the timing, cost, and success of regulatory approvals and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to obtain, or if there
are delays in obtaining, required regulatory approvals for both our current or future product candidates, we will not be able to commercialize,
or will be delayed in commercializing, our current or future product candidates, and our ability to generate revenue will be materially
impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current or future product
candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety,
efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive
regulation by the FDA and other regulatory agencies in the United&#160;States&#160;and by comparable authorities in other countries. Before
we can commercialize any of our current or future product candidates, we must obtain marketing approval. We have not received approval
to market any of our current product candidates and may not obtain regulatory approvals for our future product candidates, if any, from
regulatory authorities in any jurisdiction and it is possible that none of our current or future product candidates or any current or
future product candidates we may seek to develop in the future will ever obtain regulatory approval. We have only limited experience in
filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory
consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data
and supporting information to the various regulatory authorities for each therapeutic indication and line of treatment to establish the
product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the drug
manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our current or future product
candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities
or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining regulatory
approvals, both in the United&#160;States&#160;and abroad, is expensive, may take many&#160;years if additional clinical trials are required,
if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty
of the current or future product candidates involved. Changes in marketing approval requirements or policies during the development period,
changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted NDA or BLA.&#160;The
FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application
or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. Our current or
future product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign
regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate
to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed
indication or that it is suitable to identify appropriate patient populations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the results of clinical trials
may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be unable to demonstrate
that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign
regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the data collected from clinical
trials of our current or future product candidates may not be sufficient to support the submission of an NDA, a BLA or other submission
or to obtain regulatory approval in the United&#160;States&#160;or elsewhere;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or comparable foreign
regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract
for clinical and commercial supplies; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the approval requirements or
policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical
data insufficient for approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if we were
to obtain approval, regulatory authorities may approve any of our current or future product candidates for fewer or more limited indications
than we request, may not approve the price we intend to charge for our drugs, may grant approval contingent on the performance of costly
post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial
prospects for our current or future product candidates, and our ability to generate revenues will be materially impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our current or future product candidates
may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile
of an approved label, or result in significant negative consequences following marketing approval, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects caused
by our current or future product candidates could cause us to interrupt, delay or halt preclinical studies or could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory
approval by the FDA or other regulatory authorities. While we have initiated clinical trials for&#160;OST-HER2, and although there have
been limited side effects with this therapy to date, it is likely that there may be adverse side effects associated with its use. Results
of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials
could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development
of or deny approval of our current or future product candidates for any or all targeted indications. The drug-related side effects could
affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.
Any of these occurrences may significantly harm our business, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, our current or future
product candidates could cause undesirable side effects in clinical trials related to&#160;on-target&#160;toxicity, or exaggerated and
adverse pharmacologic effects at the target of interest in the test system. If&#160;on-target&#160;toxicity is observed, or if our current
or future product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to
more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more
acceptable from a risk-benefit perspective. In our industry, many compounds that initially showed promise in early stage testing for treating
cancer have later been found to cause side effects that prevented further development of the compound.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials by their nature
utilize a sample of the potential patient population. For example,&#160;the 41 patients in our Phase&#160;IIb trial of OST-HER2 may include
a limited number of patients with side effects. With a limited number of patients and limited duration of exposure, rare and severe side
effects of our current or future product candidates may only be uncovered with a significantly larger number of patients exposed to the
product candidate. If our current or future product candidates are tested in large numbers of patients or if they receive marketing approval
and we or others identify undesirable side effects caused by such current or future product candidates after such approval, a number of
potentially significant negative consequences could result, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may place
a hold on an ongoing clinical trial or may refuse to allow a future clinical trial to be conducted;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw
or limit their approval of current or future product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may or a regulatory authority
might require that the product or products be recalled;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require
the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be required to create
a medication guide outlining the risks of such side effects for distribution to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be required to change
the way such current or future product candidates are distributed or administered, conduct additional clinical trials or change the labeling
of the current or future product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require
a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use,
such as restricted distribution methods, patient registries and other risk minimization tools;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may be subject to regulatory
investigations and government enforcement actions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may decide to remove such
current or future product candidates from the marketplace; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we could be sued and held liable
for injury caused to individuals exposed to or taking our current or future product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that any of these
events could prevent us from achieving or maintaining market acceptance of the affected current or future product candidates and could
substantially increase the costs of commercializing our current or future product candidates, if approved, and significantly impact our
ability to successfully commercialize our current or future product candidates and generate revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A breakthrough therapy designation by the
FDA for our current or future product candidate does not convey any advantage in, or shorten the duration of, the regulatory review or
approval process, and it does not increase the likelihood that our current or future product candidates will receive marketing approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May&#160;2024, we submitted
a request to the FDA for breakthrough therapy designation for OST-HER2, and we may seek a breakthrough therapy designation for some of
our other current or future product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination
with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction
and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while
minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also
eligible for accelerated approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designation as a breakthrough
therapy is within the discretion of the FDA.&#160;Accordingly, even if we believe that one of our current or future product candidates
meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation.
In any event, the receipt of a Breakthrough Therapy Designation for a product candidate does not convey any advantage in, or shorten the
duration of, regulatory review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure
ultimate approval by the FDA.&#160;In addition, even if one or more of our current or future product candidates qualify as breakthrough
therapies, the FDA may later decide that the drugs no longer meet the conditions for qualification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A fast track designation by the FDA does
not convey any advantage in, or shorten the duration of, the regulatory review regulatory review or approval process.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug is intended for
the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this
condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation,
so even if we believe that a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide
to grant it. Even though we have received fast track designation for OST-HER2 and may receive fast track designation again in the future
for certain current or future product candidates, this designation does not convey any advantage in, or shorten the duration of, regulatory
review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation
is no longer supported by data from our clinical development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to obtain or maintain
orphan drug designation or exclusivity for any product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or
other regulatory authorities from approving other competing products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OST-HER2 received orphan drug designation for Osteosarcoma in the United&#160;States,
and we may seek orphan drug designation (&#8220;ODD&#8221;) for other current or future product candidates. We have submitted the required
information to the FDA in order to re-establish ODD for OST-HER2 in 2026.&#160; Regulatory authorities in some jurisdictions, including
the United&#160;States&#160;and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under
the Orphan Drug Act&#160;of&#160;1983, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease
or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United&#160;States.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, if a product with
an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the
product may be entitled to a period of marketing exclusivity, during which the FDA or EMA generally cannot approve another marketing
application for the same active ingredient for the same indication. The applicable period is seven years in the United States and ten
years in the European Union, although EU exclusivity may be reduced to six years if a drug no longer meets the orphan criteria or is
considered sufficiently profitable. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient drug supply to meet patient needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain orphan drug
exclusivity for a product, that exclusivity may not effectively protect the product from competition. Drugs with different active ingredients
can be approved for the same condition, and the FDA or EMA may approve the same drug for the same condition if a later product demonstrates
clinical superiority, such as being safer, more effective, or making a major contribution to patient care. In addition, we may not be
the first to obtain marketing approval for a particular orphan indication. Approval of another product for the same active ingredient
and indication could prevent or delay our ability to obtain orphan drug exclusivity, materially affecting our competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities may
also revise orphan drug regulations or policies, and it is uncertain how any such changes could impact our business or exclusivity rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although we have obtained rare pediatric
disease designation for&#160;OST-HER2&#160;for Osteosarcoma patients, we may not be eligible to receive a priority review voucher in the
event that FDA approval does not occur within the timeframe required by the applicable statutory provisions or if future law changes eliminate
or further modify the PRV Program.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rare Pediatric Disease
Priority Review Voucher Program (&#8220;PRV Program&#8221;) is intended to incentivize pharmaceutical sponsors to develop drugs for rare
diseases. A sponsor who obtains approval of an NDA or BLA for a rare disease may be eligible for a Priority Review Voucher (&#8220;PRV&#8221;)
under this program, which may be redeemed by the owner of such PRV to obtain priority review for a marketing application. A PRV is fully
transferrable and can be sold to any sponsor, who in turn can redeem the PRV for priority review of a marketing application in six&#160;months,
compared to the standard timeframe of approximately ten&#160;months. Under current law, as amended by the Consolidated Appropriations
Act, 2026, the PRV Program is authorized through September 30, 2029. The FDA may not award PRVs under this program after that date. Eligibility
for a PRV generally requires both rare pediatric disease designation and approval of a marketing application for the designated rare pediatric
disease. Even if OST-HER2 receives rare pediatric disease designation and is ultimately approved, we may not receive a PRV if the BLA
is not approved in time to meet statutory requirements or if the PRV Program is subsequently modified or allowed to expire. In addition,
even if we are eligible for and obtain a PRV, there can be no assurance that we will be able to realize significant value from the voucher,
as the market for PRVs and their perceived value may vary over time and may be affected by changes in regulatory policies, business conditions
or the supply of available PRVs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval for
any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may
result in significant additional expense. Additionally, our current or future product candidates, if approved, could be subject to labeling
and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our drugs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or a comparable
foreign regulatory authority approves any of our current or future product candidates, the manufacturing processes, labeling, packaging,
distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and
ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval.
Any regulatory approvals that we receive for our current or future product candidates may also be subject to limitations on the approved
indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase&#160;IV clinical trials, and surveillance to monitor the safety and efficacy of the drug. Later discovery of
previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers
or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">restrictions on the marketing
or manufacturing of the drug, withdrawal of the drug from the market, or drug recalls;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fines, warning or other letters
or holds on clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">refusal by the FDA to approve
pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">drug seizure or detention, or
refusal to permit the import or export of drugs; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injunctions or the imposition
of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s policies may
change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our current or future
product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely
affect our business, prospects and ability to achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Positive results from early preclinical
studies and clinical trials of our current or future product candidates are not necessarily predictive of the results of later preclinical
studies and clinical trials of our current or future product candidates. If we cannot replicate the positive results from our earlier
preclinical studies and clinical trials of our current or future product candidates in our later preclinical studies and clinical trials,
we may be unable to successfully develop, obtain regulatory approval for and commercialize our current or future product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Positive results from our
preclinical studies of our current or future product candidates, and any positive results we may obtain from our early clinical trials
of our current or future product candidates, may not necessarily be predictive of the results from required later preclinical studies
and clinical trials. Similarly, even if we are able to complete our planned preclinical studies or clinical trials of our current or future
product candidates according to our current development timeline, the positive results from our preclinical studies and clinical trials
of our current or future product candidates may not be replicated in subsequent preclinical studies or clinical trial results. For example,
our later-stage clinical trials could differ in significant ways from our Phase&#160;IIb clinical trial of&#160;OST-HER2,&#160;which could
cause the outcome of these later-stage trials to differ from our earlier-stage clinical trials. For example, these differences may include
changes to inclusion and exclusion criteria, final dosage formulation, efficacy endpoints and statistical design.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage
development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things,
preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical
trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations
and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials
nonetheless failed to obtain FDA approval. If we fail to produce positive results in our planned preclinical studies or clinical trials
of any of our current or future product candidates, the development timeline and regulatory approval and commercialization prospects for
our current or future product candidates, and, correspondingly, our business and financial prospects, would be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Manufacturing our current or future product
candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide our current
or future product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of manufacturing
of our current or future product candidates is complex and highly regulated. We do not have our own manufacturing facilities or personnel
and currently rely, and expect to continue to rely, on third parties based in the United&#160;States, Europe and Asia for the manufacture
of our current or future product candidates. These third-party manufacturing providers may not be able to provide adequate resources or
capacity to meet our needs and may incorporate their own proprietary processes into our product candidate manufacturing processes. We
have limited control and oversight of a third-party&#8217;s proprietary process, and a third-party may elect to modify its process without
our consent or knowledge. These modifications could negatively impact our manufacturing, including product loss or failure that requires
additional manufacturing runs or a change in manufacturer, both of which could significantly increase the cost of and significantly delay
the manufacture of our current or future product candidates. As our current or future product candidates progress through preclinical
studies and clinical trials towards approval and commercialization, it is expected that various aspects of the manufacturing process will
be altered in an effort to optimize processes and results. Such changes may require amendments to be made to regulatory applications which
may further delay the timeframes under which modified manufacturing processes can be used for any of our current or future product candidates
and additional bridging studies or trials may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future growth may depend, in part, on
our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
that could materially adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not permitted to market
or promote any of our current or future product candidates in foreign markets before we receive regulatory approval from the applicable
regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our current or future product
candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution
of our current or future product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our current
or future product candidates and ultimately commercialize our current or future product candidates in foreign markets, we would be subject
to additional risks and uncertainties, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">differing regulatory requirements
in foreign countries, which may cause obtaining regulatory approvals outside of the United&#160;States&#160;to take longer and be more
costly than obtaining approval in the United&#160;States;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the burden of complying with
complex and changing foreign regulatory, tax, accounting and legal requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">different medical practices
and customs in foreign countries affecting acceptance in the marketplace;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">import or export licensing requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reduced protection of intellectual
property rights and the existence of additional potentially relevant third-party intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">economic weakness, including
inflation, or political instability in particular foreign economies and markets;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">compliance with tax, employment,
immigration and labor laws for employees living or traveling abroad;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">foreign currency fluctuations,
which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">workforce uncertainty in countries
where labor unrest is more common than in the United&#160;States;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">potential liability under the
Foreign Corrupt Practices Act&#160;of&#160;1977 or comparable foreign regulations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">production shortages resulting
from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">business interruptions resulting
from&#160;geopolitical&#160;actions, including war and terrorism.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign sales of our current
or future product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability,
trade restrictions and changes in tariffs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may in the future conduct clinical trials
for current or future product candidates outside the United&#160;States, and the FDA and comparable foreign regulatory authorities may
not accept data from such trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future choose
to conduct one or more clinical trials outside the United&#160;States, including in Europe. The acceptance of study data from clinical
trials conducted outside the United&#160;States&#160;or another jurisdiction by the FDA or comparable foreign regulatory authority may
be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve
as the basis for marketing approval in the United&#160;States, the FDA will generally not approve the application on the basis of foreign
data alone unless (i)&#160;the data are applicable to the United&#160;States&#160;population and United&#160;States&#160;medical practice
and (ii)&#160;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. Additionally,
the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many
foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable
doctrines or local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable
foreign regulatory authority will accept data from trials conducted outside of the United&#160;States&#160;or the applicable jurisdiction.
If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials,
which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving
approval for commercialization in the applicable jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be successful in our efforts
to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate
or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater
likelihood of success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of our business
depends primarily upon our ability to identify, develop and commercialize our product candidates. Although some of our current product
candidates are in preclinical and clinical development, our scientific hypotheses may be incorrect or our research programs may fail to
identify other potential product candidates for clinical development for a number of reasons. Our research methodologies may be unsuccessful
in identifying potential product candidates, or our potential product candidates may be shown to have harmful side effects or may have
other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited financial
and management resources, we focus on a limited number of research programs and product candidates and are currently focused on our lead
core product candidate&#160;OST-HER2 and our other core product candidate&#160;OST-tADC, both&#160;targeting the treatment of Osteosarcoma.
As a result, we may forego or delay pursuit of opportunities with other current or future product candidates or for other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and current
or future product candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the
commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate
through future collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to
retain sole development and commercialization rights to such product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of these events occur,
we may be forced to abandon our development efforts for a program, which would have a material adverse effect on our business and could
potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial
and human resources. We may focus our efforts and resources on potential programs or current or future product candidates that ultimately
prove to be unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although a larger number of Osteosarcoma
patients reside outside the United States, our ability to generate meaningful revenues in those jurisdictions may be limited due to pricing
controls, reimbursement limitations, and other market access challenges.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The incidence of new cases
of Osteosarcoma is approximately 1,000 individuals annually in the United States and approximately 20,000 globally. Although the global
patient population is larger, our ability to generate revenues outside the United States may be limited by pricing regulations, reimbursement
restrictions, and market access barriers. In many countries, particularly in the European Union and other developed markets, the pricing
of prescription pharmaceuticals is subject to governmental control, and pricing and reimbursement approvals may be required prior to or
following marketing authorization. Pricing negotiations with governmental authorities can be lengthy and may delay the commercial launch
of a product candidate. In some jurisdictions, obtaining reimbursement or pricing approval may require the submission of health economic
data or the conduct of additional clinical studies to demonstrate cost-effectiveness relative to existing therapies. If reimbursement
for our product candidates is unavailable, limited in scope, or subject to significant restrictions, or if pricing is set at unsatisfactory
levels, our ability to generate revenues in those markets may be materially adversely affected. In addition, in certain regions, including
parts of Africa and the Middle East, limited healthcare infrastructure and diagnostic capabilities may constrain our ability to identify
and treat patients, thereby limiting commercial opportunities. In the United States, there have been significant efforts to control drug
pricing. For example, the Inflation Reduction Act of 2022 introduced measures that allow the federal government to negotiate prices for
certain drugs under Medicare and impose rebates tied to inflation. These and other pricing reforms may reduce the prices we are able to
charge for any approved products and adversely affect our revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive marketing approval for
our current or future product candidates, our current or future product candidates may not achieve broad market acceptance, which would
limit the revenue that we generate from their sales.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commercial success of
our current or future product candidates, if approved by the FDA or other applicable regulatory authorities, will depend upon the awareness
and acceptance of our current or future product candidates among the medical community, including physicians and patients, as well as
reimbursement and coverage by third party payors including Medicare and Medicaid. Market acceptance of our current or future product candidates,
if approved, will depend on a number of factors, including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the efficacy of our current
or future product candidates as demonstrated in clinical trials, and, if required by any applicable regulatory authority in connection
with the approval for the applicable indications, to provide patients with incremental health benefits, as compared with other available
medicines;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">limitations or warnings contained
in the labeling approved for our current or future product candidates by the FDA or other applicable regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the clinical indications for
which our current or future product candidates are approved;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">availability of alternative
treatments already approved or expected to be commercially launched in the near future;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the potential and perceived
advantages of our current or future product candidates over current treatment options or alternative treatments, including future alternative
treatments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the willingness of the target
patient population to try new therapies or treatment methods and of physicians to prescribe these therapies or methods;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the need to dose such product
candidates in combination with other therapeutic agents, and related costs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the strength of marketing and
distribution support and timing of market introduction of competitive products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">pricing and cost effectiveness;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the effectiveness of our sales
and marketing strategies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to increase awareness
of our current or future product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain sufficient
third-party coverage and reimbursement, including from federal healthcare programs such as Medicare and Medicaid; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the ability or willingness of
patients to pay&#160;out-of-pocket&#160;in the absence of third-party coverage.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our current or future product
candidates are approved but do not achieve an adequate level of acceptance by patients, physicians and payors, we may not generate sufficient
revenue from our current or future product candidates to become or remain profitable. Before agreeing to cover and reimburse our products,
third party payors may require us to demonstrate that our current or future product candidates, in addition to treating these target indications,
are not only safe but cost effective compared to alternative therapies. Our efforts to educate the medical community, patient organizations
and third-party payors about the benefits of our current or future product candidates may require significant resources and may never
be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face substantial competition, which may
result in others discovering, developing or commercializing drugs before or more successfully than we do.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development and commercialization
of new drugs is highly competitive and constantly evolving. We face competition with respect to our current product candidates and will
face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical
companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, government agencies and other public and
private research organizations worldwide. Some of these competitors currently market or are actively developing therapies for rare diseases
and cancers, including Osteosarcoma, and some programs may be based on scientific approaches that are similar to ours, while others may
employ entirely different approaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, if OST-HER2
receives marketing approval for the treatment of Osteosarcoma, it may face competition from other product candidates in development for
these indications, including programs from AstraZeneca, Y-mAbs Therapeutics, MD Anderson Cancer Center and others. The competitive landscape
is dynamic: competitors&#8217; programs may advance or be discontinued, and new entrants may emerge, which could materially affect our
ability to capture or maintain market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of the companies against
which we are competing or may compete in the future have significantly greater financial, technical, regulatory and commercial resources
than we do, including greater expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining
regulatory approvals and reimbursement, and marketing approved drugs. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in further consolidation and concentration of resources among a smaller number of competitors. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
These competitors may also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel,
establishing clinical trial sites and enrolling patients in clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe
side effects, are more convenient or are less expensive than any drugs that we or our collaborators may develop. Our competitors also
may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our
competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors
affecting the success of all of our current or future product candidates, if approved, are likely to be their efficacy, safety, convenience,
price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product liability lawsuits against us could
cause us to incur substantial liabilities and could limit commercialization of any current or future product candidates that we may develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will face an inherent risk
of product liability exposure related to the testing of our current or future product candidates in human clinical trials and will face
an even greater risk if we commercially sell any current or future product candidates that we may develop. If we cannot successfully defend
ourselves against claims that our current or future product candidates caused injuries, we could incur substantial liabilities. Regardless
of merit or eventual outcome, liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">decreased demand for any current
or future product candidates that we may develop;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">injury to our reputation and
significant negative media attention;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawal of clinical trial
participants;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">significant costs and resources
to defend the related litigation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards
to trial participants or patients; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the inability to commercialize
any current or future product candidates that we may develop.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain product
liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase
our insurance coverage when we initiate a large global trial and if we successfully commercialize any product candidate. Insurance coverage
is increasingly expensive. We may not be able to maintain product liability insurance coverage at a reasonable cost or in an amount adequate
to satisfy any liability that may arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we are able to commercialize any
current or future product candidates, such drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement
policies, which would harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations that govern
regulatory approvals, pricing, and reimbursement for new drugs vary widely from country to country. Some countries require approval of
the sale price of a drug before it can be marketed, and in many countries, the pricing review period begins after marketing approval is
granted. In certain markets, including the European Union, prescription pharmaceutical pricing remains subject to continuing governmental
control even after initial approval. As a result, we may obtain marketing approval for a product candidate in a particular country but
be subject to price regulations that delay commercial launch or limit the revenues we are able to generate from the sale of the product
candidate in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more current or future
product candidates, even if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been significant legislative and regulatory efforts to control drug pricing. For example, the Inflation Reduction Act of 2022 includes
provisions that permit the U.S. Department of Health and Human Services, through the CMS,
to negotiate prices for certain high-expenditure drugs covered under Medicare, impose inflation-based rebates, and redesign certain aspects
of the Medicare Part D program. While the full implementation and long-term impact of these measures are still evolving, they may reduce
the prices we are able to charge for any approved products and adversely affect our revenues and profitability. Additional federal or
state healthcare reform measures may also be adopted in the future that could further impact pricing and reimbursement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to successfully
commercialize any current or future product candidates will depend in part on the extent to which coverage and reimbursement for these
product candidates and related treatments are available from government authorities, private health insurers, and other organizations.
Government authorities and other third-party payors decide which medications they will cover and establish reimbursement levels. Factors
payors consider in determining reimbursement include whether the product is a covered benefit, safe and effective, medically necessary,
appropriate for the patient, and cost-effective, and whether it is considered experimental or investigational.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary trend in the U.S.
healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have sought to control costs by limiting
coverage, setting reimbursement levels, requiring rebates and discounts, and challenging the prices charged for drugs. We cannot be sure
that coverage will be available for any product candidate that we commercialize or, if coverage is available, the level of reimbursement.
Reimbursement levels may impact the demand for, or the price of, any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There may be significant delays
in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved
by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be
paid for in all cases or at a rate that covers our costs, including research, development, manufacturing, and distribution. Reimbursement
rates may vary based on the use of the drug, the clinical setting, and comparisons to lower-cost therapies, and may be incorporated into
bundled payments for other services. Net prices for drugs may also be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors. In the United States, coverage and reimbursement decisions for Medicare are made by CMS, and private
payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement practices. Our inability to
obtain timely and adequate coverage and reimbursement for any approved products could have a material adverse effect on our business,
financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare reform measures may have a material
adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States and many
foreign jurisdictions have enacted and continue to consider legislative and regulatory changes affecting the healthcare system that could
prevent or delay marketing approval of our current or future product candidates, restrict or regulate post-approval activities, and affect
our ability to profitably commercialize any products for which we obtain marketing approval. Changes in regulations, statutes, or the
interpretation of existing requirements could require, among other things: (i) changes to our manufacturing arrangements; (ii) additions
or modifications to product labeling; (iii) the recall or discontinuation of products; or (iv) additional recordkeeping, reporting, or
compliance obligations. Any such changes could adversely affect our operations and increase our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been significant efforts to control healthcare costs and drug pricing. For example, the Inflation Reduction Act of 2022 includes
provisions that, among other things, allow the U.S. Department of Health and Human Services to negotiate prices for certain drugs covered
under Medicare, impose inflation-based rebates, and redesign certain aspects of the Medicare Part D program. The implementation and long-term
effects of these measures are still evolving, but they may reduce the revenues we are able to generate from any approved products. In
addition, other federal and state legislative and regulatory proposals aimed at controlling drug pricing, increasing transparency, or
reforming reimbursement systems have been introduced and may be enacted in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenue prospects may
also be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry,
and new laws, regulations, or judicial decisions, or new interpretations of existing laws, regulations, or decisions, related to healthcare
availability, pricing, coverage, or reimbursement may negatively impact our business, financial condition, and results of operations.
We cannot predict the likelihood, nature, or extent of future healthcare reform measures or their potential impact on our business. If
we or any third parties we engage are unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we or such third parties fail to maintain regulatory compliance, we may lose any regulatory approvals that we may obtain and may
not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If, in the future, we are unable to establish
sales and marketing and patient support capabilities or enter into agreements with third parties to sell and market our current or future
product candidates, we may not be successful in commercializing our current or future product candidates if and when they are approved,
and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have a
sales or marketing infrastructure and have limited experience in the sales, marketing, patient support or distribution of drugs. To achieve
commercial success for any approved product candidate for which we retain sales and marketing responsibilities, we must build our sales,
marketing, patient support, managerial and other&#160;non-technical&#160;capabilities or make arrangements with third parties to perform
these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities
with our collaborators for, some of our current or future product candidates if and when they are approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are risks involved with
both establishing our own sales and marketing and patient support capabilities and entering into arrangements with third parties to perform
these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any drug launch. If
the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does
not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and
our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Factors that may inhibit our
efforts to commercialize our current or future product candidates on our own include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our inability to recruit and
retain adequate numbers of effective sales and marketing personnel;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the inability of sales personnel
to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the lack of complementary drugs
to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">unforeseen costs and expenses
associated with creating an independent sales and marketing organization.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we enter into arrangements
with third parties to perform sales, marketing, patient support and distribution services, our drug revenues or the profitability of these
drug revenues to us are likely to be lower than if we were to market and sell any current or future product candidates that we develop
ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our current or future
product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties,
and any of them may fail to devote the necessary resources and attention to sell and market our current or future product candidates effectively,
or they may engage in practices that pose legal risks to us under applicable anti-kickback, fraud and abuse and other healthcare laws
and regulations. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third
parties, we will not be successful in commercializing our current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with prescribers, customers
and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could
expose us to significant penalties and adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not currently
have any products on the market, if we begin commercializing our current or future product candidates, we will become subject to additional
healthcare statutory and regulatory requirements and enforcement by federal, state, and foreign governmental authorities. Healthcare providers,
including physicians, play a primary role in the recommendation and prescription of any products for which we obtain marketing approval.
Our arrangements with healthcare providers, third-party payors, and customers will expose us to broadly applicable fraud and abuse and
other healthcare laws and regulations that constrain the business and financial relationships through which we market, sell, and distribute
our products. Restrictions under applicable federal and state healthcare laws and regulations include, among others, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback Statute
prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly,
in cash or in kind, to induce or reward referrals or the purchase, order, or recommendation of any good or service reimbursable under
federal or state healthcare programs such as Medicare, Medicaid, and TRICARE. The term &#8220;remuneration&#8221; has been interpreted
broadly to include anything of value, and a person or entity need not have actual knowledge of the statute or specific intent to violate
it to be found in violation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the federal False Claims Act
imposes civil and criminal penalties, including through whistleblower (qui tam) actions, against individuals or entities for knowingly
presenting, or causing to be presented, false or fraudulent claims for payment to the federal government or for making false statements
to avoid an obligation to pay money to the government. Manufacturers may be held liable even when they do not submit claims directly
if they are deemed to &#8220;cause&#8221; the submission of false claims. The statute provides for treble damages and significant per-claim
penalties, and has been used to pursue a wide range of pharmaceutical company activities, including alleged improper promotional practices,
off-label promotion, and pricing-related conduct;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">HIPPA imposes criminal and civil liability for executing schemes to defraud
healthcare benefit programs or making false statements in connection with the delivery of or payment for healthcare benefits, items,
or services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">federal physician payment transparency
requirements (commonly referred to as the Open Payments program) require manufacturers of drugs, biologics, and medical supplies reimbursable
under federal healthcare programs to report annually to the U.S. Department of Health and Human Services information regarding payments
and other transfers of value to physicians, certain non-physician healthcare providers (such as physician assistants and nurse practitioners),
and teaching hospitals, as well as ownership and investment interests held by such individuals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by HITECH, and its implementing regulations, impose obligations
on covered entities and their business associates with respect to safeguarding the privacy, security, and transmission of individually
identifiable health information, including breach notification requirements and expanded enforcement authority; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">analogous state and foreign
laws and regulations, including state anti-kickback and false claims laws, transparency laws, and data privacy and security laws, many
of which differ from federal requirements and may not be preempted, thereby complicating compliance efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ensuring that our business
arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. The regulatory
and enforcement environment in the healthcare industry remains active, and governmental authorities have increased their focus on compliance
with these laws. It is possible that governmental authorities will conclude that our business practices do not comply with current or
future statutes, regulations, or case law. If our operations are found to be in violation of any of these laws or any other applicable
regulations, we may be subject to significant civil, criminal, and administrative penalties, including damages, fines, exclusion from
government-funded healthcare programs such as Medicare and Medicaid, and the curtailment or restructuring of our operations. In addition,
if any of the physicians or other providers or entities with whom we do business are found to be non-compliant, they may be subject to
sanctions, which could also adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face potential liability and increased
regulatory scrutiny if we obtain, use or fail to adequately protect identifiable patient health information in connection with our clinical
trials and operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the course of our clinical
development activities, we may obtain or have access to sensitive personally identifiable information, including protected health information,
from clinical trial participants, healthcare providers, research institutions, contract research organizations, and other third parties.
While most healthcare providers and research institutions are subject to privacy and security regulations under HIPPA, as amended by
HITECH, we may, depending on the nature of our relationships, be deemed a business associate or otherwise contractually subject to certain
HIPAA obligations. Even where we are not directly subject to HIPAA, we may be subject to criminal liability under HIPAA in certain circumstances,
including if we knowingly obtain or misuse individually identifiable health information in a manner that violates applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are or may become subject to a variety of other federal,
state, and foreign privacy and data protection laws and regulations that govern the collection, use, storage, disclosure, and protection
of personal information. These include, for example, U.S. state privacy laws such as the CCPA, as amended by the CPRA, and similar laws
in other jurisdictions, as well as international data protection regulations such as the European Union&#8217;s GDPR, to the extent we
conduct clinical trials or otherwise process personal data outside the United States. These laws are complex, evolving, and may impose
significant compliance obligations, including requirements related to consent, data minimization, cross-border data transfers, breach
notification, and individual rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our collaborators,
including CROs, CMOs, and other third-party service providers, may also be subject to data breach notification laws and consumer protection
laws that require us to notify affected individuals, regulatory authorities, and others in the event of a data breach involving personal
information. Failure to comply with these requirements could result in significant penalties, litigation, and reputational harm. We face
an increasing risk of cybersecurity incidents and data breaches, including those resulting from unauthorized access, system failures,
or cyberattacks. Any such incident could compromise the confidentiality, integrity, or availability of our data, including clinical trial
data, disrupt our operations, delay our development programs, and expose us to regulatory enforcement actions and liability. Ensuring
compliance with applicable privacy, data protection, and cybersecurity laws and regulations may require us to expend substantial resources.
Claims that we or our third-party partners have violated individuals&#8217; privacy rights or failed to adequately protect personal information,
even if unfounded, could be costly to defend and could result in adverse publicity, which could materially harm our business, financial
condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with environmental,
health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse
effect on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to numerous
environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage,
treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including
chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials.
In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages,
and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.
Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not
maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or
disposal of biological, hazardous or radioactive materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the market opportunities&#160;for OST-HER2
and&#160;our other current and future product candidates are smaller than we believe they are, our revenue may be adversely affected and
our business may suffer. Moreover, because the target patient populations we are seeking to treat are small, we must be able to successfully
identify patients and capture a significant market share to achieve profitability and growth.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We focus our research and
product development on treatments for osteosarcoma, a rare disease. The incidence of new cases of Osteosarcoma is approximately 1,000
individuals in the United States annually and approximately 20,000 individuals globally. Given the limited number of patients with the
diseases we are targeting, our ability to achieve meaningful revenue will depend on our ability to accurately identify eligible patients,
successfully commercialize our product candidates, and capture a significant share of the addressable market. Our estimates of the number
of patients who may be eligible for treatment with OST-HER2 or any of our other current or future product candidates are based on a variety
of sources, including published literature, clinical experience, and internal analyses, and may prove to be inaccurate. Although we have
completed enrollment in our Phase IIb clinical trial for OST-HER2, which enrolled a limited number of patients consistent with the rare
nature of the disease, our understanding of the addressable patient population remains subject to significant uncertainty. New studies
or real-world data may change the estimated incidence, prevalence, or treatable population for osteosarcoma, and the number of patients
ultimately eligible for our therapies may be lower than expected. In addition, identifying, diagnosing, and referring patients with osteosarcoma,
particularly in earlier stages or in certain geographic regions, can be challenging, and we may not be successful in reaching all patients
who could potentially benefit from our therapies. Even if we obtain regulatory approval and achieve meaningful market penetration, the
small size of the target patient population may limit our ability to generate sufficient revenue to achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because there
are limited standard-of-care treatments specifically directed at Osteosarcoma, the pricing and reimbursement landscape for OST-HER2 and
any other product candidates we may develop is uncertain. While therapies for rare diseases may in some cases support premium pricing,
there can be significant variability in reimbursement decisions by governmental authorities and third-party payors. If we are unable to
obtain adequate reimbursement at levels sufficient to support our anticipated commercial infrastructure, our ability to successfully market
and sell OST-HER2 and any of our other current or future product candidates would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Dependence on Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely, and expect to continue to rely,
on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties
do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be
able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially
harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the ability
to independently conduct clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third
parties, including collaboration partners, to conduct or otherwise support our clinical trials for&#160;OST-HER2&#160;and expect to rely
on them when we begin clinical trials for&#160;OST-tADC&#160;and other current or future product candidates. We rely heavily on these
parties for execution of clinical trials and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring
that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific
standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations
during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include
civil penalties up to and including criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and any third parties that
we contract with are required to comply with regulations and requirements, including GCP, for conducting, monitoring, recording and reporting
the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients
are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are
enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities
for any drugs in clinical development. The FDA enforces GCP requirements through periodic inspections of clinical trial sponsors, principal
investigators and trial sites. If we or the third parties we contract with fail to comply with applicable GCP, the clinical data generated
in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any
of our current or future clinical trials will comply with GCP.&#160;In addition, our clinical trials must be conducted with current or
future product candidates produced under cGMP regulations. Our failure or the failure of third parties that we contract with to comply
with these regulations may require us to repeat some aspects of a specific, or an entire, clinical trial, which would delay the marketing
approval process and could also subject us to enforcement action. We also are required to register certain ongoing clinical trials and
provide certain information, including information relating to the trial&#8217;s protocol, on a government-sponsored database, ClinicalTrials.gov,
within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we intend to design
the clinical trials for our current or future product candidates, or be involved in the design when other parties sponsor the trials,
we anticipate that third parties will conduct all of our clinical trials. As a result, many important aspects of our clinical development,
including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future clinical trials
will also result in less direct control over the management of data developed through clinical trials than would be the case if we were
relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well
as difficulties in coordinating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors may materially
adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases
that are beyond our control. If our CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail
to comply with regulatory requirements, the development, marketing approval and commercialization of our current or future product candidates
may be delayed, we may not be able to obtain marketing approval and commercialize our current or future product candidates, or our development
programs may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our CROs, we could be required
to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization
and require significantly greater expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs on commercially reasonable
terms, or at all. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they
need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our
clinical protocols, regulatory requirements or for other reasons, any clinical trials such CROs are associated with may be extended, delayed
or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our current or future product candidates.
As a result, we believe that our financial results and the commercial prospects for our current or future product candidates in the subject
indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The third parties upon whom we rely for
the supply of the active pharmaceutical ingredient, or API, drug product and drug substance used in our core product candidates are limited
in number, and the loss of any of these suppliers could significantly harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The API drug product and drug
substance used in our core product candidates are supplied to us from a small number of suppliers, and in some cases sole source suppliers.
Our ability to successfully develop our current or future product candidates, and to ultimately supply our commercial drugs in quantities
sufficient to meet the market demand, depends in part on our ability to obtain the API, drug product and drug substance for these drugs
in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. We do not currently
have arrangements in place for a redundant or second-source supply of all API, drug product or drug substance in the event any of our
current suppliers of such API, drug product and drug substance cease their operations for any reason.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For all of our current or
future product candidates, we intend to identify and qualify additional manufacturers to provide such API, drug product and drug substance
prior to submission of an NDA or a BLA to the FDA and/or an MAA to the EMA.&#160;We are not certain, however, that our single-source and
dual source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers,
our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to
assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand
for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Establishing additional or
replacement suppliers for the API, drug product and drug substance used in our current or future product candidates, if required, may
not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may
require additional regulatory approval, which could result in further delay. While we seek to maintain adequate inventory of the API,
drug product and drug substance used in our current or future product candidates, any interruption or delay in the supply of components
or materials, or our inability to obtain such API, drug product and drug substance from alternate sources at acceptable prices in a timely
manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial
condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our success is dependent on our executive
management team&#8217;s ability to successfully pursue business development, strategic partnerships and investment opportunities as our
company matures. We may also form or seek strategic alliances or acquisitions or enter into additional collaboration and licensing arrangements
in the future, and we may not realize the benefits of such collaborations, alliances, acquisitions or licensing arrangements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are party to licensing
arrangements with the Trustees of the University of Pennsylvania and BlinkBio, Inc., and may in the future form or seek strategic alliances
or acquisitions, create joint ventures, or enter into additional collaboration and licensing arrangements with third parties that we believe
will complement or augment our development and commercialization efforts with respect to our current product candidates and any future
product candidates that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Going forward, we are seeking
strategic partners for the further development and potential commercialization of our&#160;non-core&#160;and&#160;out-licensed&#160;programs,
including&#160;OST-tADC.&#160;However, identifying appropriate partners is competitive, and the negotiation of these arrangements is complex,
time-consuming, and resource-intensive. Potential partners may be unwilling to commit to such transactions on acceptable terms, or at
all, particularly if they determine that our product candidates do not have sufficient clinical validation, commercial potential, or likelihood
of regulatory approval. Even if we are successful in entering into such arrangements, we may not realize the anticipated benefits. Strategic
transactions typically involve significant risks, including the potential for loss of control over certain development or commercialization
activities, reliance on third parties to meet development, regulatory and commercialization milestones, disagreements or disputes with
partners, which could delay or terminate development programs, reduced economic returns as a result of profit-sharing, milestone payments
or royalties, and the diversion of management attention and internal resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, these transactions
may require us to incur substantial costs, record non-recurring charges, assume contingent liabilities, or issue equity securities that
dilute our existing stockholders. If we are unable to successfully identify and execute strategic transactions, or if any such transactions
fail to achieve their intended objectives, our ability to advance our product candidates, including OST-HER2 and our other programs, may
be adversely affected, and our business, financial condition and results of operations could be materially harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we may not realize
the anticipated benefits of our existing collaboration and licensing arrangements or any future strategic transactions, including partnerships,
acquisitions, or licensing arrangements, particularly if we are unable to effectively integrate such arrangements with our existing operations
and company culture. Any such failure could delay development timelines, disrupt our business, or otherwise adversely affect our results
of operations. In addition, we cannot assure that any strategic transaction or collaboration will generate the expected revenues, cost
savings, or other anticipated benefits that justified our entry into such arrangement. Further, delays in identifying or entering into
new collaboration or strategic partnership agreements with respect to our current or future product candidates may delay or limit the
development and commercialization of such product candidates, including in specific geographies or for particular indications, which could
materially harm our business prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our manufacturing process needs to comply
with FDA regulations relating to the quality and reliability of such processes. Any failure to comply with relevant regulations could
result in delays in or termination of our clinical programs and suspension or withdrawal of any regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to produce our product
candidates for clinical trials and our products, if any, for commercial purposes, either at our own facility or at a third-party&#8217;s
facility, we and our third-party vendors will need to comply with the FDA&#8217;s cGMP regulations and guidelines. As part of our ongoing
quality and process improvement efforts, we conducted a gap analysis of our cGMP quality system and it identified certain key areas for
necessary remediation, including with regard to documentation requirements. We may encounter difficulties in achieving compliance with
quality control and quality assurance requirements and may experience shortages in qualified personnel. We are subject to inspections
by the FDA and comparable foreign regulatory authorities to confirm compliance with applicable regulatory requirements. Any failure to
follow cGMP or other regulatory requirements, including any failure to remedy the issues identified in the cGMP gap analysis, or delay,
interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidate as a result of
a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory
authority inspection could significantly impair our ability to develop and commercialize our current or future product candidates, including
leading to significant delays in the availability of our product candidates for our clinical trials or the termination of or suspension
of a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our current or future product candidates.
Significant&#160;non-compliance&#160;could also result in the imposition of sanctions, including warning or untitled letters, fines, injunctions,
civil penalties, failure of regulatory authorities to grant marketing approvals for our current or future product candidates, delays,
suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions,
any of which could damage our reputation and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our third-party manufacturers use hazardous
and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities involve the controlled use of potentially hazardous substances, including chemical materials, by our third-party manufacturers.
Our manufacturers are subject to federal, state and local laws and regulations in the United&#160;States&#160;governing the use, manufacture,
storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using,
handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of
contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability
or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event
of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have
any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable laws and regulations is expensive,
and current or future regulations may impair our research, development and production efforts, which could harm our business, prospects,
financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we and the third parties from whom we
in-license intellectual property are unable to obtain, maintain, protect, or enforce patent and other intellectual property rights for
our technology and product candidates, or if the scope of such protection is not sufficiently broad, our competitors could develop and
commercialize similar or identical technologies and products, and our ability to successfully commercialize our product candidates may
be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position of biotechnology
and pharmaceutical companies is highly uncertain and involves complex legal and factual questions, and has been the subject of extensive
litigation in recent years. Our commercial success depends in part on our ability, and the ability of our licensors and other partners,
to obtain, maintain, protect, and enforce intellectual property rights in the United States and other jurisdictions for our current and
future product candidates, including OST-HER2, OST-tADC, our non-core programs, and our proprietary technologies and know-how.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on a combination of
owned, co-owned and in-licensed patents and patent applications to protect our intellectual property. For example, we in-license and co-own
certain intellectual property relating to OST-HER2 from the University of Pennsylvania, and we in-license intellectual property relating
to OST-tADC from BlinkBio, Inc. The intellectual property we own includes six granted U.S.&#160;utility patents and a number of foreign
patents and pending patent applications. The patents and patent applications if granted are expected to expire between 2029 and 2038,
not including any patent term extension. The intellectual property licensed from BlinkBio, Inc. includes six granted U.S.&#160;utility
patents and a number of foreign patents and pending patent applications. The patents cover methods of use of silicon-based drug conjugates
and silanol based therapeutic payloads. The patents and pending patent applications if granted are expected to expire between 2036 and
2037, not including any patent term extension. For additional information about our patents, see &#8220;<i>Business&#160;&#8212;&#160;Our
Intellectual Property</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of patent protection
required to successfully commercialize our product candidates may be unavailable or limited. We cannot assure that any of the patents
we own or in-license, or any pending patent applications, will issue with claims of sufficient scope to protect our product candidates
or provide a meaningful competitive advantage. If the scope or strength of our intellectual property protection is reduced or challenged,
it could adversely affect our ability to attract collaborators or commercial partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may have developed
or may develop technologies that compete with ours, and they may have filed or may file patent applications, or may obtain patents, that
overlap with or conflict with our intellectual property. Because patent applications are typically not published until 18 months after
filing and scientific publications often lag behind discoveries, we cannot be certain that we or our licensors were the first to make
the inventions claimed in our patents or pending applications. As a result, the validity, enforceability, scope, and commercial value
of our intellectual property cannot be predicted with certainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if our patents are issued,
they may be challenged, invalidated, narrowed, or held unenforceable in administrative proceedings or litigation in the United States
or abroad. Such challenges could result in the loss of exclusivity, freedom to operate, or other competitive advantages. Furthermore,
given the time required for clinical development and regulatory review, patent protection for our product candidates may expire before
or shortly after commercialization, thereby limiting our ability to realize the full commercial value of our intellectual property. Any
failure to obtain, maintain, protect, or enforce our intellectual property rights, or any loss or narrowing of such rights, could allow
third parties to use our technology or develop competing products and could materially adversely affect our business, financial condition,
results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our trademarks and trade names for our
products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the
launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially adverse consequences
to building our product brand recognition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our trademarks or trade names
may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely
on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade
names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets
of interest. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign
jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections,
we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third
parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition
or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations
may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks
and trade names, we may not be able to compete effectively and our business may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to adequately protect and
enforce our trade secrets, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the protection
afforded by patents we may own, co-own or&#160;in-license,&#160;we seek to rely on trade secret protection, confidentiality agreements,
and license agreements to protect proprietary&#160;know-how&#160;that may not be patentable, processes for which patents are difficult
to enforce and any other elements of our product discovery and development processes that involve proprietary&#160;know-how,&#160;information,
or technology that may not be covered by patents. Although it is our policy to require all of our employees, consultants, advisors and
any third parties who have access to our proprietary&#160;know-how,&#160;information or technology to enter into confidentiality and assignment
of inventions agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used
by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot
guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, any of these parties
might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain
adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop
substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights and
trade secrets to the same extent or in the same manner as the laws of the United&#160;States.&#160;As a result, we may encounter significant
problems in protecting and defending our intellectual property both in the United&#160;States&#160;and abroad. If we are unable to prevent
unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive
advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If
we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may
consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade
secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially
equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. If any of
our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right
to prevent them from using that technology or information to compete with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may initiate, become a defendant in,
or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming
and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe any
patents we may own, co-own or&#160;in-license.&#160;In addition, any patents we may own, co-own or&#160;in-license also may become involved
in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or
other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that
one or more of any patents we may own, co-own or&#160;in-license is not valid or is unenforceable or that the other party&#8217;s use
of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). There is also
the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology
at issue on the grounds that any patents we may own, co-own or&#160;in-license do not cover the technology in question or that such third-party&#8217;s
activities do not infringe the patent applications or any patents we in-license or may in the future own or co-own.&#160;An adverse result
in any litigation or defense proceedings could put one or more of any patents we may own, co-own or&#160;in-license at risk of being invalidated,
held unenforceable, or interpreted narrowly and could put those patent applications at risk of not issuing. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing,
patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings
adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the
initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in
the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-grant proceedings provoked
by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to the patent
applications or any patents we in-license or may in the future own or co-own.&#160;These proceedings are expensive and an unfavorable
outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to
license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially
reasonable terms. In addition to potential USPTO post-grant proceedings, we may become a party to patent opposition proceedings in the
EPO, or similar proceedings in other foreign patent offices or courts where these patents may be challenged. The costs of these proceedings
could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant
challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant
country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent
offices may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract
our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information,
particularly in countries where the laws may not protect those rights as fully as in the United&#160;States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to detect
infringement against any patents we may own, co-own or&#160;in-license.&#160;Even if we detect infringement by a third-party of any patents
we may own, co-own or&#160;in-license,&#160;we may choose not to pursue litigation against or settlement with the third-party. If we later
sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not
be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses
may make it impossible for us to enforce any patents we may own, co-own or&#160;in-license against such third-party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property litigation and administrative
patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel
from their normal responsibilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support
or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.
As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can
because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary
to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development
collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would
harm our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain patent or other
intellectual property protection for our current or future product candidates or our future products, if any, in all jurisdictions throughout
the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to pursue
patent coverage of our current or future product candidates in all countries. Filing, prosecuting and defending patents on current or
future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in
some countries outside the United&#160;States&#160;can be less extensive than those in the United&#160;States.&#160;In addition, the laws
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United&#160;States.&#160;Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United&#160;States, or from selling
or importing products made using our inventions in and into the United&#160;States&#160;or other jurisdictions. Competitors may use our
technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise
infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United&#160;States.&#160;These
products may compete with our current or future product candidates and our current intellectual property rights may not be effective or
sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection,
particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of any patents we
may own, co-own or&#160;in-license&#160;or marketing of competing products in violation of our proprietary rights generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we
may own or license that are relevant to our business, our competitive position may be impaired, and our business, financial condition,
results of operations, and prospects may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not obtain or grant licenses or sublicenses
to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It may be necessary for us
to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain
a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established
companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary.
More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development
and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights
to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable
terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize
the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual
property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay
royalties or other forms of compensation. Even if we are able to obtain a license, it may be&#160;non-exclusive,&#160;thereby giving our
competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our
business relationships with our licensors, we could lose license rights that are important to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may from time to time be
party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or future
product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding,
milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development
timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses.
In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore
terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered
by these license agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any termination of these licenses,
or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our
ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek
regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization
of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in
such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise
could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe
to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business,
financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent
or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize
the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results
of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in patent law could diminish the
value of patents in general, thereby impairing our ability to protect our current or future product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is the case with other
biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and
inherently uncertain. Recent patent reform legislation in the United&#160;States&#160;and other countries, including the Leahy-Smith America
Invents Act, or Leahy-Smith Act, signed into law on September&#160;16, 2011, could increase those uncertainties and costs. The Leahy-Smith
Act includes a number of significant changes to U.S.&#160;patent law. These include provisions that affect the way patent applications
are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of
patents. In addition, the Leahy-Smith Act has transformed the U.S.&#160;patent system into a &#8220;first inventor to file&#8221; system.
The&#160;first-inventor-to-file&#160;provisions, however, only became effective on March&#160;16, 2013. Accordingly, it is not yet clear
what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation
could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution
of the patent applications that we have in-licensed and the enforcement or defense of such issued patents, all of which could harm our
business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S.&#160;Supreme Court
has and other courts have ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals
for additional changes to the patent laws of the United&#160;States&#160;and other countries that, if adopted, could impact our ability
to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions
by the U.S.&#160;Congress, the U.S.&#160;courts, the USPTO and the relevant&#160;law-making&#160;bodies in other countries, the laws and
regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our
existing patents and patents that we might obtain in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights do not guarantee
commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive
advantage provided by our intellectual property rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights, whether owned, co-owned or&#160;in-licensed,&#160;is uncertain because intellectual property
rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential
competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover
the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following
examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">patent applications that we
own, co-own or may&#160;in-license&#160;may not lead to issued patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">patents, should they issue,
that we may own, co-own or&#160;in-license,&#160;may not provide us with any competitive advantages, may be narrowed in scope, or may
be challenged and held invalid or unenforceable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may be able to develop
and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates,
that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own, co-own
or&#160;in-license,&#160;should any patents issue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">third parties may compete with
us in jurisdictions where we do not pursue and obtain patent protection;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we, or our future licensors
or collaborators, might not have been the first to make the inventions covered by a patent application that we own, co-own or may&#160;in-license;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we, or our future licensors
or collaborators, might not have been the first to file patent applications covering a particular invention;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">others may independently develop
similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">our competitors might conduct
research and development activities in the United&#160;States&#160;and other countries that provide a safe harbor from patent infringement
claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use
the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to obtain
and/or maintain necessary licenses on reasonable terms or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">third parties may assert an
ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or
any rights at all, over that intellectual property;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may choose not to file a
patent in order to maintain certain trade secrets or&#160;know-how,&#160;and a third-party may subsequently file a patent covering such
trade secrets or&#160;know-how;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to maintain
the confidentiality of our trade secrets or other proprietary information; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">we may not develop or&#160;in-license&#160;additional
proprietary technologies that are patentable.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any of these events
occur, they could significantly harm our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Employee Matters, Managing
Growth and Other Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our current operations are located in Maryland;
and we or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster
recovery plans may not adequately protect us from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operations are
located in Maryland. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power
shortage, telecommunication failure or other natural or&#160;man-made&#160;accidents or incidents that result in us being unable to fully
utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect
on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and
operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates
or interruption of our business operations. Natural disasters or pandemics&#160;could further disrupt our operations, and have a material
and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other
event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such
as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult
or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business
continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses
as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on
our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our
business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance
will be sufficient to satisfy any damages and losses. If the manufacturing facilities of our third-party contract manufacturers are unable
to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and
development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition,
results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future success depends on our ability
to retain key executives and to attract, retain and motivate qualified personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
the research and development, clinical and business development expertise of Paul A.&#160;Romness, MPH, our Chairman, President and Chief
Executive Officer, and Robert G.&#160;Petit, Ph.D., our Chief Medical&#160;Officer and Chief Scientific Officer, as well as the other
principal members of our management, scientific and clinical teams. Although we have entered into employment agreements or arrangements
with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221;
insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be
employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit
their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth
strategy will be limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recruiting and retaining qualified
scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of
our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives
and seriously harm our ability to successfully implement our growth strategy. Further, replacing executive officers and key employees
may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth
of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from
this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring
of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more
challenging to recruit and retain qualified scientific personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to develop and expand our company,
and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2026, we had&#160;four
full-time employees, one part-time employee and a limited number of regulatory and other consultants. We expect to increase our number
of employees and the scope of our operations. To manage our anticipated growth and expansion, we must continue to implement and improve
our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel.
Also, our management may need to divert a disproportionate amount of its attention away from its&#160;day-to-day&#160;activities and devote
a substantial amount of time to managing these growth-oriented activities. Due to our limited resources, we may not be able to effectively
manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure,
give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as
the development of our current or future product candidates. If our management is unable to effectively manage our expected growth and
expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not
be able to implement our growth strategy. Our future financial performance and our ability to commercialize our current or future product
candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future growth and expansion
of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to maintain effective internal controls
in accordance with Section&#160;404 of the Sarbanes-Oxley Act could have a material adverse effect on our business, results of operation
or financial condition. In addition, current and potential stockholders could lose confidence in our financial reporting, which could
have a material adverse effect on the price of the common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective internal controls
are necessary for us to provide reliable financial reports and effectively prevent fraud. We are required to document and test our internal
control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act, which requires annual management
assessments of the effectiveness of our internal control over financial reporting. In addition, if we fail to maintain the adequacy of
our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we
can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section&#160;404.
Our management has concluded that our internal control over financial reporting was not effective as of December 31, 2025 due inadequate
segregation of duties as a result of limited personnel and insufficient written policies and procedures for accounting, information
technology and financial reporting (no control procedures in place). Disclosing deficiencies or weaknesses in our internal controls, failing to remediate
these deficiencies or weaknesses in a timely fashion or failing to achieve and maintain an effective internal control environment may
cause investors to lose confidence in our reported financial information, which could have a material adverse effect on the price of the
common stock. If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unstable market and economic conditions
may have serious adverse consequences on our business, financial condition and stock price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global financial markets have
experienced extreme volatility and disruptions in the past several&#160;years, including severely diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, increases in inflation and unemployment rates and uncertainty about economic
stability. There can be no assurance that further deterioration in financial markets and confidence in economic conditions will not occur.
Our general growth strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable
and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt
or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on
favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us
to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit
of potential&#160;in-licenses&#160;or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers
and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals
on schedule and on budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our internal computer systems, or those
of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption
of our current or future product candidates&#8217; development programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems and those of our third-party CROs and other contractors and consultants are vulnerable
to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
While we have not experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause
interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data
for our current or future product candidates could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data
or applications or other data or applications relating to our technology or current or future product candidates, or inappropriate disclosure
of confidential or proprietary information, we could incur liabilities and the further development of our current or future product candidates
could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to adequately protect our
information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal
data, damage our reputation, and subject us to significant financial and legal exposure.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on information technology
systems that we or our third-party providers operate to process, transmit and store electronic information in our&#160;day-to-day&#160;operations.
In connection with our product discovery efforts, we may collect and use a variety of personal data, such as name, mailing address, email
addresses, phone number and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual
property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our
operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect.
Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber
fraud, the deployment of harmful&#160;malware, denial-of-service, social&#160;engineering fraud or other means to threaten data security,
confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without
limitation, the disruption of operations, the misappropriation of confidential business information, including financial information,
trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information
systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches
that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of
operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure
of our clinical data or patients&#8217; personal data could result in significant liability under state (e.g., state breach notification
laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g.,&#160;the EU GDPR)
and may cause a material adverse impact to our reputation, affect our ability to use collected data, conduct new studies and potentially
disrupt our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on our third-party
providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. We also rely
on our employees and consultants to safeguard their security credentials and follow our policies and procedures regarding use and access
of computers and other devices that may contain our sensitive information. If we or our third-party providers fail to maintain or protect
our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to
our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks
and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory
sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have
a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third
parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse
consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed
to litigation and governmental investigations, which could lead to a potential disruption to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, principal investigators,
CROs and consultants may engage in misconduct or other improper activities, including&#160;non-compliance&#160;with regulatory standards
and requirements and insider trading.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct
by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate
the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities; healthcare fraud and abuse laws and regulations in the United&#160;States&#160;and abroad; or laws that
require the reporting of financial information or data accurately. In particular, sales, marketing, patient support and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper
use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials,
which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all
of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally,
we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from
participation in Medicare, Medicaid and other federal and state healthcare programs, debarment from participation in any FDA-related activities,
contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could
adversely affect our ability to operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that our
business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions including monetary penalties,
damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such
as Medicare and Medicaid, debarment from participation in any FDA-related activities, additional reporting requirements and oversight
if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these
laws, reputational harm, and we may be required to curtail or restructure our operations, any of which could adversely affect our ability
to operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of artificial intelligence, machine
learning and algorithmic tools involves risks that could materially and adversely affect our business, results of operations and development
timelines.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use, and expect to increasingly
use, artificial intelligence (&#8220;AI&#8221;), machine learning (&#8220;ML&#8221;) and other data-driven models to support discovery,
clinical trial design and operations, manufacturing planning, and other aspects of our business. The effectiveness of these systems depends
on the quality and completeness of the underlying data, proper training and validation of models, human oversight, and adherence to applicable
regulatory expectations. Errors, bias, software vulnerabilities, or misuse of AI, ML, or other algorithmic tools could compromise scientific
conclusions, produce flawed clinical trial protocols, generate inaccurate operational or manufacturing forecasts, or result in breaches
of data integrity or privacy. Such events could delay development, regulatory review, or commercialization, or could otherwise adversely
affect patient safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities, including
FDA, the EMA and other global agencies, are increasingly scrutinizing the use of AI and ML in drug development, including claims regarding
AI-assisted decision making. If our public statements regarding AI capabilities are inaccurate, incomplete, or become outdated, or if
regulators adopt new expectations regarding AI governance, model validation, data transparency, or reporting in drug development, we could
face investigations, enforcement actions, fines, or litigation. Such regulatory scrutiny could also require operational rework, additional
documentation or validation, and delays in regulatory submissions or approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, malfunction,
misuse, bias, or inaccuracies in AI, ML, or other algorithmic tools could materially and adversely affect the quality and reliability
of our research and development programs, clinical data, manufacturing processes, and commercial operations. Any of these outcomes could
materially delay development timelines, increase costs, negatively impact regulatory review, and reduce our ability to successfully develop,
obtain marketing approval for, or commercialize our product candidates, which could have a material adverse effect on our business, financial
condition, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Geopolitical events, trade restrictions,
sanctions and export controls could adversely affect our clinical operations, supply chain, data flows and financial transactions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development, manufacturing,
and supply chains, as well as certain aspects of our research and clinical programs, may be adversely affected by geopolitical events,
including military conflicts, escalating international tensions, trade or investment restrictions, sanctions regimes, export controls,
or retaliatory measures by foreign governments. Such actions could limit our ability, or the ability of our CROs, CMOs and other third-party
partners, to source active pharmaceutical ingredients, starting materials, consumables, equipment, or software, to transfer biological
materials, clinical samples, or data across international borders, or to make or receive payments in affected jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Geopolitical events may also
increase cybersecurity threats targeting life sciences companies, potentially compromising sensitive research, patient data, or operational
systems. Any of these factors could result in delays in our clinical trials, interruptions in the supply of materials or products, increased
costs, or the need to rapidly identify and qualify alternative suppliers, manufacturing sites, or trial locations. Such disruptions could
materially and adversely affect our business, results of operations, development timelines, and prospects for successfully developing
and commercializing our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A significant number of additional shares
of our common stock may be issued pursuant to outstanding preferred stock, warrants, stock options and convertible securities, which issuances
could substantially dilute existing stockholders and may depress the market price of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have issued, and may issue
in the future, a significant number of shares of our common stock upon the conversion or exercise of outstanding preferred stock, warrants,
stock options and other convertible securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the PIPE Financing completed in December 2024 and
January 2025, we issued shares of our Series A Preferred Stock, each share of which is convertible into a number of shares of common stock
at a conversion ratio equal to (x) the original issue price of the Series A Preferred Stock divided by (y) the conversion price of the
Series A Preferred Stock. The Series A Preferred Stock was initially convertible at a 1:1 ratio, subject to adjustment as set forth in
the Certificate of Designation, Preferences, Rights and Limitations of Series A Senior Convertible Preferred Stock. The number of shares
of common stock into which the Series A Preferred Stock may be converted is also subject to potential increase pursuant to applicable
resets and anti-dilution adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2025 and the first quarter of 2026, we completed three warrant
exercise inducement and exchange transactions pursuant to which holders exercised certain existing warrants for cash and received new
warrants to purchase a number of shares of our common stock equal to the number of shares received upon such exercise. In March 2026,
we completed the Bridge Financing that included the issuance of the Bridge Notes and the Bridge Warrants. The Bridge Notes are convertible
into shares of our common stock under certain circumstances. If we complete a &#8220;Qualified Offering,&#8221; defined as a registered
public offering or registered direct offering resulting in at least $2.5 million in gross proceeds from new money investments, the outstanding
principal, together with all accrued and unpaid interest, will automatically convert into the securities sold in such offering at the
offering price. Additionally, prior to any such Qualified Offering or repayment of the Bridge Notes, holders may elect to convert the
Bridge Notes, in whole or in part, into shares of our common stock at a conversion price equal to 90% of the average daily volume-weighted
average price of our common stock during the 10 trading days immediately preceding the holder&#8217;s conversion notice, subject to adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Form
10-K, (i) 1,401,786 shares of our common stock are issuable upon the conversion of outstanding shares of our Series A Preferred Stock,
with a conversion ratio of 3.571429 per share, (ii) 10,399,522 shares of our common stock are issuable upon the exercise of outstanding
warrants, (iii) 6,771,250 shares of our common stock are issuable upon the exercise of outstanding and vested stock options under our
2023 Incentive Compensation Plan and (iv) 1,392,805 shares of our common stock are issuable upon the conversion of outstanding Bridge
Notes (assuming full conversion of such notes into common stock at a conversion price of $1.39, which was the closing price of our common
stock on March 26, 2026).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of these features,
declines in the market price of our common stock or future issuances of securities at lower prices could result in additional shares of
our common stock becoming issuable upon conversion or exercise of these securities. The issuance of such shares would substantially dilute
the ownership interests and voting power of existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have agreed,
or may agree, to file registration statements covering the resale of shares of common stock issuable upon conversion or exercise of these
securities. The availability of a significant number of shares for sale in the public market, or the perception that such sales could
occur, could adversely affect the market price of our common stock and make it more difficult for us to raise additional capital in the
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of a substantial number of shares
of our common stock, including those issued pursuant to the Sales Agreement, could cause the market price of our common stock to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale of a substantial
number of shares of our common stock in the public market, or the perception that such sales may occur, could cause the market price of
our common stock to decline. Although we cannot predict the exact number of shares that may be sold pursuant to the Sales Agreement or
the price at which any sales may occur, the issuance and sale of up to $17,469,838 of our common stock pursuant to the Sales Agreement
may result in the issuance of 12,568,228 additional shares (based on an assumed offering price of $1.39 per share, the closing price of
our common stock on the NYSE American on March 26, 2026). Based on our shares outstanding as of March 26, 2026, and assuming full issuance
of such shares, we would have 52,101,455 shares of common stock outstanding (excluding any shares issuable upon the conversion or exercise,
as applicable, of outstanding convertible notes, preferred stock, warrants, or stock options). A substantial majority of the outstanding
shares of our common stock are, and all of the shares sold pursuant to the Sales Agreement upon issuance will be, freely tradable without
restriction or further registration under the Securities Act, unless such shares are owned or purchased by &#8220;affiliates&#8221; as
that term is defined in Rule&#160;144 under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as of the date
of this Form 10-K, there were outstanding (i)&#160;392,500 shares of Series A Preferred Stock convertible into an aggregate of 1,401,786
shares of common stock, (ii) warrants to purchase an aggregate of 10,399,522 shares of common stock, (iii)&#160;options to purchase an
aggregate of 6,771,250 shares of our common stock, of which options to purchase 2,866,750 shares of our common stock were then exercisable,
and (iv) $2,200,000 in aggregate principal amount of convertible notes convertible into 1,392,805 shares of common stock (including the
conversion of accrued interest and assuming a conversion price of $1.39, which was the closing price of our common stock on March 26,
2026). The shares of our common stock issuable upon conversion or exercise, as applicable, of such securities may be immediately eligible
for resale in the open market. Any such sales, or the perception that such sales could occur, could cause the market price of our common
stock to decline and may make it more difficult for us to raise capital in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is not possible to predict the aggregate
proceeds resulting from sales made under the Sales Agreement.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain limitations
in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to the Sales Agents at
any time throughout the term of the Sales Agreement. The number of shares that are sold through the Sales Agents, if any, after delivering
a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period,
the limits we set with the Sales Agents in any applicable placement notice, and the demand for our common stock during the sales period.
Because the price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the aggregate
proceeds to be raised in connection with those sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The common stock offered pursuant to the
Sales Agreement will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay
different prices.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investors who purchase shares
pursuant to the Sales Agreement at different times will likely pay different prices, and so may experience different levels of dilution
and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and
number of shares sold pursuant to the Sales Agreement. In addition, subject to the final determination by our board of directors, there
is no minimum or maximum sales price for shares to be sold pursuant to the Sales Agreement. Investors may experience a decline in the
value of the shares they purchase pursuant to the Sales Agreement as a result of sales made at prices lower than the prices they paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Paul A.&#160;Romness, MPH, and our other
executive officers, directors and their affiliates exercise significant influence over our company, which will limit your ability to influence
corporate matters and could delay or prevent a change in corporate control.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paul A.&#160;Romness, MPH, our Chairman, President and Chief Executive
Officer, beneficially owns approximately 8.3% of the outstanding shares of common stock of our company, and other executive officers and
directors beneficially own another approximately 3.4% of our outstanding shares. The existing holdings of Mr.&#160;Romness and other executive
officers, directors and their affiliates represent beneficial ownership in the aggregate of approximately 11.7% of our outstanding common
stock. As a result, these stockholders will be able to influence our management and affairs and the outcome of matters submitted to our
stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or substantially all
of our assets. These stockholders may have interests, with respect to their common stock, that are different from those of other investors
and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition,
this concentration of ownership might adversely affect the market price of our common stock by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">delaying, deferring or preventing
a change of control our company;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">impeding a merger, consolidation,
takeover or other business combination involving our company; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">discouraging a potential acquirer
from making a tender offer or otherwise attempting to obtain control of our company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are incurring increased costs as a result
of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a recently public company,
we are incurring significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting
requirements of the Exchange&#160;Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports
with respect to our business and financial condition. In addition, the&#160;Sarbanes-Oxley Act&#160;of 2002, as well as rules subsequently
adopted by the SEC and the NYSE American to implement provisions of the&#160;Sarbanes-Oxley Act, impose significant requirements on public
companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance
practices. Further, in July&#160;2010, the&#160;Dodd-Frank Wall Street Reform and Consumer Protection Act was enacted. There are significant
corporate governance and executive compensation related provisions in the&#160;Dodd-Frank Act&#160;under which the SEC adopted additional
rules and regulations in these areas, such as &#8220;say on pay&#8221; and proxy access. Recent legislation permits emerging growth companies
to implement many of these requirements over a longer period and up to five&#160;years from the pricing of our July&#160;2024 initial
public offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these
requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment
and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations,
which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect the rules and regulations
applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming
and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a
material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss
and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we
expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance
and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or
timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not paid, and do not intend to pay,
dividends on our shares of common stock and, therefore, unless our common stock appreciates in value, our investors may not benefit from
holding our shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our shares of common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.
As a result, investors in our common stock will not be able to benefit from owning these shares unless their market price becomes greater
than the price paid by such investors and they are able to sell such shares. We cannot assure you that you will ever be able to resell
our common stock at a price in excess of the price paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1B. Unresolved Staff Comments.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1C. Cybersecurity.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-5150"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cybersecurity Governance</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-5157"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="ixv-14857">board of directors</ix:nonNumeric> has
the ultimate oversight responsibility for the risk management process and regularly reviews issues that present particular risk to us,
including those involving cybersecurity. Our board is responsible for ensuring that management has processes in place designed to identify
and assess cybersecurity risks to which we are exposed and implement processes and programs designed to manage cybersecurity risks and
mitigate and remediate cybersecurity threats and incidents.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-14858">identifying</ix:nonNumeric>, considering and assessing material cybersecurity risks on an ongoing basis, establishing processes to ensure that such
potential cybersecurity risk exposures are monitored, putting in place appropriate mitigation measures and maintaining cybersecurity programs.
In managing cybersecurity risks, we adhere to a structured framework that outlines the roles and responsibilities of management positions
and committees.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_1" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-5169"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cybersecurity Risk Management and Strategy</b></p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_4"><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_2" id="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have implemented and maintain
various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical
computer networks, communications systems, hardware and software, and our critical data, including intellectual property, confidential
information that is proprietary, strategic or competitive in nature, and trade secrets, data we may collect about trial participants in
connection with clinical trials, sensitive <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-14859">third-party</ix:nonNumeric> data, business plans, transactions, and financial information (&#8220;Information
Systems and Data&#8221;). Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk
management processes. For example, the cybersecurity program works with management to prioritize our risk management processes and mitigate
cybersecurity threats that are more likely to lead to a material impact to our business.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_5"><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_3" id="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cybersecurity program
within our company helps identify, assess and manage our cybersecurity threats and risks. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-14860">Our cybersecurity program identifies and assesses
risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual
tools, internal or external audits, automated tools, subscribing to and analyzing reports and services that identify cybersecurity threats
and threat actors, conducting vulnerability assessments to identify vulnerabilities, conducting scans of the threat environment, and evaluating
threats reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures,
processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems
and Data.</ix:nonNumeric></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_6"><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_4" id="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use third-party service
providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example
cybersecurity software providers, managed cybersecurity service providers, and penetration testing firms.<b>&#160;</b>We also use third-party
service providers to perform a variety of functions throughout our business, such as application providers and hosting companies. We manage
cybersecurity risks associated with our use of these providers by reviewing their security assessments and applicable reports.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_7"><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_5" id="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-5196"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-14861">not</ix:nonNumeric> aware of any risks
from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations, or financial condition.</p></ix:nonNumeric></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_8"><ix:continuation id="_CybersecurityRiskManagementProcessesIntegratedFlag-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face risks from cybersecurity
threats that, if realized are reasonably likely to materially affect us, including our operations, business strategy, results of operations,
or financial condition. For a description of the risks from cybersecurity threats that may materially affect us and how we may do so,
see our risk factors under &#8220;Item 1A. Risk Factors.&#8221;</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2. Properties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate address is 115
Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638. This space is the accounting office of our Chief Financial Officer and
provided to us rent free. We believe that suitable additional or alternative space would be available in the future on commercially reasonable
terms, if necessary. All our operations are presently conducted remotely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><div><a id="J_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3. Legal Proceedings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
in Note 6 to our consolidated financial statements included in this Form 10-K is incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 4. Mine Safety Disclosures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="J_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5. Market for Registrant&#8217;s Common
Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is traded
on NYSE American under the symbol &#8220;OSTX.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2026, there
were 111 holders of record of our common stock. The actual number of holders is greater than this number of record holders and includes
stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid a cash
dividend on our common stock and do not expect to pay a cash dividend in the near future. We currently intend to retain future earnings,
if any, to finance our operations and expand our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information as of December 31, 2025 with respect to our common stock that may be issued under our incentive compensation plans and other
option grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Plan Category</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> Securities <br/> to be <br/> Issued Upon <br/> Exercise of <br/> Outstanding <br/> Options, <br/> Warrants and <br/> Rights<br/> (a)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average <br/> Exercise<br/> Price&#160;of<br/> Outstanding <br/> Options, <br/> Warrants and <br/> Rights<br/> (b)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> Securities <br/> Remaining <br/> Available for <br/> Future Issuance <br/> Under Equity <br/> Compensation <br/> Plans <br/> (Excluding <br/> Securities <br/> Reflected in <br/> Column (a))</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equity Compensation Plans Approved by Security Holders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#8212;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Equity Compensation Plans Not Approved by Security Holders</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">6,771,250</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1.83</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,228,750</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">6,771,250</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1.83</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">3,228,750</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales of Unregistered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December 31, 2025, we did not issue any securities
that were not registered under the Securities Act and that have not been previously disclosed in a Quarterly Report on Form 10-Q or a
Current Report on Form 8-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Issuer Purchases of Equity Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2025, we did not repurchase any equity securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="J_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 6. Reserved.</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="J_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should read the following
discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related
notes appearing elsewhere in this annual report. Some of the information contained in this discussion and analysis or set forth elsewhere
in this annual report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221;
section of this annual report, our actual results could differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our
mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is an
extremely challenging and often aggressive cancer that has particular treatment challenges due to its location, changing genotypes and
high metastases rates. We are currently seeking to answer the call for new treatments that will prevent metastasis and the recurrence
of metastases with our lead core product candidate OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate that produces
a cellular immune response against the cancer antigen HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, we opened a clinical
study to produce data for the FDA to evaluate the safety and efficacy of OST-HER2 in patients after resection of recurrent Osteosarcoma,
which achieved full enrollment of 41 patients in October 2023. In the first quarter of 2025, we announced that our Phase IIb clinical
trial achieved its primary endpoint with statistical significance. In October 2025, we announced final two-year overall survival data
from the Phase IIb trial, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients achieved two-year overall survival from
the most recent pulmonary resection, compared with 40% in historical control patients (p &lt; 0.0001). OST-HER2 was observed to be well-tolerated
in the study. In January 2026, we announced positive immune biomarker data from the Phase IIb trial indicating that activation of immune
blood biomarkers in the interferon gamma pathway correlated with, and was predictive of, overall survival, distinguishing long-term survivors
(&#8805; two years) from short-term survivors (&lt; one year). These biomarker findings are based on exploratory analyses and have not been
validated as surrogate endpoints for clinical benefit. Based on the totality of the data generated to date, including the observed survival
outcomes, safety profile and the significant unmet medical need in this patient population, we intend to engage with the FDA regarding
potential regulatory pathways for OST-HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have engaged in ongoing
regulatory interactions with the FDA, the United Kingdom MHRA, and the EMA regarding the clinical and biomarker data for OST-HER2 in recurrent,
fully resected pulmonary metastatic Osteosarcoma. Following submission of the Non-Clinical and CMC modules of our BLA to the FDA at the
end of January 2026, we anticipate submitting the clinical BLA module following an expected Type B meeting with the FDA in the second
quarter of 2026 and completing conditional MAA submissions to both the MHRA and the EMA in the second quarter of 2026. We also anticipate
releasing additional biomarker data in the second quarter of 2026 to further characterize immune pathway activation and its relationship
to clinical outcomes. We expect to initiate confirmatory clinical studies in the third quarter of 2026 in support of conditional approval
pathways. If OST-HER2 receives approval under the FDA&#8217;s Accelerated Approval Program prior to September 30, 2029, we would become
eligible to receive a Priority Review Voucher under the Rare Pediatric Disease Designation Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon success in gaining regulatory
approval from the FDA with OST-HER2 in Osteosarcoma, we intend to evaluate OST-HER2&#8217;s potential use, both alone and in combination
with HER2 targeting antibodies such as Herceptin&#174;, in other solid tumors including breast, esophageal and lung cancers. OST-HER2 has
potential uses in both the prevention of metastases in solid tumors, and therapeutically against HER2-expressing solid tumors treated
with HER targeting antibodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own rights to an OST-tADC
platform, a next generation ADC silicone dioxide linker technology. &#8220;Tunable&#8221; is a term used in drug development that refers
to the properties that can be influenced by chemical modifications, and &#8220;antibody-drug conjugate&#8221; or ADC is a term used to
describe a drug made up of a monoclonal antibody attached to a cytotoxic payload, or a highly active and toxic pharmaceutical molecule,
through chemical linkers. The ADC links an antibody that can home in on a targeted tumor to deploy the cytotoxic payload or toxic agent
against the tumor. Furthering our founding mission, we intend to investigate clinical indications for OST-tADC in Osteosarcoma and other
solid tumors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Policies and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared in accordance with generally accepted accounting principles in the United&#160;States (&#8220;GAAP&#8221;). The
preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated
financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe
are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual
results may differ from these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Critical accounting policies
are those that, in management&#8217;s view, are most important to the portrayal of a company&#8217;s financial condition and results of
operations and most demanding on their calls on judgment, often as a result of the need to make estimates about the effect of matters
that are inherently uncertain and may change in subsequent periods. While our significant accounting policies are described in more detail
in Note&#160;2 to our consolidated financial statements appearing elsewhere in this annual report, we believe that the following accounting
policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Warrant Liability</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. We evaluate all of our financial
instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The
classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A Warrants issued in connection with the PIPE Financing in December 2024 and January 2025 are recognized as a derivative liability
in accordance with ASC 815. We recognize the warrant instruments as a liability at fair value and adjust the instruments to fair value
at each reporting period. The liability is subject to re-measurement at each balance sheet date until exercised or reclassified, and any
change in fair value is recognized in our consolidated statements of operations. The fair value of the Series A Warrants was measured
using a Binomial simulation model. The determination of the fair value of the warrant liability may be subject to change as more current
information becomes available, and accordingly, the actual results could differ significantly. The derivative warrant liability is classified
as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation
of current liabilities in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
April 2025, after stockholder approval was obtained, this warrant liability was closed to stockholders&#8217; equity. The following assumptions
were made as of April 9, 2025 based on stockholder approval in the model for the aggregate warrants: (1) a fixed exercise price of $1.12
per share, which automatically reset and resulted in a reclassification of the warrant liability on April 9, 2025 to equity per ASC 815;
(2) then-current common stock price of $1.34 per share on April 9, 2025; (3) discount rate of 4.06%; and (4) expected stock price volatility
of 23.26%.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Components of Our Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Revenue. </i></b>We
did not recognize revenues for the years ended December&#160;31, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Operating Expenses.
</i></b>Our operating expenses are comprised primarily of research and development expenses, general and administrative expenses and licensing
costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and Development
Expenses. </i></b>Research and development expenses consist primarily of costs incurred for our research activities, including our drug
discovery efforts, and the development of our product candidates, which include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">personnel-related costs, including
salaries, benefits and stock-based compensation expense, for employees engaged in research and development functions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expenses incurred in connection
with our research programs, including under agreements with third parties, such as consultants and contractors and CROs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of developing and scaling
our manufacturing process and manufacturing drug substance and drug product for use in our research and preclinical and clinical studies,
including under agreements with third parties, such as consultants and contractors and contract development and manufacturing organizations
(CDMOs); and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of laboratory supplies
and research materials.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We track our direct external
research and development expenses on a program-by-program basis. These consist of costs that include fees, reimbursed materials, and other
costs paid to consultants, contractors, CDMOs, and CROs in connection with our preclinical, clinical and manufacturing activities. We
do not allocate employee costs, costs associated with our discovery efforts, and facilities expenses, including depreciation or other
indirect costs, to specific product development programs because these costs are deployed across multiple programs and, as such, are not
separately classified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our research
and development expenses will increase substantially as we advance OST-HER2 and OST-tADC into clinical development and expand our discovery,
research and preclinical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>General and Administrative
Expenses. </i></b>General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation,
for personnel in executive, finance and administrative functions. General and administrative expenses also include professional fees for
legal, consulting, investor and public relations and accounting and audit services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that our general
and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and
development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance,
and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Licensing Costs. </i></b>Costs
incurred in obtaining technology licenses and asset purchases are charged to licensing costs if the technology licensed has not reached
technological feasibility which includes manufacturing, clinical, intellectual property and/or regulatory success which has no alternative
future use. The licenses purchased by us require substantial completion of research and development and regulatory and marketing approval
efforts in order to reach technological feasibility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Interest Expense. </i></b>We
evaluated the convertible notes issued by us from July 2018 to April 2024 in accordance with ASC&#160;480, Distinguishing Liabilities
from Equity (&#8220;ASC&#160;480&#8221;), and determined the convertible notes are considered share-settled debt and should be recorded
as a liability. This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with
an aggregate fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires
obligations that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value
unless other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the convertible notes were recorded at the amortized cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Cumulative Series&#160;A
Preferred Stock Dividend. </i></b>The Series&#160;A preferred stock dividend requirement represents the coupon dividends on our preferred
stock that has since been converted and is identified as a separate component of our statement of operations to compute net income (loss)
available to common stockholders. The coupon dividends are computed at 5% of the principal per annum and are recorded monthly. The cumulative
accrued dividend as of December 31, 2025 and 2024 was $375,000 and $375,000, respectively. The Series&#160;A preferred stock was converted
into common stock on a 1:1 basis in February&#160;2024, and the last coupon dividend was issued in the quarter ended March&#160;31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Income Taxes. </i></b>Since
our inception, we have not recognized income tax benefits for the net operating losses (&#8220;NOLs&#8221;) incurred or the research and
development (&#8220;R&amp;D&#8221;) tax credits generated each year due to uncertainty regarding the realization of these benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and 2024, we had federal NOLs of $33,561,091
and $22,236,580, respectively. Our 2019 NOL carryforward of $292,144 will expire in tax years through 2037. NOLs generated in tax years
2020 and later may carry forward indefinitely; however, the deductibility of such NOLs is subject to certain limitations under the Code.
Accordingly, we have established a full valuation allowance to offset our deferred tax assets due to uncertainty regarding the realization
of these benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our issuances of common stock
have resulted in ownership changes as defined by Section 382 of the Code. We have not yet performed a formal Section 382 study, and it
is possible that a future analysis in 2026 could conclude that a substantial portion, or potentially all, of our NOL and R&amp;D tax credit
carryforwards may be limited or rendered unusable under Sections 382 and 383 of the Code. As a result, a portion of these carryforwards
could expire unused. We are subject to U.S. federal tax examinations for the year 2021, given that NOL carryforwards from 2019 and subsequent
years may be applied to current or future tax returns.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Deferred Offering Costs.
</i></b>Deferred offering costs consisted of legal, accounting, printing and filing fees that we capitalized, which were offset against
the gross proceeds from our initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 12pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 12pt"><b><i>Year Ended December&#160;31,
2025 Compared to Year Ended December&#160;31, 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the&#160;years ended December&#160;31, 2025 and 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Research&#160;and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,360,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,839,060</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">General&#160;and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,344,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,974,786</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,705,701</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,813,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28,705,701</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,813,846</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,051,839</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Non-operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,997</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,472,995</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,250</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48,143</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,069,092</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(28,753,844</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,882,938</td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Research and Development
Expenses. </i></b>Research and development expenses were approximately $16.4 million for the year ended December 31, 2025, compared to
approximately $2.8 million for the year ended December 31, 2024. The increase was primarily driven by higher vendor costs related to our
ongoing efforts to pursue FDA approval for our Phase IIb clinical trial and the preparation of data for submission to various global regulatory
authorities. This increase was partially offset by a reduction in vendor expenses associated with our OST-tADC platform technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For
the years ended December 31, 2025 and 2024, our direct research and development expenses related to OST-HER2 primarily consisted of laboratory
fees, vendor costs, and staff payroll. In 2025, these expenses included approximately $1.6 million for laboratory fees and clinical support
related to Phase IIb clinical trial preparation, $12.7 million for advisor fees, and $0.2 million for legal costs associated with the
completion of IND-enabling studies. Direct research and development expenses related to our OST-tADC platform were approximately $0.0
million for both the years ended December 31, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>General and Administrative
Expenses. </i></b>General and administrative expenses were approximately $12.3 million for the year ended December 31, 2025, compared
to approximately $4.0 million for the year ended December 31, 2024. The increase was primarily due to higher marketing and investor relations
costs of $2.4 million, as well as advisory fees of $3.3 million and legal fees of $1.6 million incurred in connection with the PIPE Financing
and equity line of credit that was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Interest Expense. </i></b>Interest
expense was approximately $0.0 million for the year ended December 31, 2025, compared to approximately $2.0 million for the year
ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Losses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
incurred significant operating losses. Our ability to generate sufficient product revenue to achieve profitability will depend on the
successful development and eventual commercialization of our product candidates. For the years ended December 31, 2025 and 2024, we reported
net losses of approximately $28.7 million and $8.6 million, respectively, and had accumulated deficits of approximately $67.2 million
and $38.0 million, respectively. We expect to continue incurring significant expenses and increasing operating losses for the foreseeable
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, we had cash of approximately $0.3 million and $5.5 million, respectively. To date, we have primarily funded our operations through
the sale of our securities in public offerings and private placements and warrant exercise inducement and exchange transactions, generating
total gross proceeds of approximately $41.1 million as of March 26, 2026. We believe that the net proceeds from these transactions, together
with our existing cash, will be sufficient to fund our operating expenses and capital expenditures for at least the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our sources and uses of cash for each of the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,239</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,283</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(466</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,442</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,777</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 20pt">Net (decrease) increase in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,263</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,494</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2025 and 2024, net cash used in operating activities was approximately $14.2 million and $7.3 million, respectively. This primarily
reflected net losses of approximately $28.8 million and $8.9 million, partially offset by non-cash charges of approximately $5.4 million
and $1.7 million, respectively, and net cash provided by changes in operating assets and liabilities of approximately $9.1 million and
$(0.1) million, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The changes in operating assets
and liabilities for the years ended December 31, 2025 and 2024 primarily consisted of: an increase (decrease) in accounts payable of approximately
$8.3 million and $(1.1) million, respectively; an increase in accrued interest of approximately $0.0 million and $0.6 million, respectively;
and changes in accrued expenses of approximately $0.9 million and $0.4 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2025 and 2024, non-cash charges were primarily due to changes in the fair value of our warrant liability of $(1.4) million and $0.0
million, respectively, as well as common stock issued for services and stock-based compensation of approximately $4.87 million and $0.3
million, respectively, and amortization of non-cash prepaids of $1.0 million and $0.0 million, respectively. Changes in accounts payable,
accrued expenses and other current liabilities, and prepaid expenses and other current assets in each period primarily reflected the growth
of our business, the advancement of our research programs, and the timing of vendor invoicing and payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2025 and 2024, net cash used in investing activities was approximately $0.5 million and $0.0 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December 31, 2025 and 2024, net cash provided by
financing activities was approximately $9.4 million and $12.8 million, respectively. During 2025, cash inflows included approximately
$1.1 million from our PIPE Financing and approximately $8.4 million from our warrant exercise inducement and related exchange and sale
of common stock.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Convertible Notes. </i></b>We
completed seven separate private financing transactions from July 2018 to April 2024 in which we issued convertible notes and raised total
gross proceeds of $19,426,449 from accredited investors. All of the convertible notes were automatically converted into shares of our
common stock at the closing of our initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Demand Notes. </i></b>On
March&#160;6, 2024 and June&#160;28, 2024, we issued demand promissory notes to a lender who was an investor in one of our prior convertible
notes rounds in a principal amount of $100,000 and $150,000, respectively. The demand notes bear interest at a rate of 8% per annum and
the principal plus all accrued interest is payable upon demand by such lender. If such notes are not paid on demand by us, interest will
accrue at a rate of the lesser of 16% per annum and the highest rate of interest allowable under Maryland law. As of August&#160;14, 2024,
we repaid the demand notes in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>BlinkBio. </i></b>On
August&#160;19, 2020, we issued a convertible note with a principal amount of $2,400,000 (the &#8220;BlinkBio Convertible Note&#8221;)
to BlinkBio, Inc., which was a related party because our former Chairman, Colin Goddard, Ph.D., is the Chairman and Chief Executive Officer
of BlinkBio, in exchange for the entry into the license agreement. On March&#160;15, 2021, the principal and unpaid accrued interest of
$100,000 of the BlinkBio Convertible Note converted into 1,302,082 shares of our Series&#160;A preferred stock and then distributed to
BlinkBio stockholders. The BlinkBio Convertible Note had a conversion capitalization ceiling of $19.2&#160;million, which limited the
price a noteholder must pay in a convertible note-to-common stock conversion occurrence. On February&#160;9, 2024, the 1,302,082 shares
of our Series&#160;A preferred stock were converted into 651,041 shares of common stock (on a post-split basis).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>TEDCO Grant. </i></b>In
May&#160;2021, we received the first of two tranches from TEDCO&#8217;s Rural&#160;&amp; Underserved Business Recovery from Impact of
Covid-19 (RUBRIC) Grant in the amount of $50,000. In October&#160;2021, we received the second tranche of $50,000, which brought the total
reimbursable grant amount to $100,000. We are obligated to report on and pay to TEDCO&#160;3% of their quarterly revenues for a five-year
period following the reward date. Income from grants and investments are not considered revenues. Royalties due to TEDCO are capped at
150% of the amount of the award, or $150,000. We have the option to eliminate the quarterly royalty obligation by making an advance payment
prior to the end of the five-year period, in which case, we will receive a 10% reduction of the royalty cap percentage for each year prior
to the expiration of the five-year reimbursement period that the grant is repaid in full. If we cease to meet eligibility requirements
at any time, the reimbursement obligation will become due to TEDCO immediately; however, the discount for meeting the obligation will
still apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>PIPE Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, we entered
the PIPE Purchase Agreement with certain institutional and accredited investors, substantially all of whom were existing stockholders,
pursuant to which we issued an aggregate of 1,775,750 shares of Series A Preferred Stock and Series A Warrants exercisable into 1,775,750
shares of common stock, generating gross proceeds of approximately $7.1 million before fees and expenses. In connection with the PIPE
Financing, we paid Brookline cash fees totaling $159,685 and $79,723 to Brookline and Brookline&#8217;s selected dealer, respectively,
plus Agent Warrants to purchase an aggregate of 59,848 shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>ATM Equity Offering
Program and Sales</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 8, 2025, we entered
into the Sales Agreement with the Sales Agents relating to shares of our common stock. Pursuant to the Sales Agreement, we may offer and
sell shares of our common stock from time to time having an aggregate offering price of up to $18,000,000 through or to the Sales Agents.
We will pay each of the Sales Agents a total commission for its services in acting as agent in the sale of common stock up to 3.0% of
the gross sales price per share of all shares sold through it as agent under the Sales Agreement. The amount of proceeds we will receive
will depend upon the actual number of shares of our common stock sold and the market price at which such shares are sold. Because there
is no minimum offering amount required as a condition to close a sale, the actual total public offering amount, commissions and proceeds
to us are not determinable at this time. Sales of our common stock under the Sales Agreement are being made pursuant to a prospectus supplement
filed with the SEC on August 25, 2025. As of March 26, 2026, we have sold an aggregate of 282,679 shares of our common stock for aggregate
gross proceeds of $530,162 pursuant to the Sales Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Warrant Exercise Inducement
and Exchange Offers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 11, 2025, we completed
a final closing of the First Inducement Offering. On September 2, 2025, we closed on the Second Inducement Offering. On January 14, 2026,
we closed on the Third Inducement Offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the First
Inducement Offerings and Second Inducement Offering, and pursuant to certain inducement offer letter agreements, holders of Series A Warrants
exercised for cash their Series A Warrants to purchase an aggregate of 7,154,338 shares of our common stock at the then current exercise
price of $1.12 per share and in exchange we issued to such holders New Warrants to purchase up to an aggregate of 7,154,338 shares of
our common stock at an exercise price of $3.00 per share, subject to adjustment as provided therein. The New Warrants are immediately
exercisable from the date of issuance and have a term of exercise of five years from such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Third Inducement Offering
was made to less than 10 accredited investors that held New Warrants to purchase up to an aggregate of 5,382,148 shares of our common
stock having a then current exercise price of $3.00 or $2.10 per share. Pursuant to certain inducement offer letter agreements, such holders
of New Warrants exercised for cash their New Warrants to purchase 2,499,558 shares of our common stock at a reduced exercise price of
$1.40 per share and in exchange we issued to such holders 2026 Warrants to purchase up to an aggregate of 2,499,558 shares of our common
stock at an exercise price of $1.40 per share, subject to adjustment as provided therein. The 2026 Warrants are immediately exercisable
from the date of issuance and have a term of exercise of five years from such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged the Solicitation
Agent to act as our exclusive warrant solicitation agent in connection with the Inducement Offerings and paid the Solicitation Agent a
cash fee equal to 5.0%, 1.5% and 8.0% of the total gross cash proceeds received from the exercise by the holders of their respective warrants
in connection with the First Inducement Offering, Second Inducement Offering and Third Inducement Offering, respectively. We also paid
the Solicitation Agent $15,000 and $25,000 for its reasonable legal and other expenses in connection with the First Inducement Offering
and Third Inducement Offering, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds to us from
the Inducement Offerings, before deducting transaction fees and other offering expenses, were approximately $11.5 million. We are using
the net proceeds from the Inducement Offerings to support U.S. and international regulatory and pre-commercial efforts aimed at securing
marketing authorizations for OST-HER2 in the prevention or delay of recurrent, fully resected, pulmonary metastatic Osteosarcoma, provide
funding for our wholly owned subsidiary OS Animal Health&#8217;s proposed spin-off transaction preparations, and for general corporate
purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Privately Negotiated
Warrant Exercise Inducement and Exchange Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 10, 2026 through February 2026, we entered into privately
negotiated inducement offer letters, pursuant to which certain remaining holders of our New Warrants exercised for cash their New Warrants
to purchase an aggregate of 123,216 shares of our common stock at a reduced exercise price of $1.40 per share and in exchange we issued
new warrants to purchase up to an aggregate of 123,216 shares of our common stock at an exercise price of $1.40 per share, subject to
adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance and have a term of exercise of
five years from such date. We received gross proceeds of approximately $172,502 from the exercise of these New Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>2026 Bridge Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, pursuant
to the Bridge SPA, we issued to certain accredited investors in the Bridge Financing (i) Bridge Notes in an aggregate principal amount
of $2,200,000 and (ii) Bridge Warrants to purchase up to an aggregate of 1,666,667 shares of our common stock, for aggregate gross proceeds
of $2,000,000, before deducting placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March 4, 2027 and
accrue interest at a rate of 4.0% per annum. The Bridge Warrants were immediately exercisable upon issuance, expire five years from the
date of issuance and have an exercise price of $1.40 per share, subject to adjustment as provided therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes were sold
at a 10% original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $110,000. The Bridge Notes are convertible into shares of our common stock under certain circumstances. If we complete a &#8220;Qualified
Offering,&#8221; defined as a registered public offering or registered direct offering resulting in at least $2.5 million in gross proceeds
from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically convert into
the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment of the Bridge
Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of our common stock at a conversion price equal
to 90% of the average daily volume-weighted average price of our common stock during the 10 trading days immediately preceding the holder&#8217;s
conversion notice, subject to adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
of the Bridge Financing to fund clinical development activities, including ongoing and planned clinical trials, and advance our research
and development programs, as well as for working capital and general corporate purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We engaged a SEC-registered
broker dealer and FINRA member to act as the exclusive placement agent for the Bridge Financing. In connection with the Bridge Financing,
we paid to the placement agent (a) a cash fee equal to 7.0% of the aggregate gross cash proceeds received by us in connection with the
Bridge Financing and (b) a one-time expense reimbursement of $25,000 for its legal and other expenses incurred in connection with the
Bridge Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations and Other Commitments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into contracts in
the normal course of business with our CDMOs, CROs and other third parties to support preclinical research studies and testing and other
development activities. These contracts are generally cancellable by us. Payments due upon cancellation consist only of payments for services
provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>License Obligations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>BlinkBio. </i></b>In
August&#160;2020, we entered into a licensing agreement with BlinkBio, Inc., a privately held developer of drug conjugate therapies designed
to facilitate the treatment of cancer. Pursuant to this agreement, BlinkBio granted a license to us that allows us to utilize BlinkBio&#8217;s
proprietary technology to develop, manufacture and commercialize certain of our products. BlinkBio granted us an exclusive license for
tunable drug conjugates that are directed towards, binds to or modifies the folate receptor alpha and a co-exclusive license for tunable
drug conjugates that are directed towards, binds to or modifies any target other than the folate receptor alpha, such as HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the agreement,
we are required to pay to BlinkBio (i)&#160;an upfront, non-refundable, non-creditable license fee of $300,000 (the &#8220;Up-Front Fee&#8221;),
(ii)&#160;a royalty of 6% of net sales of our products that were made using BlinkBio&#8217;s proprietary technology, subject to potential
reductions on such royalty, and (iii)&#160;certain amounts based on the achievement of the milestones described in the payment schedule
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we
had paid the Up-Front Fee. The payment schedule for milestones and corresponding payment amounts is set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone Bearing Event</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone <br/> Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">1.</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">License Fee to utilize proprietary technology (paid)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">Up-front fee + <br/> $2.4 million <br/>
Convertible <br/> Note</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 5%; text-indent: -10pt; padding-left: 10pt; vertical-align: top">2.</td><td style="width: 1%">&#160;</td>
    <td style="width: 78%; text-align: left">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (under 21 CFR Part&#160;58), such that any resulting positive data would be admissible&#160;to applicable Regulatory Authorities to support an IND (commonly referred to as &#8220;GLP-Tox&#8221;)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; vertical-align: top">3.</td><td>&#160;</td>
    <td style="text-align: left">Completion of a Phase&#160;I Clinical Trial</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; vertical-align: top">4.</td><td>&#160;</td>
    <td style="text-align: left">Completion of a Phase&#160;IIb Clinical Trial</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; vertical-align: top">5.</td><td>&#160;</td>
    <td style="text-align: left">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; vertical-align: top">6.</td><td>&#160;</td>
    <td style="text-align: left">Regulatory Approval in the first of the United&#160;States, within the European Union or within the United Kingdom</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to make the
above cash payments to BlinkBio within 30&#160;days of the achievement of each milestone with respect to the first product to attain each
such milestone, except that the first milestone only applies to our first product candidate. The aggregate amount of payments relating
to milestones 2 through 6 payable thereunder cannot exceed $22,375,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the license
agreement, we also agreed to issue the BlinkBio Convertible Note. See &#8220;<i>Financing Activities</i>&#8212;&#160;<i>BlinkBio</i>&#8221;
above for more information on the BlinkBio Convertible Note.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Biolacuna
Ltd.</i></b> We have contracted with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements
to register OST-HER2 and gain approval of its use in the respective regions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">European Medicines Agency (EMA, Europe);</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines Evaluation Board (MEB, Netherlands);</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines and Healthcare products Regulatory Agency (MHRA,
United Kingdom); and</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">U.S. Food and Drug Administration (FDA, United States).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">For
the year ended December 31, 2025, we paid $11,629,063 in consulting fees, which includes refundable value-added tax (&#8220;VAT&#8221;) expenses. As
of December 31, 2025, accounts payable related to consulting fees and VAT totaled $6,468,216.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>University of Pennsylvania.</i></b>
On April 9, 2025, we acquired from Ayala the HER2 Assets. Pursuant to the terms of the HER2 Purchase Agreement, the amended and restated
development, license and supply agreement with Advaxis terminated. In connection with the acquisition of the HER2 Assets, we were assigned
by Ayala a license agreement with the Trustees of the University of Pennsylvania covering the use of HER2 construct patents. Under the
terms of the license agreement, we are required to pay an annual license fee to the Trustees of the University of Pennsylvania. In April
2025, we paid a fee of $266,317 for the year ended December 31, 2025. In addition, we are obligated to pay a royalty equal to 1.5% of
net sales related to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">OST-HER2-related sales;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-503-related sales;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-504-related sales; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Sales related to any new immunotherapy
drug candidates created from the <i>Lm</i> platform during the term of such licensing agreement.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of recently
issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2
to Notes to the consolidated financial statements appearing elsewhere in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The JOBS Act</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The JOBS Act permits an emerging
growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable
to public companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of the extended
transition period for complying with new or revised financial accounting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of (i)&#160;the last&#160;day of our first fiscal year in which we have total annual gross revenues
of $1.235&#160;billion or more; (ii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules
of the SEC with at least $700.0&#160;million of outstanding equity securities held by non-affiliates; (iii)&#160;the date on which we
have issued more than $1.0&#160;billion in non-convertible debt securities during the previous three&#160;years; or (iv)&#160;the last&#160;day
of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><div><a id="J_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7A. Quantitative and Qualitative Disclosures
about Market Risks.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. Financial Statements and Supplementary
Data.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS THERAPIES I<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NCORPORATED</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: top; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_028">Report of Independent Registered Public Accounting Firm (PCAOB ID No. <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-14862">206</ix:nonNumeric>)</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_029">Consolidated Balance Sheets as of December 31, 2025 and 2024</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_030">Consolidated Statements of Operations for the years ended December 31, 2025 and 2024</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_031">Consolidated Statements of Stockholders&#8217; Deficit for the years ended December 31, 2025 and 2024</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_032">Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr> <tr> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#J_033">Notes to the Consolidated Financial Statements</a></span></td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><div><a id="J_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">To the Shareholders and Board of Directors of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">OS Therapies Incorporated</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-6592"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Opinion on the Financial Statements</i></b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance
sheets of OS Therapies Incorporated and its subsidiaries (collectively, the &#8220;Company&#8221;) as of December 31, 2025 and 2024,
and the related consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended,
and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of
its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Going Concern Matter</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue
as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-14863">MaloneBailey, LLP</ix:nonNumeric></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">www.malonebailey.com</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have served as the Company&#8217;s auditor since
2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-14864">Houston, Texas</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">March 30, 2026</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="J_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9pt">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-14865">269,830</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-14866">5,533,527</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14867">63,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-14868">332,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-14869">5,533,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt">Long-Term Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Fixed assets (net)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14870">2,490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14871">5,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Patent (net of amortization)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-14872">6,504,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total-Long Term Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-14873">6,506,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-14874">5,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14875">6,839,534</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14876">5,538,797</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-14877">9,936,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd" id="ixv-14878">1,662,068</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14879">1,415,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14880">521,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued payroll and payroll taxes &#8211; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="osti:AccruedPayrollAndPayrollTaxesRelatedParty" scale="0" unitRef="usd" id="ixv-14881">36,792</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="osti:AccruedPayrollAndPayrollTaxesRelatedParty" scale="0" unitRef="usd" id="ixv-14882">97,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued payroll and payroll taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-14883">1,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Preferred dividends payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableCurrent" scale="0" unitRef="usd" id="ixv-14884">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableCurrent" scale="0" unitRef="usd" id="ixv-14885">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-14886">1,971,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14887">11,764,460</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14888">4,627,310</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt">Long-Term Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">TEDCO grant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="osti:TEDCOGrantNonCurrent" scale="0" unitRef="usd" id="ixv-14889">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="osti:TEDCOGrantNonCurrent" scale="0" unitRef="usd" id="ixv-14890">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total Long-Term Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-14891">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-14892">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-14893">11,864,460</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-14894">4,727,310</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (See Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">MEZZANINE EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Series A Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14895"><ix:nonFraction contextRef="c6" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14896">0.001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-14897"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-14898">2,500,000</ix:nonFraction></ix:nonFraction> shares
authorized; <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-14899"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-14900">392,500</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-14901"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-14902">1,775,750</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-14903">1,070,705</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-14904">4,078,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Mezzanine Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" unitRef="usd" id="ixv-14905">1,070,705</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" unitRef="usd" id="ixv-14906">4,078,025</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Common Stock A, par value $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14907"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14908">0.001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14909"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14910">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14911"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14912">37,113,082</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-14913"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14914">20,869,908</ix:nonFraction></ix:nonFraction> issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-14915">37,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-14916">20,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Preferred Stock, par value $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14917"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-14918">0.001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14919"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14920">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-14921"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14922">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-14923"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-14924">0</ix:nonFraction></ix:nonFraction> shares outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-14925">61,053,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-14926">35,144,967</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-14927">67,186,219</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-14928">38,432,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total Stockholders&#8217; Deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14929">6,095,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14930">3,266,538</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-14931">6,839,534</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-14932">5,538,797</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="J_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">For the Year Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14933">16,360,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14934">2,839,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14935">12,344,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14936">3,974,786</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14937">28,705,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14938">6,813,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER INCOME/EXPENSE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-14939">249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-14940">2,051,839</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Non-operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="0" unitRef="usd" id="ixv-14941">33,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-14942">1,472,995</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-14943">51,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-14944">1,424,603</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL OTHER INCOME/EXPENSE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14945">48,143</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14946">2,069,092</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14947">28,753,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14948">8,882,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cumulative Series&#160;A preferred stock dividend requirement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:DeemedDividendOnSeriesAConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-14949">31,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-transform: uppercase; text-align: left; padding-bottom: 4pt">NET LOSS available to common shareholders</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-14950">28,753,844</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-14951">8,914,188</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Weighted average # of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14952">29,253,292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14953">6,950,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted loss per common share outstanding</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14954"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14955">0.98</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14956"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14957">1.28</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><div><a id="J_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Statements of Stockholders&#8217;
Deficit</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">CS &#8211; Shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Shares Par</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CS &#8211; Par</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 30%; padding-bottom: 1.5pt">Balances,
    December 31, 2023</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14958">5,340,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14959">5,340</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-14960">1,302,082</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14961">1,302</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-14962">5,495,330</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14963">29,518,187</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-14964">24,016,215</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Preferred Stock to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-14965">651,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" unitRef="usd" id="ixv-14966">651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" sign="-" unitRef="shares" id="ixv-14967">1,302,082</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" sign="-" unitRef="usd" id="ixv-14968">1,302</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="0" unitRef="usd" id="ixv-14969">651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Preferred Dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStock" scale="0" unitRef="usd" id="ixv-14970">31,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStock" scale="0" unitRef="usd" id="ixv-14971">31,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock IPO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14972">1,600,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14973">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14974">4,473,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-14975">4,475,226</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Convertible Notes to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-14976">13,153,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-14977">13,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-14978">24,743,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-14979">24,756,815</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Warrants to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-14980">411,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" scale="0" unitRef="usd" id="ixv-14981">411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" scale="0" sign="-" unitRef="usd" id="ixv-14982">411</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock to Investment Advisor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" scale="0" unitRef="shares" id="ixv-14983">320,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" scale="0" unitRef="usd" id="ixv-14984">320</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" scale="0" sign="-" unitRef="usd" id="ixv-14985">320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock to Investment Advisor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" scale="0" unitRef="shares" id="ixv-14986">32,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor" scale="0" unitRef="usd" id="ixv-14987">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor" scale="0" unitRef="usd" id="ixv-14988">129,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor" scale="0" unitRef="usd" id="ixv-14989">130,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Surrender of Common Stock Investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" scale="0" sign="-" unitRef="shares" id="ixv-14990">669,958</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" scale="0" sign="-" unitRef="usd" id="ixv-14991">669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" scale="0" unitRef="usd" id="ixv-14992">669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14993">268,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-14994">268,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shares issued for Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-14995">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14996">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14997">24,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-14998">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shares issued for Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-14999">6,506</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-15000">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-15001">8,516</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-15002">8,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15003">8,882,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15004">8,882,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balances, December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-15005">20,869,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-15006">20,870</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-15007">35,144,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-15008">38,432,375</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-15009">3,266,538</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitment shares issued for Equity Line of Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" scale="0" unitRef="shares" id="ixv-15010">157,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" scale="0" unitRef="usd" id="ixv-15011">157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" scale="0" unitRef="usd" id="ixv-15012">568,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" scale="0" unitRef="usd" id="ixv-15013">568,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common Stock issued for Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesCommonStockIssuedForServices" scale="0" unitRef="shares" id="ixv-15014">450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices" scale="0" unitRef="usd" id="ixv-15015">450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices" scale="0" unitRef="usd" id="ixv-15016">4,599,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices" scale="0" unitRef="usd" id="ixv-15017">4,599,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-15018">4,265,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-15019">4,265,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Preferred Shares Mezzanine Equity to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" scale="0" unitRef="shares" id="ixv-15020">4,939,808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" scale="0" unitRef="usd" id="ixv-15021">4,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" scale="0" unitRef="usd" id="ixv-15022">3,725,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" scale="0" unitRef="usd" id="ixv-15023">3,730,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock for Patent License</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" scale="0" unitRef="shares" id="ixv-15024">4,774,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense" scale="0" unitRef="usd" id="ixv-15025">4,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense" scale="0" unitRef="usd" id="ixv-15026">6,393,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense" scale="0" unitRef="usd" id="ixv-15027">6,398,015</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of Common Stock to Investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" scale="0" unitRef="shares" id="ixv-15028">282,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" scale="0" unitRef="usd" id="ixv-15029">282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" scale="0" unitRef="usd" id="ixv-15030">529,878</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" scale="0" unitRef="usd" id="ixv-15031">530,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Warrants to Common Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15032">5,638,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" scale="0" unitRef="usd" id="ixv-15033">5,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" scale="0" unitRef="usd" id="ixv-15034">7,138,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" scale="0" unitRef="usd" id="ixv-15035">7,144,201</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Warrants Liability Reclass Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" scale="0" unitRef="usd" id="ixv-15036">878,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" scale="0" unitRef="usd" id="ixv-15037">878,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Warrants exercised and proceeds received, shares pending issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" scale="0" unitRef="usd" id="ixv-15038">1,579,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" scale="0" unitRef="usd" id="ixv-15039">1,579,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15040">28,753,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15041">28,753,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Balances, December 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-15042">37,113,082</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-15043">37,113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-15044">61,053,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-15045">67,186,219</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-15046">6,095,631</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><div><a id="J_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15047">28,753,844</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15048">8,882,938</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Depreciation and amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-15049">363,085</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-15050">2,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Amortization of debt discounts issuance and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-15051">1,425,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:SharesIssuedForServices" scale="0" unitRef="usd" id="ixv-15052">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Shares issued for interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="0" unitRef="usd" id="ixv-15053">8,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Change in value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15054">1,424,603</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Commitment shares issued for equity line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:CommitmentSharesIssuedForEquityLineOfCredit" scale="0" unitRef="usd" id="ixv-15055">568,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Common shares issuance for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" unitRef="usd" id="ixv-15056">595,841</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-15057">4,265,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-15058">268,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of non-cash prepaids</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" sign="-" unitRef="usd" id="ixv-15059">1,037,631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" unitRef="usd" id="ixv-15060">8,274,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd" id="ixv-15061">1,053,331</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-15062">893,992</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-15063">358,510</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accrued interest on convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" sign="-" unitRef="usd" id="ixv-15064">613,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accrued Payroll and payroll taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-15065">59,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-15066">48,423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15067">14,238,576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15068">7,282,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Patent License Acquisition</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" unitRef="usd" id="ixv-15069">466,423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash used in investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-15070">466,423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Prepaid warrants (net of fees)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-15071">530,162</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Common stock issuance (net of fees)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-15072">7,858,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Short-term borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="0" unitRef="usd" id="ixv-15073">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term loan repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="0" unitRef="usd" id="ixv-15074">250,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Sale of preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants" scale="0" unitRef="usd" id="ixv-15075">1,053,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants" scale="0" unitRef="usd" id="ixv-15076">6,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Initial public offering (net of fees)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd" id="ixv-15077">5,225,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Net proceeds from conversion of debt A, B, C, D, E &amp; F</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15078">1,501,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Net cash provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-15079">9,441,302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-15080">12,776,840</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-15081">5,263,697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-15082">5,495,545</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Cash &#8211;&#160;beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15083">5,533,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15084">38,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Cash &#8211;&#160;end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15085">269,830</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15086">5,533,527</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Cash paid for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NON-CASH INVESTING AND FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Discount on notes payable&#160;&#8211;&#160;redemption premium</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesIssued1" scale="0" unitRef="usd" id="ixv-15087">750,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Dividends payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="0" unitRef="usd" id="ixv-15088">31,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Deemed dividend on Series A convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Dividends" scale="0" unitRef="usd" id="ixv-15089">1,971,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Mezzanine equity conversion (net of costs)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-15090">3,730,121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Conversion of preferred stock to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:ConversionOfPreferredStockToCommonStock" scale="0" unitRef="usd" id="ixv-15091">1,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Amortization of deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:DeferredOfferingCostsRecordedAsAccountsPayable" scale="0" unitRef="usd" id="ixv-15092">751,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Conversion of convertible notes into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15093">24,757,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Conversion of warrants into common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:ConversionOfWarrantsIntoCommonStock" scale="0" unitRef="usd" id="ixv-15094">411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Issuance of common stock to investor advisor &#8211; settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:IssuanceOfCommonStockToInvestorAdvisorSettlement" scale="0" unitRef="usd" id="ixv-15095">320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Conversion of make-whole liability to common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:ConversionOfMakewholeLiabilityToCommonStock" scale="0" unitRef="usd" id="ixv-15096">130,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Clawback of common stock for over issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:ClawbackOfCommonStockForOverIssuance" scale="0" sign="-" unitRef="usd" id="ixv-15097">670</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Common stock issued for patent purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:CommonStockIssuedForPatentPurchase" scale="0" unitRef="usd" id="ixv-15098">6,398,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Reclassification of warrants liability to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:ReclassificationOfWarrantLiabilityToEquity" scale="0" unitRef="usd" id="ixv-15099">878,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Shares issued for prepaid services</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:SharesIssuedForPrepaidServices" scale="0" unitRef="usd" id="ixv-15100">1,100,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><div><a id="J_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-8862"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1&#160;&#8212;&#160;ORGANIZATION AND DESCRIPTION
OF BUSINESS, LIQUIDITY, AND RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>OS Therapies Incorporated</b>
(&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a Delaware corporation incorporated on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-15101">June&#160;24,
2019</ix:nonNumeric>. It is based in Rockville, Maryland. The Company is the successor to an LLC formed in 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company intends to focus
on the identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. As of December 31,
2025, there is one ongoing clinical trial for Osteosarcoma therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OS Animal Health Corp
&#8211; Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2025, the Company
formed OS Animal Health Corp, a Delaware corporation and wholly owned subsidiary. The subsidiary had minimal activity during the year
ended December 31, 2025, consisting primarily of investor relations and audit-related expenses. During this period, the Company entered
into a license agreement with the subsidiary, pursuant to which it granted the subsidiary rights to use the HER2 Assets (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OS Therapies UK LTD
&#8211; Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 29, 2025, the Company
formed OS Therapies UK LTD, a United Kingdom corporation and wholly owned subsidiary. This subsidiary serves as the Company&#8217;s research
and development arm and had substantial operating activity during 2025. The Company has transitioned its research and development activities
to this subsidiary and intends to enter into an intercompany loan agreement, which is currently pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has prepared its
consolidated financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. Since inception, the Company has incurred significant net losses and negative cash flows from operations.
During the year ended December 31, 2025, the Company incurred a net loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-15102">28.8</ix:nonFraction> million and used $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" sign="-" unitRef="usd" id="ixv-15103">14.2</ix:nonFraction> million in cash for operating
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the
Company had cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-15104">269,830</ix:nonFraction>. Management has evaluated whether there are conditions and events, considered in the
aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="osti:GoingConcernTerm" id="ixv-15105">one year</ix:nonNumeric> after the date
that these consolidated financial statements are issued. The Company&#8217;s current cash balance is insufficient to fund operations.
During 2025, the Company incurred significant expenses, primarily related to activities in preparation for potential regulatory approvals
by the U.S. Food and Drug Administration and other regulatory authorities. The Company expects vendor and related costs associated with
these efforts to total approximately $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" unitRef="usd" id="ixv-15106">25.0</ix:nonFraction> million and continue into 2026. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s ability
to continue as a going concern is dependent upon its ability to raise additional capital to fund its research and development and future
operations. Management&#8217;s plans to mitigate these conditions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Equity and Debt Financing: The Company is actively
seeking additional capital through public or private equity offerings or debt financings.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, there can be no assurance
that the Company will be successful in sequestering additional financing on favorable terms, or at all. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-8929"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-8935"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements are presented in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;)
and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accounting and reporting
policies of the Company conform to accounting principles generally accepted in the United&#160;States of America, and the Company&#8217;s
fiscal year end is December&#160;31.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-8943"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries and majority-owned subsidiaries. The Company consolidates
all entities in which it has a controlling interest.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-8953"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated
financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments,
which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable
under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may
differ from management&#8217;s estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-8963"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash consists primarily of
deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both
interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation
(FDIC) for a combined total of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-15107">250,000</ix:nonFraction>. In the normal course of business, the Company may have deposits that exceed the FDIC insured
limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking
relationships. As of December 31, 2025 and December 31, 2024, JPMorgan Chase Bank checking account had $<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15108">233,490</ix:nonFraction> and $<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15109">5,216,354</ix:nonFraction>, respectively,
and the JPM Chase savings account had $<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15110">20,269</ix:nonFraction> and $<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15111">20,021</ix:nonFraction>, respectively. As of December 31, 2025 and December 31, 2024, Silicon Valley
Bank checking account had $<ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15112">6,071</ix:nonFraction> and $<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15113">287,173</ix:nonFraction>, respectively, and the SVB money market account had $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDomesticDepositMoneyMarket" scale="0" unitRef="usd" id="ixv-15114">10,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDomesticDepositMoneyMarket" scale="0" unitRef="usd" id="ixv-15115">10,000</ix:nonFraction>, respectively. The
JPM Chase and SVB checking accounts were in excess of the FDIC limits for the year ended December 31, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock-c0_cont_1" escape="true" name="osti:RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" id="ixv-8971"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redeemable Preferred Stock and Mezzanine
Equity</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Series
A Senior Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c35" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15116">0.001</ix:nonFraction> per share (the &#8220;Series A Preferred Stock&#8221;), is classified as mezzanine
equity in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 480 (&#8220;ASC 480&#8221;) due to its redemption features upon the occurrence of a deemed liquidation event, including (i) a merger
or consolidation or (ii) the sale, lease, transfer, or other disposition of substantially all of the Company&#8217;s assets. Proceeds
from the issuance were allocated between the Series A Preferred Stock and the accompanying warrants to purchase shares of common stock
(the &#8220;Series A Warrants&#8221;) on a relative fair value basis. Of the initial $<ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-15117">6,050,000</ix:nonFraction> in proceeds, a portion was allocated to
the Series A Warrants, with the residual allocated to the Series A Preferred Stock. Similarly, of the subsequent $<ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-15118">1,053,000</ix:nonFraction> in proceeds,
a portion was allocated to the Series A Warrants, with the residual allocated to the Series A Preferred Stock.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="osti_FixedAssetPolicyPolicyTextBlock-c0_cont_1" escape="true" name="osti:FixedAssetPolicyPolicyTextBlock" id="ixv-9009"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Asset Policy</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><ix:continuation id="osti_FixedAssetPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A capital asset is defined
as a unit of property that has an economic useful life that extends beyond 12&#160;months. Any items costing below the threshold or not
fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at
historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="osti:StraightLineDepreciatedOverPeriod" id="ixv-15119">five years</ix:nonNumeric> for financial
statement purposes.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="ixv-9017"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Amortization</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation id="_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, in connection
with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below),
including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. These intangible assets
are amortized on a straight-line basis over their estimated useful lives, with amortization recorded quarterly. Amortization expense for
the years ended December 31, 2025 and 2024 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="0" unitRef="usd" id="ixv-15120">360,305</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="0" unitRef="usd" id="ixv-15121">0</ix:nonFraction>, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_1" escape="true" name="osti:PatentLicenseAcquisitionPolicyTextBlock" id="ixv-9029"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent and License Acquisition</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_2" id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#8220;HER2 Purchase Agreement&#8221;), between the Company
and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (&#8220;Ayala&#8221;), the Company completed the acquisition of the <i>Lm</i>-based
immune-oncology programs and related intellectual property assets (the &#8220;HER2 Assets&#8221;) from Ayala, including the assignment
by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The transaction was accounted for as an asset acquisition
in accordance with ASC 805.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_3" id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the acquisition,
the Company assumed certain specified liabilities and paid an aggregate purchase price of $<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-15122">8,000,000</ix:nonFraction>, with a fair value of $<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueAdjustment" scale="0" unitRef="usd" id="ixv-15123">6,864,438</ix:nonFraction>,
consisting of: (i) $<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-15124">400,000</ix:nonFraction> to Ayala ($<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-15125">150,000</ix:nonFraction> of which was transferred upon signing of the HER2 Purchase Agreement and the remainder
on the closing date); (ii) $<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-15126">100,000</ix:nonFraction> to a third party on behalf of Ayala on the closing date; and (iii) $<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-15127">7,500,000</ix:nonFraction> worth of shares of common
stock, or <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" scale="0" unitRef="shares" id="ixv-15128">4,774,637</ix:nonFraction> shares based on the volume-weighted average price of the Company&#8217;s common stock over the <ix:nonNumeric contextRef="c0" format="ixt-sec:durday" name="osti:NumberOfTradingDays" id="ixv-15129">30</ix:nonNumeric> trading days immediately
preceding the closing date of $<ix:nonFraction contextRef="c43" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15130">1.5708</ix:nonFraction>. The fair value of the common stock issued was determined using the closing price of $<ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="osti:ClosingPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15131">1.34</ix:nonFraction> per share
on April 9, 2025, resulting in a total equity value of $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="osti:TotalEquityValue" scale="0" unitRef="usd" id="ixv-15132">6,398,014</ix:nonFraction> and a corresponding reduction in total purchase consideration. <ix:nonNumeric contextRef="c0" continuedAt="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock" id="ixv-15133">The fair
value of the purchase consideration is summarized below:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_AssetAcquisitionContingentConsiderationTableTextBlock-c0_cont_1"><ix:continuation continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_4" id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-15134">400,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Legal fees paid on behalf of Ayala</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-15135">66,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Company common stock (<ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-15136">4,774,637</ix:nonFraction> shares at $<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15137">1.34</ix:nonFraction> per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-15138">6,398,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="0" unitRef="usd" id="ixv-15139">6,864,438</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_5" id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquired intangible assets
consist primarily of a portfolio of patents and related licenses, including patents covering &#8220;Compositions and Methods for Evaluating
Potency of Listeria-Based Immunotherapeutics,&#8221; which underpin the Company&#8217;s lead programs. These patents have an effective
filing date of April 19, 2019 and an estimated remaining useful life of approximately <ix:nonNumeric contextRef="c46" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-15140">14</ix:nonNumeric> years. The assets are amortized on a straight-line
basis over their estimated useful lives. Amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="0" unitRef="usd" id="ixv-15141">360,305</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentForAmortization" scale="0" unitRef="usd" id="ixv-15142">0</ix:nonFraction> for the years ended December 31, 2025 and 2024, respectively.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="ixv-9105"><ix:continuation continuedAt="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_6" id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, expected
future amortization expense is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:continuation id="osti_PatentLicenseAcquisitionPolicyTextBlock-c0_cont_6"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" unitRef="usd" id="ixv-15143">496,972</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" unitRef="usd" id="ixv-15144">496,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" unitRef="usd" id="ixv-15145">496,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" unitRef="usd" id="ixv-15146">496,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" unitRef="usd" id="ixv-15147">496,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2031 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" unitRef="usd" id="ixv-15148">4,019,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-15149">6,504,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-9159"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reviews long-lived
assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability
is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising
from the assets or asset groups. <span style="-sec-ix-hidden: hidden-fact-95"><span style="-sec-ix-hidden: hidden-fact-96">No</span></span> impairment losses on long-lived assets have been recorded for&#160;the year ended December 31, 2025
or the year ended December&#160;31, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DeferredChargesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock" id="ixv-9171"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_DeferredChargesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred offering costs consist
of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to
the Company&#8217;s initial public offering and that were charged to stockholders&#8217; equity upon the completion of such offering.
As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden: hidden-fact-97"><span style="-sec-ix-hidden: hidden-fact-98">no</span></span> capitalized deferred offering costs. Upon the completion of the Company&#8217;s initial
public offering on August 2, 2024, all deferred offering costs were charged to stockholders&#8217; deficit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-9183"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Costs</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, and supplies.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-9192"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of incorporation,
the Company adopted ASU&#160;2014-09, <i>Revenue from Contracts with Customers</i>, and all subsequent amendments to the ASU (collectively,
&#8220;ASC&#160;606&#8221;), which (i)&#160;creates a single framework for recognizing revenue from contracts with customers that fall
within its scope and (ii)&#160;revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-9203"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, in accordance
with ASC&#160;718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees
is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation
expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be
probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized
and any previously recognized compensation expense is reversed.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-9241"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term Leases</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For short-term leases with
a term of 12 months or less, the Company recognizes lease expense on a straight-line basis over the lease term. The Company&#8217;s current
lease arrangements qualify for this short-term lease exemption and are expensed as incurred. The Company did not renew its prior lease
due to landlord restrictions related to renovations of the premises and has temporarily relocated its primary office to 115 Pullman Crossing
Road, Suite #103, Grasonville, Maryland 21638. This space, which serves as the primary office of the Company&#8217;s Chief Financial Officer,
is being provided at no cost. In May 2024, the Company entered into a month-to-month lease agreement with JLabs for general office space
in New York City, primarily for meetings and use by staff when visiting. The monthly lease payment was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-15150">750</ix:nonFraction> and increased to $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-15151">787.50</ix:nonFraction> effective
January 1, 2025.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-9249"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Income taxes</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income
taxes using the asset-and-liability method in accordance with ASC&#160;740, <i>Income Taxes </i>(&#8220;ASC&#160;740&#8221;). Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &#8220;more likely than not&#8221;
that some portion or all of the deferred tax assets will not be realized in future periods.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company follows the guidance
in ASC Topic&#160;740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition
of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first
step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits.
The second step involves measurement of the amount to be recognized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_4" id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax positions that meet the
more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-15152">50</ix:nonFraction>% likely of being realized upon
ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated
financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredIncomeTableTextBlock" id="ixv-9264"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_5" id="_IncomeTaxPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_5"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15153">9,900,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-15154">6,559,791</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">General business credit carryover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="0" unitRef="usd" id="ixv-15155">3,045,651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="0" unitRef="usd" id="ixv-15156">1,672,876</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">R&amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" unitRef="usd" id="ixv-15157">268,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" unitRef="usd" id="ixv-15158">268,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-15159">13,214,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-15160">8,501,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="0" unitRef="usd" id="ixv-15161">13,214,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="0" unitRef="usd" id="ixv-15162">8,501,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-9353"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes loss
per share in accordance with ASC&#160;260, <i>Earnings per Share </i>(&#8220;ASC&#160;260&#8221;). ASC&#160;260 requires presentation
of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statements of operations. Basic EPS is computed by
dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock
method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect
is antidilutive.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b> (cont.)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="osti:ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" id="ixv-9392"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a table listing all
preferred stock and common stock equivalents:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock Equivalents</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Series A Senior Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15163">1,401,786</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Underwriter/Placement Agent Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15164">319,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15165">280,448</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15166">7,154,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid Common Stock Not Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15167">1,441,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15168">1,512,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15169">10,317,353</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15170">1,792,948</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_5" id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Convertible Preferred
Stock issued on December 31, 2024, is not reflected in the table above as of December 31, 2024, because stockholder approval was required
for the issuance of common stock upon conversion. Stockholder approval was obtained on April 9, 2025, for the issuance of the shares of
common stock underlying the Series A Preferred Stock, which is classified as mezzanine equity, and for the Series A Warrants. Upon approval,
the conversion price of the Series A Preferred Stock and the exercise price of the Series A Warrants were automatically adjusted to $<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15171">1.12</ix:nonFraction>
per share, based on the volume-weighted average price of the Company&#8217;s common stock for the <ix:nonNumeric contextRef="c45" format="ixt-sec:durday" name="osti:NumberOfTradingDays" id="ixv-15172">10</ix:nonNumeric> trading days immediately preceding
April 9, 2025. This adjustment established a conversion multiplier of <ix:nonFraction contextRef="c49" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15173">3.571429</ix:nonFraction> common shares per preferred share. As of December 31, 2025,
<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15174">392,500</ix:nonFraction> non-converted shares of Series A Preferred Stock were outstanding, which, using the conversion multiplier, are exercisable into
<ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15175">1,401,786</ix:nonFraction> shares of common stock.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_6" id="_EarningsPerSharePolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, a
total of <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15176">319,711</ix:nonFraction> shares of common stock were underlying outstanding underwriter and placement agent warrants, consisting of <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15177">112,000</ix:nonFraction> shares
issued in connection with the Company&#8217;s initial public offering and <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd" id="ixv-15178">207,711</ix:nonFraction> shares issued to placement agents in connection with
the PIPE financing in December 2024 and January 2025.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_7" id="_EarningsPerSharePolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Company&#8217;s two warrant exercise and inducement offerings,
held June 23 to July 10, 2025, and August 29 to September 1, 2025, warrant holders who exercised their existing warrants received new
warrants with an exercise price of $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15179">3.00</ix:nonFraction> per share. In total, warrants to purchase <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-15180">7,154,338</ix:nonFraction> shares of common stock were exercised in
exchange for new warrants to purchase an equal number of shares.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant holders who pre-funded
conversions during the August 29 to September 30, 2025 offering received an aggregate of <ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="osti:PrepaidShare" scale="0" unitRef="shares" id="ixv-15181">937,500</ix:nonFraction> prepaid shares of common stock and additionally
funded <ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="osti:PrepaidShare" scale="0" unitRef="shares" id="ixv-15182">504,018</ix:nonFraction> prepaid shares, resulting in a total of <ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="osti:PrepaidShares" scale="0" unitRef="shares" id="ixv-15183">1,441,518</ix:nonFraction> prepaid warrants.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-9513"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company applies ASC&#160;820
<i>Fair Value Measurement </i>(&#8220;ASC&#160;820&#8221;), which establishes a framework for measuring fair value and clarifies the definition
of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an
asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market
participants on the measurement date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy established
in ASC&#160;820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and
are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s
own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing
the asset or liability and are to be developed based on the best information available in the circumstances.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value of the
Company&#8217;s cash, accounts payable, and accrued expenses are approximate fair value because of the short-term maturity of these financial
instruments. The redemption feature of the debt instruments is recorded at fair value (See Note&#160;3).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant liability is recorded
at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective
Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates
on behalf of management in developing model assumptions. As of December 31, 2025 and December 31, 2024, the carrying value of the warrant
liability in the aggregate was $<ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15184">0</ix:nonFraction> and $<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15185">1,971,975</ix:nonFraction>, respectively (See Note 8).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The valuation hierarchy is
composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. The levels within the valuation hierarchy are described below:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1&#160;&#8212;&#160;Assets and
liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs,
such as quoted prices in active markets for identical assets or liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2&#160;&#8212;&#160;Inputs to
the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well
as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3&#160;&#8212;&#160;Inputs to
the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market
data exists for the assets or liabilities.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING POLICIES</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="osti_WarrantLiabilityPolicyTextBlock-c0_cont_1" escape="true" name="osti:WarrantLiabilityPolicyTextBlock" id="ixv-9575"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Warrant Liability</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p>

<ix:continuation continuedAt="osti_WarrantLiabilityPolicyTextBlock-c0_cont_2" id="osti_WarrantLiabilityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<ix:continuation id="osti_WarrantLiabilityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A Warrants issued in connection with a Securities Purchase Agreement, dated as of December 24, 2024 (the &#8220;Purchase Agreement&#8221;),
are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at
fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance
sheet date until exercised or reclassified, and any change in fair value is recognized in the Company&#8217;s consolidated statements
of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation
model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available
and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-9588"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated
all recently issued accounting pronouncements and plans to adopt ASU 2024-03, Disaggregated Income Statement Disclosure, in the notes
to its audited financial statements for the year ending December 31, 2026.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring
entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For the public business
entities, the guidance is effective for annual periods beginning after December 15, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No other recently issued accounting pronouncements are expected
to have a material impact on the Company&#8217;s financial statements at this time.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-9606"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accrued Payroll</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the Company had payroll payable to the CEO of $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-15186">36,792</ix:nonFraction> and $<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-15187">8,871</ix:nonFraction>, respectively, and related payroll taxes payable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15188">1,279</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15189">88,386</ix:nonFraction>,
respectively. During the years ended December 31, 2025 and 2024, the Company made advances on payroll payable, and the CEO repaid amounts
previously advanced.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-9647"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes activity
in respect to payroll advances to the CEO:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2023</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15190">191,198</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-15191">222,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15192">414,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-15193">134,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayments 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherDebt" scale="0" unitRef="usd" id="ixv-15194">134,184</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second and third
quarters of 2024, the Company issued paychecks to Paul Romness, CEO, representing the remaining balance of backpay, net of all 2024 payroll
advances. Payroll taxes related to both backpay and regular compensation were fully paid. All related-party payroll advances to Mr. Romness, previously recorded as employee advances, were
fully repaid during 2025. The balance of related-party payroll advances for Mr. Romness was $<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15195">0</ix:nonFraction> during 2025. All advances for 2024
were repaid in full as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Parties&#160;&#8212;&#160;Convertible
Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mill River Partners LLC, an
entity affiliated with Ted Search and John Ciccio, members of the Company&#8217;s board of directors, held convertible notes with face
amounts of $<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd" id="ixv-15196">0</ix:nonFraction> as of December 31, 2025, and December 31, 2024. These notes were converted into shares of the Company&#8217;s common stock
upon the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Accounting Fees</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the Company had accounts payable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15197">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15198">26,765</ix:nonFraction>, respectively, to Shore Accountants MD Inc., an outside accounting firm that
provides payroll, bookkeeping, and tax preparation services. Shore Accountants MD Inc. is wholly owned by Christopher Acevedo, the Company&#8217;s
Chief Financial Officer.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-9717"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-9727"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s convertible
notes are separated into seven groups&#160;&#8212;&#160;A, B, C, D, E, F and BlinkBio&#160;&#8212;&#160;per the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,<br/> 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Conversion</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Collateral</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">A</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15199">10</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c77" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15200">10/31/2024</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c77" name="us-gaap:DebtInstrumentCollateral" id="ixv-15201">None</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15202">80</ix:nonFraction>% - <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15203">87.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>B</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15204">6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c81" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15205">10/31/2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c81" name="us-gaap:DebtInstrumentCollateral" id="ixv-15206">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15207">80</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>C</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15208">6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c85" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15209">10/31/2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c85" name="us-gaap:DebtInstrumentCollateral" id="ixv-15210">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15211">80</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>D</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15212">6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c90" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15213">10/31/2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c90" name="us-gaap:DebtInstrumentCollateral" id="ixv-15214">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15215">50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>E</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15216">6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c94" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15217">10/31/2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c94" name="us-gaap:DebtInstrumentCollateral" id="ixv-15218">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15219">50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>F</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15220">6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c86" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15221">10/31/2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c86" name="us-gaap:DebtInstrumentCollateral" id="ixv-15222">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15223">50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BlinkBio</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15224">10</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c139" format="ixt:date-month-day-year" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-15225">3/15/2022</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c139" name="us-gaap:DebtInstrumentCollateral" id="ixv-15226">None</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15227">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above convertible notes
were all converted into common stock on August 2, 2024 upon consummation of the Company&#8217;s initial public offering.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in July 2018 through
November 2021, the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;)
with certain lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;). Interest on the unpaid principal
balance accrues at a rate of <ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15228">10</ix:nonFraction>% per annum, computed on the basis of the actual number of&#160;days elapsed and a year of 365&#160;days.
Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on
demand by the Holders at any time after the earlier of (i)&#160;the Maturity Date (as defined in each Agreement) and (ii)&#160;the closing
of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until
October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15229">80</ix:nonFraction>&#160;&#8211;&#160;<ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15230">87.5</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next
Equity Financing. Equity Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the
next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less
than $<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15231">3,000,000</ix:nonFraction> (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of
promissory notes) or $<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15232">5,000,000</ix:nonFraction>, depending upon the signed agreement terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15233">3,000,000</ix:nonFraction> or $<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15234">5,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities,
excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without
any action on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such
qualified financing at <ix:nonFraction contextRef="c77" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15235">12.5</ix:nonFraction>% of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest
and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC&#160;480&#8221;), and determined the
Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing
the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument&#8217;s outstanding
principal. The general measurement guidance in ASC&#160;480 requires obligations that can be settled in shares with a fixed monetary value
at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute.
It has been determined that the appropriate guidance for share-settled debt is ASC&#160;835. As a result, the Notes were recorded at the
amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest,
converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15236">0</ix:nonFraction> and $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15237">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15238"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15239">263,499</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group B</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in May&#160;2020,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of <ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15240">6</ix:nonFraction>% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15241">80</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15242">10,000,000</ix:nonFraction> (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15243">10,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at <ix:nonFraction contextRef="c81" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15244">12.5</ix:nonFraction>% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15245">0</ix:nonFraction> and $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15246">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15247"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15248">1,288,500</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group C</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in July&#160;2021,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15249">6</ix:nonFraction>% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15250">80</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to the Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series
of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15251">10,000,000</ix:nonFraction>
(including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15252">10,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at <ix:nonFraction contextRef="c85" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15253">12.5</ix:nonFraction>% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15254">0</ix:nonFraction> and $<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15255">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15256"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15257">986,250</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group D</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in November&#160;2022,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
Investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of <ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15258">6</ix:nonFraction>% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15259">50</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15260">10,000,000</ix:nonFraction> (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15261">10,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15262">50</ix:nonFraction>% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Group
D Convertible Notes, the Company agreed to issue an additional <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" unitRef="shares" id="ixv-15263">125,000</ix:nonFraction> shares of common stock to the Group D Holders, prorated based on
such Holder&#8217;s investment amount, as an inducement for their investment in the Group D Convertible Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15264">0</ix:nonFraction> and $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15265">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15266"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15267">500,000</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group E</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in February 2023,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of <ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15268">6</ix:nonFraction>% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15269">50</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="osti:GrossProceeds" scale="0" unitRef="usd" id="ixv-15270">10,000,000</ix:nonFraction> (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15271">10,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at <ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15272">50</ix:nonFraction>% of the equity stock conversion price. In connection with the Group E Convertible Notes, the Company agreed to issue an
additional <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" unitRef="shares" id="ixv-15273">68,750</ix:nonFraction> shares of common stock to the Group E Holders, prorated based on such Holder&#8217;s investment amount, as an inducement
for their investment in the Group E Convertible Notes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8212;&#160;CONVERTIBLE DEBT</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15274">0</ix:nonFraction> and $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15275">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15276"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15277">262,500</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group F</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in June 2023, the
Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of <ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" unitRef="pure" id="ixv-15278">6</ix:nonFraction>% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-15279">50</ix:nonFraction>% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-15280">10,000,000</ix:nonFraction> (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8212;&#160;CONVERTIBLE DEBT</b> (cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateAdditionalCashProceeds" scale="0" unitRef="usd" id="ixv-15281">10,000,000</ix:nonFraction> through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-15282">50</ix:nonFraction>% of the equity stock conversion price. In connection with the Group F Convertible Notes, the Company agreed to issue an
additional&#160;<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" unitRef="shares" id="ixv-15283">214,594</ix:nonFraction> shares of common stock to the Group F Holders, prorated based on such Holder&#8217;s investment amount, as an
inducement for their investment in the Group F Convertible Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2025 and
2024, the balance of the convertible notes was $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15284">0</ix:nonFraction> and $<ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-15285">0</ix:nonFraction>, respectively, as the notes were converted into <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15286"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15287">773,805</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Redemption Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the redemption
liability was calculated under Level 3 of the fair value hierarchy, is determined based upon a Probability-Weighted of Expected Returns
Model (&#8220;PWERM&#8221;). This PWERM was determined to be the most appropriate method of estimating the value of possible redemption
or conversion outcomes over time, since the Company has not entered into a priced equity round through June 30, 2024. The fair value of
the redemption liability is calculated using the initial value of the convertible note less the debt discount rate of <ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15288">12.5</ix:nonFraction>% in Group A,
<ix:nonFraction contextRef="c101" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15289">20</ix:nonFraction>% in Groups B and C, and <ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-15290">50</ix:nonFraction>% in Groups D, E and F.&#160;The resulting redemption liability was amortized over the remaining life of
the notes using interest rates of <ix:nonFraction contextRef="c103" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15291">10</ix:nonFraction>% for Group A and <ix:nonFraction contextRef="c104" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15292">6</ix:nonFraction>% for Groups B&#8211;F. Group A notes had a fixed term of three years, while Groups
B&#8211;F had variable terms ranging from 12 months to three years. The Company retained the option to negotiate extended maturity dates
for Groups B&#8211;F. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued
interest, converted into shares of the Company&#8217;s common stock. The redemption liability was closed to stockholders&#8217; equity
on such date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fees Associated with Convertible Debt Raise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fees associated with the
issuance of the convertible notes for Groups A, B, C and D consist of legal and investment banking fees. No related parties received any
portion of these fees. These fees are capitalized and amortized over the life of the respective convertible notes using an effective interest
rate of <ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15293">10</ix:nonFraction>% for Group A and <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15294"><ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15295"><ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15296">6</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for Groups B, C and D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Make-whole liability&#160;&#8212;&#160;Shares
due Noble Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Company
entered into an advisory agreement with Noble Capital under which, in lieu of cash compensation, the Company agreed to issue <ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="osti:AgreedToIssuedCashRemunerationPercentage" scale="-2" unitRef="pure" id="ixv-15297">4</ix:nonFraction>% of its
common stock, subject to an anti-dilution clause. The make-whole liability represents shares earned due to adjustments under the anti-dilution
provision during 2020 and 2021. As of year-end 2021, the Company held an aggregate of <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-15298">233,202</ix:nonFraction> shares, valued at $<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" unitRef="usd" id="ixv-15299">408,413</ix:nonFraction>, after issuing
<ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-15300">200,000</ix:nonFraction> shares in 2020. Advisory fee expense of $<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseInvestmentAdvisoryFees" scale="0" unitRef="usd" id="ixv-15301">152,482</ix:nonFraction> was recorded in 2021 to reflect the share value earned under the anti-dilution
provision. In 2022, <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-15302">70,624</ix:nonFraction> shares were set aside to satisfy the anti-dilution clause, with an associated advisory fee expense of $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseInvestmentAdvisoryFees" scale="0" unitRef="usd" id="ixv-15303">282,496</ix:nonFraction>
recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 1, 2023, the make-whole
liability for Noble Capital was contractually nullified and unwound, and the adjustment was reflected in the Consolidated Statements of
Stockholders&#8217; Deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, Noble Capital
and the Company settled various investment fees in dispute, as well as shares related to the anti-dilution clause that had expired. Under
the settlement, Noble Capital received <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:CommonStockSharesAwarded" scale="0" unitRef="shares" id="ixv-15304">320,033</ix:nonFraction> shares of common stock and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="osti:CommonStockSharesAwardedInCash" scale="0" unitRef="usd" id="ixv-15305">50,000</ix:nonFraction> in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Make-whole liability&#160;&#8212;&#160;Shares
Officers &amp; Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023, the Company
issued <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-15306">350,000</ix:nonFraction> shares of Class A common stock to officers, key employees, key advisors and directors, leaving <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-15307">20,000</ix:nonFraction> shares to be issued
to Joacim Borg, a former director, with a value of $<ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" unitRef="usd" id="ixv-15308">80,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2023, the Company
hired Alan Musso, former CFO, and as part of his compensation, awarded him <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-15309">12,500</ix:nonFraction> shares of common stock at $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="osti:SharesAwardedParValue" scale="0" unitRef="usdPershares" id="ixv-15310">4.00</ix:nonFraction> per share, totaling
$<ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" unitRef="usd" id="ixv-15311">50,000</ix:nonFraction>. This amount was reflected in the Company&#8217;s make-whole stock liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon Mr. Musso&#8217;s resignation
on June 30, 2023, Christopher Acevedo, the current CFO, assumed the role and was awarded the balance of Mr. Musso&#8217;s shares following
the successful completion of the Company&#8217;s initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="osti:ScheduleOfMakeWholeShareLiabilityTableTextBlock" id="ixv-10318"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s make-whole
share liability as of September 30, 2024 is summarized in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"># Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date&#160;Earned</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Alan Musso</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c141" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" id="ixv-15312">Former CFO</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="osti:BusinessAcquisitionNumberofShares" scale="0" unitRef="shares" id="ixv-15313">3,125</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" unitRef="usd" id="ixv-15314">12,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c141" format="ixt:date-monthname-day-year-en" name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" id="ixv-15315">March&#160;1,&#160;2023</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Christopher Acevedo</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c143" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" id="ixv-15316">Current CFO</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="osti:BusinessAcquisitionNumberofShares" scale="0" unitRef="shares" id="ixv-15317">9,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" unitRef="usd" id="ixv-15318">37,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">Upon IPO</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Joacim Borg</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c145" name="us-gaap:BusinessAcquisitionNameOfAcquiredEntity" id="ixv-15319">Former&#160;Director</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="osti:BusinessAcquisitionNumberofShares" scale="0" unitRef="shares" id="ixv-15320">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" unitRef="usd" id="ixv-15321">80,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c145" format="ixt:date-monthname-day-year-en" name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" id="ixv-15322">July&#160;1,&#160;2022</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="osti:BusinessAcquisitionNumberofShares" scale="0" unitRef="shares" id="ixv-15323">32,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="0" unitRef="usd" id="ixv-15324">130,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All make-whole shares due
to directors and officers were issued in October 2024. As a result, the balance of the make-whole stock liability was $<ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-15325"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-15326">0</ix:nonFraction></ix:nonFraction> as of December
31, 2025 and December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants for Placement Agent&#160;&#8212;&#160;Noble
Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Company
entered into an advisory agreement with Noble Capital, under which, in lieu of cash remuneration, it was granted a <ix:nonFraction contextRef="c105" decimals="2" format="ixt:num-dot-decimal" name="osti:CashRemunerationofWarrantFeePercentage" scale="-2" unitRef="pure" id="ixv-15327">10</ix:nonFraction>% warrant fee in
addition to cash compensation for debt raises from investments procured by Noble Capital. The warrants have a five-year term, with an
exercise price equal to the average price paid by the convertible debt holders in each respective debt raise round.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants earned were as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2020: <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15328">248,855</ix:nonFraction> warrants, valued at $<ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15329">248,855</ix:nonFraction></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2021: <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15330">213,782</ix:nonFraction> warrants, valued at $<ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15331">427,564</ix:nonFraction></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2022: <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15332">162,644</ix:nonFraction> warrants, valued at $<ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15333">325,288</ix:nonFraction></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were earned from
2023 through December 31, 2024. Warrants issued in 2020, 2021, and 2022 were accounted for as a discount to the related convertible debt,
with the discount amortized over the life of the debt. Debt discount accretion expense for these warrants was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:DebtDiscountAccretionExpenseInWarrants" scale="0" unitRef="usd" id="ixv-15334">0</ix:nonFraction> for the year ended December
31, 2025, and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:DebtDiscountAccretionExpenseInWarrants" scale="0" unitRef="usd" id="ixv-15335">49,840</ix:nonFraction> for the year ended December 31, 2024. The total unamortized warrant discount was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="0" unitRef="usd" id="ixv-15336">0</ix:nonFraction> as of both December 31, 2025
and December 31, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, Noble Capital
warrant holders exercised <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-15337">116,313</ix:nonFraction> warrants in a cashless transaction, and in December 2024, the remaining <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-15338">294,977</ix:nonFraction> warrants were exercised
in a reduced cashless transaction, resulting in the issuance of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants for Underwriter and Placement Agents&#160;&#8212;&#160;Brookline
Capital Markets and Ceros Financial Services, Inc.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2024, the Company
issued a warrant to Brookline Capital Markets to purchase <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-15339">112,000</ix:nonFraction> shares of the Company&#8217;s common stock pursuant to an underwriting
agreement. The warrant became exercisable <ix:nonNumeric contextRef="c121" format="ixt-sec:durday" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15340">180</ix:nonNumeric> days after July 31, 2024, expires on July 31, 2029, and has an exercise price of $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15341">4.40</ix:nonFraction> per
share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, in connection
with the Company&#8217;s Purchase Agreement, Brookline earned warrants initially exercisable for <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-15342">39,918</ix:nonFraction> shares at $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="osti:ExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15343">4.40</ix:nonFraction> per share. These
warrants were subsequently adjusted to <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-15344">156,821</ix:nonFraction> shares at an exercise price of $<ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-15345">1.12</ix:nonFraction> per share, subject to further adjustment as provided
in the agreement. The warrants are exercisable for <ix:nonNumeric contextRef="c124" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15346">five years</ix:nonNumeric> from April 9, 2025. As of December 31, 2025, warrants to purchase <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15347">156,821</ix:nonFraction>
shares remained outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ceros, in connection with
the same Purchase Agreement, earned warrants initially exercisable for <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="osti:AggregateWarrantsExercisable" scale="0" unitRef="shares" id="ixv-15348">13,951</ix:nonFraction> shares at $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15349">4.40</ix:nonFraction> per share, which were subsequently adjusted
to <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-15350">54,807</ix:nonFraction> shares at $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15351">1.12</ix:nonFraction> per share, also subject to further adjustment under the agreement. These warrants are exercisable for <ix:nonNumeric contextRef="c128" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15352">five years</ix:nonNumeric>
from April 9, 2025. As of December 31, 2025, <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15353">52,872</ix:nonFraction> warrants remained outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Loan </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investor lent the Company
$<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-15354">100,000</ix:nonFraction> on March 7, 2024. The note is a demand note, carrying interest at <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" unitRef="pure" id="ixv-15355">8</ix:nonFraction>% and was used for working capital purposes. An investor lent
the Company $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-15356">150,000</ix:nonFraction> on June 28, 2024. The note is a demand note, carrying interest at <ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" unitRef="pure" id="ixv-15357">8</ix:nonFraction>% and was also used for working capital purposes.
The Company repaid these loans, including accrued interest thereon, in August 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="osti:TedcoGrantDisclosureTextBlock" id="ixv-10501"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5&#160;&#8212;&#160;TEDCO GRANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May of 2021, the Company
received the first of <ix:nonFraction contextRef="c149" decimals="0" format="ixt-sec:numwordsen" name="osti:NumberOfTranches" scale="0" unitRef="pure" id="ixv-15358">two</ix:nonFraction> tranches from TEDCO&#8217;s <i>Rural&#160;&amp; Underserved Business Recovery from Impact of COVID-19 (RUBRIC)
Grant </i>in the amount of $<ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivable" scale="0" unitRef="usd" id="ixv-15359">50,000</ix:nonFraction>. A second tranche of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivable" scale="0" unitRef="usd" id="ixv-15360">50,000</ix:nonFraction> was received in October&#160;2021 for a total reimbursable grant amount
of $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="osti:ReimbursableGrantAmount" scale="0" unitRef="usd" id="ixv-15361">100,000</ix:nonFraction>. The Company is obligated to report on and pay to TEDCO&#160;3% of their quarterly revenues for a five-year period following
the reward date. Income from grants and investments are not considered revenues. Royalties due to TEDCO are capped at <ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="osti:PercentageOfRoyalties" scale="-2" unitRef="pure" id="ixv-15362">150</ix:nonFraction>% of the amount
of the award or $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="0" unitRef="usd" id="ixv-15363">150,000</ix:nonFraction> total. The Company has the option to eliminate the quarterly royalty obligation by making an advance payment
prior to the end of the five-year period, in which case, the Company will receive a <ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="osti:RoyaltyReductionPercentage" scale="-2" unitRef="pure" id="ixv-15364">10</ix:nonFraction>% reduction of the royalty cap percentage for each
year prior to the expiration of the <ix:nonNumeric contextRef="c152" format="ixt-sec:durwordsen" name="osti:ReimbursementExpirationPeriod" id="ixv-15365">five-year</ix:nonNumeric> reimbursement period that the grant is repaid in full. If the Company ceases to meet eligibility
requirements the reimbursement obligation will become due to TEDCO immediately; however, the discount for meeting the obligation will
still apply.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-10511"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employee Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no employee commitments
as the Company operates on an At-Will employment basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rental Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company rents a virtual
office on a month-to-month basis at JLabs in New York, New York, a facility owned by Johnson &amp; Johnson. The current monthly rent is
$<ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-15366">787.50</ix:nonFraction>. Rent expense for the years ended December 31, 2025 and 2024 was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:RentExpense" scale="0" unitRef="usd" id="ixv-15367">10,390</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:RentExpense" scale="0" unitRef="usd" id="ixv-15368">1,750</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License Obligation and Manufacturing Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advaxis (now Ayala)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2018, the Company
entered into an exclusive license agreement with Advaxis, Inc., as amended, under which it acquired the rights to develop and commercialize
the Advaxis HER2 Construct, including related patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the agreement, all milestone
payments were non-refundable, non-creditable and payable only once upon the achievement of the corresponding milestone. As of December
31, 2020, the first milestone was achieved and paid ($<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="osti:MilestonePayments" scale="0" sign="-" unitRef="usd" id="ixv-15369">1,550,000</ix:nonFraction>) in January 2021. The second milestone was completed and paid ($<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="osti:MilestonePayments" scale="0" sign="-" unitRef="usd" id="ixv-15370">1,375,000</ix:nonFraction>)
in May 2021. No milestone payments were made for the year ended December 31, 2025 or December 31, 2024. The license agreement was terminated
upon the Company&#8217;s purchase of the HER2 Assets from Ayala on April 9, 2025, which included a payment of $<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15371">400,000</ix:nonFraction> and the issuance
of common stock as consideration.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BlinkBio</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July&#160;2020, the Company
entered into a Licensing Agreement with BlinkBio, Inc., to utilize their proprietary technology. As of August&#160;2020, the $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="0" unitRef="usd" id="ixv-15372">300,000</ix:nonFraction>
License fee was fully paid and recorded in license expense. These payments have been recorded in the Licensing expenses of the accompanying
statement of operations. No payments were due or made in 2024 or 2025. The Company is currently conducting early-stage research on the
licensed drug, including studies to support future toxicology evaluations. <ix:nonNumeric contextRef="c0" continuedAt="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock-c0_cont_1" escape="true" name="osti:ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" id="ixv-15373">A payment schedule for future milestones is summarized below.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone Bearing Event</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone<br/> Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">1.</td><td>&#160;</td> <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c161" name="osti:MilestoneBearingEventDescription" id="ixv-15374">License Fee to utilize proprietary technology (paid)</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15375">300,000</ix:nonFraction> + $<ix:nonFraction contextRef="c163" decimals="-5" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="6" unitRef="usd" id="ixv-15376">2.4</ix:nonFraction> million Convertible Note</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; width: 3%; vertical-align: top">2.</td><td style="width: 1%">&#160;</td> <td style="width: 82%; text-align: left"><ix:nonNumeric contextRef="c164" name="osti:MilestoneBearingEventDescription" id="ixv-15377">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#8220;GLP-Tox&#8221;)</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15378">375,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">3.</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c165" name="osti:MilestoneBearingEventDescription" id="ixv-15379">Completion of a Phase I Clinical Trial</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15380">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">4.</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c166" name="osti:MilestoneBearingEventDescription" id="ixv-15381">Completion of a Phase II Clinical Trial</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15382">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">5.</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c167" name="osti:MilestoneBearingEventDescription" id="ixv-15383">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15384">6,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">6.</td><td>&#160;</td> <td style="text-align: left"><ix:nonNumeric contextRef="c168" name="osti:MilestoneBearingEventDescription" id="ixv-15385">Regulatory Approval in the first of the United States, within the EU or within the UK</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="osti:FutureMilestones" scale="0" unitRef="usd" id="ixv-15386">12,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will make the
cash payments set forth in the table above by wire transfer of immediately available funds, to BlinkBio within 30&#160;days of the occurrence
of each milestone set forth with respect to the first Product to attain each such milestone, except that the first Milestone above will
apply with respect to The Company&#8217;s first product candidate. During the Royalty Term, the Company will pay BlinkBio a royalty of
<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="osti:RoyaltyNetSalesPecentage" scale="-2" unitRef="pure" id="ixv-15387">6</ix:nonFraction>% on Net Sales on a Product-by-Product and country-by-country basis during the Royalty Term, in a country in which no Valid Claim Covers
the manufacture, use, or sale of a Product, the royalty on Net Sales of such Product in such country will be reduced to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="osti:RoyaltyReductionPercentage" scale="-2" unitRef="pure" id="ixv-15388">3</ix:nonFraction>%. No royalties
were due in the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
each milestone payment will be payable only once, and the aggregate amount of Milestone payments payable hereunder will not exceed $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:MilestonePayments" scale="0" unitRef="usd" id="ixv-15389">22,375,000</ix:nonFraction>.
A Milestone may be achieved by the Company or a Commercial Sublicensee.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>George Clinical Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June&#160;2020, the Company
entered into a Research Service Agreement, as amended, with George Clinical Inc., to use their clinical research services for the Company&#8217;s
study: &#8220;<i>An Open Label, Phase&#160;2 Study of Maintenance Therapy with OST-HER2&#160;after Resection of Recurrent Osteosarcoma</i>&#8221;.
Under the terms of the agreement, the Company was required to pay to George Clinical certain fees described in the fee schedule below.
The total budget under the agreement was approximately $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="osti:BundgerUnderAgreement" scale="0" unitRef="usd" id="ixv-15390">2,436,928</ix:nonFraction>. For the years ended December 31, 2025 and 2024, the total research
and development expenses recorded in the statement of operations was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15391">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15392">86,687</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c0" continuedAt="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock-c0_cont_1" escape="true" name="osti:ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" id="ixv-15393">The fee schedule for certain fees
and corresponding payment amounts is set forth below.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>George Clinical Payment Schedule</b></span></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment <br/>
Amount</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 3%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">1.</span></td> <td style="width: 1%">&#160;</td> <td style="width: 82%"><ix:nonNumeric contextRef="c169" name="osti:PaymentScheduleofServiceFees" id="ixv-10701"><span style="font-size: 10pt">Service Fee Advance (paid)</span></ix:nonNumeric></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15394">49,989</ix:nonFraction></span></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">2.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c170" name="osti:PaymentScheduleofServiceFees" id="ixv-10714"><span style="font-size: 10pt">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15395">193,671</ix:nonFraction></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">3.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c171" name="osti:PaymentScheduleofServiceFees" id="ixv-10727"><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Electronic Data Capture (EDC) Go Live Date</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15396">47,740</ix:nonFraction></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">4.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c172" name="osti:PaymentScheduleofServiceFees" id="ixv-10740"><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Development of SAP tables</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15397">47,740</ix:nonFraction></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">5.</span></td> <td>&#160;</td> <td><ix:nonNumeric contextRef="c173" name="osti:PaymentScheduleofServiceFees" id="ixv-10753"><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;30% on Final Analysis</span></ix:nonNumeric></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15398">40,920</ix:nonFraction></span></td> <td>&#160;</td></tr> <tr> <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">6.</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top"><ix:nonNumeric contextRef="c174" name="osti:PaymentScheduleServiceFeesRemainderDue" id="ixv-10766"><span style="font-size: 10pt">Service Fees&#160;&#8211;&#160;Remainder Due</span></ix:nonNumeric></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c174" name="osti:ServiceFeesRemainderDue" id="ixv-10771"><span style="font-size: 10pt">Split monthly <br/>
over course <br/>
of study</span></ix:nonNumeric></td> <td style="vertical-align: bottom">&#160;</td></tr> </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">George Clinical tracked and
invoiced the Company for the number of task units completed and pass-through costs were invoiced each month in arrears based on actual
costs without mark-up. The PTC Advance Fee was used to offset final pass-through fees payable. As of December 31, 2025, the balance payable
to George Clinical was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:OutstandingBalanceFees" scale="0" unitRef="usd" id="ixv-15399">0</ix:nonFraction>, and the services agreement has terminated in accordance with its terms. All fees due under the agreement have
been satisfied, and no further obligations to the vendor remain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Biolacuna Ltd</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has contracted
with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements to register OST-HER2 and
gain approval of its use in the respective regions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">European Medicines Agency (EMA, Europe);</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines Evaluation Board (MEB, Netherlands);</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines and Healthcare products Regulatory Agency (MHRA,
United Kingdom); and</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">U.S. Food and Drug Administration (FDA, United States).</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b>
(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, the Company paid $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15400">11,629,063</ix:nonFraction> in consulting fees, which includes refundable value-added tax (VAT) expenses. As of December 31,
2025, accounts payable related to consulting fees and VAT totaled $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivable" scale="0" unitRef="usd" id="ixv-15401">7,323,386</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trustees of the University of Pennsylvania</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, the Company
acquired from Ayala the HER2 Assets. Pursuant to the terms of the HER2 Purchase Agreement, the amended and restated development, license
and supply agreement with Advaxis terminated. In connection with the acquisition of the HER2 Assets, the Company was assigned by Ayala
a license agreement with the Trustees of the University of Pennsylvania covering the use of HER2 construct patents. Under the terms of
the license agreement, the Company is required to pay an annual license fee to the Trustees of the University of Pennsylvania. In April
2025, the Company paid a fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="0" unitRef="usd" id="ixv-15402">266,317</ix:nonFraction> for the year ended December 31, 2025. In addition, the Company is obligated to pay a royalty
equal to <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="osti:PercentageOfRoyaltyPayments" scale="-2" unitRef="pure" id="ixv-15403">1.5</ix:nonFraction>% of net sales related to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">OST-HER2-related sales;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-503-related sales;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-504-related sales; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Sales related to any new immunotherapy
drug candidates created from the <i>Lm</i> platform during the term of such licensing agreement.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company
may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any
of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate
insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company&#8217;s
future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this
were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position.
Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently
not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, could
have a material adverse effect on the Company&#8217;s results of operations or financial position. The Company recently participated in
an arbitration hearing related to a claim brought by its former investment advisor concerning underwriter compensation for the Company&#8217;s
initial public offering in August 2024 and any subsequent equity offerings during the following 12 months. The hearing concluded on November
7, 2025, and the arbitrators issued a ruling on January 28, 2026, awarding the former investment advisor $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AlternativeInvestment" scale="0" unitRef="usd" id="ixv-15404">1,055,428</ix:nonFraction> and their attorneys
$<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd" id="ixv-15405">308,804.88</ix:nonFraction>. The Company also incurred $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-15406">15,128.32</ix:nonFraction> in arbitration-related fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total amount of $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15407">1,379,361.20</ix:nonFraction>
has been accrued in the Company&#8217;s financial statements as of December 31, 2025 and is recorded as Other expense, payable in 2026.
The Company does not intend to challenge the ruling. In accordance with ASC 450, the obligation is considered both probable and reasonably
estimable.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-10915"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7&#160;&#8212;&#160;EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, the Company&#8217;s
common stock was initially split into two classes: <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-15408">50,000,000</ix:nonFraction> shares of Class A common stock, $<ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15409">0.001</ix:nonFraction> par value per share (&#8220;Class
A Common Stock&#8221;), and <ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares" id="ixv-15410">20,000,000</ix:nonFraction> shares of Class B common stock, $<ix:nonFraction contextRef="c178" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15411">0.001</ix:nonFraction> par value per share (&#8220;Class B Common Stock&#8221;).
On February 9, 2024, the Company combined the two classes under the name common stock with <ix:nonFraction contextRef="c179" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15412">50,000,000</ix:nonFraction> shares authorized. On October 21,
2025, stockholders approved an increase in authorized common stock from <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15413">50,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15414">150,000,000</ix:nonFraction> shares. As of December 31, 2025 and
2024, the Company had <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15415">37,113,082</ix:nonFraction> and <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15416">20,869,908</ix:nonFraction> shares of common stock outstanding, respectively. <ix:nonNumeric contextRef="c0" name="us-gaap:CommonStockVotingRights" id="ixv-15417">Common stock has voting rights</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&#160;2, 2024, the
Company consummated its initial public offering and sold&#160;<ix:nonFraction contextRef="c183" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares" id="ixv-15418">1.6</ix:nonFraction> million shares of common stock at a price of $<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-15419">4.00</ix:nonFraction>&#160;per share. Concurrent
with this consummation, all outstanding convertible notes, including accrued interest thereon, automatically converted into approximately&#160;<ix:nonFraction contextRef="c185" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="6" unitRef="shares" id="ixv-15420">13.2</ix:nonFraction>&#160;million
shares of common stock, at conversion prices ranging from $<ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-15421">0.39</ix:nonFraction>&#160;per share to $<ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15422">2.59</ix:nonFraction>&#160;per share, after applying share discounts
ranging from&#160;<ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="osti:CommonStockConversionAfterShareDiscountsPercentage" scale="-2" unitRef="pure" id="ixv-15423">50</ix:nonFraction>% to&#160;<ix:nonFraction contextRef="c188" decimals="3" format="ixt:num-dot-decimal" name="osti:CommonStockConversionAfterShareDiscountsPercentage" scale="-2" unitRef="pure" id="ixv-15424">87.5</ix:nonFraction>% and valuation ceilings ranging from $<ix:nonFraction contextRef="c187" decimals="-6" format="ixt:num-dot-decimal" name="osti:ValuationCeilingsAmount" scale="6" unitRef="usd" id="ixv-15425">5</ix:nonFraction>&#160;million to $<ix:nonFraction contextRef="c188" decimals="-6" format="ixt:num-dot-decimal" name="osti:ValuationCeilingsAmount" scale="6" unitRef="usd" id="ixv-15426">50</ix:nonFraction>&#160;million, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2025, the Company issued (i) <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15427">157,407</ix:nonFraction> shares of common stock in connection with its equity line of credit, (ii) <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15428">300,000</ix:nonFraction> shares
of common stock to a scientific and technical advisor in exchange for scientific and technical services, which will be amortized over
a 12-month period with the remaining balance in prepaid expenses, and (iii) <ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15429">20,000</ix:nonFraction> shares of common stock to an advisor in exchange for
services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
June 30, 2025, the Company issued (i) <ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-15430">3,962,129</ix:nonFraction> shares of common stock in connection with conversions of Series A Preferred Stock, (ii)
<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15431">2,164,215</ix:nonFraction> shares of common stock in connection with the purchase of the HER2 Assets, (iii) <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15432">2,166,381</ix:nonFraction> pre-funded warrants in connection
with the purchase of the HER2 Assets, (iv) <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15433">10,000</ix:nonFraction> shares of common stock to an advisor in exchange for services and (v) <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15434">2,181,257</ix:nonFraction> shares
of common stock in connection with the Company&#8217;s warrant exercise inducement and exchange offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
September 30, 2025, the Company issued (i) <ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" unitRef="shares" id="ixv-15435">977,679</ix:nonFraction> shares of common stock in connection with conversions of Series A Preferred Stock,
(ii) <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15436">2,507,386</ix:nonFraction> shares of common stock in connection with the Company&#8217;s warrant exercise inducement and exchange offering and (iii)
<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15437">120,000</ix:nonFraction> shares of common stock to an advisor in exchange for services. Additionally, the Company received $<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15438">1,050,000</ix:nonFraction> in gross proceeds,
which was recorded as additional paid-in capital, from the exercise of Series A Warrants to purchase <ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15439">937,500</ix:nonFraction> shares of common stock, which
were issued subsequent to September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
December 31, 2025, the Company issued (i) <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15440">950,000</ix:nonFraction> shares of common stock in connection with its warrant exercise inducement and exchange
offering related to pre-funded warrants, (ii) <ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15441">2,610,422</ix:nonFraction> shares of common stock upon exercise of the pre-funded warrant issued in connection
with the purchase of the HER2 Assets, and (iii) <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-15442">282,679</ix:nonFraction> shares of common stock sold pursuant to the Company&#8217;s ATM program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in three months ended December 31, 2025, the Company
received $<ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="osti:GrossProceeds" scale="0" unitRef="usd" id="ixv-15443">1,426,109</ix:nonFraction> in gross proceeds from the exercise of Series A Warrants to purchase <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" scale="0" unitRef="shares" id="ixv-15444">1,441,518</ix:nonFraction> shares of common stock at a future
date. These proceeds were recorded as additional paid-in capital and are reflected in the Company&#8217;s warrant register.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7&#160;&#8212;&#160;EQUITY </b>(cont.)</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, the Company authorized
<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15445">5,000,000</ix:nonFraction> shares of Preferred Stock, of which <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="osti:PreferredStockSharesDesignated" scale="0" unitRef="shares" id="ixv-15446">1,400,000</ix:nonFraction> were designated as Series A Preferred Stock. A total of <ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-15447">1,302,082</ix:nonFraction> shares of Series
A Preferred Stock were issued, which carried a <ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" unitRef="pure" id="ixv-15448">5</ix:nonFraction>% cumulative dividend and liquidation preference over common stock. Dividends were computed
at <ix:nonFraction contextRef="c208" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" unitRef="pure" id="ixv-15449">5</ix:nonFraction>% of the principal annually and recorded monthly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
February 9, 2024, all outstanding Series A Preferred Stock was converted into common stock on a one-for-two basis pursuant to the filing
of the Company&#8217;s third amended and restated certificate of incorporation. As of that date, the Company had <ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-15450">5,000,000</ix:nonFraction> shares of authorized
Preferred Stock, with <ix:nonFraction contextRef="c209" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-15451">none</ix:nonFraction> outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred Stock
dividend for the year ended December 31, 2025 was $<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStockCash" scale="0" unitRef="usd" id="ixv-15452">0</ix:nonFraction>, and for the year ended December 31, 2024 was $<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPreferredStockCash" scale="0" unitRef="usd" id="ixv-15453">31,250</ix:nonFraction>, resulting in a total accrued
dividend payable of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-15454">375,000</ix:nonFraction> as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Preferred Stock has the
following rights and privileges:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting&#160;</i>&#8212;&#160;Votes
together with the common stock on all matters on an as-converted basis. Approval of a&#160;majority of the New Preferred Stock voting
as a separate class will be required to, among other things: (i)&#160;adversely change rights of the New Preferred Stock, (ii)&#160;change
the authorized number of shares of New Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Conversion&#160;</i>&#8212;&#160;Each
share of New Preferred Stock is convertible into one share of common stock (subject to proportional adjustments for stock splits, stock
dividends and the like) at any time at the option of the holder. Conversion ratio will be subject to adjustment on a broad-based, weighted
average basis in the event of subsequent issuances at a price less than the original issue price (as adjusted) subject to customary exceptions.
The conversion into common stock occurred on February 9, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Liquidation&#160;</i>&#8212;&#160;One
times the original issue price of the New Preferred Stock plus declared but unpaid dividends on each share of New Preferred Stock (or,
if greater, the amount that the New Preferred Stock would receive on an as-converted basis) will be paid first on each share of New Preferred
Stock, and the balance of proceeds to be paid to common stock. A merger, reorganization, or similar transaction (including a sale, exclusive
license or other disposition of all or substantially all of the assets of the Company or its subsidiaries) will be treated as a liquidation,
thereby triggering payment of the liquidation preference described above. For the avoidance of doubt, the liquidation preference is intended
to provide the Investor (and its permitted assigns) with an aggregate liquidation payment of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="0" unitRef="usd" id="ixv-15455">2,500,000</ix:nonFraction>.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7&#160;&#8212;&#160;EQUITY </b>(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-11023"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the common stock options issued to employees and consultants for services during the year ended December 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Intrinsic Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-15456">2,866,750</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15457">1.86</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-11088">4<span style="font-family: Times New Roman, Times, Serif">.92</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-15458">3,904,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15459">1.80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="ixv-11124"><span style="font-family: Times New Roman, Times, Serif">5.00</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-15460">6,771,250</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15461">1.83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-11229"><span style="font-family: Times New Roman, Times, Serif">4.43</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-15462">2,866,750</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15463">1.86</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-15464">3.92</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-11273"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the options
granted during the year ended December 31, 2025 was estimated at the date of grant using the Black-Scholes option-pricing model with the
following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Volatility (based on peer companies)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-15465">112</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk Free Interest Rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-15466">3.55</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividends</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-size: 10pt">None</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Estimated Life in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-15467">2.88</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December 31, 2025 and 2024, the Company recognized
combined share-based compensation expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-15468">4,265,374</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-15469">268,300</ix:nonFraction>, respectively, related to these common stock options. At the Company&#8217;s
annual meeting on October 21, 2025, stockholders approved an amendment to the Company&#8217;s 2023 Incentive Compensation Plan, increasing
the shares of common stock authorized for issuance thereunder from <ix:nonFraction contextRef="c212" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" scale="6" unitRef="shares" id="ixv-15470">4</ix:nonFraction> million to <ix:nonFraction contextRef="c213" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" scale="6" unitRef="shares" id="ixv-15471">10</ix:nonFraction> million.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PreferredStockTextBlock-c0_cont_1" escape="true" name="us-gaap:PreferredStockTextBlock" id="ixv-11331"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8&#160;&#8212;&#160;REDEEMABLE PREFERRED
STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Securities Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, the
Company entered into the Purchase Agreement with various institutional and accredited investors. The Company completed the initial closing
on December 31, 2024 and sold an aggregate of <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" scale="0" unitRef="shares" id="ixv-15472">1,512,500</ix:nonFraction> immediately separable units (the &#8220;Units&#8221;), each Unit consisting of
(i) one share of the Company&#8217;s Series A Preferred Stock, and (ii) a Warrant to purchase <ix:nonFraction contextRef="c214" decimals="0" format="ixt-sec:numwordsen" name="osti:PurchaseOfCommonStock" scale="0" unitRef="usd" id="ixv-15473">one</ix:nonFraction> share of common stock, at a price per
Unit of $<ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-15474">4.00</ix:nonFraction>. The Warrant has an exercise price of $<ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15475">4.40</ix:nonFraction> per share, subject to adjustment therein, and a term of five years from the
date stockholder approval of the common stock issuances contemplated by the Purchase Agreement is obtained. The gross proceeds from the
initial closing to the Company, before deducting transaction fees and other estimated expenses, was $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-15476">6,050,000</ix:nonFraction>. On January 14, 2025 the
Company sold and issued an additional <ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="osti:StockIssuedDuringPeriodSharesAdditionalUnits" scale="0" unitRef="shares" id="ixv-15477">263,250</ix:nonFraction> Units. The gross proceeds from the second closing to the Company, before deducting transaction
fees and other estimated expenses, was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="0" unitRef="usd" id="ixv-15478">1,053,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based
on the terms of the Series A Preferred Stock and the Company&#8217;s Certificate of Designation, and in accordance with ASC 480, the Series
A Preferred Stock is accounted for as mezzanine equity due to the redemption feature upon a deemed liquidation event: (i) a merger or
consolidation, or (ii) the sale, lease, transfer or other disposition of substantially all the assets of the Company. $<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15479">1,971,975</ix:nonFraction> of the
initial cash proceeds of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" unitRef="usd" id="ixv-15480">6,050,000</ix:nonFraction> were allocated to the Warrants and $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-15481">4,078,025</ix:nonFraction> of the residual proceeds were allocated to the Series
A Preferred Stock. $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-15482">330,781</ix:nonFraction> of the additional cash proceeds of $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="0" unitRef="usd" id="ixv-15483">1,053,000</ix:nonFraction> were allocated to the Warrants and $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd" id="ixv-15484">722,219</ix:nonFraction> of the residual
proceeds were allocated to the Series A Preferred Stock from the January 14, 2025 settlement, with all the same terms as the first settlement
above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">From
April 9, 2025 through December 31, 2025, Mezzanine Equity converted into <ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15485">4,939,808</ix:nonFraction> shares of common stock. Of the original <ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="osti:OriginalShares" scale="0" unitRef="shares" id="ixv-15486">1,775,750</ix:nonFraction> shares
of Series A Preferred Stock, <ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15487">273,750</ix:nonFraction> and <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-15488">1,383,250</ix:nonFraction> shares were converted during the three- and nine-month periods ended December 31, 2025,
respectively. As of December 31, 2025, <ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15489">392,500</ix:nonFraction> shares of Series A Preferred Stock remain outstanding, convertible into <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-15490">1,401,786</ix:nonFraction> shares
of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based
on the terms of the Warrants and in accordance with ASC 815, the Warrants are accounted for as a liability due to the variable exercise
price subject to adjustment. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and
market reflective Level 1 and Level 2 inputs, the Company valued the Warrant liability using Level 3 inputs, which require significant
judgment and estimates on behalf of management in developing model assumptions. The Company determined the value of the Warrant liability
using a Binomial Simulation, which takes into consideration the fair market value of the Company&#8217;s stock, the variable nature of
the exercise price, the estimated exercise period, the volatility of its common stock, and the risk-free interest rate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The following assumptions
were made as of December 31, 2024 in the model: (1) a variable exercise price with a floor of $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15491">4.40</ix:nonFraction> per share, (2) current common stock
price of $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15492">4.28</ix:nonFraction> per share December 31, 2024, (3) discount rate of <ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15493">4.38</ix:nonFraction>%, and (4) expected stock price volatility of <ix:nonFraction contextRef="c223" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15494">24.90</ix:nonFraction>%. As of December
31, 2024, the carrying value of the Warrant liability in aggregate was $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15495">1,971,975</ix:nonFraction> on December 31, 2024. The following assumptions were
made as of January 14, 2025 in the model: (1) a variable exercise price with a floor of $<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-15496">4.40</ix:nonFraction> per share, (2) current common stock price
of $<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-15497">4.16</ix:nonFraction> per share on January 14, 2025, (3) discount rate of <ix:nonFraction contextRef="c215" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" unitRef="pure" id="ixv-15498">4.59</ix:nonFraction>%, and (4) expected stock price volatility of <ix:nonFraction contextRef="c225" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15499">25.77</ix:nonFraction>%. As of January 14,
the carrying value of the <ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="0" unitRef="usd" id="ixv-15500">263,250</ix:nonFraction> issued warrants was $<ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-15501">330,781</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8&#160;&#8212;&#160;PREFERRED STOCK AND WARRANT LIABILITY </b>(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_PreferredStockTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following assumptions
were made as of April 9, 2025 based on stockholder approval in the model for the aggregate warrants: (1) a fixed exercise price of $<ix:nonFraction contextRef="c227" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15502">1.12</ix:nonFraction>
per share, which automatically reset and resulted in a reclassification of the warrant liability on April 9, 2025 to equity per ASC 815;
(2) then-current common stock price of $<ix:nonFraction contextRef="c228" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15503">1.34</ix:nonFraction> per share on April 9, 2025; (3) discount rate of <ix:nonFraction contextRef="c229" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15504">4.06</ix:nonFraction>%; and (4) expected stock price volatility
of <ix:nonFraction contextRef="c230" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-15505">23.26</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the
carrying value of the Warrant liability in aggregate was <span style="-sec-ix-hidden: hidden-fact-127">$0</span>. For the year ended December 31, 2025, the Company recorded a gain on the
change in fair value of the Warrant Liability in the amount of $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15506">1,424,603</ix:nonFraction> and a $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-15507">878,153</ix:nonFraction> deduction due to reclassification to equity.
As of December 31, 2025 and December 31, 2024, the carrying value of the Warrant liability in aggregate was <span style="-sec-ix-hidden: hidden-fact-128">$0</span> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15508">1,971,975</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred Stock
and Warrants were issued in a basket transaction. When two or more instruments are issued in a basket transaction and some instruments
will be remeasured at fair value, the proceeds are first allocated to the instruments recorded at their fair value. Next, the residual
method is used to allocate the proceeds to the instrument(s) that are not remeasured at fair value. In this case, the Warrant is subsequently
measured at fair value, and the Series A Preferred Stock instrument is measured at initial carrying value. The Company will first allocate
the proceeds to the Warrant liability, with the residual allocated to the Series A Preferred Stock liability. <ix:nonNumeric contextRef="c0" continuedAt="_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" id="ixv-15509">The following tables reflect
the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period
from December 31, 2024 to December 31, 2025.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash proceeds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" unitRef="usd" id="ixv-15510">7,103,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fair value of Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15511">2,302,756</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Residual value allocated to Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="osti:ResidualValueAllocatedToSeriesAPreferredStock" scale="0" sign="-" unitRef="usd" id="ixv-15512">4,800,244</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Unallocated cash proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-11423"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the&#160;<br/> year ended<br/>
    December&#160;31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Warrant Liability as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15513">1,971,975</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Additional Warrant Liability on January 14, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-15514">330,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on the change in fair value of Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15515">1,122,561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitRef="usd" id="ixv-15516">1,180,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on the change in fair value of Warrant Liability as of April 9, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15517">302,042</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stockholder approval on April 9, 2025 - warrants turn into Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" scale="0" sign="-" unitRef="usd" id="ixv-15518">878,153</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrant Liability as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-11499"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8212; SEGMENT AND GEOGRAPHIC INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates as&#160;<ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="Segment" id="ixv-15519"><ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="Segment" id="ixv-15520">one</ix:nonFraction></ix:nonFraction>&#160;operating
segment. <ix:nonNumeric contextRef="c0" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" id="ixv-11504">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its <span style="-sec-ix-hidden: hidden-fact-133">Chief Executive Officer</span>, who reviews financial
information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance
and allocate resources.</ix:nonNumeric> These financial metrics are used by the CODM to make key operating decisions, such as the determination of the
rate at which the Company seeks to grow global operating margin and the allocation of budget between cost of revenues, sales and marketing,
technology and development, and general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="ixv-11507"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
selected financial information with respect to the Company&#8217;s single operating segment for the years ended December&#160;31, 2025
and 2023:</p>

<p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15521">16,360,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-15522">2,839,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General&#160;and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-15523">12,344,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-15524">3,974,786</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15525">28,705,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15526">6,813,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" unitRef="usd" id="ixv-15527">249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-15528">2,051,839</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Non-operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="0" unitRef="usd" id="ixv-15529">33,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-15530">1,472,995</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-15531">51,250</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-15532">1,424,603</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-15533">48,143</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-15534">2,069,092</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15535">28,753,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-15536">8,882,938</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "><b>&#160;</b>&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-11674"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 10&#160;&#8212;&#160;SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Third Warrant Exercise
Inducement and Exchange Offering&#160;</i>&#8212;&#160;On January 14, 2026, the Company closed on a third warrant exercise inducement
and exchange offer (the &#8220;Third Inducement Offering&#8221;). The Third Inducement Offering was made to less than 10 accredited investors
that held certain existing warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-15537">5,382,148</ix:nonFraction> shares of the Company&#8217;s common stock having a then
current exercise price of $<ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15538">3.00</ix:nonFraction> or $<ix:nonFraction contextRef="c242" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-15539">2.10</ix:nonFraction> per share. Pursuant to certain inducement offer letter agreements, such holders exercised for
cash their warrants to purchase <ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-15540">2,499,558</ix:nonFraction> shares of the Company&#8217;s common stock at a reduced exercise price of $<ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15541">1.40</ix:nonFraction> per share and
in exchange the Company issued to such holders new warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares" id="ixv-15542">2,499,558</ix:nonFraction> shares of common stock at an exercise
price of $<ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15543">1.40</ix:nonFraction> per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of <ix:nonNumeric contextRef="c240" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15544">five years</ix:nonNumeric> from such date. The gross proceeds to the Company from the Third Inducement Offering, before
deducting transaction fees and other offering expenses, were approximately $<ix:nonFraction contextRef="c240" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherOwnershipInterestsOfferingCosts" scale="6" unitRef="usd" id="ixv-15545">3.5</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file
a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if not then eligible to register securities on
Form S-3) providing for the resale of the shares of common stock issued or issuable upon exercise of the new warrants issued within 30
calendar days of March 2, 2026, and to use commercially reasonable efforts to have such registration statement declared effective by the
SEC within 60 calendar days (or within 90 calendar days in case of &#8220;full review&#8221; by the SEC) following its initial filing
and to keep such registration statement effective at all times until the earlier of (i) the time no holder owns any new warrants or shares
of common stock issuable upon exercise thereof and (ii) the Delegend Date (as defined in the inducement offer letter agreements entered
into in connection with the Third Inducement Offering).</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OS Therapies Incorporated<br/>
Notes to the Consolidated Financial Statements<br/>
For the Years Ended December 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b>NOTE
10&#160;&#8212;&#160;SUBSEQUENT EVENTS  </b>(cont.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b>&#160;</b></p><div>


</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Privately Negotiated
Warrant Exercise Inducement and Exchange Agreements &#8211; </i>From January 10, 2026 through February 2026, the Company entered
into privately negotiated inducement offer letters, pursuant to which certain remaining holders of existing warrants exercised for
cash their warrants to purchase an aggregate of <ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-15546">74,108</ix:nonFraction> shares of common stock at a reduced exercise price of $<ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15547">1.40</ix:nonFraction> per share and in
exchange the Company issued new warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-15548">74,108</ix:nonFraction> shares of common stock at an exercise price of
$<ix:nonFraction contextRef="c246" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15549">1.40</ix:nonFraction> per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of <ix:nonNumeric contextRef="c245" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15550">five years</ix:nonNumeric> from such date. The Company received gross proceeds of approximately $<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15551">103,750</ix:nonFraction> from the
exercise of these warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file a registration statement on Form S-3
(or other appropriate form, including on Form S-1, if not then eligible to register securities on Form S-3) providing for the resale of
the shares of common stock issued or issuable upon exercise of these warrants on or before March 30, 2026, and to use commercially reasonable
efforts to have such registration statement declared effective by the SEC within 60 calendar days (or within 90 calendar days in case
of &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time no holder of these warrants owns any such warrants or shares of common stock issuable upon exercise thereof
and (ii) the Delegend Date (as defined in the privately negotiated inducement offer letters).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bridge Financing &#8211;
</i>On March 4, 2026, pursuant to a securities purchase agreement (the &#8220;Bridge SPA&#8221;), the Company issued to certain accredited
investors in a private placement transaction (i) <ix:nonFraction contextRef="c247" decimals="3" format="ixt:num-dot-decimal" name="osti:OriginalIssueDiscount" scale="-2" unitRef="pure" id="ixv-15552">10.0</ix:nonFraction>% original issue discount unsecured convertible promissory notes in an aggregate
principal amount of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-15553">2,200,000</ix:nonFraction> (the &#8220;Bridge Notes&#8221;) and (ii) warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-15554">1,666,667</ix:nonFraction> shares of
common stock (the &#8220;Bridge Warrants&#8221; and such private placement transaction, the &#8220;Bridge Financing&#8221;), for aggregate
gross proceeds of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-15555">2,000,000</ix:nonFraction>, before deducting placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March
4, 2027 and accrue interest at a rate of <ix:nonFraction contextRef="c247" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-15556">4.0</ix:nonFraction>% per annum. The Bridge Warrants were immediately exercisable upon issuance, expire <ix:nonNumeric contextRef="c248" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-15557">five years</ix:nonNumeric>
from the date of issuance and have an exercise price of $<ix:nonFraction contextRef="c249" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares" id="ixv-15558">1.40</ix:nonFraction> per share, subject to adjustment as provided therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes were sold
at a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="osti:OriginalIssueDiscount" scale="-2" unitRef="pure" id="ixv-15559">10</ix:nonFraction>% original issue discount, such that for each $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="osti:InvestedPurchaser" scale="0" unitRef="usd" id="ixv-15560">100,000</ix:nonFraction> invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-15561">110,000</ix:nonFraction>. The Bridge Notes are convertible into shares of common stock under certain circumstances. If the Company completes
a &#8220;Qualified Offering,&#8221; defined as a registered public offering or registered direct offering resulting in at least $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="osti:GrossProceeds" scale="6" unitRef="usd" id="ixv-15562">2.5</ix:nonFraction> million
in gross proceeds from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically
convert into the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment
of the Bridge Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of common stock at a conversion price
equal to <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="osti:ConversionPricePercentage" scale="-2" unitRef="pure" id="ixv-15563">90</ix:nonFraction>% of the average daily volume-weighted average price of the Company&#8217;s common stock during the 10 trading days immediately
preceding the holder&#8217;s conversion notice, subject to adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file
a registration statement on Form S-3 (or Form S-1 if not then eligible to register securities for Form S-3) by April 3, 2026 to register
for resale the shares of common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulatory
Meetings &#8211; </i>During early 2026, the Company continued its regulatory engagement with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
related to its Biologics License Application (&#8220;BLA&#8221;) for OST-HER2. As outlined in recent press releases, this included planned
interactions with the FDA, including a Type D meeting that was elevated to a Type B pre-BLA meeting. These activities are consistent
with the Company&#8217;s ongoing regulatory efforts. The Company does not believe these interactions currently have a measurable impact
on its consolidated financial statements; however, the outcome of these discussions may affect future development timelines and regulatory
strategy.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="J_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9. Changes In and Disagreements with Accountants on Accounting
and Financial Disclosure.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9A. Controls and Procedures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are controls and other procedures that are designed to ensure that
information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the
Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial
officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls
and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be
detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur
because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion
of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance
that the above objectives have been met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we
carried out an evaluation, with the participation of our management, including our principal executive officer and our principal financial
officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act). Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our
disclosure controls and procedures were not effective at the reasonable assurance level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Management&#8217;s Report on Internal Control
Over Financial Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13(a)-15(f) and 15(d)-15(f) under
the Exchange Act. Management assessed our internal control over financial reporting as of December&#160;31, 2024, based on criteria established
in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).
Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting
controls, process documentation, accounting policies, and our overall control environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on such assessment, management has concluded that our internal
control over financial reporting was not effective as of the year ended December 31, 2025 to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance
with U.S. GAAP. We reviewed the results of management&#8217;s assessment with the audit committee of our board of directors. We determined
that we have inadequate segregation of duties as a result of limited personnel and insufficient written policies and procedures for accounting,
information technology and financial reporting (no control procedures in place) and insufficient number of personnel with appropriate
levels of accounting knowledge and experience in U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our auditors will not be required
to formally opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer
an &#8220;emerging growth company&#8221; as defined in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no changes
in our internal control over financial reporting during the three months ended December&#160;31, 2025 that have materially affected, or
are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9B. Other Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-15564"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-15565"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-15566"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-15567">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="J_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="J_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. Directors, Executive Officers and
Corporate Governance.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Information About Our Executive Officers, Key
Employees and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the name, age and position of each of our executive officers, key employees and directors as of March 26, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 35%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 53%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt"><b><i>Executive Officers and Key Employees:</i></b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Paul A.&#160;Romness, MPH</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Founder, Chairman, President and Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Robert G.&#160;Petit, Ph.D.</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">66</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Medical Officer and Chief Scientific Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Christopher P.&#160;Acevedo</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">63</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Gerald Commissiong</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Business Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><b><i>Non-Executive Directors:</i></b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">John Ciccio</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">45</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Avril McKean Dieser</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Karim Galzahr</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Olivier R.&#160;Jarry</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">64</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">Theodore F.&#160;Search, Pharm.D.</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">44</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Paul A.&#160;Romness,
MPH</i></b> has served as our President, Chief Executive Officer and a member of our board of directors since he founded our company in
April&#160;2018. He has served as Chairman of our board of directors since October&#160;2024. Through his research, Mr.&#160;Romness has
grown OS Therapies into a clinical research and development biotechnology company with two platform technologies, including the initial
OST-HER2&#160;<i>Listeria monocytogenes</i>, as well as OST-tADC, a next generation tunable drug conjugate delivery system. Prior to founding
our company, Mr.&#160;Romness served as a Principal for PR Strategies from 2014 to March&#160;2018. Prior to PR Strategies, Mr.&#160;Romness
served as the Vice President of Government Affairs and Public Policy at Boehringer Ingelheim from 2008 to 2014, and the Director of State
Government Affairs at Amgen Inc. from March&#160;2005 to March&#160;2008. Earlier in his career, Mr.&#160;Romness served in several roles
at Johnson&#160;&amp; Johnson from March&#160;1990 to March&#160;2003. Mr.&#160;Romness holds a Masters of Public Health from the Milken
Institute School of Public Health of George Washington University and a B.S. degree in Finance from American University. As our founder,
Chairman, President and Chief Executive Officer, Mr.&#160;Romness leads our company. His more than 25&#160;years of experience in the
biopharmaceutical industry,&#160;day-to-day&#160;operational leadership of our company and in-depth&#160;knowledge of our product candidates
and platform technologies make him well qualified as a member of our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Robert G.&#160;Petit,
Ph.D.</i></b> has served as our Chief Medical Officer and Chief Scientific Officer since September&#160;2019. Dr.&#160;Petit has also
served as Principal for RGP Biotech, LLC, where he advises clients on non-clinical and clinical development programs, since June&#160;2019,
and Senior Vice President, Head of Early Clinical Development for Orionis Biosciences Inc., an early stage drug discovery and development
biotech company, since March&#160;2022. Dr.&#160;Petit currently serves as the Chairman of the Scientific Advisory Board of Advaxis, Inc.
(now Ayala Pharmaceuticals, Inc.), where he previously served as the Chief Scientific Officer and Executive Vice President from March&#160;2013
to June&#160;2019. He is also a member of the scientific advisory boards of Systems Oncology, LLC, a cancer therapy discovery and development
company, and Saros Therapeutics, an early-stage biotech company committed to re-engineering innate immune activation to improve cancer
immunotherapy. From June&#160;2019 to December&#160;2019, Dr.&#160;Petit served as the Chief Scientific Officer of Carisma Therapeutics,
Inc., a biotechnology company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors. Prior to joining
Advaxis as Chief Scientific Officer, Dr.&#160;Petit served in various roles for Bristol-Myers Squibb, including U.S.&#160;Medical Strategy
Lead, Director of Medical Strategy for New Oncology Products and Director of Global Clinical Research, from 2005 to 2010. Prior to joining
Bristol-Myers Squibb, Dr.&#160;Petit served as Vice President of Clinical Development at MGI Pharma Inc. and Aesgen Inc. Dr.&#160;Petit
is an accomplished biopharmaceutical executive and medical scientist who has been instrumental in securing FDA approvals for six new drug
applications and biologic license applications for oncology and immunotherapy product candidates and is named in more than 100 patents.
His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr.&#160;Petit
has provided expert guidance and counsel to a multitude of emerging biotech companies in the fields of immunology and oncology as a member
of their respective scientific advisory boards. He earned his Ph.D. from the Ohio State University College of Medicine and B.S. degree
from Indiana State University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Christopher P.&#160;Acevedo</i></b>
has served as our Chief Financial Officer on a part-time basis since July&#160;2023. Pursuant to his employment letter with us, he has
agreed to spend 12&#160;hours a month, on average, performing services in such position. Mr.&#160;Acevedo also owns and operates a certified
public accounting firm with offices in Delaware and Maryland, serving a wide range of small to medium businesses, mainly in the service
sector, since 2010. He holds CPA certificates in the states of Delaware, Maryland and Pennsylvania. Mr.&#160;Acevedo graduated from the
University of Delaware with an M.B.A. in Business Administration and a B.S. degree in Accounting, minoring in Finance. Mr.&#160;Acevedo
demonstrates extensive knowledge of complex financial, accounting and operational issues highly relevant to our growing biotechnology
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Key Employees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Gerald Commissiong</i></b>
has served as our Chief Business Officer since April&#160;2024. He also currently acts as a Managing Partner at Fortitude Advisors LLC,
an executive advisory firm, since July&#160;2018 and currently serves as the President and CEO of Tollo Health. For more than 15&#160;years,
Mr.&#160;Commissiong has been a senior executive officer of publicly held, emerging growth healthcare companies. He served as the Chief
Executive Officer and director of Todos Medical Ltd., an in vitro diagnostics company focused on the development of novel blood tests
for the early detection of cancer and neurodegenerative disorders, from January&#160;2020 to July&#160;2023. Prior to that position, Mr.&#160;Commissiong
was the co-founder and served as Chief Executive Officer, President and a member of the Board of Directors of Amarantus BioScience Holdings,
Inc., a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and
orphan diseases, from 2008 to December&#160;2021. Mr.&#160;Commissiong has helped secured $90&#160;million in investment capital throughout
his career. Mr.&#160;Commissiong graduated from Stanford University receiving a B.S. degree in Management Science and Engineering with
a focus on financial decisions. Mr.&#160;Commissiong played professional football in the Canadian Football League for the Calgary Stampeders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Executive Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>John Ciccio</i></b>
has served as a member of our Board since December&#160;2020. Mr.&#160;Ciccio has served as the Chief Operating Officer&#160;&#8212;&#160;Technology&#160;&amp;
Data Solutions of Syneos Health, Inc. (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization built to accelerate
customer success, since July&#160;2022. Prior to joining Syneos Health, Mr.&#160;Ciccio served as the President and Chief Executive Officer
of Adheris Health from 2019 to July&#160;2022 and the President and a member of the board of managers of Skipta LLC from 2014 to 2018,
where he played a critical role in Skipta&#8217;s sale to Informa PLLC.&#160;Mr.&#160;Ciccio has also served as a member of the board
of directors of Full Code Medical Simulation since March&#160;2022. In 2018, Mr.&#160;Ciccio was awarded the PharmaVOICE 100 &#8212;&#160;Commanders&#160;&amp;
Chiefs and the PM360 ELITE 100 as a Transformational Leader. Mr.&#160;Ciccio holds a B.A. degree in Government from Harvard University.
Mr.&#160;Ciccio is well qualified to serve as a director of our company due to his substantial knowledge and&#160;years of working experience
in the biotechnology and pharmaceutical industry and with growth-stage&#160;companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Avril McKean Dieser</i></b>
joined our board of directors on October&#160;28, 2024. She is currently the Vice President, Head of Legal Patient Evidence of UCB, Inc.,
a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions
to transform the lives of people living with severe diseases of the immune system or the central nervous system, since August&#160;2016,
and previously from April&#160;2008 to April&#160;2013. At UCB, she leads a team of attorneys supporting UCB&#8217;s global assets, global
payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member
of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing
lawyer for all pharmaceutical and combination products from May&#160;2013 to July&#160;2016. Prior to joining the pharmaceutical industry,
Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from
The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving
her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A.
degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January&#160;2024 at
the age of 21. Ms. McKean Dieser is well qualified to serve as a director of our company due to her substantial knowledge of the pharmaceutical
regulatory and commercialization environment and more than 21&#160;years of working experience in corporate controls and governance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Karim Galzahr</i></b>
joined our board of directors on January&#160;28, 2025 in accordance with the terms of the Purchase Agreement. He is currently a managing
partner at OKG Capital, an early stage medtech and life science investor, which he founded in 2022, and the Chief Executive Officer of
OKG Services SA, a life science and medtech management company. Mr.&#160;Galzahr has served on the board of directors of various privately
held companies in the medical diagnostics, medtech, life science, and healthcare technology sectors since 2022. Notably, he has served
as a director of NeoTX Holdings, Inc., a privately held clinical stage immune oncology drug discovery company developing innovative therapies
for the treatment of solid cold tumors, since November&#160;2024, 52 North Health Ltd., a privately held company focused on remote monitoring
and home diagnostics solutions for acute oncology and other serious diseases including neutropenic sepsis, since October&#160;2024, iQure
Pharma Inc., a privately held global biotech company focused on the development of new therapeutics for neurodegenerative diseases, since
March&#160;2023, and Deeplook Medical, Inc., a privately held breast cancer detection and diagnostic imaging software provider, since
January&#160;2023. Mr.&#160;Galzahr also serves as an Investment Manager of Edo Investments Limited, a privately held public and private
investment management company, and Investment Advisor of MJ Assets Limited, a private wealth investor focusing on disruptive technologies
that have significant positive social impact, positions he has held since 2021. Mr.&#160;Galzahr received a B.A. degree in Philosophy,
Politics and Economics from the University of Oxford. Mr.&#160;Galzahr brings over 30&#160;years of experience in all aspects of finance
including M&amp;A, asset management, corporate development and strategic advisory work across the technology sector and medical technology
sectors, making him highly qualified to be a director of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Olivier R.&#160;Jarry</i></b>
joined our board of directors on October&#160;28, 2024. He is currently the Co-founder&#160;and Chief Executive Officer of Libera Bio
S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therapeutics to address intracellular
cancer targets, since April&#160;2018. He also serves as the Chief Operating Officer of Advantage Therapeutics Inc., an investigational-stage&#160;company
focused on the diseases of aging, since May&#160;2023 and as Chief Financial Officer of Rational Vaccines, Inc., an investigational-stage&#160;infectious
disease company focused on combating herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections, since August&#160;2021.
Mr.&#160;Jarry served as an advisor to DarioHealth Corp. (Nasdaq: DRIO) from November&#160;2016 to September&#160;2017, and then as its
President and Chief Commercial Officer until January&#160;2020. Between 2015 and 2016, he served as Senior Vice President of the Consumer
Sector and Officer at Intrexon Corp. (NYSE:&#160;XON), a biotechnology company focused on engineering biological systems to enable DNA-based&#160;control
over the function and output of living cells. Prior to Intrexon, from 2011 to 2012, Mr.&#160;Jarry served as the Head of Strategy, Operations
and Market Access, focusing on Emerging Markets, for Bristol-Myers&#160;Squibb (NYSE:&#160;BMY), where he oversaw the product launch and
growth of innovative medicines relating to oncology, virology, rheumatology, cardiovascular and diabetes. Prior to that, between 2009
and 2010, Mr.&#160;Jarry served as the Global Business Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare Pharmaceuticals
LLC.&#160;Prior to his time at Bayer HealthCare, from 2001 to 2009, Mr.&#160;Jarry served in several leadership roles at Novartis International
AG (NYSE:&#160;NVS), including working as Global Division Head of Strategy, Business Development&#160;&amp; Licensing at Novartis Headquarters
in Switzerland, Senior Vice President and Region Head for Latin America and for Asia-Pacific&#160;for Novartis&#8217; Consumer Health
Division, Head of India Rural Business and Head of Western/Eastern Europe, Russia, CIS&#160;&#8212;&#160;Vaccines division. Mr.&#160;Jarry
holds a M.Sc. degree from Ecole Centrale de Paris, a MEng. degree from D&#233;l&#233;gation G&#233;n&#233;rale pour l&#8217;Armement,
and a Trium Executive MBA degree jointly awarded by NYU Stern School of Business, London School of Economics and Political Science and
Hautes &#201;tudes Commerciales Paris. Mr.&#160;Jarry&#8217;s more than 40&#160;years of building fast-growing&#160;companies in neuroimmunology,
oncology, cell&#160;&amp; gene therapy, synthetic biology and digital therapeutics makes him well qualified as a member of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Theodore F.&#160;Search,
Pharm.D.</i></b> has served as a member of our Board since December&#160;2020. Dr.&#160;Search is the Founder of Skipta, an Informa Pharma
Intelligence Company, and served as the Chief Executive Officer and Chairman of Skipta from 2009 to 2017, when Skipta was sold to Informa
Health. Since the completion of the sale in 2017, Dr.&#160;Search has served as the Chief Executive Officer&#160;&#8212;&#160;RWD Intelligence
of Norstella, a provider of pharmaceutical consultancy services and solutions. Dr.&#160;Search has been invited to speak at various conferences
around the globe and was named among the Top 100 Most Inspiring People in the Life Sciences Industry in 2015 and among the Top 100 Elite
Entrepreneurs in the pharmaceutical and healthcare industry in 2016. Dr.&#160;Search holds a Doctor of Pharmacy degree from the University
of Pittsburgh and is a board licensed Pharmacist in the Commonwealth of Pennsylvania. Dr.&#160;Search provides decades of experience in
leading and managing technology and product development operations in the pharmaceutical industry and with early-stage&#160;companies,
making him well qualified to be a member of our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">John Ciccio (chair), Olivier
R. Jarry and Theodore F.&#160;Search, Pharm.D. serve on our Audit Committee. Our board has determined that each member of the Audit Committee
is &#8220;independent&#8221; for Audit Committee purposes as that term is defined by the rules of the SEC and NYSE American, and that
each has sufficient knowledge in financial and auditing matters to serve on the Audit Committee. Our board of directors has designated
Mr.&#160;Ciccio as an &#8220;Audit Committee financial expert,&#8221; as defined under the applicable rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee&#8217;s
responsibilities include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">appointing, approving the compensation
of, and assessing the independence of our independent registered public accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">pre-approving auditing and permissible
non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing the overall audit
plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing and discussing with
management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures
as well as critical accounting policies and practices used by us;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">coordinating the oversight and
reviewing the adequacy of our internal control over financial reporting;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Value: 107; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">establishing policies and procedures
for the receipt and retention of accounting-related complaints and concerns;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recommending, based upon the
Audit Committee&#8217;s review and discussions with management and our independent registered public accounting firm, whether our audited
financial statements will be included in our annual report on Form&#160;10-K;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">monitoring the integrity of
our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting
matters;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">preparing the Audit Committee
report required by SEC rules to be included in our annual proxy statement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing all related person
transactions for potential conflict of interest situations and approving all such transactions; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reviewing quarterly earnings
releases.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive
officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions. A current
copy of this code is posted on the Governance section of our website, which is located at <i>www.ostherapies.com</i>. The information
on our website is deemed not to be incorporated in this annual report or to be a part of this annual report. If we make any substantive
amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature
of such amendment or waiver on our website or in a current report on Form&#160;8-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Insider Trading Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-15568">not
adopted</ix:nonNumeric>&#160;a formal insider trading policy governing the purchase, sale and/or other disposition of our securities by the Company, our
directors, officers, employees and consultants that is reasonably designed to promote compliance with insider trading laws, rules and
regulations, and any applicable NYSE American listing standards. While we do not currently have a written insider trading policy, it is
our policy to comply, and to seek to enforce compliance by our directors, officers, employees and consultants, with insider trading laws,
rules and regulations, and any applicable NYSE American listing standards, when engaging in transactions in the Company&#8217;s securities.
Our board of directors intends to adopt an insider trading policy during 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Delinquent Section 16(a) Reports</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the Exchange
Act requires our executive officers, directors and persons who own more than 10% of a registered class of our equity securities to file
with the SEC statements on Form 3, Form 4 and Form 5 of ownership and changes in ownership. Officers, directors and greater than 10% stockholders
are required by regulation to furnish us with copies of all Section 16(a) reports that they file.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based solely upon a review
of Forms 3, 4 and 5 and any amendments to those forms that have been furnished to us, we believe that all parties subject to the reporting
requirements of Section 16(a) filed all such required reports during and with respect to the fiscal year ended December 31, 2024, except
that each of Paul&#160;A.&#160;Romness, Christopher P.&#160;Acevedo, Robert G. Petit, John Ciccio, Karim Galzahr, Olivier Jarry, Avril
McKean Dieser and Theodore&#160;F.&#160;Search filed late a Form 4 with respect to stock option award grants that occurred on October
21, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="J_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. Executive Compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>As an &#8220;emerging growth
company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected
to comply with the scaled disclosure requirements applicable to emerging growth companies.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation provided
to our named executive officers for the&#160;years ended December&#160;31, 2025 and 2024 is detailed in the Summary Compensation Table
and accompanying footnotes and narrative that follow. Our named executive officers for the year ended December&#160;31, 2025 were:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Paul A.&#160;Romness, MPH, our
President and Chief Executive Officer;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Robert G.&#160;Petit, Ph.D.,
our Chief Medical&#160;Officer and Chief Scientific Officer; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Christopher Acevedo, our Chief
Financial Officer.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive compensation program is designed to attract, retain and motivate high-quality executive leadership by providing compensation
that is competitive and appropriately aligned with our stage of development and long-term strategic objectives. We operate in a highly
competitive and capital-intensive industry where the ability to recruit and retain experienced leadership is critical to advancing our
pipeline and delivering value to stockholders. Given our size, scale and market capitalization, our compensation approach reflects the
need to manage cash resources prudently while incentivizing performance and long-term value creation. Accordingly, we place significant
emphasis on equity-based compensation to align the interests of our executives with those of our stockholders and to promote a culture
of ownership. We seek to provide compensation opportunities that reward progress toward our scientific, regulatory and operational milestones,
while maintaining the flexibility to adapt our program as we grow and our needs evolve as a public company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
December 31, 2025, the compensation of our named executive officers consisted of annual base salaries, equity-based awards granted under
our 2023 Incentive Compensation Plan and, in certain instances, transaction-based cash bonuses approved by our board of directors. Our
named executive officers, like all full-time employees, are also eligible to participate in our health and welfare benefit plans. We
periodically review our executive compensation program, including our compensation philosophy and compensation arrangements, and adjust
them as we deem appropriate in light of our evolving business needs and market conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table shows
the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the&#160;years
ended December&#160;31, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and principal position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option <br/> awards <br/> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity <br/> incentive <br/> plan <br/> compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All other <br/> compensation <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left">Paul A.&#160;Romness, MPH</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">480,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">242,168</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,220,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,942,168</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">President&#160;and&#160;Chief&#160;Executive&#160;Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">480,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">984,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,664,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Robert G.&#160;Petit, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,030,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Chief Medical and Scientific Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">492,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">912,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Christopher Acevedo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-size: 10pt">The bonus for 2025 represents an incentive bonus approved by our board
of directors and awarded to Mr. Romness for completion of our warrant inducement exercise and exchange transactions. The bonus for 2024
represents an incentive bonus approved by our board of directors and awarded to Mr.&#160;Romness for the successful completion of our
equity line of credit transaction with Square Gate Capital Master Fund, LLC&#160;&#8212;&#160;Series&#160;3 in October&#160;2024 and the
PIPE Financing.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td style="text-align: justify"><span style="font-size: 10pt">The dollar amounts shown with
respect to each of the named executive officers for the fiscal&#160;years ended December&#160;31, 2025 and 2024 reflect the aggregate
grant date fair value of option awards granted in the fiscal year indicated, computed in accordance with ASC&#160;718. For a discussion
of the assumptions we made in valuing the option awards, see &#8220;Note&#160;2&#160;&#8212;&#160;Significant Accounting Policies&#160;&#8212;&#160;Stock-Based&#160;Compensation&#8221;
and &#8220;Note&#160;7 &#8212;&#160;Equity&#8221; in the notes to our consolidated financial statements contained elsewhere in this Annual
Report.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Narrative Disclosure to Summary Compensation
Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Annual Base Salaries.
</i></b>Our named executive officers each receive a base salary to compensate them for services rendered to our company. The base salary
payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill
set, experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review
process, approved by our board of directors, and may be adjusted from time to time to realign salaries with market levels after taking
into account individual responsibilities, performance and experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the&#160;years ended December&#160;31,
2025 and 2024, the annual base salary for each of Mr.&#160;Romness, Dr.&#160;Petit, and Mr. Acevedo was $480,000, $420,000 and $36,000,
respectively. Mr. Acevedo&#8217;s base salary reflects a part-time service arrangement during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity-Based
Compensation.</i></b> We grant equity-based awards to our named executive officers under our 2023 Incentive Compensation Plan to align
their interests with those of our stockholders and to incentivize long-term value creation. We rely significantly on equity compensation
to attract and retain highly qualified executives in a competitive market while preserving cash resources for research and development
activities. Equity awards are designed to reward achievement of key value-driving milestones, including clinical development progress,
regulatory advancement and operational execution, and to encourage a long-term focus on advancing our product candidates through the
development pipeline. The size and terms of equity awards are determined by our board of directors, taking into account factors such
as the executive&#8217;s role and responsibilities, individual performance, market practices and our stage of development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, Mr. Romness, Dr. Petit and Mr. Acevedo were granted options under our 2023 Incentive Compensation Plan
to purchase 1,000,000 shares, 500,000 shares and 200,000 shares of common stock, respectively, each with an exercise price of $1.80 per
share. During the year ended December 31, 2024, Mr. Romness, Dr. Petit and Mr. Acevedo were granted options to purchase 800,000 shares,
400,000 shares and 200,000 shares of common stock, respectively, each at an exercise price of $1.86 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment Agreements and Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Paul A.&#160;Romness Employment
Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February&#160;21, 2023,
Paul A.&#160;Romness, MPH entered into an employment agreement with us. Pursuant to the employment agreement, Mr.&#160;Romness has agreed to devote substantially all of his
time, attention and ability to our business as our Chief Executive Officer. The employment agreement provides that Mr.&#160;Romness will
receive a base salary during the first year of his employment at an annual rate of $360,000 for services rendered in such position. During
the second year of his employment under the employment agreement, Mr.&#160;Romness&#8217; annual base salary will be determined by our
board of directors but will not be less than $360,000. In addition, Mr.&#160;Romness may be entitled to receive, as determined by our
board of directors, a cash bonus in respect of each fiscal year. Mr.&#160;Romness is entitled to participate in our regular employee fringe
benefit programs, including our medical and hospitalization insurance and life insurance, as well as our 2023 Incentive Compensation Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment agreement provides
for termination by us upon (i)&#160;the death or disability of Mr.&#160;Romness (defined as a period of more than 60 consecutive&#160;days
or more than a total of 90&#160;days in the aggregate during any period of 12 consecutive&#160;months), (ii)&#160;his willful and material
malfeasance, dishonesty or substance abuse, (iii)&#160;his material and continuing breach, non-performance or non-observance of any of
the terms of his employment agreement (or confidentiality agreement and non-competition agreement referenced below), but only after notice
to him and his failure to timely cure any such default, or (iv)&#160;his conviction of a crime involving moral turpitude. In the event
the employment agreement is terminated by us for any other reason, Mr.&#160;Romness will be entitled to compensation for the balance of
the term. The employment agreement with Mr.&#160;Romness does not have any change of control provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Together with his employment
agreement, Mr.&#160;Romness entered into our standard form of confidentiality and non-competition agreement. This agreement contains covenants
restricting Mr.&#160;Romness from engaging in any activities competitive with our business during the term of his employment agreement
and one year thereafter and prohibiting him from disclosure of confidential information regarding our company at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Robert G.&#160;Petit Employment
Letter</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&#160;23, 2020, Robert
G.&#160;Petit, Ph.D. entered into an employment letter with us. Pursuant to the employment letter, Dr.&#160;Petit has agreed to devote
his business time, best efforts, skill, knowledge, attention and energies to the advancement of our business and interests and to the
performance of his duties and responsibilities, on a full-time, &#8220;at-will&#8221; basis, as our Chief Medical and Scientific Officer.
The employment letter provides that Dr.&#160;Petit will receive a base salary at a rate of $20,000 per monthly pay period for services
rendered in such position. In addition, Dr.&#160;Petit will be eligible to receive a performance bonus of up to 50% of the base salary
paid to him based on his personal performance and our company&#8217;s performance during the calendar year, as determined by our board
of directors in its sole discretion. Dr.&#160;Petit is entitled to participate in all of our bonus and benefit programs that we establish
and make available to our employees, including our 2023 Incentive Compensation Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment letter provides
that if we terminate Dr.&#160;Petit&#8217;s employment without &#8220;Cause&#8221; or he terminates his employment for &#8220;Good Reason,&#8221;
we will provide him with severance pay in the form of continuation of his base salary for a total of 12&#160;months and a prorated bonus
payment equivalent to 35% of his annualized base salary. For these purposes, &#8220;Cause&#8221; means, among others, (a)&#160;his engagement
in any conduct that materially and adversely affects the business interests or reputation of our company, (b)&#160;any breach by him of
his employment letter or of the restrictive covenants contained in his invention and non-disclosure agreement and non-competition and
non-solicitation agreement with us, (c)&#160;his failure to perform, or negligence in his performance of, any material duties required
of or assigned to him, (d)&#160;his fraud or embezzlement or (e)&#160;his conviction of any crime involving dishonesty or moral turpitude,
or any felony, in the cases of (a), (b)&#160;and (c), following written notice and an opportunity for Dr.&#160;Petit to timely cure any
such conduct, breach or deficiency; and &#8220;Good Reason&#8221; means, among others, (i)&#160;a material reduction in Dr.&#160;Petit&#8217;s
authority, duties or responsibilities, (ii)&#160;a material reduction of his base salary or (iii)&#160;a material breach by our company
of our obligations under his employment letter, in all cases, following written notice and an opportunity for our company to timely cure
the circumstances. The employment letter with Dr.&#160;Petit does not have any change of control provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Together with his employment
letter, Dr.&#160;Petit entered into an invention and non-disclosure agreement and a non-competition and non-solicitation agreement, which
contained covenants (a)&#160;restricting him from engaging in any activities competitive with our business during the term of his employment
letter and for a period of one year thereafter, (b)&#160;prohibiting him from disclosing confidential information regarding our company
at any time, (c)&#160;confirming that all intellectual property developed by him and relating to our business constitutes our sole and
exclusive property, and (d)&#160;preventing him from recruiting, soliciting or hiring away employees of our company for a period of one
year after his employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Christopher P.&#160;Acevedo Employment
Letter</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&#160;1, 2023, Christopher
P.&#160;Acevedo entered into an employment letter with us. Pursuant to the employment letter, Mr.&#160;Acevedo has agreed to devote his
business time, best efforts, skill, knowledge, attention and energies to the advancement of our business and interests and to the performance
of his duties and responsibilities, on an &#8220;at-will&#8221; basis, as our Chief Financial Officer. Mr.&#160;Acevedo will serve in
such position on a part-time basis consisting of 12&#160;hours per month, on average. The employment letter provides that Mr.&#160;Acevedo
will receive a base salary at a rate of $3,000 per monthly pay period for services rendered in such position. Mr.&#160;Acevedo also received
200,000 shares of our common stock pursuant to his employment letter for his past service to our company. In addition, following the end
of calendar year 2023 and subject to the approval of our board of directors, Mr.&#160;Acevedo will be eligible to receive a performance
bonus of up to 50% of the base salary paid to him based on his personal performance and our company&#8217;s performance during the calendar
year, as determined by our board of directors in its sole discretion. Mr.&#160;Acevedo is entitled to participate in all of our bonus
and benefit programs that we establish and make available to our employees, including our 2023 Incentive Compensation Plan. We agreed
to grant as an incentive to Mr.&#160;Acevedo, effective on March&#160;31, 2023, stock options to purchase 100,000 shares of our common
stock at an exercise price of $0.001 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment letter provides
that if we terminate Mr.&#160;Acevedo&#8217;s employment without &#8220;Cause&#8221; or he terminates his employment for &#8220;Good Reason,&#8221;
we will provide him with severance pay in the form of continuation of his base salary for a total of 12&#160;months and a prorated bonus
payment equivalent to 35% of his annualized base salary. For these purposes, &#8220;Cause&#8221; means (a)&#160;his engagement in any
conduct that materially and adversely affects the business interests or reputation of our company, (b)&#160;any breach by him of his employment
letter or of the restrictive covenants contained in his invention and non-disclosure agreement or non-competition and non-solicitation
agreement with us, (c)&#160;his failure to perform, or negligence in his performance of, any material duties required of or assigned to
him, (d)&#160;his fraud or embezzlement or (e)&#160;his conviction of any crime involving dishonesty or moral turpitude, or any felony,
in the cases of (a), (b)&#160;and (c), following written notice and an opportunity for Mr.&#160;Acevedo to timely cure any such conduct,
breach or deficiency; and &#8220;Good Reason&#8221; means (i)&#160;a material reduction in Mr.&#160;Acevedo&#8217;s authority, duties
or responsibilities, (ii)&#160;a material reduction of his base salary or (iii)&#160;a material breach by our company of our obligations
under his employment letter, in all cases, following written notice and an opportunity for our company to timely cure the circumstances.
The employment letter with Mr.&#160;Acevedo does not have any change of control provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Together with his employment
letter, Mr.&#160;Acevedo entered into an invention and non-disclosure agreement and a non-competition and non-solicitation agreement,
which contained covenants (a)&#160;restricting him from engaging in any activities competitive with our business during the term of his
employment letter and for a period of one year thereafter, (b)&#160;prohibiting him from disclosing confidential information regarding
our company at any time, (c)&#160;confirming that all intellectual property developed by him and relating to our business constitutes
our sole and exclusive property, and (d)&#160;preventing him from recruiting, soliciting or hiring away employees of our company for a
period of one year after his employment with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at Fiscal Year End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&#160;31, 2025,
we had outstanding the following stock option awards for our named executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> securities <br/> underlying <br/> unexercised <br/> options&#160;(#) <br/> exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> securities <br/> underlying <br/> unexercised <br/> options&#160;(#) <br/> unexercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <br/> incentive <br/> plan <br/> awards: <br/> number&#160;of <br/> securities <br/> underlying <br/> unexercised <br/> unearned <br/> options <br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> exercise <br/> price <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option <br/> expiration <br/> date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> shares <br/> or&#160;units <br/> of&#160;stock <br/> that&#160;have <br/> not&#160;vested <br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Market <br/> value&#160;of <br/> shares <br/> or&#160;units <br/> of&#160;stock <br/> that&#160;have <br/> not&#160;vested <br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <br/> incentive <br/> plan <br/> awards: <br/> number&#160;of <br/> unearned <br/> shares, <br/> units&#160;or <br/> other <br/> rights <br/> that&#160;have <br/> not&#160;vested <br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity <br/> incentive <br/> plan <br/> awards: <br/> market <br/> or&#160;payout <br/> value&#160;of <br/> unearned <br/> shares, <br/> units&#160;or <br/> other <br/> rights <br/> that&#160;have <br/> not&#160;vested <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 16%">Paul&#160;A.&#160;Romness, MPH</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">800,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1.86</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">12/05/2034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10/21/2035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Robert G.&#160;Petit, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12/05/2034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10/21/2035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Christopher P. Acevedo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12/05/2034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10/21/2035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2023 Incentive Compensation Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors and
stockholders adopted the OS Therapies Incorporated 2023 Incentive Compensation Plan and reserved 4,000,000 shares of our common stock
for issuance under the plan. On October 21, 2025, at our 2025 annual meeting of stockholders, our stockholders approved an amendment to
our plan to increase the number of shares authorized thereunder from 4,000,000 to 10,000,000. The purpose of the 2023 Incentive Compensation
Plan is to assist us in attracting, motivating, retaining and rewarding high-quality executives and other employees, officers, directors,
consultants and other persons who provide services to us by enabling such persons to acquire or increase a proprietary interest in our
company in order to strengthen the mutuality of interests between such persons and our stockholders, and providing such persons with performance
incentives to expend their maximum efforts in the creation of stockholder value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
the total compensation for each person who served as a non-executive member of our board of directors during the year ended December&#160;31,
2025. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or
non-equity awards to, or pay any other compensation to any of the non-executive members of our board of directors in 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees earned or paid in cash<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value of options granted&#160;<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All other compensation<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">John Ciccio</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,800</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170,800</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Avril McKean Dieser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Karim Galzahr</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Olivier R. Jarry</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Theordore F.&#160;Search, Pharm.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,800</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dollar
    amounts shown with respect to each of non-executive director reflect the aggregate grant date fair value of option awards granted
    in 2025 and described below, computed in accordance with ASC&#160;718. For a discussion of the assumptions we made in valuing the
    option awards, see &#8220;Note&#160;2&#160;&#8212;&#160;Significant Accounting Policies&#160;&#8212;&#160;Stock-Based&#160;Compensation&#8221;
    and &#8220;Note&#160;7 &#8212;&#160;Equity&#8221; in the notes to our consolidated financial statements contained elsewhere in this
    Annual Report.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, each of our non-executive directors was granted options under our 2023 Incentive Compensation Plan
to purchase 140,000 shares of common stock at an exercise price of $1.80 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-Executive Director Compensation Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted a non-executive director compensation policy that is designed to enable us to attract and retain, on a long-term basis, highly
qualified non-executive directors. Under the policy, each director who is not an employee will be paid cash compensation, as set forth
below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Annual<span style="text-decoration:underline"><br/> </span>retainer</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Board of Directors:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Members</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Annual retainer for Chairman</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Additional retainer for Audit Committee chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Additional retainer for Compensation Committee chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Additional retainer for Nominating and Corporate Governance Committee chair</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will reimburse all reasonable
out-of-pocket expenses incurred by non-executive directors in attending meetings of the board of directors and committees thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="J_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information known to us regarding the beneficial ownership of shares of our common stock as of March 26, 2026 by (i)&#160;each person
known by us to be the beneficial owner of more than 5% of our common stock, (ii)&#160;each of our named executive officers and directors
and (iii)&#160;all of our executive officers and directors as a group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined in accordance with the applicable rules and regulations of the SEC and includes voting or investment
power with respect to our capital stock. Under such rules, beneficial ownership includes any shares over which the individual has the
sole or shared voting power or investment power and any shares that the individual has the right to acquire within 60 days of March 26,
2026, through the exercise of stock options, warrants or other convertible securities (including our Series A Preferred Stock) or any
other right. Shares of our common stock that a person has the right to acquire within 60 days of March 26, 2026 are deemed outstanding
for purposes of computing the percentage ownership of the person holding such rights but are not deemed outstanding for purposes of computing
the percentage ownership of any other person (except with respect to the percentage ownership of all directors and executive officers
as a group). Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with
respect to all shares of common stock beneficially owned by them. Unless otherwise indicated, the address of each beneficial owner listed
in the table below is c/o OS Therapies Incorporated, 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2026, we had
39,533,227&#160;shares of common stock outstanding and 392,500&#160;shares of Series&#160;A Preferred Stock outstanding, which are deemed
to be convertible into 1,401,785 shares of common stock for voting purposes. The information in the following table regarding the beneficial
owners of more than 5% of our common stock is based upon information supplied by our principal stockholders or set forth in Schedules
13D and 13G filed with the SEC.&#160;The determination that there were no other persons, entities or groups known to us to beneficially
own more than 5% of our outstanding common stock was based on a review of all statements filed with the SEC with respect to our company
pursuant to Section&#160;13(d)&#160;or 13(g)&#160;of the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the &#8220;Exchange&#160;Act&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> Shares&#160;of <br/> Common <br/> Stock <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 6pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&#160;of <br/> Outstanding <br/> Common <br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> Shares&#160;of <br/> Series&#160;A <br/> Preferred<br/> Stock <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of <br/> Outstanding <br/> Series&#160;A <br/> Preferred <br/> Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Percent&#160;of <br/> Voting <br/> Power<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Executive Officers and Directors</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 6pt">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Paul A.&#160;Romness, MPH</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,273,000</td><td style="padding-bottom: 6pt; width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Robert G.&#160;Petit, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="padding-bottom: 6pt; text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.5</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">1.5</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Christopher P.&#160;Acevedo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,375</td><td style="padding-bottom: 6pt; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">John Ciccio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,917</td><td style="padding-bottom: 6pt; text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Avril McKean Dieser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,500</td><td style="padding-bottom: 6pt; text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Karim Galzahr</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="padding-bottom: 6pt; text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Olivier R.&#160;Jarry</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="padding-bottom: 6pt; text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">*</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Theodore F.&#160;Search, Pharm.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,918</td><td style="padding-bottom: 6pt; text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">All directors and executive officers as&#160;a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,820,710</td><td style="padding-bottom: 6pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.4</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Represents less than 1% of
outstanding shares.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Each share of common stock
is entitled to one vote per share and each share of Series A Preferred Stock is entitled to one vote for each share of common stock into
which it is convertible for voting purposes.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes 800,000 shares of
common stock issuable pursuant to outstanding options, which are exercisable as of March 26, 2026, and excludes (i) 1,000,000 shares
of common stock issuable pursuant to outstanding options, which vest in full on October 21, 2026, and (ii) 1,000,000 shares of common
stock issuable pursuant to outstanding options, which vest in full on January 22, 2027, in each case provided that Mr. Romness is serving
as an employee of the Company on each such date.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes 400,000 shares of common stock issuable pursuant to outstanding
options, which are exercisable as of March 26, 2026, and excludes (i) 500,000 shares of common stock issuable pursuant to outstanding
options, which vest in full on October 21, 2026, and (ii) 100,000 shares of common stock issuable pursuant to outstanding options, which
vest in full on January 22, 2027, in each case provided that Mr. Petit is serving as an employee of the Company on each such date.</p></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes 200,000 shares of common stock issuable pursuant to outstanding
options, which are exercisable as of March 26, 2026, and excludes (i) 200,000 shares of common stock issuable pursuant to outstanding
options, which vest in full on October 21, 2026, and (ii) 100,000 shares of common stock issuable pursuant to outstanding options, which
vest in full on January 22, 2027, in each case provided that Mr. Acevedo is serving as an employee of the Company on each such date.</p></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes (i) 217,917 shares of common stock held of record by Mill
River Partners LLC, with respect to which Mr. Ciccio shares investment and dispositive power with Dr. Search, and (ii) 40,000 shares of
common stock issuable pursuant to outstanding options, which are exercisable as of March 26, 2026, and excludes (i) 140,000 shares of
common stock issuable pursuant to outstanding options, which vest in full on October 21, 2026, and (ii) 50,000 shares of common stock
issuable pursuant to outstanding options, which vest in full on January 22, 2027, in each case provided that Mr. Ciccio is serving as
a director of the Company on each such date.</p></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(6)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes 40,000 shares of common stock issuable pursuant to outstanding
options, which are exercisable as of March 26, 2026, and excludes (i) 140,000 shares of common stock issuable pursuant to outstanding
options, which vest in full on October 21, 2026, and (ii) 50,000 shares of common stock issuable pursuant to outstanding options, which
vest in full on January 22, 2027, in each case provided that Ms. McKean Dieser is serving as a director of the Company on each such date.</p></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Excludes (i) 140,000 shares
of common stock issuable pursuant to outstanding options, which vest in full on October 21, 2026, and (ii) 50,000 shares of common stock
issuable pursuant to outstanding options, which vest in full on January 22, 2027, in each case provided that Mr. Galzahr is serving as
a director of the Company on each such date.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(8)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes 40,000 shares of common stock issuable pursuant to outstanding
options, which are exercisable as of March 26, 2026, and excludes (i) 140,000 shares of common stock issuable pursuant to outstanding
options, which vest in full on October 21, 2026, and (ii) 50,000 shares of common stock issuable pursuant to outstanding options, which
vest in full on January 22, 2027, in each case provided that Mr. Jarry is serving as a director of the Company on each such date.</p></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(9)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Includes (i) 217,918 shares of common stock owned of record by Mill
River Partners LLC, with respect to which Dr. Search shares investment and dispositive power with Mr. Ciccio, and (ii) 40,000 shares of
common stock issuable pursuant to outstanding options, which are exercisable as of March 26, 2026, and excludes (i) 140,000 shares of
common stock issuable pursuant to outstanding options, which vest in full on October 21, 2026, and (ii) 50,000 shares of common stock
issuable pursuant to outstanding options, which vest in full on January 22, 2027, in each case provided that Dr. Search is serving as
a director of the Company on each such date.</p></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="J_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><b>Item 13. Certain
Relationships and Related Transactions, and Director Independence.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Relationships and Related Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Our Policy Regarding
Related Party Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors recognizes
the fact that transactions with related persons present a heightened risk of conflicts of interest and/or improper valuation (or the perception
thereof). Our board of directors has adopted a written policy on transactions with related persons that is in conformity with the requirements
for issuers having publicly held common stock that is listed on the NYSE American. Under our policy:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">any related person transaction,
and any material amendment or modification to a related person transaction, must be reviewed and approved or ratified by the Audit Committee;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">any employment relationship
or transaction involving an executive officer and any related compensation must be approved by the compensation committee of the board
of directors or recommended by the compensation committee to the board of directors for its approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the review
and approval or ratification of a related person transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">management must disclose to
the committee or disinterested directors, as applicable, the name of the related person and the basis on which the person is a related
person, the material terms of the related person transaction, including the approximate dollar value of the amount involved in the transaction,
and all the material facts as to the related person&#8217;s direct or indirect interest in, or relationship to, the related person transaction;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">management must advise the committee
or disinterested directors, as applicable, as to whether the related person transaction complies with the terms of our agreements governing
our material outstanding indebtedness that limit or restrict our ability to enter into a related person transaction;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">management must advise the committee
or disinterested directors, as applicable, as to whether the related person transaction will be required to be disclosed in our applicable
filings under the Securities Act or the Exchange&#160;Act, and related rules, and, to the extent required to be disclosed, management
must ensure that the related person transaction is disclosed in accordance with the Securities Act and the Exchange&#160;Act and related
rules; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">management must advise the committee
or disinterested directors, as applicable, as to whether the related person transaction constitutes a &#8220;personal loan&#8221; for
purposes of Section&#160;402 of SOX.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the related person
transaction policy provides that the committee or disinterested directors, as applicable, in connection with any approval or ratification
of a related person transaction involving a non-employee director, should consider whether such transaction would compromise the director&#8217;s
status as an &#8220;independent,&#8221; &#8220;outside,&#8221; or &#8220;non-employee&#8221; director, as applicable, under the rules
and regulations of the SEC and the NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Related Party Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of transactions or series of transactions since January&#160;1, 2025, to which we were or will be a party, in which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the amount involved in the transaction
exceeds, or will exceed, the lesser of $120,000 or one percent of the average of the Company&#8217;s total assets for the last two completed
fiscal&#160;years; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">in which any of our executive
officers, directors or holder of 5% or more of any class of our capital stock, including their immediate family members or affiliated
entities, had or will have a direct or indirect material interest.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compensation
arrangements for our named executive officers and our directors are described elsewhere in this annual report under &#8220;Executive
Compensation&#8221; And &#8220;Director Compensation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accrued Payroll</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, we had payroll payable to the Paul A. Romness, our Chief Executive Officer, of $0 and $8,871, respectively, and related payroll
taxes payable of $0 and $88,386, respectively. During the years ended December 31, 2025 and 2024, we made advances on payroll payable,
and Mr. Romness repaid amounts previously advanced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes activity
in respect to payroll advances to Mr. Romness:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2023</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">191,198</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,875</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(414,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayments 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(134,184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second and third
quarters of 2024, we issued paychecks to Mr. Romness, representing the remaining balance of backpay, net of all 2024 payroll advances.
Payroll taxes related to both backpay and regular compensation were fully paid. All related-party payroll advances to Mr. Romness, previously recorded as employee advances, were fully repaid during
2025. The balance of related-party payroll advances for Mr. Romness was $0 during 2025. All advances for 2024 were repaid in full
as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Accounting Fees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, we had accounts payable of $0 and $26,765, respectively, to Shore Accountants MD Inc., an outside accounting firm that provides
payroll, bookkeeping, and tax preparation services. Shore Accountants MD Inc. is wholly owned by Christopher P. Acevedo, our Chief Financial
Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that all members of the board of directors, except Paul A.&#160;Romness, are independent directors, including for purposes
of the rules of the NYSE American and the SEC.&#160;In making such independence determination, our board of directors considered the relationships
that each non-employee&#160;director has with us and all other facts and circumstances that our board of directors deemed relevant in
determining their independence, including the beneficial ownership of our capital stock by each non-employee&#160;director. In considering
the independence of the directors listed above, our board of directors considered the association of our directors with the holders of
more than 5% of our outstanding common stock. We believe that the composition and functioning of our board of directors and each of our
committees will comply with all applicable requirements of the NYSE American exchange and the rules and regulations of the SEC.&#160;There
are no family relationships among any of our directors or executive officers. Mr.&#160;Romness is not an independent director under these
rules because he is the current President and Chief Executive Officer of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. Principal Accounting Fees and Services.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principal Accountant Fees and Services</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents
aggregate fees billed to us for services related to the year ended December&#160;31, 2025 and 2024 by MaloneBailey, LLP, our independent
registered public accounting firm.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="font-size: 10pt">Audit Fees<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">302,625</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">255,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">All Other Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">309,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">255,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="text-align: justify"><span style="font-size: 10pt">Audit fees consist of fees for
professional services provided primarily in connection with the annual audit of our financial statements, quarterly reviews and services
associated with SEC registration statements and other documents issued in connection with our initial public offering, including comfort
letters and consents.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the services described
above were pre-approved by our Audit Committee. The Audit Committee concluded that the provision of these services by MaloneBailey would
not affect their independence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee&#8217;s Pre-Approval Policies
and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee pre-approves
all services, including both audit and non-audit services, provided by our independent registered public accounting firm. For audit services,
each year the independent registered public accounting firm provides the Audit Committee with an engagement letter outlining the scope
of the audit services proposed to be performed during the year, which must be formally accepted by the Audit Committee before the audit
commences. The independent registered public accounting firm also submits an audit services fee proposal, which also must be approved
by the Audit Committee before the audit commences. None of the fees for services described above under the captions &#8220;Tax Fees&#8221;
or &#8220;All Other Fees&#8221; approved by the Audit Committee were approved pursuant to the exception provided by paragraph (c)(7)(i)(C)
of Rule 2-01 of Regulation S-X.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="J_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART IV.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="J_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. Exhibits and Financial Statement Schedules.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify">The following documents are filed as a part of this annual report:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Financial Statements</b>.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Information in response to this Item
is included in Part II, Item 8 of this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Financial Statement Schedule</b>.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All schedules are omitted because they are not applicable
or the required information is shown in the financial statements or notes thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Exhibits</b>.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a list of exhibits
filed or furnished as part of this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit number</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex3-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024050739/ea020576106ex3-2_ostherap.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.2 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed June 7, 2024.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025104724/ea026250401ex3-3_osthera.htm">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.3 to the Company&#8217;s Registration Statement on Form S-8 filed October 31, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea022625801ex3-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Rights, Preferences and Limitations of Series A Senior Convertible Preferred Stock of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex3-3_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.3 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025077431/ea025333801ex3-1_ostherap.htm">Amendment No. 1 to the Amended and Restated Bylaws of OS Therapies Incorporated (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed August 15, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex4-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 the Company&#8217;s Registration Statement on Form&#160;S-1 filed May&#160;30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024052373/ea020576108ex4-2_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Representative&#8217;s Warrant (incorporated herein by reference to Exhibit 4.2 to Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 filed June 13, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea022625801ex4-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Series A Warrant (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on December&#160;30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea022625801ex4-2_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Agent Warrant (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form&#160;8-K filed on December&#160;30,
2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/ea024659001ex4-1_ostherap.htm">Form of Warrant for First and Second Inducement Offering (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on June 24, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390026003166/ea027251601ex4-1_ostherap.htm">Form of Warrant for the Third Inducement Offering (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on January 12, 2026).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/ea028001401ex4-1.htm">Form of 10.0% Original Issue Discount Unsecured Convertible Promissory Note (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on March 6, 2026).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/ea028001401ex4-2.htm">Form of Warrant for the Bridge Financing (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on March 6, 2026).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex4-9.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registered Securities.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025100821/ea026193901ex10-1_ostherap.htm">OS Therapies Incorporated 2023 Incentive Compensation Plan, as amended (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K filed October 21, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex10-6_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated as of August&#160;19, 2020, by and between OS Therapies Incorporated and BlinkBio, Inc. (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex10-7_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of February&#160;21, 2023, between OS Therapies Incorporated and Paul&#160;A.&#160;Romness, MPH (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex10-8_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Letter, dated June&#160;23, 2020, between OS Therapies Incorporated and Robert G.&#160;Petit, Ph.D. (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex10-10_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement between OS Therapies Incorporated and each of its directors (incorporated herein by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024048049/ea020576103ex10-12_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Letter, dated January&#160;1, 2023, between OS Therapies Incorporated and Christopher P. Acevedo (incorporated herein by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed May 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea022625801ex10-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated December 24, 2024, by and among OS Therapies Incorporated and the purchasers party thereto (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390024113561/ea022625801ex10-2_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement by and among OS Therapies Incorporated and the purchasers party thereto (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on December 30, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025003460/ea022769701ex10-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Securities Purchase Agreement and Amendment to Registration Rights Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on January&#160;14, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea022905501ex10-1_osthera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, dated as of January 28, 2025, between OS Therapies Incorporated and Ayala Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 29, 2025).</span></a></td></tr>
  </table><div>
</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025056911/ea024659001ex10-1_ostherap.htm">Form of Inducement Offer Letter for the First Inducement Offering (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 24, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025083396/ea025556801ex10-1_ostherap.htm">Form of Inducement Offer Letter for the Second Inducement Offering (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on September 2, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390026003166/ea027251601ex10-1_ostherap.htm">Form of Inducement Offer Letter for the Third Inducement Offering (incorporating herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on January 12, 2026).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025073734/ea025177301ex1-2_ostherap.htm">At Market Issuance Sales Agreement, dated August 8, 2025, between OS Therapies Incorporated and B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (incorporated herein by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form S-3 filed with the SEC on August 8, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390026024726/ea028001401ex10-1.htm">Form of Securities Purchase Agreement for the Bridge Financing (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 6, 2026).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex21-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of the Registrant.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028314601ex23-1.htm">Consent of MaloneBailey, LLP, independent registered public accounting firm.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="#c_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (set forth on signature page of this annual report).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to 18 U.S.C. &#167; 1350 As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea028314601ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to 18 U.S.C. &#167; 1350 As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1795091/000121390025026238/ea023559701ex97-1_ostherap.htm">OS Therapies Incorporated Clawback Policy (incorporated herein by reference to Exhibit 97.1 to the Company&#8217;s Annual Report on Form 10-K filed on March 31, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td/><td style="text-align: left"><span style="font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td/><td style="text-align: left"><span style="font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-size: 10pt">Pursuant to Item&#160;601(a)(5)&#160;of
Regulation&#160;S-K, certain schedules and exhibits have been omitted. The registrant agrees to furnish supplementally a copy of any
omitted schedule or exhibit to the SEC upon its request.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td/><td style="text-align: left"><span style="font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-size: 10pt">Indicates a management contract
or any compensatory plan, contract or arrangement.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td/><td style="text-align: left"><span style="font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The exhibits required by Item
601 of Regulation S-K are filed herewith or incorporated herein by reference. Please see the Index to Exhibits to this annual report,
which is incorporated into this Item 15(b) by reference.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td/><td style="text-align: left"><span style="font-size: 10pt">(c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">All schedules are omitted because
they are not applicable or the required information is shown in the financial statements or notes thereto.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="J_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. Form 10-K Summary.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="c_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td><span style="font-size: 10pt">Date: March 30, 2026</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>OS THERAPIES INCORPORATED</b></span></td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/&#160;Paul A. Romness</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Paul A. Romness</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman, President and Chief Executive Officer</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Christopher P. Acevedo</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Christopher P. Acevedo</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below hereby constitutes and appoints Paul A. Romness and Christopher P. Acevedo, and
each of them, his or her true and lawful attorney in fact and agent, with full power of substitution and re-substitution, for him or her
and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K
and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary
to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and conforming all that said
attorney in fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 31%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 47%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Position</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/ Paul A.&#160;Romness</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-size: 10pt">Chairman, President, Chief&#160;Executive&#160;Officer&#160;and&#160;Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Paul A.&#160;Romness, MPH</span></td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">(principal executive officer)</span></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;Christopher P.&#160;Acevedo</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Christopher P.&#160;Acevedo</span></td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">(principal financial officer and principal accounting officer)</span></td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;John Ciccio</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">John Ciccio</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;Avril McKean Dieser</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Avril McKean Dieser</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;Karim Galzahr</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Karim Galzahr</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;Olivier R.&#160;Jarry</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Olivier R.&#160;Jarry</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-bottom: 1pt"><span style="font-size: 10pt">/s/&#160;Theodore F.&#160;Search, Pharm.D.</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">March 30, 2026</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">Theodore F.&#160;Search, Pharm.D.</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


























































































































































































































































































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:DepositsAssetsNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:AccruedPayrollTaxesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-8" name="us-gaap:InvestmentIncomeInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="us-gaap:InterestExpenseNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:OtherNonoperatingIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-11" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="osti:DeemedDividendOnSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-13" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-14" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-15" name="us-gaap:DividendsPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-16" name="us-gaap:DividendsPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-17" name="us-gaap:DividendsPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-22" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-23" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-24" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-25" name="osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-26" name="osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-27" name="osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-31" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-33" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-35" name="osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-36" name="osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-37" name="osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-38" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-39" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-41" name="osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-42" name="osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-43" name="osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-44" name="osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-45" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-46" name="osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-47" name="osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-48" name="osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-50" name="osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-51" name="osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-52" name="osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-53" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-54" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-55" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-56" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-57" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-59" name="osti:SharesIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-60" name="us-gaap:OtherNoncashExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-61" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-62" name="osti:CommitmentSharesIssuedForEquityLineOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-63" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-64" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-66" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-67" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-68" name="us-gaap:ProceedsFromOtherEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-69" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-70" name="us-gaap:ProceedsFromShortTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-71" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-72" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-73" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-74" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-75" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-76" name="us-gaap:NotesIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-77" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-78" name="us-gaap:Dividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-79" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-80" name="osti:ConversionOfPreferredStockToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="osti:DeferredOfferingCostsRecordedAsAccountsPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-82" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="osti:ConversionOfWarrantsIntoCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="osti:IssuanceOfCommonStockToInvestorAdvisorSettlement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="osti:ConversionOfMakewholeLiabilityToCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="osti:ClawbackOfCommonStockForOverIssuance" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-87" name="osti:CommonStockIssuedForPatentPurchase" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="osti:ReclassificationOfWarrantLiabilityToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="osti:SharesIssuedForPrepaidServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-90" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-91" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-92" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-93" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-94" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-95" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-96" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-97" name="us-gaap:DeferredCostsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-98" name="us-gaap:DeferredCostsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-99" name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-100" name="us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-101" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c132" id="hidden-fact-102" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-103" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c133" id="hidden-fact-104" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-105" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c134" id="hidden-fact-106" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-107" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c135" id="hidden-fact-108" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-109" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c136" id="hidden-fact-110" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-111" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-112" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-113" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-114" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-118" name="osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c0" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-121" name="osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-123" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c217" id="hidden-fact-125" name="osti:UnallocatedCashProceeds" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-126" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c231" id="hidden-fact-127" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-128" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c239" id="hidden-fact-129" name="us-gaap:InvestmentIncomeInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c238" id="hidden-fact-130" name="us-gaap:InterestExpenseOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c238" id="hidden-fact-131" name="us-gaap:OtherNonoperatingIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c239" id="hidden-fact-132" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-133" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-15705">0001795091</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-15706">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-15707">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="osti-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-03-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankCheckingAccountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankCheckingAccountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankSavingsAccountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankSavingsAccountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:SVBBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:SVBBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:AyalaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-09</xbrli:startDate>
    <xbrli:endDate>2025-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-29</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-29</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-29</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:PatentLicenseAcquisitionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:UnderwriterPlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:UnderwriterPlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:InducementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:InducementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:PrepaidCommonStockNotIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:PrepaidCommonStockNotIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:MrRomnessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:MillRiverPartnersLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-31</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-31</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-31</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-31</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-24</xbrli:startDate>
    <xbrli:endDate>2024-12-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">osti:ShortTermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">osti:ShortTermLoanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:AlanMussoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:AlanMussoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:ChristopherAcevedoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:ChristopherAcevedoMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-01</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:JohnsonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-31</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-05-31</xbrli:startDate>
    <xbrli:endDate>2021-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BlinkBioMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-31</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:ConsultingFeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-01-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-28</xbrli:startDate>
    <xbrli:endDate>2026-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:GLPToxMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:IClinicalTrialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:IIClinicalTrialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeeAdvancepaidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees35OnDevelopmentOfSAPTablesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees30OnFinalAnalysisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeesRemainderDueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-02</xbrli:startDate>
    <xbrli:endDate>2024-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-02</xbrli:startDate>
    <xbrli:endDate>2024-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-02</xbrli:startDate>
    <xbrli:endDate>2024-08-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:EquityLineOfCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-31</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-31</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MedianMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-21</xbrli:startDate>
    <xbrli:endDate>2025-10-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-21</xbrli:startDate>
    <xbrli:endDate>2025-10-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-14</xbrli:startDate>
    <xbrli:endDate>2025-01-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-14</xbrli:startDate>
    <xbrli:endDate>2025-01-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-09</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-09</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-14</xbrli:startDate>
    <xbrli:endDate>2025-01-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">osti:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">osti:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-14</xbrli:startDate>
    <xbrli:endDate>2026-01-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-01-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-10</xbrli:startDate>
    <xbrli:endDate>2026-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-03-04</xbrli:startDate>
    <xbrli:endDate>2026-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-03-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-03-04</xbrli:startDate>
    <xbrli:endDate>2026-03-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][4G5VvxIeEv9X8QfVMNvGd3mexlNH9XoWmbrr1dte1nzVkDx+aCK4GQdbcHBb/J/Lat0YFNWLtIUIahIskWl373lBlvCI+uHpNQuoEMvleKq6vQ7TyDMHoVmz9+4Q9Z1SEK4xoTcf6KRmtlBRYWVfmpPSQQbSbO0Iyzw/ECVsrycJIVPoKDlkvSoybWFoJ8+EbNr964CYAcc/CdF6/OrqVambEmoJebgSKm7Cp6P3ouIU0R522EWZyuXntkUe68LBIrlAdy3bp7vU/P2pWdpZekIcseMOHvPdacOKPSqFwQLcbpViXvEU3Z66eVrtNb4LnWhG+JmBrp1kQKGkcv8By+9IlA==] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Segment">
  <xbrli:measure>osti:Segment</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>ea028314601ex4-9.htm
<DESCRIPTION>DESCRIPTION OF REGISTERED SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS Therapies Incorporated
(&ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo;) has authority to issue 155,000,000 shares of capital stock, consisting of 150,000,000
shares of common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share, of which 2,500,000
shares are designated as Series A senior convertible preferred stock, $0.001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, our
common stock was the only class of our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.
The following is a summary of the material terms of our common stock. This summary is qualified in its entirety by reference to our Third
Amended and Restated Certificate of Incorporation (as amended, the &ldquo;charter&rdquo;) and our Amended and Restated Bylaws (as amended,
our &ldquo;bylaws&rdquo;), which are incorporated herein by reference as Exhibits 3.1, 3.2 and 3.3, with respect to our charter, and Exhibits
3.5 and 3.6, with respect to our bylaws, to our Annual Report on Form 10-K of which this exhibit is a part. Please read our charter and
bylaws and applicable provisions of the Delaware General Corporation Law for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock
do not have any cumulative voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject
to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or
other subscription rights or redemption or sinking fund provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all
debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares of common stock to be issued
by us in this offering will be, when issued and paid for, validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the authority, without further action by our stockholders, to issue up to 5,000,000&nbsp;shares of preferred stock in one or more series
and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend
rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting,
or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred
stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments
and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing
a change in control of our company or other corporate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series A Senior Convertible Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of designation
sets forth the rights, preferences and limitations of our Series A senior convertible preferred stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right of the holder to convert such shares of Series A senior convertible preferred stock into shares of our common stock, with mandatory conversion upon (i) a qualified firm commitment underwritten public offering of common stock raising gross proceeds in excess of $10.0 million, with a per share price not less than $12.00, (ii) a qualified PIPE financing raising gross proceeds in excess of $20.0 million, with a per share price not less than $12.00, (iii) a closing of a third-party acquisition where all outstanding shares of common stock (including the shares of common stock issued pursuant to the mandatory conversion of the Series A senior convertible preferred stock) are purchased or exchanged by an unaffiliated third party and in which the consideration paid to all holders of outstanding shares of common stock for such purchase or exchange consists solely of cash at a purchase price per share of common stock not less than $12.00, or (iv) such time as the daily VWAP for the common stock is greater than 300% of the then applicable conversion price for a period of 20 consecutive trading days with minimum average daily trading volume of $2.0 million;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a liquidation preference of 150% of the original issue price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to one vote per share and vote together with the common stock on an as-converted&nbsp;basis (subject to a voting price floor equal to $3.78), except that holders of Series A senior convertible preferred stock shall vote as a separate class with respect to certain specified matters; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such other terms and provisions as are set forth in the certificate of designation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Series A senior
convertible preferred stock is convertible into a number of shares of common stock at a conversion ratio equal to (A) the original issue
price of the Series A senior convertible preferred stock divided by (B) the conversion price of the Series A senior convertible preferred
stock. The original issue price and the conversion price of the Series A senior convertible preferred stock was initially $4.00 (resulting
in an initial conversion ratio of 1:1). The Series A Preferred Stock is not traded on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The conversion price of the
Series A senior convertible preferred stock was automatically reset to $1.12 per share on April 23, 2025 and is subject to further adjustment
upon the occurrence of certain events, including the sale of equity securities by the Company at an effective price per share less than
the then conversion price during the two-year&nbsp;period beginning from the initial issuance date, subject to certain exceptions (the
&ldquo;Series A Dilutive Issuances&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, we had
392,500 shares of Series A Preferred Stock outstanding, with a conversion ratio of 3.571429 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>IPO Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We issued warrants to Brookline
Capital Markets, a division of Arcadia Securities, LLC, the representative of the underwriters in our initial public offering, to purchase
an aggregate of 112,000 shares of common stock at an exercise price of $4.40 per share. These warrants are currently exercisable and have
a cashless exercise provision and will terminate on the fifth anniversary of July 31, 2024. These warrants also provide for customary
anti-dilution&nbsp;provisions, a single demand registration right, and immediate &ldquo;piggyback&rdquo; registration rights with respect
to the registration of the shares of common stock underlying the warrants, with a term of such demand and &ldquo;piggyback&rdquo; registration
rights not exceeding five&nbsp;years from July 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>2025 Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From June 2025 through September 2025, in connection with our first
and second warrant exercise inducement and exchange transactions, we issued warrants to purchase up to an aggregate of 7,154,338 shares
of common stock at an exercise price of $3.00 per share, subject to adjustment as set forth therein. These warrants are exercisable by
the holder for a period of five years from the applicable issuance date. The exercise price and number of shares issuable upon exercise
of these warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro
rata distributions, reorganizations or similar events affecting our common stock and the exercise price. The exercise price of certain
of these warrants is also subject to adjustment upon the occurrence of subsequent sales of equity securities by us during such time any
of these warrants are outstanding at an effective price per share less than the exercise price of these warrants then in effect (such
lower price, the &ldquo;Dilutive Issuance Price&rdquo; and such issuances, collectively, &ldquo;Dilutive Issuances&rdquo;), subject to
certain exceptions. In the event of a Dilutive Issuance, the exercise price will be reduced to the greater of (x) such lower Dilutive
Issuance Price and (y) $1.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants also provide
that, at any time any of these warrants are outstanding, if the closing price of our common stock on the applicable trading market equals
or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of certain
equity conditions, require the holder to exercise all or a portion of the warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, warrants to purchase up to an aggregate of 4,531,564
shares of common stock remained outstanding and exercisable. Of these, warrants to purchase up to an aggregate of 3,206,703 do not provide
for exercise price adjustments in connection with Dilutive Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>2026 Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From January 2026 through February 2026, in connection with our third
warrant exercise inducement and exchange transaction and privately negotiated warrant exercise inducement and exchange agreements, we
issued warrants to purchase up to an aggregate of 2,622,774 shares of common stock at an exercise price of $1.40 per share, subject to
adjustment as set forth therein (the &ldquo;2026 Warrants&rdquo;). The 2026 Warrants are exercisable by the holder for a period of five
years from the applicable issuance date. The exercise price and number of shares issuable upon exercise of the 2026 Warrants are subject
to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations
or similar events affecting our common stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2026 Warrants also provide
that, at any time any of the 2026 Warrants are outstanding, if the closing price of our common stock on the applicable trading market
equals or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of
certain equity conditions, require the holder to exercise all or a portion of the warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, 2026 Warrants to purchase up to an aggregate
of 2,622,774 shares of common stock remained outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Bridge Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, in connection
with our bridge financing, we issued warrants to purchase up to an aggregate of 1,666,667 shares of common stock at an exercise price
of $1.40 per share, subject to adjustment as set forth therein (the &ldquo;Bridge Warrants&rdquo;). The Bridge Warrants are exercisable
by the holder for a period of five years from the issuance date. The exercise price and number of shares issuable upon exercise of the
Bridge Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro
rata distributions, reorganizations or similar events affecting our common stock and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These warrants also provide
that, at any time any of the Bridge Warrants are outstanding, if the closing price of our common stock on the applicable trading market
equals or exceeds 300% of the exercise price then in effect for any 20 consecutive trading days, we may, subject to the satisfaction of
certain equity conditions, require the holder to exercise all or a portion of the warrants for cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, Bridge
Warrants to purchase up to an aggregate of 1,666,667 shares of common stock remained outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unsecured Convertible Promissory Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, in connection
with our bridge financing, we issued 10.0% original issue discount unsecured convertible promissory notes in an aggregate principal amount
of $2,200,000. The notes bear interest at a rate of 4% per annum and mature on March 4, 2027 (the &ldquo;Maturity Date&rdquo;). Interest
on the notes accrues from the funding date until the earlier of the Maturity Date or conversion of the notes, and all accrued and unpaid
interest under the notes will convert together with principal upon any conversion of the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The notes are convertible
into shares of our common stock or other securities of our company under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Mandatory Conversion</I>.
If we consummate a &ldquo;Qualified Offering&rdquo; on or before the Maturity Date, the outstanding principal amount of each note, together
with all accrued and unpaid interest, will automatically convert into securities of our company sold in such Qualified Offering at a conversion
price per share equal to the offering price per share (or per unit, as applicable) in the Qualified Offering, without any discount. A
&ldquo;Qualified Offering&rdquo; means a registered public offering or registered direct offering of our securities from which we receive
gross cash proceeds of not less than $2,500,000 from new money investments (excluding any proceeds attributable to the conversion of the
notes or any other of our outstanding convertible securities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voluntary Conversion</I>.
At any time prior to repayment and prior to a mandatory conversion, the notes are convertible, in whole or in part, at the option of the
holder, into shares of common stock at a conversion price equal to 90% of the average daily volume weighted average price of our common
stock for the 10 trading days immediately preceding the date the holder delivers a notice of conversion, subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The conversion price of the
notes is subject to adjustment upon the occurrence of certain events, including stock dividends, stock splits, combinations, reclassifications
and certain dilutive issuances. If we issue common stock or common stock equivalents at an effective price per share that is lower than
the then-current conversion price (other than exempt issuances), the conversion price will be reduced to such lower price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 30, 2026, $2,200,000 in aggregate principal amount of the
Bridge Notes remained outstanding and convertible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>2026 Warrants</I></B>.
Pursuant to inducement offer letter agreements entered into in connection with the issuance of the 2026 Warrants, we agreed to file a
registration statement on Form S-3 (or other appropriate form, including on Form S-1, if we are not then eligible to register securities
on Form S-3) providing for the resale of the shares of common stock issued or issuable upon exercise of the 2026 Warrants either (i) within
30 calendar days of March 2, 2026 or (ii) before March 30, 2026, as applicable, and to use commercially reasonable efforts to have such
registration statement declared effective by the SEC within 60 calendar days (or within 90 calendar days in case of &ldquo;full review&rdquo;
by the SEC) following its initial filing and to keep such registration statement effective at all times until the earlier of (i) the time
no holder owns any 2026 Warrants or shares of common stock issuable upon exercise thereof and (ii) the Delegend Date (as defined in the
inducement offer letter agreements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Bridge Notes and Warrants</I></B>.
Pursuant to a securities purchase agreement, dated as of March 4, 2026 (the &ldquo;Bridge SPA&rdquo;), we agreed to file a registration
statement on Form S-3 (or Form S-1 if we are not then eligible to register securities for Form S-3) by April 3, 2026 to register for resale
the shares of our common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &ldquo;full review&rdquo; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Our Certificate of
Incorporation and Bylaws and Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our third amended and restated
certificate of incorporation and amended and restated bylaws include a number of provisions that may have the effect of delaying, deferring
or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral
takeover proposals to negotiate with our board of directors rather than pursue non-negotiated&nbsp;takeover attempts. These provisions
include the items described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Board composition and
filling vacancies</I></B><I>. </I>Our certificate of incorporation provides that directors may be removed with or without cause only by
the affirmative vote of the holders of two-thirds&nbsp;or more of the shares then entitled to vote at an election of directors. Further,
any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may
only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The limitations on removal
of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our
board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>No written consent of
stockholders</I></B><I>. </I> Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote
of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting.
This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal
of directors by our stockholders without holding a meeting of stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Meetings of stockholders</I></B><I>.
</I>Our certificate of incorporation and bylaws provide that a special meeting of stockholders may be called only by resolution adopted
by our board of directors, chairman of the board of directors or chief executive officer or upon the written request of stockholders owning
at least 33&frac13;% of the outstanding common stock and only those matters set forth in the notice of the special meeting may be considered
or acted upon at a special meeting of stockholders. Stockholders owning less than 33&frac13;% may not call a special meeting, which may
delay the ability of our stockholders to force consideration of a proposal or for holders controlling a majority of our capital stock
to take any action, including the removal of directors. Our bylaws limit the business that may be conducted at an annual meeting of stockholders
to those matters properly brought before the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Advance notice requirements</I></B><I>.
</I>Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election
as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals
must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely,
notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary
date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&rsquo;
notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Amendment to certificate
of incorporation and bylaws</I></B><I>. </I>Any amendment of our certificate of incorporation must first be approved by a majority of
our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding
shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except
that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by
not less than two-thirds&nbsp;of the outstanding shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding
shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors
then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the
outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating
to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds&nbsp;of the outstanding
shares entitled to vote on the amendment, and not less than two-thirds&nbsp;of the outstanding shares of each class entitled to vote thereon
as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority
of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Undesignated preferred
stock</I></B><I>.</I> Our certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The existence of authorized
but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of
a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors
were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares
of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute
the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of
incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders
of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and
may have the effect of delaying, deterring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NYSE American Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock trades on
the NYSE American under the symbol &ldquo;OSTX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is VStock Transfer, LLC, Woodmere, New&nbsp;York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ea028314601ex21-1.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028314601_ex21-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction of Organization / Incorporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">OS Animal Health Corp</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">OS Therapies UK LTD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea028314601ex23-1.htm
<DESCRIPTION>CONSENT OF MALONEBAILEY, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We consent to the incorporation by reference
in the Registration Statements on Form S-1 (Nos. 333-289216 and 333-287569), on Form S-3 (No. 333-289443) and on Form S-8 (Nos. 333-291202
and 333-284242) of our report dated March 30, 2026 with respect to the audited consolidated financial statements of OS Therapies Incorporated
appearing in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>/s/ MaloneBailey, LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">www.malonebailey.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 36.2pt; margin-bottom: 0pt">March 30, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ea028314601ex31-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Paul Romness, as Chief Executive Officer (Principal
Executive Officer), certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of OS Therapies
Incorporated;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: March 30, 2026</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Paul Romness</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul Romness</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ea028314601ex31-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Christopher Acevedo, as Chief Financial Officer
(Principal Financial Officer), certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of OS Therapies
Incorporated;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: March 30, 2026</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Christopher Acevedo</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Christopher Acevedo</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ea028314601ex32-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report on Form 10-K
(the &ldquo;Report&rdquo;) of OS Therapies Incorporated (the &ldquo;Corporation&rdquo;) for the year ended December 31, 2025, as filed
with the Securities and Exchange Commission on the date hereof, I, Paul Romness, Chief Executive Officer of the Corporation, certify,
pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: March 30, 2026</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Paul Romness</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul Romness</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished
solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United
States Code) and is not being filed as part of the Report or as a separate disclosure document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Corporation and will be retained by
the Corporation and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ea028314601ex32-2.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report on Form 10-K
(the &ldquo;Report&rdquo;) of OS Therapies Incorporated (the &ldquo;Corporation&rdquo;) for the year ended December 31, 2025, as filed
with the Securities and Exchange Commission on the date hereof, I, Christopher Acevedo, Chief Financial Officer of the Corporation, certify,
pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 44pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: March 30, 2026</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Christopher Acevedo</I></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Christopher Acevedo</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished
solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United
States Code) and is not being filed as part of the Report or as a separate disclosure document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement required
by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within
the electronic version of this written statement required by Section 906, has been provided to the Corporation and will be retained by
the Corporation and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ea028314601_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028314601_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $[ G # 2(  A$! Q$!_\0
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MTW46MVCDUS0M9>_LXI%G6VEF B^7O^"V-_8_#ZY_X)B?M$>++I=(^%'[//\
MP4V^ _BWXP^*[S='H?@3P-XN\-^/_ALGC;Q'>!6BTW0]%\3>+?#T6H:A<[+:
MT@OGEEFC"C=^S=CX]\#:L^GPZ7XT\)ZE-K"!M)BT_P 1Z/>2:HK1&96TY+>\
MD:]5H095-L)08@9 =@S0!^*O[''[77QU^+7[&WPO^*7Q2_:A^''P\\<ZY_P4
M)^)WP9N_%/Q*\'^'8;;XB> O#7[1OCGP/X<^!_A/3=!A\/:=9>./$WAC1]/\
M.>&M=%O<:B;NV-[>C4+R661_N/XW?\%0O^"?7[.7B3Q5X+^-/[6?P<\"^-_
M^JZ9HOBSP1J/B:.Z\9Z#J.L:=%J^GQ:AX5TR*^UV&&?2YXK]KS[ ;*&UD22>
MXC#*#_-]X >,_P#!-O\ 8>)="O\ P_Z*@EE(W_\ #;?Q.  .<;L\ #G/O7ZT
M_P#!.KPUX8U'_@I;_P %O=:O?#^@WVN+\>/V;]";5[K2M/N=571;K]G?39KC
M1FOY8'NQI=S+^]FTXRBTFD^>2%FYH ^[OB7^T7X3\9>"?V6?BC\#/VJ_@CX7
M^&WQD^-OP\TS1?&&J#3_ !GX?^/GA775U<2_"[X9ZK::A%;6WC3Q9+:%-(U.
M%[J?3YM+OK>6S,RRI&G[1?\ P4E_84_9+\;:;\-OVB/VGOA9\+_B!JEE:ZI#
MX,UO6VN?$MII%\95LM8U?1])M]1OM#TB\:"9;74]8AL;*Y,;B":3:V/YB_@W
M'9Z9^R[^QIX7TV.WLO#W@S_@Y+^(7A3PKI%OB.PT/0;#XP?$RXLM%TRW!\JT
ML;.6]N1:65NL<%LC^5!%'&JJ/U>_X)B:CX!TS]N[_@MC)\2;[PMI_P :I/VT
MM!B$WBVZTFU\72_ 63X->"9/A?%ISZK(FHGP 737FT^*T/\ 8QU);^1D^UEV
M(!^A/QT_X*;?L%?LU1^#W^-G[3_PR\#2^/\ PII7CKP997>HWFI:EXC\&ZX6
M_LGQ/IVFZ+8ZC?2:)J&US:W[P1P2A)"C'RWV_-?_  4(_;ANM(_8G^#O[2W[
M%GQL\+:YH7Q)_:G_ &3O >F?$OP4OA;QUX?\0^ ?B-\>?"O@;QYH]I)JMCK.
MF1RZAH][JFB7DR6\&M:+=&;[/+I^I6P>+F?B5^U]^T=\4?V\?C?^QI^RSJ7[
M+OP6M/V</@O\&_B-X[^,W[0&CZ_XWU3QDGQH@UJ_\.:=\./!'AGQ'X&M[KPK
MX7T[1)5US7=0\7QVYU>ZBTZUMXQ&\M?AKX2EDM?^"0GBW0[[Q/X(\3ZGX>_X
M+U^'M-U/4OAW8VF@>!IKZ3]O/PE=7-WX1\*6NLZ]'X4\-ZI>W%SJ.D:(NKZC
M'!%<LT=_>EWN' /[<*_'7]L/]H[]JWQ?^W?\'O\ @G7^R?\ $OX9_LYZUXL_
M9P\9_M0_$?X^?$?X=O\ %;6#X6\/>/\ 2/AQI'@#X2^ [OQ)X5T#5/%=QJ^H
M2ZQXDU#6[^]ATK0!;SPV(F8"Y]]_:,^'/_!3CQ)\3;_5/V7/VF_V6?A=\)9-
M+TF+3O"7Q7_9S\9?$GQA;ZO#:*FM7=SXHT7XL>$;&>RO;S=-8VJ:-%)9P$12
M37##?5#]IK]A[]F7]K;PE\&]+_;.O- NOV@_AEX=BN?"OQK^%GCCQ!\ OB;X
M4\5:AI]I9>+_ !#\*]?\.^*[3Q;X?T#6=4MI9H=!O]3U_2H!Y,=U'=WD'V@@
M&-I&M?M*_L.?![X\_&S]N+]M?X5_'7X;^!_ DVO>&=:N?@!IW[/]SX;\06@G
MCM[7Q-J^@^/_ !AINNV'B#49M*TFQ2VTC1KBUNKHY><.NW@_V#/^"P7[*'[6
M_P"R?X=^._BKXW?!GP9XZ\-?!71_B[^T=X)TWQ8\MC\$;2\N8[#4?^$ANM22
M.>STZRU.>WL$FN7::2XGBB56=U!^+/V>-?\ B)\+OVJO^"@O_!/S0?VG?B5^
MVC^S/\.OV$=+^,FC>(OC1KVA_%7XD? _XO>-+_QKX>;X*:U\4]'TG3IO%T>O
M^%=/M?'>E:9XJ6]\2Z5;_9E$ODN]Q><_^S7^V9X7_8K_ .#>;]E/]H3P;X1\
M _%'QAI7P-^ /@#3_#FH:QINF^'QXK^)?Q!T'X8:5JGQ&U>PMM0OM+\(^%_$
M?B"'4O%UT]K)<VMKIMY&HCN@'0 _8']G/_@I5^PE^UKX[U+X8?L[_M.?#'XG
M_$+2]/NM7E\':+JL]KXAO=(L?+%_J^BZ9J]IIUSKVEV'G1?;[[1H[ZVLA+&;
MF2)74G)^(O\ P5+_ ."=WPE^.UI^S-\2/VP_@5X/^.EUJ^G^'Y/AUK/CG3+?
M6=,U[5O(_LO1->D$CZ?X?U;4#=6HM-/UJ\L+J8W-N!%^^CW?D+\5U_:4T?\
MX*J_\$A-=_::^./[(WC#5[_Q?^T[H?AK0/V?? FK^"O$'AJVU+]G[5)M8LM6
M\:^*?B-XAUGQ7X1UJ:.QMM/T8>&/#=K<:G##=$75SMMT_-OX(_"O]F+X1?M-
M_P#!;']E3XF?L$>-/^"D'[0WB?XW^)/B#H?Q-\$_L]Z9\6I= T+X]^%+[Q#X
M!^&&N^.O&5M')\&=8\(:AK4GF^(;'4K+0I;:*TUJRUB:\TH16P!_8-\9?VPO
MV7/V?/AX_P 5OC'\>?ACX&^'XUX^%+?Q)J7BO2[FUU+Q6$:3_A%='@TR>]O-
M9\2[$9SH6EVUWJB(ID>U5 6&Y^SY^TY\ /VK? [_ !'_ &=?BSX+^+O@V#4I
M]%O]8\':O#J/]CZY:QQRW6AZ]8GR]2T'6K:.:*2?2]7M+*^CCD21H-CJQ_D=
M^&W[,?[0_P"Q1^T9_P $2?@!I/A7]E#X9_$SPI^Q#^T9JU_8?&F"XTSX/2_M
M27>I^$I/$^I66L^ ]+ED\1?'2R^'$JZ3'XIECGU75M(T[5Y(M0<%<_NW^P;^
MRE^T)\-/VO\ ]L/]JOXU?$#]FJ\?]IGPI\%],U+X;?LRW/B^3PQ8^-/AA8ZU
MI%W\0O$D7BC3]/,WB?Q1HM]86%WJ*1R7=S#ID*7,TPB1Z .1_;&^.7[<&N_\
M%(/@9^Q'^RE\;OA5\!= \;?LF?$?]H+Q1XO^(/P1?XT7MWK7@WXCZ3X.L]&T
M_3E\=>!EL+2ZM-7CFFN#>SF-[=V6&0R!1F>!/VF_VX_V??VNK?\ 8J_;&^)?
MP$^)NG_&;]F+XP_''X$?M1_#[X::U\)QX.\2?!QM,@\;>&/BM\-]1\9>-=)O
M=,TS3_$6F^*]*US1M;LHIM.TV^L=2C-S.AA^??VYM(_:JUW_ (+C_LM:?^Q_
MX_\ @C\._BE_P[G^-L]_K7QZ\!>*_B)X0F\*Q_''PP+^QL]#\'>+?!NKP:S-
M>FP>WU%M5:UAM8KN*2UF:9-ONK?L*?M%6GB#X\_MQ_MR_M$>!/C;\<O"?[&?
MQO\ @?\ "'P5\%OAAJ?PK^"_PG\&^*M!O_$'CC6M/L/$GB[QIXH\2^,_&=UH
M^CVU_K&K:E;)IFF6!T^QBDMKDK  ?9V@?MP?L[_ _P#9P_9M\=?M4?MD? ">
M^^+GPVLM8T'XT#5]+\!_#_XY:AHOAG3-;\4>+OAMIMW>SQ'1[VUU"UUFSTNS
MNKN:*TU&S@@,\DD:MZS^S+^VO^RE^V5HOB77_P!F+XZ_#_XQV'@N^M].\81>
M$]7$NJ>%;N]CGFT]/$6B7D=IK&CQZE!;7%QIEQ?V,%MJ,$,LUE+.D4A7^;?X
M$:9X0U;0?^#3V'QG8>&-1T*W^ 'QFU%(_%5OI5SI$&HV'[(?@FZTJ]1=75K)
M+^TOHX)]-G4"YBO4A>T(G$9KU_\ ;*OUF_X**?\ !2K6/V49X+GXEV7_  09
M^*R_$C4/AJ]O,?\ A=W_  FOB:;X#Q^(;C1BUM+\1T\.0ZZ^BB^=]<7PZ+!8
MBMD(!0!^T/@G_@IO^P#\2/C0G[/7@;]K'X,^)OB]<:Y?>%]-\(Z9XLM)GUWQ
M3I;RQZGX7\.:P0N@^(_$>G2031WFAZ)JE_J<$L4D;VPDC=5^.K7]JOXWWOQJ
M_P""U?@O6_VA_!'P?\%_LJ^$/V>M0^"'Q$^)?A/P]=?#_P" 3^.?@KXP\5^+
MO&7C 6=MI&J>*O#T.NZ99:WJEOXAUF[^SVUH]K83V-M)(C?FE\,?V7?VMOVS
MO^"8W[%OP9\#?$K_ ()I_#_X/:/X7_92^*/PO\:^ -1^)R?$_P $:U\-;_P9
MXU74M',6AIIFF_$[4;W2]2T/QG=V]S'<3ZSJOB2"^GN&N[GS+/[8+QGP[_P=
M>#*?+^S-\ 0ZD@[<_LL?$?[P[;L$C/6@#]\_'7[?'[)/[-?@SX:K^TU^UA\%
M/"/BCQ3\)-"^(=EJFL>(;#PXOQ(T466E6>H^./ _AUYI[_4=%UK6+Z&;2[#2
MDO[E4U"UM8DF(#'U;]G[]KC]FG]JCX;ZA\7?V??C3X"^*/PZT6YO;'Q!XG\.
M:W;O:>&;_3;5;[4+#Q1#=_9;SPU?6-BZ7MU::W;6$\-HZW3H(&60_BO\"]!\
M.ZY_P5"_X)M7&LZ+HNL7>A?\$58]5T"?4].LM0N-%U!O%_P@M6U+1Y;J&633
MKQK:62V:\LS%,8)'A,FQRI^//V[4UKP5)_P<VZ+\)[:30+G5_P!G']D7XAZK
M9^%[>XM);K6M<\"ZYIGQ \2W,6CJMZ9]5\'6=TGB6]M$-_>Z;:RRLTLL2$ '
M]"7P7_X*6_L%_M$?%"3X,_!7]JGX0?$/XF$:BVF^%= \3P27?B5-'5WU>3P;
M<7"6]AXSBTI4=]1D\+7>K):1HTLK+$"]<O\ \%6OVE_%/[(__!/O]IKXV_#X
ML?BAI7@,^$?A-'%(([Q_BE\2M6TWX>> YM.# B74--\0^)K+6+6 JXFDT[RS
M'("4;\L(_P!EG]L+]JSX;_\ !/F#3OB9_P $W? 'PS_9Z^*'[.WQY^$?B?X&
MW/Q)G^(-EX1\':)"EWX/\!_VAH4.DV$/CSPC?SZ)K=O;3PV]Y;MY5TLHCRGT
M[_P<"6-T/V#_  KXODROA7X7_MD_L8?$SXC3,Q6VM?A]X7_: \'-XAO;X$A&
ML;+[7:7=RLI\K9#N;[HH ].\,_&WX[?!+]J3_@F;^QEX@\7S>.]'^*G[)WQK
M\3_&OQCXYMCJ?Q%\4_$7X/>&/A>]GK4NN^9"MI)>ZQXFUV?6(/LC_:-]O&K1
M"#YOM/\ :O\ '.L^ / /@S5M#^.7PY^ %UJ?QM^#7ABX\6_$[2(]9T/Q+IWB
M3QWI.E:A\,=(MI;NS6W\8?$FVN'\*>$]0$LCV&M:A:W*6\[((V_/7]ISQ-X<
MT[_@LA_P3&U[4M>T;3-%NOV9/VXY[;5=3U.RT[3YX[RR^#<EHT5W>SP0.;B-
MU>%%<O(F652JL1!_P6A\5^%?$O[,/P&;P[XD\/\ B!;/_@HI_P $^Q='1=8T
M[55MFF_:7\%>0+@V-S.(3*481"3:7*MLR0< 'V7^T9_P4J_81_9*\;6/PV_:
M(_:>^%WPR^(%_9VFI+X,UC69+SQ+8Z5?AVL-6UK1]&MM2OM!TN^6*1K+4-9A
ML;6[6-VMI951B/DC]KO_ (+0?LL?LV>,_P!A>TT[XR_!;7/AU^UEXXFE\0^.
M=2\631V7A?X'GPIXRO+/XKZ--8QO;W>F7'C7PW:>$_-N_P!RMU=S1LBSQ@#S
M[XM?LN?M7?LZ?M9?M8_M8_L9_'W]C+4X?VE8_ ?BCXU?!/\ :Z\/ZQI&I:-J
MGPP\ 6/A+3;/PK\9O!.M76L:%X9UO1-/-]+HWBSPE>:+I-[<&[MV6![FYD^5
M_''[5GA#]LOP?_P;^_M::O\ #WP_\']+^)_[:GB"WU?PO?WNE7WAS0=8M/A'
M\=?"=QI>D>));+3;+6/#NN^(M&NK[PG>M:6?]M6-Y878M$N92H /VX\<_P#!
M0W]B;X;?!7P'^T1XU_:5^%NA_!OXISW%I\,?&T^OI-:?$2\M);R&ZL_!&GVT
M4VL^)[NUDT^]^U6^CZ==RVT=M+-.L<*^972^'?VWOV1O%OP(E_:=\.?M#_"O
M5O@!;:C!HU_\5K7Q7I[>$=)UNXU.RT5-$UK4&D4Z-K2:MJ-CI\^DZI':7]M=
M7<$5Q;Q&5,_BY^U=J?QKB_X+<_ H_!;5/V5K P?\$]/'\_P,N?VFKK7[;P./
M$DOQMT:+XM'X077@RQOY%^(?_".P^%UUTVXBG'A!-302B!KF-_D;]NO]D?XL
M_"#]@S_@K'\5?CSXN_9T\1Q?MC?&;]D#Q7??#K]G.X\52?#WPOJ>@>,O"?@;
MQO?ZE!XHM-/F36_B-:MI%YK5Q:0JVHSZ?+<W;/<N9' /WW^*/[9/P>\>6-OI
MW[/?[:'[/?AC6OA]^TI\&_A;\5]7OKS2OB!H\VH^+]8O$D^!=O<:=J*Z?IGQ
M+^(%K876F>'VCO+B\TF^@9I[,N1&=3X_?\%1/^"?_P"RYX^F^%OQ[_:G^%WP
MW^(5F-/DU/PIK.I7L^K:+!JD2SV-WKT.F6%\FB6<]NZW/VK5)+6&.VS<2ND(
MWU\+_P#!5GX-_"+X%?LV?L5> /@S\-/ 7PH\$Z=_P4L_8=AL?"W@#PMHGA'0
MXWB^)!@BE:PT6SLK>>\9%'FWEPDMY<.6DGFEE=W;+\1?M9?M2?M4_&7_ (*"
M_"#X'>(_V._V=_A9^R5XSF^!7CK7OC]X4UOXJ>/_ (H:Q?\ PWLO%.MZ_=>#
M]/\ &GPVT'0?!-QINN)HNB-K>M:H^KI#>W,D?V5#;L ?N?X.\8^$_B%X5\/^
M.? GB31/&'@WQ9I-EKWAGQ3X;U*TUC0=?T74H$N;#5-)U2PEGL[^QNX'26"Y
MMY9(I$8%6-?@9\(/BY_P5&_;,_:5_P""A7A;X,_M:? +X _#3]DS]K/5_P!G
M[P9X8\3_ +*TOQ8UO6-%L/!GAKQ3%K&J^)U^+7@O;=>9KQLV@32Y=ZQ-,9T)
M6*OIK_@@C>6EW_P2)_8E2TU'3]26Q^'&OZ;)/I<T,EDCV/Q'\:VZP6T4,]PE
ME:Q0I$MGIWFO]@L_L]JK,D2L?S"_8L\+?\%&_$?[9?\ P66F_8P^-'[)?PV\
M"V__  48\2V_BO3/C[\&_B1\2O%%WXH;X7^ 'DU#1]4\%?$KP386.DKIALH8
MM,OK&[N/ML=S.;M8IEB4 ]?^(7_!27]M+0OV3OVOO"WCZ]^'W@#]K[]BK]MC
M]EW]GCQC\2OA/H$=W\._B?\ #[XR_%#X2SZ=XU\/>#?B"GBJ3PQ)XP^'/C34
M-'U?1[V[U.[T34TN+S2[VTD^R/!^NG[1?_!2S]A7]DCQ9:_#_P#:,_:7^''P
MP\=W&G:=JQ\(ZS?7MUXA@TS5<BPU.]TO1[#4;G3["["O)#=7D=O"\2/*K>4C
M,/QE_;8_8HU3]CS_ ()P_M >)/B/\7[_ .//[0?[3O[='[(OQI^/WQ9NO#EI
MX*TC7/%MQ^TA\%?#VBZ!X/\ !UI?ZK%X8\%^#_#NE:?H/A[2WU2^G,$,EW/*
ML]U)$GVGXQ_:I_:B^-O[9O[67[+W[.>O?LD_ ?PY^RCH?P>T_P"(/Q(_:'T#
MQ!\1/&?Q"U?XL^!E\:VL^B_#_1/%OP[M;3P+X>TF8Z2VK:OXIN%U35!=00I;
MQ1R(@!Z#^WY_P5J_9]_9!_9J^"'[1'A+XG_![QUH7Q^^)OPM\/\ PTU&Z\8+
M-X8\:?#CQ#X_\)>'_B=XZ\+ZOH;7,6I0_#SPGXDD\1WI20PP/;I#>*,2QK\9
M_P#!3[_@L3\%M&^$'[*&G_LE?MT_"OX;VG[3W[6GA'X-^-/VA_#D?AKQM>_"
MWX/:1;W.I_%[QMX=TSQ;I>I^&CJ6@-/X6T:YO]9TF_MM,'B6*9+<W+0R1_G7
M\.WT:V_X( ?!275]9\%:S:^#/^"HGA"'6=?T.VTW3O!^E6%K_P %+W2_O-.L
M/M^J6OA+PO- 5FM--?49;:STJ>VB:YN+=DED_7#_ (*[Q>$+_P ??\$?&T2+
MPS?:;)_P5G^ =H6TR+2KJQD:?P7\2'N+4FU62W?SE6!YX#GS56%I$8+&0 ?6
MWA+]MS]DO]F3]D[X/?$[X[?M]^%_BOX'\<_VW:> OVAOB/>>"='\1?&R>UUG
M56FC\/\ ASX<>&O#>G>(;OP_%"^D3CPKX15X[32UO-4#W$EQ>3>_> _VX?V1
M/B=\"O$_[37@+]H?X6^)_@-X(BOY?&_Q.TWQ192>&_!9TI()=3M_%\SLESX:
MO=/CN;>6\L=:MK*\@BGAE> 12QNWYP^.O^$1TC_@O;\&!\45\-:7X>M/^"<'
MQ)/[.1\4#2[+2[;XDO\ '+PL?BH/ GVX1VT'BU_ _P#9)U7^SRFI-X>-SC-G
M]IK\Q?VYV\(7NH?\'*\GPFDT"Y^%UY^Q;^S;%\49O"<UE)X;N/C_ '/ACQV-
M>%]/IS&S?Q@_@670QXE>.0WHCDTW^T66<PT ?T9W?_!17]A6RM/B)J-Q^U?\
M#1I7PCL_!]]\4-9A\?:)=:)X!@^(%[;Z=X,7Q9K-K<S:9HESXBO+NWBTZSOK
MJ*[?SDDD@CB8/7E>C_\ !8'_ ()@Z[?^,=-L/VX_V>$N/ =M)>^(GU'Q_IFC
MVBVD,H@FN=&OM6:RL_$T$5PRV[R>&Y]643.D8)9T#?EQ_P %,O@9\$O@[_P1
M ^''A#X6?"CX<?#KPIKOBK]@R?7M"\(>$- \/Z7XAN=1^*'PM>_N_$,&G6-N
MFO7NH/=W+7U[JYO+J]>YG:YFE::0M[C_ ,%4? W@2W_;H_X(4!/!OA&,6G[9
M7Q%\+V$1\/:-Y5KX>/P$\5WRZ'9V[69AATV&]T^RO;:RAC6&UNK6&XMDBE0/
M0!^A_P ._P!K;]FO_@H'\'_C9X=_8W_:=\)^+O$UMX1\1^$[CQ'\/-?GM?%_
MPQ\3>)-#U.Q\*^)[C3)X[#7M(:VU'R]5T749K*.SU V1:UFN$5Q7G7_!(;]I
MSQ;^UC^P'\$?B3\2=8FU_P"+GAR+Q7\'OC'K-Q;K;2ZM\4_@UXKU?X=>,-6>
M)<#=J]_H U9WVKYCWS/M^;)\.TC2])\.?\%]O%UQH=C8:1=>/?\ @E_X9U/Q
MK+8P0V\WB:]\*_M%:MI'AV_UAD4-=W.BZ7-+IUC<R?O(+)S;!S$%0<[_ ,$"
M[^#Q#^R1\>/'.D6S6/@[X@_\% /VV/%W@6P:'RQ!X8NOC-J^G0RPR!V6:WO=
M0TS4+N%D5(U67";Q\Y /W!HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**:[I&CR2,J1QJSN[D*J(H+,S,<!550223@ $FDVDFVTDDVVVDDDFVVVTDDD
MVVVDDFVTDVC?1:MZ)>;/.OB=\8/A=\%_#S>*OBOX^\*_#_P^)#"FI^*=9L])
M@N)PI?[/9K<RI+>W.T%A;VL<TQ'.S%>7? _]LC]E[]I+4-2T?X'?&WP+\1]8
MTB%KC4=(T#51)JEM;)*(7N6L+B.WN7MDF(B>>*.2)'*J[*67/\JW_!=OX1_%
M?]K#XS^'/B7^SM\6)/B_\-O!NFZ/X<^(?[.^C'5='\=:=8>'M9>X\7ZU\-['
M4$M;7XAV6NZ3]IDU/3?#,LNM&YLXRMK=V6)4?X!^,.G?LQ6&@6/PK\,W9^&N
MLZ%9R^#M:\'6=S"FL64IANK.[CU73[6=W\1Z7=K_ &9KFGZBRZA'J%C-8WBJ
M81G.IFW#V=< 8[B;PRS3*?$[B##X;,%A\GR+BCAZAEE7/, E+_5O$YPJV9T,
MMQU91JPCB<QC0PRJ1A449X.53$TQT,7@,[PV7<20J<.X/$U:/[[%X#'5<72R
M^I*,9YJ\'RX>OB,/3E.G>E@Z=6:C+EE55=PH3_L^HKQ3X+>/]:\2? 3P#\2?
MB-I5UX0UC4/ %AXH\5:;JJ/'>:.$TTWMW)?1E%D246D7VR=/+#*9&4+D8KQ?
M_AIWXD#PG_PN1O@?<#X$[!JAUT>+;-OB$O@XS"/_ (34^!EL#"=+6W(U1]-7
M6SK"Z7FY^RDJ4KNP&"QN/HPJ1PWU>HUAX5,/B,1A(3I8NO2C/Z@JD:TL/B,7
M"?M:7+A:M6G4E1E.E5=*I0G5\W,\XRW*JBIXC$3J)PQ&(C/#83&8A+ X::A5
MS&M"E0E5PN!@I4Y3KXF%/V?/RRIRG2KQH_:=%?&EW^T]XHUOXL:U\.?AIX$\
M+>)+?PVGA:XOI?$GQ$L/!OB/Q#I_B?3[758]6\$Z!J&G3)K6EV5E=+YEU-?6
M@GN8Y+>%=ZU4_;=_:&^-O[,?PIU?XR?#3X0^"/BCX1\#^'M8\1_$:'Q1\2;[
MP)J^E6=D]A'81^'K:S\(>)X=<FNWN;D7"SSZ<+;R(BAG\X[.B>5XRG5PM"I&
ME3JXR,)T:<\11C*U11=)5$W^ZE54X^S4W[[ERJ2FI0AEAL\R[&4\=6PM2M6H
MY?6J4,16AA<0Z3J493A6]A.UL1&C*G-594DN11YG%TYTZE7[6HK\]?#O[8/Q
M)\-?$;]GWX;?M%?#CX9_"S4?COH_Q8\1V^L:+\6WU_0= T7X?:%X0U;15EU'
M6_"OA:*[U3Q'/XDNK6>RS;KIZV$,L,M\UTT</GGQ?_X*/S>!M%_:CU/P1X#\
M'>-O^&?_ (K?L^_"W0-1N?B5#I?A;QC<_')M"ADU?5O$5EH>KVWANR\*W&M&
M.[\I-6$ZVDC2R6A+*BCEF-G.-.%.,W)0E&<:L'2DIXB6%BXU?X;3KQE!V=TH
MN3CRZOHEF6#A"4YU)047)2A*E-58N%!8F2=+6HK491DKJS<E%2YG9?J;17Y;
M^,?VW/CU\.?@/X[^+7B?X3_ #Q'KND>.OA7X#\$^'/A;^T5)XYT76M3^(WBJ
MT\+S/XJ\26W@&U/A0:5+?VEW;Q+IVIR:A"9N+<1%C[/\&OVHOB7JGQG\3_ #
M]HSX3>&OA+X_T?X7-\9M%U?P9\2+?XB>!]:\!6NO1>&]7FO-2N=#\,:QX>U;
M2M3N(&>TU31DM;RQ>2[M+V002+2GEN*A3G5:I2C3=2ZA7I2FU2]C[64*?NU)
MQI_6*//*,?=<UH[-IQS'"SJ0IWJQE4Y.5SH58P3J^V]E&=1\T(3J>PJN$92]
MY0;NKI/[AHK\Z?V9?V_+;]H:[^.MG>?#/4/ $OP]T*Z^)7PF&K:P+IOC3\$)
M)M=TO1?B?IBKIUO_ &18ZCX@\.7^FSV!-_):17&F79ED6]11Y5\(/^"AGQK\
M1:%^SE\2_B]^SGX1\%?!C]J#Q+8>#/ 7BSP7\7_^$R\3Z'XE\06VN77A6+Q7
MX-U/PAX8NAIFJKH%W%?7V@WFKOH[R0275LT)+U3RK&QE5C*E",Z/(I0E6HJ4
MI5*%3$QC27._;3]C2JS<:;;BZ52#M4A*"E9I@FJ4HU92C5YW&4:-5QC&%:&'
ME*JU!>RA[:K2BI5$E)5:<U[DXS?ZUT5^/<O_  4M^(_B#1/V6)/ ?P@^%5MX
MA_:/\$?%SQO<)\5?C<_P]\)^$K7X5>*CX9FTZ/Q,_@O5%U;4-9WQ7=M"]G8%
M +A%\Y83(>N^+'[?GQ7^&$O[._@";X5_!:Y^,/Q]TSQMKUC?:G\?H=#^ %CI
MWA&]MX+71](^,%WX.9/$GC'Q)!>6T^E:#;:%;85+N1[EH+<R&O['QZE"#ITU
M.;K6@Z]+F4<.ZRK3DM4J<'0JWES2ORW4&FF3_:V!Y9352HX05&\E0J\K==4G
M2A%Z-SFJ]*T;1LY6<TTT?JM17!_##7_&/BGP!X5\0_$'P=;?#_QGJVDV]YXA
M\'V7B73/&%EH>H29\RTL_$^CA=.UJT*A)K>^MDC66*1"T:.&4=Y7G2BX2E%V
M;C)Q;C)2BW%M/EE%N,E=:2BVFK-:-'H1DIQC)72E%22E%QE:237-&24HNSUC
M))IW35TSD_'7@/P3\3_!_B+X??$?PEX=\=^!O%NEW.B^)_"'BW1[#7_#FOZ3
M=KLN=/U;1]3@N;&^M91@F*X@=0ZI(NV1$8?$OP5_X)3_ /!.[]G7XA^'?BQ\
M%OV3_AAX"^(?A"2]E\)>*--@UN\O?"KZA:R6-XWAF'6-9U&QT#S[*66T9=)M
M;11;R/"@6-F4_$'Q?^,?_!P9IGQ9^)^F_!G]CC]CCQ/\']/^('BZR^%7B3Q/
M\>AH_B3Q!\.K77;Z'P;K7B#22X.EZUJ>@)87FIZ?@?8[R::WY\O)\[_X7C_P
M<K?]&._L.?\ B1:__%UZ,<KJ2C&7US*US1C*TLRP\9+F2E:47&\9*]I1>JDF
MGJF<3Q\$VOJN/=FU=8.JT[-JZ?-JG:Z?5-/J?M':_LG?LW6/A#PWX M/@WX(
MM_!G@_XI_P#"[O#'AN/2R-+T/XL_\))>^+_^$^L(/-/D^(O^$GU&^UO[9N/^
MGW,LNSYL#T#PA\(OAGX!\7?$GQ[X,\%:%X<\9?&#5]&U[XG>(M,M?(U/QMK/
MA[2$T'1-1UZ?>WVNYTS1HTTZU?:GEVRA,'&:_!X?'#_@Y3_B_8>_8='T_:+4
M_P#LW]?\*L+\;_\ @Y+/WOV(/V'Q]/VB ?\ VI5+**C_ .8[*/GFF&7_ +80
M\R@O^8/,G_AP%9_E(_96Q_9(_9JTW2M$T.P^#'@:UTCPY\9;W]H70M/ATLK;
M:7\;=1OKO4[[XEVB>;^[\4W.H7UY=RW^3NFN)&\OYJ\N_:(_X)O_ +#'[6/C
M:P^)7[0W[,OPS^)GQ!T[2DT*+QKJFG7NF>)[O1(@5AT?6-:\.W^CW^O:5;HS
M1VNGZY/J%I:QLT5O#'&Q4_F$OQM_X.1/XOV)/V(OH/VAQ_\ %597XV?\''7\
M7[$W[$OU'[0HR>O^W]*M9-5?_,PR7YYMAE_[89RSBG'_ )@,X?\ ARO$/\IG
MZ8?%K_@FS^PK\==1\"ZO\6/V9?AKXRU3X:^$+'X?>#=0O;+4;*\TOP)IBQII
M_@VYN-)U+3Y=<\+V:Q(+?0M?;5-,B&[;;#>^[9\,_P#!/?\ 8D\%:7XLT'P9
M^S'\(O"'ASQQXS\!?$3Q1X7\+>%K7P]X4U/QS\+[VUU'P%XJ7PMI!L_#]AK?
MAK4+*TO;*^TW3;.66Z@CGO#<R+NK\O5^-?\ P<9G[W[%/[% _P"[@P?TW_U-
M3I\:?^#BO^/]BS]BL?3]H'/X</\ YQ5+(ZK_ .9CD:]<XPJ_]L,GGM)?\RW/
M7_AR?%/\JA_0#7R3^TA^P=^Q]^U[JOAW7OVD_P!G[X??%S7_  C87&E^%_$/
MB73[I/$.@Z;=7/VRYT_2]=TJ\T[5K.RGNR;F2VAO%A:8F0IO)-?EVOQH_P"#
MB0_>_8O_ &+1]/V@,_C]^IT^,W_!PY_'^QE^QB.F<?'X'/K_ !?7]*I9#6?_
M #,\@^>=81?^XS)\145OE7$3],BQC_*H?K?^SU^R?^S;^R?X/U3P%^SC\%?
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M4\=J\1N?^"&G[+NF7_[-N@6_QP^+-SXE^(>FZ3XL\4:-I^G6^K7'Q0\,ZO\
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M-\=_$/7OCEX2\2Q?&+P!X9\:>(/"MO9_$O1]:^%7B[XJ>,?AW-XST+PGX?\
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M$:%3$.4HP]@JBG*HU3C+XZE/X;,<W\4,/CL#@I\15,'+,:F-AAZD*&%QJIK
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M%O#[:6UIKVC?%WQ[HWQ&NO[(N)+FU75OB+IVM0>+=521Y"EXE]J<RWD*1PW
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MUAE'%.&99E.=*K&.$@\3DT%BZ+DU.M4F\!-8*4(VDJ,XXF4V^558M7?\S?\
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MP>$]K[>>:\*RJ2QCIW>#<*E:<_9JJW3^O.LX-?O?JMFX&I_P4T^!7QF\?_\
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M>39M[.G&"P7+Q!PY36-<IP]I&K"6)DL"H6<DZBQ:JNG!)0;C*'\BFL?L/_\
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MA>,?"G@C4M6\/ZLNG?!_P)I=^UAJ,"F&X%IJ-E=V4Y0_N[FWEB/S(:_(Y?\
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MP5JM%T/R?@]^VQ;Q^&H[6/P]Y;_$5(] AT^)H;&+1@-5V:;%:P,\$,=H(HQ
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M;2/QC;/-HS+IZV^G2>U2:C^U'X#LOBYK_C#P]\>KCPMXB\/ZW#\.KOPGXO\
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M^*,-1S/):-+!OC#'5,KS/$8QX:.*IU,PH8;#8''PS+^T,)@\=AJ=+!X_$83
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MX/\ !UN;34TUG6DMUUM'\3ZBGA@^$XYM4G;5G>)+;3<M91:>+1;.=Y&A*JV
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M<327$2100.I9)II&<)%$RJS+(Y5&520Q )J>.2.:-)8I$EBE19(Y8V5XY(W
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M%J'AU/QM%H6G7-QYS &SM[F6["9D,/E@M5/PCX*_9K\;?%X? KP[\??B'/\
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M11);RVDJR;Q9UC]N/QEXKTOPY%XK\$>&O$/B+P[J'A.\C\1WE]?++JEKX?\
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MQUJ<)XWY9)Q<_P N(T?L$<J\;7\.:X?_ ,+,G_\ G:?4:?\ !"GX<I_S</\
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MR::FKP_])7V554L]P<:KIU%3?]I<.JU1TY^S=WDKC93<'=II6U35T^]^"?\
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M%'AVW_JE.I'_  3.\(]_BOXI/_< T4?^UJE'_!-/PD"#_P +5\4<?]0#1O\
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MDX8****X3L"BBB@ HHHH *^=OVO?^33_ -IO_LW[XQ_^J\\15]$U\[?M>_\
M)I_[3?\ V;]\8_\ U7GB*ML/_O&'_P"O]#_T_1,J_P# K_\ 7FM_Z:JGF_\
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ML@ZS^S3I7@2^;X6V7CCQQXF;XJWFHWOAS5#H-QJ&H1Z3H%W\/=)MM;\.S:Y
M^@Z%)=Z]HOBK4[:"Y\2-X7@TB-6;]Q* /S$_X++_ /*,[]J__L1M*_\ 4R\-
MU+\<_P#@E3^SK^T+\5_%_P 9?&VN?$FT\4^.)M)NM7MM#U[2[328I-*T'2]
MMQ9VUQH=W/$K6>E6SRA[F4M.TKJ55@@B_P""R_\ RC._:O\ ^Q&TK_U,O#=?
M!O[:?_!5']I3]GW]J#XK_!SP-I7PUG\)^"+[PU:Z/+KGA_4[W5GBU7P7X<UZ
MY-Y=0:W:Q2L+[5+H1E+>,+ (D(8J7/Y)XYY[X7Y!P1DN+\6,D>>Y!5XHJX?
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M:TX?^"K7[3,GWM,^&8^GAS4\]_\ J.#T]*\^IXN?L_E?G\*9OO\ \:_S%_\
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ME[_]1GVK2A_X*6_M"28SIOP]&<9QH6H^V>NL'U_SW\BKXS?LY%?VGA#-]_\
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M\7Q<U""FWQ)A7>:A!2=_[#L[R4G?2][V5[+ZY'["'P>7IJ?C3KG_ )"UC_\
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M,LM&T:R@T_3-/@2VM+2V01Q0Q(,  #JS'+.[99W+.Q+$FOSA\>_\I=/V</\
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MQPGW=,^(OISXW?\ E_9F*M)_P2*_8^3A=-^(?MGQJ_';_H&#L*_"JV_X*/\
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M4HZ8>'GC*[<OB'35]O\ A3S3O_V+&?0OAW]D?X07W_!2_P"(_P"RQ/;>(/\
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M8I0=2I*$?]3."%RP<YRC&RXS:7+!QC9-I6LFTDVX>&_CHH04O$Z$I1A!3?\
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MT0_XE+^C%))_\0&\+I)I--<+T&FFDTTUF3333333::::;33?X?\ \1+\0O\
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M]W;G5;J_LM+TG3[4BYFE>6XPT<; ?(DGQ-^(^HKK,=]X[\6W$7B2[GO_ !!
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M]E7]I9?7X!?%\?G\/_$ K;#J^(PZ[UZ"_P#*]$QQ#MAZ[[4*S^ZC5?Z'F?\
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ML>OCS_@GHNW]@W]C%?3]EWX%#_S&GANOL.KQVF.QJ[8S&+[L5B5^AGE[O@,
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M'EF_B:&23PYI?B7POXCU_P"'_@"#P4UMX6\0Z1X/L%OO[73PI/=VD"#]AZ*
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M'U/5?$FM:S:Z18B&6SGF,9>,RD>6OC?Q-^"O@GP/X=MY='UCQ+?>)(?B):>
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M]HD>OP-^+ _/P)KU;X7_ 'K"_P#83AO_ %(P_P#F<V-=L'C'VPF+?W87$O\
M0\Y_X)]#;^PE^QLO]W]F'X&#\OAMX;%?7U?(W[ *[?V&/V.U]/V9/@>/_,;^
M'*^N:TS#3,,>NV.QJ^[&8LRRQWRS+7WR[+W]^ P3_4****Y#N"BBB@ HHHH
M**** "BO(/CY\;_ W[-WP@\=_&_XDR:O'X(^'FC'6]?.@:3<Z[K+VOVFWLXX
MM-TBS!N;^[FN;J"**"+YF9\D@ D?-?A+_@II^Q)XG\+W_B74?CQX0^'UQH<4
MLOBKPC\3;H>"?'/A#RO'>K?#1%\2>%M7\O4M/6]\;Z'JFA:7.(YK;5;BTEDT
M^:Y@5I% /O.BOB>__P""C?[$%CXK\,^"H_VD_ACJ_B'Q9XYA^&^EVOAW78_$
M<$7C2Z\%WOQ"LM$U2_T1+ZQTF>^\(V$^KV<E_<007$)A6.0O*BG"A_X*@_L
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M:YIC:*G&HJ.,S''XJESQNHS]EB<97I\\5*7++DYH\SY9*[N4445]6><%%%%
M!7Y[^-%_XVA? 1O3]C/]H,>_/Q8^"-?H17Y_>,P/^'G7P';N/V./V@!^!^*W
MP4/]*]+*U>IC?^Q3FC^[#4CR,Y=J67>>>Y*OOQ=?_(_0&BBBO-/7"BBB@ HH
MHH **** ..^(G/P_\<_]B=XF_P#3+?5X]^QN,?LD?LQ#T^ /PB'Y> ]!%>Q_
M$$9\!>-QZ^$/$H_/1KVO(/V.QM_9,_9F7T^ GPE'Y>!-"%=R7_"9-_\ 4QI+
M[\!6_P CSI/_ (6*:_ZE-=_^9/#H^CJ***X3T0HHHH **** "BBB@#\S+I?^
M-PFCO_UCPUQ?S_:%T0_TK],Z_-.Y7_C;WI#]_P#AWOK:^W_)P.BD_EQ^=?I9
M7K9JK+*O/),N?WRS \3)'=YWY<1YJONAE7^84445Y)[84444 %%%% !7A7[4
M0S^S1^T*/7X(?%8?GX%UVO=:\-_:>&?V;/V@AZ_!+XIC_P L;7*Z,)KB\(N^
M*PJ_\N<,<F/TP&.?; XU_=@\6_T///V!QM_8>_9 7IM_9H^"(_+X<^'17UHS
M!%9F.%52Q/H ,D_@!7R?^P:NW]B/]D5?[O[-GP47\OAWX>']*^DO%>GW>K^%
MO$NE6!5;[4] UG3[)FD,2B[O=.N;:V+2CF-1-*A,@Y098=*VS!)YGCXM\J>8
MXV+D]HIX_%Q;?E%-OT1AE<FLFRR:7-)91E\U%;R:RS!245YR:45YR1\Y_#O]
ML3X5_$_XE_\ "JO#?A[XSVWB$S^((%U;Q)\$?B9X8\$R-X;6Y>^DB\<ZWX<L
M_"\L%R+63^R9TU-HM7+0C3WG,T>XUS]L/X7>'_B[_P *5O?#/QLF\6#7].\.
M?VKIOP-^*&I^!/MVIVUM=6\__"?67AJ;PG_9<<=U&MWJO]J?8;.598;B>.2&
M15W?V0?AKXQ^#O[,/P,^%OQ"EMY_&_@/X<>'?#7BB6UOVU2VDUC3;18;MH=1
M8LUY&7'RW!),@YS7E?[<?[75S^R;X6^'-YH^F^!-2\2_$KQM=>%M*/Q)\6W_
M (,\(:=9Z1X;U?Q3KFIZCK&E:)X@U$RPZ?I+6^GV=KI<SWE_=6]ON3>"?0AA
M<'BLUJ9?@,%5Q:DZ^&PKCF4H1K5:,L0UCO;/!2M0J4:/MEAW3<8P:7MI-H\B
MKCLPP614LUS3,:. E".&QN-4LGIU)X>AB(85/+/J\<QC?%4L1B?JSQ:JJ4IQ
M;^KP2;7H/QD_:W^&?P-\5V/@[Q?X;^,VKZKJ&G6^IP7/P_\ @G\3/B)HB6]U
M</;1QW.N^$/#FK:7;7:R(6EM)KE+B*(K+)&L;!JV_C'^TS\/_@=I7A'6?%^@
M_%75K7QJDKZ3'X ^$OC_ .(5[:"*S@O6&NV/A'0M5NM 8Q7"(BZK%:EYQ);J
M#+&Z#\\?@_\ \%>_!?B75/$EK\8_A=XT^&$*:#I=QX(AL="UKQ'-XI\7V7AW
M3-4\9^ ;2X2SM4O/%D.H>(/#]KX9TBU@%SJ,&IQ&]6SN \2>SZ/_ ,%4/V==
M3U"UTJ]T#XL>&]0MK3QM?>,;;Q'X'N-,/@.T\!:D^C:Y+KTDMT8KEAK"+IEO
M!HCZI/)=S01O&GG+794X>S##SHPJY!CJCH1<L7*CCXSIXGGA)PE1J4Z4XT%"
M249JE]:3J6HRE"I.$9>?2XMRK%4\15H<5Y916)GRX"&)RN5.K@O9U(QJ1Q%*
MM6IRQ3J0O*FZ_P!2:I<V)C&=*E4E#ZI\2?M+^ /"WP:\._'/4="^*EQX/\3G
M21I^D:3\)O'VL?$" ZT9Q:?VK\.]/T*?QAI'E?9I/MW]H:3;_8 8C=>5YL>Y
MWA;]I3P#XO\ A%K_ ,:M+T+XI6WA/PV=16_TK6OA1X]T/QW.=+DBCN/[+\ Z
MIH=MXKU42-*IM#8:7.+Q0[V_F*C$>9>"_P!M'PM\4_V=/B7^T#\,/AY\0]9'
MPUF\5V&H_#_Q9I5O\/?%,^I^$DCN-01Y/%%S:Z9:Z<FG3)J\FHO=R1IIZ3A(
MY;R,6C_._P -/^"E,WB'QI\"M ^(?PDUGPAH?QA^&/PHUG5?$&@C4?%6D^ /
MBS\:-4\23> _ASXCU>*QL[6!-5\):%!K,-\T*32S:@ICMS8PM<'GADV)J4\4
MHY375;!XRJL0I9C3C4ITJ-)8N>$6&=-RG56%DFL5"<N=ZTZ-2HG2.NIQ%@Z5
M; N6?89X?,,OH2PDH9/6E1JU\17E@*>/>-550IT)8Z+4L#.G%4HV5;$4J358
M^TO@O^TQX ^.]CXIU#P;H/Q5TB#PC%:S:FGQ"^$OC_X<W-RMW#=3Q#1;7QCH
M6D3ZXZI9RB:/3$N6@D:&*4*\\2MN? CX_P#PV_:/\&WWCKX7W^LW>C:5XJ\1
M^"-7M_$/AO7/"6N:1XI\)W[:9K^CZIH/B.QT[5;&[L+Q#$ZSVJ!N&0LIS7M-
M?.W[.M_\#+^R^+S? NQ-C:6OQ]^+-E\3P;;6K8W7QIMO$<L?Q+O<:W)(\PN=
M>\R07&F[='FSNTY%AP*\V2PE6CC:M'"8NE[.>#=!JO\ 6*.'A4G5IUH8JI*A
M1E*5>48O#348<LXU*;C*-IGL0ECZ&)RVAB,?@:_M:>8+%1>%^J8C%5*5.A6P
M]3 TH8G$0A'#1G-8VG*=12I3I5HSA*\''^UQ\.?A#\6OV</BU\//CW/JD'P@
M\3>%YK3QXVB7<EEJTFB075K>R6VGSPVUW.;FZGMH+:.&"VFFN3+]GB3?*I'Y
MT>-OV;_^";7C*_\ $%AX4USQ%\,?$OC:3X*>%?"-C\$A#X8U]'^!>N_&;Q%X
M;U7X0:2_A'58-4BU6;XC_%3_ (6!K\-CKMKKMC'+>74UK?6EOJ,_ZD_'/X:W
M'Q:^&/B+P38W]MIFK7ATO4]"OKY9Y--@U[P]JUEKVBG58+8B>XTI]2TZVCU*
MWBR\UF\T:JQ8*?DK4?V$]9U32;/3+[XSVNHMX0\*V7PW^$M]J?PJTF6^^&OP
MSM;NTN'T6ROM/\4:7J6H^+9(-'\/6$?CV*_TC44L]+N(;C3[M-7U!9///6/C
MWX/?\$U_V#-6\0^._#WPC\<_M->#KSX<:]X5>]LM'\47/@;1?AVO@7X:WGPF
MA\.>%<^!M/TZVBUSP'JAB\2ZP/[1\9ZY$;/5)?%$9C1J\OTK_@G-_P $L9?A
MU:^"K']I7XQ7&@Z[JZ6<>NW/Q1TM]7UCQAH_C?0?%VB^*+K4;OX;BSN]6\,^
M*M+M%T[5;FR/A^9]6O;36H-6EU&(K^T.E?L[^&K;2[O2M=\0^+/$Z3^(O#_B
M=+V^UO4-/U*;5?#_ (/T?P?'-K=YH]U8-X@&I6^D#4-6@U%6M+Z]NYVDM=H3
M'R?J/_!.RZU36_&6LR_'C7-,7XAZ!#\/?%>B^'_!-EIN@6WPJM=;/B.W\.>"
M-+NO$FIQ>"/%<FL):7.H>.]/:ZDOUT^QC?0(C:Q2* 9/B;]C_P#9A\?^*O!F
MF>&/C?\ &[P#>^+O@G=?L[O:?"#Q]I7A/1/BMX1^"[_91;:]<6G@ZZB7QA\/
MY!=&&_\ "-SX6:."74+.YM;S3FFLQR&C_P#!%']C?2?A;+\))-0^-&L>')/$
M6D^+EU#5_'VG2Z_!XFT'2/[*T;68+ZS\*V5JEUISK!JT49L&M9=7MH+BZM[B
MW$EK)]+?"[]C*/X2_$SPCXKT7XL?$+Q;X0\):AXNUS2_#7Q&U>#Q+>Z)J/BO
MPS-X<O-,\-7UMIVE0:7H%U->ZAXCU&)X+B]N];F5GG:)F(^X* /R^T7_ ()+
M?LTZ=\6T^-NM>*?C/XY\?R^(O ?C75]2\:^*_"NJ1^(/'7@*TAL[;QIJJV?@
M33;A-:\1I;6TOBVVTFZTO0-6N+:"6'1;$Q*!] _M??L;>!/VQO#W@CPSXWU_
M7_#6G>%-8\=-J,WAH6T>H^(/!_Q/^$?Q ^#7C_PA]LN0XTI=:\-^/[B_M-9@
MAN;K3-:T72;M+:YB2>"7[ HH _.J]_X)G_ [PY%X=NOV?O$/CK]F+7_#/PHU
MSX1B^^#]QX:L='\<^'M3AGFTYOBYX>UCPYJ4?C^;1==GEU^"Z2_T#6KFYN;R
MUDUN.TGCCM_L;X)_"CPY\"/@]\+_ (+>$'NI?"_PH\!>%?A]X?EOF5[R;2?"
M6BV>B6,UTR@*;B6"S227;\H=F"Y !KT^B@#\_/\ @J>N[]@3]I!?7PAIW_J4
M:$:_G5_X*&^'Y?%O_!2SXL>%H9(89/$7COX6Z*)KF5(+>)-1\ ^ K:66>>5D
MCABCADD=Y)&5% )) K^CO_@IS:&^_85_:'M1UF\)V"\<'CQ+HAX_*OYF?^"H
MDL(_;[_:&1WCS_:_@@,K,O0_##P5P0>V#SGMR>*_DWZ;DZ</!W@>=6D\12I^
M*52I6H*3@ZU&'#3G4I<ZA-T_:TX5*7M.27)[3GY9.*B_T+P3C.7B+Q-&#Y)2
MX(RR,)\O-RS>=YDE+ENE+DE*$N6ZYN7E;5[K]G?BZOP>\/ZIH45U+X0T33_A
M=K'CSQ9I%OJ0^&%QKNE>$/AQ\,X_"?A'6_"L_A>VNI;KPMXM\67=MJ-WI_BB
M:\UV^OHY9HK2*-4D3YQU3]D;]G&PUC1=-M_#]KXA\9:+I7C?Q)X>\*V?Q9T_
M[5^TEHVA^#=+U:P\4:E=A$L_!4.N^,]0O8+'3[*19I]$LW@CC$Z,X_!6Q^R(
MJA?LZ $-\OEJ 01AN,<CG!ZBNOL98=R$219SP0ZY '0 YX R< <<GU.?X.XD
M\=LGSO$XBMF?A;D6,IRK4IX>.(Q4:TL+"ER07LE4R66']K1HX;!1PK5'V'-@
MZ>'QU+'936Q&42_H3+N!L9@:=.&%XFS"DU":J.%&4%5E)RE[_)C%4Y)SJ5W5
M]_GM6E4H3H8N%/%K]VK;X8_L]^.?A/\ #GX6>*=-T'X;ZAIC^$/$@U#2O&]M
M?3>#O%GQD^(%[;7W@F666(OK5M9>&O#[K+K.HS&339KRVC,$4>)9+?B;]E_]
MFO\ X2S7H=%\!>,H+?PI;^"/"]_X7T[QK)9177B+6KW6-<U[Q5%J5_I]_J4N
MCZ-\-M&FU>]D>RMK9]7DA13%;3*S?B/8-:@I@P# 7&-G&1AL8]3C..N!UQ7?
MZ)K-]I;-)IFKWVFRRQW$4LFG:C<V4DL=S$8+F.1[6:)Y([F M!<(Y9)X28I0
M\;;3\+F'C1PMC*=.GF_A'PSC*M*GE>%68>RP-3&?4<GP.*PF P_LJV64,&G2
MJUU7FZ=.G3Q--O"8N%?#X;+5@_;H<'9K2<Y83BK-*,)3Q57ZO>O&@J^,KTZU
M>IS0Q52LU*,/9Q4ISE2DE5I2A4JXEUOV7^'GP6_9[T^&SU/0]7U'P7H7QC\#
M>!O"B1>)?%6AZUK.G_\ "P/&VKW;W NI=/B32Y]4\$^&M/C9HX@NDW^LH9+O
M:P1KWA3X%?!.XL_%NN^*OA%I_AJW\/ZKX[T?Q%H@^+*SOX)T3P3X/.MZ%JMC
MNVW.O^*?'>HS0Q06</F6,,$,_E?O5"-^/5K/'(4,DPD,<:1QEY-YCB4 +&A8
MDI&H&%1<*H "@#%=5:20,06>-B,MDE2<Y!#<YR<G(/4$Y]:^1K^-W"U&G@J4
M_!SA6K2R^&,E2P\OJ<\)4Q.-P=%UJLL'C,CS"GAJ']L4Z^8K!9?4P]&>'QV)
MPE:I4Q%'*\QRSU(<%YK.5><>+<VC+$2HJ=1*NJT:="K/D@JM'&X=U9_5)4\.
MZV(C4G&I0IU81C3GBL/BOW%TSP#X \1>'_"GP3W>'KF_UK1M&\$VD5CJ.E_:
M+R[\"_#'4O'$]W<7UK(\Z&3Q_P",H8;E@R_;'TEH0SQ@JGA?P<TGX4:#\<OB
M/J.DZS9:%X-^&7@F]\/Z+XFU6VM/$+:EXVU!M/\ !4?BF'1;_?!J*SZSJ-_K
M-K91Q/!;VL,!?:B-(/S[\%>+-6\%ZO!X@\,:BNE:Q;VM[:VVH0Q6[SVL>HVD
M]A=/;F:.1(9S:W,R17"J)8&<R0LD@5A=M)(F(+/&QRYRS*3N;ECDGJV22>^?
M2OG^(_'_ "/&XK@K.L-X9Y+2SOA'.I8J+JUJDJ=7),IR2>"X7RB.8T,+A<;&
M.%SO&8K/<QG0H8>K7>7Y/A*6)@X5L0N_+^ \=1I9S@ZG$6.G@LVP:I-0II2C
MC<5C56S/%O#SJ5:#=3!4:6"P\9SJ1@L1BZLJ;YH4W^O7C+P!\#/$UM\1/'7B
M/27GO;'4KSP%-JFAW>GZ2;'5?#&FZ1IMMXWDTC1A_8L0\5:I=7&K3M(XMFT]
M(OL\;W!N"N2G[/7PVO\ Q'XK\+6_AVPT*V\(7_@:RLM>NO'5M=W/B?PKK6I^
M?K?CZ>-I8K*!4TO2M3M[6QLI)"DFH6^]!)''O_,:T\L1@@H(]P .0$W*AP!_
M#N4$X[@$XP":V8FC)4%D(P."P(XQP<G!QC@=L#&,"OGLW^D+P7F^/^NYMX$\
M'8JI5KU*^:U*%7 X7&9Q4Q&(SS$XM8W,/]7,1B4ZF*QV2XJ%?#PPV-A4RG%4
M*N+Q&!S7ZM@^S#< YS@Z"H87C;.*<(TXT\+&<,14I82-.&"ITG1P_P#:%.D^
M6G1QE*4*CJ4'#%TIPI4Z^%]K5_027P/\ M(M[R>?P[)J2Z#\/==^(VK,GBTV
MR:@FLZ]J&F^ _"VG1H)&2^BLQI][J4X,LX@+E[;][O7N]:^"GP'TW2M&,ECJ
MT8@\/:IXYO\ 7-.\1I]GUG2+;PXNKOHJ7%S$\,5P-5N[;2+"2RAFD58))+D&
M9GC7\V(##\I!CX*D'*\$]2/0^I_.MBVE52<2A<KY;8DVYC)!*'!&4)Y*'*D\
MD9KY:/CUP=3HYA0Q/@+X<XJ.)PL*&$<LNP,982<,72KRG.2RNE6Q"JTL'@:$
MY+$4<3>..J1K\N:8N@=53@C-W.A*EQMQ%3=.K*=6U>NU53IR@DD\1.%-QG5K
M5$O9RIV="/)?#4JA]Z?$GPO\-/!?PG\53^%_"FFWM[J^H^ M.GNSXACU2^\'
M7\OAQ-9OFMY@@N)TFOIA9/'&B0S2F3[0R+&D=>N:?X=L-+\+>%_ WB!O!\7A
M+4_ G@[1;%-WA^XU?7?'_B#6+75=9U>*]B634[ >'M(%REU=3W$5LJ[(MK;B
M#^8]NT8 PR 9'0@#DGT.*U[?RNWE\D9^[R,DG/KZG-<N'^DGD^6Y[FF;X/PF
MR+!X7&\+9)PG0R'+<=@LJR>CEV#SO/\ -L_HXZE@N$76S?"<3_V\UC,)BJM.
M5"OEV7TX8VIDV&H9/0QK< 8O$8.A@ZO$N.K5*.98S-)X[$4*V)Q4Z];!X'"8
M*5&5;-%#"U<N^I7I5:49*I#$5Y2H1Q=2>+G^D-[\-/AIXRN-'UR^MX;";QCX
MUU&WGO-1UI;'5I]+LXM0FTF+PW8V,3:8^EW-IIEM97;W'DWL$]TK)&TKJAN6
MWPH^"[ZAJNH1>'Y$T_3[MM-\1Z;J7BH:?'X8BT[PS)K-WJ>FI*1J&I3ZE=F&
MTL()E(!2=RH/R#\ZX&3*@LO'3D<?,#QSQSSQCGGK6Q$4XY4\ ]0<GKD^IZG/
M7J:RQ'TF> ZN(ECL=]'+P]S',:^)HX['8_&_4:]?&YA1R[$TYXAJKPY5I4*6
M,SC'8_'YCAE3QL<?@\;6P]:M2S*AE6:9+SKP_P ZC3]C2XZSZA0A3G1HT*2K
MPC2H2KTY*FG''1E.5+"TJ-"A4O1="K2C.$)4)XG#XO[\T+X-_#6XM?!<5U80
MV]U=:%?ZW?V6H>()X_$&LZCI\=J6TY;6U26T_L2Y:_CN+:YLI#>M'920;26=
MU^,_VN/B)XG^'W[/'[87AWX6?#KQ]XY^&VM_"OXD^%M:T32;==4?P-;ZMX-U
MC3KWQQJ<[S(EEHF@RK<WNIRHTLS:5%NDBDDB$B=G\)?A;XB^*WB*+1="C,-G
M 4EU?671C9Z39[@&D=UP'N'&5MK93OF<] @9A]N?M5?#CP]X!_8,_:C\)^&[
M00P-^SS\6TNKI@OVS4KR7P)K4<EY>2@9>5R?D3[D*8CB 4<_W!]![@+.O&WC
MKPW\3.&?#3+? O@3PVXYR?,\?QSPY4CA>)O$ZOE>3Y/P[/@;*\52R?+_ &?#
M>(Q%/%X_CFM"CFN1XQXN&7<N*XB;Q^5?AOCGF^'X5X3XQX>QG$6)XJSO/N&,
MXP^'RO&TU7P/#T:\<TQZSC$4*N*K0GCXT^3#Y1"<L-BZ48RQ%Z>"C&CB7_L*
M_%[6/B%^RS\/;[4?@Y\5OAQ)X$^&7@/P_8Z;X^T.STS4/'5OHW@'1FAU_P &
MQ6VH7:ZCHNL>4JZ7<SM:R3O+&'ACR2+OP6_:W\7?%SQ_8^"-7_9#_:B^$%C>
M6.J7C^./BEX+TC1?!]F^G6SW$=G=ZA9Z_?SI=ZDR"WL$6V999W569 =U>S?L
MUQ&#]G3X!PGK#\%OA;$<]<Q^!]#0_P J]KK_ &ZQF(P?UO-;Y=!NMBL2L/+Z
M[C%]3:KXF+E%*-L3S3O4Y<191<N1>XDS^1LOPF8/+\B:S>I%4,%@I8N/]G9>
M_P"T(O"X2<83DY7P?)3:H\V$O*2C[27[QM'Q1\5_VO/%_P ,_B-?^ =,_8^_
M:G^)UA92Z5%'X_\ AYX)T?5O!%\-22%Y9;34KKQ!97$D>F&5DU M:J8FAE"A
M\#/IGQX^/6O?!;P]X3UW1?@%\;/C9/XFO);2ZT+X1>'+#7]9\,)'IZWPN_$5
MO>ZIIL=I:R2-]AC>*68F\5HRH4;J^BZ*P^LX*^%?]F0:HQ:Q,?KV-_VUN'*I
M2=KX:TO?Y<->+?N/W3K>#S+EQR6=55+$23P<_P"S,M?]FQ4^9PA%RY<:I0_=
M\V,M)+WU[Y\\^#OCKKOBOX):O\7[OX#_ !H\)ZQI<.MRQ?!WQ-X=L+/XJ:J=
M'D\N&+3=$AU2>SFDU@?O-*5]0C\].7,9XKDO@!^T[XG^-_B+5]!US]E[]HOX
M&V^EZ/%JL6O_ !B\):7X?T75)9+D6YTK3KBQUK4Y)=2C4_:)(7B11 "P<D8K
MZSHJ7B,(X8J*RZ"G6FY8>I]<QC>#A[MJ<8-<F)2L_?Q-IOFUV12PF8*I@IO-
MZDJ>'IJ&,H_V=EZ68U%S7K3J*7M,&W>/[O!WIKDT?O2/B+4_VPO&&G_%RX^%
M\?[''[5>HZ7!XTA\(K\4K'P/HTOPXGLYK^&R/B^'5V\0I=-X7A24WLMZ;(3+
M9Q2R" L I[G]H+]I#Q)\#=4\/:=H?[-?Q_\ CK'KMA=7L^I?!KPMIOB&PT%[
M:?R5LM:EOM8TQK>[N1^^@CC256A^8L#Q7U)15_6L#[6A/^RZ?LZ=)PK4?K^.
MMB:CC%*M*IR^TH.,E*7LZ"=-N7*_=C$S^I9G['%4_P"W*OMJU:-3#8C^RLKY
ML%14I.6'C1YO8XI2BXP]MB6JT5#FBN:4CY[U7XZ:[IGP&M?C5%\"/C-J>M7&
MFZ;?M\$M.\/6$OQ>MI-0U&&PDT^XT!M32Q2^T^.4W]]&-298K**217=@$/Y_
M_#'X[:_\<?\ @H_\,-3USX ?&[X%OX;_ &1_C?:VUE\9/#FG^'KOQ,+WXF?!
M^=Y?#T=CJ>IK=1:>;=8[YI983')=VJJA#%J_82OA7Q?:%O\ @H]\$;W!Q%^R
M5\=+?/;,OQ-^#[@?7$9/TKORNOA7'-*?U&$:M3+<VG1Q'UO%.5"FZ%%QP\:+
M7L:R23A[6J_:M/F:YDCR\ZPV.4\DJO,ZDZ%+.,AI8C"?4,#&.*K+%8F,L5+$
M1E]8P\G)JI]7PZ=!-<B?*V7_  !^V!XP\;_%#3_AS??L=?M5>!M.OM8U'2I/
MB1XQ\$:-I_@&QBL#<"/5;W58/$-S<QZ;?B!393+9NTGGPY1=QQJ_'3]JWQ7\
M&?&J^$-%_9-_:9^--F=%L=6_X3#X2^#=)UWPL)KR6ZC?2#>WNNZ=-_:ED+=9
M+N'[/LC2YMRLC;CM^QJ*X?K6 ]O"I_9-/V,:+A+#?VAF'+4JW5J[K\OMX-)-
M>R@O9.]V[I'I?4<U^JU*/]O5?K,L0JL,;_9.5<U*@DT\*L+S?5JD6VG[>H_;
MKELE9L^>_BQ\=-=^&7PS\-?$/3/@1\9OB?J/B'^P_M'PZ^'?AZPU?QWX=_MC
M3UOIO[=TRZU.RMK;^QI&^PZKY=W+Y%XK1IYBC=1\'_CIKOQ4^'?B7QYJOP(^
M,_PIO_#TFK1V_@+XE>'K#1_&OB(:98&]BDT+3K35+ZWN4U1Q]ATXR74)EO"(
MW"+\U?0E%8^WPOU?V7U&'M_;>T^M?6L5S*ES\WU?V%O8<O)^[]M?VUO?MSZ'
M3]6QOUM5O[3G]6^K^R>"^HX'E=?V?)]:^M<WUE2]I^]^KI>PO^[O[/4^-?@=
M^UCXL^,?CB+P=K/[)/[3OP9LY-(U#5#XR^+'@S2-"\*1RV/D[-+DOK+7M1F&
MHWWFD6<(MRLGE2[G3:,Y_P 1OVO_ !AX"^)NH?#NP_8[_:J\?Z=8ZGIFGQ_$
M7P3X(T;4O =]'J#0"34;/5+CQ!:7$ECIWG,;^5K16B$,Q5'VC/VU16_UO ?6
M)5?[)I^P=%0CA?[0S#EA5NVZZK\OMY-II>RDO9*UT[MG-]1S7ZK"C_;U7ZS'
M$.K/&_V1E/-4H626%>%YOJT(IIR]O!^W?-9JR1\W_'_X_>(/@AI_A.^T3]GW
MXX?'*3Q--?0W5A\'/#>G^(+WPP+*WM9TF\11WVK:8MI%>M<M!:-$TWF36UPI
M"A 3<T'XZ:[K?P)O_C//\"/C-HFM65CJMXGP5U?P]80?%N]?3=0>QBL[304U
M.2RDNM31!?:>C:BHELW21V1B4'T)16*KX54:--X"#K4ZRG5Q'UO%*5>DIN3H
M.BE[&DG%J'M:3=5)<R7,V=#PV.>)Q%59I46'JX>5*AA/J&!<<+7<%%8J.(<O
MK%>49IU/85TJ#<N1OD2/BGX>?M)^)?CEX<^*FDZ[^S1^T%\"H=%^'^MW\.K?
M&7PKIGA[3-:DN-/O+=M/TB:PUG4WN+ZV4_:)XGCC58,L')^6OG']C[]K[Q@?
MA?\ LS?"QOV-_P!JVWTMOAW\)_"/_"T)_!&C+\.4LAX6T2P'C)]8&OBZ'A26
M(#4XKW["9CITD<ODLW!_3GQXN_P/XS3^]X4\1+_WUI%X/ZUY3^R=";?]EW]G
M2 \&'X'_  MB_P"_?@G14_I7IK%8'ZABI_V73]G4QU"%&A]?Q]L/4678A.M&
MKR^UKMR<9>RK)4X\J2=I2/&>"S3^U,#3_MRK[6CEN)J8C$_V5E?-C*3S?"..
M&E0YO8X91BI1]MAFZTE-RDN:,3DOV@/VF?$WP/U[1=%T/]F/]H?XYP:OI4VI
M3:U\'/">F>(-(TB6&X,"Z9JD]]K.F/!J$RC[1%$D<BF'#%P2!74^*?CIKOAO
MX':9\8[;X$?&?Q+K.HVNC7,GP9T#P]877Q8TYM6NDMIK:_T.34XK**XTA&-S
MJB+J+B&W5F0R, I^A:*\U8C"*GAHO+X.=&HI8BK]<Q:>,AK>G*"7)AD[KW\/
M>:Y=-V>P\+CW5QLUFU14\12<,)1_L_+VLOJ-1M6A5<O:XQJTG[+&6IOFL_AB
M?.7P$^/FO_&S1?%FK:W\ /C=\$)O#%U:V]KI'Q@\-Z?H&J>*%N;.>Z:Y\.PV
M.JZDEW!;/"MI<-+) 4N9H4 96+#S/X8_M?>+_B+\2M/^'VH_L>?M4?#C3[Z[
MU2UD^(7CWP3H^E^!K%--\XQ75YJ=MX@O+B.WU+RA]@=;1C*98@RIN./MFBJ^
MLX+FQ3_LR"C6BEAH_7L=_L<E!Q<XRMS8EN7O\N)M%-<B]TCZGF7)@H_VU5<L
M/-RQD_[,RV^8Q<U)4YQYN7!*,+T^?!WFT^=^^DCXQ^-W[6OBWX/^.[KP7H_[
M(O[4'QCLK?3--U!?&OPJ\%Z1KGA&YDU")I)-.@O[S7M/G:^T\KY=]&;8+'(R
MA7<$D>D_&?XZ:[\)? GAKQII'P'^,_Q=O?$-QI\%SX*^%_AZPUKQ=X=6^L!>
MR3Z[87FJ6$%M#8N?L5XT5S,8[L>6H9?FKZ%HI+$8/_9;Y;!^Q_WG_;<:OKON
MV]ZT?]EM+W_]FO\ R_"-X3,7]>MG%1?6;?4O^$W+G_9OOJ7N7E_MUXWA_MO+
M9/G^))'SW\,/CGKOQ%^%7B3XEZC\"/C-\.-3\/IK[6_PR\>^'K#2_B%XA.B6
M!O8$T/2;;5+RVN6UQQ]BT<27D0N+LB-S&OS5P?P(_:H\5?&CQC<>%-:_92_:
M5^"EI!HMWJZ^+/BYX/TK0?#,\UK<6L":/#>V6N:C,VJ72W+3VT!@"/#:W#&1
M2BAOL"BAXC!\N*2RZ"E6=\-+Z[C']25DN6,6N7%:IROB;/6VR0UA,P4L"WF]
M1QP\;8R']G9<O[2ES2?/.2ES8+W6H\N"3C[O-\39^(/CS]H;Q'X2_P""N@^R
M?LU_M ^+UTS]DR?X;17/A?POIM[;ZEINH_&K0=4E^)M@TVJ6_F?#S3IG_L._
MU5V2YBU@&);5D'/Z4?M!_M!^(?@8?"XT+]GCXZ?';_A(QJ9N3\&O#.G>(1X;
M_L_[)Y8U_P"W:MIGV4ZC]J?[#Y?G>;]EN=Q38N[P6XLV_P"'K&EW^#M'[!^L
MVF>V3\==&EQ]>,_2OT0KULTQ&#4\BE++X5(4\BP"K4_KF,@L0VL=&'-.*<Z/
MLY1E-*C=3=1QG:,('@Y+A,QE3XGA'-JE*I6XGS3ZM6679?-X2,'EDI\M.<E3
MQ"K0E"F_K#3IJDJE.\ZE0^>[3XZ:[<_ 23XV/\"/C/:ZW'I=WJ(^"%QX>L%^
M,$DEKJ,M@FFIH"ZHUB;^ZCC&H6\1U(*]E)'(75B5&'^S[^T;XC^.5_XCLM<_
M9O\ C[\"DT"UL[FWOOC+X6TWP]9Z^UU*T;6VB26&L:FUS<6H7S+E)%B"1D$,
MQ.!]045X[KX1TL1!9?!5*M5SH5OKF+;PM-M-48TFO98A12<?:5VJCYKO5(]]
M87'JOA*CS6I*C0HQIXK#?V?@%''55&2>(G64O;81RDU+V.%3HQY>5/EDSXBT
M']L+QAK7Q9M/AC/^QQ^U9HFF77B^Y\+-\4-7\#Z-!\.K6TM[JXME\57.KIX@
MDND\-W"P+<P78LFE:WGA<P L57IOC[^U!XH^"7B?3/#NB?LM_M'?'"WU'1FU
M:3Q'\'O".E:_H.G3"Y>#^R+^ZOM;TR2+4RJBX$*PNGDNK>9DD#ZWHK7ZU@/;
M4JG]DT_8PI.%3#_VAC[5JKM:NZW+[:DXV?[JDO9/FU>B,?J.:?5J]+^W:OUB
MI7C4HXO^R<JYL-17-?#1P_-]7K1E=?OZS5>/+HO>9\]>.OCKKO@WX+Z)\6[+
MX#_&?QIJ^L)H3S?"+PEX=L+[XH:,=:1GF35=%FU.WM('T4J$U<)?R?9V90GF
MU'\"_CQKWQF\+^*O$>L_ 3XU?!>Y\-7IL[;PW\6O#EAH6O\ B9!IHO\ [9X>
MM;+5-1BN[4R$Z>'EFA)O@8]NWYZ^B:*Q=?"^PG36!@JTJSJ0Q/UO%.5.DYJ2
MPZH->PFE#]W[:;]LT^=KG1T+#8U8JE6>9S>&AAU2J8+ZC@5&M75-Q>*>)4OK
M-*3G:K]7IIT$U[-/V;9\5_"']KKQ=\4OB'8^!-5_9 _:E^%=A>C52_CSXD^"
MM'TCP79?V;#-+$+O4;37[ZXC.IF(1:?MM6\V66)7V!B1Y-^V_P#M2^*O ?@S
MX\?"W3_V4OVE?B%I=Q\(/&%H?BCX&\'Z5J7PZB77O ^HFXNI-7N-:MKI;?0/
MM3_VVXL2UO\ 9;D1K+M4G]+:\7_:0B\[]GGX[0CK+\'?B9$,=?WG@S6D_K7?
MA,5@'F>$J+*J<:/M<+3^K?VACW%5?K6&:Q'MG'VS:6GL6O8NVKU/+Q^!S19+
MCZ+SVK+$JCC:KQG]DY4I2PZP.+O@_JRE]649/_F)3^L*^BLD?'WP3^-FM_ W
M]@K]BW6=#^!WQA^.4VL? 7X,Z7/H?P<T"Q\0:QHL2_#'0KH:GJUO?:EID<&G
M,Z"U65)9&^TNB;,'=7TOX5^,GBKXE_ ?QE\18O@Q\8/AGXHL](\80:/\-_'&
MA66E?$>]U#2])DDTR?3-+M]0O;60ZK=RQQ:0SW0\ZXB8.JA>:'[$<!M?V-_V
M5K8\&W_9Y^#T)!ZCRO .@I@^_P O/O7T%XKU"\TGPMXEU73U5K_3- UC4+%7
MB:96O++3KFYME:%2&E4S1(#$I#2 E0031CZV&^O8RE'!0EB%G.,F\7+%8E>U
MI_VGBFJ$L/9X>$))QA*K%NHHWE9R;097A\8LMP%>6958X27#V7P6!C@L&_8U
M?[%P*>)AB^98NI.,E*I&C-*BY<L&U&S/#?V/?^%I?\,N_ G_ (7:OB%/BW_P
MK;PY_P +"3Q9&L7B5?%'V0?VF-;C145-1$V1<*J@!^@KB/&WC3]C7QO^TKX"
M\#>.?&7P]UW]HGX;IK%MX*\":UJ2W6I:1>>,M&CFO?)T2Z1])EUV_P!$M!-9
M"8/JD-FLLUFB*SL>Z_9"^)7C3XQ?LP_ SXI?$6"WM?'7CSX<^'?$OBJWM-*G
MT.VAUK4K037D<&D73R7&G1K(<+:S.TD0^5B37YB_%7_@G]^UA\5]5^,]Q-XS
M^%_@P:O\;_'G[0OP\\4>'=1\1CQKJWC&7P=IW@/X5^&M:N_L$47ACPYX2T&Q
MO)K^^TJ\N=1N;[56^SQQI&\A[L)AL+5S;-_[1S"GD\Z=;&4E+"U>2E"MB,9B
ML/6A12I2G6P=%-QE2I>QJ5,+)<LX1A-/S,?B\;0R'A_^R,JK<0TZN&R^M*&.
MH>TKU,/A,OP.+P]7$N5>%/#YAB9)3A7K_6*-'&PDI4ZDZE-K[3\=_L<_L5^)
MKVPTKQ;I6DQ>(/'WB;QE?^'+B+QQJ&G>(M3\::]K.F^-O%>I>%[RVU2.\3Q%
M'=:!97#3Z:?M.FZ=:?9H!!;C:.+\6_\ !/?]@_2?"LGB?QQX<DN? 7@/PAXD
MTE'UWQWXEU?P[X7L]<N)KCQ'XCM\ZC=7$7B:]N[AYK_6FFGO;JZV37*37"[Z
M^"+G_@E5\?);6#6+(?"[0/$L5C\;-1\)Z5HWCWXF3:-\)/$_BO3?".A^ [GP
MKJ>I7DVJ7EROAW3/%%AKVJ2*DR:SXAFU15N8E15^QOA3^R_^U1\ _P!EWXJ^
M$?@U)\'O"WQT^)WQ4U'Q)I-M>Z[XV\2_#7X8>"K^'3-,M;3PY)XB-_JVJ>(=
M%TG3GNH&OXTTZ\\1WTVHW:S0QB.7U*TEAJ5!8/C2O5G]8H472>)EAX0C5JNG
M6K*M%UW0I4,-37/5C3G%R25.$H5*:GXE",L76Q+S#PYPU"FL)BL1&O'!PQE2
MI+#T%5P^'>'FL,L57Q.,JOV="56E*,+NK4A4HU72]2\*>.?V#?"?[/'@[X):
M7\:?!TOP=^,.G^)_AMX134O'\UQJ'C*'5;B3PUXET>VUB26+489UO-2.AW#R
M?85LKRXBL5:&X9(SS^E^!?\ @GI9?&WQ3\1K3QAX8A^(?P"TKPE<^+?#][X\
MUF#PWX%'@#P^_P -_!GB?4?!U[>Q:++JGA[1$F\,:+K*VMXT<\\L5N7U.=9#
M\FW'_!,WXPPW=KX>T*+X667@GXB_#OX7Z/\ %G4]8UWQ'KWC'PUXC\#_ !-G
M^+_Q#/A/4I]-A75[KXW>,8]/DU[Q!+#I3Z6!=2K92"WL5K9\?_L#?M'_ !ST
M/QQXS^.T?PYU[XN:K\3? NJZ?9>!_'/B7PKH5S\%_ P\77_A[X0Z'>_V*S>$
M;;2/%NN:%XSO]8FBU6[\4:SHD\]Z;1Y+*.&E0RB,ZLJ?%&+A3QDJKQ,EB:'M
MZDL565)RJT8T81GST*5>GB92K0E'FPN(35"O.C")8G/YTJ,:O!& J5<OA06"
MA+!XGZM2A@L-*M&%#$SQ-2=+DQ5;#UL%".&JQDXXW"23Q.&IXBK^QOP^^(O@
MGXJ^%;#QO\//$5CXJ\*:I)>1:?K>F^?]DNI-/NYK&\2/[1#!-FWN[>:"3=$O
MSQMC(P3Y7^SKX!^%O@&Q^+T/PL\5MXLM_%?Q]^+/CGQQ*VJVFJ_V#\2_%'B.
M74/&OA<-:1QBQ70M5=[0:;.&NK(#RIW9AFKG[+OPW^(/PB^ /PO^''Q5\<-\
M1_B%X4\,VVG>*?&+&5QJ^I"6:9BD]Q'%=7<5G%+%817MW&MW>);+<W \V5JQ
M_P!FGX&S_ RQ^,UI/XDL_$A^)W[0_P 8/C1&]E;&U&C0_$KQ/+KT7AZX!=_.
MN](63[-<7 VB9QO"+TKY2HL/1AF]&AC)RI+$8>&&A%<U/'TJ6,Q*56<W2@TJ
M--0Q-)N-%R==IP=N2/W5)XO$5,@Q.)RZG&N\)BZN,J3:A5RJOB,NP;E0IPC7
MJQD\16=3!UDIXA0CAE*-17YY?2E%>&?M*?';0_V:?@EX]^-?B#0]8\3V7@K3
M+>>V\,^'_LXUGQ)K.J:A9Z+H&@:?+>/':6T^KZWJ-A8"\NG%O9K.UU,&CB93
M\V>(_P#@I%\ OA-K5G\.?VB;Z3X/?'3_ (0:U\=ZM\'K26X^).MVMCJ&NPZ)
MI^FZ/?\ @[39QXCU6[-[I=W%:V6G0M)%J"I )W@F*^8>T?H-17YD:;_P5M_8
MTN=5>WU'X@-IVA7DWADZ'XEAT;Q-J=F=,\06UL+G6/&,%MX?5_A[I_A_6+E-
M!UF;Q++%%:ZDKQ2RQNICJOK7_!6;]E>_^%^F_%?X.>(E^-/AM_C[:? ?Q&?#
M,YL)O#-_!I>M^)?$_B2=-0MQ_:&G:%X3\/:EKMK;6Q276H_LUO;S023,T8!^
MG]%?BOX>_P""RGAS7O$O@+P->?LZ>.?!OC#QSK_PNB:7QSXPT+1/AWX:\&?'
M/P0/'_P:\1>)/B?::7JOAO1?$'CO0MUK:>"M7&G7-OX@0Z"FL7E]+;K/^D_[
M+?Q_TK]J#X&>"OC9I'A[4O"5OXL?Q+9W7AC6)X;G4]"U7PGXMUWP=K&GWD]N
MB0RO'J>@74D;QHH:"2(D DT ?0-%%% !1110!\;?\% [/^T/V//CA9XSY_AJ
MR7!&<XU_2&''U&:^DM2^&OPZUR]FU;6O /@K6-5O!$UWJ>J>%="U#4+IHH8X
M(VN;R[L)KF=HX(XX4,LC%(HTC7"(H'B_[9UG]O\ V9?BS:8R)]"M5(Z]-8TU
MNG?I7\M/_!3CQMXWTK]NW]H#3]*\;>,]*T^WU;P6MOI^F>+/$.G6%NLGPV\'
M22+;V5GJ4%M KRN\KB*) \KO(P+NS'\H\<_%3+O"?@3(\]S/AM<44,;Q7B<J
MA@76P-#V-6MD\<6L4I8_ 9C2?+#!RH\L:,*G[RZJ**E&7N<"\+8CBGBW-\)A
M\R>5SI<.Y=B'75.O4<XT\SQU/V7+0Q&&FDW74[N<H^[\-VFOZ\Q\(_A0.GPQ
M^'@^G@OPV/Y:;3A\)OA6.GPT^'X^G@WPY_\ *VOX*1X\^)ZY+^//B2J@1$EO
M&/BX!?/*B G.IC'GD@0YQYI($>[(SK'QG\5H9+B";QI\3XIK50]S#+XJ\91S
M6RD;@]Q$^HB2!2N"&E5%QSG%?R9/Z:/"JU_X@US)-)OZYP]NTW;_ ))-ZVC)
MVO>T9.UHR:_8EX.9G>RXP:_[E\P75+_H;[)M?>NK5_[PQ\*_A@.GPX\!#Z>#
M_#P_EIU/'PN^&8Z?#OP*/IX1\/C_ -Q]?P@P^/?B5)%)-'X]^(LD$6T23)XR
M\6/#$6!*B25=4,<98<J'92PY7(JW%\0?B%G_ )*%X^ZK_P SKXH]3_U%:XJG
MTVN#X6YO!BD[JZ;QW#*NM=5S<):JZ:NKJZ:O=,VCX+YK+;C*?FOJV9:/3>V;
M;Z];,_NV'PR^&XZ?#[P0/IX4T$?^V%/'PV^'0Z> ?!0^GA;0Q_[85_"K'\0O
MB$,X^(/CWC_J=/$_?/\ U%:V;/QG\3KP2M9^,_B1=B$Q"5K7Q5XNN1$9W\J$
M2F'49!&9Y2(H0Y7S9"$CW.<5S/Z;_!LFHQ\$J523O:,<;PO*3LKM\L>#YRT5
MV[)V5V[+4T7@MFJWXUJ17=X;,TM6EN\YBMW_ ,.S^Y,?#KX?#IX$\&CZ>&-$
M'\K&GCX>^ 1T\#^$!]/#6BC_ -LJ_AUA\;?$F1[B./QO\0WDM%9[J-/%OBMG
MMDB(61[E%U(M D;,JR-,%5&958@L ;,?C_Q_S_Q7WCKM_P SEXE]_P#J*5R5
M/IS<%4TG+P-H6?-;FQO"JOROE:7-P99N+T:5^5Z.ST-8^">;O;C:ITVP^::7
MU3TSGJM5W6JNM3^K'1/!'AK_ (>#>/K9_#>AG15_9-\ 30:4='L/[*BU!OBG
MXQ26_BL#;_8TOI856"6[6$7$D$4<+R-'$B+]J?\ "">!QT\&^%!_W+ND?_(=
M?Q Q>,?&0O'OT\8>+AJ,L$=F]^OB;7?[1EM4=I(K-[T7_P!KDM4E=I(K5I6@
M25V=(P[L3NR>-?B):S2V]UXU\?VUQ"P26WN?%?BB">%L9V2PS:BDD;8(.UU4
MX(XP:,;]/7@?$>PJ?\0&P\8X?"83!2D\=PA*,I4*=6*DY1X'C&+J*;DH2<JE
MH-N5364>; > N<X18J#X\J5'B<PQV/7^S9NG".+J49^R2EGLVU2]ERN45&#Y
MURPAM+^V/_A!O!(Z>#O"P_[E[2?_ )$I?^$'\%_]"AX7_P#!!I/_ ,B5_%*G
MCOQX<Y\=^.#TZ^,/$?O_ -1.KZ>.O'?/_%=>-^W_ #-_B/\ ^6?M7ES^GIP+
M&]_ ?"O_ +G^$/\ Z"3T5X&YR]/]>:O_ (2YM_\ /H_M,'@GP8.GA+PP/IH.
ME#_VTI__  AG@\=/"GAH?]P+2_\ Y%K^,!/'/CG&?^$Y\;9SU_X2[Q%Z#_J)
M5?B\<>. 3GQQXTQE<Y\6^(2,<^NI?G7+/Z?? <=_ /"/?_F/X.Z>O [-8^!&
M<R_YKJHO^Y7-O_GWYG]F/_"'>$?^A6\.?^"/3/\ Y%I?^$/\)#IX7\.C_N":
M9_\ (M?QQR>,/']JYANO%_CJVF 1S#<>)O$D$H210\;F.6_1PLB$.C%<.I#*
M2"#5N#QGXZE=8HO&7C6621T2.*/Q3XBDDDD<[42-$U L[NQ"JJ@LS$  D@5A
M4^G_ ,"0ER2^C[AN=/EY'C>#U-2NERN$N U-2;:7+R\UVE:[2=Q\!<XDKKCR
M=K7NL+FK5K7NFL\M:R;O>UM;VO;^R2PTK3-*22/3--L-.CE8/*EA9V]FDCJ"
M%:1;>.-78 D!F!(!(!Q7@/[8-M]L_92_:0M<%OM'P0^)T1 &<A_!^KJ1CZ$Y
M]J_EL7Q9X^5KA&\6>.0UI_Q](WB3Q(&M0'$9^TJ;[-OB1EC/FA,2,J'#$"GR
M>+/%MU!/:W7BSQ3=VMQ$T-Q:W7B/6KFUN()5*RP7%O/?20SPRJ2LD4J/'(I*
MNK*2*]'!?M*N'LHGA%A_!3,\-A\'7I5:6$PW%62X&A%4,5"M.G1HT.&<-AZ-
MZM.<9>SP\5&K*<IP<^=2XL;]&[&YCAL90GQIAY3QF%Q.'E6J91C:\E]9PM;#
MJ<W+-)U)J,:ZDDZEY1BE&23BU_6+\!8OL_P,^#$&,>3\*/AY%C&,>7X1TA,8
M[=*]8K^/2W\7^+X(DA@\7>*X((42*&&#Q+K<,$,4:[4BAACOUCBBC4!4CC54
M10%50H K8/BKQU 4$_BOQM"TT<<T*S>(_$41EAESY4L2R7RF2*3!\N1 R/@[
M2<&LZ_[3C)JE2O77@WG7+*K.I*W&6624/;UJLX1E-</.*;<W%-N//*+Y4W[J
MUPWT:<51H8>@^,<&W2H4:*?]BXI<_L*%&DY*+S&Z35/FLN;E4E=Z7?\ 7G17
M\CA\4^.H,>?XI\:P;ON>?XA\11;L9SM$MZN<9&<>HSVK2B\1^/3"UP/$?C<V
MXC,QN!KGB(P"%9/*:8S"[\OREE(C,F[8)"$+;CBN67[3G*E*4%X+9]*4$Y3B
MN,,OYH16O-.*X;<H1MKS248VUYK:G0OHVXEI/_7+!)-I)O)\19M]$_[3LWY)
MM^1_6C17\FT7B_Q?Q_Q5WBO[W_0RZW[?]/\ 5^+Q=XN)Y\7>*SRO7Q)K?K_U
M_5Q2_:CY''_FS.<O2_\ R6V4K_WWS6/T9L7+_FL<(O\ NB8O_P">)_5U17\J
MB>+?%N,_\)9XIR#_ -#)K7M_T_5=3Q9XL).?%?BD\?\ 0QZUZC_I^KFE^U/R
M*-_^-+9T[*__ "7&4_\ T/&L?HQ8MZ_ZYX1?]T/%_P#SQ/ZGJ^/?$UF7_;M^
M$E_@GR?V:/C#;[L' \WX@_"Y\$]!DH/QQZBOPO@\2^,9C((?$OBV811M-+Y6
MO:[)Y428WRR;+QO+B3(WR/A%R-S#(J$^(O$+7*7I\0:ZU['#);17K:SJ37D5
MM,Z22V\5VUT;B.WFDCBDE@218I7BC=T9HT*[8?\ :M9)A?:U)>"&>RCB,)B\
M-%_Z\93!/VT(4I3C*7#3C-4I)<\8-N[47*$M'QXSZ+.+Q<</!<;8*#P^88+%
MN^18N3?U6K4K*#2S-.+J*5HR:LK.5I(_J8HK^7A?%OBL,,^*_$X^OB+6!V/_
M $^U>;Q+XQA;9/XD\60NR)(J3ZYK<3-'("T<BK)=J3'(OS(X!5QRI(KA?[5;
M).64UX(YXX1<5*2XXRIQBY-J*E)<-N,7)IJ*E*+DTU%2::76OHQXMV_XS/!I
MN]D\DQ2;M:]E_:5W:ZO9.UU>UU?^GFBOYB8_%?BKG_BJ?$W;_F8-8]_^GVIT
M\4^*3G/BGQ,<8_YF#6/?_I]K&7[5S(H_\V2SM_\ =]91_P#0X#^C%C%;_C,L
M'U_YD>+Z*_\ T,3^F^BOYGX/$'C.9#)%K_BV6(/Y9DBUC7)(Q+MW^672Z90_
MEJ7V9W; 6Q@9I4\4>*"/^1G\2'G_ *#^KGL/^GRIG^U=R6FHN?@;GT8S7-"4
MN.,JC&:[PE+AF,9K3>$I+S%'Z,F*D[+C3!MK=+),4[/LTLS;3\FD_(_I?HK^
M:E/%'BC:/^*G\2=_^8_J_J?^GRK*^*/%! )\3^)/_!_JWK_U^5@_VLN0J_\
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MNK&RBD@N8BSI.S6R^+ZMH?\ P3?\*>!?@_\ "KX?>#]=UG1/$'Q<T3X\>"?
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ML?$W7=)L/#^A6$%G>74-DUJUO.Z3"+^>Q 2H0JQ12"B%6**<ELHI!53DY^4
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M^UCQ/X-T#P&NMZYJ?C-HM2:R\.1:]XHO[72M*$B6GV&*W=)7CE7!T-.^#?P
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MTTQRJ3$HF/Y^@[R[OEF=B[,P8LS,278DC)+$G<3UR0<U849QN&< !,@G:!G
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MPV,Q>*J+V56HZ*J5*[ISNH2I^TA4P_TKX.\"?#CQUXW^+MO/I>E>"-/T?4=
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M0,8_AQR/P[>M?4YI])G@##4^'\;P]X)<)RSS"1J9OC<1BLEX=R'#Y5Q5+/\
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MBZ99H+:.YD6.]O<F,1".OSS50"" !SC('J<D9_6K**N<;1C'3;D=1V IY?\
M2MR++,'_ &=0\!N!'EL8T\)]4EC)5%5RB&.HYP\!7EBN%,="K4J9[@L#FU:O
M&A0P>*Q$<7/,,FS2O4RRMD>-?PZQF(J^WGQCG2KMNK[54HQY<2Z4L+[:"IYE
M2<5'!UJV&A!SG5IP=-4<7AH1KPQGV?8>#?@@S3VVHQ6=A'K&E:SK$.K2^(YA
M)I-O>>+3HWA:ST^R,[02SBPB:^O'EBDECMG6615B!:MBV\(_">S7QM?Z]X8\
M/(OAV>XTS3M'T7Q7%?7$VABSNY=.\1/<RZXD=QJE\\=MYAMENO)#-&;))9%Q
M\1(=W4,V  N0S8 SP,@X ]!@"MS0-!U7Q)J]AH>B6$^H:GJ,ZV]I:01DO([=
M6;C$<2 ;Y97PD:*78@"O)RKZ0^28C%99EV5_1R\-LPS:IBL9@\IPN"R/!8RO
MF>.SG 5\NRK#8O*?]5<P><ULMX@S*IF^486E/#U,5B<;4R[,)9AA:.34LBZ,
M3P3BZ=/$5\1QSGU'#J%*IB:E7&5:4,/1PM:-?$5:>)_M*@L+"O@J$<-BJDE.
M-.%%5Z'L*DL5+&=5\/+SQ?9^-=%F\ "[_P"$D:\$>FP6VZ0SH[?/;WBC"263
M1\79FQ$L8:1BI4$?M/I+:D^F6#:S';0ZLUI =1BLW:2TCO3&IN$MW?#O"LNX
M(S<E0#7B7P.^!VD_"G21=W8AU#QCJ,"C5-4VADM$;#'3=-+#,=LAP)IAA[IQ
MN;$85![[7^U'[/[Z,W''T>_#K-,9Q_Q#FD<^X^J8'.<1X=T\7&KP[P4H4G*D
MYT5[:G/B[&T*U*EGU? UZ6!PM"AA<HY,QQ6!KYC3_E/QFX]RGC7.\/2R;!8=
MX/)HUL+#.Y4G''9KS2M)1G[LEEE&<92P4*L)5JDYU,5>A3K0P[****_O\_&0
MKC?B-%]H^'WCJ#&?.\'^)8L>OF:->KCCZUV5<]XMB\_PKXE@Z^=H&L18]?,T
M^X3^M72=JM)]JM-_=4IO]#*NN:A7C_-1K1^^E57ZG)?!2W^R?![X6VN-OV?X
M?>$(<=,>7H-@F/PQ7IU<;\.K?[)X \%6N,?9O"N@08]/*TNU3_V6NRJL0^:O
M7E_-7K2_\"K57^I.%CR87"Q_EPV'C_X#AZ$?_;0HHHK(W"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y[Q79_VAX?U.SQN$\*J1ZXEC;^E:$^CZ
M3<RO/<:7IUQ/)@R33V-M+*Y4!07DDB9VPH"C<3@  < 5?95=2K@,K#!!Z$4Z
ME.,*D%"<(3C&3DE.$)I-I*Z4XS2=EO:]M+BBG&<IQ;3E&,6XMIVBY/=-:7D9
M/]@:%_T!=)_\%UG_ /&:/[ T+_H"Z3_X+K/_ .,UK45E]7P__0/0_P#!%#_Y
M2:>TJ?\ /R?_ ('/_P"3,K^PM$_Z VE?^"ZT_P#C-']A:)_T!M*_\%UI_P#&
M:U:*/J^'_P"@>A_X(H?_ "D/:5/YY_\ @<__ ),RO["T3_H#:5_X+[3_ .,T
MO]AZ+_T!]+_\%]I_\9K4HH^KX?\ Z!\/_P""*'_RD/:5/^?E3_P.?_R9E_V'
MHO\ T!]+_P#!?:?_ !FC^P]%_P"@/I?_ (+[3_XS6I11]6P__0/A_P#PGH?_
M "@/:5/^?E3_ ,&3_P#DSB8_#6D#Q9=7W]D:9MDT&TMO^0=9CF.^N9?O>3DG
M$G<G@#T&.C_L71O^@3IG_@!:_P#QJM'8N\R;1O*A"W<J"2!] 233JJ5##RY;
MX?#^[&,5_L]#:*:7_+CS(A*I#FM4J>].<W^\J;R:;^WY&9_8NC?] G3/_ "U
M_P#C5+_8VC_] K3?_ &U_P#C5:5%3]6PW_0-A_\ PGH?_*"_:5/^?E3_ ,&5
M/_DS-_L;1_\ H%:;_P" -K_\:H_L;2/^@5IO_@#:_P#QJM*BE]6PW_0-AO\
MPGP__P H#VE3_GY4_P#!E3_Y,SO['TG_ *!>G?\ @%;?_&J/['TG_H%Z=_X!
M6W_QJM&BCZMAO^@;#?\ A/A__E >TJ?\_*G_ (,J?_)F=_8^D_\ 0+T[_P
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MA/\ H$PG_A+AO_F8/:U?^?M7_P &5/\ Y84O[-T[_GPLO_ 6#_XW1_9NG?\
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M\11_9VG_ //C9_\ @-!_\15RBCZG@_\ H#PG_A)A?_F8/:U?^?M7_P &5/\
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L0 < 4M#=VWW;?WMO]0BN6,8K:,8Q7I%)?H%%%%(84444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ea028314601_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028314601_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ## HH# 2(  A$! Q$!_\0
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MG.< #).!DCD@9QTR>3P.:?5>YA,Z&/C:RR(X+,NY70H0&3#J2&.'1E=#RIH
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M'\0>+K&QU^+Q'\2KW0=,TO0+7P/X?U;QI\3/%7C36=&L;+0M2.M)J+R> /\
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M^&_!+>*?$5Q\6/$.MV-JMIKC>'M#TF'4+3^T=03WCX^_\%5/V:_V=Y?'VO\
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M[RI !)PHS4YY!Z]QCH?3C/KV/T-?R_?'W]N_XY_#;_@JQ^SU^TA_PDEY;?\
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M_P 6;_XX#Q==Z=<P2>.;P:CXKG\$W\CZC=2WLOA)_"\7A/[/FPM=,M;<QF(
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M@A#^U=\'?AXVO>+[GPB?#NC?$S2)_#?BK7-!:_OX-4LM4>9+F?S-3T6*^?\
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MB"WEUJ66V4ZJJN?Z4L#@DXQ@ JS 8!! ."-W(Z'/!(Z,P+&0!@Y52PS@C(8
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M5Z1X4\.^)] O/$.L^&K#5[*.;4/LT5W=WUOJ%M;?K5^W9\;_  9XF_X*-_\
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M3T:6^A^HXWBG"8'%U\)4PV,J3H5'3E.G&CR/1237-5B[<LH[K>Y_L%DG(PV
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M_P!-_>O^UVQE6!.?0$#/N!R*>DH+%2&! R=R'W ^;&.H(QDD8Y !&?\ ,?\
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MC/)"L>V?[OL>?7@\X%)YONW_ 'RP_3'?''KVZU_EZ:3_ ,% ?VY[@@G]L_\
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M9.Y5VJV J@]R,KD G+!"-V&&><D"-1NQP"1M+-R>,DX'3@5_E.Z;_P %#_\
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M0K1Y5*\)QG&2B_?@GRR;DV?USF&3YIB,-D:HX*M.>&R'*<)B(N5"+IXG#X+
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M>&=>TV]\.WL>C7FDZ_<^&?&/A/Q!XXT/XB:[8^'?%GP_GU;XH?&,:WX$\;>
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MB(87!X.AFE>I0K5L-3PN-KXRK+"PA7P\N3&SQ,HU*=>56I0HPI4J56$8.+_
M7(Q(0?O!3R03N^8YP,XZ_0Y/.>G])G_!LDQ_X:B_:B!P1_PS_P""FR "I ^)
M%^%&XNSC/S$C 0D[C@\5YK_Q#;_MY%=I^(O[,XVCY<>+?B"<<8QSX Q[\CJ
M01UK]=_^".W_  2L_:)_X)^?&3XT?$3XV>*OA-K>A_$+X6>'_!FC1> -<\2:
MG?6NIZ+XKN=>N9]3CUOPQH-M#8/92X2:*>603@J\>PF0+C?B_A?,N%,[R_ Y
MW@L3B\50ITZ-##K%N527M,,VH3J8:C&Z4)RES**35DY71IX;\ \:93QQPYF.
M9\.9E@\!@L97K8C%5Z,(4J,9X/%T>:<ECJME[U.WN2=Y:Z;?Q _\%P@!_P %
M>?\ @H,8P2__  O/10=K;7#'X*_")D+;F5517+L'V950Y$A*BORL8*""23EF
MWX0Y8!2TB1@8'S%1*6",L$;JDBN_*?VK?\%&_P#@VY_;O_:X_;Q_:D_:;^&/
MQ!_9JTWP!\:OB7IOC'PM8>+_ !;XZM?$5MI-MX!\%>&3!K%AI?@/4].AN3>^
M&KN8I#J%[#+:SP8?!>)?BH_\&E?_  4H"A4^*/[)3?*P#GQM\2E(^5E!8?\
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MP;1_MU1EWE\>_LN--("7<^)?'H=G,"0%_,7X?&0M(JMO#$HT;"+8$4*--/\
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M&930PN/Q^-7U6%.7M?K<^6DG36+BTZ.&5*CRQJ0A)4U-T^9.3_.?_@F*V/\
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MT_JX6$P/0<]>.O\ DX/X48Q[Y.3QT]/QSCGK^5+119>?3JUMZ-?\$-.R^X3
M]!^(S3=HZ<9XYX'<GC@XX_.GT?Y_I_GVIV_J_P#P;"LOTZ?Y$#J-K@G "D<=
M\J,9/;&#TP._? _'K]B=6/\ P5+_ ."U9+$A/''[ PC3>^U%_P"&2[5V"H<H
M@:2:21C&JM([.79N /V$E/#C(&0< D#HA.1]XCC/4>G!R*_'W]B;C_@J7_P6
MLY&?^$W_ &!C@!AP?V2;0?Q8SQDY7*]<="!K1NJ68-I.U&@XW[K%8=/KYO\
M7H<]3^-@U>R=>LFNK_V7$.WY/T\FC]@XLD/E3PPQGC(V* 5 Z=CT!YY.>:F
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ME6E)KGP6#H*K5K8:$[-5<3.K[?E:C24'*<TV- B*50#Y H 4*%'   Q@!!@
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M$G@O]D__ ()LOIFD^(OM@T>[?6?''QRT"=+PZ?+#>?):ZI-+!Y$J$7$<98%
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M_C-9ZYX9^$FN_$>X\7ZM;?&K1OA58:II\<'BCP"_@&;QAK]GKW@1=>^'FD^
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M=P(QM;DX!Z[2&P1^C)[DG@ Y']3[8SUX_I^=_P#P4%3?8_L;DKD1_P#!0/\
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M (H?"CPS?ZOX-\+:CJUMH?AG4M1N=!CLM6\26FG:1\.-)^)LE]%8>*XI]?\
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MO_5I&VDYP?@C\(EVLQ .0,9 X7& 2,Y_5B/&Q?IC/X\C/UKTLUC;,J[?_/C
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4Y %%%%, HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ea028314601_ex21-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028314601_ex21-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 8 # 2(  A$! Q$!_\0
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M;\1[>U6(ZEI^C:FD?B#1VEA2=8M9\-WRVNN:5+Y4B,5O;"$8888Y%?G!>?\
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MB.M3_>8E5G44\-+$*$5B>6E%5%)RJ2BZ<YPJRP]>B=I7P9_P5$_Y1Y?MA?\
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MC.\=@ZE# 5EB:&$P%"I3A/$15H5*TZKNU#1V5V[**Y4Y2?\ %3_P<L?\GE_
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M^&G[</P3\3:+X=C^(WB)O#[:)H<6A_$3X4Z#/J#/IOA+Q1X5U.:SM_$T.DV
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MR1YWN2 H[U[)\1]?^*_[1_Q(UGXH_%*=='DU>2)++0K%FF;1M$LT$&EZ#IL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>osti-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.ostherapies.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:osti="http://www.ostherapies.com/20251231" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="osti-20251231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="osti-20251231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="osti-20251231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="osti-20251231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet" id="osti_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals" id="osti_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConsolidatedIncomeStatement" id="osti_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ShareholdersEquityType2or3" id="osti_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConsolidatedCashFlow" id="osti_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors" id="osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactors">
        <link:definition>995306 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SignificantAccountingPolicies" id="osti_r_SignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RelatedPartyTransactions" id="osti_r_RelatedPartyTransactions">
        <link:definition>995308 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConvertibleDebt" id="osti_r_ConvertibleDebt">
        <link:definition>995309 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/TedcoGrant" id="osti_r_TedcoGrant">
        <link:definition>995310 - Disclosure - Tedco Grant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/CommitmentsandContingencies" id="osti_r_CommitmentsandContingencies">
        <link:definition>995311 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/Equity" id="osti_r_Equity">
        <link:definition>995312 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability" id="osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiability">
        <link:definition>995313 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformation" id="osti_r_SegmentandGeographicInformation">
        <link:definition>995314 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SubsequentEvents" id="osti_r_SubsequentEvents">
        <link:definition>995315 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/AccountingPoliciesByPolicy" id="osti_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesTables" id="osti_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsTables" id="osti_r_RelatedPartyTransactionsTables">
        <link:definition>996002 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConvertibleDebtTables" id="osti_r_ConvertibleDebtTables">
        <link:definition>996003 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesTables" id="osti_r_CommitmentsandContingenciesTables">
        <link:definition>996004 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/EquityTables" id="osti_r_EquityTables">
        <link:definition>996005 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables" id="osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables">
        <link:definition>996006 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationTables" id="osti_r_SegmentandGeographicInformationTables">
        <link:definition>996007 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails" id="osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails">
        <link:definition>996008 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails" id="osti_r_SignificantAccountingPoliciesDetails">
        <link:definition>996009 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable" id="osti_r_ScheduleofFairValueofthePurchaseConsiderationTable">
        <link:definition>996010 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals" id="osti_r_ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals">
        <link:definition>996011 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable" id="osti_r_ScheduleofEstimatedAmortizationExpensesTable">
        <link:definition>996012 - Disclosure - Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" id="osti_r_ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable">
        <link:definition>996013 - Disclosure - Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable" id="osti_r_ScheduleofPreferredStockandCommonStockEquivalentsTable">
        <link:definition>996014 - Disclosure - Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsDetails" id="osti_r_RelatedPartyTransactionsDetails">
        <link:definition>996015 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable" id="osti_r_ScheduleofPayrollAdvancestotheCEOTable">
        <link:definition>996016 - Disclosure - Related Party Transactions - Schedule of Payroll Advances to the CEO (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ConvertibleDebtDetails" id="osti_r_ConvertibleDebtDetails">
        <link:definition>996017 - Disclosure - Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable" id="osti_r_ScheduleofConvertibleDebtTable">
        <link:definition>996018 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable" id="osti_r_ScheduleofCompanysMakeWholeShareLiabilityTable">
        <link:definition>996019 - Disclosure - Convertible Debt - Schedule of Company&#8217;s Make-Whole Share Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/TedcoGrantDetails" id="osti_r_TedcoGrantDetails">
        <link:definition>996020 - Disclosure - Tedco Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesDetails" id="osti_r_CommitmentsandContingenciesDetails">
        <link:definition>996021 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable" id="osti_r_ScheduleofFutureMilestonesTable">
        <link:definition>996022 - Disclosure - Commitments and Contingencies - Schedule of Future Milestones (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable" id="osti_r_ScheduleofCertainFeesandCorrespondingPaymentAmountsTable">
        <link:definition>996023 - Disclosure - Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/EquityDetails" id="osti_r_EquityDetails">
        <link:definition>996024 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable" id="osti_r_ScheduleofCommonStockOptionsIssuedTable">
        <link:definition>996025 - Disclosure - Equity - Schedule of Common Stock Options Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable" id="osti_r_ScheduleofBlackScholesOptionPricingModelTable">
        <link:definition>996026 - Disclosure - Equity - Schedule of Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails" id="osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails">
        <link:definition>996027 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" id="osti_r_ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable">
        <link:definition>996028 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable" id="osti_r_ScheduleofWarrantsLiabilityTable">
        <link:definition>996029 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationDetails" id="osti_r_SegmentandGeographicInformationDetails">
        <link:definition>996030 - Disclosure - Segment and Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable" id="osti_r_ScheduleofFinancialInformationofOperatingSegmentTable">
        <link:definition>996031 - Disclosure - Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/SubsequentEventsDetails" id="osti_r_SubsequentEventsDetails">
        <link:definition>996032 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ostherapies.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfFairValueOfThePurchaseConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract"/>
  <xs:element name="ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract"/>
  <xs:element name="ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract"/>
  <xs:element name="ScheduleOfConvertibleDebtAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfConvertibleDebtAbstract"/>
  <xs:element name="ScheduleOfCompanySMakeWholeShareLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract"/>
  <xs:element name="ScheduleOfFutureMilestonesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfFutureMilestonesAbstract"/>
  <xs:element name="ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract"/>
  <xs:element name="ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract"/>
  <xs:element name="ScheduleOfWarrantsLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfWarrantsLiabilityAbstract"/>
  <xs:element name="ScheduleOfFinancialInformationOfOperatingSegmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract"/>
  <xs:element name="AccruedPayrollAndPayrollTaxesRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_AccruedPayrollAndPayrollTaxesRelatedParty"/>
  <xs:element name="TEDCOGrantNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_TEDCOGrantNonCurrent"/>
  <xs:element name="DeemedDividendOnSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_DeemedDividendOnSeriesAConvertiblePreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor"/>
  <xs:element name="StockIssuedDuringPeriodSharesToInvestmentAdvisor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors"/>
  <xs:element name="StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors"/>
  <xs:element name="StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors"/>
  <xs:element name="StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit"/>
  <xs:element name="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit"/>
  <xs:element name="StockIssuedDuringPeriodValueCommonStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices"/>
  <xs:element name="StockIssuedDuringPeriodSharesCommonStockIssuedForServices" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices"/>
  <xs:element name="StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodValueofCommonStockforPatentLicense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense"/>
  <xs:element name="StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors"/>
  <xs:element name="StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock"/>
  <xs:element name="WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance"/>
  <xs:element name="SharesIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_SharesIssuedForServices"/>
  <xs:element name="CommitmentSharesIssuedForEquityLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_CommitmentSharesIssuedForEquityLineOfCredit"/>
  <xs:element name="ProceedsFromSaleOfPreferredStockAndRelatedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants"/>
  <xs:element name="ConversionOfPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_ConversionOfPreferredStockToCommonStock"/>
  <xs:element name="DeferredOfferingCostsRecordedAsAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_DeferredOfferingCostsRecordedAsAccountsPayable"/>
  <xs:element name="ConversionOfWarrantsIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ConversionOfWarrantsIntoCommonStock"/>
  <xs:element name="IssuanceOfCommonStockToInvestorAdvisorSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement"/>
  <xs:element name="ConversionOfMakewholeLiabilityToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ConversionOfMakewholeLiabilityToCommonStock"/>
  <xs:element name="ClawbackOfCommonStockForOverIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_ClawbackOfCommonStockForOverIssuance"/>
  <xs:element name="CommonStockIssuedForPatentPurchase" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_CommonStockIssuedForPatentPurchase"/>
  <xs:element name="ReclassificationOfWarrantLiabilityToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ReclassificationOfWarrantLiabilityToEquity"/>
  <xs:element name="SharesIssuedForPrepaidServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_SharesIssuedForPrepaidServices"/>
  <xs:element name="TedcoGrantDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_TedcoGrantDisclosureTextBlock"/>
  <xs:element name="RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock"/>
  <xs:element name="FixedAssetPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_FixedAssetPolicyPolicyTextBlock"/>
  <xs:element name="PatentLicenseAcquisitionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PatentLicenseAcquisitionPolicyTextBlock"/>
  <xs:element name="WarrantLiabilityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_WarrantLiabilityPolicyTextBlock"/>
  <xs:element name="ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock"/>
  <xs:element name="ScheduleOfMakeWholeShareLiabilityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock"/>
  <xs:element name="ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock"/>
  <xs:element name="ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable"/>
  <xs:element name="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable"/>
  <xs:element name="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable"/>
  <xs:element name="BusinessAcquisitionNumberofShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_BusinessAcquisitionNumberofShares"/>
  <xs:element name="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable"/>
  <xs:element name="MilestoneBearingEventDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_MilestoneBearingEventDescription"/>
  <xs:element name="FutureMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_FutureMilestones"/>
  <xs:element name="CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable"/>
  <xs:element name="PaymentScheduleofServiceFees" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PaymentScheduleofServiceFees"/>
  <xs:element name="PaymentScheduleServiceFeesRemainderDue" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PaymentScheduleServiceFeesRemainderDue"/>
  <xs:element name="ServiceFeesRemainderDue" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ServiceFeesRemainderDue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
  <xs:element name="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable"/>
  <xs:element name="ResidualValueAllocatedToSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ResidualValueAllocatedToSeriesAPreferredStock"/>
  <xs:element name="UnallocatedCashProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_UnallocatedCashProceeds"/>
  <xs:element name="OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable"/>
  <xs:element name="GoingConcernTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GoingConcernTerm"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="StraightLineDepreciatedOverPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StraightLineDepreciatedOverPeriod"/>
  <xs:element name="NumberOfTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_NumberOfTradingDays"/>
  <xs:element name="ClosingPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="osti_ClosingPricePerShare"/>
  <xs:element name="TotalEquityValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_TotalEquityValue"/>
  <xs:element name="PrepaidShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PrepaidShare"/>
  <xs:element name="PrepaidShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PrepaidShares"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="ConvertibleDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_ConvertibleDebtDetailsTable"/>
  <xs:element name="AggregateAdditionalCashProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_AggregateAdditionalCashProceeds"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_GrossProceeds"/>
  <xs:element name="AgreedToIssuedCashRemunerationPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_AgreedToIssuedCashRemunerationPercentage"/>
  <xs:element name="CommonStockSharesAwarded" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_CommonStockSharesAwarded"/>
  <xs:element name="CommonStockSharesAwardedInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_CommonStockSharesAwardedInCash"/>
  <xs:element name="SharesAwardedParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SharesAwardedParValue"/>
  <xs:element name="CashRemunerationofWarrantFeePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_CashRemunerationofWarrantFeePercentage"/>
  <xs:element name="DebtDiscountAccretionExpenseInWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_DebtDiscountAccretionExpenseInWarrants"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ExercisePrice"/>
  <xs:element name="AggregateWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_AggregateWarrantsExercisable"/>
  <xs:element name="TedcoGrantDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_TedcoGrantDetailsTable"/>
  <xs:element name="NumberOfTranches" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="osti_NumberOfTranches"/>
  <xs:element name="ReimbursableGrantAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_ReimbursableGrantAmount"/>
  <xs:element name="PercentageOfRoyalties" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PercentageOfRoyalties"/>
  <xs:element name="RoyaltyReductionPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_RoyaltyReductionPercentage"/>
  <xs:element name="ReimbursementExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ReimbursementExpirationPeriod"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="RentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="osti_RentExpense"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_MilestonePayments"/>
  <xs:element name="RoyaltyNetSalesPecentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_RoyaltyNetSalesPecentage"/>
  <xs:element name="BundgerUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_BundgerUnderAgreement"/>
  <xs:element name="OutstandingBalanceFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_OutstandingBalanceFees"/>
  <xs:element name="PercentageOfRoyaltyPayments" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PercentageOfRoyaltyPayments"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_EquityDetailsTable"/>
  <xs:element name="CommonStockConversionAfterShareDiscountsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="osti_CommonStockConversionAfterShareDiscountsPercentage"/>
  <xs:element name="ValuationCeilingsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_ValuationCeilingsAmount"/>
  <xs:element name="PreferredStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="osti_PreferredStockSharesDesignated"/>
  <xs:element name="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable"/>
  <xs:element name="StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits"/>
  <xs:element name="PurchaseOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_PurchaseOfCommonStock"/>
  <xs:element name="StockIssuedDuringPeriodSharesAdditionalUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StockIssuedDuringPeriodSharesAdditionalUnits"/>
  <xs:element name="OriginalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_OriginalShares"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="osti_SubsequentEventsDetailsTable"/>
  <xs:element name="OriginalIssueDiscount" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_OriginalIssueDiscount"/>
  <xs:element name="InvestedPurchaser" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="osti_InvestedPurchaser"/>
  <xs:element name="ConversionPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="osti_ConversionPricePercentage"/>
  <xs:element name="AlanMussoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_AlanMussoMember"/>
  <xs:element name="AyalaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_AyalaMember"/>
  <xs:element name="BlinkBioMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_BlinkBioMember"/>
  <xs:element name="BrooklineCapitalMarketsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_BrooklineCapitalMarketsMember"/>
  <xs:element name="CerosFinancialServicesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_CerosFinancialServicesIncMember"/>
  <xs:element name="ChaseBankCheckingAccountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ChaseBankCheckingAccountMember"/>
  <xs:element name="ChaseBankSavingsAccountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ChaseBankSavingsAccountMember"/>
  <xs:element name="ChiefOperatingDecisionMakerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ChiefOperatingDecisionMakerMember"/>
  <xs:element name="ChristopherAcevedoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ChristopherAcevedoMember"/>
  <xs:element name="ConsultingFeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ConsultingFeeMember"/>
  <xs:element name="EquityLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_EquityLineOfCreditMember"/>
  <xs:element name="FairValueOfHER2AssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_FairValueOfHER2AssetsMember"/>
  <xs:element name="FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember"/>
  <xs:element name="GLPToxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GLPToxMember"/>
  <xs:element name="GroupAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupAMember"/>
  <xs:element name="GroupBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupBMember"/>
  <xs:element name="GroupCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupCMember"/>
  <xs:element name="GroupDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupDMember"/>
  <xs:element name="GroupEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupEMember"/>
  <xs:element name="GroupFMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_GroupFMember"/>
  <xs:element name="HER2AssetAmortizationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_HER2AssetAmortizationMember"/>
  <xs:element name="HER2AssetsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_HER2AssetsMember"/>
  <xs:element name="IClinicalTrialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_IClinicalTrialMember"/>
  <xs:element name="IIClinicalTrialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_IIClinicalTrialMember"/>
  <xs:element name="InducementWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_InducementWarrantsMember"/>
  <xs:element name="JoacimBorgMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_JoacimBorgMember"/>
  <xs:element name="JohnsonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_JohnsonMember"/>
  <xs:element name="LicenseFeeToUtilizeProprietaryTechnologypaidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember"/>
  <xs:element name="MillRiverPartnersLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_MillRiverPartnersLLCMember"/>
  <xs:element name="MrRomnessMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_MrRomnessMember"/>
  <xs:element name="PatentLicenseAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PatentLicenseAcquisitionMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PlacementAgentWarrantsMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PrefundedWarrantsMember"/>
  <xs:element name="PrepaidCommonStockNotIssuedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PrepaidCommonStockNotIssuedMember"/>
  <xs:element name="PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember"/>
  <xs:element name="RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember"/>
  <xs:element name="SVBBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SVBBankMember"/>
  <xs:element name="SecurityPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SecurityPurchaseAgreementMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesASeniorConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SeriesASeniorConvertiblePreferredStockMember"/>
  <xs:element name="SeriesAWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_SeriesAWarrantsMember"/>
  <xs:element name="ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember"/>
  <xs:element name="ServiceFeeAdvancepaidMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ServiceFeeAdvancepaidMember"/>
  <xs:element name="ServiceFeesRemainderDueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ServiceFeesRemainderDueMember"/>
  <xs:element name="ShortTermLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ShortTermLoanMember"/>
  <xs:element name="StatisticsFees30OnFinalAnalysisMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StatisticsFees30OnFinalAnalysisMember"/>
  <xs:element name="StatisticsFees35OnDevelopmentOfSAPTablesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember"/>
  <xs:element name="StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember"/>
  <xs:element name="ThirdPartyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ThirdPartyMember"/>
  <xs:element name="ThirdWarrantExerciseInducementAndExchangeOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember"/>
  <xs:element name="UnderwriterPlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_UnderwriterPlacementAgentWarrantsMember"/>
  <xs:element name="WarrantLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_WarrantLiabilityMember"/>
  <xs:element name="WarrantsForPlacementAgentNobleCapitalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_WarrantsForPlacementAgentNobleCapitalMember"/>
  <xs:element name="TedcoGrantAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_TedcoGrantAbstract"/>
  <xs:element name="TedcoGrantLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_TedcoGrantLineItems"/>
<!-- [WMV6][PBjatAjRb8k171nYKfR43KJQtLoJfX7OhUGKkxweQwvQd8o2vHy8r8cVrxhJsMw3DaqiXdJpImbG+wNaJdTIZmyKMHZK9nHy82QXKxLRZVwoj6QqFQKQy0dnsVwCiSjyHhx/XX9rmh9N5uo+uNVG+tWfejFxZMkvI2mOJZZa7TasJE8N4hO8U531Kpddo0mBuRSWrkGdSaqHdl50WBNrWHXLSdD/v2IMk6bFtkJ66xe5UVcWNr9wJbDpzkkgM2hL4HIj4PgxDNFcO3ZuNq5EkOyjdGLHKKbLN5TTzNI6rTd+zcfwKZbzc5WONV6W3Tv++QaWEV9GcmzdPN21SaPvh1ZBkL8=] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="osti_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>osti-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedBalanceSheet" roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedIncomeStatement" roleURI="http://www.ostherapies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedCashFlow" roleURI="http://www.ostherapies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofEstimatedAmortizationExpensesTable" roleURI="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" roleURI="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" roleURI="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFinancialInformationofOperatingSegmentTable" roleURI="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"/>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:href="osti-20251231.xsd#osti_AccruedPayrollAndPayrollTaxesRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="osti_AccruedPayrollAndPayrollTaxesRelatedParty" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DividendsPayableCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="osti_TEDCOGrantNonCurrent" xlink:href="osti-20251231.xsd#osti_TEDCOGrantNonCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="osti_TEDCOGrantNonCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:href="osti-20251231.xsd#osti_DeemedDividendOnSeriesAConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_SharesIssuedForServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForServices"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="osti_SharesIssuedForServices" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_CommitmentSharesIssuedForEquityLineOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="osti_CommitmentSharesIssuedForEquityLineOfCredit" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:href="osti-20251231.xsd#osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="osti_UnallocatedCashProceeds" xlink:href="osti-20251231.xsd#osti_UnallocatedCashProceeds"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="osti_UnallocatedCashProceeds" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="osti_UnallocatedCashProceeds" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:href="osti-20251231.xsd#osti_ResidualValueAllocatedToSeriesAPreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="osti_UnallocatedCashProceeds" xlink:to="osti_ResidualValueAllocatedToSeriesAPreferredStock" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
<!-- [WMV6][uhZpb8BuL5hAKD0TDs36cbIAURYJ6ZaWG3hJjKP/3H2buHde14s1O9p7qklnfu+LtCmgJ8boEZMmlDC08WrausBGc3ly5SSUGXI7kQMy4GuDCgb4OfwHdKnhrjStbye7m6cAPIkoc25oCm9jg8Qh1hcaPD6051BMR5MKmJRJgPOtkYJa7CIXd/9DoQCp0Kw0d8AYzsoJgPBK4ZAX8KNuP2Bxo/hbX0FQePdhA2LxHxTuDBS8rso1gB/Zf0pFhGMvZ3K8amGMoLqFeIhar9mi5RYcvuK6P53AHw4kQkcV9MNGkoNf8yCmWUoGkPJ8jjtySnAsVobMWAPEnSl8PKN3N7nz] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>osti-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedBalanceSheet" roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedIncomeStatement" roleURI="http://www.ostherapies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ShareholdersEquityType2or3" roleURI="http://www.ostherapies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedCashFlow" roleURI="http://www.ostherapies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactors" roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPolicies" roleURI="http://www.ostherapies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactions" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebt" roleURI="http://www.ostherapies.com/role/ConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_TedcoGrant" roleURI="http://www.ostherapies.com/role/TedcoGrant"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingencies" roleURI="http://www.ostherapies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_Equity" roleURI="http://www.ostherapies.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiability" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformation" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformation"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SubsequentEvents" roleURI="http://www.ostherapies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_AccountingPoliciesByPolicy" roleURI="http://www.ostherapies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPoliciesTables" roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactionsTables" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebtTables" roleURI="http://www.ostherapies.com/role/ConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingenciesTables" roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_EquityTables" roleURI="http://www.ostherapies.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformationTables" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFairValueofthePurchaseConsiderationTable" roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals" roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofEstimatedAmortizationExpensesTable" roleURI="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" roleURI="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofPreferredStockandCommonStockEquivalentsTable" roleURI="http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofPayrollAdvancestotheCEOTable" roleURI="http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofConvertibleDebtTable" roleURI="http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCompanysMakeWholeShareLiabilityTable" roleURI="http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFutureMilestonesTable" roleURI="http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCertainFeesandCorrespondingPaymentAmountsTable" roleURI="http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCommonStockOptionsIssuedTable" roleURI="http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofBlackScholesOptionPricingModelTable" roleURI="http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" roleURI="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofWarrantsLiabilityTable" roleURI="http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFinancialInformationofOperatingSegmentTable" roleURI="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails" roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPoliciesDetails" roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactionsDetails" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebtDetails" roleURI="http://www.ostherapies.com/role/ConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_TedcoGrantDetails" roleURI="http://www.ostherapies.com/role/TedcoGrantDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingenciesDetails" roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_EquityDetails" roleURI="http://www.ostherapies.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformationDetails" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SubsequentEventsDetails" roleURI="http://www.ostherapies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd#eedm1" roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:href="osti-20251231.xsd#osti_AccruedPayrollAndPayrollTaxesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="osti_AccruedPayrollAndPayrollTaxesRelatedParty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DividendsPayableCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_TEDCOGrantNonCurrent" xlink:href="osti-20251231.xsd#osti_TEDCOGrantNonCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="osti_TEDCOGrantNonCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockValue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:href="osti-20251231.xsd#osti_DeemedDividendOnSeriesAConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:href="osti-20251231.xsd#osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:href="osti-20251231.xsd#osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" order="34" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharesIssuedForServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_SharesIssuedForServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_CommitmentSharesIssuedForEquityLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_CommitmentSharesIssuedForEquityLineOfCredit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:href="osti-20251231.xsd#osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NotesIssued1" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Dividends" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfPreferredStockToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfPreferredStockToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ConversionOfPreferredStockToCommonStock" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_DeferredOfferingCostsRecordedAsAccountsPayable" xlink:href="osti-20251231.xsd#osti_DeferredOfferingCostsRecordedAsAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_DeferredOfferingCostsRecordedAsAccountsPayable" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfWarrantsIntoCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfWarrantsIntoCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ConversionOfWarrantsIntoCommonStock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:href="osti-20251231.xsd#osti_IssuanceOfCommonStockToInvestorAdvisorSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfMakewholeLiabilityToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfMakewholeLiabilityToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ConversionOfMakewholeLiabilityToCommonStock" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ClawbackOfCommonStockForOverIssuance" xlink:href="osti-20251231.xsd#osti_ClawbackOfCommonStockForOverIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ClawbackOfCommonStockForOverIssuance" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockIssuedForPatentPurchase" xlink:href="osti-20251231.xsd#osti_CommonStockIssuedForPatentPurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_CommonStockIssuedForPatentPurchase" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ReclassificationOfWarrantLiabilityToEquity" xlink:href="osti-20251231.xsd#osti_ReclassificationOfWarrantLiabilityToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_ReclassificationOfWarrantLiabilityToEquity" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharesIssuedForPrepaidServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForPrepaidServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="osti_SharesIssuedForPrepaidServices" order="41" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/TedcoGrant" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantAbstract" xlink:href="osti-20251231.xsd#osti_TedcoGrantAbstract"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantDisclosureTextBlock" xlink:href="osti-20251231.xsd#osti_TedcoGrantDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantAbstract" xlink:to="osti_TedcoGrantDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_FixedAssetPolicyPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_FixedAssetPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="osti_FixedAssetPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PatentLicenseAcquisitionPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="osti_PatentLicenseAcquisitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantLiabilityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="osti_WarrantLiabilityPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredIncomeTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PatentLicenseAcquisitionMember" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_PatentLicenseAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PatentLicenseAcquisitionMember" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_PatentLicenseAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_UnderwriterPlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_UnderwriterPlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_UnderwriterPlacementAgentWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_InducementWarrantsMember" xlink:href="osti-20251231.xsd#osti_InducementWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_InducementWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidCommonStockNotIssuedMember" xlink:href="osti-20251231.xsd#osti_PrepaidCommonStockNotIssuedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_PrepaidCommonStockNotIssuedMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_SeriesAWarrantsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_RepaymentsOfOtherDebt" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupAMember" xlink:href="osti-20251231.xsd#osti_GroupAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupBMember" xlink:href="osti-20251231.xsd#osti_GroupBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupCMember" xlink:href="osti-20251231.xsd#osti_GroupCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupDMember" xlink:href="osti-20251231.xsd#osti_GroupDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupDMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupEMember" xlink:href="osti-20251231.xsd#osti_GroupEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupEMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupFMember" xlink:href="osti-20251231.xsd#osti_GroupFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupFMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_BlinkBioMember" xlink:href="osti-20251231.xsd#osti_BlinkBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_BlinkBioMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCollateral"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentCollateral" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_ShareRepurchaseProgramLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AlanMussoMember" xlink:href="osti-20251231.xsd#osti_AlanMussoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="osti_AlanMussoMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ChristopherAcevedoMember" xlink:href="osti-20251231.xsd#osti_ChristopherAcevedoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="osti_ChristopherAcevedoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_JoacimBorgMember" xlink:href="osti-20251231.xsd#osti_JoacimBorgMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="osti_JoacimBorgMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_BusinessAcquisitionNumberofShares" xlink:href="osti-20251231.xsd#osti_BusinessAcquisitionNumberofShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="osti_BusinessAcquisitionNumberofShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PresentValueOfFutureInsuranceProfitLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember" xlink:href="osti-20251231.xsd#osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GLPToxMember" xlink:href="osti-20251231.xsd#osti_GLPToxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_GLPToxMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_IClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IClinicalTrialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_IClinicalTrialMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_IIClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IIClinicalTrialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_IIClinicalTrialMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" xlink:href="osti-20251231.xsd#osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" xlink:href="osti-20251231.xsd#osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_MilestoneBearingEventDescription" xlink:href="osti-20251231.xsd#osti_MilestoneBearingEventDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="osti_MilestoneBearingEventDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_FutureMilestones" xlink:href="osti-20251231.xsd#osti_FutureMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="osti_FutureMilestones" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeeAdvancepaidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvancepaidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_ServiceFeeAdvancepaidMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnDevelopmentOfSAPTablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees30OnFinalAnalysisMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees30OnFinalAnalysisMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_StatisticsFees30OnFinalAnalysisMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeesRemainderDueMember" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="osti_ServiceFeesRemainderDueMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PaymentScheduleofServiceFees" xlink:href="osti-20251231.xsd#osti_PaymentScheduleofServiceFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="osti_PaymentScheduleofServiceFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_PaymentsForFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PaymentScheduleServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_PaymentScheduleServiceFeesRemainderDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="osti_PaymentScheduleServiceFeesRemainderDue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="osti_ServiceFeesRemainderDue" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:href="osti-20251231.xsd#osti_ResidualValueAllocatedToSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_ResidualValueAllocatedToSeriesAPreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_UnallocatedCashProceeds" xlink:href="osti-20251231.xsd#osti_UnallocatedCashProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_UnallocatedCashProceeds" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantLiabilityMember" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="osti_WarrantLiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ChiefOperatingDecisionMakerMember" xlink:href="osti-20251231.xsd#osti_ChiefOperatingDecisionMakerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="osti_ChiefOperatingDecisionMakerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" xlink:href="osti-20251231.xsd#osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GoingConcernTerm" xlink:href="osti-20251231.xsd#osti_GoingConcernTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="osti_GoingConcernTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_SignificantAccountingPoliciesDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="osti_SeriesAConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_HER2AssetsMember" xlink:href="osti-20251231.xsd#osti_HER2AssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_HER2AssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_HER2AssetAmortizationMember" xlink:href="osti-20251231.xsd#osti_HER2AssetAmortizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_HER2AssetAmortizationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AyalaMember" xlink:href="osti-20251231.xsd#osti_AyalaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_AyalaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesASeniorConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesASeniorConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="osti_SeriesASeniorConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="osti_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="osti_PlacementAgentWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ChaseBankCheckingAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankCheckingAccountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_ChaseBankCheckingAccountMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ChaseBankSavingsAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankSavingsAccountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_ChaseBankSavingsAccountMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SVBBankMember" xlink:href="osti-20251231.xsd#osti_SVBBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_SVBBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ThirdPartyMember" xlink:href="osti-20251231.xsd#osti_ThirdPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_ThirdPartyMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_Cash" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDomesticDepositMoneyMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDomesticDepositMoneyMarket"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_InterestBearingDomesticDepositMoneyMarket" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StraightLineDepreciatedOverPeriod" xlink:href="osti-20251231.xsd#osti_StraightLineDepreciatedOverPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_StraightLineDepreciatedOverPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_NumberOfTradingDays" xlink:href="osti-20251231.xsd#osti_NumberOfTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_NumberOfTradingDays" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ClosingPricePerShare" xlink:href="osti-20251231.xsd#osti_ClosingPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_ClosingPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_TotalEquityValue" xlink:href="osti-20251231.xsd#osti_TotalEquityValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_TotalEquityValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LeaseCost" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidShare" xlink:href="osti-20251231.xsd#osti_PrepaidShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_PrepaidShare" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidShares" xlink:href="osti-20251231.xsd#osti_PrepaidShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="osti_PrepaidShares" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_RelatedPartyTransactionsDetailsTable" xlink:href="osti-20251231.xsd#osti_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="osti_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_MrRomnessMember" xlink:href="osti-20251231.xsd#osti_MrRomnessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="osti_MrRomnessMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_MillRiverPartnersLLCMember" xlink:href="osti-20251231.xsd#osti_MillRiverPartnersLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="osti_MillRiverPartnersLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertibleDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_ConvertibleDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ShortTermLoanMember" xlink:href="osti-20251231.xsd#osti_ShortTermLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="osti_ShortTermLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_JoacimBorgMember" xlink:href="osti-20251231.xsd#osti_JoacimBorgMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="osti_JoacimBorgMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantsForPlacementAgentNobleCapitalMember" xlink:href="osti-20251231.xsd#osti_WarrantsForPlacementAgentNobleCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="osti_WarrantsForPlacementAgentNobleCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_BrooklineCapitalMarketsMember" xlink:href="osti-20251231.xsd#osti_BrooklineCapitalMarketsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_BrooklineCapitalMarketsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CerosFinancialServicesIncMember" xlink:href="osti-20251231.xsd#osti_CerosFinancialServicesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_CerosFinancialServicesIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupAMember" xlink:href="osti-20251231.xsd#osti_GroupAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupBMember" xlink:href="osti-20251231.xsd#osti_GroupBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupCMember" xlink:href="osti-20251231.xsd#osti_GroupCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupFMember" xlink:href="osti-20251231.xsd#osti_GroupFMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupFMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupDMember" xlink:href="osti-20251231.xsd#osti_GroupDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupDMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GroupEMember" xlink:href="osti-20251231.xsd#osti_GroupEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="osti_GroupEMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AggregateAdditionalCashProceeds" xlink:href="osti-20251231.xsd#osti_AggregateAdditionalCashProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_AggregateAdditionalCashProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_GrossProceeds" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AgreedToIssuedCashRemunerationPercentage" xlink:href="osti-20251231.xsd#osti_AgreedToIssuedCashRemunerationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_AgreedToIssuedCashRemunerationPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockSharesAwarded" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwarded"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_CommonStockSharesAwarded" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockSharesAwardedInCash" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwardedInCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_CommonStockSharesAwardedInCash" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SharesAwardedParValue" xlink:href="osti-20251231.xsd#osti_SharesAwardedParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_SharesAwardedParValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CashRemunerationofWarrantFeePercentage" xlink:href="osti-20251231.xsd#osti_CashRemunerationofWarrantFeePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_CashRemunerationofWarrantFeePercentage" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_DebtDiscountAccretionExpenseInWarrants" xlink:href="osti-20251231.xsd#osti_DebtDiscountAccretionExpenseInWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_DebtDiscountAccretionExpenseInWarrants" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ExercisePrice" xlink:href="osti-20251231.xsd#osti_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_ExercisePrice" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_AggregateWarrantsExercisable" xlink:href="osti-20251231.xsd#osti_AggregateWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="osti_AggregateWarrantsExercisable" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRate" order="39" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/TedcoGrantDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantLineItems" xlink:href="osti-20251231.xsd#osti_TedcoGrantLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantDetailsTable" xlink:href="osti-20251231.xsd#osti_TedcoGrantDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_TedcoGrantDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_TedcoGrantDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_NumberOfTranches" xlink:href="osti-20251231.xsd#osti_NumberOfTranches"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_NumberOfTranches" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="us-gaap_GrantsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ReimbursableGrantAmount" xlink:href="osti-20251231.xsd#osti_ReimbursableGrantAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_ReimbursableGrantAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PercentageOfRoyalties" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_PercentageOfRoyalties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RoyaltyReductionPercentage" xlink:href="osti-20251231.xsd#osti_RoyaltyReductionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_RoyaltyReductionPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ReimbursementExpirationPeriod" xlink:href="osti-20251231.xsd#osti_ReimbursementExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_ReimbursementExpirationPeriod" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ConsultingFeeMember" xlink:href="osti-20251231.xsd#osti_ConsultingFeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_ConsultingFeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_JohnsonMember" xlink:href="osti-20251231.xsd#osti_JohnsonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_JohnsonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_BlinkBioMember" xlink:href="osti-20251231.xsd#osti_BlinkBioMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_BlinkBioMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RentExpense" xlink:href="osti-20251231.xsd#osti_RentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_RentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_MilestonePayments" xlink:href="osti-20251231.xsd#osti_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_MilestonePayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RoyaltyNetSalesPecentage" xlink:href="osti-20251231.xsd#osti_RoyaltyNetSalesPecentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_RoyaltyNetSalesPecentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_RoyaltyReductionPercentage" xlink:href="osti-20251231.xsd#osti_RoyaltyReductionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_RoyaltyReductionPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_BundgerUnderAgreement" xlink:href="osti-20251231.xsd#osti_BundgerUnderAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_BundgerUnderAgreement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_OutstandingBalanceFees" xlink:href="osti-20251231.xsd#osti_OutstandingBalanceFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_OutstandingBalanceFees" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ValueAddedTaxReceivable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PercentageOfRoyaltyPayments" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyaltyPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="osti_PercentageOfRoyaltyPayments" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AlternativeInvestment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LegalFees" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_EquityDetailsTable" xlink:href="osti-20251231.xsd#osti_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="osti_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="srt_RangeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MedianMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MedianMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MedianMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_EquityLineOfCreditMember" xlink:href="osti-20251231.xsd#osti_EquityLineOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_EquityLineOfCreditMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="osti_SeriesAWarrantsMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_FairValueOfHER2AssetsMember" xlink:href="osti-20251231.xsd#osti_FairValueOfHER2AssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="osti_FairValueOfHER2AssetsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PrefundedWarrantsMember" xlink:href="osti-20251231.xsd#osti_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="osti_PrefundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockConversionAfterShareDiscountsPercentage" xlink:href="osti-20251231.xsd#osti_CommonStockConversionAfterShareDiscountsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="osti_CommonStockConversionAfterShareDiscountsPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ValuationCeilingsAmount" xlink:href="osti-20251231.xsd#osti_ValuationCeilingsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="osti_ValuationCeilingsAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="osti_GrossProceeds" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PreferredStockSharesDesignated" xlink:href="osti-20251231.xsd#osti_PreferredStockSharesDesignated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="osti_PreferredStockSharesDesignated" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStockCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesASeniorConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesASeniorConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="osti_SeriesASeniorConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_SecurityPurchaseAgreementMember" xlink:href="osti-20251231.xsd#osti_SecurityPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="osti_SecurityPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PurchaseOfCommonStock" xlink:href="osti-20251231.xsd#osti_PurchaseOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_PurchaseOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesAdditionalUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesAdditionalUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_StockIssuedDuringPeriodSharesAdditionalUnits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_OriginalShares" xlink:href="osti-20251231.xsd#osti_OriginalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="osti_OriginalShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.ostherapies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="osti_SubsequentEventsDetailsTable" xlink:href="osti-20251231.xsd#osti_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="osti_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="osti_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember" xlink:href="osti-20251231.xsd#osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" xlink:href="osti-20251231.xsd#osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_OriginalIssueDiscount" xlink:href="osti-20251231.xsd#osti_OriginalIssueDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="osti_OriginalIssueDiscount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_InvestedPurchaser" xlink:href="osti-20251231.xsd#osti_InvestedPurchaser"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="osti_InvestedPurchaser" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="osti_GrossProceeds" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionPricePercentage" xlink:href="osti-20251231.xsd#osti_ConversionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="osti_ConversionPricePercentage" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
<!-- [WMV6][eCiZN0THNhhsNrWIIftER73Sb3q6s9yd3pWv3T6hDRVYCLnox8/+0MHYJArn6qxMSjhDLShEtAXp0wJWKA4Wn2K5RN0xbFDUdzUF5BnovJvOGRuvbrLfyg+NCx9RWi1WKcLlmiVCMsw/n4sq+pWFAdSDlgZRiTJmAh3F1REsyxRAZ/MjpNG6rg372DEfLyuiWzBQMpXIXqtjBFGN/23kbpNkvupWrlbez6jBTXi/2ZNysvfD5uZQgwVWEeGssURzaNm+KxKnT4c4kwUFlK6QSuZl8Z3SPZ9lGI6vOy8nQw2sZGidfDeZhWnoKENRh76sSaTFBMSaIlWL54JaFheNgSgmiQk=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>osti-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-Term Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Total Mezzanine Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER INCOME/EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">TOTAL OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS available to common shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Preferred Stock to Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Preferred Stock to Common Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Converted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl2" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl3" xml:lang="en-US">Converted to shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash &#8211; beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash &#8211; end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business, Liquidity, and Risk Factors [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract_lbl" xml:lang="en-US">Schedule of Fair Value of the Purchase Consideration [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:to="osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Estimated Amortization Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense [Abstract]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Schedule of Payroll Advances [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl" xml:lang="en-US">Balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl1" xml:lang="en-US">Accrued payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Convertible Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantAbstract" xlink:href="osti-20251231.xsd#osti_TedcoGrantAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TedcoGrantAbstract_lbl" xml:lang="en-US">TEDCO Grant [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantAbstract" xlink:to="osti_TedcoGrantAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Schedule Of Common Stock Options Issued [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Shares, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Schedule of Closing Stock Price [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US">Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfWarrantsLiabilityAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfWarrantsLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfWarrantsLiabilityAbstract_lbl" xml:lang="en-US">Schedule of Warrants Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfWarrantsLiabilityAbstract" xlink:to="osti_ScheduleOfWarrantsLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant Liability as of December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrant Liability as of December 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl2" xml:lang="en-US">Warrants, valued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment and Geographic Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash checking account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets (net)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Patent (net of amortization)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total-Long Term Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:href="osti-20251231.xsd#osti_AccruedPayrollAndPayrollTaxesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl" xml:lang="en-US">Accrued payroll and payroll taxes &#8211; related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:to="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll and payroll taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Payroll payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Preferred dividends payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TEDCOGrantNonCurrent" xlink:href="osti-20251231.xsd#osti_TEDCOGrantNonCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_TEDCOGrantNonCurrent_lbl" xml:lang="en-US">TEDCO grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TEDCOGrantNonCurrent" xlink:to="osti_TEDCOGrantNonCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (See Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">MEZZANINE EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Company common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, par value $0.001, 5,000,000 shares authorized; 0 and 0 shares outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME/EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Non-operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average # of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per common share outstanding (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per common share outstanding (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock IPO (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Convertible Notes to Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Convertible Notes to Common Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl" xml:lang="en-US">Conversion of Warrants to Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of Warrants to Common Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Conversion shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl1" xml:lang="en-US">Remain outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl1"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl" xml:lang="en-US">Issuance of Common Stock to Investment Advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl" xml:lang="en-US">Issuance of Common Stock to Investment Advisor (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl" xml:lang="en-US">Issuance of Common Stock to Investment Advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl" xml:lang="en-US">Issuance of Common Stock to Investment Advisor (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl" xml:lang="en-US">Surrender of Common Stock Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl" xml:lang="en-US">Surrender of Common Stock Investors (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for Services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Share value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued for Interest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl" xml:lang="en-US">Commitment shares issued for Equity Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl" xml:lang="en-US">Commitment shares issued for Equity Line of Credit (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl" xml:lang="en-US">Common Stock issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl" xml:lang="en-US">Common Stock issued for Services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl" xml:lang="en-US">Conversion of Preferred Shares Mezzanine Equity to Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl" xml:lang="en-US">Conversion of Preferred Shares Mezzanine Equity to Common Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl" xml:lang="en-US">Issuance of Common Stock for Patent License</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:to="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl" xml:lang="en-US">Issuance of Common Stock for Patent License (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl" xml:lang="en-US">Sale of Common Stock to Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl" xml:lang="en-US">Sale of Common Stock to Investors (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:href="osti-20251231.xsd#osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl" xml:lang="en-US">Warrants Liability Reclass Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:to="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:href="osti-20251231.xsd#osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl" xml:lang="en-US">Warrants exercised and proceeds received, shares pending issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:to="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discounts issuance and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharesIssuedForServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForServices" xlink:to="osti_SharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Shares issued for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in value of warrant liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Fair value of Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xml:lang="en-US">Gain on the change in fair value of Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl3" xml:lang="en-US">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl4" xml:lang="en-US">Change in fair value of the warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl4"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_CommitmentSharesIssuedForEquityLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl" xml:lang="en-US">Commitment shares issued for equity line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common shares issuance for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued Payroll and payroll taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Prepaid warrants (net of fees)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Common stock issuance (net of fees)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Initial cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US">Cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Short-term borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:href="osti-20251231.xsd#osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl" xml:lang="en-US">Sale of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:to="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Initial public offering (net of fees)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Initial cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Net proceeds from conversion of debt A, B, C, D, E &amp; F</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Discount on notes payable &#8211; redemption premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl" xml:lang="en-US">Dividends payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Deemed dividend on Series A convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Mezzanine equity conversion (net of costs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfPreferredStockToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfPreferredStockToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfPreferredStockToCommonStock" xlink:to="osti_ConversionOfPreferredStockToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_DeferredOfferingCostsRecordedAsAccountsPayable" xlink:href="osti-20251231.xsd#osti_DeferredOfferingCostsRecordedAsAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl" xml:lang="en-US">Amortization of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeferredOfferingCostsRecordedAsAccountsPayable" xlink:to="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Conversion of convertible notes into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Notes converted amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfWarrantsIntoCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfWarrantsIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ConversionOfWarrantsIntoCommonStock_lbl" xml:lang="en-US">Conversion of warrants into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfWarrantsIntoCommonStock" xlink:to="osti_ConversionOfWarrantsIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:href="osti-20251231.xsd#osti_IssuanceOfCommonStockToInvestorAdvisorSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl" xml:lang="en-US">Issuance of common stock to investor advisor &#8211; settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:to="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionOfMakewholeLiabilityToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfMakewholeLiabilityToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl" xml:lang="en-US">Conversion of make-whole liability to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfMakewholeLiabilityToCommonStock" xlink:to="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ClawbackOfCommonStockForOverIssuance" xlink:href="osti-20251231.xsd#osti_ClawbackOfCommonStockForOverIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ClawbackOfCommonStockForOverIssuance_lbl" xml:lang="en-US">Clawback of common stock for over issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClawbackOfCommonStockForOverIssuance" xlink:to="osti_ClawbackOfCommonStockForOverIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockIssuedForPatentPurchase" xlink:href="osti-20251231.xsd#osti_CommonStockIssuedForPatentPurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CommonStockIssuedForPatentPurchase_lbl" xml:lang="en-US">Common stock issued for patent purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockIssuedForPatentPurchase" xlink:to="osti_CommonStockIssuedForPatentPurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ReclassificationOfWarrantLiabilityToEquity" xlink:href="osti-20251231.xsd#osti_ReclassificationOfWarrantLiabilityToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ReclassificationOfWarrantLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of warrants liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReclassificationOfWarrantLiabilityToEquity" xlink:to="osti_ReclassificationOfWarrantLiabilityToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharesIssuedForPrepaidServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForPrepaidServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharesIssuedForPrepaidServices_lbl" xml:lang="en-US">Shares issued for prepaid services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForPrepaidServices" xlink:to="osti_SharesIssuedForPrepaidServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Non-operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Non-operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:href="osti-20251231.xsd#osti_DeemedDividendOnSeriesAConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl" xml:lang="en-US">Cumulative Series A preferred stock dividend requirement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:to="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Preferred Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Amortization of non-cash prepaids</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Accrued interest on convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Patent License Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Short-term loan repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock CS &#8211; Shares CS &#8211; Par</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock Shares Par Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS, LIQUIDITY, AND RISK FACTORS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Purchase Consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Legal fees paid on behalf of Ayala</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Total fair value of consideration transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Amortization Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2030</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">2031 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTableTextBlock" xlink:to="us-gaap_DeferredIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US">General business credit carryover</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D credit (available for payroll tax offset)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:to="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Preferred stock and common stock equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilution shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Payroll Advances to the CEO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Advances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCollateral"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCollateral_lbl" xml:lang="en-US">Collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateral" xlink:to="us-gaap_DebtInstrumentCollateral_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Conversion Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl0" xml:lang="en-US">Conversion price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xml:lang="en-US">Carrying Amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Make-Whole Share Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:to="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US">Position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_BusinessAcquisitionNumberofShares" xlink:href="osti-20251231.xsd#osti_BusinessAcquisitionNumberofShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_BusinessAcquisitionNumberofShares_lbl" xml:lang="en-US">Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BusinessAcquisitionNumberofShares" xlink:to="osti_BusinessAcquisitionNumberofShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xml:lang="en-US">Date Earned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantDisclosureTextBlock" xlink:href="osti-20251231.xsd#osti_TedcoGrantDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_TedcoGrantDisclosureTextBlock_lbl" xml:lang="en-US">TEDCO GRANT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantDisclosureTextBlock" xlink:to="osti_TedcoGrantDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:to="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_MilestoneBearingEventDescription" xlink:href="osti-20251231.xsd#osti_MilestoneBearingEventDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_MilestoneBearingEventDescription_lbl" xml:lang="en-US">Milestone Bearing Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestoneBearingEventDescription" xlink:to="osti_MilestoneBearingEventDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_FutureMilestones" xlink:href="osti-20251231.xsd#osti_FutureMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_FutureMilestones_lbl" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FutureMilestones" xlink:to="osti_FutureMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl" xml:lang="en-US">Schedule of Certain Fees and Corresponding Payment Amounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:to="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PaymentScheduleofServiceFees" xlink:href="osti-20251231.xsd#osti_PaymentScheduleofServiceFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PaymentScheduleofServiceFees_lbl" xml:lang="en-US">George Clinical Payment Schedule</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleofServiceFees" xlink:to="osti_PaymentScheduleofServiceFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Fees amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_PaymentScheduleServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_PaymentScheduleServiceFeesRemainderDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PaymentScheduleServiceFeesRemainderDue_lbl" xml:lang="en-US">George Clinical Payment Schedule, Remainder Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleServiceFeesRemainderDue" xlink:to="osti_PaymentScheduleServiceFeesRemainderDue_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ServiceFeesRemainderDue_lbl" xml:lang="en-US">Service Fees &#8211; Remainder Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeesRemainderDue" xlink:to="osti_ServiceFeesRemainderDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Options Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Years, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Years, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Years, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Years, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Years, Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Years, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes Option Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility (based on peer companies)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xml:lang="en-US">Dividends (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Estimated Life in years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:to="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:href="osti-20251231.xsd#osti_ResidualValueAllocatedToSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl" xml:lang="en-US">Residual value allocated to Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:to="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_UnallocatedCashProceeds" xlink:href="osti-20251231.xsd#osti_UnallocatedCashProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="osti_UnallocatedCashProceeds_lbl" xml:lang="en-US">Unallocated cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_UnallocatedCashProceeds" xlink:to="osti_UnallocatedCashProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Additional Warrant Liability on January 14, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Additional warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Stockholder approval on April 9, 2025 - warrants turn into Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT AND GEOGRAPHIC INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Information of Operating Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl" xml:lang="en-US">Repayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PatentLicenseAcquisitionMember" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PatentLicenseAcquisitionMember_lbl" xml:lang="en-US">Patent &amp; License Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PatentLicenseAcquisitionMember" xlink:to="osti_PatentLicenseAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Senior Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesAConvertiblePreferredStockMember" xlink:to="osti_SeriesAConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="osti_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesAConvertiblePreferredStockMember" xlink:to="osti_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_UnderwriterPlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_UnderwriterPlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_UnderwriterPlacementAgentWarrantsMember_lbl" xml:lang="en-US">Underwriter/Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_UnderwriterPlacementAgentWarrantsMember" xlink:to="osti_UnderwriterPlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_InducementWarrantsMember" xlink:href="osti-20251231.xsd#osti_InducementWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_InducementWarrantsMember_lbl" xml:lang="en-US">Inducement Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_InducementWarrantsMember" xlink:to="osti_InducementWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidCommonStockNotIssuedMember" xlink:href="osti-20251231.xsd#osti_PrepaidCommonStockNotIssuedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PrepaidCommonStockNotIssuedMember_lbl" xml:lang="en-US">Prepaid Common Stock Not Issued [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidCommonStockNotIssuedMember" xlink:to="osti_PrepaidCommonStockNotIssuedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesAWarrantsMember" xlink:to="osti_SeriesAWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupAMember" xlink:href="osti-20251231.xsd#osti_GroupAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupAMember_lbl" xml:lang="en-US">Group A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupAMember" xlink:to="osti_GroupAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupBMember" xlink:href="osti-20251231.xsd#osti_GroupBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupBMember_lbl" xml:lang="en-US">Group B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupBMember" xlink:to="osti_GroupBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupCMember" xlink:href="osti-20251231.xsd#osti_GroupCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupCMember_lbl" xml:lang="en-US">Group C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupCMember" xlink:to="osti_GroupCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupDMember" xlink:href="osti-20251231.xsd#osti_GroupDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupDMember_lbl" xml:lang="en-US">Group D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupDMember" xlink:to="osti_GroupDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupEMember" xlink:href="osti-20251231.xsd#osti_GroupEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupEMember_lbl" xml:lang="en-US">Group E [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupEMember" xlink:to="osti_GroupEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GroupFMember" xlink:href="osti-20251231.xsd#osti_GroupFMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GroupFMember_lbl" xml:lang="en-US">Group F [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupFMember" xlink:to="osti_GroupFMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_BlinkBioMember" xlink:href="osti-20251231.xsd#osti_BlinkBioMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_BlinkBioMember_lbl" xml:lang="en-US">Blink Bio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BlinkBioMember" xlink:to="osti_BlinkBioMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AlanMussoMember" xlink:href="osti-20251231.xsd#osti_AlanMussoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AlanMussoMember_lbl" xml:lang="en-US">Alan Musso [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AlanMussoMember" xlink:to="osti_AlanMussoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Shares Officers &amp; Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ChristopherAcevedoMember" xlink:href="osti-20251231.xsd#osti_ChristopherAcevedoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ChristopherAcevedoMember_lbl" xml:lang="en-US">Christopher Acevedo [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChristopherAcevedoMember" xlink:to="osti_ChristopherAcevedoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_JoacimBorgMember" xlink:href="osti-20251231.xsd#osti_JoacimBorgMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_JoacimBorgMember_lbl" xml:lang="en-US">Joacim Borg [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_JoacimBorgMember" xlink:to="osti_JoacimBorgMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember" xlink:href="osti-20251231.xsd#osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember_lbl" xml:lang="en-US">License Fee to utilize proprietary technology (paid) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember" xlink:to="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GLPToxMember" xlink:href="osti-20251231.xsd#osti_GLPToxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GLPToxMember_lbl" xml:lang="en-US">Good Laboratory Practices [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GLPToxMember" xlink:to="osti_GLPToxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_IClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_IClinicalTrialMember_lbl" xml:lang="en-US">Completion of a Phase I Clinical Trial [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IClinicalTrialMember" xlink:to="osti_IClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_IIClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IIClinicalTrialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_IIClinicalTrialMember_lbl" xml:lang="en-US">Completion of a Phase II Clinical Trial [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IIClinicalTrialMember" xlink:to="osti_IIClinicalTrialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" xlink:href="osti-20251231.xsd#osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember_lbl" xml:lang="en-US">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" xlink:to="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" xlink:href="osti-20251231.xsd#osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember_lbl" xml:lang="en-US">Regulatory Approval in the first of the United States, within the EU or within the UK [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" xlink:to="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeeAdvancepaidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvancepaidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ServiceFeeAdvancepaidMember_lbl" xml:lang="en-US">Service Fee Advance (paid) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeeAdvancepaidMember" xlink:to="osti_ServiceFeeAdvancepaidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember_lbl" xml:lang="en-US">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" xlink:to="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember_lbl" xml:lang="en-US">Statistics Fees &#8211; 35% on Electronic Data Capture (EDC) Go Live Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" xlink:to="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnDevelopmentOfSAPTablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember_lbl" xml:lang="en-US">Statistics Fees &#8211; 35% on Development of SAP tables [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember" xlink:to="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StatisticsFees30OnFinalAnalysisMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees30OnFinalAnalysisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StatisticsFees30OnFinalAnalysisMember_lbl" xml:lang="en-US">Statistics Fees &#8211; 30% on Final Analysis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees30OnFinalAnalysisMember" xlink:to="osti_StatisticsFees30OnFinalAnalysisMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ServiceFeesRemainderDueMember" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ServiceFeesRemainderDueMember_lbl" xml:lang="en-US">Service Fees &#8211; Remainder Due [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeesRemainderDueMember" xlink:to="osti_ServiceFeesRemainderDueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantLiabilityMember" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_WarrantLiabilityMember_lbl" xml:lang="en-US">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantLiabilityMember" xlink:to="osti_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ChiefOperatingDecisionMakerMember" xlink:href="osti-20251231.xsd#osti_ChiefOperatingDecisionMakerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ChiefOperatingDecisionMakerMember_lbl" xml:lang="en-US">CODM [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChiefOperatingDecisionMakerMember" xlink:to="osti_ChiefOperatingDecisionMakerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Incorporated date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GoingConcernTerm" xlink:href="osti-20251231.xsd#osti_GoingConcernTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GoingConcernTerm_lbl" xml:lang="en-US">Going concern term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GoingConcernTerm" xlink:to="osti_GoingConcernTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">Total approximately amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDomesticDepositMoneyMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDomesticDepositMoneyMarket"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestBearingDomesticDepositMoneyMarket_lbl" xml:lang="en-US">Money market account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDomesticDepositMoneyMarket" xlink:to="us-gaap_InterestBearingDomesticDepositMoneyMarket_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StraightLineDepreciatedOverPeriod" xlink:href="osti-20251231.xsd#osti_StraightLineDepreciatedOverPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StraightLineDepreciatedOverPeriod_lbl" xml:lang="en-US">Straight line depreciated over period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StraightLineDepreciatedOverPeriod" xlink:to="osti_StraightLineDepreciatedOverPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Issued value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xml:lang="en-US">Fair value of acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xml:lang="en-US">Volume-weighted average price (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_NumberOfTradingDays" xlink:href="osti-20251231.xsd#osti_NumberOfTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_NumberOfTradingDays_lbl" xml:lang="en-US">Number of trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTradingDays" xlink:to="osti_NumberOfTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ClosingPricePerShare" xlink:href="osti-20251231.xsd#osti_ClosingPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ClosingPricePerShare_lbl" xml:lang="en-US">Closing price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClosingPricePerShare" xlink:to="osti_ClosingPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TotalEquityValue" xlink:href="osti-20251231.xsd#osti_TotalEquityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_TotalEquityValue_lbl" xml:lang="en-US">Equity value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TotalEquityValue" xlink:to="osti_TotalEquityValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment losses on long lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Tax benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Warrant exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Current exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant purchase shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Number of warrants adjusted in to shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidShare" xlink:href="osti-20251231.xsd#osti_PrepaidShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PrepaidShare_lbl" xml:lang="en-US">Prepaid shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShare" xlink:to="osti_PrepaidShare_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PrepaidShares" xlink:href="osti-20251231.xsd#osti_PrepaidShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PrepaidShares_lbl" xml:lang="en-US">Prepaid warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShares" xlink:to="osti_PrepaidShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Related payroll taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Principal balance accrues rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AggregateAdditionalCashProceeds" xlink:href="osti-20251231.xsd#osti_AggregateAdditionalCashProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AggregateAdditionalCashProceeds_lbl" xml:lang="en-US">Aggregate additional cash proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateAdditionalCashProceeds" xlink:to="osti_AggregateAdditionalCashProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Equity stock conversion percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GrossProceeds" xlink:to="osti_GrossProceeds_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="osti_GrossProceeds_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GrossProceeds" xlink:to="osti_GrossProceeds_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Fees amortized interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Accrue interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_AgreedToIssuedCashRemunerationPercentage" xlink:href="osti-20251231.xsd#osti_AgreedToIssuedCashRemunerationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AgreedToIssuedCashRemunerationPercentage_lbl" xml:lang="en-US">Cash remuneration agreed to issue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AgreedToIssuedCashRemunerationPercentage" xlink:to="osti_AgreedToIssuedCashRemunerationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversions of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl" xml:lang="en-US">Expense to advisory fees amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockSharesAwarded" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwarded"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CommonStockSharesAwarded_lbl" xml:lang="en-US">Common stock shares awarded (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwarded" xlink:to="osti_CommonStockSharesAwarded_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockSharesAwardedInCash" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwardedInCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CommonStockSharesAwardedInCash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwardedInCash" xlink:to="osti_CommonStockSharesAwardedInCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Common stock shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Shares of gross proceeds (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" xml:lang="en-US">Purchase of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Awarded shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SharesAwardedParValue" xlink:href="osti-20251231.xsd#osti_SharesAwardedParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SharesAwardedParValue_lbl" xml:lang="en-US">Awarded shares value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesAwardedParValue" xlink:to="osti_SharesAwardedParValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Compensation amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Purchase of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_CashRemunerationofWarrantFeePercentage" xlink:href="osti-20251231.xsd#osti_CashRemunerationofWarrantFeePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CashRemunerationofWarrantFeePercentage_lbl" xml:lang="en-US">Warrant fee percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CashRemunerationofWarrantFeePercentage" xlink:to="osti_CashRemunerationofWarrantFeePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Aggregate warrants to purchase shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Aggregate warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_DebtDiscountAccretionExpenseInWarrants" xlink:href="osti-20251231.xsd#osti_DebtDiscountAccretionExpenseInWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_DebtDiscountAccretionExpenseInWarrants_lbl" xml:lang="en-US">Debt discount accretion expense in warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DebtDiscountAccretionExpenseInWarrants" xlink:to="osti_DebtDiscountAccretionExpenseInWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Total unamortized discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Exercise years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ExercisePrice" xlink:href="osti-20251231.xsd#osti_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ExercisePrice" xlink:to="osti_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Share exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AggregateWarrantsExercisable" xlink:href="osti-20251231.xsd#osti_AggregateWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AggregateWarrantsExercisable_lbl" xml:lang="en-US">Aggregate warrants exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateWarrantsExercisable" xlink:to="osti_AggregateWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Investor amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Interest rate of working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_NumberOfTranches" xlink:href="osti-20251231.xsd#osti_NumberOfTranches"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_NumberOfTranches_lbl" xml:lang="en-US">Number of tranches</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTranches" xlink:to="osti_NumberOfTranches_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ReimbursableGrantAmount" xlink:href="osti-20251231.xsd#osti_ReimbursableGrantAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ReimbursableGrantAmount_lbl" xml:lang="en-US">Reimbursable grant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursableGrantAmount" xlink:to="osti_ReimbursableGrantAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PercentageOfRoyalties" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PercentageOfRoyalties_lbl" xml:lang="en-US">Royalties percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyalties" xlink:to="osti_PercentageOfRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US">Royalties amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RoyaltyReductionPercentage" xlink:href="osti-20251231.xsd#osti_RoyaltyReductionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_RoyaltyReductionPercentage_lbl" xml:lang="en-US">Royalty reduction percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyReductionPercentage" xlink:to="osti_RoyaltyReductionPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="osti_RoyaltyReductionPercentage_lbl0" xml:lang="en-US">Royalties reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyReductionPercentage" xlink:to="osti_RoyaltyReductionPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ReimbursementExpirationPeriod" xlink:href="osti-20251231.xsd#osti_ReimbursementExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ReimbursementExpirationPeriod_lbl" xml:lang="en-US">Reimbursement expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursementExpirationPeriod" xlink:to="osti_ReimbursementExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Monthly rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RentExpense" xlink:href="osti-20251231.xsd#osti_RentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_RentExpense_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RentExpense" xlink:to="osti_RentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_MilestonePayments" xlink:href="osti-20251231.xsd#osti_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_MilestonePayments_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestonePayments" xlink:to="osti_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US">License fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RoyaltyNetSalesPecentage" xlink:href="osti-20251231.xsd#osti_RoyaltyNetSalesPecentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_RoyaltyNetSalesPecentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyNetSalesPecentage" xlink:to="osti_RoyaltyNetSalesPecentage_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_BundgerUnderAgreement" xlink:href="osti-20251231.xsd#osti_BundgerUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_BundgerUnderAgreement_lbl" xml:lang="en-US">Total budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BundgerUnderAgreement" xlink:to="osti_BundgerUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_OutstandingBalanceFees" xlink:href="osti-20251231.xsd#osti_OutstandingBalanceFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_OutstandingBalanceFees_lbl" xml:lang="en-US">Balance due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OutstandingBalanceFees" xlink:to="osti_OutstandingBalanceFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl" xml:lang="en-US">VAT total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PercentageOfRoyaltyPayments" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyaltyPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PercentageOfRoyaltyPayments_lbl" xml:lang="en-US">Percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyaltyPayments" xlink:to="osti_PercentageOfRoyaltyPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AlternativeInvestment_lbl" xml:lang="en-US">Investment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestment" xlink:to="us-gaap_AlternativeInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Attorneys fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Arbitration-related fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Common stock, split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Common stock, conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Common stock, conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommonStockConversionAfterShareDiscountsPercentage" xlink:href="osti-20251231.xsd#osti_CommonStockConversionAfterShareDiscountsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl" xml:lang="en-US">After share discounts percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockConversionAfterShareDiscountsPercentage" xlink:to="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ValuationCeilingsAmount" xlink:href="osti-20251231.xsd#osti_ValuationCeilingsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ValuationCeilingsAmount_lbl" xml:lang="en-US">Valuation ceilings (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ValuationCeilingsAmount" xlink:to="osti_ValuationCeilingsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US">Exercise purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PreferredStockSharesDesignated" xlink:href="osti-20251231.xsd#osti_PreferredStockSharesDesignated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock, shares designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PreferredStockSharesDesignated" xlink:to="osti_PreferredStockSharesDesignated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividends percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStockCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US">Dividend due (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Dividend payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Aggregate liquidation payment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Shares of common stock authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl" xml:lang="en-US">Sold aggregate of separable units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:to="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PurchaseOfCommonStock" xlink:href="osti-20251231.xsd#osti_PurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PurchaseOfCommonStock" xlink:to="osti_PurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_StockIssuedDuringPeriodSharesAdditionalUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesAdditionalUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl" xml:lang="en-US">Stock issued during period shares additional units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesAdditionalUnits" xlink:to="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US">Gross proceeds form before deducting transaction fees and other estimated expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Warrants proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_OriginalShares" xlink:href="osti-20251231.xsd#osti_OriginalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_OriginalShares_lbl" xml:lang="en-US">Original shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalShares" xlink:to="osti_OriginalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Stock price volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Issued warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US">Reclassification to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Operating reportable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xml:lang="en-US">Description of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xml:lang="en-US">Chief executive officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl" xml:lang="en-US">Other offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_OriginalIssueDiscount" xlink:href="osti-20251231.xsd#osti_OriginalIssueDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_OriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalIssueDiscount" xlink:to="osti_OriginalIssueDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_InvestedPurchaser" xlink:href="osti-20251231.xsd#osti_InvestedPurchaser"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_InvestedPurchaser_lbl" xml:lang="en-US">Invested purchaser</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_InvestedPurchaser" xlink:to="osti_InvestedPurchaser_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConversionPricePercentage" xlink:href="osti-20251231.xsd#osti_ConversionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionPricePercentage" xlink:to="osti_ConversionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl" xml:lang="en-US">Redeemable Preferred Stock and Mezzanine Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:to="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_FixedAssetPolicyPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_FixedAssetPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_FixedAssetPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fixed Asset Policy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FixedAssetPolicyPolicyTextBlock" xlink:to="osti_FixedAssetPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Patent Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PatentLicenseAcquisitionPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl" xml:lang="en-US">Patent &amp; License Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PatentLicenseAcquisitionPolicyTextBlock" xlink:to="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Short-term Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantLiabilityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantLiabilityPolicyTextBlock" xlink:to="osti_WarrantLiabilityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ChaseBankCheckingAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankCheckingAccountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ChaseBankCheckingAccountMember_lbl" xml:lang="en-US">Chase Bank Checking Account [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChaseBankCheckingAccountMember" xlink:to="osti_ChaseBankCheckingAccountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ChaseBankSavingsAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankSavingsAccountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ChaseBankSavingsAccountMember_lbl" xml:lang="en-US">Chase Bank Savings Account [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChaseBankSavingsAccountMember" xlink:to="osti_ChaseBankSavingsAccountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SVBBankMember" xlink:href="osti-20251231.xsd#osti_SVBBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SVBBankMember_lbl" xml:lang="en-US">SVB Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SVBBankMember" xlink:to="osti_SVBBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SeriesASeniorConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesASeniorConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SeriesASeniorConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Senior Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesASeniorConvertiblePreferredStockMember" xlink:to="osti_SeriesASeniorConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_HER2AssetsMember" xlink:href="osti-20251231.xsd#osti_HER2AssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_HER2AssetsMember_lbl" xml:lang="en-US">HER2 Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_HER2AssetsMember" xlink:to="osti_HER2AssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_HER2AssetAmortizationMember" xlink:href="osti-20251231.xsd#osti_HER2AssetAmortizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_HER2AssetAmortizationMember_lbl" xml:lang="en-US">HER2 Asset Amortization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_HER2AssetAmortizationMember" xlink:to="osti_HER2AssetAmortizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_AyalaMember" xlink:href="osti-20251231.xsd#osti_AyalaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_AyalaMember_lbl" xml:lang="en-US">Ayala [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AyalaMember" xlink:to="osti_AyalaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ThirdPartyMember" xlink:href="osti-20251231.xsd#osti_ThirdPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ThirdPartyMember_lbl" xml:lang="en-US">Third Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ThirdPartyMember" xlink:to="osti_ThirdPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PlacementAgentWarrantsMember" xlink:to="osti_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">CEO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_MrRomnessMember" xlink:href="osti-20251231.xsd#osti_MrRomnessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_MrRomnessMember_lbl" xml:lang="en-US">Mr. Romness [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MrRomnessMember" xlink:to="osti_MrRomnessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_MillRiverPartnersLLCMember" xlink:href="osti-20251231.xsd#osti_MillRiverPartnersLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_MillRiverPartnersLLCMember_lbl" xml:lang="en-US">Mill River Partners LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MillRiverPartnersLLCMember" xlink:to="osti_MillRiverPartnersLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Class A common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonClassAMember_lbl0" xml:lang="en-US">Class A Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_WarrantsForPlacementAgentNobleCapitalMember" xlink:href="osti-20251231.xsd#osti_WarrantsForPlacementAgentNobleCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_WarrantsForPlacementAgentNobleCapitalMember_lbl" xml:lang="en-US">Warrants for Placement Agent &#8212; Noble Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantsForPlacementAgentNobleCapitalMember" xlink:to="osti_WarrantsForPlacementAgentNobleCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_BrooklineCapitalMarketsMember" xlink:href="osti-20251231.xsd#osti_BrooklineCapitalMarketsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_BrooklineCapitalMarketsMember_lbl" xml:lang="en-US">Brookline Capital Markets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BrooklineCapitalMarketsMember" xlink:to="osti_BrooklineCapitalMarketsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CerosFinancialServicesIncMember" xlink:href="osti-20251231.xsd#osti_CerosFinancialServicesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_CerosFinancialServicesIncMember_lbl" xml:lang="en-US">Ceros Financial Services, Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CerosFinancialServicesIncMember" xlink:to="osti_CerosFinancialServicesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ShortTermLoanMember" xlink:href="osti-20251231.xsd#osti_ShortTermLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ShortTermLoanMember_lbl" xml:lang="en-US">Short-Term Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ShortTermLoanMember" xlink:to="osti_ShortTermLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Second Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_JohnsonMember" xlink:href="osti-20251231.xsd#osti_JohnsonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_JohnsonMember_lbl" xml:lang="en-US">Johnson [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_JohnsonMember" xlink:to="osti_JohnsonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConsultingFeeMember" xlink:href="osti-20251231.xsd#osti_ConsultingFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ConsultingFeeMember_lbl" xml:lang="en-US">Consulting Fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConsultingFeeMember" xlink:to="osti_ConsultingFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Class B Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_EquityLineOfCreditMember" xlink:href="osti-20251231.xsd#osti_EquityLineOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_EquityLineOfCreditMember_lbl" xml:lang="en-US">Equity Line of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_EquityLineOfCreditMember" xlink:to="osti_EquityLineOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_FairValueOfHER2AssetsMember" xlink:href="osti-20251231.xsd#osti_FairValueOfHER2AssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_FairValueOfHER2AssetsMember_lbl" xml:lang="en-US">HER2 Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FairValueOfHER2AssetsMember" xlink:to="osti_FairValueOfHER2AssetsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="osti_FairValueOfHER2AssetsMember_lbl0" xml:lang="en-US">Fair Value of HER2 Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FairValueOfHER2AssetsMember" xlink:to="osti_FairValueOfHER2AssetsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_PrefundedWarrantsMember" xlink:href="osti-20251231.xsd#osti_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrefundedWarrantsMember" xlink:to="osti_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MedianMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MedianMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MedianMember_lbl" xml:lang="en-US">Median [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MedianMember" xlink:to="srt_MedianMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US">Cash [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SecurityPurchaseAgreementMember" xlink:href="osti-20251231.xsd#osti_SecurityPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_SecurityPurchaseAgreementMember_lbl" xml:lang="en-US">Security Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SecurityPurchaseAgreementMember" xlink:to="osti_SecurityPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Stock Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember" xlink:href="osti-20251231.xsd#osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember_lbl" xml:lang="en-US">Third Warrant Exercise Inducement and Exchange Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember" xlink:to="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" xlink:href="osti-20251231.xsd#osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember_lbl" xml:lang="en-US">Privately Negotiated Warrant Exercise Inducement and Exchange Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" xlink:to="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Purchase Consideration [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems_lbl0" xml:lang="en-US">Schedule of Fair Value of the Purchase Consideration [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:to="osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable_lbl" xml:lang="en-US">Convertible Debt - Schedule of Convertible Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Schedule of Convertible Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Combination [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable_lbl" xml:lang="en-US">Convertible Debt - Schedule of Company&#8217;s Make-Whole Share Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ShareRepurchaseProgramLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ShareRepurchaseProgramLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Make-Whole Share Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="srt_ShareRepurchaseProgramLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies - Schedule of Future Milestones (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PresentValueOfFutureInsuranceProfitLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PresentValueOfFutureInsuranceProfitLineItems_lbl" xml:lang="en-US">Schedule of Future Milestones [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="us-gaap_PresentValueOfFutureInsuranceProfitLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:to="osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingenciesLineItems_lbl" xml:lang="en-US">Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_GainContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable_lbl" xml:lang="en-US">Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:to="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US">Schedule of Cash Proceeds [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrants Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Schedule of Financial Information of Operating Segment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" xlink:href="osti-20251231.xsd#osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable_lbl" xml:lang="en-US">Organization and Description of Business, Liquidity, and Risk Factors (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" xlink:to="osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Organization and Description of Business, Liquidity, and Risk Factors [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SignificantAccountingPoliciesDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SignificantAccountingPoliciesDetailsTable" xlink:to="osti_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RelatedPartyTransactionsDetailsTable" xlink:href="osti-20251231.xsd#osti_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RelatedPartyTransactionsDetailsTable" xlink:to="osti_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_ConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConvertibleDebtDetailsTable_lbl" xml:lang="en-US">Convertible Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConvertibleDebtDetailsTable" xlink:to="osti_ConvertibleDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Convertible Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantDetailsTable" xlink:href="osti-20251231.xsd#osti_TedcoGrantDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TedcoGrantDetailsTable_lbl" xml:lang="en-US">Tedco Grant (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantDetailsTable" xlink:to="osti_TedcoGrantDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_TedcoGrantLineItems" xlink:href="osti-20251231.xsd#osti_TedcoGrantLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TedcoGrantLineItems_lbl" xml:lang="en-US">Tedco Grant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantLineItems" xlink:to="osti_TedcoGrantLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_CommitmentsandContingenciesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentsandContingenciesDetailsTable" xlink:to="osti_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_EquityDetailsTable" xlink:href="osti-20251231.xsd#osti_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_EquityDetailsTable" xlink:to="osti_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable_lbl" xml:lang="en-US">Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl0" xml:lang="en-US">Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="osti_SubsequentEventsDetailsTable" xlink:href="osti-20251231.xsd#osti_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SubsequentEventsDetailsTable" xlink:to="osti_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl0" xml:lang="en-US">Represent the amount of accrued payroll and payroll taxes &#8211; related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:to="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl0" xml:lang="en-US">Represents the amount of adjustments to additional paid in capital, warrants liability reclass preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:to="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_AggregateAdditionalCashProceeds_lbl0" xml:lang="en-US">Represent the amount of aggregate additional cash proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateAdditionalCashProceeds" xlink:to="osti_AggregateAdditionalCashProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_AggregateWarrantsExercisable_lbl0" xml:lang="en-US">The number of warrants are exercisable under purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateWarrantsExercisable" xlink:to="osti_AggregateWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_AgreedToIssuedCashRemunerationPercentage_lbl0" xml:lang="en-US">Agreed to issued cash remuneration percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AgreedToIssuedCashRemunerationPercentage" xlink:to="osti_AgreedToIssuedCashRemunerationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_BundgerUnderAgreement_lbl0" xml:lang="en-US">It represents the amount of budget under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BundgerUnderAgreement" xlink:to="osti_BundgerUnderAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_BusinessAcquisitionNumberofShares_lbl0" xml:lang="en-US">Number of shares in business acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BusinessAcquisitionNumberofShares" xlink:to="osti_BusinessAcquisitionNumberofShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CashRemunerationofWarrantFeePercentage_lbl0" xml:lang="en-US">Represent the percentage of cash remuneration of warrant fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CashRemunerationofWarrantFeePercentage" xlink:to="osti_CashRemunerationofWarrantFeePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ClawbackOfCommonStockForOverIssuance_lbl0" xml:lang="en-US">Clawback of common stock for over issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClawbackOfCommonStockForOverIssuance" xlink:to="osti_ClawbackOfCommonStockForOverIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ClosingPricePerShare_lbl0" xml:lang="en-US">Closing price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClosingPricePerShare" xlink:to="osti_ClosingPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl0" xml:lang="en-US">Amount of commitment shares issued for the equity line of credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl0" xml:lang="en-US">Common stock conversion after share discounts percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockConversionAfterShareDiscountsPercentage" xlink:to="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CommonStockIssuedForPatentPurchase_lbl0" xml:lang="en-US">The amount of common stock issued for patent purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockIssuedForPatentPurchase" xlink:to="osti_CommonStockIssuedForPatentPurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CommonStockSharesAwarded_lbl0" xml:lang="en-US">Common stock shares awarded.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwarded" xlink:to="osti_CommonStockSharesAwarded_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_CommonStockSharesAwardedInCash_lbl0" xml:lang="en-US">It represents the amount of common stock awarded in cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwardedInCash" xlink:to="osti_CommonStockSharesAwardedInCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl0" xml:lang="en-US">The amount of conversion of make-whole liability to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfMakewholeLiabilityToCommonStock" xlink:to="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ConversionOfPreferredStockToCommonStock_lbl0" xml:lang="en-US">Represent the amount of conversion of preferred stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfPreferredStockToCommonStock" xlink:to="osti_ConversionOfPreferredStockToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ConversionOfWarrantsIntoCommonStock_lbl0" xml:lang="en-US">Conversion of warrants into Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfWarrantsIntoCommonStock" xlink:to="osti_ConversionOfWarrantsIntoCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ConversionPricePercentage_lbl0" xml:lang="en-US">Percentage conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionPricePercentage" xlink:to="osti_ConversionPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_DebtDiscountAccretionExpenseInWarrants_lbl0" xml:lang="en-US">Debt Discount Accretion Expense in Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DebtDiscountAccretionExpenseInWarrants" xlink:to="osti_DebtDiscountAccretionExpenseInWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl0" xml:lang="en-US">The amount of deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:to="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl0" xml:lang="en-US">The amount of deferred offering costs recorded as accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeferredOfferingCostsRecordedAsAccountsPayable" xlink:to="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ExercisePrice_lbl0" xml:lang="en-US">Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ExercisePrice" xlink:to="osti_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_FixedAssetPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for fixed asset policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FixedAssetPolicyPolicyTextBlock" xlink:to="osti_FixedAssetPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_FutureMilestones_lbl0" xml:lang="en-US">Represent the amount of future milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FutureMilestones" xlink:to="osti_FutureMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_GoingConcernTerm_lbl0" xml:lang="en-US">Going concern term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GoingConcernTerm" xlink:to="osti_GoingConcernTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_GrossProceeds_lbl1" xml:lang="en-US">Gross proceeds refers to the total amount of money received from selling a product or service. It&apos;s the total amount of money received before any deductions are made. In other words, gross proceeds are the total income from a sale before taxes, shipping, and any other discounts are considered.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GrossProceeds" xlink:to="osti_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_InvestedPurchaser_lbl0" xml:lang="en-US">The amount of invested purchaser.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_InvestedPurchaser" xlink:to="osti_InvestedPurchaser_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl0" xml:lang="en-US">Issuance of common stock to investor advisor settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:to="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_MilestoneBearingEventDescription_lbl0" xml:lang="en-US">Description of milestone bearing events.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestoneBearingEventDescription" xlink:to="osti_MilestoneBearingEventDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_MilestonePayments_lbl0" xml:lang="en-US">Represent the amount of milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestonePayments" xlink:to="osti_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_NumberOfTradingDays_lbl0" xml:lang="en-US">Number of trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTradingDays" xlink:to="osti_NumberOfTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_NumberOfTranches_lbl0" xml:lang="en-US">Represents the number of tranches.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTranches" xlink:to="osti_NumberOfTranches_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_OriginalIssueDiscount_lbl0" xml:lang="en-US">Percentage of original issue discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalIssueDiscount" xlink:to="osti_OriginalIssueDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_OriginalShares_lbl0" xml:lang="en-US">The number of original shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalShares" xlink:to="osti_OriginalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_OutstandingBalanceFees_lbl0" xml:lang="en-US">Represent the amount of outstanding balance fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OutstandingBalanceFees" xlink:to="osti_OutstandingBalanceFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl0" xml:lang="en-US">Dizclosure of accounting policy for patent &amp; license acquisition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PatentLicenseAcquisitionPolicyTextBlock" xlink:to="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PaymentScheduleServiceFeesRemainderDue_lbl0" xml:lang="en-US">Description of payment schedule service fees remainder due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleServiceFeesRemainderDue" xlink:to="osti_PaymentScheduleServiceFeesRemainderDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PaymentScheduleofServiceFees_lbl0" xml:lang="en-US">Description of george clinical payment schedule service fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleofServiceFees" xlink:to="osti_PaymentScheduleofServiceFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PercentageOfRoyalties_lbl0" xml:lang="en-US">Percentage of royalties capped.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyalties" xlink:to="osti_PercentageOfRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PercentageOfRoyaltyPayments_lbl0" xml:lang="en-US">Percentage of royalty payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyaltyPayments" xlink:to="osti_PercentageOfRoyaltyPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PreferredStockSharesDesignated_lbl0" xml:lang="en-US">Number of preferred stock, shares designated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PreferredStockSharesDesignated" xlink:to="osti_PreferredStockSharesDesignated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PrepaidShare_lbl0" xml:lang="en-US">The number of prepaid shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShare" xlink:to="osti_PrepaidShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PrepaidShares_lbl0" xml:lang="en-US">The number of shares prepaid shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShares" xlink:to="osti_PrepaidShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl0" xml:lang="en-US">Represents the amount of proceeds from sale of  preferred stock and related warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:to="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_PurchaseOfCommonStock_lbl0" xml:lang="en-US">It represents the amount of purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PurchaseOfCommonStock" xlink:to="osti_PurchaseOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ReclassificationOfWarrantLiabilityToEquity_lbl0" xml:lang="en-US">The amount of reclassification of warrant liability to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReclassificationOfWarrantLiabilityToEquity" xlink:to="osti_ReclassificationOfWarrantLiabilityToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl0" xml:lang="en-US">Redeemable preferred stock and mezzanine equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:to="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ReimbursableGrantAmount_lbl0" xml:lang="en-US">Amount of total reimbursable grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursableGrantAmount" xlink:to="osti_ReimbursableGrantAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ReimbursementExpirationPeriod_lbl0" xml:lang="en-US">Reimbursement Expiration Period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursementExpirationPeriod" xlink:to="osti_ReimbursementExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_RentExpense_lbl0" xml:lang="en-US">The amount of rent expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RentExpense" xlink:to="osti_RentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl0" xml:lang="en-US">Value of residual value allocated to Series A Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:to="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_RoyaltyNetSalesPecentage_lbl0" xml:lang="en-US">Royalty net sales percentage of products.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyNetSalesPecentage" xlink:to="osti_RoyaltyNetSalesPecentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_RoyaltyReductionPercentage_lbl1" xml:lang="en-US">Percentage of royalty reduction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyReductionPercentage" xlink:to="osti_RoyaltyReductionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of certain fees and corresponding payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:to="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of whole share liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:to="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of payment for future milestone events.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:to="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of preferred stock and common stock equivalents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:to="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ServiceFeesRemainderDue_lbl0" xml:lang="en-US">Discloses the service fees &#8211; remainder due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeesRemainderDue" xlink:to="osti_ServiceFeesRemainderDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual life (years), exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted Average Remaining Years, Forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted Average Remaining Years, Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharesAwardedParValue_lbl0" xml:lang="en-US">Represent the per share value of awarded shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesAwardedParValue" xlink:to="osti_SharesAwardedParValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharesIssuedForPrepaidServices_lbl0" xml:lang="en-US">The amount of shares issued for prepaid services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForPrepaidServices" xlink:to="osti_SharesIssuedForPrepaidServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_SharesIssuedForServices_lbl0" xml:lang="en-US">The amount of shares issued for services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForServices" xlink:to="osti_SharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl0" xml:lang="en-US">Number of shares issued during the period additional units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesAdditionalUnits" xlink:to="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl0" xml:lang="en-US">Commitment shares issued for Equity Line of Credit .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl0" xml:lang="en-US">Common Stock issued for Services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl0" xml:lang="en-US">Number of shares issued during the period conversion of preferred shares mezzanine stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl0" xml:lang="en-US">Issuance of Common Stock for Patent License.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl0" xml:lang="en-US">Issuance of Common Stock to Investment Advisor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl0" xml:lang="en-US">Issuance of Common Stock to Investment Advisor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl0" xml:lang="en-US">Number of shares of stock issued during the period, shares of preferred stock, separable units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:to="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl0" xml:lang="en-US">Sale of Common Stock to Investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl0" xml:lang="en-US">Surrender of Common Stock Investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl0" xml:lang="en-US">Issuance of common stock to investment advisor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl0" xml:lang="en-US">Value of stock issued during the period in commitment shares issued for equity line of credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl0" xml:lang="en-US">Common Stock issued for Services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl0" xml:lang="en-US">Value of stock issued during the period conversion of preferred shares mezzanine stock to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl0" xml:lang="en-US">Conversion of warrants to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl0" xml:lang="en-US">The value of issuance of common stock to investment advisors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl0" xml:lang="en-US">Sale of Common Stock to Investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl0" xml:lang="en-US">Surrender of Common Stock Investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl0" xml:lang="en-US">Represent the amount for issuance of common stock for patent license.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:to="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_StraightLineDepreciatedOverPeriod_lbl0" xml:lang="en-US">Straight line depreciated over period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StraightLineDepreciatedOverPeriod" xlink:to="osti_StraightLineDepreciatedOverPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_TEDCOGrantNonCurrent_lbl0" xml:lang="en-US">It represents the amount of TEDCO grant, non current portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TEDCOGrantNonCurrent" xlink:to="osti_TEDCOGrantNonCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_TedcoGrantDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure of Tedco grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantDisclosureTextBlock" xlink:to="osti_TedcoGrantDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_TotalEquityValue_lbl0" xml:lang="en-US">The amount of total equity value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TotalEquityValue" xlink:to="osti_TotalEquityValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_UnallocatedCashProceeds_lbl0" xml:lang="en-US">Represents of unallocated cash proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_UnallocatedCashProceeds" xlink:to="osti_UnallocatedCashProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_ValuationCeilingsAmount_lbl0" xml:lang="en-US">It represents the amount of valuation ceilings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ValuationCeilingsAmount" xlink:to="osti_ValuationCeilingsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_WarrantLiabilityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for warrant liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantLiabilityPolicyTextBlock" xlink:to="osti_WarrantLiabilityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl0" xml:lang="en-US">Warrants exercised and proceeds received, shares pending issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:to="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SeriesAConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesAConvertiblePreferredStockMember" xlink:to="osti_SeriesAConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl0" xml:lang="en-US">Proceeds from Royalties Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl0" xml:lang="en-US">Common Class B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_IClinicalTrialMember_lbl0" xml:lang="en-US">IClinical Trial Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IClinicalTrialMember" xlink:to="osti_IClinicalTrialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Payment For Future Milestone Events Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:to="osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_OutstandingBalanceFees_lbl1" xml:lang="en-US">Outstanding Balance Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OutstandingBalanceFees" xlink:to="osti_OutstandingBalanceFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_InducementWarrantsMember_lbl0" xml:lang="en-US">Inducement Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_InducementWarrantsMember" xlink:to="osti_InducementWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RentExpense_lbl1" xml:lang="en-US">Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RentExpense" xlink:to="osti_RentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl0" xml:lang="en-US">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AggregateWarrantsExercisable_lbl1" xml:lang="en-US">Aggregate Warrants Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateWarrantsExercisable" xlink:to="osti_AggregateWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_OriginalShares_lbl1" xml:lang="en-US">Original Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalShares" xlink:to="osti_OriginalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0" xml:lang="en-US">Business Combination, Transaction Cost, Excluding Separately Recognized Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_FutureMilestones_lbl1" xml:lang="en-US">Future Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FutureMilestones" xlink:to="osti_FutureMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupBMember_lbl0" xml:lang="en-US">Group BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupBMember" xlink:to="osti_GroupBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AlanMussoMember_lbl0" xml:lang="en-US">Alan Musso Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AlanMussoMember" xlink:to="osti_AlanMussoMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Company SMake Whole Share Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract" xlink:to="osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl0" xml:lang="en-US">Temporary Equity, Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl1" xml:lang="en-US">Commitment Shares Issued For Equity Line Of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_CommitmentSharesIssuedForEquityLineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AggregateAdditionalCashProceeds_lbl1" xml:lang="en-US">Aggregate Additional Cash Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AggregateAdditionalCashProceeds" xlink:to="osti_AggregateAdditionalCashProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember_lbl0" xml:lang="en-US">License Fee To Utilize Proprietary Technologypaid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember" xlink:to="osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_EquityLineOfCreditMember_lbl0" xml:lang="en-US">Equity Line Of Credit Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_EquityLineOfCreditMember" xlink:to="osti_EquityLineOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Dividends Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ServiceFeesRemainderDueMember_lbl0" xml:lang="en-US">Service Fees Remainder Due Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeesRemainderDueMember" xlink:to="osti_ServiceFeesRemainderDueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl2"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract_lbl" xml:lang="en-US">Schedule Of Certain Fees And Corresponding Payment Amounts Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract" xlink:to="osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl3" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ChaseBankCheckingAccountMember_lbl0" xml:lang="en-US">Chase Bank Checking Account Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChaseBankCheckingAccountMember" xlink:to="osti_ChaseBankCheckingAccountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SecurityPurchaseAgreementMember_lbl0" xml:lang="en-US">Security Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SecurityPurchaseAgreementMember" xlink:to="osti_SecurityPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_BundgerUnderAgreement_lbl1" xml:lang="en-US">Bundger Under Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BundgerUnderAgreement" xlink:to="osti_BundgerUnderAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TEDCOGrantNonCurrent_lbl1" xml:lang="en-US">TEDCOGrant Non Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TEDCOGrantNonCurrent" xlink:to="osti_TEDCOGrantNonCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl1" xml:lang="en-US">Proceeds From Sale Of Preferred Stock And Related Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:to="osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period Value Common Stock Issued For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl0" xml:lang="en-US">Asset Acquisition, Contingent Consideration [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl1" xml:lang="en-US">Stock Issued During Period Value Conversion Of Warrants To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl1" xml:lang="en-US">Conversion Of Makewhole Liability To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfMakewholeLiabilityToCommonStock" xlink:to="osti_ConversionOfMakewholeLiabilityToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl1" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Preferred Shares Mezzanine Stock To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl1" xml:lang="en-US">Stock Issued During Period Valueof Common Stockfor Patent License</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:to="osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl1" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_MillRiverPartnersLLCMember_lbl0" xml:lang="en-US">Mill River Partners LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MillRiverPartnersLLCMember" xlink:to="osti_MillRiverPartnersLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AyalaMember_lbl0" xml:lang="en-US">Ayala Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AyalaMember" xlink:to="osti_AyalaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl0" xml:lang="en-US">Proceeds from License Fees Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl0" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl1" xml:lang="en-US">Accrued Payroll And Payroll Taxes Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AccruedPayrollAndPayrollTaxesRelatedParty" xlink:to="osti_AccruedPayrollAndPayrollTaxesRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestment_lbl0" xml:lang="en-US">Alternative Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestment" xlink:to="us-gaap_AlternativeInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupEMember_lbl0" xml:lang="en-US">Group EMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupEMember" xlink:to="osti_GroupEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl1" xml:lang="en-US">Stock Issued During Period Value Conversion Of Preferred Shares Mezzanine Stock To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:to="osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember_lbl0" xml:lang="en-US">Statistics Fees35 On Development Of SAPTables Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember" xlink:to="osti_StatisticsFees35OnDevelopmentOfSAPTablesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl1" xml:lang="en-US">Common Stock Conversion After Share Discounts Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockConversionAfterShareDiscountsPercentage" xlink:to="osti_CommonStockConversionAfterShareDiscountsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RoyaltyNetSalesPecentage_lbl1" xml:lang="en-US">Royalty Net Sales Pecentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyNetSalesPecentage" xlink:to="osti_RoyaltyNetSalesPecentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember_lbl0" xml:lang="en-US">Service Fee Advance Of212335 Minus The Amount Already Paid Plus PTCFee Advance Of31325paid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" xlink:to="osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PatentLicenseAcquisitionMember_lbl0" xml:lang="en-US">Patent License Acquisition Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PatentLicenseAcquisitionMember" xlink:to="osti_PatentLicenseAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupDMember_lbl0" xml:lang="en-US">Group DMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupDMember" xlink:to="osti_GroupDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MedianMember_lbl0" xml:lang="en-US">Median [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MedianMember" xlink:to="srt_MedianMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl1" xml:lang="en-US">Stock Issued During Period Shares Additional Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesAdditionalUnits" xlink:to="osti_StockIssuedDuringPeriodSharesAdditionalUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ReimbursementExpirationPeriod_lbl1" xml:lang="en-US">Reimbursement Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursementExpirationPeriod" xlink:to="osti_ReimbursementExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl1" xml:lang="en-US">Issuance Of Common Stock To Investor Advisor Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:to="osti_IssuanceOfCommonStockToInvestorAdvisorSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PaymentScheduleServiceFeesRemainderDue_lbl1" xml:lang="en-US">Payment Schedule Service Fees Remainder Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleServiceFeesRemainderDue" xlink:to="osti_PaymentScheduleServiceFeesRemainderDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember_lbl0" xml:lang="en-US">Filing Of An NDABLAOr MAARegistrationor The Equivalent In Any Other Territory Around The World Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" xlink:to="osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl1" xml:lang="en-US">Stock Issued During Period Value Sale Of Common Stock To Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl0" xml:lang="en-US">Repayments of Other Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ClosingPricePerShare_lbl1" xml:lang="en-US">Closing Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClosingPricePerShare" xlink:to="osti_ClosingPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharesAwardedParValue_lbl1" xml:lang="en-US">Shares Awarded Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesAwardedParValue" xlink:to="osti_SharesAwardedParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl1" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTableTextBlock_lbl0" xml:lang="en-US">Deferred Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTableTextBlock" xlink:to="us-gaap_DeferredIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl0" xml:lang="en-US">Business Combination, Date of Acquisition Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl1" xml:lang="en-US">Stock Issued During Period Value Surrender Of Common Stock Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TotalEquityValue_lbl1" xml:lang="en-US">Total Equity Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TotalEquityValue" xlink:to="osti_TotalEquityValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl1" xml:lang="en-US">Stock Issued During Period Value Commitment Shares Issued For Equity Line Of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl1" xml:lang="en-US">Patent License Acquisition Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PatentLicenseAcquisitionPolicyTextBlock" xlink:to="osti_PatentLicenseAcquisitionPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Payables Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl0" xml:lang="en-US">Preferred Stock [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AgreedToIssuedCashRemunerationPercentage_lbl1" xml:lang="en-US">Agreed To Issued Cash Remuneration Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AgreedToIssuedCashRemunerationPercentage" xlink:to="osti_AgreedToIssuedCashRemunerationPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CashRemunerationofWarrantFeePercentage_lbl1" xml:lang="en-US">Cash Remunerationof Warrant Fee Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CashRemunerationofWarrantFeePercentage" xlink:to="osti_CashRemunerationofWarrantFeePercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract_lbl" xml:lang="en-US">Schedule Of Financial Information Of Operating Segment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract" xlink:to="osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl0" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember_lbl0" xml:lang="en-US">Privately Negotiated Warrant Exercise Inducement And Exchange Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" xlink:to="osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_HER2AssetsMember_lbl0" xml:lang="en-US">HER2 Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_HER2AssetsMember" xlink:to="osti_HER2AssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_OriginalIssueDiscount_lbl1" xml:lang="en-US">Original Issue Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_OriginalIssueDiscount" xlink:to="osti_OriginalIssueDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GLPToxMember_lbl0" xml:lang="en-US">GLPTox Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GLPToxMember" xlink:to="osti_GLPToxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StatisticsFees30OnFinalAnalysisMember_lbl0" xml:lang="en-US">Statistics Fees30 On Final Analysis Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees30OnFinalAnalysisMember" xlink:to="osti_StatisticsFees30OnFinalAnalysisMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl0" xml:lang="en-US">Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ServiceFeeAdvancepaidMember_lbl0" xml:lang="en-US">Service Fee Advancepaid Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeeAdvancepaidMember" xlink:to="osti_ServiceFeeAdvancepaidMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConversionPricePercentage_lbl1" xml:lang="en-US">Conversion Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionPricePercentage" xlink:to="osti_ConversionPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SeriesAWarrantsMember_lbl0" xml:lang="en-US">Series AWarrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesAWarrantsMember" xlink:to="osti_SeriesAWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember_lbl0" xml:lang="en-US">Statistics Fees35 On Electronic Data Capture EDCGo Live Date Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" xlink:to="osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance_lbl0" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_DebtDiscountAccretionExpenseInWarrants_lbl1" xml:lang="en-US">Debt Discount Accretion Expense In Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DebtDiscountAccretionExpenseInWarrants" xlink:to="osti_DebtDiscountAccretionExpenseInWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Cash Proceeds And Changes In Warrant Liability In The Consolidated Statement Of Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract" xlink:to="osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_NumberOfTradingDays_lbl1" xml:lang="en-US">Number Of Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTradingDays" xlink:to="osti_NumberOfTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SVBBankMember_lbl0" xml:lang="en-US">SVBBank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SVBBankMember" xlink:to="osti_SVBBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_WarrantLiabilityPolicyTextBlock_lbl1" xml:lang="en-US">Warrant Liability Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantLiabilityPolicyTextBlock" xlink:to="osti_WarrantLiabilityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period Shares Common Stock Issued For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:to="osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RoyaltyReductionPercentage_lbl2" xml:lang="en-US">Royalty Reduction Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RoyaltyReductionPercentage" xlink:to="osti_RoyaltyReductionPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl0" xml:lang="en-US">Other Nonoperating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConversionOfWarrantsIntoCommonStock_lbl1" xml:lang="en-US">Conversion Of Warrants Into Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfWarrantsIntoCommonStock" xlink:to="osti_ConversionOfWarrantsIntoCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl0" xml:lang="en-US">Repayments of Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockCash_lbl0" xml:lang="en-US">Dividends, Preferred Stock, Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl0" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ChristopherAcevedoMember_lbl0" xml:lang="en-US">Christopher Acevedo Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChristopherAcevedoMember" xlink:to="osti_ChristopherAcevedoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember_lbl0" xml:lang="en-US">Regulatory Approval In The First Of The United States Within The EUOr Within The UKMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" xlink:to="osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl0" xml:lang="en-US">Investment Advisory Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PreferredStockSharesDesignated_lbl1" xml:lang="en-US">Preferred Stock Shares Designated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PreferredStockSharesDesignated" xlink:to="osti_PreferredStockSharesDesignated_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl1" xml:lang="en-US">Stock Issued During Period Shares Sale Of Common Stock To Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GoingConcernTerm_lbl1" xml:lang="en-US">Going Concern Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GoingConcernTerm" xlink:to="osti_GoingConcernTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StraightLineDepreciatedOverPeriod_lbl1" xml:lang="en-US">Straight Line Depreciated Over Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StraightLineDepreciatedOverPeriod" xlink:to="osti_StraightLineDepreciatedOverPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_BrooklineCapitalMarketsMember_lbl0" xml:lang="en-US">Brookline Capital Markets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BrooklineCapitalMarketsMember" xlink:to="osti_BrooklineCapitalMarketsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl0" xml:lang="en-US">Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_IIClinicalTrialMember_lbl0" xml:lang="en-US">IIClinical Trial Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_IIClinicalTrialMember" xlink:to="osti_IIClinicalTrialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestBearingDomesticDepositMoneyMarket_lbl0" xml:lang="en-US">Interest-Bearing Domestic Deposit, Money Market</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDomesticDepositMoneyMarket" xlink:to="us-gaap_InterestBearingDomesticDepositMoneyMarket_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl0" xml:lang="en-US">Notes Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl0" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PrepaidShares_lbl1" xml:lang="en-US">Prepaid Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShares" xlink:to="osti_PrepaidShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PrepaidCommonStockNotIssuedMember_lbl0" xml:lang="en-US">Prepaid Common Stock Not Issued Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidCommonStockNotIssuedMember" xlink:to="osti_PrepaidCommonStockNotIssuedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GrossProceeds_lbl2" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GrossProceeds" xlink:to="osti_GrossProceeds_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_UnallocatedCashProceeds_lbl1" xml:lang="en-US">Unallocated Cash Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_UnallocatedCashProceeds" xlink:to="osti_UnallocatedCashProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupAMember_lbl0" xml:lang="en-US">Group AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupAMember" xlink:to="osti_GroupAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CerosFinancialServicesIncMember_lbl0" xml:lang="en-US">Ceros Financial Services Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CerosFinancialServicesIncMember" xlink:to="osti_CerosFinancialServicesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl1" xml:lang="en-US">Residual Value Allocated To Series APreferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ResidualValueAllocatedToSeriesAPreferredStock" xlink:to="osti_ResidualValueAllocatedToSeriesAPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl1" xml:lang="en-US">Warrants Exercised And Proceeds Received Shares Pending Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:to="osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PercentageOfRoyaltyPayments_lbl1" xml:lang="en-US">Percentage Of Royalty Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyaltyPayments" xlink:to="osti_PercentageOfRoyaltyPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl1" xml:lang="en-US">Stock Issued During Period Shares To Investment Advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_MrRomnessMember_lbl0" xml:lang="en-US">Mr Romness Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MrRomnessMember" xlink:to="osti_MrRomnessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommonStockSharesAwarded_lbl1" xml:lang="en-US">Common Stock Shares Awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwarded" xlink:to="osti_CommonStockSharesAwarded_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl1" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrants Liability Reclass Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:to="osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PaymentScheduleofServiceFees_lbl1" xml:lang="en-US">Payment Scheduleof Service Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PaymentScheduleofServiceFees" xlink:to="osti_PaymentScheduleofServiceFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_MilestonePayments_lbl1" xml:lang="en-US">Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestonePayments" xlink:to="osti_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupCMember_lbl0" xml:lang="en-US">Group CMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupCMember" xlink:to="osti_GroupCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_NumberOfTranches_lbl1" xml:lang="en-US">Number Of Tranches</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_NumberOfTranches" xlink:to="osti_NumberOfTranches_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_GroupFMember_lbl0" xml:lang="en-US">Group FMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_GroupFMember" xlink:to="osti_GroupFMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ShortTermLoanMember_lbl0" xml:lang="en-US">Short Term Loan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ShortTermLoanMember" xlink:to="osti_ShortTermLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Employee-related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ValuationCeilingsAmount_lbl1" xml:lang="en-US">Valuation Ceilings Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ValuationCeilingsAmount" xlink:to="osti_ValuationCeilingsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl0" xml:lang="en-US">Cash [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConsultingFeeMember_lbl0" xml:lang="en-US">Consulting Fee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConsultingFeeMember" xlink:to="osti_ConsultingFeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_TedcoGrantDisclosureTextBlock_lbl1" xml:lang="en-US">Tedco Grant Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_TedcoGrantDisclosureTextBlock" xlink:to="osti_TedcoGrantDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl0" xml:lang="en-US">Temporary Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl1" xml:lang="en-US">Scheduleof Preferred Stockand Common Stock Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:to="osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract_lbl" xml:lang="en-US">Schedule Of Preferred Stock And Common Stock Equivalents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract" xlink:to="osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl1" xml:lang="en-US">Stock Issued During Period Shares Surrender Of Common Stock Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:to="osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl1" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_WarrantLiabilityMember_lbl0" xml:lang="en-US">Warrant Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantLiabilityMember" xlink:to="osti_WarrantLiabilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfConvertibleDebtAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfConvertibleDebtAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfConvertibleDebtAbstract_lbl" xml:lang="en-US">Schedule Of Convertible Debt Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfConvertibleDebtAbstract" xlink:to="osti_ScheduleOfConvertibleDebtAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_MilestoneBearingEventDescription_lbl1" xml:lang="en-US">Milestone Bearing Event Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_MilestoneBearingEventDescription" xlink:to="osti_MilestoneBearingEventDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US">Common Class A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_BusinessAcquisitionNumberofShares_lbl1" xml:lang="en-US">Business Acquisition Numberof Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BusinessAcquisitionNumberofShares" xlink:to="osti_BusinessAcquisitionNumberofShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl1" xml:lang="en-US">Stock Issued During Period Shares Preferred Stock Seperable Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:to="osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits_lbl1"/>
    <loc xlink:type="locator" xlink:label="osti_ScheduleOfFutureMilestonesAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFutureMilestonesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfFutureMilestonesAbstract_lbl" xml:lang="en-US">Schedule Of Future Milestones Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfFutureMilestonesAbstract" xlink:to="osti_ScheduleOfFutureMilestonesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_FairValueOfHER2AssetsMember_lbl1" xml:lang="en-US">Fair Value Of HER2 Assets Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FairValueOfHER2AssetsMember" xlink:to="osti_FairValueOfHER2AssetsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_InvestedPurchaser_lbl1" xml:lang="en-US">Invested Purchaser</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_InvestedPurchaser" xlink:to="osti_InvestedPurchaser_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Certain Fees And Corresponding Payment Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:to="osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl1" xml:lang="en-US">Stock Issued During Period Shares Commitment Shares Issued For Equity Line Of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_JoacimBorgMember_lbl0" xml:lang="en-US">Joacim Borg Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_JoacimBorgMember" xlink:to="osti_JoacimBorgMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl2" xml:lang="en-US">Accrued Payroll Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_HER2AssetAmortizationMember_lbl0" xml:lang="en-US">HER2 Asset Amortization Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_HER2AssetAmortizationMember" xlink:to="osti_HER2AssetAmortizationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl0" xml:lang="en-US">Assets, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl0" xml:lang="en-US">Payments to Acquire Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PlacementAgentWarrantsMember" xlink:to="osti_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ClawbackOfCommonStockForOverIssuance_lbl1" xml:lang="en-US">Clawback Of Common Stock For Over Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ClawbackOfCommonStockForOverIssuance" xlink:to="osti_ClawbackOfCommonStockForOverIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, at Point in Time</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_lbl0" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-Based Payment Awards [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:to="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:to="osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SeriesASeniorConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series ASenior Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SeriesASeniorConvertiblePreferredStockMember" xlink:to="osti_SeriesASeniorConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_BlinkBioMember_lbl0" xml:lang="en-US">Blink Bio Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_BlinkBioMember" xlink:to="osti_BlinkBioMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrefundedWarrantsMember" xlink:to="osti_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ChaseBankSavingsAccountMember_lbl0" xml:lang="en-US">Chase Bank Savings Account Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChaseBankSavingsAccountMember" xlink:to="osti_ChaseBankSavingsAccountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl1" xml:lang="en-US">Deemed Dividend On Series AConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:to="osti_DeemedDividendOnSeriesAConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommonStockIssuedForPatentPurchase_lbl1" xml:lang="en-US">Common Stock Issued For Patent Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockIssuedForPatentPurchase" xlink:to="osti_CommonStockIssuedForPatentPurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance To Investment Advisors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharesIssuedForPrepaidServices_lbl1" xml:lang="en-US">Shares Issued For Prepaid Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForPrepaidServices" xlink:to="osti_SharesIssuedForPrepaidServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ServiceFeesRemainderDue_lbl1" xml:lang="en-US">Service Fees Remainder Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ServiceFeesRemainderDue" xlink:to="osti_ServiceFeesRemainderDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_FixedAssetPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Fixed Asset Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_FixedAssetPolicyPolicyTextBlock" xlink:to="osti_FixedAssetPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl1" xml:lang="en-US">Redeemable Preferred Stock And Mezzanine Equity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:to="osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember_lbl0" xml:lang="en-US">Third Warrant Exercise Inducement And Exchange Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember" xlink:to="osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PurchaseOfCommonStock_lbl1" xml:lang="en-US">Purchase Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PurchaseOfCommonStock" xlink:to="osti_PurchaseOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Business Combination, Series of Individually Immaterial Business Combinations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl0" xml:lang="en-US">Dividends Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_CommonStockSharesAwardedInCash_lbl1" xml:lang="en-US">Common Stock Shares Awarded In Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_CommonStockSharesAwardedInCash" xlink:to="osti_CommonStockSharesAwardedInCash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl0" xml:lang="en-US">Dividends, Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ReimbursableGrantAmount_lbl1" xml:lang="en-US">Reimbursable Grant Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReimbursableGrantAmount" xlink:to="osti_ReimbursableGrantAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl0" xml:lang="en-US">Business Combination, Name of Acquiree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_SharesIssuedForServices_lbl1" xml:lang="en-US">Shares Issued For Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_SharesIssuedForServices" xlink:to="osti_SharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Make Whole Share Liability Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:to="osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ChiefOperatingDecisionMakerMember_lbl0" xml:lang="en-US">Chief Operating Decision Maker Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ChiefOperatingDecisionMakerMember" xlink:to="osti_ChiefOperatingDecisionMakerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock For Patent License</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PercentageOfRoyalties_lbl1" xml:lang="en-US">Percentage Of Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PercentageOfRoyalties" xlink:to="osti_PercentageOfRoyalties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl0" xml:lang="en-US">Grants Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl0" xml:lang="en-US">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ExercisePrice_lbl1" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ExercisePrice" xlink:to="osti_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl1" xml:lang="en-US">Deferred Offering Costs Recorded As Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_DeferredOfferingCostsRecordedAsAccountsPayable" xlink:to="osti_DeferredOfferingCostsRecordedAsAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_UnderwriterPlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Underwriter Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_UnderwriterPlacementAgentWarrantsMember" xlink:to="osti_UnderwriterPlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl1" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_WarrantsForPlacementAgentNobleCapitalMember_lbl0" xml:lang="en-US">Warrants For Placement Agent Noble Capital Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_WarrantsForPlacementAgentNobleCapitalMember" xlink:to="osti_WarrantsForPlacementAgentNobleCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_PrepaidShare_lbl1" xml:lang="en-US">Prepaid Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_PrepaidShare" xlink:to="osti_PrepaidShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCollateral_lbl0" xml:lang="en-US">Debt Instrument, Collateral</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateral" xlink:to="us-gaap_DebtInstrumentCollateral_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ConversionOfPreferredStockToCommonStock_lbl1" xml:lang="en-US">Conversion Of Preferred Stock To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ConversionOfPreferredStockToCommonStock" xlink:to="osti_ConversionOfPreferredStockToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock To Investment Advisor</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ThirdPartyMember_lbl0" xml:lang="en-US">Third Party Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ThirdPartyMember" xlink:to="osti_ThirdPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_JohnsonMember_lbl0" xml:lang="en-US">Johnson Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_JohnsonMember" xlink:to="osti_JohnsonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl0" xml:lang="en-US">Value Added Tax Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Common Stock To Investment Advisors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:to="osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="osti_ReclassificationOfWarrantLiabilityToEquity_lbl1" xml:lang="en-US">Reclassification Of Warrant Liability To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="osti_ReclassificationOfWarrantLiabilityToEquity" xlink:to="osti_ReclassificationOfWarrantLiabilityToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
<!-- [WMV6][REXdlokU5unvmmKbCeo5j020YV3bWC7IiVNda7/tSGj2tdFkmRMfS3W74+9z2V3t17rXPx1+QiHTqEetZXWgtwQADZ2Hk7l2eSTcvvePvRWsiQUEtlb6wjbPNJ2pQRnaYTMEd1Wo9+jX1HI8ycNwddtkQR07a79N1um7uy3WxjXoLFhPJWBGO/IPu0eDgMPDcLEXAbveo2ZFdfqGPPpSjqKGRRyRRwzhXYaKLA3n8/uVB/PGAgwOQOgXhqNinTUBZdw7GFVgrhaRI8g4cCAkyWmLKhZcqU47pJJ4WDVgINB6XUADWPR/MXZQc14jmI5u8/1AFE4pmaCxfXQ/XjmuBBmc] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>osti-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 30 23:36:19 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedBalanceSheet" roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedIncomeStatement" roleURI="http://www.ostherapies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ShareholdersEquityType2or3" roleURI="http://www.ostherapies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConsolidatedCashFlow" roleURI="http://www.ostherapies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactors" roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPolicies" roleURI="http://www.ostherapies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactions" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebt" roleURI="http://www.ostherapies.com/role/ConvertibleDebt"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_TedcoGrant" roleURI="http://www.ostherapies.com/role/TedcoGrant"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingencies" roleURI="http://www.ostherapies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_Equity" roleURI="http://www.ostherapies.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiability" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformation" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformation"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SubsequentEvents" roleURI="http://www.ostherapies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_AccountingPoliciesByPolicy" roleURI="http://www.ostherapies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPoliciesTables" roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactionsTables" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebtTables" roleURI="http://www.ostherapies.com/role/ConvertibleDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingenciesTables" roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_EquityTables" roleURI="http://www.ostherapies.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformationTables" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFairValueofthePurchaseConsiderationTable" roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals" roleURI="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofEstimatedAmortizationExpensesTable" roleURI="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" roleURI="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofPreferredStockandCommonStockEquivalentsTable" roleURI="http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofPayrollAdvancestotheCEOTable" roleURI="http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofConvertibleDebtTable" roleURI="http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCompanysMakeWholeShareLiabilityTable" roleURI="http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFutureMilestonesTable" roleURI="http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCertainFeesandCorrespondingPaymentAmountsTable" roleURI="http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCommonStockOptionsIssuedTable" roleURI="http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofBlackScholesOptionPricingModelTable" roleURI="http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" roleURI="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofWarrantsLiabilityTable" roleURI="http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ScheduleofFinancialInformationofOperatingSegmentTable" roleURI="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails" roleURI="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SignificantAccountingPoliciesDetails" roleURI="http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RelatedPartyTransactionsDetails" roleURI="http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_ConvertibleDebtDetails" roleURI="http://www.ostherapies.com/role/ConvertibleDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_TedcoGrantDetails" roleURI="http://www.ostherapies.com/role/TedcoGrantDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_CommitmentsandContingenciesDetails" roleURI="http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_EquityDetails" roleURI="http://www.ostherapies.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails" roleURI="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SegmentandGeographicInformationDetails" roleURI="http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="osti-20251231.xsd#osti_r_SubsequentEventsDetails" roleURI="http://www.ostherapies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedPayrollAndPayrollTaxesRelatedParty" xlink:href="osti-20251231.xsd#osti_AccruedPayrollAndPayrollTaxesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AccruedPayrollAndPayrollTaxesRelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DividendsPayableCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TEDCOGrantNonCurrent" xlink:href="osti-20251231.xsd#osti_TEDCOGrantNonCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="TEDCOGrantNonCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividendOnSeriesAConvertiblePreferredStock" xlink:href="osti-20251231.xsd#osti_DeemedDividendOnSeriesAConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="DeemedDividendOnSeriesAConvertiblePreferredStock" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodValueCommonStockIssuedForServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesCommonStockIssuedForServices" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodSharesCommonStockIssuedForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueofCommonStockforPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodValueofCommonStockforPatentLicense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" xlink:href="osti-20251231.xsd#osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" xlink:href="osti-20251231.xsd#osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit" xlink:to="WarrantsExercisedAndProceedsReceivedSharesPendingIssuance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesToInvestmentAdvisor" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesToInvestmentAdvisor" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedForServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="SharesIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentSharesIssuedForEquityLineOfCredit" xlink:href="osti-20251231.xsd#osti_CommitmentSharesIssuedForEquityLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="CommitmentSharesIssuedForEquityLineOfCredit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromSaleOfPreferredStockAndRelatedWarrants" xlink:href="osti-20251231.xsd#osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromSaleOfPreferredStockAndRelatedWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NotesIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Dividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_Dividends" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfPreferredStockToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfPreferredStockToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfPreferredStockToCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsRecordedAsAccountsPayable" xlink:href="osti-20251231.xsd#osti_DeferredOfferingCostsRecordedAsAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="DeferredOfferingCostsRecordedAsAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfWarrantsIntoCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfWarrantsIntoCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfWarrantsIntoCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToInvestorAdvisorSettlement" xlink:href="osti-20251231.xsd#osti_IssuanceOfCommonStockToInvestorAdvisorSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockToInvestorAdvisorSettlement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfMakewholeLiabilityToCommonStock" xlink:href="osti-20251231.xsd#osti_ConversionOfMakewholeLiabilityToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfMakewholeLiabilityToCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClawbackOfCommonStockForOverIssuance" xlink:href="osti-20251231.xsd#osti_ClawbackOfCommonStockForOverIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ClawbackOfCommonStockForOverIssuance" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForPatentPurchase" xlink:href="osti-20251231.xsd#osti_CommonStockIssuedForPatentPurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CommonStockIssuedForPatentPurchase" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantLiabilityToEquity" xlink:href="osti-20251231.xsd#osti_ReclassificationOfWarrantLiabilityToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ReclassificationOfWarrantLiabilityToEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedForPrepaidServices" xlink:href="osti-20251231.xsd#osti_SharesIssuedForPrepaidServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="SharesIssuedForPrepaidServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/TedcoGrant" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="TedcoGrantAbstract" xlink:href="osti-20251231.xsd#osti_TedcoGrantAbstract"/>
    <loc xlink:type="locator" xlink:label="TedcoGrantDisclosureTextBlock" xlink:href="osti-20251231.xsd#osti_TedcoGrantDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantAbstract" xlink:to="TedcoGrantDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssetPolicyPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_FixedAssetPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FixedAssetPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentLicenseAcquisitionPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentLicenseAcquisitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityPolicyTextBlock" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WarrantLiabilityPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredIncomeTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMakeWholeShareLiabilityTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ScheduleOfMakeWholeShareLiabilityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" xlink:href="osti-20251231.xsd#osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PatentLicenseAcquisitionMember" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="PatentLicenseAcquisitionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfThePurchaseConsiderationAbstract" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PatentLicenseAcquisitionMember" xlink:href="osti-20251231.xsd#osti_PatentLicenseAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="PatentLicenseAcquisitionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTable" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract" xlink:to="SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwriterPlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_UnderwriterPlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwriterPlacementAgentWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InducementWarrantsMember" xlink:href="osti-20251231.xsd#osti_InducementWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="InducementWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidCommonStockNotIssuedMember" xlink:href="osti-20251231.xsd#osti_PrepaidCommonStockNotIssuedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrepaidCommonStockNotIssuedMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SeriesAWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfOtherDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_RepaymentsOfOtherDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleDebtAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfConvertibleDebtAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleDebtAbstract" xlink:to="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="GroupAMember" xlink:href="osti-20251231.xsd#osti_GroupAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupBMember" xlink:href="osti-20251231.xsd#osti_GroupBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupCMember" xlink:href="osti-20251231.xsd#osti_GroupCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupDMember" xlink:href="osti-20251231.xsd#osti_GroupDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupDMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupEMember" xlink:href="osti-20251231.xsd#osti_GroupEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupFMember" xlink:href="osti-20251231.xsd#osti_GroupFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupFMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BlinkBioMember" xlink:href="osti-20251231.xsd#osti_BlinkBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="BlinkBioMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtConversionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCollateral"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentCollateral" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySMakeWholeShareLiabilityAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="srt_ShareRepurchaseProgramLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySMakeWholeShareLiabilityAbstract" xlink:to="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AlanMussoMember" xlink:href="osti-20251231.xsd#osti_AlanMussoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AlanMussoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChristopherAcevedoMember" xlink:href="osti-20251231.xsd#osti_ChristopherAcevedoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ChristopherAcevedoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JoacimBorgMember" xlink:href="osti-20251231.xsd#osti_JoacimBorgMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JoacimBorgMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable" xlink:to="srt_ShareRepurchaseProgramLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionNumberofShares" xlink:href="osti-20251231.xsd#osti_BusinessAcquisitionNumberofShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="BusinessAcquisitionNumberofShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMilestonesAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFutureMilestonesAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PresentValueOfFutureInsuranceProfitLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMilestonesAbstract" xlink:to="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LicenseFeeToUtilizeProprietaryTechnologypaidMember" xlink:href="osti-20251231.xsd#osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LicenseFeeToUtilizeProprietaryTechnologypaidMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GLPToxMember" xlink:href="osti-20251231.xsd#osti_GLPToxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="GLPToxMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IClinicalTrialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="IClinicalTrialMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IIClinicalTrialMember" xlink:href="osti-20251231.xsd#osti_IIClinicalTrialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="IIClinicalTrialMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" xlink:href="osti-20251231.xsd#osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" xlink:href="osti-20251231.xsd#osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable" xlink:to="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MilestoneBearingEventDescription" xlink:href="osti-20251231.xsd#osti_MilestoneBearingEventDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="MilestoneBearingEventDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FutureMilestones" xlink:href="osti-20251231.xsd#osti_FutureMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PresentValueOfFutureInsuranceProfitLineItems" xlink:to="FutureMilestones" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainContingenciesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract" xlink:to="CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ServiceFeeAdvancepaidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvancepaidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ServiceFeeAdvancepaidMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" xlink:href="osti-20251231.xsd#osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatisticsFees35OnDevelopmentOfSAPTablesMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees35OnDevelopmentOfSAPTablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="StatisticsFees35OnDevelopmentOfSAPTablesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatisticsFees30OnFinalAnalysisMember" xlink:href="osti-20251231.xsd#osti_StatisticsFees30OnFinalAnalysisMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="StatisticsFees30OnFinalAnalysisMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceFeesRemainderDueMember" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ServiceFeesRemainderDueMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable" xlink:to="us-gaap_GainContingenciesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PaymentScheduleofServiceFees" xlink:href="osti-20251231.xsd#osti_PaymentScheduleofServiceFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="PaymentScheduleofServiceFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_PaymentsForFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentScheduleServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_PaymentScheduleServiceFeesRemainderDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="PaymentScheduleServiceFeesRemainderDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceFeesRemainderDue" xlink:href="osti-20251231.xsd#osti_ServiceFeesRemainderDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="ServiceFeesRemainderDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="osti-20251231.xsd#osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract" xlink:to="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ResidualValueAllocatedToSeriesAPreferredStock" xlink:href="osti-20251231.xsd#osti_ResidualValueAllocatedToSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="ResidualValueAllocatedToSeriesAPreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnallocatedCashProceeds" xlink:href="osti-20251231.xsd#osti_UnallocatedCashProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="UnallocatedCashProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsLiabilityAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfWarrantsLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsLiabilityAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityMember" xlink:href="osti-20251231.xsd#osti_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantLiabilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationOfOperatingSegmentAbstract" xlink:href="osti-20251231.xsd#osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationOfOperatingSegmentAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ChiefOperatingDecisionMakerMember" xlink:href="osti-20251231.xsd#osti_ChiefOperatingDecisionMakerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ChiefOperatingDecisionMakerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" xlink:href="osti-20251231.xsd#osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GoingConcernTerm" xlink:href="osti-20251231.xsd#osti_GoingConcernTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="GoingConcernTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="osti-20251231.xsd#osti_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="HER2AssetsMember" xlink:href="osti-20251231.xsd#osti_HER2AssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="HER2AssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="HER2AssetAmortizationMember" xlink:href="osti-20251231.xsd#osti_HER2AssetAmortizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="HER2AssetAmortizationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AyalaMember" xlink:href="osti-20251231.xsd#osti_AyalaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="AyalaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ChaseBankCheckingAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankCheckingAccountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChaseBankCheckingAccountMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChaseBankSavingsAccountMember" xlink:href="osti-20251231.xsd#osti_ChaseBankSavingsAccountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ChaseBankSavingsAccountMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SVBBankMember" xlink:href="osti-20251231.xsd#osti_SVBBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SVBBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdPartyMember" xlink:href="osti-20251231.xsd#osti_ThirdPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ThirdPartyMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesASeniorConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesASeniorConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SeriesASeniorConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SeriesAWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="osti-20251231.xsd#osti_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PlacementAgentWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDomesticDepositMoneyMarket" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDomesticDepositMoneyMarket"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_InterestBearingDomesticDepositMoneyMarket" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StraightLineDepreciatedOverPeriod" xlink:href="osti-20251231.xsd#osti_StraightLineDepreciatedOverPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="StraightLineDepreciatedOverPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AdjustmentForAmortization" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfTradingDays" xlink:href="osti-20251231.xsd#osti_NumberOfTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NumberOfTradingDays" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SharePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClosingPricePerShare" xlink:href="osti-20251231.xsd#osti_ClosingPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="ClosingPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalEquityValue" xlink:href="osti-20251231.xsd#osti_TotalEquityValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="TotalEquityValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LeaseCost" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidShare" xlink:href="osti-20251231.xsd#osti_PrepaidShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="PrepaidShare" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidShares" xlink:href="osti-20251231.xsd#osti_PrepaidShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="PrepaidShares" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="osti-20251231.xsd#osti_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrRomnessMember" xlink:href="osti-20251231.xsd#osti_MrRomnessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrRomnessMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MillRiverPartnersLLCMember" xlink:href="osti-20251231.xsd#osti_MillRiverPartnersLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MillRiverPartnersLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertibleDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/ConvertibleDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtDetailsTable" xlink:href="osti-20251231.xsd#osti_ConvertibleDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ConvertibleDebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BrooklineCapitalMarketsMember" xlink:href="osti-20251231.xsd#osti_BrooklineCapitalMarketsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BrooklineCapitalMarketsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CerosFinancialServicesIncMember" xlink:href="osti-20251231.xsd#osti_CerosFinancialServicesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CerosFinancialServicesIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShortTermLoanMember" xlink:href="osti-20251231.xsd#osti_ShortTermLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="ShortTermLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JoacimBorgMember" xlink:href="osti-20251231.xsd#osti_JoacimBorgMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JoacimBorgMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GroupAMember" xlink:href="osti-20251231.xsd#osti_GroupAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupBMember" xlink:href="osti-20251231.xsd#osti_GroupBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupCMember" xlink:href="osti-20251231.xsd#osti_GroupCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupFMember" xlink:href="osti-20251231.xsd#osti_GroupFMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupFMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupDMember" xlink:href="osti-20251231.xsd#osti_GroupDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupDMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GroupEMember" xlink:href="osti-20251231.xsd#osti_GroupEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="GroupEMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WarrantsForPlacementAgentNobleCapitalMember" xlink:href="osti-20251231.xsd#osti_WarrantsForPlacementAgentNobleCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantsForPlacementAgentNobleCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateAdditionalCashProceeds" xlink:href="osti-20251231.xsd#osti_AggregateAdditionalCashProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="AggregateAdditionalCashProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="GrossProceeds" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreedToIssuedCashRemunerationPercentage" xlink:href="osti-20251231.xsd#osti_AgreedToIssuedCashRemunerationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="AgreedToIssuedCashRemunerationPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockSharesAwarded" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwarded"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="CommonStockSharesAwarded" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockSharesAwardedInCash" xlink:href="osti-20251231.xsd#osti_CommonStockSharesAwardedInCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="CommonStockSharesAwardedInCash" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesAwardedParValue" xlink:href="osti-20251231.xsd#osti_SharesAwardedParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="SharesAwardedParValue" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashRemunerationofWarrantFeePercentage" xlink:href="osti-20251231.xsd#osti_CashRemunerationofWarrantFeePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="CashRemunerationofWarrantFeePercentage" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountAccretionExpenseInWarrants" xlink:href="osti-20251231.xsd#osti_DebtDiscountAccretionExpenseInWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtDiscountAccretionExpenseInWarrants" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="osti-20251231.xsd#osti_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ExercisePrice" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWarrantsExercisable" xlink:href="osti-20251231.xsd#osti_AggregateWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="AggregateWarrantsExercisable" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ShortTermDebtWeightedAverageInterestRate" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/TedcoGrantDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="TedcoGrantAbstract" xlink:href="osti-20251231.xsd#osti_TedcoGrantAbstract"/>
    <loc xlink:type="locator" xlink:label="TedcoGrantDetailsTable" xlink:href="osti-20251231.xsd#osti_TedcoGrantDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TedcoGrantLineItems" xlink:href="osti-20251231.xsd#osti_TedcoGrantLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantAbstract" xlink:to="TedcoGrantDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantDetailsTable" xlink:to="TedcoGrantLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfTranches" xlink:href="osti-20251231.xsd#osti_NumberOfTranches"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="NumberOfTranches" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="us-gaap_GrantsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReimbursableGrantAmount" xlink:href="osti-20251231.xsd#osti_ReimbursableGrantAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="ReimbursableGrantAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyalties" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="PercentageOfRoyalties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReductionPercentage" xlink:href="osti-20251231.xsd#osti_RoyaltyReductionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="RoyaltyReductionPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReimbursementExpirationPeriod" xlink:href="osti-20251231.xsd#osti_ReimbursementExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TedcoGrantLineItems" xlink:to="ReimbursementExpirationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="osti-20251231.xsd#osti_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConsultingFeeMember" xlink:href="osti-20251231.xsd#osti_ConsultingFeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ConsultingFeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JohnsonMember" xlink:href="osti-20251231.xsd#osti_JohnsonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="JohnsonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BlinkBioMember" xlink:href="osti-20251231.xsd#osti_BlinkBioMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BlinkBioMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RentExpense" xlink:href="osti-20251231.xsd#osti_RentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="osti-20251231.xsd#osti_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="MilestonePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyNetSalesPecentage" xlink:href="osti-20251231.xsd#osti_RoyaltyNetSalesPecentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RoyaltyNetSalesPecentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyReductionPercentage" xlink:href="osti-20251231.xsd#osti_RoyaltyReductionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RoyaltyReductionPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BundgerUnderAgreement" xlink:href="osti-20251231.xsd#osti_BundgerUnderAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="BundgerUnderAgreement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingBalanceFees" xlink:href="osti-20251231.xsd#osti_OutstandingBalanceFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="OutstandingBalanceFees" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ValueAddedTaxReceivable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRoyaltyPayments" xlink:href="osti-20251231.xsd#osti_PercentageOfRoyaltyPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfRoyaltyPayments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AlternativeInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AlternativeInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AlternativeInvestment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LegalFees" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="osti-20251231.xsd#osti_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityLineOfCreditMember" xlink:href="osti-20251231.xsd#osti_EquityLineOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="EquityLineOfCreditMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="osti-20251231.xsd#osti_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="SeriesAWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairValueOfHER2AssetsMember" xlink:href="osti-20251231.xsd#osti_FairValueOfHER2AssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="FairValueOfHER2AssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonClassBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MedianMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MedianMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MedianMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="osti-20251231.xsd#osti_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockConversionAfterShareDiscountsPercentage" xlink:href="osti-20251231.xsd#osti_CommonStockConversionAfterShareDiscountsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockConversionAfterShareDiscountsPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationCeilingsAmount" xlink:href="osti-20251231.xsd#osti_ValuationCeilingsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ValuationCeilingsAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="GrossProceeds" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockSharesDesignated" xlink:href="osti-20251231.xsd#osti_PreferredStockSharesDesignated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PreferredStockSharesDesignated" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStockCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:href="osti-20251231.xsd#osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesASeniorConvertiblePreferredStockMember" xlink:href="osti-20251231.xsd#osti_SeriesASeniorConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesASeniorConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecurityPurchaseAgreementMember" xlink:href="osti-20251231.xsd#osti_SecurityPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SecurityPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesPreferredStockSeperableUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStock" xlink:href="osti-20251231.xsd#osti_PurchaseOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="PurchaseOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesAdditionalUnits" xlink:href="osti-20251231.xsd#osti_StockIssuedDuringPeriodSharesAdditionalUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesAdditionalUnits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalShares" xlink:href="osti-20251231.xsd#osti_OriginalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="OriginalShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SegmentandGeographicInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.ostherapies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="osti-20251231.xsd#osti_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThirdWarrantExerciseInducementAndExchangeOfferingMember" xlink:href="osti-20251231.xsd#osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ThirdWarrantExerciseInducementAndExchangeOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" xlink:href="osti-20251231.xsd#osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherOwnershipInterestsOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssueDiscount" xlink:href="osti-20251231.xsd#osti_OriginalIssueDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="OriginalIssueDiscount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestedPurchaser" xlink:href="osti-20251231.xsd#osti_InvestedPurchaser"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="InvestedPurchaser" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="osti-20251231.xsd#osti_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="GrossProceeds" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPricePercentage" xlink:href="osti-20251231.xsd#osti_ConversionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ConversionPricePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
<!-- [WMV6][Jy2v0mplq54VgGaMVPE0lowC2BvD9boYQxHzcMGTvMkBtC+1E8x6IXfSgKdFDKAJx1lSr7PUQBdth+lBbTZKOLw94JRYPv0HEirCAyG8UkJi4r6aYVKnsxxR397Sgix75oJTZYMGVPwKmNHmROH28mWfmHZh4tgeXyByqGCup1FvmDfeL2wIBs7jljv+7IKPKxDc/RgsFXDJ522SDezbQ7p7veuY+cRUEmKA46HLYlmMX16HjjmgII4l2/zIsmnoTwuTO7/B30m71c36Geq34KT7SgqqUjutDuaauOkdXdQ2KsPGOMSP77nJYongWXR1pkB/XJKnr4FIX1OccJzFx7U=] CSR-->
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 26, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OS THERAPIES INCORPORATED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001795091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5118368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Jun. 24,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">115 Pullman Crossing Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Grasonville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-7793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OSTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,533,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">MaloneBailey, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Houston, Texas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Opinion on the Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance
sheets of OS Therapies Incorporated and its subsidiaries (collectively, the &#8220;Company&#8221;) as of December 31, 2025 and 2024,
and the related consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended,
and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of
its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 269,830<span></span>
</td>
<td class="nump">$ 5,533,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">63,082<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">332,912<span></span>
</td>
<td class="nump">5,533,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-Term Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets (net)</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">5,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Patent (net of amortization)</a></td>
<td class="nump">6,504,132<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total-Long Term Assets</a></td>
<td class="nump">6,506,622<span></span>
</td>
<td class="nump">5,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">6,839,534<span></span>
</td>
<td class="nump">5,538,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,936,387<span></span>
</td>
<td class="nump">1,662,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,415,002<span></span>
</td>
<td class="nump">521,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AccruedPayrollAndPayrollTaxesRelatedParty', window );">Accrued payroll and payroll taxes &#8211; related party</a></td>
<td class="nump">36,792<span></span>
</td>
<td class="nump">97,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll and payroll taxes</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Preferred dividends payable</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,971,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">11,764,460<span></span>
</td>
<td class="nump">4,627,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TEDCOGrantNonCurrent', window );">TEDCO grant</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">11,864,460<span></span>
</td>
<td class="nump">4,727,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>MEZZANINE EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively</a></td>
<td class="nump">1,070,705<span></span>
</td>
<td class="nump">4,078,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total Mezzanine Equity</a></td>
<td class="nump">1,070,705<span></span>
</td>
<td class="nump">4,078,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively</a></td>
<td class="nump">37,116<span></span>
</td>
<td class="nump">20,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $0.001, 5,000,000 shares authorized; 0 and 0 shares outstanding, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">61,053,472<span></span>
</td>
<td class="nump">35,144,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(67,186,219)<span></span>
</td>
<td class="num">(38,432,375)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Deficit</a></td>
<td class="num">(6,095,631)<span></span>
</td>
<td class="num">(3,266,538)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="nump">$ 6,839,534<span></span>
</td>
<td class="nump">$ 5,538,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_AccruedPayrollAndPayrollTaxesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of accrued payroll and payroll taxes &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_AccruedPayrollAndPayrollTaxesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_TEDCOGrantNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of TEDCO grant, non current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_TEDCOGrantNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">20,869,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in Shares)</a></td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">20,869,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in Shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued (in Shares)</a></td>
<td class="nump">392,500<span></span>
</td>
<td class="nump">1,775,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">392,500<span></span>
</td>
<td class="nump">1,775,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,360,725<span></span>
</td>
<td class="nump">$ 2,839,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,344,976<span></span>
</td>
<td class="nump">3,974,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,705,701)<span></span>
</td>
<td class="num">(6,813,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME/EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">249<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,051,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Non-operating income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Non-operating expenses</a></td>
<td class="num">(1,472,995)<span></span>
</td>
<td class="num">(51,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,424,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME/EXPENSE</a></td>
<td class="num">(48,143)<span></span>
</td>
<td class="num">(2,069,092)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(28,753,844)<span></span>
</td>
<td class="num">(8,882,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_DeemedDividendOnSeriesAConvertiblePreferredStock', window );">Cumulative Series A preferred stock dividend requirement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS available to common shareholders</a></td>
<td class="num">$ (28,753,844)<span></span>
</td>
<td class="num">$ (8,914,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average # of shares (in Shares)</a></td>
<td class="nump">29,253,292<span></span>
</td>
<td class="nump">6,950,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share outstanding (in Dollars per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share outstanding (in Dollars per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_DeemedDividendOnSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_DeemedDividendOnSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock CS &#8211; Shares CS &#8211; Par</div></th>
<th class="th"><div>Preferred Stock Shares Par Amount</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 5,340<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 5,495,330<span></span>
</td>
<td class="num">$ (29,518,187)<span></span>
</td>
<td class="num">$ (24,016,215)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">5,340,000<span></span>
</td>
<td class="nump">1,302,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Preferred Stock to Common Stock</a></td>
<td class="nump">$ 651<span></span>
</td>
<td class="num">$ (1,302)<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Preferred Stock to Common Stock (in Shares)</a></td>
<td class="nump">651,041<span></span>
</td>
<td class="num">(1,302,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred Dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock IPO</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,473,626<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,475,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock IPO (in Shares)</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Convertible Notes to Common Stock</a></td>
<td class="nump">$ 13,153<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,743,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,756,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Convertible Notes to Common Stock (in Shares)</a></td>
<td class="nump">13,153,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock', window );">Conversion of Warrants to Common Stock</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(411)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Warrants to Common Stock (in Shares)</a></td>
<td class="nump">411,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors', window );">Issuance of Common Stock to Investment Advisor</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor', window );">Issuance of Common Stock to Investment Advisor (in Shares)</a></td>
<td class="nump">320,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor', window );">Issuance of Common Stock to Investment Advisor</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors', window );">Issuance of Common Stock to Investment Advisor (in Shares)</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors', window );">Surrender of Common Stock Investors</a></td>
<td class="num">$ (669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors', window );">Surrender of Common Stock Investors (in Shares)</a></td>
<td class="num">(669,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for Services</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,975<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for Services (in Shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for Interest</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued for Interest (in Shares)</a></td>
<td class="nump">6,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,882,938)<span></span>
</td>
<td class="num">(8,882,938)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 20,870<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">35,144,967<span></span>
</td>
<td class="num">(38,432,375)<span></span>
</td>
<td class="num">(3,266,538)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">20,869,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit', window );">Commitment shares issued for Equity Line of Credit</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">568,078<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">568,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit', window );">Commitment shares issued for Equity Line of Credit (in Shares)</a></td>
<td class="nump">157,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices', window );">Common Stock issued for Services</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,599,054<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,599,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices', window );">Common Stock issued for Services (in Shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock', window );">Conversion of Preferred Shares Mezzanine Equity to Common Stock</a></td>
<td class="nump">$ 4,939<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,725,181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,730,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock', window );">Conversion of Preferred Shares Mezzanine Equity to Common Stock (in Shares)</a></td>
<td class="nump">4,939,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense', window );">Issuance of Common Stock for Patent License</a></td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,393,239<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,398,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense', window );">Issuance of Common Stock for Patent License (in Shares)</a></td>
<td class="nump">4,774,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors', window );">Sale of Common Stock to Investors</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors', window );">Sale of Common Stock to Investors (in Shares)</a></td>
<td class="nump">282,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock', window );">Warrants Liability Reclass Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">878,153<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">878,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance', window );">Warrants exercised and proceeds received, shares pending issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,579,870<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,579,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock', window );">Conversion of Warrants to Common Stock</a></td>
<td class="nump">$ 5,639<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,138,562<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,144,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Warrants to Common Stock (in Shares)</a></td>
<td class="nump">5,638,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,265,374<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,265,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(28,753,844)<span></span>
</td>
<td class="num">(28,753,844)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2025</a></td>
<td class="nump">$ 37,113<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 61,053,475<span></span>
</td>
<td class="num">$ (67,186,219)<span></span>
</td>
<td class="num">$ (6,095,631)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Dec. 31, 2025</a></td>
<td class="nump">37,113,082<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of adjustments to additional paid in capital, warrants liability reclass preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued for Equity Line of Credit .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for Services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period conversion of preferred shares mezzanine stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock for Patent License.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock to Investment Advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock to Investment Advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Common Stock to Investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender of Common Stock Investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to investment advisor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period in commitment shares issued for equity line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock issued for Services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period conversion of preferred shares mezzanine stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrants to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of issuance of common stock to investment advisors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Common Stock to Investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender of Common Stock Investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount for issuance of common stock for patent license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised and proceeds received, shares pending issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,753,844)<span></span>
</td>
<td class="num">$ (8,882,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">363,085<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts issuance and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,425,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Shares issued for interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in value of warrant liabilities</a></td>
<td class="num">(1,424,603)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommitmentSharesIssuedForEquityLineOfCredit', window );">Commitment shares issued for equity line of credit</a></td>
<td class="nump">568,235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common shares issuance for services</a></td>
<td class="nump">595,841<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,265,957<span></span>
</td>
<td class="nump">268,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Amortization of non-cash prepaids</a></td>
<td class="nump">1,037,631<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">8,274,316<span></span>
</td>
<td class="num">(1,053,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">893,992<span></span>
</td>
<td class="nump">358,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest on convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">613,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued Payroll and payroll taxes</a></td>
<td class="num">(59,186)<span></span>
</td>
<td class="num">(48,423)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,238,576)<span></span>
</td>
<td class="num">(7,282,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Patent License Acquisition</a></td>
<td class="num">(466,423)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(466,423)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Prepaid warrants (net of fees)</a></td>
<td class="nump">530,162<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Common stock issuance (net of fees)</a></td>
<td class="nump">7,858,140<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Short-term borrowings</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Short-term loan repayments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants', window );">Sale of preferred stock</a></td>
<td class="nump">1,053,000<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering (net of fees)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,225,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from conversion of debt A, B, C, D, E &amp; F</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,501,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,441,302<span></span>
</td>
<td class="nump">12,776,840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash</a></td>
<td class="num">(5,263,697)<span></span>
</td>
<td class="nump">5,495,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; beginning of period</a></td>
<td class="nump">5,533,527<span></span>
</td>
<td class="nump">38,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash &#8211; end of period</a></td>
<td class="nump">269,830<span></span>
</td>
<td class="nump">5,533,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Discount on notes payable &#8211; redemption premium</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">750,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Dividends payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividend on Series A convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,971,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Mezzanine equity conversion (net of costs)</a></td>
<td class="nump">3,730,121<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_DeferredOfferingCostsRecordedAsAccountsPayable', window );">Amortization of deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">751,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,757,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ConversionOfWarrantsIntoCommonStock', window );">Conversion of warrants into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_IssuanceOfCommonStockToInvestorAdvisorSettlement', window );">Issuance of common stock to investor advisor &#8211; settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ConversionOfMakewholeLiabilityToCommonStock', window );">Conversion of make-whole liability to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ClawbackOfCommonStockForOverIssuance', window );">Clawback of common stock for over issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommonStockIssuedForPatentPurchase', window );">Common stock issued for patent purchase</a></td>
<td class="nump">6,398,015<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrants liability to equity</a></td>
<td class="nump">878,153<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharesIssuedForPrepaidServices', window );">Shares issued for prepaid services</a></td>
<td class="nump">$ 1,100,713<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ClawbackOfCommonStockForOverIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clawback of common stock for over issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ClawbackOfCommonStockForOverIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CommitmentSharesIssuedForEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment shares issued for the equity line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CommitmentSharesIssuedForEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CommonStockIssuedForPatentPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock issued for patent purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CommonStockIssuedForPatentPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ConversionOfMakewholeLiabilityToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of conversion of make-whole liability to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ConversionOfMakewholeLiabilityToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of conversion of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ConversionOfWarrantsIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of warrants into Common Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ConversionOfWarrantsIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_DeferredOfferingCostsRecordedAsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred offering costs recorded as accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_DeferredOfferingCostsRecordedAsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_IssuanceOfCommonStockToInvestorAdvisorSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to investor advisor settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_IssuanceOfCommonStockToInvestorAdvisorSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of proceeds from sale of  preferred stock and related warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharesIssuedForPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued for prepaid services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharesIssuedForPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business, Liquidity, and Risk Factors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business, Liquidity, and Risk Factors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS, LIQUIDITY, AND RISK FACTORS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1&#160;&#8212;&#160;ORGANIZATION AND DESCRIPTION
OF BUSINESS, LIQUIDITY, AND RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>OS Therapies Incorporated</b>
(&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221;) is a Delaware corporation incorporated on June&#160;24,
2019. It is based in Rockville, Maryland. The Company is the successor to an LLC formed in 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company intends to focus
on the identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. As of December 31,
2025, there is one ongoing clinical trial for Osteosarcoma therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OS Animal Health Corp
&#8211; Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 25, 2025, the Company
formed OS Animal Health Corp, a Delaware corporation and wholly owned subsidiary. The subsidiary had minimal activity during the year
ended December 31, 2025, consisting primarily of investor relations and audit-related expenses. During this period, the Company entered
into a license agreement with the subsidiary, pursuant to which it granted the subsidiary rights to use the HER2 Assets (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>OS Therapies UK LTD
&#8211; Subsidiary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 29, 2025, the Company
formed OS Therapies UK LTD, a United Kingdom corporation and wholly owned subsidiary. This subsidiary serves as the Company&#8217;s research
and development arm and had substantial operating activity during 2025. The Company has transitioned its research and development activities
to this subsidiary and intends to enter into an intercompany loan agreement, which is currently pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has prepared its
consolidated financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. Since inception, the Company has incurred significant net losses and negative cash flows from operations.
During the year ended December 31, 2025, the Company incurred a net loss of $28.8 million and used $14.2 million in cash for operating
activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the
Company had cash and cash equivalents of $269,830. Management has evaluated whether there are conditions and events, considered in the
aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date
that these consolidated financial statements are issued. The Company&#8217;s current cash balance is insufficient to fund operations.
During 2025, the Company incurred significant expenses, primarily related to activities in preparation for potential regulatory approvals
by the U.S. Food and Drug Administration and other regulatory authorities. The Company expects vendor and related costs associated with
these efforts to total approximately $25.0 million and continue into 2026. These factors raise substantial doubt about the Company&#8217;s
ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s ability
to continue as a going concern is dependent upon its ability to raise additional capital to fund its research and development and future
operations. Management&#8217;s plans to mitigate these conditions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Equity and Debt Financing: The Company is actively
seeking additional capital through public or private equity offerings or debt financings.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, there can be no assurance
that the Company will be successful in sequestering additional financing on favorable terms, or at all. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2&#160;&#8212;&#160;SIGNIFICANT ACCOUNTING
POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements are presented in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;)
and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accounting and reporting
policies of the Company conform to accounting principles generally accepted in the United&#160;States of America, and the Company&#8217;s
fiscal year end is December&#160;31.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries and majority-owned subsidiaries. The Company consolidates
all entities in which it has a controlling interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated
financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments,
which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable
under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may
differ from management&#8217;s estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash consists primarily of
deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both
interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation
(FDIC) for a combined total of $250,000. In the normal course of business, the Company may have deposits that exceed the FDIC insured
limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking
relationships. As of December 31, 2025 and December 31, 2024, JPMorgan Chase Bank checking account had $233,490 and $5,216,354, respectively,
and the JPM Chase savings account had $20,269 and $20,021, respectively. As of December 31, 2025 and December 31, 2024, Silicon Valley
Bank checking account had $6,071 and $287,173, respectively, and the SVB money market account had $10,000 and $10,000, respectively. The
JPM Chase and SVB checking accounts were in excess of the FDIC limits for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redeemable Preferred Stock and Mezzanine
Equity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Series
A Senior Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series A Preferred Stock&#8221;), is classified as mezzanine
equity in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 480 (&#8220;ASC 480&#8221;) due to its redemption features upon the occurrence of a deemed liquidation event, including (i) a merger
or consolidation or (ii) the sale, lease, transfer, or other disposition of substantially all of the Company&#8217;s assets. Proceeds
from the issuance were allocated between the Series A Preferred Stock and the accompanying warrants to purchase shares of common stock
(the &#8220;Series A Warrants&#8221;) on a relative fair value basis. Of the initial $6,050,000 in proceeds, a portion was allocated to
the Series A Warrants, with the residual allocated to the Series A Preferred Stock. Similarly, of the subsequent $1,053,000 in proceeds,
a portion was allocated to the Series A Warrants, with the residual allocated to the Series A Preferred Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Asset Policy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A capital asset is defined
as a unit of property that has an economic useful life that extends beyond 12&#160;months. Any items costing below the threshold or not
fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at
historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over five years for financial
statement purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Amortization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, in connection
with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below),
including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. These intangible assets
are amortized on a straight-line basis over their estimated useful lives, with amortization recorded quarterly. Amortization expense for
the years ended December 31, 2025 and 2024 was $360,305 and $0, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent and License Acquisition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#8220;HER2 Purchase Agreement&#8221;), between the Company
and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (&#8220;Ayala&#8221;), the Company completed the acquisition of the <i>Lm</i>-based
immune-oncology programs and related intellectual property assets (the &#8220;HER2 Assets&#8221;) from Ayala, including the assignment
by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The transaction was accounted for as an asset acquisition
in accordance with ASC 805.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the acquisition,
the Company assumed certain specified liabilities and paid an aggregate purchase price of $8,000,000, with a fair value of $6,864,438,
consisting of: (i) $400,000 to Ayala ($150,000 of which was transferred upon signing of the HER2 Purchase Agreement and the remainder
on the closing date); (ii) $100,000 to a third party on behalf of Ayala on the closing date; and (iii) $7,500,000 worth of shares of common
stock, or 4,774,637 shares based on the volume-weighted average price of the Company&#8217;s common stock over the 30 trading days immediately
preceding the closing date of $1.5708. The fair value of the common stock issued was determined using the closing price of $1.34 per share
on April 9, 2025, resulting in a total equity value of $6,398,014 and a corresponding reduction in total purchase consideration. The fair
value of the purchase consideration is summarized below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Legal fees paid on behalf of Ayala</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Company common stock (4,774,637 shares at $1.34 per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,398,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,864,438</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquired intangible assets
consist primarily of a portfolio of patents and related licenses, including patents covering &#8220;Compositions and Methods for Evaluating
Potency of Listeria-Based Immunotherapeutics,&#8221; which underpin the Company&#8217;s lead programs. These patents have an effective
filing date of April 19, 2019 and an estimated remaining useful life of approximately 14 years. The assets are amortized on a straight-line
basis over their estimated useful lives. Amortization expense was $360,305 and $0 for the years ended December 31, 2025 and 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, expected
future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">496,972</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2031 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,019,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,504,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reviews long-lived
assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability
is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising
from the assets or asset groups. <span style="-sec-ix-hidden: hidden-fact-95"><span style="-sec-ix-hidden: hidden-fact-96">No</span></span> impairment losses on long-lived assets have been recorded for&#160;the year ended December 31, 2025
or the year ended December&#160;31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred offering costs consist
of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to
the Company&#8217;s initial public offering and that were charged to stockholders&#8217; equity upon the completion of such offering.
As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden: hidden-fact-97"><span style="-sec-ix-hidden: hidden-fact-98">no</span></span> capitalized deferred offering costs. Upon the completion of the Company&#8217;s initial
public offering on August 2, 2024, all deferred offering costs were charged to stockholders&#8217; deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, and supplies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of incorporation,
the Company adopted ASU&#160;2014-09, <i>Revenue from Contracts with Customers</i>, and all subsequent amendments to the ASU (collectively,
&#8220;ASC&#160;606&#8221;), which (i)&#160;creates a single framework for recognizing revenue from contracts with customers that fall
within its scope and (ii)&#160;revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, in accordance
with ASC&#160;718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees
is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation
expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be
probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized
and any previously recognized compensation expense is reversed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For short-term leases with
a term of 12 months or less, the Company recognizes lease expense on a straight-line basis over the lease term. The Company&#8217;s current
lease arrangements qualify for this short-term lease exemption and are expensed as incurred. The Company did not renew its prior lease
due to landlord restrictions related to renovations of the premises and has temporarily relocated its primary office to 115 Pullman Crossing
Road, Suite #103, Grasonville, Maryland 21638. This space, which serves as the primary office of the Company&#8217;s Chief Financial Officer,
is being provided at no cost. In May 2024, the Company entered into a month-to-month lease agreement with JLabs for general office space
in New York City, primarily for meetings and use by staff when visiting. The monthly lease payment was $750 and increased to $787.50 effective
January 1, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Income taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income
taxes using the asset-and-liability method in accordance with ASC&#160;740, <i>Income Taxes </i>(&#8220;ASC&#160;740&#8221;). Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &#8220;more likely than not&#8221;
that some portion or all of the deferred tax assets will not be realized in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company follows the guidance
in ASC Topic&#160;740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition
of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first
step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits.
The second step involves measurement of the amount to be recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax positions that meet the
more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated
financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,900,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,559,791</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">General business credit carryover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,045,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,672,876</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">R&amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,214,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,501,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,214,741</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,501,235</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes loss
per share in accordance with ASC&#160;260, <i>Earnings per Share </i>(&#8220;ASC&#160;260&#8221;). ASC&#160;260 requires presentation
of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statements of operations. Basic EPS is computed by
dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock
method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect
is antidilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a table listing all
preferred stock and common stock equivalents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock Equivalents</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Series A Senior Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,401,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Underwriter/Placement Agent Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">319,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,448</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,154,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid Common Stock Not Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,441,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,512,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,317,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,792,948</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Convertible Preferred
Stock issued on December 31, 2024, is not reflected in the table above as of December 31, 2024, because stockholder approval was required
for the issuance of common stock upon conversion. Stockholder approval was obtained on April 9, 2025, for the issuance of the shares of
common stock underlying the Series A Preferred Stock, which is classified as mezzanine equity, and for the Series A Warrants. Upon approval,
the conversion price of the Series A Preferred Stock and the exercise price of the Series A Warrants were automatically adjusted to $1.12
per share, based on the volume-weighted average price of the Company&#8217;s common stock for the 10 trading days immediately preceding
April 9, 2025. This adjustment established a conversion multiplier of 3.571429 common shares per preferred share. As of December 31, 2025,
392,500 non-converted shares of Series A Preferred Stock were outstanding, which, using the conversion multiplier, are exercisable into
1,401,786 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, a
total of 319,711 shares of common stock were underlying outstanding underwriter and placement agent warrants, consisting of 112,000 shares
issued in connection with the Company&#8217;s initial public offering and 207,711 shares issued to placement agents in connection with
the PIPE financing in December 2024 and January 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Company&#8217;s two warrant exercise and inducement offerings,
held June 23 to July 10, 2025, and August 29 to September 1, 2025, warrant holders who exercised their existing warrants received new
warrants with an exercise price of $3.00 per share. In total, warrants to purchase 7,154,338 shares of common stock were exercised in
exchange for new warrants to purchase an equal number of shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant holders who pre-funded
conversions during the August 29 to September 30, 2025 offering received an aggregate of 937,500 prepaid shares of common stock and additionally
funded 504,018 prepaid shares, resulting in a total of 1,441,518 prepaid warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company applies ASC&#160;820
<i>Fair Value Measurement </i>(&#8220;ASC&#160;820&#8221;), which establishes a framework for measuring fair value and clarifies the definition
of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an
asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market
participants on the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy established
in ASC&#160;820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and
are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s
own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing
the asset or liability and are to be developed based on the best information available in the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value of the
Company&#8217;s cash, accounts payable, and accrued expenses are approximate fair value because of the short-term maturity of these financial
instruments. The redemption feature of the debt instruments is recorded at fair value (See Note&#160;3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant liability is recorded
at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective
Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates
on behalf of management in developing model assumptions. As of December 31, 2025 and December 31, 2024, the carrying value of the warrant
liability in the aggregate was $0 and $1,971,975, respectively (See Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The valuation hierarchy is
composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. The levels within the valuation hierarchy are described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1&#160;&#8212;&#160;Assets and
liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs,
such as quoted prices in active markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2&#160;&#8212;&#160;Inputs to
the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well
as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3&#160;&#8212;&#160;Inputs to
the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market
data exists for the assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A Warrants issued in connection with a Securities Purchase Agreement, dated as of December 24, 2024 (the &#8220;Purchase Agreement&#8221;),
are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at
fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance
sheet date until exercised or reclassified, and any change in fair value is recognized in the Company&#8217;s consolidated statements
of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation
model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available
and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated
all recently issued accounting pronouncements and plans to adopt ASU 2024-03, Disaggregated Income Statement Disclosure, in the notes
to its audited financial statements for the year ending December 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring
entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For the public business
entities, the guidance is effective for annual periods beginning after December 15, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No other recently issued accounting pronouncements are expected
to have a material impact on the Company&#8217;s financial statements at this time.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accrued Payroll</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the Company had payroll payable to the CEO of $36,792 and $8,871, respectively, and related payroll taxes payable of $1,279 and $88,386,
respectively. During the years ended December 31, 2025 and 2024, the Company made advances on payroll payable, and the CEO repaid amounts
previously advanced.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes activity
in respect to payroll advances to the CEO:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2023</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">191,198</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,875</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(414,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayments 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(134,184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the second and third
quarters of 2024, the Company issued paychecks to Paul Romness, CEO, representing the remaining balance of backpay, net of all 2024 payroll
advances. Payroll taxes related to both backpay and regular compensation were fully paid. All related-party payroll advances to Mr. Romness, previously recorded as employee advances, were
fully repaid during 2025. The balance of related-party payroll advances for Mr. Romness was $0 during 2025. All advances for 2024
were repaid in full as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Parties&#160;&#8212;&#160;Convertible
Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mill River Partners LLC, an
entity affiliated with Ted Search and John Ciccio, members of the Company&#8217;s board of directors, held convertible notes with face
amounts of $0 as of December 31, 2025, and December 31, 2024. These notes were converted into shares of the Company&#8217;s common stock
upon the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related Party Accounting Fees</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the Company had accounts payable of $0 and $26,765, respectively, to Shore Accountants MD Inc., an outside accounting firm that
provides payroll, bookkeeping, and tax preparation services. Shore Accountants MD Inc. is wholly owned by Christopher Acevedo, the Company&#8217;s
Chief Financial Officer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE DEBT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4&#160;&#8212;&#160;CONVERTIBLE DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s convertible
notes are separated into seven groups&#160;&#8212;&#160;A, B, C, D, E, F and BlinkBio&#160;&#8212;&#160;per the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,<br/> 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Conversion</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Collateral</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">A</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">10/31/2024</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">None</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">80% - 87.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>B</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>C</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>D</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>E</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>F</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BlinkBio</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">3/15/2022</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above convertible notes
were all converted into common stock on August 2, 2024 upon consummation of the Company&#8217;s initial public offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in July 2018 through
November 2021, the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;)
with certain lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;). Interest on the unpaid principal
balance accrues at a rate of 10% per annum, computed on the basis of the actual number of&#160;days elapsed and a year of 365&#160;days.
Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on
demand by the Holders at any time after the earlier of (i)&#160;the Maturity Date (as defined in each Agreement) and (ii)&#160;the closing
of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until
October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80&#160;&#8211;&#160;87.5% of the price paid per share for Equity Securities by the investors in the Next
Equity Financing. Equity Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the
next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less
than $3,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of
promissory notes) or $5,000,000, depending upon the signed agreement terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $3,000,000 or $5,000,000 through the sale of the Company&#8217;s equity securities,
excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without
any action on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such
qualified financing at 12.5% of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest
and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480, <i>Distinguishing Liabilities from Equity </i>(&#8220;ASC&#160;480&#8221;), and determined the
Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing
the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument&#8217;s outstanding
principal. The general measurement guidance in ASC&#160;480 requires obligations that can be settled in shares with a fixed monetary value
at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute.
It has been determined that the appropriate guidance for share-settled debt is ASC&#160;835. As a result, the Notes were recorded at the
amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest,
converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 263,499 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group B</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in May&#160;2020,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at 12.5% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 1,288,500 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group C</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in July&#160;2021,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to the Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series
of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000
(including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at 12.5% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 986,250 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group D</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in November&#160;2022,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
Investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Group
D Convertible Notes, the Company agreed to issue an additional 125,000 shares of common stock to the Group D Holders, prorated based on
such Holder&#8217;s investment amount, as an inducement for their investment in the Group D Convertible Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 500,000 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group E</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in February 2023,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price. In connection with the Group E Convertible Notes, the Company agreed to issue an
additional 68,750 shares of common stock to the Group E Holders, prorated based on such Holder&#8217;s investment amount, as an inducement
for their investment in the Group E Convertible Notes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 262,500 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Group F</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commencing in June 2023, the
Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#8220;Agreements&#8221;) with certain
lenders (together, the &#8220;Holders&#8221; or individually, the &#8220;Holder&#8221;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#8220;Note&#8221; or together the &#8220;Notes&#8221;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#8217;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#8217;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#8217;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price. In connection with the Group F Convertible Notes, the Company agreed to issue an
additional&#160;214,594 shares of common stock to the Group F Holders, prorated based on such Holder&#8217;s investment amount, as an
inducement for their investment in the Group F Convertible Notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#8217;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 773,805 shares of the Company&#8217;s
common stock in connection with the closing of the Company&#8217;s initial public offering on August 2, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Redemption Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the redemption
liability was calculated under Level 3 of the fair value hierarchy, is determined based upon a Probability-Weighted of Expected Returns
Model (&#8220;PWERM&#8221;). This PWERM was determined to be the most appropriate method of estimating the value of possible redemption
or conversion outcomes over time, since the Company has not entered into a priced equity round through June 30, 2024. The fair value of
the redemption liability is calculated using the initial value of the convertible note less the debt discount rate of 12.5% in Group A,
20% in Groups B and C, and 50% in Groups D, E and F.&#160;The resulting redemption liability was amortized over the remaining life of
the notes using interest rates of 10% for Group A and 6% for Groups B&#8211;F. Group A notes had a fixed term of three years, while Groups
B&#8211;F had variable terms ranging from 12 months to three years. The Company retained the option to negotiate extended maturity dates
for Groups B&#8211;F. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued
interest, converted into shares of the Company&#8217;s common stock. The redemption liability was closed to stockholders&#8217; equity
on such date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fees Associated with Convertible Debt Raise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fees associated with the
issuance of the convertible notes for Groups A, B, C and D consist of legal and investment banking fees. No related parties received any
portion of these fees. These fees are capitalized and amortized over the life of the respective convertible notes using an effective interest
rate of 10% for Group A and 6% for Groups B, C and D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Make-whole liability&#160;&#8212;&#160;Shares
due Noble Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Company
entered into an advisory agreement with Noble Capital under which, in lieu of cash compensation, the Company agreed to issue 4% of its
common stock, subject to an anti-dilution clause. The make-whole liability represents shares earned due to adjustments under the anti-dilution
provision during 2020 and 2021. As of year-end 2021, the Company held an aggregate of 233,202 shares, valued at $408,413, after issuing
200,000 shares in 2020. Advisory fee expense of $152,482 was recorded in 2021 to reflect the share value earned under the anti-dilution
provision. In 2022, 70,624 shares were set aside to satisfy the anti-dilution clause, with an associated advisory fee expense of $282,496
recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 1, 2023, the make-whole
liability for Noble Capital was contractually nullified and unwound, and the adjustment was reflected in the Consolidated Statements of
Stockholders&#8217; Deficit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, Noble Capital
and the Company settled various investment fees in dispute, as well as shares related to the anti-dilution clause that had expired. Under
the settlement, Noble Capital received 320,033 shares of common stock and $50,000 in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Make-whole liability&#160;&#8212;&#160;Shares
Officers &amp; Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023, the Company
issued 350,000 shares of Class A common stock to officers, key employees, key advisors and directors, leaving 20,000 shares to be issued
to Joacim Borg, a former director, with a value of $80,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 1, 2023, the Company
hired Alan Musso, former CFO, and as part of his compensation, awarded him 12,500 shares of common stock at $4.00 per share, totaling
$50,000. This amount was reflected in the Company&#8217;s make-whole stock liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon Mr. Musso&#8217;s resignation
on June 30, 2023, Christopher Acevedo, the current CFO, assumed the role and was awarded the balance of Mr. Musso&#8217;s shares following
the successful completion of the Company&#8217;s initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s make-whole
share liability as of September 30, 2024 is summarized in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"># Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date&#160;Earned</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Alan Musso</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">Former CFO</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">March&#160;1,&#160;2023</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Christopher Acevedo</td><td>&#160;</td> <td style="text-align: center">Current CFO</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,375</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">Upon IPO</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Joacim Borg</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">Former&#160;Director</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">July&#160;1,&#160;2022</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All make-whole shares due
to directors and officers were issued in October 2024. As a result, the balance of the make-whole stock liability was $0 as of December
31, 2025 and December 31, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants for Placement Agent&#160;&#8212;&#160;Noble
Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2020, the Company
entered into an advisory agreement with Noble Capital, under which, in lieu of cash remuneration, it was granted a 10% warrant fee in
addition to cash compensation for debt raises from investments procured by Noble Capital. The warrants have a five-year term, with an
exercise price equal to the average price paid by the convertible debt holders in each respective debt raise round.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants earned were as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2020: 248,855 warrants, valued at $248,855</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2021: 213,782 warrants, valued at $427,564</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">2022: 162,644 warrants, valued at $325,288</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrants were earned from
2023 through December 31, 2024. Warrants issued in 2020, 2021, and 2022 were accounted for as a discount to the related convertible debt,
with the discount amortized over the life of the debt. Debt discount accretion expense for these warrants was $0 for the year ended December
31, 2025, and $49,840 for the year ended December 31, 2024. The total unamortized warrant discount was $0 as of both December 31, 2025
and December 31, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, Noble Capital
warrant holders exercised 116,313 warrants in a cashless transaction, and in December 2024, the remaining 294,977 warrants were exercised
in a reduced cashless transaction, resulting in the issuance of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants for Underwriter and Placement Agents&#160;&#8212;&#160;Brookline
Capital Markets and Ceros Financial Services, Inc.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 2, 2024, the Company
issued a warrant to Brookline Capital Markets to purchase 112,000 shares of the Company&#8217;s common stock pursuant to an underwriting
agreement. The warrant became exercisable 180 days after July 31, 2024, expires on July 31, 2029, and has an exercise price of $4.40 per
share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, in connection
with the Company&#8217;s Purchase Agreement, Brookline earned warrants initially exercisable for 39,918 shares at $4.40 per share. These
warrants were subsequently adjusted to 156,821 shares at an exercise price of $1.12 per share, subject to further adjustment as provided
in the agreement. The warrants are exercisable for five years from April 9, 2025. As of December 31, 2025, warrants to purchase 156,821
shares remained outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ceros, in connection with
the same Purchase Agreement, earned warrants initially exercisable for 13,951 shares at $4.40 per share, which were subsequently adjusted
to 54,807 shares at $1.12 per share, also subject to further adjustment under the agreement. These warrants are exercisable for five years
from April 9, 2025. As of December 31, 2025, 52,872 warrants remained outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Short-Term Loan </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investor lent the Company
$100,000 on March 7, 2024. The note is a demand note, carrying interest at 8% and was used for working capital purposes. An investor lent
the Company $150,000 on June 28, 2024. The note is a demand note, carrying interest at 8% and was also used for working capital purposes.
The Company repaid these loans, including accrued interest thereon, in August 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tedco Grant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TedcoGrantAbstract', window );"><strong>TEDCO Grant [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TedcoGrantDisclosureTextBlock', window );">TEDCO GRANT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5&#160;&#8212;&#160;TEDCO GRANT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May of 2021, the Company
received the first of two tranches from TEDCO&#8217;s <i>Rural&#160;&amp; Underserved Business Recovery from Impact of COVID-19 (RUBRIC)
Grant </i>in the amount of $50,000. A second tranche of $50,000 was received in October&#160;2021 for a total reimbursable grant amount
of $100,000. The Company is obligated to report on and pay to TEDCO&#160;3% of their quarterly revenues for a five-year period following
the reward date. Income from grants and investments are not considered revenues. Royalties due to TEDCO are capped at 150% of the amount
of the award or $150,000 total. The Company has the option to eliminate the quarterly royalty obligation by making an advance payment
prior to the end of the five-year period, in which case, the Company will receive a 10% reduction of the royalty cap percentage for each
year prior to the expiration of the five-year reimbursement period that the grant is repaid in full. If the Company ceases to meet eligibility
requirements the reimbursement obligation will become due to TEDCO immediately; however, the discount for meeting the obligation will
still apply.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_TedcoGrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_TedcoGrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_TedcoGrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of Tedco grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_TedcoGrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employee Commitments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no employee commitments
as the Company operates on an At-Will employment basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rental Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company rents a virtual
office on a month-to-month basis at JLabs in New York, New York, a facility owned by Johnson &amp; Johnson. The current monthly rent is
$787.50. Rent expense for the years ended December 31, 2025 and 2024 was $10,390 and $1,750, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>License Obligation and Manufacturing Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Advaxis (now Ayala)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2018, the Company
entered into an exclusive license agreement with Advaxis, Inc., as amended, under which it acquired the rights to develop and commercialize
the Advaxis HER2 Construct, including related patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the agreement, all milestone
payments were non-refundable, non-creditable and payable only once upon the achievement of the corresponding milestone. As of December
31, 2020, the first milestone was achieved and paid ($1,550,000) in January 2021. The second milestone was completed and paid ($1,375,000)
in May 2021. No milestone payments were made for the year ended December 31, 2025 or December 31, 2024. The license agreement was terminated
upon the Company&#8217;s purchase of the HER2 Assets from Ayala on April 9, 2025, which included a payment of $400,000 and the issuance
of common stock as consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>BlinkBio</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July&#160;2020, the Company
entered into a Licensing Agreement with BlinkBio, Inc., to utilize their proprietary technology. As of August&#160;2020, the $300,000
License fee was fully paid and recorded in license expense. These payments have been recorded in the Licensing expenses of the accompanying
statement of operations. No payments were due or made in 2024 or 2025. The Company is currently conducting early-stage research on the
licensed drug, including studies to support future toxicology evaluations. A payment schedule for future milestones is summarized below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone Bearing Event</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone<br/> Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">1.</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">License Fee to utilize proprietary technology (paid)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">$300,000 + $2.4 million Convertible Note</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; width: 3%; vertical-align: top">2.</td><td style="width: 1%">&#160;</td> <td style="width: 82%; text-align: left">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#8220;GLP-Tox&#8221;)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">3.</td><td>&#160;</td> <td style="text-align: left">Completion of a Phase I Clinical Trial</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">4.</td><td>&#160;</td> <td style="text-align: left">Completion of a Phase II Clinical Trial</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">5.</td><td>&#160;</td> <td style="text-align: left">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">6,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">6.</td><td>&#160;</td> <td style="text-align: left">Regulatory Approval in the first of the United States, within the EU or within the UK</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">12,000,000</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will make the
cash payments set forth in the table above by wire transfer of immediately available funds, to BlinkBio within 30&#160;days of the occurrence
of each milestone set forth with respect to the first Product to attain each such milestone, except that the first Milestone above will
apply with respect to The Company&#8217;s first product candidate. During the Royalty Term, the Company will pay BlinkBio a royalty of
6% on Net Sales on a Product-by-Product and country-by-country basis during the Royalty Term, in a country in which no Valid Claim Covers
the manufacture, use, or sale of a Product, the royalty on Net Sales of such Product in such country will be reduced to 3%. No royalties
were due in the years ended December 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
each milestone payment will be payable only once, and the aggregate amount of Milestone payments payable hereunder will not exceed $22,375,000.
A Milestone may be achieved by the Company or a Commercial Sublicensee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>George Clinical Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June&#160;2020, the Company
entered into a Research Service Agreement, as amended, with George Clinical Inc., to use their clinical research services for the Company&#8217;s
study: &#8220;<i>An Open Label, Phase&#160;2 Study of Maintenance Therapy with OST-HER2&#160;after Resection of Recurrent Osteosarcoma</i>&#8221;.
Under the terms of the agreement, the Company was required to pay to George Clinical certain fees described in the fee schedule below.
The total budget under the agreement was approximately $2,436,928. For the years ended December 31, 2025 and 2024, the total research
and development expenses recorded in the statement of operations was $0&#160;and $86,687, respectively. The fee schedule for certain fees
and corresponding payment amounts is set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>George Clinical Payment Schedule</b></span></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment <br/>
Amount</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 3%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">1.</span></td> <td style="width: 1%">&#160;</td> <td style="width: 82%"><span style="font-size: 10pt">Service Fee Advance (paid)</span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="font-size: 10pt">49,989</span></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">2.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">193,671</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">3.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Electronic Data Capture (EDC) Go Live Date</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">47,740</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">4.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Development of SAP tables</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">47,740</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">5.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;30% on Final Analysis</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">40,920</span></td> <td>&#160;</td></tr> <tr> <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">6.</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top"><span style="font-size: 10pt">Service Fees&#160;&#8211;&#160;Remainder Due</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Split monthly <br/>
over course <br/>
of study</span></td> <td style="vertical-align: bottom">&#160;</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">George Clinical tracked and
invoiced the Company for the number of task units completed and pass-through costs were invoiced each month in arrears based on actual
costs without mark-up. The PTC Advance Fee was used to offset final pass-through fees payable. As of December 31, 2025, the balance payable
to George Clinical was $0, and the services agreement has terminated in accordance with its terms. All fees due under the agreement have
been satisfied, and no further obligations to the vendor remain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Biolacuna Ltd</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has contracted
with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements to register OST-HER2 and
gain approval of its use in the respective regions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">European Medicines Agency (EMA, Europe);</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines Evaluation Board (MEB, Netherlands);</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">Medicines and Healthcare products Regulatory Agency (MHRA,
United Kingdom); and</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman">&#9679;</span></td><td style="text-align: justify">U.S. Food and Drug Administration (FDA, United States).</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, the Company paid $11,629,063 in consulting fees, which includes refundable value-added tax (VAT) expenses. As of December 31,
2025, accounts payable related to consulting fees and VAT totaled $7,323,386.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Trustees of the University of Pennsylvania</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, the Company
acquired from Ayala the HER2 Assets. Pursuant to the terms of the HER2 Purchase Agreement, the amended and restated development, license
and supply agreement with Advaxis terminated. In connection with the acquisition of the HER2 Assets, the Company was assigned by Ayala
a license agreement with the Trustees of the University of Pennsylvania covering the use of HER2 construct patents. Under the terms of
the license agreement, the Company is required to pay an annual license fee to the Trustees of the University of Pennsylvania. In April
2025, the Company paid a fee of $266,317 for the year ended December 31, 2025. In addition, the Company is obligated to pay a royalty
equal to 1.5% of net sales related to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">OST-HER2-related sales;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-503-related sales;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">ADXS-504-related sales; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Sales related to any new immunotherapy
drug candidates created from the <i>Lm</i> platform during the term of such licensing agreement.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company
may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any
of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate
insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company&#8217;s
future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this
were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position.
Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently
not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, could
have a material adverse effect on the Company&#8217;s results of operations or financial position. The Company recently participated in
an arbitration hearing related to a claim brought by its former investment advisor concerning underwriter compensation for the Company&#8217;s
initial public offering in August 2024 and any subsequent equity offerings during the following 12 months. The hearing concluded on November
7, 2025, and the arbitrators issued a ruling on January 28, 2026, awarding the former investment advisor $1,055,428 and their attorneys
$308,804.88. The Company also incurred $15,128.32 in arbitration-related fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total amount of $1,379,361.20
has been accrued in the Company&#8217;s financial statements as of December 31, 2025 and is recorded as Other expense, payable in 2026.
The Company does not intend to challenge the ruling. In accordance with ASC 450, the obligation is considered both probable and reasonably
estimable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7&#160;&#8212;&#160;EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, the Company&#8217;s
common stock was initially split into two classes: 50,000,000 shares of Class A common stock, $0.001 par value per share (&#8220;Class
A Common Stock&#8221;), and 20,000,000 shares of Class B common stock, $0.001 par value per share (&#8220;Class B Common Stock&#8221;).
On February 9, 2024, the Company combined the two classes under the name common stock with 50,000,000 shares authorized. On October 21,
2025, stockholders approved an increase in authorized common stock from 50,000,000 to 150,000,000 shares. As of December 31, 2025 and
2024, the Company had 37,113,082 and 20,869,908 shares of common stock outstanding, respectively. Common stock has voting rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August&#160;2, 2024, the
Company consummated its initial public offering and sold&#160;1.6 million shares of common stock at a price of $4.00&#160;per share. Concurrent
with this consummation, all outstanding convertible notes, including accrued interest thereon, automatically converted into approximately&#160;13.2&#160;million
shares of common stock, at conversion prices ranging from $0.39&#160;per share to $2.59&#160;per share, after applying share discounts
ranging from&#160;50% to&#160;87.5% and valuation ceilings ranging from $5&#160;million to $50&#160;million, as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
March 31, 2025, the Company issued (i) 157,407 shares of common stock in connection with its equity line of credit, (ii) 300,000 shares
of common stock to a scientific and technical advisor in exchange for scientific and technical services, which will be amortized over
a 12-month period with the remaining balance in prepaid expenses, and (iii) 20,000 shares of common stock to an advisor in exchange for
services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
June 30, 2025, the Company issued (i) 3,962,129 shares of common stock in connection with conversions of Series A Preferred Stock, (ii)
2,164,215 shares of common stock in connection with the purchase of the HER2 Assets, (iii) 2,166,381 pre-funded warrants in connection
with the purchase of the HER2 Assets, (iv) 10,000 shares of common stock to an advisor in exchange for services and (v) 2,181,257 shares
of common stock in connection with the Company&#8217;s warrant exercise inducement and exchange offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
September 30, 2025, the Company issued (i) 977,679 shares of common stock in connection with conversions of Series A Preferred Stock,
(ii) 2,507,386 shares of common stock in connection with the Company&#8217;s warrant exercise inducement and exchange offering and (iii)
120,000 shares of common stock to an advisor in exchange for services. Additionally, the Company received $1,050,000 in gross proceeds,
which was recorded as additional paid-in capital, from the exercise of Series A Warrants to purchase 937,500 shares of common stock, which
were issued subsequent to September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
December 31, 2025, the Company issued (i) 950,000 shares of common stock in connection with its warrant exercise inducement and exchange
offering related to pre-funded warrants, (ii) 2,610,422 shares of common stock upon exercise of the pre-funded warrant issued in connection
with the purchase of the HER2 Assets, and (iii) 282,679 shares of common stock sold pursuant to the Company&#8217;s ATM program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in three months ended December 31, 2025, the Company
received $1,426,109 in gross proceeds from the exercise of Series A Warrants to purchase 1,441,518 shares of common stock at a future
date. These proceeds were recorded as additional paid-in capital and are reflected in the Company&#8217;s warrant register.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2021, the Company authorized
5,000,000 shares of Preferred Stock, of which 1,400,000 were designated as Series A Preferred Stock. A total of 1,302,082 shares of Series
A Preferred Stock were issued, which carried a 5% cumulative dividend and liquidation preference over common stock. Dividends were computed
at 5% of the principal annually and recorded monthly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>On
February 9, 2024, all outstanding Series A Preferred Stock was converted into common stock on a one-for-two basis pursuant to the filing
of the Company&#8217;s third amended and restated certificate of incorporation. As of that date, the Company had 5,000,000 shares of authorized
Preferred Stock, with none outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred Stock
dividend for the year ended December 31, 2025 was $0, and for the year ended December 31, 2024 was $31,250, resulting in a total accrued
dividend payable of $375,000 as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Preferred Stock has the
following rights and privileges:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Voting&#160;</i>&#8212;&#160;Votes
together with the common stock on all matters on an as-converted basis. Approval of a&#160;majority of the New Preferred Stock voting
as a separate class will be required to, among other things: (i)&#160;adversely change rights of the New Preferred Stock, (ii)&#160;change
the authorized number of shares of New Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Conversion&#160;</i>&#8212;&#160;Each
share of New Preferred Stock is convertible into one share of common stock (subject to proportional adjustments for stock splits, stock
dividends and the like) at any time at the option of the holder. Conversion ratio will be subject to adjustment on a broad-based, weighted
average basis in the event of subsequent issuances at a price less than the original issue price (as adjusted) subject to customary exceptions.
The conversion into common stock occurred on February 9, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Liquidation&#160;</i>&#8212;&#160;One
times the original issue price of the New Preferred Stock plus declared but unpaid dividends on each share of New Preferred Stock (or,
if greater, the amount that the New Preferred Stock would receive on an as-converted basis) will be paid first on each share of New Preferred
Stock, and the balance of proceeds to be paid to common stock. A merger, reorganization, or similar transaction (including a sale, exclusive
license or other disposition of all or substantially all of the assets of the Company or its subsidiaries) will be treated as a liquidation,
thereby triggering payment of the liquidation preference described above. For the avoidance of doubt, the liquidation preference is intended
to provide the Investor (and its permitted assigns) with an aggregate liquidation payment of $2,500,000.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the common stock options issued to employees and consultants for services during the year ended December 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Intrinsic Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,866,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.86</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right">4<span style="font-family: Times New Roman, Times, Serif">.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,904,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,771,250</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.83</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.43</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2,866,750</p></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.86</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.92</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the options
granted during the year ended December 31, 2025 was estimated at the date of grant using the Black-Scholes option-pricing model with the
following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Volatility (based on peer companies)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">112</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk Free Interest Rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.55</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividends</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-size: 10pt">None</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Estimated Life in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December 31, 2025 and 2024, the Company recognized
combined share-based compensation expense of $4,265,374 and $268,300, respectively, related to these common stock options. At the Company&#8217;s
annual meeting on October 21, 2025, stockholders approved an amendment to the Company&#8217;s 2023 Incentive Compensation Plan, increasing
the shares of common stock authorized for issuance thereunder from 4 million to 10 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">REDEEMABLE PREFERRED STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8&#160;&#8212;&#160;REDEEMABLE PREFERRED
STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Securities Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, the
Company entered into the Purchase Agreement with various institutional and accredited investors. The Company completed the initial closing
on December 31, 2024 and sold an aggregate of 1,512,500 immediately separable units (the &#8220;Units&#8221;), each Unit consisting of
(i) one share of the Company&#8217;s Series A Preferred Stock, and (ii) a Warrant to purchase one share of common stock, at a price per
Unit of $4.00. The Warrant has an exercise price of $4.40 per share, subject to adjustment therein, and a term of five years from the
date stockholder approval of the common stock issuances contemplated by the Purchase Agreement is obtained. The gross proceeds from the
initial closing to the Company, before deducting transaction fees and other estimated expenses, was $6,050,000. On January 14, 2025 the
Company sold and issued an additional 263,250 Units. The gross proceeds from the second closing to the Company, before deducting transaction
fees and other estimated expenses, was $1,053,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based
on the terms of the Series A Preferred Stock and the Company&#8217;s Certificate of Designation, and in accordance with ASC 480, the Series
A Preferred Stock is accounted for as mezzanine equity due to the redemption feature upon a deemed liquidation event: (i) a merger or
consolidation, or (ii) the sale, lease, transfer or other disposition of substantially all the assets of the Company. $1,971,975 of the
initial cash proceeds of $6,050,000 were allocated to the Warrants and $4,078,025 of the residual proceeds were allocated to the Series
A Preferred Stock. $330,781 of the additional cash proceeds of $1,053,000 were allocated to the Warrants and $722,219 of the residual
proceeds were allocated to the Series A Preferred Stock from the January 14, 2025 settlement, with all the same terms as the first settlement
above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">From
April 9, 2025 through December 31, 2025, Mezzanine Equity converted into 4,939,808 shares of common stock. Of the original 1,775,750 shares
of Series A Preferred Stock, 273,750 and 1,383,250 shares were converted during the three- and nine-month periods ended December 31, 2025,
respectively. As of December 31, 2025, 392,500 shares of Series A Preferred Stock remain outstanding, convertible into 1,401,786 shares
of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Based
on the terms of the Warrants and in accordance with ASC 815, the Warrants are accounted for as a liability due to the variable exercise
price subject to adjustment. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and
market reflective Level 1 and Level 2 inputs, the Company valued the Warrant liability using Level 3 inputs, which require significant
judgment and estimates on behalf of management in developing model assumptions. The Company determined the value of the Warrant liability
using a Binomial Simulation, which takes into consideration the fair market value of the Company&#8217;s stock, the variable nature of
the exercise price, the estimated exercise period, the volatility of its common stock, and the risk-free interest rate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The following assumptions
were made as of December 31, 2024 in the model: (1) a variable exercise price with a floor of $4.40 per share, (2) current common stock
price of $4.28 per share December 31, 2024, (3) discount rate of 4.38%, and (4) expected stock price volatility of 24.90%. As of December
31, 2024, the carrying value of the Warrant liability in aggregate was $1,971,975 on December 31, 2024. The following assumptions were
made as of January 14, 2025 in the model: (1) a variable exercise price with a floor of $4.40 per share, (2) current common stock price
of $4.16 per share on January 14, 2025, (3) discount rate of 4.59%, and (4) expected stock price volatility of 25.77%. As of January 14,
the carrying value of the 263,250 issued warrants was $330,781.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following assumptions
were made as of April 9, 2025 based on stockholder approval in the model for the aggregate warrants: (1) a fixed exercise price of $1.12
per share, which automatically reset and resulted in a reclassification of the warrant liability on April 9, 2025 to equity per ASC 815;
(2) then-current common stock price of $1.34 per share on April 9, 2025; (3) discount rate of 4.06%; and (4) expected stock price volatility
of 23.26%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, the
carrying value of the Warrant liability in aggregate was <span style="-sec-ix-hidden: hidden-fact-127">$0</span>. For the year ended December 31, 2025, the Company recorded a gain on the
change in fair value of the Warrant Liability in the amount of $1,424,603 and a $878,153 deduction due to reclassification to equity.
As of December 31, 2025 and December 31, 2024, the carrying value of the Warrant liability in aggregate was <span style="-sec-ix-hidden: hidden-fact-128">$0</span> and $1,971,975, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Preferred Stock
and Warrants were issued in a basket transaction. When two or more instruments are issued in a basket transaction and some instruments
will be remeasured at fair value, the proceeds are first allocated to the instruments recorded at their fair value. Next, the residual
method is used to allocate the proceeds to the instrument(s) that are not remeasured at fair value. In this case, the Warrant is subsequently
measured at fair value, and the Series A Preferred Stock instrument is measured at initial carrying value. The Company will first allocate
the proceeds to the Warrant liability, with the residual allocated to the Series A Preferred Stock liability. The following tables reflect
the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period
from December 31, 2024 to December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash proceeds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;7,103,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fair value of Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,302,756</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Residual value allocated to Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,800,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Unallocated cash proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the&#160;<br/> year ended<br/>
    December&#160;31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Warrant Liability as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,971,975</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Additional Warrant Liability on January 14, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on the change in fair value of Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;(1,122,561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,180,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on the change in fair value of Warrant Liability as of April 9, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(302,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stockholder approval on April 9, 2025 - warrants turn into Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(878,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrant Liability as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment and Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND GEOGRAPHIC INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 &#8212; SEGMENT AND GEOGRAPHIC INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates as&#160;one&#160;operating
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its <span style="-sec-ix-hidden: hidden-fact-133">Chief Executive Officer</span>, who reviews financial
information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance
and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the
rate at which the Company seeks to grow global operating margin and the allocation of budget between cost of revenues, sales and marketing,
technology and development, and general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
selected financial information with respect to the Company&#8217;s single operating segment for the years ended December&#160;31, 2025
and 2023:</p>

<p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,360,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,839,060</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General&#160;and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,344,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,974,786</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,705,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,813,846</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,051,839</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Non-operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,997</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,472,995</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,250</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,143</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,069,092</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,753,844</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,882,938</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 10&#160;&#8212;&#160;SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Third Warrant Exercise
Inducement and Exchange Offering&#160;</i>&#8212;&#160;On January 14, 2026, the Company closed on a third warrant exercise inducement
and exchange offer (the &#8220;Third Inducement Offering&#8221;). The Third Inducement Offering was made to less than 10 accredited investors
that held certain existing warrants to purchase up to an aggregate of 5,382,148 shares of the Company&#8217;s common stock having a then
current exercise price of $3.00 or $2.10 per share. Pursuant to certain inducement offer letter agreements, such holders exercised for
cash their warrants to purchase 2,499,558 shares of the Company&#8217;s common stock at a reduced exercise price of $1.40 per share and
in exchange the Company issued to such holders new warrants to purchase up to an aggregate of 2,499,558 shares of common stock at an exercise
price of $1.40 per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of five years from such date. The gross proceeds to the Company from the Third Inducement Offering, before
deducting transaction fees and other offering expenses, were approximately $3.5 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file
a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if not then eligible to register securities on
Form S-3) providing for the resale of the shares of common stock issued or issuable upon exercise of the new warrants issued within 30
calendar days of March 2, 2026, and to use commercially reasonable efforts to have such registration statement declared effective by the
SEC within 60 calendar days (or within 90 calendar days in case of &#8220;full review&#8221; by the SEC) following its initial filing
and to keep such registration statement effective at all times until the earlier of (i) the time no holder owns any new warrants or shares
of common stock issuable upon exercise thereof and (ii) the Delegend Date (as defined in the inducement offer letter agreements entered
into in connection with the Third Inducement Offering).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Privately Negotiated
Warrant Exercise Inducement and Exchange Agreements &#8211; </i>From January 10, 2026 through February 2026, the Company entered
into privately negotiated inducement offer letters, pursuant to which certain remaining holders of existing warrants exercised for
cash their warrants to purchase an aggregate of 74,108 shares of common stock at a reduced exercise price of $1.40 per share and in
exchange the Company issued new warrants to purchase up to an aggregate of 74,108 shares of common stock at an exercise price of
$1.40 per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of five years from such date. The Company received gross proceeds of approximately $103,750 from the
exercise of these warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file a registration statement on Form S-3
(or other appropriate form, including on Form S-1, if not then eligible to register securities on Form S-3) providing for the resale of
the shares of common stock issued or issuable upon exercise of these warrants on or before March 30, 2026, and to use commercially reasonable
efforts to have such registration statement declared effective by the SEC within 60 calendar days (or within 90 calendar days in case
of &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time no holder of these warrants owns any such warrants or shares of common stock issuable upon exercise thereof
and (ii) the Delegend Date (as defined in the privately negotiated inducement offer letters).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Bridge Financing &#8211;
</i>On March 4, 2026, pursuant to a securities purchase agreement (the &#8220;Bridge SPA&#8221;), the Company issued to certain accredited
investors in a private placement transaction (i) 10.0% original issue discount unsecured convertible promissory notes in an aggregate
principal amount of $2,200,000 (the &#8220;Bridge Notes&#8221;) and (ii) warrants to purchase up to an aggregate of 1,666,667 shares of
common stock (the &#8220;Bridge Warrants&#8221; and such private placement transaction, the &#8220;Bridge Financing&#8221;), for aggregate
gross proceeds of $2,000,000, before deducting placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March
4, 2027 and accrue interest at a rate of 4.0% per annum. The Bridge Warrants were immediately exercisable upon issuance, expire five years
from the date of issuance and have an exercise price of $1.40 per share, subject to adjustment as provided therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bridge Notes were sold
at a 10% original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $110,000. The Bridge Notes are convertible into shares of common stock under certain circumstances. If the Company completes
a &#8220;Qualified Offering,&#8221; defined as a registered public offering or registered direct offering resulting in at least $2.5 million
in gross proceeds from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically
convert into the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment
of the Bridge Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of common stock at a conversion price
equal to 90% of the average daily volume-weighted average price of the Company&#8217;s common stock during the 10 trading days immediately
preceding the holder&#8217;s conversion notice, subject to adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agreed to file
a registration statement on Form S-3 (or Form S-1 if not then eligible to register securities for Form S-3) by April 3, 2026 to register
for resale the shares of common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &#8220;full review&#8221; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulatory
Meetings &#8211; </i>During early 2026, the Company continued its regulatory engagement with the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
related to its Biologics License Application (&#8220;BLA&#8221;) for OST-HER2. As outlined in recent press releases, this included planned
interactions with the FDA, including a Type D meeting that was elevated to a Type B pre-BLA meeting. These activities are consistent
with the Company&#8217;s ongoing regulatory efforts. The Company does not believe these interactions currently have a measurable impact
on its consolidated financial statements; however, the outcome of these discussions may affect future development timelines and regulatory
strategy.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (28,753,844)<span></span>
</td>
<td class="num">$ (8,882,938)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cybersecurity Governance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the ultimate oversight responsibility for the risk management process and regularly reviews issues that present particular risk to us,
including those involving cybersecurity. Our board is responsible for ensuring that management has processes in place designed to identify
and assess cybersecurity risks to which we are exposed and implement processes and programs designed to manage cybersecurity risks and
mitigate and remediate cybersecurity threats and incidents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for identifying, considering and assessing material cybersecurity risks on an ongoing basis, establishing processes to ensure that such
potential cybersecurity risk exposures are monitored, putting in place appropriate mitigation measures and maintaining cybersecurity programs.
In managing cybersecurity risks, we adhere to a structured framework that outlines the roles and responsibilities of management positions
and committees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cybersecurity Risk Management and Strategy</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have implemented and maintain
various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical
computer networks, communications systems, hardware and software, and our critical data, including intellectual property, confidential
information that is proprietary, strategic or competitive in nature, and trade secrets, data we may collect about trial participants in
connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information (&#8220;Information
Systems and Data&#8221;). Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk
management processes. For example, the cybersecurity program works with management to prioritize our risk management processes and mitigate
cybersecurity threats that are more likely to lead to a material impact to our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cybersecurity program
within our company helps identify, assess and manage our cybersecurity threats and risks. Our cybersecurity program identifies and assesses
risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual
tools, internal or external audits, automated tools, subscribing to and analyzing reports and services that identify cybersecurity threats
and threat actors, conducting vulnerability assessments to identify vulnerabilities, conducting scans of the threat environment, and evaluating
threats reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures,
processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems
and Data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use third-party service
providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example
cybersecurity software providers, managed cybersecurity service providers, and penetration testing firms.<b>&#160;</b>We also use third-party
service providers to perform a variety of functions throughout our business, such as application providers and hosting companies. We manage
cybersecurity risks associated with our use of these providers by reviewing their security assessments and applicable reports.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any risks
from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations, or financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face risks from cybersecurity
threats that, if realized are reasonably likely to materially affect us, including our operations, business strategy, results of operations,
or financial condition. For a description of the risks from cybersecurity threats that may materially affect us and how we may do so,
see our risk factors under &#8220;Item 1A. Risk Factors.&#8221;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
the ultimate oversight responsibility for the risk management process and regularly reviews issues that present particular risk to us,
including those involving cybersecurity. Our board is responsible for ensuring that management has processes in place designed to identify
and assess cybersecurity risks to which we are exposed and implement processes and programs designed to manage cybersecurity risks and
mitigate and remediate cybersecurity threats and incidents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for identifying, considering and assessing material cybersecurity risks on an ongoing basis, establishing processes to ensure that such
potential cybersecurity risk exposures are monitored, putting in place appropriate mitigation measures and maintaining cybersecurity programs.
In managing cybersecurity risks, we adhere to a structured framework that outlines the roles and responsibilities of management positions
and committees.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity program identifies and assesses
risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual
tools, internal or external audits, automated tools, subscribing to and analyzing reports and services that identify cybersecurity threats
and threat actors, conducting vulnerability assessments to identify vulnerabilities, conducting scans of the threat environment, and evaluating
threats reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures,
processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems
and Data.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of any risks
from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations, or financial condition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements are presented in conformity with accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;)
and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accounting and reporting
policies of the Company conform to accounting principles generally accepted in the United&#160;States of America, and the Company&#8217;s
fiscal year end is December&#160;31.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries and majority-owned subsidiaries. The Company consolidates
all entities in which it has a controlling interest.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated
financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments,
which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable
under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may
differ from management&#8217;s estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash consists primarily of
deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both
interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation
(FDIC) for a combined total of $250,000. In the normal course of business, the Company may have deposits that exceed the FDIC insured
limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking
relationships. As of December 31, 2025 and December 31, 2024, JPMorgan Chase Bank checking account had $233,490 and $5,216,354, respectively,
and the JPM Chase savings account had $20,269 and $20,021, respectively. As of December 31, 2025 and December 31, 2024, Silicon Valley
Bank checking account had $6,071 and $287,173, respectively, and the SVB money market account had $10,000 and $10,000, respectively. The
JPM Chase and SVB checking accounts were in excess of the FDIC limits for the year ended December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock', window );">Redeemable Preferred Stock and Mezzanine Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redeemable Preferred Stock and Mezzanine
Equity</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s Series
A Senior Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series A Preferred Stock&#8221;), is classified as mezzanine
equity in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 480 (&#8220;ASC 480&#8221;) due to its redemption features upon the occurrence of a deemed liquidation event, including (i) a merger
or consolidation or (ii) the sale, lease, transfer, or other disposition of substantially all of the Company&#8217;s assets. Proceeds
from the issuance were allocated between the Series A Preferred Stock and the accompanying warrants to purchase shares of common stock
(the &#8220;Series A Warrants&#8221;) on a relative fair value basis. Of the initial $6,050,000 in proceeds, a portion was allocated to
the Series A Warrants, with the residual allocated to the Series A Preferred Stock. Similarly, of the subsequent $1,053,000 in proceeds,
a portion was allocated to the Series A Warrants, with the residual allocated to the Series A Preferred Stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FixedAssetPolicyPolicyTextBlock', window );">Fixed Asset Policy</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fixed Asset Policy</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A capital asset is defined
as a unit of property that has an economic useful life that extends beyond 12&#160;months. Any items costing below the threshold or not
fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at
historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over five years for financial
statement purposes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Amortization</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Amortization</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, in connection
with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below),
including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. These intangible assets
are amortized on a straight-line basis over their estimated useful lives, with amortization recorded quarterly. Amortization expense for
the years ended December 31, 2025 and 2024 was $360,305 and $0, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PatentLicenseAcquisitionPolicyTextBlock', window );">Patent &amp; License Acquisition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent and License Acquisition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#8220;HER2 Purchase Agreement&#8221;), between the Company
and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (&#8220;Ayala&#8221;), the Company completed the acquisition of the <i>Lm</i>-based
immune-oncology programs and related intellectual property assets (the &#8220;HER2 Assets&#8221;) from Ayala, including the assignment
by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The transaction was accounted for as an asset acquisition
in accordance with ASC 805.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the acquisition,
the Company assumed certain specified liabilities and paid an aggregate purchase price of $8,000,000, with a fair value of $6,864,438,
consisting of: (i) $400,000 to Ayala ($150,000 of which was transferred upon signing of the HER2 Purchase Agreement and the remainder
on the closing date); (ii) $100,000 to a third party on behalf of Ayala on the closing date; and (iii) $7,500,000 worth of shares of common
stock, or 4,774,637 shares based on the volume-weighted average price of the Company&#8217;s common stock over the 30 trading days immediately
preceding the closing date of $1.5708. The fair value of the common stock issued was determined using the closing price of $1.34 per share
on April 9, 2025, resulting in a total equity value of $6,398,014 and a corresponding reduction in total purchase consideration. The fair
value of the purchase consideration is summarized below:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Legal fees paid on behalf of Ayala</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Company common stock (4,774,637 shares at $1.34 per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,398,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,864,438</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The acquired intangible assets
consist primarily of a portfolio of patents and related licenses, including patents covering &#8220;Compositions and Methods for Evaluating
Potency of Listeria-Based Immunotherapeutics,&#8221; which underpin the Company&#8217;s lead programs. These patents have an effective
filing date of April 19, 2019 and an estimated remaining useful life of approximately 14 years. The assets are amortized on a straight-line
basis over their estimated useful lives. Amortization expense was $360,305 and $0 for the years ended December 31, 2025 and 2024, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, expected
future amortization expense is as follows:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">496,972</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2031 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,019,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,504,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reviews long-lived
assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability
is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising
from the assets or asset groups. <span style="-sec-ix-hidden: hidden-fact-95"><span style="-sec-ix-hidden: hidden-fact-96">No</span></span> impairment losses on long-lived assets have been recorded for&#160;the year ended December 31, 2025
or the year ended December&#160;31, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred offering costs consist
of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to
the Company&#8217;s initial public offering and that were charged to stockholders&#8217; equity upon the completion of such offering.
As of December 31, 2025 and 2024, the Company had <span style="-sec-ix-hidden: hidden-fact-97"><span style="-sec-ix-hidden: hidden-fact-98">no</span></span> capitalized deferred offering costs. Upon the completion of the Company&#8217;s initial
public offering on August 2, 2024, all deferred offering costs were charged to stockholders&#8217; deficit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, and supplies.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of incorporation,
the Company adopted ASU&#160;2014-09, <i>Revenue from Contracts with Customers</i>, and all subsequent amendments to the ASU (collectively,
&#8220;ASC&#160;606&#8221;), which (i)&#160;creates a single framework for recognizing revenue from contracts with customers that fall
within its scope and (ii)&#160;revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, in accordance
with ASC&#160;718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees
is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation
expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be
probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized
and any previously recognized compensation expense is reversed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Short-term Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Short-term Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For short-term leases with
a term of 12 months or less, the Company recognizes lease expense on a straight-line basis over the lease term. The Company&#8217;s current
lease arrangements qualify for this short-term lease exemption and are expensed as incurred. The Company did not renew its prior lease
due to landlord restrictions related to renovations of the premises and has temporarily relocated its primary office to 115 Pullman Crossing
Road, Suite #103, Grasonville, Maryland 21638. This space, which serves as the primary office of the Company&#8217;s Chief Financial Officer,
is being provided at no cost. In May 2024, the Company entered into a month-to-month lease agreement with JLabs for general office space
in New York City, primarily for meetings and use by staff when visiting. The monthly lease payment was $750 and increased to $787.50 effective
January 1, 2025.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Income taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company accounts for income
taxes using the asset-and-liability method in accordance with ASC&#160;740, <i>Income Taxes </i>(&#8220;ASC&#160;740&#8221;). Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &#8220;more likely than not&#8221;
that some portion or all of the deferred tax assets will not be realized in future periods.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company follows the guidance
in ASC Topic&#160;740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition
of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first
step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits.
The second step involves measurement of the amount to be recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax positions that meet the
more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated
financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,900,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,559,791</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">General business credit carryover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,045,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,672,876</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">R&amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,214,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,501,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,214,741</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,501,235</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basic and Diluted Loss per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company computes loss
per share in accordance with ASC&#160;260, <i>Earnings per Share </i>(&#8220;ASC&#160;260&#8221;). ASC&#160;260 requires presentation
of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statements of operations. Basic EPS is computed by
dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock
method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect
is antidilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a table listing all
preferred stock and common stock equivalents:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock Equivalents</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Series A Senior Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,401,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Underwriter/Placement Agent Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">319,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,448</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,154,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid Common Stock Not Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,441,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,512,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,317,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,792,948</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Series A Convertible Preferred
Stock issued on December 31, 2024, is not reflected in the table above as of December 31, 2024, because stockholder approval was required
for the issuance of common stock upon conversion. Stockholder approval was obtained on April 9, 2025, for the issuance of the shares of
common stock underlying the Series A Preferred Stock, which is classified as mezzanine equity, and for the Series A Warrants. Upon approval,
the conversion price of the Series A Preferred Stock and the exercise price of the Series A Warrants were automatically adjusted to $1.12
per share, based on the volume-weighted average price of the Company&#8217;s common stock for the 10 trading days immediately preceding
April 9, 2025. This adjustment established a conversion multiplier of 3.571429 common shares per preferred share. As of December 31, 2025,
392,500 non-converted shares of Series A Preferred Stock were outstanding, which, using the conversion multiplier, are exercisable into
1,401,786 shares of common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, a
total of 319,711 shares of common stock were underlying outstanding underwriter and placement agent warrants, consisting of 112,000 shares
issued in connection with the Company&#8217;s initial public offering and 207,711 shares issued to placement agents in connection with
the PIPE financing in December 2024 and January 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Company&#8217;s two warrant exercise and inducement offerings,
held June 23 to July 10, 2025, and August 29 to September 1, 2025, warrant holders who exercised their existing warrants received new
warrants with an exercise price of $3.00 per share. In total, warrants to purchase 7,154,338 shares of common stock were exercised in
exchange for new warrants to purchase an equal number of shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant holders who pre-funded
conversions during the August 29 to September 30, 2025 offering received an aggregate of 937,500 prepaid shares of common stock and additionally
funded 504,018 prepaid shares, resulting in a total of 1,441,518 prepaid warrants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company applies ASC&#160;820
<i>Fair Value Measurement </i>(&#8220;ASC&#160;820&#8221;), which establishes a framework for measuring fair value and clarifies the definition
of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an
asset or paid to transfer a liability in the Company&#8217;s principal or most advantageous market in an orderly transaction between market
participants on the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy established
in ASC&#160;820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and
are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#8217;s
own assumptions based on market data and the entity&#8217;s judgments about the assumptions that market participants would use in pricing
the asset or liability and are to be developed based on the best information available in the circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The carrying value of the
Company&#8217;s cash, accounts payable, and accrued expenses are approximate fair value because of the short-term maturity of these financial
instruments. The redemption feature of the debt instruments is recorded at fair value (See Note&#160;3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Warrant liability is recorded
at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective
Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates
on behalf of management in developing model assumptions. As of December 31, 2025 and December 31, 2024, the carrying value of the warrant
liability in the aggregate was $0 and $1,971,975, respectively (See Note 8).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The valuation hierarchy is
composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. The levels within the valuation hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 1&#160;&#8212;&#160;Assets and
liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs,
such as quoted prices in active markets for identical assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 2&#160;&#8212;&#160;Inputs to
the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well
as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Level 3&#160;&#8212;&#160;Inputs to
the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market
data exists for the assets or liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Warrant Liability</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Series A Warrants issued in connection with a Securities Purchase Agreement, dated as of December 24, 2024 (the &#8220;Purchase Agreement&#8221;),
are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at
fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance
sheet date until exercised or reclassified, and any change in fair value is recognized in the Company&#8217;s consolidated statements
of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation
model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available
and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has evaluated
all recently issued accounting pronouncements and plans to adopt ASU 2024-03, Disaggregated Income Statement Disclosure, in the notes
to its audited financial statements for the year ending December 31, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring
entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For the public business
entities, the guidance is effective for annual periods beginning after December 15, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No other recently issued accounting pronouncements are expected
to have a material impact on the Company&#8217;s financial statements at this time.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_FixedAssetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fixed asset policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_FixedAssetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PatentLicenseAcquisitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dizclosure of accounting policy for patent &amp; license acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PatentLicenseAcquisitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable preferred stock and mezzanine equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock', window );">Schedule of Fair Value of the Purchase Consideration</a></td>
<td class="text">The fair
value of the purchase consideration is summarized below:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Legal fees paid on behalf of Ayala</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,424</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Company common stock (4,774,637 shares at $1.34 per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,398,014</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,864,438</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, expected
future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">496,972</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">496,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2031 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,019,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,504,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTableTextBlock', window );">Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,900,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,559,791</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">General business credit carryover</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,045,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,672,876</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">R&amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,568</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,214,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,501,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,214,741</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,501,235</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock', window );">Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a table listing all
preferred stock and common stock equivalents:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Common Stock Equivalents</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Series A Senior Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,401,786</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Underwriter/Placement Agent Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">319,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,448</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,154,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid Common Stock Not Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,441,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,512,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,317,353</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,792,948</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preferred stock and common stock equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Payroll Advances to the CEO</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes activity
in respect to payroll advances to the CEO:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2023</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">191,198</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,875</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(414,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Advances during 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Repayments 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(134,184</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s convertible
notes are separated into seven groups&#160;&#8212;&#160;A, B, C, D, E, F and BlinkBio&#160;&#8212;&#160;per the table below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,<br/> 2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31, <br/> 2024</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Conversion</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maturity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Collateral</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">A</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">10/31/2024</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">None</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">80% - 87.5</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>B</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>C</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>D</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>E</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>F</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">10/31/2024</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">BlinkBio</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: center">3/15/2022</td><td>&#160;</td> <td style="text-align: center">None</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock', window );">Schedule of Company&#8217;s Make-Whole Share Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s make-whole
share liability as of September 30, 2024 is summarized in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"># Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date&#160;Earned</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Alan Musso</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">Former CFO</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 11%; text-align: center">March&#160;1,&#160;2023</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Christopher Acevedo</td><td>&#160;</td> <td style="text-align: center">Current CFO</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,375</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">Upon IPO</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Joacim Borg</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">Former&#160;Director</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">80,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">July&#160;1,&#160;2022</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">130,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of whole share liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock', window );">Schedule of Future Milestones</a></td>
<td class="text">A payment schedule for future milestones is summarized below.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid">Milestone Bearing Event</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Milestone<br/> Payment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">1.</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">License Fee to utilize proprietary technology (paid)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">$300,000 + $2.4 million Convertible Note</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; width: 3%; vertical-align: top">2.</td><td style="width: 1%">&#160;</td> <td style="width: 82%; text-align: left">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#8220;GLP-Tox&#8221;)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">375,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">3.</td><td>&#160;</td> <td style="text-align: left">Completion of a Phase I Clinical Trial</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">4.</td><td>&#160;</td> <td style="text-align: left">Completion of a Phase II Clinical Trial</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,500,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">5.</td><td>&#160;</td> <td style="text-align: left">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">6,000,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">6.</td><td>&#160;</td> <td style="text-align: left">Regulatory Approval in the first of the United States, within the EU or within the UK</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">12,000,000</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock', window );">Schedule of Certain Fees and Corresponding Payment Amounts</a></td>
<td class="text">The fee schedule for certain fees
and corresponding payment amounts is set forth below.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="3" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>George Clinical Payment Schedule</b></span></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Payment <br/>
Amount</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 3%; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">1.</span></td> <td style="width: 1%">&#160;</td> <td style="width: 82%"><span style="font-size: 10pt">Service Fee Advance (paid)</span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td style="width: 11%; text-align: right"><span style="font-size: 10pt">49,989</span></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">2.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">193,671</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">3.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Electronic Data Capture (EDC) Go Live Date</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">47,740</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">4.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;35% on Development of SAP tables</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">47,740</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">5.</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">Statistics Fees&#160;&#8211;&#160;30% on Final Analysis</span></td> <td>&#160;</td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt">40,920</span></td> <td>&#160;</td></tr> <tr> <td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt">6.</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top"><span style="font-size: 10pt">Service Fees&#160;&#8211;&#160;Remainder Due</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Split monthly <br/>
over course <br/>
of study</span></td> <td style="vertical-align: bottom">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of certain fees and corresponding payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of payment for future milestone events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Common Stock Options Issued</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the common stock options issued to employees and consultants for services during the year ended December 31, 2025:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Common Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Years</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Intrinsic Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at January 1, 2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,866,750</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.86</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right">4<span style="font-family: Times New Roman, Times, Serif">.92</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,904,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.00</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,771,250</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.83</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.43</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable at December 31, 2025</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2,866,750</p></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.86</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.92</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the options
granted during the year ended December 31, 2025 was estimated at the date of grant using the Black-Scholes option-pricing model with the
following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Volatility (based on peer companies)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">112</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk Free Interest Rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.55</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividends</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-size: 10pt">None</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Estimated Life in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.88</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations</a></td>
<td class="text">The following tables reflect
the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period
from December 31, 2024 to December 31, 2025.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash proceeds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;7,103,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Fair value of Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,302,756</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Residual value allocated to Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,800,244</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Unallocated cash proceeds</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Warrants Liability</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the&#160;<br/> year ended<br/>
    December&#160;31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Warrant Liability as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,971,975</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Additional Warrant Liability on January 14, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330,781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on the change in fair value of Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;(1,122,561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Warrant Liability as of March 31, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,180,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on the change in fair value of Warrant Liability as of April 9, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(302,042</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stockholder approval on April 9, 2025 - warrants turn into Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(878,153</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Warrant Liability as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment and Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of Financial Information of Operating Segment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
selected financial information with respect to the Company&#8217;s single operating segment for the years ended December&#160;31, 2025
and 2023:</p>

<p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">OPERATING EXPENSES</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Research&#160;and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,360,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,839,060</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General&#160;and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,344,976</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,974,786</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,705,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,813,846</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,051,839</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Non-operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,997</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Non-operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,472,995</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(51,250</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,603</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL OTHER INCOME (EXPENSE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,143</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,069,092</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,753,844</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,882,938</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business, Liquidity, and Risk Factors (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of Business, Liquidity, and Risk Factors [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporated date</a></td>
<td class="text">Jun. 24,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,753,844)<span></span>
</td>
<td class="num">$ (8,882,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Operating activities</a></td>
<td class="num">(14,238,576)<span></span>
</td>
<td class="num">(7,282,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 269,830<span></span>
</td>
<td class="nump">$ 5,533,527<span></span>
</td>
<td class="nump">$ 38,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GoingConcernTerm', window );">Going concern term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Total approximately amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_GoingConcernTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_GoingConcernTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2025</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 14, 2025</div></th>
<th class="th"><div>Apr. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash checking account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,830<span></span>
</td>
<td class="nump">$ 5,533,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestBearingDomesticDepositMoneyMarket', window );">Money market account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,858,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StraightLineDepreciatedOverPeriod', window );">Straight line depreciated over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,305<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Volume-weighted average price (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,774,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_NumberOfTradingDays', window );">Number of trading days</a></td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TotalEquityValue', window );">Equity value</a></td>
<td class="nump">$ 6,398,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred Costs, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 787.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Tax benefit percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,225,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PrepaidShares', window );">Prepaid warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,441,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=osti_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,154,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PrepaidShare', window );">Prepaid shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=osti_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PrepaidShare', window );">Prepaid shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=osti_SeriesASeniorConvertiblePreferredStockMember', window );">Series A Senior Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankCheckingAccountMember', window );">Chase Bank Checking Account [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash checking account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,490<span></span>
</td>
<td class="nump">5,216,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankSavingsAccountMember', window );">Chase Bank Savings Account [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash checking account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
<td class="nump">20,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_SVBBankMember', window );">SVB Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash checking account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">$ 287,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ThirdPartyMember', window );">Third Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.571429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=osti_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_HER2AssetsMember', window );">HER2 Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ClosingPricePerShare', window );">Closing price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_HER2AssetsMember', window );">HER2 Assets [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_HER2AssetAmortizationMember', window );">HER2 Asset Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair value of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,864,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_AyalaMember', window );">Ayala [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_NumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_NumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PrepaidShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of prepaid shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PrepaidShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PrepaidShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares prepaid shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PrepaidShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StraightLineDepreciatedOverPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Straight line depreciated over period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StraightLineDepreciatedOverPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_TotalEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of total equity value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_TotalEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestBearingDomesticDepositMoneyMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest-bearing domestic money market demand account deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestBearingDomesticDepositMoneyMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 101: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 102: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 103: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 104: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 105: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 106: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=osti_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=osti_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=osti_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=osti_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=osti_SeriesASeniorConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=osti_SeriesASeniorConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankCheckingAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankCheckingAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankSavingsAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ChaseBankSavingsAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_SVBBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_SVBBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=osti_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=osti_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_HER2AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_HER2AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_HER2AssetAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_HER2AssetAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_AyalaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_AyalaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details) - Patent &amp; License Acquisition [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLineItems', window );"><strong>Schedule of Fair Value of the Purchase Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees paid on behalf of Ayala</a></td>
<td class="nump">66,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Company common stock</a></td>
<td class="nump">6,398,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Total fair value of consideration transferred</a></td>
<td class="nump">$ 6,864,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_PatentLicenseAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_PatentLicenseAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details) - Patent &amp; License Acquisition [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLineItems', window );"><strong>Schedule of Fair Value of the Purchase Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock (in Shares) | shares</a></td>
<td class="nump">4,774,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_PatentLicenseAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_PatentLicenseAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Estimated Amortization Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 496,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">496,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">496,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">496,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">496,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2031 and thereafter</a></td>
<td class="nump">4,019,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 6,504,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 9,900,522<span></span>
</td>
<td class="nump">$ 6,559,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credit carryover</a></td>
<td class="nump">3,045,651<span></span>
</td>
<td class="nump">1,672,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit (available for payroll tax offset)</a></td>
<td class="nump">268,568<span></span>
</td>
<td class="nump">268,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">13,214,741<span></span>
</td>
<td class="nump">8,501,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(13,214,741)<span></span>
</td>
<td class="num">(8,501,235)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="nump">10,317,353<span></span>
</td>
<td class="nump">1,792,948<span></span>
</td>
<td class="nump">70,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAConvertiblePreferredStockMember', window );">Series A Senior Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="nump">1,401,786<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_UnderwriterPlacementAgentWarrantsMember', window );">Underwriter/Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="nump">319,711<span></span>
</td>
<td class="nump">280,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_InducementWarrantsMember', window );">Inducement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="nump">7,154,338<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_PrepaidCommonStockNotIssuedMember', window );">Prepaid Common Stock Not Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="nump">1,441,518<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Preferred Stock and Common Stock Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred stock and common stock equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_UnderwriterPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_UnderwriterPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_InducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_InducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_PrepaidCommonStockNotIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_PrepaidCommonStockNotIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll payable</a></td>
<td class="nump">$ 1,279<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Related payroll taxes payable</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">88,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 191,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=osti_MrRomnessMember', window );">Mr. Romness [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=osti_MillRiverPartnersLLCMember', window );">Mill River Partners LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll payable</a></td>
<td class="nump">$ 36,792<span></span>
</td>
<td class="nump">$ 8,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=osti_MrRomnessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=osti_MrRomnessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=osti_MillRiverPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=osti_MillRiverPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Payroll Advances to the CEO (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Schedule of Payroll Advances [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Balance beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 191,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Advances</a></td>
<td class="nump">134,184<span></span>
</td>
<td class="nump">222,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Repayment</a></td>
<td class="num">(134,184)<span></span>
</td>
<td class="num">(414,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent', window );">Balance ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 24, 2024</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 09, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,757,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AgreedToIssuedCashRemunerationPercentage', window );">Cash remuneration agreed to issue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Share value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 408,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees', window );">Expense to advisory fees amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,496<span></span>
</td>
<td class="nump">$ 152,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilution shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,317,353<span></span>
</td>
<td class="nump">1,792,948<span></span>
</td>
<td class="nump">70,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommonStockSharesAwarded', window );">Common stock shares awarded (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommonStockSharesAwardedInCash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Awarded shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharesAwardedParValue', window );">Awarded shares value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Compensation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CashRemunerationofWarrantFeePercentage', window );">Warrant fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_DebtDiscountAccretionExpenseInWarrants', window );">Debt discount accretion expense in warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 49,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Total unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">20,869,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Investor amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Interest rate of working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=osti_WarrantsForPlacementAgentNobleCapitalMember', window );">Warrants for Placement Agent &#8212; Noble Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Aggregate warrants to purchase shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,644<span></span>
</td>
<td class="nump">213,782<span></span>
</td>
<td class="nump">248,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,288<span></span>
</td>
<td class="nump">$ 427,564<span></span>
</td>
<td class="nump">$ 248,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants adjusted in to shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,154,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupAMember', window );">Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupBMember', window );">Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupCMember', window );">Group C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupFMember', window );">Group F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupDMember', window );">Group D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupEMember', window );">Group E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Principal balance accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Equity stock conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value [Member] | Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value [Member] | Group D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=osti_JoacimBorgMember', window );">Joacim Borg [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=osti_ShortTermLoanMember', window );">Short-Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Investor amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Interest rate of working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BrooklineCapitalMarketsMember', window );">Brookline Capital Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares (in Shares)</a></td>
<td class="nump">39,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Aggregate warrants to purchase shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants adjusted in to shares (in Shares)</a></td>
<td class="nump">156,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Share exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_CerosFinancialServicesIncMember', window );">Ceros Financial Services, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Aggregate warrants to purchase shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants adjusted in to shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateWarrantsExercisable', window );">Aggregate warrants exercisable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.571429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Fees amortized interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_AggregateAdditionalCashProceeds', window );">Aggregate additional cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,499<span></span>
</td>
<td class="nump">263,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,500<span></span>
</td>
<td class="nump">1,288,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,250<span></span>
</td>
<td class="nump">986,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,805<span></span>
</td>
<td class="nump">773,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Group E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_AggregateAdditionalCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of aggregate additional cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_AggregateAdditionalCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_AggregateWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants are exercisable under purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_AggregateWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_AgreedToIssuedCashRemunerationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed to issued cash remuneration percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_AgreedToIssuedCashRemunerationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CashRemunerationofWarrantFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of cash remuneration of warrant fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CashRemunerationofWarrantFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CommonStockSharesAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares awarded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CommonStockSharesAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CommonStockSharesAwardedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of common stock awarded in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CommonStockSharesAwardedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_DebtDiscountAccretionExpenseInWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount Accretion Expense in Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_DebtDiscountAccretionExpenseInWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds refers to the total amount of money received from selling a product or service. It's the total amount of money received before any deductions are made. In other words, gross proceeds are the total income from a sale before taxes, shipping, and any other discounts are considered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharesAwardedParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the per share value of awarded shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharesAwardedParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment advisory service, including, but not limited to, managing money in fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseInvestmentAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=osti_WarrantsForPlacementAgentNobleCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=osti_WarrantsForPlacementAgentNobleCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=osti_JoacimBorgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=osti_JoacimBorgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=osti_ShortTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=osti_ShortTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BrooklineCapitalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BrooklineCapitalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_CerosFinancialServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_CerosFinancialServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupAMember', window );">Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupBMember', window );">Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupCMember', window );">Group C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupDMember', window );">Group D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupEMember', window );">Group E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_GroupFMember', window );">Group F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=osti_BlinkBioMember', window );">Blink Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity</a></td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateral', window );">Collateral</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying Amount (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Schedule of Convertible Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion Rate</a></td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_GroupFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_GroupFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=osti_BlinkBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=osti_BlinkBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Company&#8217;s Make-Whole Share Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Schedule of Company&#8217;s Make-Whole Share Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_BusinessAcquisitionNumberofShares', window );">Shares | shares</a></td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Value | $</a></td>
<td class="nump">$ 130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=osti_AlanMussoMember', window );">Alan Musso [Member] | Shares Officers &amp; Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Schedule of Company&#8217;s Make-Whole Share Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Position</a></td>
<td class="text">Former CFO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_BusinessAcquisitionNumberofShares', window );">Shares | shares</a></td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Value | $</a></td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Date Earned</a></td>
<td class="text">Mar.  01,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=osti_ChristopherAcevedoMember', window );">Christopher Acevedo [Member] | Shares Officers &amp; Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Schedule of Company&#8217;s Make-Whole Share Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Position</a></td>
<td class="text">Current CFO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_BusinessAcquisitionNumberofShares', window );">Shares | shares</a></td>
<td class="nump">9,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Value | $</a></td>
<td class="nump">$ 37,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=osti_JoacimBorgMember', window );">Joacim Borg [Member] | Shares Officers &amp; Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramLineItems', window );"><strong>Schedule of Company&#8217;s Make-Whole Share Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Position</a></td>
<td class="text">Former&#160;Director<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_BusinessAcquisitionNumberofShares', window );">Shares | shares</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Value | $</a></td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Date Earned</a></td>
<td class="text">Jul.  01,  2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_BusinessAcquisitionNumberofShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares in business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_BusinessAcquisitionNumberofShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred to effect business combination. Excludes separately recognized transaction and indirect cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when acquisition agreement is executed in business combination, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of acquiree in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=osti_AlanMussoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=osti_AlanMussoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=osti_ChristopherAcevedoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=osti_ChristopherAcevedoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=osti_JoacimBorgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=osti_JoacimBorgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tedco Grant (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TedcoGrantLineItems', window );"><strong>Tedco Grant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_NumberOfTranches', window );">Number of tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ReimbursableGrantAmount', window );">Reimbursable grant amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PercentageOfRoyalties', window );">Royalties percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_RoyaltyReductionPercentage', window );">Royalty reduction percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ReimbursementExpirationPeriod', window );">Reimbursement expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_TedcoGrantLineItems', window );"><strong>Tedco Grant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of tranches.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PercentageOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties capped.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PercentageOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ReimbursableGrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total reimbursable grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ReimbursableGrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ReimbursementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Expiration Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ReimbursementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_RoyaltyReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_RoyaltyReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_TedcoGrantLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_TedcoGrantLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2026</div></th>
<th class="th"><div>Apr. 09, 2025</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_RentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,390<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,375,000)<span></span>
</td>
<td class="num">$ (1,550,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_RoyaltyNetSalesPecentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_RoyaltyReductionPercentage', window );">Royalties reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_BundgerUnderAgreement', window );">Total budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,436,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 86,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_OutstandingBalanceFees', window );">Balance due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">VAT total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,323,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PercentageOfRoyaltyPayments', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestment', window );">Investment amount</a></td>
<td class="nump">$ 1,055,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Attorneys fees</a></td>
<td class="nump">$ 308,804.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Arbitration-related fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,128.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,379,361.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_JohnsonMember', window );">Johnson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BlinkBioMember', window );">Blink Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_ConsultingFeeMember', window );">Consulting Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,629,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_BundgerUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of budget under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_BundgerUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_OutstandingBalanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of outstanding balance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_OutstandingBalanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PercentageOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PercentageOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_RentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_RentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_RoyaltyNetSalesPecentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty net sales percentage of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_RoyaltyNetSalesPecentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_RoyaltyReductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_RoyaltyReductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 54B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482134/820-10-35-54B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_JohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_JohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BlinkBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_BlinkBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_ConsultingFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_ConsultingFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Milestones (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember', window );">License Fee to utilize proprietary technology (paid) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">License Fee to utilize proprietary technology (paid)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember', window );">License Fee to utilize proprietary technology (paid) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember', window );">License Fee to utilize proprietary technology (paid) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_GLPToxMember', window );">Good Laboratory Practices [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#8220;GLP-Tox&#8221;)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IClinicalTrialMember', window );">Completion of a Phase I Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">Completion of a Phase I Clinical Trial<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IIClinicalTrialMember', window );">Completion of a Phase II Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">Completion of a Phase II Clinical Trial<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember', window );">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember', window );">Regulatory Approval in the first of the United States, within the EU or within the UK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems', window );"><strong>Schedule of Future Milestones [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_MilestoneBearingEventDescription', window );">Milestone Bearing Event</a></td>
<td class="text">Regulatory Approval in the first of the United States, within the EU or within the UK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_FutureMilestones', window );">Milestone Payment</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_FutureMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of future milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_FutureMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_MilestoneBearingEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of milestone bearing events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_MilestoneBearingEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PresentValueOfFutureInsuranceProfitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PresentValueOfFutureInsuranceProfitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_GLPToxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_GLPToxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IIClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_IIClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_ServiceFeeAdvancepaidMember', window );">Service Fee Advance (paid) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleofServiceFees', window );">George Clinical Payment Schedule</a></td>
<td class="text">Service Fee Advance (paid)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment Amount</a></td>
<td class="nump">$ 49,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember', window );">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleofServiceFees', window );">George Clinical Payment Schedule</a></td>
<td class="text">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment Amount</a></td>
<td class="nump">$ 193,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember', window );">Statistics Fees &#8211; 35% on Electronic Data Capture (EDC) Go Live Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleofServiceFees', window );">George Clinical Payment Schedule</a></td>
<td class="text">Statistics Fees&#160;&#8211;&#160;35% on Electronic Data Capture (EDC) Go Live Date<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment Amount</a></td>
<td class="nump">$ 47,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_StatisticsFees35OnDevelopmentOfSAPTablesMember', window );">Statistics Fees &#8211; 35% on Development of SAP tables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleofServiceFees', window );">George Clinical Payment Schedule</a></td>
<td class="text">Statistics Fees&#160;&#8211;&#160;35% on Development of SAP tables<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment Amount</a></td>
<td class="nump">$ 47,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_StatisticsFees30OnFinalAnalysisMember', window );">Statistics Fees &#8211; 30% on Final Analysis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleofServiceFees', window );">George Clinical Payment Schedule</a></td>
<td class="text">Statistics Fees&#160;&#8211;&#160;30% on Final Analysis<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment Amount</a></td>
<td class="nump">$ 40,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=osti_ServiceFeesRemainderDueMember', window );">Service Fees &#8211; Remainder Due [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PaymentScheduleServiceFeesRemainderDue', window );">George Clinical Payment Schedule, Remainder Due</a></td>
<td class="text">Service Fees&#160;&#8211;&#160;Remainder Due<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ServiceFeesRemainderDue', window );">Service Fees &#8211; Remainder Due</a></td>
<td class="text">Split monthly
over course
of study<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PaymentScheduleServiceFeesRemainderDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment schedule service fees remainder due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PaymentScheduleServiceFeesRemainderDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PaymentScheduleofServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of george clinical payment schedule service fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PaymentScheduleofServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ServiceFeesRemainderDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the service fees &#8211; remainder due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ServiceFeesRemainderDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_ServiceFeeAdvancepaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_ServiceFeeAdvancepaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_StatisticsFees35OnDevelopmentOfSAPTablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_StatisticsFees35OnDevelopmentOfSAPTablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_StatisticsFees30OnFinalAnalysisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_StatisticsFees30OnFinalAnalysisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=osti_ServiceFeesRemainderDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=osti_ServiceFeesRemainderDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 21, 2025</div></th>
<th class="th"><div>Apr. 09, 2025</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">20,869,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common stock has voting rights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock, conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Common stock, conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversions of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividends percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate liquidation payment (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,265,374<span></span>
</td>
<td class="nump">$ 268,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=osti_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,610,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,939,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommonStockConversionAfterShareDiscountsPercentage', window );">After share discounts percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ValuationCeilingsAmount', window );">Valuation ceilings (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_CommonStockConversionAfterShareDiscountsPercentage', window );">After share discounts percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ValuationCeilingsAmount', window );">Valuation ceilings (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares of common stock authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MedianMember', window );">Median [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Shares of common stock authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Common stock, split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Common stock, split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">37,113,082<span></span>
</td>
<td class="nump">20,869,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.571429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,507,386<span></span>
</td>
<td class="nump">2,164,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversions of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividend due (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_FairValueOfHER2AssetsMember', window );">Fair Value of HER2 Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_FairValueOfHER2AssetsMember', window );">Fair Value of HER2 Assets [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,166,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=osti_FairValueOfHER2AssetsMember', window );">Fair Value of HER2 Assets [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937,500<span></span>
</td>
<td class="nump">2,181,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_EquityLineOfCreditMember', window );">Equity Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares', window );">Exercise purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,441,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversions of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_CommonStockConversionAfterShareDiscountsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock conversion after share discounts percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_CommonStockConversionAfterShareDiscountsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds refers to the total amount of money received from selling a product or service. It's the total amount of money received before any deductions are made. In other words, gross proceeds are the total income from a sale before taxes, shipping, and any other discounts are considered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ValuationCeilingsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of valuation ceilings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ValuationCeilingsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=osti_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=osti_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MedianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MedianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=osti_FairValueOfHER2AssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=osti_FairValueOfHER2AssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_EquityLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_EquityLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=osti_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Common Stock Options Issued (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Schedule Of Common Stock Options Issued [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding Balance | shares</a></td>
<td class="nump">2,866,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance | $ / shares</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Years, Outstanding Balance</a></td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding Balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted | shares</a></td>
<td class="nump">3,904,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Years, Granted</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Years, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Years, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding Balance | shares</a></td>
<td class="nump">6,771,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Balance | $ / shares</a></td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Years, Outstanding Balance</a></td>
<td class="text">4 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable | shares</a></td>
<td class="nump">2,866,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Years, Exercisable</a></td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life (years), exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Years, Forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Years, Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Closing Stock Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (based on peer companies)</a></td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">3.55%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Dividends (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Estimated Life in years</a></td>
<td class="text">2 years 10 months 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 14, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 09, 2025 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits', window );">Sold aggregate of separable units (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per unit (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of gross proceeds (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_StockIssuedDuringPeriodSharesAdditionalUnits', window );">Stock issued during period shares additional units (in Shares) | shares</a></td>
<td class="nump">263,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Gross proceeds form before deducting transaction fees and other estimated expenses</a></td>
<td class="nump">$ 1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,858,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants proceeds</a></td>
<td class="nump">$ 722,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_OriginalShares', window );">Original shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount rate</a></td>
<td class="nump">4.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issued warrants</a></td>
<td class="nump">$ 263,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,424,603)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrants proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,078,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional warrant liability</a></td>
<td class="nump">$ 330,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,302,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted to shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,939,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Remain outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,638,643<span></span>
</td>
<td class="nump">411,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Stock price volatility</a></td>
<td class="nump">25.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=osti_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted to shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,750<span></span>
</td>
<td class="nump">1,383,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=osti_SecurityPurchaseAgreementMember', window );">Security Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,424,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=osti_SeriesASeniorConvertiblePreferredStockMember', window );">Series A Senior Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_PurchaseOfCommonStock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per unit (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional warrant liability</a></td>
<td class="nump">$ 330,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted to shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.571429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Remain outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5708<span></span>
</td>
<td class="nump">$ 1.5708<span></span>
</td>
<td class="nump">$ 1.5708<span></span>
</td>
<td class="nump">$ 1.5708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Remain outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_OriginalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of original shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_OriginalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_PurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_PurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesAdditionalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period additional units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesAdditionalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period, shares of preferred stock, separable units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=osti_SecurityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=osti_SecurityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=osti_SeriesASeniorConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=osti_SeriesASeniorConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details) - Warrant Liability [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Schedule of Cash Proceeds [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Cash proceeds</a></td>
<td class="nump">$ 7,103,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of Warrant liability</a></td>
<td class="num">(2,302,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ResidualValueAllocatedToSeriesAPreferredStock', window );">Residual value allocated to Series A Preferred Stock</a></td>
<td class="num">(4,800,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_UnallocatedCashProceeds', window );">Unallocated cash proceeds</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ResidualValueAllocatedToSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of residual value allocated to Series A Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ResidualValueAllocatedToSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_UnallocatedCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of unallocated cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_UnallocatedCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details) - Warrant Liability [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant Liability as of December 31, 2024</a></td>
<td class="nump">$ 1,971,975<span></span>
</td>
<td class="nump">$ 1,180,195<span></span>
</td>
<td class="nump">$ 1,971,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional Warrant Liability on January 14, 2025</a></td>
<td class="nump">330,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain on the change in fair value of Warrant Liability</a></td>
<td class="num">(1,122,561)<span></span>
</td>
<td class="num">(302,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Stockholder approval on April 9, 2025 - warrants turn into Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(878,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant Liability as of December 31, 2025</a></td>
<td class="nump">$ 1,180,195<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=osti_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=osti_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment and Geographic Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Operating reportable</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Description of segment</a></td>
<td class="text">The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer, who reviews financial
information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance
and allocate resources.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Chief executive officer</a></td>
<td class="text">CEO [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details) - CODM [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,360,725<span></span>
</td>
<td class="nump">$ 2,839,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,344,976<span></span>
</td>
<td class="nump">3,974,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,705,701)<span></span>
</td>
<td class="num">(6,813,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">249<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,051,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Non-operating income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Non-operating expenses</a></td>
<td class="num">(1,472,995)<span></span>
</td>
<td class="num">(51,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,424,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
<td class="num">(48,143)<span></span>
</td>
<td class="num">(2,069,092)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (28,753,844)<span></span>
</td>
<td class="num">$ (8,882,938)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=osti_ChiefOperatingDecisionMakerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=osti_ChiefOperatingDecisionMakerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2026</div></th>
<th class="th"><div>Jan. 14, 2026</div></th>
<th class="th"><div>Apr. 09, 2025</div></th>
<th class="th"><div>Feb. 28, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Current exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_OriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_InvestedPurchaser', window );">Invested purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_ConversionPricePercentage', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_osti_OriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase of shares</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Accrue interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Third Warrant Exercise Inducement and Exchange Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,382,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Privately Negotiated Warrant Exercise Inducement and Exchange Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Aggregate warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Third Warrant Exercise Inducement and Exchange Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Accrue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Third Warrant Exercise Inducement and Exchange Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Current exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Accrue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Third Warrant Exercise Inducement and Exchange Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Current exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds refers to the total amount of money received from selling a product or service. It's the total amount of money received before any deductions are made. In other words, gross proceeds are the total income from a sale before taxes, shipping, and any other discounts are considered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_InvestedPurchaser">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of invested purchaser.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_InvestedPurchaser</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_osti_OriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original issue discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">osti_OriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>osti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>250</ContextCount>
  <ElementCount>401</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors</Role>
      <ShortName>Organization and Description of Business, Liquidity, and Risk Factors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Tedco Grant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/TedcoGrant</Role>
      <ShortName>Tedco Grant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability</Role>
      <ShortName>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/RelatedPartyTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/ConvertibleDebt</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/Equity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables</Role>
      <ShortName>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails</Role>
      <ShortName>Organization and Description of Business, Liquidity, and Risk Factors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals</Role>
      <ShortName>Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Related Party Transactions - Schedule of Payroll Advances to the CEO (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable</Role>
      <ShortName>Related Party Transactions - Schedule of Payroll Advances to the CEO (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/ConvertibleDebtTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable</Role>
      <ShortName>Convertible Debt - Schedule of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Convertible Debt - Schedule of Company???s Make-Whole Share Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable</Role>
      <ShortName>Convertible Debt - Schedule of Company???s Make-Whole Share Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Tedco Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/TedcoGrantDetails</Role>
      <ShortName>Tedco Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/TedcoGrant</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Commitments and Contingencies - Schedule of Future Milestones (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Milestones (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/EquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Equity - Schedule of Common Stock Options Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable</Role>
      <ShortName>Equity - Schedule of Common Stock Options Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Equity - Schedule of Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable</Role>
      <ShortName>Equity - Schedule of Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails</Role>
      <ShortName>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable</Role>
      <ShortName>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable</Role>
      <ShortName>Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Segment and Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SegmentandGeographicInformationDetails</Role>
      <ShortName>Segment and Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SegmentandGeographicInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable</Role>
      <ShortName>Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0283146-10k_ostherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ostherapies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ostherapies.com/role/SubsequentEvents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0283146-10k_ostherap.htm">ea0283146-10k_ostherap.htm</File>
    <File>osti-20251231.xsd</File>
    <File>osti-20251231_cal.xml</File>
    <File>osti-20251231_def.xml</File>
    <File>osti-20251231_lab.xml</File>
    <File>osti-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ea028314601_img1.jpg</File>
    <File>ea028314601_img2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="695">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0283146-10k_ostherap.htm": {
   "nsprefix": "osti",
   "nsuri": "http://www.ostherapies.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "ea0283146-10k_ostherap.htm"
     ]
    },
    "schema": {
     "local": [
      "osti-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "osti-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "osti-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "osti-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "osti-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 308,
   "keyCustom": 93,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 53,
   "hidden": {
    "total": 137,
    "http://fasb.org/us-gaap/2025": 97,
    "http://www.ostherapies.com/20251231": 37,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 250,
   "entityCount": 1,
   "segmentCount": 85,
   "elementCount": 815,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 695,
    "http://xbrl.sec.gov/dei/2025": 42,
    "http://xbrl.sec.gov/cyd/2025": 9,
    "http://xbrl.sec.gov/ecd/2025": 5,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "i",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "i",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Stockholders\u2019 Deficit",
     "shortName": "Consolidated Statements of Stockholders\u2019 Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c8",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ostherapies.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors",
     "longName": "995306 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors",
     "shortName": "Organization and Description of Business, Liquidity, and Risk Factors",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ostherapies.com/role/SignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ostherapies.com/role/RelatedPartyTransactions",
     "longName": "995308 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ostherapies.com/role/ConvertibleDebt",
     "longName": "995309 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ostherapies.com/role/TedcoGrant",
     "longName": "995310 - Disclosure - Tedco Grant",
     "shortName": "Tedco Grant",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "osti:TedcoGrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "osti:TedcoGrantDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ostherapies.com/role/CommitmentsandContingencies",
     "longName": "995311 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ostherapies.com/role/Equity",
     "longName": "995312 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability",
     "longName": "995313 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability",
     "shortName": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ostherapies.com/role/SegmentandGeographicInformation",
     "longName": "995314 - Disclosure - Segment and Geographic Information",
     "shortName": "Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ostherapies.com/role/SubsequentEvents",
     "longName": "995315 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ostherapies.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ostherapies.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ostherapies.com/role/RelatedPartyTransactionsTables",
     "longName": "996002 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ostherapies.com/role/ConvertibleDebtTables",
     "longName": "996003 - Disclosure - Convertible Debt (Tables)",
     "shortName": "Convertible Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ostherapies.com/role/CommitmentsandContingenciesTables",
     "longName": "996004 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "osti:ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "osti:ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ostherapies.com/role/EquityTables",
     "longName": "996005 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables",
     "longName": "996006 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)",
     "shortName": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ostherapies.com/role/SegmentandGeographicInformationTables",
     "longName": "996007 - Disclosure - Segment and Geographic Information (Tables)",
     "shortName": "Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails",
     "longName": "996008 - Disclosure - Organization and Description of Business, Liquidity, and Risk Factors (Details)",
     "shortName": "Organization and Description of Business, Liquidity, and Risk Factors (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "osti:GoingConcernTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996009 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
     "longName": "996010 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals",
     "longName": "996011 - Disclosure - Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Fair Value of the Purchase Consideration (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c58",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable",
     "longName": "996012 - Disclosure - Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Estimated Amortization Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable",
     "longName": "996013 - Disclosure - Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable",
     "longName": "996014 - Disclosure - Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "osti:ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c59",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "osti:ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails",
     "longName": "996015 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedPayrollTaxesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable",
     "longName": "996016 - Disclosure - Related Party Transactions - Schedule of Payroll Advances to the CEO (Details)",
     "shortName": "Related Party Transactions - Schedule of Payroll Advances to the CEO (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c12",
      "name": "us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ostherapies.com/role/ConvertibleDebtDetails",
     "longName": "996017 - Disclosure - Convertible Debt (Details)",
     "shortName": "Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c105",
      "name": "osti:AgreedToIssuedCashRemunerationPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable",
     "longName": "996018 - Disclosure - Convertible Debt - Schedule of Convertible Debt (Details)",
     "shortName": "Convertible Debt - Schedule of Convertible Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c72",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c77",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable",
     "longName": "996019 - Disclosure - Convertible Debt - Schedule of Company\u2019s Make-Whole Share Liability (Details)",
     "shortName": "Convertible Debt - Schedule of Company\u2019s Make-Whole Share Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c147",
      "name": "osti:BusinessAcquisitionNumberofShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "osti:ScheduleOfMakeWholeShareLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c147",
      "name": "osti:BusinessAcquisitionNumberofShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "osti:ScheduleOfMakeWholeShareLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ostherapies.com/role/TedcoGrantDetails",
     "longName": "996020 - Disclosure - Tedco Grant (Details)",
     "shortName": "Tedco Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c149",
      "name": "osti:NumberOfTranches",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "osti:TedcoGrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c149",
      "name": "osti:NumberOfTranches",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "osti:TedcoGrantDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
     "longName": "996021 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "osti:RentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "osti:RentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable",
     "longName": "996022 - Disclosure - Commitments and Contingencies - Schedule of Future Milestones (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Milestones (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c161",
      "name": "osti:MilestoneBearingEventDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c161",
      "name": "osti:MilestoneBearingEventDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable",
     "longName": "996023 - Disclosure - Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c169",
      "name": "osti:PaymentScheduleofServiceFees",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c169",
      "name": "osti:PaymentScheduleofServiceFees",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ostherapies.com/role/EquityDetails",
     "longName": "996024 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable",
     "longName": "996025 - Disclosure - Equity - Schedule of Common Stock Options Issued (Details)",
     "shortName": "Equity - Schedule of Common Stock Options Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable",
     "longName": "996026 - Disclosure - Equity - Schedule of Black-Scholes Option Pricing Model (Details)",
     "shortName": "Equity - Schedule of Black-Scholes Option Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
     "longName": "996027 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)",
     "shortName": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "osti:StockIssuedDuringPeriodSharesPreferredStockSeperableUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "osti:StockIssuedDuringPeriodSharesPreferredStockSeperableUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable",
     "longName": "996028 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details)",
     "shortName": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c217",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c217",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable",
     "longName": "996029 - Disclosure - Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details)",
     "shortName": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Warrants Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c233",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c234",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ostherapies.com/role/SegmentandGeographicInformationDetails",
     "longName": "996030 - Disclosure - Segment and Geographic Information (Details)",
     "shortName": "Segment and Geographic Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable",
     "longName": "996031 - Disclosure - Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details)",
     "shortName": "Segment and Geographic Information - Schedule of Financial Information of Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c238",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c238",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ostherapies.com/role/SubsequentEventsDetails",
     "longName": "996032 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c48",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c249",
      "name": "us-gaap:WarrantExercisePriceDecrease",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0283146-10k_ostherap.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r834"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Other",
        "documentation": "Amount of obligations incurred and payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "osti_AccruedPayrollAndPayrollTaxesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AccruedPayrollAndPayrollTaxesRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and payroll taxes \u2013 related party",
        "documentation": "Represent the amount of accrued payroll and payroll taxes \u2013 related party.",
        "label": "Accrued Payroll And Payroll Taxes Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and payroll taxes",
        "verboseLabel": "Payroll payable",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedPayrollTaxesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails",
      "http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "terseLabel": "Accrued payroll",
        "label": "Accrued Payroll Taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal fees paid on behalf of Ayala",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1140",
      "r1202"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder approval on April 9, 2025 - warrants turn into Equity",
        "label": "Adjustment of Warrants Granted for Services",
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1097"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Warrant Liability on January 14, 2025",
        "verboseLabel": "Additional warrant liability",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r69"
     ]
    },
    "osti_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Liability Reclass Preferred Stock",
        "documentation": "Represents the amount of adjustments to additional paid in capital, warrants liability reclass preferred stock.",
        "label": "Adjustments To Additional Paid In Capital Warrants Liability Reclass Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_AggregateAdditionalCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AggregateAdditionalCashProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate additional cash proceeds",
        "documentation": "Represent the amount of aggregate additional cash proceeds.",
        "label": "Aggregate Additional Cash Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "osti_AggregateWarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AggregateWarrantsExercisable",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate warrants exercisable (in Shares)",
        "documentation": "The number of warrants are exercisable under purchase agreement.",
        "label": "Aggregate Warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r895",
      "r911",
      "r946"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r898",
      "r914",
      "r949"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "osti_AgreedToIssuedCashRemunerationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AgreedToIssuedCashRemunerationPercentage",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash remuneration agreed to issue percentage",
        "documentation": "Agreed to issued cash remuneration percentage.",
        "label": "Agreed To Issued Cash Remuneration Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "osti_AlanMussoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AlanMussoMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alan Musso [Member]",
        "label": "Alan Musso Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r941",
      "r950",
      "r954",
      "r962"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r417",
      "r427"
     ]
    },
    "us-gaap_AlternativeInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AlternativeInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment amount",
        "label": "Alternative Investment",
        "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r561",
      "r565",
      "r566",
      "r567",
      "r825",
      "r827",
      "r828",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discounts issuance and warrants",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r805",
      "r806",
      "r1053",
      "r1147"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock and common stock equivalents",
        "verboseLabel": "Antidilution shares (in Shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Preferred Stock and Common Stock Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r664",
      "r1136"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of consideration transferred",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Purchase Consideration [Line Items]",
        "terseLabel": "Schedule of Fair Value of the Purchase Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Purchase Consideration",
        "label": "Asset Acquisition, Contingent Consideration [Table Text Block]",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r664",
      "r1136"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r88",
      "r130",
      "r156",
      "r159",
      "r160",
      "r197",
      "r210",
      "r229",
      "r233",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r516",
      "r518",
      "r568",
      "r612",
      "r613",
      "r617",
      "r713",
      "r793",
      "r794",
      "r807",
      "r834",
      "r840",
      "r841",
      "r854",
      "r1086",
      "r1087",
      "r1153"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r135",
      "r156",
      "r159",
      "r160",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r516",
      "r518",
      "r568",
      "r834",
      "r1086",
      "r1087",
      "r1153"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of acquisition",
        "label": "Assets, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total-Long Term Assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r159",
      "r160",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r516",
      "r518",
      "r568",
      "r1086",
      "r1087",
      "r1153"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/TedcoGrantDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "osti_AyalaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "AyalaMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ayala [Member]",
        "label": "Ayala Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "osti_BlinkBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "BlinkBioMember",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blink Bio [Member]",
        "label": "Blink Bio Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_BrooklineCapitalMarketsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "BrooklineCapitalMarketsMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brookline Capital Markets [Member]",
        "label": "Brookline Capital Markets Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_BundgerUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "BundgerUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total budget",
        "documentation": "It represents the amount of budget under agreement.",
        "label": "Bundger Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r664",
      "r816",
      "r817",
      "r1132",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r664",
      "r816",
      "r817",
      "r1132",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value",
        "label": "Business Combination, Transaction Cost, Excluding Separately Recognized Transaction",
        "documentation": "Amount of transaction cost incurred to effect business combination. Excludes separately recognized transaction and indirect cost."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Date Earned",
        "label": "Business Combination, Date of Acquisition Agreement",
        "documentation": "Date when acquisition agreement is executed in business combination, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1133"
     ]
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Position",
        "label": "Business Combination, Name of Acquiree",
        "documentation": "Name of acquiree in business combination."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r820",
      "r821"
     ]
    },
    "osti_BusinessAcquisitionNumberofShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "BusinessAcquisitionNumberofShares",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "documentation": "Number of shares in business acquisition.",
        "label": "Business Acquisition Numberof Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r891"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactors"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS, LIQUIDITY, AND RISK FACTORS",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1054"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash checking account",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r620",
      "r688",
      "r708",
      "r834",
      "r840",
      "r841",
      "r854",
      "r1002"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash \u2013 beginning of period",
        "periodEndLabel": "Cash \u2013 end of period",
        "terseLabel": "Cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r57",
      "r153"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r57"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FDIC amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash [Member]",
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations",
        "label": "Cash Proceeds Received and Tax Benefit from Share-Based Payment Awards [Table Text Block]",
        "documentation": "Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "osti_CashRemunerationofWarrantFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CashRemunerationofWarrantFeePercentage",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant fee percentage",
        "documentation": "Represent the percentage of cash remuneration of warrant fee.",
        "label": "Cash Remunerationof Warrant Fee Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "osti_CerosFinancialServicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CerosFinancialServicesIncMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ceros Financial Services, Inc [Member]",
        "label": "Ceros Financial Services Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "osti_ChaseBankCheckingAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ChaseBankCheckingAccountMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chase Bank Checking Account [Member]",
        "label": "Chase Bank Checking Account Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ChaseBankSavingsAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ChaseBankSavingsAccountMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chase Bank Savings Account [Member]",
        "label": "Chase Bank Savings Account Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEO [Member]",
        "label": "Chief Executive Officer",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "osti_ChiefOperatingDecisionMakerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ChiefOperatingDecisionMakerMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CODM [Member]",
        "label": "Chief Operating Decision Maker Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "osti_ChristopherAcevedoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ChristopherAcevedoMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Christopher Acevedo [Member]",
        "label": "Christopher Acevedo Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r132",
      "r133",
      "r134",
      "r156",
      "r160",
      "r187",
      "r188",
      "r191",
      "r193",
      "r199",
      "r200",
      "r242",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r329",
      "r330",
      "r332",
      "r333",
      "r335",
      "r339",
      "r342",
      "r343",
      "r346",
      "r349",
      "r357",
      "r568",
      "r668",
      "r669",
      "r670",
      "r671",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r700",
      "r721",
      "r743",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r994",
      "r1057",
      "r1059",
      "r1066"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r199",
      "r332",
      "r342",
      "r343",
      "r344",
      "r346",
      "r349",
      "r355",
      "r357",
      "r520",
      "r668",
      "r669",
      "r670",
      "r671",
      "r808",
      "r994",
      "r1055",
      "r1057"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable",
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "verboseLabel": "Warrant exercise price (in Dollars per share)",
        "netLabel": "Warrant exercise price per share (in Dollars per share)",
        "label": "Current exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r161",
      "r358"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant purchase shares (in Shares)",
        "verboseLabel": "Number of warrants adjusted in to shares (in Shares)",
        "netLabel": "Aggregate shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate warrants to purchase shares outstanding (in Shares)",
        "verboseLabel": "Aggregate warrants to purchase shares",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "osti_ClawbackOfCommonStockForOverIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ClawbackOfCommonStockForOverIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clawback of common stock for over issuance",
        "documentation": "Clawback of common stock for over issuance.",
        "label": "Clawback Of Common Stock For Over Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ClosingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ClosingPricePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing price per share (in Dollars per share)",
        "documentation": "Closing price per share.",
        "label": "Closing Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business, Liquidity, and Risk Factors [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "osti_CommitmentSharesIssuedForEquityLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommitmentSharesIssuedForEquityLineOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment shares issued for equity line of credit",
        "documentation": "Amount of commitment shares issued for the equity line of credit.",
        "label": "Commitment Shares Issued For Equity Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (See Note 6)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r81",
      "r619",
      "r699"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r278",
      "r279",
      "r770",
      "r1077",
      "r1082"
     ]
    },
    "osti_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommitmentsandContingenciesScheduleofCertainFeesandCorrespondingPaymentAmountsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Schedule of Certain Fees and Corresponding Payment Amounts (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommitmentsandContingenciesScheduleofFutureMilestonesDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Schedule of Future Milestones (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A common Stock [Member]",
        "verboseLabel": "Class A Common Stock [Member]",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Common Stock [Member]",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "osti_CommonStockConversionAfterShareDiscountsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommonStockConversionAfterShareDiscountsPercentage",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After share discounts percentage",
        "documentation": "Common stock conversion after share discounts percentage.",
        "label": "Common Stock Conversion After Share Discounts Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion price per share (in Dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Decrease",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion price (in Dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "osti_CommonStockIssuedForPatentPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommonStockIssuedForPatentPurchase",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for patent purchase",
        "documentation": "The amount of common stock issued for patent purchase.",
        "label": "Common Stock Issued For Patent Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock CS \u2013 Shares CS \u2013 Par",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r845",
      "r847",
      "r848",
      "r849",
      "r850",
      "r1062",
      "r1063",
      "r1065",
      "r1140",
      "r1196",
      "r1202"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock per share (in Dollars per share)",
        "netLabel": "Price per unit (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in Shares)",
        "verboseLabel": "Common stock authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r700"
     ]
    },
    "osti_CommonStockSharesAwarded": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommonStockSharesAwarded",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares awarded (in Shares)",
        "documentation": "Common stock shares awarded.",
        "label": "Common Stock Shares Awarded"
       }
      }
     },
     "auth_ref": []
    },
    "osti_CommonStockSharesAwardedInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "CommonStockSharesAwardedInCash",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "documentation": "It represents the amount of common stock awarded in cash.",
        "label": "Common Stock Shares Awarded In Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in Shares)",
        "verboseLabel": "Common stock (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in Shares)",
        "verboseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r700",
      "r719",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock A, par value $0.001, 150,000,000 shares authorized; 37,113,082 and 20,869,908 issued and outstanding, respectively",
        "verboseLabel": "Company common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r330",
      "r338",
      "r622",
      "r834"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]",
        "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r157",
      "r164",
      "r615",
      "r995"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r783"
     ]
    },
    "osti_ConsultingFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConsultingFeeMember",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting Fee [Member]",
        "label": "Consulting Fee Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "osti_ConversionOfMakewholeLiabilityToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConversionOfMakewholeLiabilityToCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of make-whole liability to common stock",
        "documentation": "The amount of conversion of make-whole liability to common stock.",
        "label": "Conversion Of Makewhole Liability To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of preferred stock to common stock",
        "documentation": "Represent the amount of conversion of preferred stock to common stock.",
        "label": "Conversion Of Preferred Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Preferred Stock to Common Stock",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Preferred Stock to Common Stock (in Shares)",
        "verboseLabel": "Shares of common stock (in Shares)",
        "netLabel": "Converted (in Shares)",
        "label": "Converted shares",
        "totalLabel": "Converted to shares of common stock (in Shares)",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in Shares)",
        "verboseLabel": "Conversions of shares",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "osti_ConversionOfWarrantsIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConversionOfWarrantsIntoCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of warrants into common stock",
        "documentation": "Conversion of warrants into Common Stock.",
        "label": "Conversion Of Warrants Into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ConversionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConversionPricePercentage",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "documentation": "Percentage conversion price.",
        "label": "Conversion Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r80",
      "r1165"
     ]
    },
    "osti_ConvertibleDebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConvertibleDebtDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConvertibleDebtScheduleofCompanysMakeWholeShareLiabilityDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt - Schedule of Company\u2019s Make-Whole Share Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ConvertibleDebtScheduleofConvertibleDebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ConvertibleDebtScheduleofConvertibleDebtDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt - Schedule of Convertible Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29",
      "r45",
      "r68",
      "r352"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r973"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r974"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r975"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r969"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r970"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r972"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r971"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes into common stock",
        "verboseLabel": "Notes converted amount",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Rate",
        "verboseLabel": "Conversion price percentage",
        "label": "Debt Conversion, Converted Instrument, Rate",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r20"
     ]
    },
    "us-gaap_DebtConversionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r156",
      "r158",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r284",
      "r285",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r312",
      "r319",
      "r320",
      "r322",
      "r520",
      "r577"
     ]
    },
    "osti_DebtDiscountAccretionExpenseInWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "DebtDiscountAccretionExpenseInWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount accretion expense in warrants",
        "documentation": "Debt Discount Accretion Expense in Warrants.",
        "label": "Debt Discount Accretion Expense In Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r78",
      "r80",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r832",
      "r1055",
      "r1056",
      "r1058",
      "r1061",
      "r1078",
      "r1079",
      "r1080",
      "r1146",
      "r1148",
      "r1162"
     ]
    },
    "us-gaap_DebtInstrumentCollateral": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCollateral",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral",
        "label": "Debt Instrument, Collateral",
        "documentation": "Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r38"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Amount (in Dollars)",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity stock conversion percentage",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees amortized interest rate",
        "verboseLabel": "Accrue interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r315",
      "r1146"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate",
        "verboseLabel": "Debt discount rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r324",
      "r577",
      "r578",
      "r832"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r520",
      "r615",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r832",
      "r1055",
      "r1056",
      "r1058",
      "r1061",
      "r1146",
      "r1148"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r802",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r832",
      "r1055",
      "r1056",
      "r1058",
      "r1061",
      "r1078",
      "r1079",
      "r1080",
      "r1146",
      "r1148",
      "r1162"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unamortized discount",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r323",
      "r576",
      "r577",
      "r578",
      "r803",
      "r804",
      "r832"
     ]
    },
    "osti_DeemedDividendOnSeriesAConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "DeemedDividendOnSeriesAConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cumulative Series A preferred stock dividend requirement",
        "documentation": "The amount of deemed dividend.",
        "label": "Deemed Dividend On Series AConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_DeferredCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Costs, Current",
        "label": "Deferred Costs, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_DeferredIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense",
        "label": "Deferred Income [Table Text Block]",
        "documentation": "Tabular disclosure of deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1193"
     ]
    },
    "osti_DeferredOfferingCostsRecordedAsAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "DeferredOfferingCostsRecordedAsAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred offering costs",
        "documentation": "The amount of deferred offering costs recorded as accounts payable.",
        "label": "Deferred Offering Costs Recorded As Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General business credit carryover",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D credit (available for payroll tax offset)",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r918"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent (net of amortization)",
        "label": "Deposits Assets, Noncurrent",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1073",
      "r1197"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r918"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deemed dividend on Series A convertible preferred stock",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r69"
     ]
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred dividends payable",
        "label": "Dividends Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend payable (in Dollars)",
        "label": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r41",
      "r79",
      "r851",
      "r1163"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred Dividends",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r69"
     ]
    },
    "us-gaap_DividendsPreferredStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPreferredStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend due (in Dollars)",
        "label": "Dividends, Preferred Stock, Cash",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r69"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891",
      "r942"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891",
      "r942"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per common share outstanding (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r142",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r184",
      "r187",
      "r191",
      "r192",
      "r193",
      "r196",
      "r328",
      "r415",
      "r452",
      "r514",
      "r545",
      "r546",
      "r611",
      "r630",
      "r784"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per common share outstanding (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r142",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r187",
      "r191",
      "r192",
      "r193",
      "r196",
      "r328",
      "r415",
      "r452",
      "r514",
      "r545",
      "r546",
      "r611",
      "r630",
      "r784"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r195"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r819"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related payroll taxes payable",
        "label": "Employee-related Liabilities",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1163"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Payroll Advances [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incorporated date",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r115",
      "r122",
      "r123",
      "r139",
      "r140",
      "r141",
      "r165",
      "r166",
      "r167",
      "r170",
      "r178",
      "r180",
      "r182",
      "r198",
      "r243",
      "r246",
      "r268",
      "r327",
      "r359",
      "r415",
      "r440",
      "r441",
      "r448",
      "r449",
      "r450",
      "r453",
      "r513",
      "r514",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r544",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r579",
      "r581",
      "r592",
      "r629",
      "r653",
      "r654",
      "r655",
      "r676",
      "r743"
     ]
    },
    "osti_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_EquityLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "EquityLineOfCreditMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Line of Credit [Member]",
        "label": "Equity Line Of Credit Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r895",
      "r911",
      "r946"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r908",
      "r943"
     ]
    },
    "us-gaap_ExcessStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExcessStockSharesIssued",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock (in Shares)",
        "verboseLabel": "Purchase of common stock",
        "label": "Excess Stock, Shares Issued",
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "osti_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "documentation": "Exercise price.",
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable": {
       "parentTag": "osti_UnallocatedCashProceeds",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable",
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in value of warrant liabilities",
        "negatedLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Fair value of Warrant liability",
        "netLabel": "Gain on the change in fair value of Warrant Liability",
        "negatedTerseLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of the warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r558",
      "r559",
      "r561",
      "r564",
      "r603",
      "r604",
      "r605",
      "r775",
      "r803",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r825",
      "r827",
      "r831"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r548",
      "r549",
      "r550",
      "r551",
      "r559",
      "r564",
      "r605",
      "r775",
      "r803",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r825",
      "r827",
      "r831"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r560"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r557",
      "r560"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r558",
      "r559",
      "r561",
      "r564",
      "r603",
      "r604",
      "r605",
      "r775",
      "r803",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r825",
      "r827",
      "r831"
     ]
    },
    "osti_FairValueOfHER2AssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "FairValueOfHER2AssetsMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HER2 Assets [Member]",
        "verboseLabel": "Fair Value of HER2 Assets [Member]",
        "label": "Fair Value Of HER2 Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world) [Member]",
        "label": "Filing Of An NDABLAOr MAARegistrationor The Equivalent In Any Other Territory Around The World Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2031 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1204"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r773",
      "r777"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r773",
      "r777"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r773",
      "r777"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r773",
      "r777"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r773",
      "r777"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Amortization Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofEstimatedAmortizationExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r1075"
     ]
    },
    "osti_FixedAssetPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "FixedAssetPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Asset Policy",
        "documentation": "Disclosure of accounting policy for fixed asset policy.",
        "label": "Fixed Asset Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r950"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r950"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r902"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "osti_FutureMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "FutureMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment",
        "documentation": "Represent the amount of future milestone payment.",
        "label": "Future Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GLPToxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GLPToxMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Good Laboratory Practices [Member]",
        "label": "GLPTox Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainContingenciesLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Certain Fees and Corresponding Payment Amounts [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r723"
     ]
    },
    "osti_GoingConcernTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GoingConcernTerm",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going concern term",
        "documentation": "Going concern term.",
        "label": "Going Concern Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Amortization",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r264",
      "r266"
     ]
    },
    "us-gaap_GrantsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant amount",
        "label": "Grants Receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "osti_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "documentation": "Gross proceeds refers to the total amount of money received from selling a product or service. It's the total amount of money received before any deductions are made. In other words, gross proceeds are the total income from a sale before taxes, shipping, and any other discounts are considered.",
        "label": "Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupAMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group A [Member]",
        "label": "Group AMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupBMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group B [Member]",
        "label": "Group BMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupCMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group C [Member]",
        "label": "Group CMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupDMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group D [Member]",
        "label": "Group DMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupEMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group E [Member]",
        "label": "Group EMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_GroupFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "GroupFMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group F [Member]",
        "label": "Group FMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_HER2AssetAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "HER2AssetAmortizationMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HER2 Asset Amortization [Member]",
        "label": "HER2 Asset Amortization Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_HER2AssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "HER2AssetsMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HER2 Assets [Member]",
        "label": "HER2 Assets Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_IClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "IClinicalTrialMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completion of a Phase I Clinical Trial [Member]",
        "label": "IClinical Trial Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_IIClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "IIClinicalTrialMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Completion of a Phase II Clinical Trial [Member]",
        "label": "IIClinical Trial Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r870",
      "r891"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses on long lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r63",
      "r145",
      "r778",
      "r826"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r432",
      "r433",
      "r435",
      "r436",
      "r438",
      "r439",
      "r667"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued interest on convertible notes",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Payroll and payroll taxes",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of non-cash prepaids",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r941",
      "r950",
      "r954",
      "r962"
     ]
    },
    "osti_InducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "InducementWarrantsMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Warrants",
        "label": "Inducement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r966"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r966"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r966"
     ]
    },
    "us-gaap_InterestBearingDomesticDepositMoneyMarket": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestBearingDomesticDepositMoneyMarket",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market account",
        "label": "Interest-Bearing Domestic Deposit, Money Market",
        "documentation": "Amount of interest-bearing domestic money market demand account deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r779",
      "r782",
      "r1010"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r152"
     ]
    },
    "osti_InvestedPurchaser": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "InvestedPurchaser",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invested purchaser",
        "documentation": "The amount of invested purchaser.",
        "label": "Invested Purchaser"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r213",
      "r233",
      "r793",
      "r1009"
     ]
    },
    "osti_IssuanceOfCommonStockToInvestorAdvisorSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "IssuanceOfCommonStockToInvestorAdvisorSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to investor advisor \u2013 settlement",
        "documentation": "Issuance of common stock to investor advisor settlement.",
        "label": "Issuance Of Common Stock To Investor Advisor Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issuance for services",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "osti_JoacimBorgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "JoacimBorgMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Joacim Borg [Member]",
        "label": "Joacim Borg Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_JohnsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "JohnsonMember",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Johnson [Member]",
        "label": "Johnson Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r833"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attorneys fees",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37",
      "r40",
      "r41",
      "r42",
      "r43",
      "r156",
      "r159",
      "r160",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r517",
      "r518",
      "r519",
      "r568",
      "r698",
      "r786",
      "r807",
      "r854",
      "r1086",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r82",
      "r625",
      "r834",
      "r840",
      "r841",
      "r1055",
      "r1060",
      "r1074",
      "r1145"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r127",
      "r156",
      "r159",
      "r160",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r517",
      "r518",
      "r519",
      "r568",
      "r834",
      "r1086",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r40",
      "r41",
      "r42",
      "r43",
      "r156",
      "r159",
      "r160",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r517",
      "r518",
      "r519",
      "r568",
      "r1086",
      "r1153",
      "r1154"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_LicenseFeeToUtilizeProprietaryTechnologypaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "LicenseFeeToUtilizeProprietaryTechnologypaidMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Fee to utilize proprietary technology (paid) [Member]",
        "label": "License Fee To Utilize Proprietary Technologypaid Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal balance accrues rate",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "documentation": "The effective interest rate at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r39"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total approximately amount",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r157",
      "r164",
      "r314",
      "r615"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable",
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r204",
      "r280",
      "r281",
      "r282",
      "r283",
      "r379",
      "r406",
      "r407",
      "r408",
      "r429",
      "r551",
      "r608",
      "r649",
      "r650",
      "r663",
      "r690",
      "r691",
      "r751",
      "r753",
      "r756",
      "r757",
      "r758",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r800",
      "r808",
      "r818",
      "r820",
      "r822",
      "r823",
      "r827",
      "r828",
      "r829",
      "r830",
      "r836",
      "r1088",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate [Member]",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r822",
      "r823",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Exercise Price [Member]",
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price Volatility [Member]",
        "verboseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r827",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Share Price [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r549",
      "r550",
      "r551",
      "r820",
      "r822",
      "r823",
      "r827"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r820",
      "r822",
      "r823",
      "r827"
     ]
    },
    "srt_MedianMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MedianMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Median [Member]",
        "label": "Median [Member]",
        "documentation": "Middle value in data set."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "osti_MilestoneBearingEventDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "MilestoneBearingEventDescription",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Bearing Event",
        "documentation": "Description of milestone bearing events.",
        "label": "Milestone Bearing Event Description"
       }
      }
     },
     "auth_ref": []
    },
    "osti_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "Represent the amount of milestone payments.",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "osti_MillRiverPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "MillRiverPartnersLLCMember",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mill River Partners LLC [Member]",
        "label": "Mill River Partners LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable",
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r204",
      "r280",
      "r281",
      "r282",
      "r283",
      "r379",
      "r406",
      "r407",
      "r408",
      "r429",
      "r551",
      "r608",
      "r649",
      "r650",
      "r663",
      "r690",
      "r691",
      "r751",
      "r753",
      "r756",
      "r757",
      "r758",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r800",
      "r808",
      "r818",
      "r820",
      "r822",
      "r823",
      "r827",
      "r828",
      "r829",
      "r836",
      "r1088",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "osti_MrRomnessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "MrRomnessMember",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Romness [Member]",
        "label": "Mr Romness Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r61"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net Loss",
        "netLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r61",
      "r84",
      "r123",
      "r125",
      "r136",
      "r137",
      "r141",
      "r156",
      "r159",
      "r160",
      "r163",
      "r169",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r189",
      "r242",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r328",
      "r331",
      "r334",
      "r340",
      "r415",
      "r452",
      "r514",
      "r546",
      "r568",
      "r628",
      "r720",
      "r741",
      "r742",
      "r779",
      "r781",
      "r782",
      "r852",
      "r1086"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS available to common shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r144",
      "r174",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r190",
      "r193",
      "r331",
      "r334",
      "r340",
      "r514"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r146",
      "r147",
      "r148",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r183",
      "r196",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r267",
      "r268",
      "r275",
      "r325",
      "r326",
      "r327",
      "r328",
      "r413",
      "r414",
      "r415",
      "r416",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r490",
      "r491",
      "r492",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r562",
      "r563",
      "r579",
      "r580",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906",
      "r907"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r899",
      "r915",
      "r941",
      "r950"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends payable",
        "label": "Noncash or Part Noncash Acquisition, Payables Assumed",
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseInvestmentAdvisoryFees",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense to advisory fees amount",
        "label": "Investment Advisory Fee",
        "documentation": "Amount of expense for investment advisory service, including, but not limited to, managing money in fund."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r723",
      "r852",
      "r1198"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME/EXPENSE",
        "terseLabel": "TOTAL OTHER INCOME (EXPENSE)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME/EXPENSE",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount on notes payable \u2013 redemption premium",
        "label": "Notes Issued",
        "documentation": "The fair value of notes issued in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r1068"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating reportable",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r798",
      "r1068"
     ]
    },
    "osti_NumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "NumberOfTradingDays",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days",
        "documentation": "Number of trading days.",
        "label": "Number Of Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "osti_NumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "NumberOfTranches",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "documentation": "Represents the number of tranches.",
        "label": "Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING EXPENSES",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r779",
      "r782",
      "r787",
      "r1067",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payment",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r585"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business, Liquidity, and Risk Factors [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/OrganizationandDescriptionofBusinessLiquidityandRiskFactorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business, Liquidity, and Risk Factors (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_OriginalIssueDiscount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "OriginalIssueDiscount",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issue discount",
        "documentation": "Percentage of original issue discount.",
        "label": "Original Issue Discount"
       }
      }
     },
     "auth_ref": []
    },
    "osti_OriginalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "OriginalShares",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original shares (in Shares)",
        "documentation": "The number of original shares.",
        "label": "Original Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued total amount",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-operating expenses",
        "negatedTerseLabel": "Non-operating expenses",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSE)",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other offering expenses",
        "label": "Other Ownership Interests, Offering Costs",
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r897",
      "r913",
      "r948"
     ]
    },
    "osti_OutstandingBalanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "OutstandingBalanceFees",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance due amount",
        "documentation": "Represent the amount of outstanding balance fees.",
        "label": "Outstanding Balance Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r916",
      "r951"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r900",
      "r916",
      "r951"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PatentLicenseAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PatentLicenseAcquisitionMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable",
      "http://www.ostherapies.com/role/ScheduleofFairValueofthePurchaseConsiderationTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent &amp; License Acquisition [Member]",
        "label": "Patent License Acquisition Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PatentLicenseAcquisitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PatentLicenseAcquisitionPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent &amp; License Acquisition",
        "documentation": "Dizclosure of accounting policy for patent &amp; license acquisition.",
        "label": "Patent License Acquisition Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "osti_PaymentScheduleServiceFeesRemainderDue": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PaymentScheduleServiceFeesRemainderDue",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "George Clinical Payment Schedule, Remainder Due",
        "documentation": "Description of payment schedule service fees remainder due.",
        "label": "Payment Schedule Service Fees Remainder Due"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PaymentScheduleofServiceFees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PaymentScheduleofServiceFees",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "George Clinical Payment Schedule",
        "documentation": "Description of george clinical payment schedule service fees.",
        "label": "Payment Scheduleof Service Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Amount",
        "verboseLabel": "Fees amount",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Patent License Acquisition",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "osti_PercentageOfRoyalties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PercentageOfRoyalties",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties percentage",
        "documentation": "Percentage of royalties capped.",
        "label": "Percentage Of Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PercentageOfRoyaltyPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PercentageOfRoyaltyPayments",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales",
        "documentation": "Percentage of royalty payments.",
        "label": "Percentage Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends percentage",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r752",
      "r754",
      "r755",
      "r759"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock Shares Par Amount",
        "verboseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r847",
      "r848",
      "r849",
      "r850",
      "r1196",
      "r1202"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, par value (in Dollars per share)",
        "verboseLabel": "Par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares authorized (in Shares)",
        "verboseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r700"
     ]
    },
    "osti_PreferredStockSharesDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PreferredStockSharesDesignated",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares designated",
        "documentation": "Number of preferred stock, shares designated.",
        "label": "Preferred Stock Shares Designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares issued (in Shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r342"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares outstanding (in Shares)",
        "verboseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r700",
      "r719",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REDEEMABLE PREFERRED STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r332"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, par value $0.001, 5,000,000 shares authorized; 0 and 0 shares outstanding, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r330",
      "r337",
      "r621",
      "r834"
     ]
    },
    "osti_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PrepaidCommonStockNotIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PrepaidCommonStockNotIssuedMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Common Stock Not Issued [Member]",
        "label": "Prepaid Common Stock Not Issued Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "osti_PrepaidShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PrepaidShare",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid shares (in Shares)",
        "documentation": "The number of prepaid shares.",
        "label": "Prepaid Share"
       }
      }
     },
     "auth_ref": []
    },
    "osti_PrepaidShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PrepaidShares",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid warrants (in Shares)",
        "documentation": "The number of shares prepaid shares.",
        "label": "Prepaid Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PresentValueOfFutureInsuranceProfitLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PresentValueOfFutureInsuranceProfitLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Milestones [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "osti_PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Privately Negotiated Warrant Exercise Inducement and Exchange Agreements [Member]",
        "label": "Privately Negotiated Warrant Exercise Inducement And Exchange Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from conversion of debt A, B, C, D, E &amp; F",
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial public offering (net of fees)",
        "verboseLabel": "Initial cash proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock consideration",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "netLabel": "Aggregate gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mezzanine equity conversion (net of costs)",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable": {
       "parentTag": "osti_UnallocatedCashProceeds",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds form before deducting transaction fees and other estimated expenses",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issuance (net of fees)",
        "verboseLabel": "Initial cash proceeds",
        "netLabel": "Cash proceeds",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLicenseFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License fee",
        "label": "Proceeds from License Fees Received",
        "documentation": "Cash received from licensees for license fees during the current period."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid warrants (net of fees)",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties amount",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "osti_ProceedsFromSaleOfPreferredStockAndRelatedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ProceedsFromSaleOfPreferredStockAndRelatedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of preferred stock",
        "documentation": "Represents the amount of proceeds from sale of  preferred stock and related warrants.",
        "label": "Proceeds From Sale Of Preferred Stock And Related Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term borrowings",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants proceeds",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r236",
      "r609",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r776",
      "r778",
      "r781",
      "r782",
      "r809",
      "r810",
      "r835",
      "r836",
      "r837",
      "r839",
      "r842",
      "r996",
      "r1000",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1083",
      "r1084",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arbitration-related fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r793",
      "r852",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets (net)",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r586",
      "r616",
      "r627",
      "r834"
     ]
    },
    "osti_PurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "PurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock",
        "documentation": "It represents the amount of purchase of common stock.",
        "label": "Purchase Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable",
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r204",
      "r280",
      "r281",
      "r282",
      "r283",
      "r368",
      "r379",
      "r406",
      "r407",
      "r408",
      "r412",
      "r429",
      "r551",
      "r606",
      "r607",
      "r608",
      "r649",
      "r650",
      "r663",
      "r690",
      "r691",
      "r751",
      "r753",
      "r756",
      "r757",
      "r758",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r800",
      "r808",
      "r818",
      "r820",
      "r822",
      "r823",
      "r827",
      "r828",
      "r829",
      "r830",
      "r836",
      "r845",
      "r1081",
      "r1088",
      "r1143",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofConvertibleDebtTable",
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r204",
      "r280",
      "r281",
      "r282",
      "r283",
      "r368",
      "r379",
      "r406",
      "r407",
      "r408",
      "r412",
      "r429",
      "r551",
      "r606",
      "r607",
      "r608",
      "r649",
      "r650",
      "r663",
      "r690",
      "r691",
      "r751",
      "r753",
      "r756",
      "r757",
      "r758",
      "r766",
      "r767",
      "r768",
      "r769",
      "r771",
      "r772",
      "r800",
      "r808",
      "r818",
      "r820",
      "r822",
      "r823",
      "r827",
      "r828",
      "r829",
      "r830",
      "r836",
      "r845",
      "r1081",
      "r1088",
      "r1143",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "osti_ReclassificationOfWarrantLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ReclassificationOfWarrantLiabilityToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of warrants liability to equity",
        "documentation": "The amount of reclassification of warrant liability to equity.",
        "label": "Reclassification Of Warrant Liability To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification to equity",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r1089",
      "r1091",
      "r1092",
      "r1093"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r908",
      "r943"
     ]
    },
    "osti_RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Preferred Stock and Mezzanine Equity",
        "documentation": "Redeemable preferred stock and mezzanine equity.",
        "label": "Redeemable Preferred Stock And Mezzanine Equity Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RedeemablePreferredStockMezzainineEquityandWarrantLiabilityScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability - Schedule of Cash Proceeds and Changes in Warrant Liability in the Consolidated Statement of Operations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "osti_RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFutureMilestonesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Approval in the first of the United States, within the EU or within the UK [Member]",
        "label": "Regulatory Approval In The First Of The United States Within The EUOr Within The UKMember"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ReimbursableGrantAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ReimbursableGrantAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursable grant amount",
        "documentation": "Amount of total reimbursable grant.",
        "label": "Reimbursable Grant Amount"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ReimbursementExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ReimbursementExpirationPeriod",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement expiration period",
        "documentation": "Reimbursement Expiration Period.",
        "label": "Reimbursement Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162",
      "r163",
      "r241",
      "r375",
      "r378",
      "r596",
      "r597",
      "r618",
      "r626",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r718",
      "r750",
      "r1199"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162",
      "r163",
      "r596",
      "r597",
      "r1152"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162",
      "r163",
      "r1152"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162",
      "r163",
      "r241",
      "r596",
      "r597",
      "r598",
      "r724",
      "r725",
      "r728"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162",
      "r163",
      "r241",
      "r375",
      "r378",
      "r596",
      "r597",
      "r618",
      "r626",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r718",
      "r750",
      "r1152",
      "r1199"
     ]
    },
    "osti_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r594",
      "r595",
      "r597",
      "r599",
      "r673",
      "r674",
      "r675",
      "r726",
      "r727",
      "r728",
      "r747",
      "r749"
     ]
    },
    "osti_RentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "documentation": "The amount of rent expense.",
        "label": "Rent Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfOtherDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPayrollAdvancestotheCEOTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment",
        "label": "Repayments of Other Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Short-term loan repayments",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement",
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r773",
      "r779",
      "r780",
      "r793",
      "r1161"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "osti_ResidualValueAllocatedToSeriesAPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ResidualValueAllocatedToSeriesAPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable": {
       "parentTag": "osti_UnallocatedCashProceeds",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Residual value allocated to Series A Preferred Stock",
        "documentation": "Value of residual value allocated to Series A Preferred Stock.",
        "label": "Residual Value Allocated To Series APreferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r894",
      "r910",
      "r945"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r901",
      "r917",
      "r952"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r69",
      "r624",
      "r657",
      "r662",
      "r672",
      "r701",
      "r834"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r122",
      "r123",
      "r165",
      "r166",
      "r167",
      "r170",
      "r178",
      "r180",
      "r182",
      "r243",
      "r246",
      "r268",
      "r327",
      "r415",
      "r440",
      "r441",
      "r448",
      "r449",
      "r450",
      "r453",
      "r513",
      "r514",
      "r523",
      "r526",
      "r527",
      "r530",
      "r544",
      "r579",
      "r581",
      "r653",
      "r655",
      "r676",
      "r1202"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r774"
     ]
    },
    "osti_RoyaltyNetSalesPecentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RoyaltyNetSalesPecentage",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales percentage",
        "documentation": "Royalty net sales percentage of products.",
        "label": "Royalty Net Sales Pecentage"
       }
      }
     },
     "auth_ref": []
    },
    "osti_RoyaltyReductionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "RoyaltyReductionPercentage",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty reduction percent",
        "verboseLabel": "Royalties reduction",
        "documentation": "Percentage of royalty reduction.",
        "label": "Royalty Reduction Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "osti_SVBBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SVBBankMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SVB Bank [Member]",
        "label": "SVBBank Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share",
        "verboseLabel": "Issued value",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares issued (in Shares)",
        "verboseLabel": "Shares sold",
        "netLabel": "Shares of gross proceeds (in Shares)",
        "label": "Purchase of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfCashProceedsAndChangesInWarrantLiabilityInTheConsolidatedStatementOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Proceeds And Changes In Warrant Liability In The Consolidated Statement Of Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfCertainFeesAndCorrespondingPaymentAmountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Certain Fees And Corresponding Payment Amounts Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Certain Fees and Corresponding Payment Amounts",
        "documentation": "Tabular disclosure of certain fees and corresponding payment.",
        "label": "Schedule Of Certain Fees And Corresponding Payment Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfCompanySMakeWholeShareLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfCompanySMakeWholeShareLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SMake Whole Share Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Information of Operating Segment",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1056",
      "r1061",
      "r1162"
     ]
    },
    "osti_ScheduleOfConvertibleDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfConvertibleDebtAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Convertible Debt Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfFairValueOfThePurchaseConsiderationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfFairValueOfThePurchaseConsiderationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Purchase Consideration [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfFinancialInformationOfOperatingSegmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfFinancialInformationOfOperatingSegmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Information Of Operating Segment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfFutureMilestonesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfFutureMilestonesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Future Milestones Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfMakeWholeShareLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfMakeWholeShareLiabilityTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Make-Whole Share Liability",
        "documentation": "Tabular disclosure of whole share liability.",
        "label": "Schedule Of Make Whole Share Liability Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Milestones",
        "documentation": "Tabular disclosure of payment for future milestone events.",
        "label": "Schedule Of Payment For Future Milestone Events Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfPreferredStockAndCommonStockEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Preferred Stock And Common Stock Equivalents Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfRecognizeInterestAndPenaltiesRelatedToTaxPositionsInIncomeTaxExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense [Abstract]]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Payroll Advances to the CEO",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Options Issued",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Black-Scholes Option Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "osti_ScheduleOfWarrantsLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleOfWarrantsLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Amortization Expenses",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r1076"
     ]
    },
    "osti_ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognize Interest and Penalties Related to Tax Positions in Income Tax Expense",
        "documentation": "Tabular disclosure of preferred stock and common stock equivalents.",
        "label": "Scheduleof Preferred Stockand Common Stock Equivalents Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "osti_SecurityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SecurityPurchaseAgreementMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Purchase Agreement [Member]",
        "label": "Security Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment and Geographic Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief executive officer",
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r792",
      "r799"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of segment",
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r789",
      "r796"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SegmentandGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r197",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r222",
      "r224",
      "r225",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r788",
      "r790",
      "r791",
      "r793",
      "r795",
      "r797",
      "r798"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Information of Operating Segment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "osti_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Senior Convertible Preferred Stock [Member]",
        "verboseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1004",
      "r1005",
      "r1090",
      "r1094"
     ]
    },
    "osti_SeriesASeniorConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SeriesASeniorConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Senior Convertible Preferred Stock [Member]",
        "label": "Series ASenior Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Warrants [Member]",
        "label": "Series AWarrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Officers &amp; Directors [Member]",
        "label": "Business Combination, Series of Individually Immaterial Business Combinations [Member]",
        "documentation": "Series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r1132",
      "r1134",
      "r1135"
     ]
    },
    "osti_ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid) [Member]",
        "label": "Service Fee Advance Of212335 Minus The Amount Already Paid Plus PTCFee Advance Of31325paid Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ServiceFeeAdvancepaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ServiceFeeAdvancepaidMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Fee Advance (paid) [Member]",
        "label": "Service Fee Advancepaid Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ServiceFeesRemainderDue": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ServiceFeesRemainderDue",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Fees \u2013 Remainder Due",
        "documentation": "Discloses the service fees \u2013 remainder due.",
        "label": "Service Fees Remainder Due"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ServiceFeesRemainderDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ServiceFeesRemainderDueMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Fees \u2013 Remainder Due [Member]",
        "label": "Service Fees Remainder Due Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)",
        "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Closing Stock Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (based on peer companies)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk Free Interest Rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares of common stock (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic Value, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Shares, Outstanding Balance",
        "periodEndLabel": "Shares, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Options Issued [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation amount",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded shares of common stock (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/TedcoGrantDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r384",
      "r403",
      "r404",
      "r405",
      "r406",
      "r409",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCompanysMakeWholeShareLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Make-Whole Share Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofBlackScholesOptionPricingModelTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Exercised",
        "documentation": "Weighted average remaining contractual life (years), exercised.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Forfeited",
        "documentation": "Weighted Average Remaining Years, Forfeited.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeited Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Granted",
        "documentation": "Weighted Average Remaining Years, Granted.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "osti_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Years, Outstanding Balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SharesAwardedParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharesAwardedParValue",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded shares value (in Dollars per share)",
        "documentation": "Represent the per share value of awarded shares of common stock.",
        "label": "Shares Awarded Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SharesIssuedForPrepaidServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharesIssuedForPrepaidServices",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for prepaid services",
        "documentation": "The amount of shares issued for prepaid services.",
        "label": "Shares Issued For Prepaid Services"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SharesIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SharesIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for services",
        "documentation": "The amount of shares issued for services.",
        "label": "Shares Issued For Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balances (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor amount",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r78",
      "r834",
      "r1164"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r1078",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate of working capital",
        "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r286"
     ]
    },
    "osti_ShortTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ShortTermLoanMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Loan [Member]",
        "label": "Short Term Loan Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SignificantAccountingPoliciesScheduleofPreferredStockandCommonStockEquivalentsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies - Schedule of Preferred Stock and Common Stock Equivalents (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofFinancialInformationofOperatingSegmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r124",
      "r197",
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r238",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r265",
      "r269",
      "r276",
      "r277",
      "r503",
      "r506",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r789",
      "r793",
      "r794",
      "r801",
      "r838",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r132",
      "r133",
      "r134",
      "r156",
      "r160",
      "r187",
      "r188",
      "r191",
      "r193",
      "r199",
      "r200",
      "r242",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r329",
      "r330",
      "r332",
      "r333",
      "r335",
      "r339",
      "r342",
      "r343",
      "r346",
      "r349",
      "r357",
      "r568",
      "r668",
      "r669",
      "r670",
      "r671",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r700",
      "r721",
      "r743",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r994",
      "r1057",
      "r1059",
      "r1066"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r49",
      "r50",
      "r115",
      "r122",
      "r123",
      "r139",
      "r140",
      "r141",
      "r165",
      "r166",
      "r167",
      "r170",
      "r178",
      "r180",
      "r182",
      "r198",
      "r243",
      "r246",
      "r268",
      "r327",
      "r359",
      "r415",
      "r440",
      "r441",
      "r448",
      "r449",
      "r450",
      "r453",
      "r513",
      "r514",
      "r523",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r544",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r579",
      "r581",
      "r592",
      "r629",
      "r653",
      "r654",
      "r655",
      "r676",
      "r743"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r198",
      "r329",
      "r330",
      "r332",
      "r335",
      "r581",
      "r609",
      "r666",
      "r677",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r781",
      "r782",
      "r846",
      "r1199"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r198",
      "r241",
      "r329",
      "r330",
      "r332",
      "r335",
      "r581",
      "r609",
      "r666",
      "r677",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r709",
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r722",
      "r723",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r781",
      "r782",
      "r846",
      "r1199"
     ]
    },
    "osti_StatisticsFees30OnFinalAnalysisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StatisticsFees30OnFinalAnalysisMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistics Fees \u2013 30% on Final Analysis [Member]",
        "label": "Statistics Fees30 On Final Analysis Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StatisticsFees35OnDevelopmentOfSAPTablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StatisticsFees35OnDevelopmentOfSAPTablesMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistics Fees \u2013 35% on Development of SAP tables [Member]",
        "label": "Statistics Fees35 On Development Of SAPTables Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCertainFeesandCorrespondingPaymentAmountsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistics Fees \u2013 35% on Electronic Data Capture (EDC) Go Live Date [Member]",
        "label": "Statistics Fees35 On Electronic Data Capture EDCGo Live Date Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r896",
      "r912",
      "r947"
     ]
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued warrants",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "documentation": "Value of preferred stock and warrants for common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "osti_StockIssuedDuringPeriodSharesAdditionalUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesAdditionalUnits",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period shares additional units (in Shares)",
        "documentation": "Number of shares issued during the period additional units.",
        "label": "Stock Issued During Period Shares Additional Units"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment shares issued for Equity Line of Credit (in Shares)",
        "documentation": "Commitment shares issued for Equity Line of Credit .",
        "label": "Stock Issued During Period Shares Commitment Shares Issued For Equity Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesCommonStockIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedForServices",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock issued for Services (in Shares)",
        "documentation": "Common Stock issued for Services.",
        "label": "Stock Issued During Period Shares Common Stock Issued For Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Convertible Notes to Common Stock (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r46",
      "r49",
      "r69",
      "r313"
     ]
    },
    "osti_StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Preferred Shares Mezzanine Equity to Common Stock (in Shares)",
        "documentation": "Number of shares issued during the period conversion of preferred shares mezzanine stock to common stock.",
        "label": "Stock Issued During Period Shares Conversion Of Preferred Shares Mezzanine Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Warrants to Common Stock (in Shares)",
        "verboseLabel": "Conversion shares (in Shares)",
        "netLabel": "Remain outstanding (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r45",
      "r46",
      "r69"
     ]
    },
    "osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock for Patent License (in Shares)",
        "documentation": "Issuance of Common Stock for Patent License.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock For Patent License"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock to Investment Advisor (in Shares)",
        "documentation": "Issuance of Common Stock to Investment Advisor.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock To Investment Advisor"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock to Investment Advisor (in Shares)",
        "documentation": "Issuance of Common Stock to Investment Advisor.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock To Investment Advisors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for Services (in Shares)",
        "verboseLabel": "Shares of common stock",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock IPO (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r46",
      "r69",
      "r668",
      "r743",
      "r761"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for Interest (in Shares)",
        "verboseLabel": "Aggregate shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesPreferredStockSeperableUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesPreferredStockSeperableUnits",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold aggregate of separable units (in Shares)",
        "documentation": "Number of shares of stock issued during the period, shares of preferred stock, separable units.",
        "label": "Stock Issued During Period Shares Preferred Stock Seperable Units"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Common Stock to Investors (in Shares)",
        "documentation": "Sale of Common Stock to Investors.",
        "label": "Stock Issued During Period Shares Sale Of Common Stock To Investors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCommonStockOptionsIssuedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r46",
      "r69",
      "r390"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, split",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "documentation": "Number of shares issued during the period as a result of a stock split."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r46",
      "r69"
     ]
    },
    "osti_StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surrender of Common Stock Investors (in Shares)",
        "documentation": "Surrender of Common Stock Investors.",
        "label": "Stock Issued During Period Shares Surrender Of Common Stock Investors"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodSharesToInvestmentAdvisor": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesToInvestmentAdvisor",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock to Investment Advisor",
        "documentation": "Issuance of common stock to investment advisor.",
        "label": "Stock Issued During Period Shares To Investment Advisor"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment shares issued for Equity Line of Credit",
        "documentation": "Value of stock issued during the period in commitment shares issued for equity line of credit.",
        "label": "Stock Issued During Period Value Commitment Shares Issued For Equity Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueCommonStockIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock issued for Services",
        "documentation": "Common Stock issued for Services.",
        "label": "Stock Issued During Period Value Common Stock Issued For Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Convertible Notes to Common Stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r49",
      "r50",
      "r69"
     ]
    },
    "osti_StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Preferred Shares Mezzanine Equity to Common Stock",
        "documentation": "Value of stock issued during the period conversion of preferred shares mezzanine stock to common stock.",
        "label": "Stock Issued During Period Value Conversion Of Preferred Shares Mezzanine Stock To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Warrants to Common Stock",
        "documentation": "Conversion of warrants to common stock.",
        "label": "Stock Issued During Period Value Conversion Of Warrants To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock to Investment Advisor",
        "documentation": "The value of issuance of common stock to investment advisors.",
        "label": "Stock Issued During Period Value Issuance To Investment Advisors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for Services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock IPO",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r46",
      "r69",
      "r676",
      "r743",
      "r761",
      "r853"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for Interest",
        "verboseLabel": "Share value",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Common Stock to Investors",
        "documentation": "Sale of Common Stock to Investors.",
        "label": "Stock Issued During Period Value Sale Of Common Stock To Investors"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Surrender of Common Stock Investors",
        "documentation": "Surrender of Common Stock Investors.",
        "label": "Stock Issued During Period Value Surrender Of Common Stock Investors"
       }
      }
     },
     "auth_ref": []
    },
    "osti_StockIssuedDuringPeriodValueofCommonStockforPatentLicense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StockIssuedDuringPeriodValueofCommonStockforPatentLicense",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock for Patent License",
        "documentation": "Represent the amount for issuance of common stock for patent license.",
        "label": "Stock Issued During Period Valueof Common Stockfor Patent License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share exercise price (in Dollars per share)",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r62",
      "r702",
      "r719",
      "r744",
      "r745",
      "r834",
      "r854",
      "r1055",
      "r1059",
      "r1060",
      "r1074",
      "r1145",
      "r1202"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 DEFICIT",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise purchase shares",
        "label": "Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares",
        "documentation": "Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r341",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r356",
      "r359",
      "r520",
      "r535",
      "r746",
      "r748",
      "r765"
     ]
    },
    "osti_StraightLineDepreciatedOverPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "StraightLineDepreciatedOverPeriod",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight line depreciated over period",
        "documentation": "Straight line depreciated over period.",
        "label": "Straight Line Depreciated Over Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r601"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r601"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r601"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r601"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r602"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/EquityDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "osti_TEDCOGrantNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TEDCOGrantNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TEDCO grant",
        "documentation": "It represents the amount of TEDCO grant, non current portion.",
        "label": "TEDCOGrant Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofRecognizeInterestandPenaltiesRelatedtoTaxPositionsinIncomeTaxExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "osti_TedcoGrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TedcoGrantAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TEDCO Grant [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_TedcoGrantDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TedcoGrantDetailsTable",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tedco Grant (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "osti_TedcoGrantDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TedcoGrantDisclosureTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrant"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TEDCO GRANT",
        "documentation": "The entire disclosure of Tedco grant.",
        "label": "Tedco Grant Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "osti_TedcoGrantLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TedcoGrantLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/TedcoGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tedco Grant [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MEZZANINE EQUITY:",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Mezzanine Equity",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r329",
      "r330",
      "r332",
      "r336",
      "r426",
      "r428",
      "r623"
     ]
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Proceeds [Line Items]",
        "terseLabel": "Redeemable Preferred Stock, Mezzainine Equity and Warrant Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332",
      "r333",
      "r335",
      "r339"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate liquidation payment (in Dollars)",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in Dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized (in Shares)",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r332"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued (in Shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r332"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding (in Shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r332"
     ]
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock, par value $0.001, 2,500,000 shares authorized; 392,500 and 1,775,750 issued and outstanding, respectively",
        "label": "Temporary Equity, Par Value",
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "osti_ThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ThirdPartyMember",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Party [Member]",
        "label": "Third Party Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_ThirdWarrantExerciseInducementAndExchangeOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ThirdWarrantExerciseInducementAndExchangeOfferingMember",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Warrant Exercise Inducement and Exchange Offering [Member]",
        "label": "Third Warrant Exercise Inducement And Exchange Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1151"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "osti_TotalEquityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "TotalEquityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity value",
        "documentation": "The amount of total equity value.",
        "label": "Total Equity Value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "osti_UnallocatedCashProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "UnallocatedCashProceeds",
     "crdr": "debit",
     "calculation": {
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unallocated cash proceeds",
        "documentation": "Represents of unallocated cash proceeds.",
        "label": "Unallocated Cash Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "osti_UnderwriterPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "UnderwriterPlacementAgentWarrantsMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofPreferredStockandCommonStockEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter/Placement Agent Warrants [Member]",
        "label": "Underwriter Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r201",
      "r202",
      "r203",
      "r204",
      "r612",
      "r614",
      "r785"
     ]
    },
    "osti_ValuationCeilingsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "ValuationCeilingsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ostherapies.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation ceilings (in Dollars)",
        "documentation": "It represents the amount of valuation ceilings.",
        "label": "Valuation Ceilings Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValueAddedTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT total",
        "label": "Value Added Tax Receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "osti_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability [Member]",
        "label": "Warrant Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "osti_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.ostherapies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "documentation": "Disclosure of accounting policy for warrant liability.",
        "label": "Warrant Liability Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofCashProceedsandChangesinWarrantLiabilityintheConsolidatedStatementofOperationsTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability [Member]",
        "verboseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r843",
      "r844",
      "r847",
      "r848",
      "r849",
      "r850"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedBalanceSheet",
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails",
      "http://www.ostherapies.com/role/ScheduleofWarrantsLiabilityTable",
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant Liability as of December 31, 2024",
        "periodEndLabel": "Warrant Liability as of December 31, 2025",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Warrants, valued",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.ostherapies.com/role/RedeemablePreferredStockMezzainineEquityandWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price volatility",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails",
      "http://www.ostherapies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable term",
        "verboseLabel": "Exercise years",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "osti_WarrantsExercisedAndProceedsReceivedSharesPendingIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "WarrantsExercisedAndProceedsReceivedSharesPendingIssuance",
     "crdr": "debit",
     "presentation": [
      "http://www.ostherapies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised and proceeds received, shares pending issuance",
        "documentation": "Warrants exercised and proceeds received, shares pending issuance.",
        "label": "Warrants Exercised And Proceeds Received Shares Pending Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "osti_WarrantsForPlacementAgentNobleCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ostherapies.com/20251231",
     "localname": "WarrantsForPlacementAgentNobleCapitalMember",
     "presentation": [
      "http://www.ostherapies.com/role/ConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants for Placement Agent \u2014 Noble Capital [Member]",
        "label": "Warrants For Placement Agent Noble Capital Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.ostherapies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average # of shares (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r193"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://www.ostherapies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume-weighted average price (in Shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-7"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-7"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001213900-26-036629-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-036629-xbrl.zip
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M"U05;,G!8[E2J07Y#\8@/BM9X,.O8G@T2F *;Y2A3KF,"U*A:9A&<9C@@8Y
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MUR]S'\>?]0B>E""EU))+BB^U[-"T(XF^"1_#+2VQ? @'CL:;#KY/O?%Z(;L
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M0E;7/ 0NA"^H?@JA.AFH;(X_H>CC4 K"1WAL" 8@2"@RN!DE#X:,7V Q-3,
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MSTOY=-^GP"HB/I'J#(^V_11&6-:Y*825K.7^*9#(S'B&\&R9;#"X =F@^MG
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MXJ/5;5U1#M$+:BZKX!91G\FI6W=BN3H=(Q.,4.4>R^*QKO%4?5(0<7=:?-2
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M>O.S2ZSGDJXT03S#U+) -2WH 3[-\M(+7WCQAWJ-6F@"!SZA/GO'B%+(L3L
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M'N%:C8VXC;G91&,Y/,RD]!M&O5J>B^17HER=P!-@$=T#.'^Z_XRC3]@:DLH
MJU*;"!DLX12$A2H&QEHZODK5'M?>S*I4=B03OS)>!J^Y0II8WASPT]PP+OH;
M)? P:W8KD(E=I]JK"Q68'C,Y\"B1%28@ (=)&,\*S"68L3-#9^& 3FQ:6@ZK
M#A/]4R?>8(D.J0,>3\*U]N,\K$95@@HJXJ=(9P0SO(EM.XATMR$80%E5B,:A
MZ?<(0QTWJU_K8/=PX S9#!RT2>A(\V /679*T4"P^8HQH9?'2)S'K2/:=N"#
MWQ*>ZLPU,4LG6+HE7:.I:"I.QPF!'[#L"BFS,;HRS^/(Z4I/5].2K%/6[4S,
MEK/?&,&T!1%)-2)3]A!'>"#$V_C=,8R*M]>9)B\F2UG(/6XS*68UB6UA>/?W
MBB.@6/*<*'<<QLS_S/^ $Y%*\'(]Y%&;^5AB1#730Y(XAQ^:?)F4T?$ L'(N
M@J4CI'W/E!K;:K5PE,U+_^A5(??0@.T@#^@T)E_"#DQ1'F$0U3\'9^ :5+DA
M9X4Q@>6 HZ\E%(=5\@E3?=$T+$2O881"8SOC2[!98O+O+2MM8.5%R@^]Z*_M
MP5PH_1G)\Y;;.*)2TGDKW,QF7+GNT97=+;^R9[*8)7GP._NP@1 LK=46-"PZ
M*>,LV.3T()EVF_A6Q&ISAJ6/+)K.4KQ61).W!7NK$PPQ!%YO6G_Q<1=4<[1P
MT;H4HF-8>1P)&&NE]S[F8$."2]XASAQVA(EN9R]K)^D5_%VZBOZYI.9FR,']
M#7)P&3FXNT$.WF<8TK7;Z\:7IK7+&TQ+>H"T>Q/)N'? K9-Z*(*!!,0@2)Y$
MA'Q@$=L95:$M&0);=6@K>;RKV/F%%'B-E]99,WP$=0W-.",<R"UG6L,H2U-9
M,(YMUIM*=!P-L-_4V]IH0W2 $)'CWH=* D(ION9J@WQUG*4>8NG48BQSEBXZ
MB6G@<R==]Z_%Q+T3,Q[0S\>G!URW\//QQ='ASSUE!G?<VJ<3/W*003!]42V?
MHN4K+83P5MB2#VQ3\Q&Z'+"6_>?/GUA8(#W7 0,1U#IC>*?0[-B'.+[@"QU-
M4^JQ3":(I?TA9*DIE9'?R3,'.SO/O6?B&[J'NMXPA0MV>[V G/(JB/N81#(0
M*=/&8JX1>)C:$GZ/]GB5@?PFIO>F=UF4:*+$GF85U?%XCACWN3<[*@B+(HMB
M9NWV@HD2":C9:[2[R9/BT )I#>1]2#(*>YG.6]@><21U[YCCAP%7#):3EAL4
M/5E^:[\2QD<,8$L<#AOB#B;UA"MHFU_3\Z1K?4X$V&E6VL8Y?HRBIYIRRMZ=
MS"K706$5&BF#Y3(TSB3%F?4!,<$B5%"ZEIX6Z:,HUQOD)R]-UEH$BX9 7(R"
MDVVAPJNEI *)#H.1D:=Z84&(]T<=W3NE=%SKY=>P' *T')R:.JG* D6@15?Y
M.[CU@+#.<>DH@47^;W9P!MS#[RT5S(98AM:I\XK!R++48@S?L00LV41GKD+
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MM2J-'UPIS*S'S<!?K9_[L^451E-1V]RS@V@;Q1\K@K:EAK D19O%:Z019M0
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MA#@:&XY)W172A-/%("V8)<7C8)O@S<#Y_N/@A55=2U1N5 *C]ZE.W&A @,I
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M*\K)]-O*QX9))'DE[4F$-S>22P;D'JB;B0T8P69RGD%EH!]^Y ?]W;F_FBQ
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M6C X1%9PB)+51<XM4$3^M,SLCL8AT0HZH88(2N)7(^IP$Z]Z^((-A?3$=2(
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MHQQ 81<BI/WQW4L**YS7/M2L8Y$(W^<<F7(,2\#I1$+WTY\OPQIRJAT1$VQ
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M!R;;ZV?H\D>+Y^&(55Y01J&Z@6ZZ-@2!HF5B\B'+(O 29"/L<3H99H&5![^
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MP#]K.(C4DQ\\96*C!T\?Z%[\2N>4WDF*^KQ:D<F>/WOZ&-LQ!H+>DKK)TOC
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M 9FCH7@-AL;\0<E[(1),OG_W\O7['V;;FVWOR!@NS"Y<JAN Q10[Q%4\^+4
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M76?HLW'/QGV\<3=(?3",#PQ1NHB(MM0 9P.;#>QX QM+#3'@)&V:7A ,_HY
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MZB/,P;PB^84%O' D9BBM:Y?U0J73Y#T"W/A$AM1\D?<9M1GRNJ_[0 JH'H>
M?;2<5":0,1G3@P ^Z=30E1M:0 F./1X2U(K*<+6]SN&]$ BXP=9RMOP@I!.9
M$QY?#;%W@7X$!(6.K8H_'1#=CNJDCY*.WA< 'IW<Z[0@&":F\66LY)JI& U^
MA@V$6DW:&T@]YF3T$:,/ <^\.0(&H'(H/7A.CRL8L9Y"\TB715R6T8=X8/\H
M]$'/U/O83'=&;X"&%\DWJ)CQM2[AS:$G'E+H*7T<QM?7C$3*FJ9:YD3LK0PT
M>3W@TATLV1ARPU]ANAK'G.NG#E!PF@:34V/11V<H.8;#6/7J@[4[^K0G?&C
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MQ#L=FOG$:]&,(P QC6\9T@O, YH[5[FZX_5@H"N C&(?0.^#[<3O'V2X7(B
MA<E-K]:GI&B88"2NV. =?U]Z70[2>ZU1"8Y<?BYCV<AHQ29I/^[R?EYH@N8.
MWG7L%G"25%0T\(2I\'/+*BNE<D*3$?3R47U#! \RMX/R,$$(\+O&\-3/8\E6
MFIJL">:SZ K(X"0MSVNLD4D'A ^!C_F:1"40<$@/4!NTBV!*8[&?D)#WN8O+
M0#PHQ6CRRF4@-+KK+"_HQO"Z[E7/,2CWJ$U/J+V;(S54TM!J@O%2I6RK%D4T
M6,I:)SAU-8"O!-N0&9=I".@(D#VV1#]PZ7Z'A>]/'+<)YL'<'3A*@V B6UG^
M]6[$UK6/+@)8H_.V<+E9P8TL>@\JTD6\Z-R*CQ])[#?P?NL<LQ[8P!%*N\QW
MY!_A%L"DMXV7=.1FU!PA.MQ/4!3, J)^<X"HWVT(S;&B0FFO6AW)K:7.JG#V
M?_DAN\(?34@.D#KA!$Y*:HN("OI& Y<(":5\HH5\@HX#CKARNQHL;\CW/UB[
M<VS "B4:6:7PO& 5T197KHRNV0DSI+"BL;%I*HF"5TUD0AS6M_5+IZ==%/:,
M^;+Q+IM4F1 $B 1;RHV%J\Z:P''0BLEIVR*;7_[I]5M>CG]Z_M9K'O0)2W2+
M4VX3NB*';29M@1&?Z+_G,$-WGXP1=2JLQ/5\"U($:A&NU+21G)&*NL.-$I6U
M[ZM%./Z%;K0B3%'U,9D:JA*YJQ2;6<8R>'L4-0=DKRPTU7M91KBE@UY[1#K\
MGT,E*AI?[.IK"R;'\04$1E69MZZB[,R#T/+9T@E!X1V>)G]F+&K>$,OOGDAI
M<9>HNJ9 -MP/)60E/=_'O:_P*J.51(\D]IU..03?8<U5)29==\YT4@[14#U_
M8I431"\OT"CNYN)3@:7)K@=/$!Z7XFFPZ'#5S'RZ\TS[ 6:<(#(1C^(7\,!4
M@[66AM%+\/L^X0(9M700<.AG)@&9C?1((T6L$28,GL*1_5MAVU8\*I(^DP'/
M(N.SL7VF1UQW3:RLYB61#4IZ]8I/HAH"OPB8O;3 $WT.%0:I+-'Q5L\288U@
M<R%,J98./D<>$[Z*R:H/*F=SGLWY.'-F2)/-_]:QV@RBJTK.%ZO:J+%3G:%6
M7<Q\BTF55 _H)[;'68Y[-L%/,$&D1"J7SE6JA3$4!XD_E_EU3JH,RYHZF84O
M>LVD1Y^/#+F8D2$#9,B#LQD9\H<U?^E28F?Z_,F/C>OG4 = R(6I<^C+_@$O
M90AD<VCR;,GC*4Y16O"(*A?M8(EC[8^I*N^(\A^I1$G3K4'1F:H.$<FK;-=Z
MAF;J6SD^C7YEGXI_JVJG$6-)H[WQ9URGRW +4<Y,/4@YIXZ-A7?F*Z6NK5E4
M&(>6^S&\J%8Z\7,1;D<[,SR9*56U8J^JL+',JA=DIW?GH9],U&8E8A;X */,
MZ3/WJB/WEO9-ZL.1\#&76Y@!)="T-JII3;VS/@7WD4)E:"ZEQ1IE5N=\GI5H
M5DOA1R^&M!D8!/V;7XHN'9G2J"UG5E:&IL<>"QX:'TUN:S,F^/VY#T>4] :W
M?.@$J?%M/K_R(SX^P0.EVH6?:+DFRD9S/'??W.632QA?3DB6."H0?TP[C[Q8
MN1^:IBKO\,N-#'70?3)'G5+Q)^%B7=@#ZY5.[H"(DW9L1NSX-'D/.V.!%QW-
M"A,OD%BUT^[&6T .])(:SR,/MK[S.AR3T\V4$(<0!,&W(KU7,!@XATUO<1AW
M7,?'O)D09^K\%J%_/(#G;L]%+S?6^33."YVPJFO_87),P],R?7#$3;8/[KZG
M"MI7SEO'&%M1& W8\0UKPQ+^KVN73*Z&_VQL=(7:7*WTJOH.>_Q.XON6X^H4
MD"JZJVBI1E&,Q,3Q ND:R[!!Y:?:6.4=@;L-GA6;S!(DIK[3Z!C*N$^)C=BF
M%6X"?*+W?F+AM0H19Z5,7M-2BY"OY$L6.0YZ;4H4H=ZKDC%^1>;%Z7U&3+9)
M8]L%Y)D-ZZ6V=L+2&9/HN7T'ZUSUC_G[)O 0CD)0(@P4?91YE@CFAG];P_W
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M1%$?P<;Z&W7UE#X8K[:1IA .]5K5S%AD3<Y%OA%:G@,#3WKS-,_L]5E"]=L
MBLDNM0S.B/K.?+V&IWH+-(VNI,G8[_,?!"JTL7[H-Y"W$M+QJ9<6Z$CCBI_Z
M6+^W3JWU[_/PY.&TM)__700L&WEYC23E5_BJZ;:0!_^J)*$<5HZD[A0>>M?5
M39=QS>E/S]^&N5)/3<*T/8*J 8=#2.#M%T:@1-L0+'$]+A_>(Q_853>6)Y8(
M68IH+-N>)CB,?TBJP(_;RQB[,YR8O#_2$R7?J0?5QSL"[NX!>5?5$CY<\D1)
M4>%54WE:L&9ZP CU*2LD>(^9WW!PL/"7PZHTH7J##HS?0;^!EL1@SYCT/K>@
MY92GRQM_>(^GIJ<R$5WG86?D).;D6GD<%RZ8AJ9N>H57/ D."3+FV3=:'2=1
M4*Y=6.7SI\T7-I@3G*_KM@P@1@"O0Q;Z,]QIMP^9PE3US LFB<2V!V</Q\_S
M\N#SO"?QV%%320_GJ:3A5-+%/)7TK1MYF'1(-.59TI0X@P<Y&PQ2J2&$0\*5
M%P"),"4CR4?M*!"P";5B-C>9:O93USCDA)N_C56Q!P<DDD4O;$U\%JK6E.WR
M5H8-RHE+\5\51ZEZ+14[4V(\+*PR'SAQ%PP087-,KL F88&9(O]@BQR"]Y6(
M+R[GT:>8^$#'3:0*H14AP]-N.-:<;YD]K=M599_60@TM=5O8.!'?Z'"U2MPV
MPHP5CIZ,$'9P]'^ 4R>D+\)C-10_XD!XLMGO*IJF<=.[1 Q0TU0<:Q&!C=NL
M7FY4TI$_*49K_(H2*29M0$Q0=XQ=E2A[EATI35* G344,K\)SP\1ZZ9:(1U4
M[B^W*_V"QQD'O1[F=9J^F%1O[^ 5J]3:!LD1X+52+(Q45>A>*+:S5&!R*1U^
MP$AG&3Z'E+$UQ>#!<MWB:$2[<<$/SG-S:J9+%Y(D7)_[4&=XF+S=>RJQGRP/
MK:@4M'IE1Q!DA H*-D2A]15W31-9ZVK9D1Y(YKX9FF#?ZBF_&Q\:HZ3#,9#0
M<3'\%^9/FZW,LAH+=F.B/,8Q=+6;!SS\E?;RQ7-FA9!D%IXB&PBG0^#HZ:;A
M9D)QZU-SB1L!!^6.NA=CE*O*4QC37I;3EZL=(H&[DK-!%J_B"[Q3[8XW(OY&
ML'OQ:*ZR25(Q09:7;%$1:X^N4><1Z#62@JELI"N[% UL/\S4T;8\OKU>YY3F
M!2=A964>:]5M5#08HT? U]"HRD?ETQK:S/E)./.A2<C U47F=&?"(V2Q('\=
M[O\:].PQ[M.\4.X&S)#O4!0;93I22'8R5!SG(4>+<JE" F/&'CDAP<BT]&FP
MMSX4Y#BSJA$_]M<N;S8DRTH7)/!>*@!D[4B$I#PAKGQ<$(1"\)4>D>[,JJ[V
M68$SK76-U7<5#Y0B&OS 89!+>3WE'H5-V0JAP^ C<+P6;X[LQB"]'$[P5D5,
MBC;.>>;OBI+LP5W=>V?]RO'1\?2NZN:A*89\QX2I88GN!3P\<:+A"Y!X7NTP
MUAD/WG#F&\:.B5#F_<LAJQPSDT:"A8$361*OC@#2*#1Y-]@@POP"B=9'UK(2
MPR"E:YOQ^B*22PR)TM[&M>FVI$4N>Q:Q9+&OIGW+9S;*1J,$4&4<U/#5W;79
M0HO23T$;YYQ[P=9]J:/0R5U(#J$"^L(ZB!3"S=5(+99:Q4QKUV] )%I?[V4,
M7&%'2BV;X4PL1IB"<)29]ZH_\ZY+1J.752?<8#2$;WQ#L[;Y=@$[.D=!@4!H
MB)T4[YYQV@/1:U%8[&7.66&0%0JHE/M0N,AICS$],Z!<&Z/TC\HE<)Z>G9W1
M[GV=KSHF4"@[<C-1"T:LPXO:NR-<G-$AKHIJ@5\+TD3\-O_:#%L!>"ELLM,6
MY\QLTEK[EK;8.ZJ'H,71,S03=L>5EC6TL05LV#GX9>H?"&.KFTSW\85_1MP2
M!*<(%R?%DTI8LFA[L&Z"0@B\925@DP0N9EGGK(01LPT3/V'0EQA#!:02_GMZ
MBWA-^1'Y'@D6?H<U=*O:K"&4J6[P"$$VQ]5Z#B-.D[=RBA+"<7#@TN7 H#NZ
MK+!!(]T-7*WM9N\8_CQS6!#6%5E7+C=$#CL2H^![H*)#Y&;2B!4@O&L*EN61
M:$T^Y#\C.5XGWHQ+9F,A4MLX3 5W!J4!XCK(T9C7@.@3X=QV"]?%A$+8ACCA
M?1W29-K.(>K,B$&75*A%&@7M!#( T8B(#55EE\>I*[LRNX8< H/7U*T C R7
M8'$BTN>,)Z2CCNV?U57T>:')X4IH<5/-'-GPWA1HR@>VA^&>H!PZ3KKY$ %N
MW*K#(%G:TRB.':.6#"Y!*H!=KN&J,X>S>)VO5A 4O\R:UC\0?K-++D:M:_A;
MW3&S()/!9%=EA860&*1'R1J_RWRRB$;1$"6TVNOD]5U;\$-T?@+_>2OOY6NO
M1CRL'"#(!<(WIX&5<(<B<27F44;>WI!A'LXA$V 0&"K"\9*-^>+LX@+;\\SO
MO,(-OH'G(J$6YK WW.&T*^RQASI$<'YU!.S-.!\T^M(X9V6$[VOJ=<OS)IP3
M&LN"@[J<0VHWIZ;$E]Z%>G^.+7#E,21&:G6E3$T4B#<@>W[-5/@4W#M)2U?9
M8O+ $;HM->/?/8SDCM*7"B#T;,>UWQ[-[;=A^^W!W'Z[W<P6SJY___@\..D[
M8JMZ9XF^&1W+\WY!Y"LD:5\U0WSIU6VF*_9'\N$?+1VC*FB$? ^#;<;.1342
MPZ)UK/1#OM@A+URLH7Q[><V0W#D5#%+!D/W.]0J/>+M@+&Z_C+&&O"$'^)5Q
M9%;*."1N2'(7DG O-[!#4ZN2-M\(.7EW23>B "0^&8'0X>UB1+6/2*\W^P;"
MADP09SXZRS!40)!48WJ)$I7:("! +TFWK2SLD%)F>T38^<-'(0W_(U\A:JUG
MV$>I7)C@P<>/D%I!OK##$7D8$4?4B,U,R#=/D!QD'_,R.\>04#9A>DN)9E\=
MD(52\K4O,BSV&G\?<!DRG5J63,!BF"A@8V.RTQYT+F@XI:'P@"MTTE%H9EM*
M$Y+B+\ 'K7/Q!0Q8A L-VH<NJ3;D8K 2/\\3SLOLN&46U+()J941A2V!<%E>
MUDCI$"Q-N"QTS]6BSYWVPT_:H&=SGLWY^%TCF#OPO7Y,'#AX/TJ55XU]ML39
M$H^S1-F=N1:+%7G41BFIK&X<M@B,K("?5T'ECZD#18FEXCF! )3"_0>OM%3:
M3&UXMM'91H_WEA[I0 DH&!K67E;&@7J.4^LF0+A^,L#0[5R($2P$_X%H1$N.
M/KYB9BN?K?QX*\<J!=Q]*8!T G@2)F^LXX_(NIHA2*[IR7QN:LZ,I!8!E758
MQ:$,CSKE"RM K>@8\LW9BF<K/MZ*:;B0V-@:&\$D(_E1K%%L%WG)QAP4#-@0
M";21@&/G.B,A,;@-@4B V3)GR_P$RVS -R)ZAF5.7=NF7)E0Q89XAY 56V9>
M"82L7W =?B47X=%PEG+6?OALG;-U'DN8Y2%G).D909UF>YKMZ9/Z$@%:3M(C
M:O :#])DB4_L05S-I<S9T(XVM#Z63[6)?7OZB+Q\-K_9_#[+_%2.T;'GF% I
MP@$2!L#NJ*Y#%$P"T@S@KF[$AE*:K!F'+?P(!CY;\6S%1^_6K@A?]\I ?M@(
MJS;97MB$NO:D6I_LJB5LXOPK)<19-#JY,F;\,R7EQ-CB775?HXY; BFC'[=E
M6%Z&T'O[5QJW)9@_-58\B@FG:AR":@"MVA,6Z<:3G3B87N#5%,I'ONK.56]J
MU"R);0*1V=N,Z"1T"OHT^8G5>;.KVEJ:I:@2H4X)_64X0M&D9@39%<Z&=(-)
M#H(?'H&?\X,,7/*TF0YZ-%H>C> K1N6,J[+8DPXNO:0XJ_)0%9Q #6O]?G[D
M33!ZB2,F<&DR03V&EM,*;55?9:6@8SG0#E>A/*%L >N72?0$/W-4^R)\P+U)
M%!D.U>D@DC\V$5_.O9KH_-4BOB^>Q'45&QR-<?QEQO.7,>[/,0<1(E!&SV0@
M/1P,QU_Q@(:H6RLMIG_DJH1*H_DSNC9 U]XZ<6]D ).?<-XDF_QJPZK-KNS&
M7RSI!1/7055<T_B.OOW@C7.E&=[U3B:Y1EAW^KP?N!^;6P^$R+Q;>.X::S^P
M.V2RH)XE.7%'6?GDW;?9?^/\733*2+JFX&7P)1!G!/$BQ)])@L\L\HK&SY%4
M9Q_^(5O"3J6DQWG;"0 P&$W""OQ2=:MDA*A;%%B;+U<X*'7-TVHR)1]YO^2F
MJHL5!%NPM[P7DB-VV_H<T1=Z1A6EX:AYBR5'7>S#I>>;5 CKJO%CL$HM#>>2
M%> &&V%YHX%=;B30Z&/$<K0@,E/F<@E8DVB3AUW=S7#5GB&3+8>EE9'-AUT&
M^A'66$KP(#5=OI, ]<>[]S01QPU./9X'IX:#4P_GP:D_K/F_%Z(?X@A&B+>2
M0QF9*FHFQHH.DSX1WRO3MO4V*TX49 )T./U<]GG:#/OI"!8>S(.H\Z3#7F)@
M_W\ACEW"!?S7R?9RT1 AKS1QX9NO7R27.+S:P)4\)Q>=/*>5Y'>5AAG PVV]
M@#\V2SB*@6U_M2\SV*C^.=PZA%0Y]N6$"%I2%+:P',.AI'>'4R!X-@PFX-QU
M5LHLM87]]\H-33'O;3A<[89935!H@LNB+9KXX'("(>OVU< V//, O?8L0#[@
M@&@BPTA#,*XR92QOE"-KGA0GMNU>-"0$U2[;@7>C'&*.4"<-:79"M'846OH\
MR?BP/+1O/2Y"'.LVIX4PR?65)I$Z31HQ-+:6: E293V@"?;^G(?C73#A)3NJ
MB9%J9=R_<<4((0%[C09=RU3V$GFY<M7*XR'O.%#$CT41HH%WV36L01XS.Z^[
M6DCK2MHG,\=N"K]9TK+2OGB0B](P598T6^2:"3EU@K4,$:+\&:&ER 9RTB"N
MSX>ZO+I1^B/D*@K3W^!P/6(1Y1H+2,8P;PB)Q"B<)PH5E@-!$9 B;S;"_DZ7
M<&I^&82O[JK4:NE 7<,FLZR[7$$&"5.-X;_^VL$:6N.TO@\W4^[-I?[%ZGMV
MQ(8[<J&E+5+CKF]H4?!,-'.Q95U1+=$/\HP.&KDQ/BJWH,F0T)(S">(?0>U1
MGOZIT0<BU84!IP\I+OX"-HU42T/DC>^]"\3ZT2A;Q=XX=G45N42CQR&7DH?!
MI!84F-DTORQGQCY!R=9( D05"%?N2ME[KNT-+S 29VBP-F1-R&^:TB%$NK"\
MMJ64M.C7]"66Z.1*&18ZP<L'%W!CE6_5KS1=)'('7%<+;PU7C\%/2/<FFKX9
M\8@:!^6UG)JN%_/"55!H"0X8?=%E;2.:I+C)AU<6+;(,^^25(_5)G,*0E'VF
M[CT@TD@XZ*$*(AV$@YX/-JYGR$2J\;)H;<Q4#([RJ%G8))J%I7?IB&<9 )K7
M;HPQ)1/"DJ8S@:5-B1-%2%!<49M*T\CU$D2:RA[3GRR(YX,I< S+#*ZZ,*R6
MWJN"Y5MY>U[8$=4Q.JP02_"$>PNS&(;,A1"\='54YM0C:/&&C9WI (;$EA7S
M-GZJ=,-<U/3R231K3AD8J;YNN/A3Y\T'9BCKOV!PJ57#;+*.:(/2/(X=C^H,
M@!-C/LF!=I#4,>G"#'P .T@NT,6+$UJ+:(ZGH:C@<^Q"&&GA4]B2B4KB*[NV
MY0JI%. TUSX[@&O/\FUS7*.(:3QQX A)S83ZF4W^X-) AL^KK%X5 E6!>\_I
M3$1<VN&^W;78,TN#-R87&,7&,TW W."?/.#*JMCYRFZ)/UHE?N["%3"RKF:D
MU&R"QYD@.<:]=KQJN^M:E[V;,(LNP1]2&(I-[BS)6IJ\J\K9Y&:3.\[DL!*R
MJK.;C)*%."(Q7)_)=]D\+3F;UM&F%9?]FCXYNJ$F.X:7PGS&@36&?%?9[,QF
MB_L$BPORAVU56JJ"(LI]1=;&E=?0J1%MLE1=9WGZV>0^#1:<EV'7,2S\FL^L
MU\PHX,$E.*Y]>EC2UE4$L$__\U+59154[1KOJO6L^%\/H2WBBESX3JA 06@U
M]"_H/EK/TDE%&QVIUO$:XI\<7@;JY%+Q.T=.;#R*"%F(<(!X*6*.IK),5(^)
MVPJC<#8DV>Z?%+OS<EVP3(N];Q$X*1-]*E(%[S_:Y-"C);ELD8IC3X1 7M)(
M)*3U%K4$W -'5\P\ZTR5YX_L=-FR.F^^6'_^:]>4CX)9/9EA5D.8U:,99O6M
M&WF?F3GLN V<FKE;QXPUM+F]2 A1FIL(%""Z<IU=5ZS./2*2PFH7=YD],SM8
M"DLN64?:5O4VDJ^:6RP!;CQ\TN39N9<X"J!)]?VDPX=/A5B/+[_&H!X!RZCO
MB"U*5JJ1X(M^%"BSD[!Q@QBNRURM#?5K,[$,PCUG= ;M%>>MRKEP'UC!:?E0
M("<0N$$&[QP5Q^#Y50@?@,<'B>^Z=;).$5PP;\P5PMQ$#D3%)+8JG>/Q3D/1
MG?20DDYP/;B51ZHZ@K8C%%6@9*,J5=QVXDOF(*7P0J?)F&2E]/ GX) C\C84
M&(2ZA?H.%UW+DS#N8OGM#&R))74&<CH$G.BSJ?>U,H:LZFP( H4;C),Q)BMK
MO7E=BHB=/N20^Y2T9W/2 >E-OM;@H+I=PG'AM6T8'XJ8AM)/I Q<GQES?58\
MJ2(&[CV0YX"PC!D7EBE@:3:B3L0^Q[FE"<V9Y',T9W =VX8T_$0=E34W;:W6
M^A^G[T^3%Q97A0*'_Y4)G/'R_I5:QO"4KO,EWUKM),>>OWZ?F@F!&N=3<"CG
MA(73<]I2V9W2I@>/+%:N256VQLG4G/#TA<C8J)N&6X)'ZLZ1T:0--6E)G4BG
MK]_"/24O%'8&.0<-9#!P%%*GW*'6'#REJ,JK$_! 6_QCQD^2\<Y.LX>05"VF
M7CI-1.]BGWB]'#.IEY-\OEZ.RA#3;"8M<G0,3BU+Q].KVC1HCN&<.BO[^%MQ
M $7*2ZM=ZVDY)?Y1_U.L',!3'LRD$MJ]]PEO8O<;)M)FF$C?J4P3:A1@<HQV
M+6(/< &B$Z7 M:EH4L%QS9AOCWC40GK7VGJ>]B$V*]2BT(DOH7^G?)TFKCR"
M*YH!.S5_&CW20<07R3ROK YG6D^03&N0'I2?3'8HO;X )DFL@4,5.)T<&['+
M^8KB#S@/NH$QS3MQJEA1458Z]\Y0]M'Y-AG@9=0<7X]'7<J<<(&#N *430VY
M WB.%"3(2,?_S]Z[-K=Q9-FBW_-7("9F(NR((D>2W^,S':&6Y;;FM$>ZLCL<
M]].-(E @JP54X50!I-"__N1>^Y$[JPH@*+MMS24^M%LD@7KD8^=^K+V6)(H+
M(X"Z<%<!=D>>H\;M]1WB_8%1KX64O]737\H<9_7X/SVG);L&9+F3G:4'8LC$
M[ !YYU:!N&RJ.^C&8:P)DL1$\S!]LR,K>F(M<]\"G:=;?^ASU<HIVX643.RK
M[7:\)%4RD ,._ON5;6MTNNR,+5&%7=6]EX.*3R;&GTBWP"^&SH)SW%5!S@/-
M*=)NN\H,A)QK8]=;DY:Y!21D>+U,5Z3]DZ06,T1I?LB$MQ,#P"E3/I^V:"%6
M1$VA$I,:=14''I->P%I0#@88CW[K_(PM( VRWKU%@-23YL(AR5 )JU?[07.*
M&CA9":IEV79)=!8 ;LSBKB,WL7?3A?DF;UF5=XD#.A=M8&('7:<5>9#3L@V7
MLQ_CW^E)"L+>7]=RFJ.S.'N911L?@C8(^9*225;@NVZ/>+K4O*W(5:7S":KT
MM%.0O[;=@7?O!2?>YW&XMA@51_N+9+<;7R5!&#,]7N.(0#K#.IMID @P+ XT
M/3WOOJ2]RG9')XD&LNY;Y@M>M7=5=P%C:%W8VJ""28ROT<8)4SF;;1NNHM^_
MJD!JPG[&TF#]O<0:EW'5;GU$D5)NZK-JB\05.=_-@N?1K!U3F5QYV75\-/DO
M88K#B25MX<D(R/R ?.@13XN<E%YE&QP;%/;, CPO%#RII##=3'V0=AG]N1GK
M!*=OVKTT(ZB4,$,];\C2RAG!X/WVKAD\W::C!OJY$IGX.F(0D[>-5F*UEV!$
M"E;W>);3X<Q<,I84[5KOI 8XX@_1"O3IS")8UQZ:XX2/0V <NY50HFRJ3AS)
M<\5F7+'Y^ERQ&5=LOCQ7;#[V18Z;_W \9S$P)^&X.3EJ.,YU$ZV;9*>;MI?N
M@WI*F2 \ST#5E%!YD29?M-)+',-A])%<9XPV&I+FR!O9W'G<[_MMM78)J+!!
M!@R9$D[#3R3^']3ZINKL["C@T>B C1&V70],,Y+?P&&(QPV##+LQI1U!2O2G
MAA:S%S(TM;FG3+) Z;P=R\(BEHE.=ES_&VH=UCXMT[H7?X=]*^UEQ*\R!4L*
M2IOK_C]FG]2?VI0(#CQS+;.&Z&_CQ^/GE7NM#R@B+! "2"ZF30 .D5W#E^*W
MN$ R1Y]BYT@8[!V,*9W^_DE]FVZ$]OSH22[>5=4&SFA74>,L_MER?^:J9HJ'
MJY7D.:*3\SS. HJV^H8\()-9UF0<I.HFI+7FE#_ZT._A)8^)NH;;Z FC^T\J
M=DRM^(("L?;NP060V7WECJRZ$7[+ZL;LONH&&?%C)8T@G=PGUC2NF(;0US4>
M4-V<C 8HD@JZFPN9$"U8@']KR\R8!X\-2H^V/;H6XV)>S,JM+JF5DNVEDGZ"
MGLV(U*4G5L>&NIBCK6"W8IR=X&-'#CBL9%5UD(-.0EH]^[)RR:.W#:]3G8JF
M2A8N49]9F0EKD /Q>3KH_,&/4J%4EA#N[BTS.W)12@B=(U/)EEMJ_$(%J*?Z
MPI*X15"F'VJ>+O(3-N[CO^](B;9<I1 >OZ8OY,=MGYVWTQ=SUW -O.E=@^^$
M=UB4E.X=)9R8N9/;L%:6[,RBY]D#H^>0TKSQ[<C%X\0K\0#4-VV[*&9-2<N[
M8&V_K1A))=\Y[*L;&4/2:-,'SEUTZ@4.S)) AB,1Q]9L9ZKF&HD'8HUMU."4
MBW*SE9JJKJ-I!TA%C1>LXC83XLCA9PQM10X-X\7:CCV'_(F6<=8RM*IW;,T)
M,9S*BFP^O=<DAX^'^RHK!=N9X*F#\22]8F-=\?>1)#]P\U?+(K>XA9Y":5E8
MS2^ -&=(B)1$ZDW,9UYN$OJ:EGC#&"1:8T1X[%B \G5 U5UN@]=;3$<?DUB:
MNPP G:K$HG^5D<B>WN2_U))@PX>W9Z1FVW<W";RVTYO7*4SX.3Q.S U"Y)T8
M23D'(6NL]2B[Z-UU93QK=G-6@6PD_ZE5#"[+(O$D:WG,[C1<HAPJ)1VJ:,&D
M1O=SJR;"@0N,$>908O90Q8MYJ&93.X?X;"FPUYW"*S@.6[3B=0RG3$*F"(=?
MI!#.*FLV@ _(4]Q$?]@XVOA7PYVY+M]-<7.-=F4<8#J)A*HP511>C6P'2.7B
M(=<S:QC>I(QC,@=EQ-0X#*97;$#!/5V=-6FD4;040F INQ$-$.J3O;#@_C9;
M_=%[HER@A%-2]^_(-Z# IEI@P82KN.QR"B?$_G?3*__>,X/YU+;@ Y=SX\/7
M:!;W#FCB8AC#)=52'C1>88ZJ>2+?*EF:#C1=_6Z=I,,HY\&),ZM0,GH5WI>P
M,0YQK<M)'.W 9N 9!\^4PV_28&8#1^R=]$1,<T;%5/@\[9QH6=1V<8,/=NM=
MJB9M"&%,>V,%88Q=HS":>B5M4Z#P5U*^ :<1#U<%:M':F)XI%4&LJR5SSWBX
M[)W2LJVHS%E[YAJQF7#5C?G+K.%@+1E/WZ/?H8*]2MU7=7,3#Q?F4\U21AE@
MY&0=Y\;VM"2&SC0\YX;:@Q=L!X7P9-6B+9 =;I5PIBGE#(#)AAS=[6=2@?."
M_#4=WG&E\?JR%162IEG)OC[Y%$DRB-S1^-D=P4VF%NXAR6\Z<<6J(L(XK]SS
MRGWXR@4X1&B<$S,P%E1@9M$6TA?( P]6ME/>F6UV(+4$4,[SH,9@&&SNQ /-
MN=7Z5ILZA1,:7C=SW5+*LG<JS#$4;ZK^VW!FWCBO[H>N[EU#B(B>*D.I<JGA
M1"C[OIW7R/1C_<U5DPQ\G]S!@3!RPEGPS1&/G81C"NWV4<#JOCG#ZL:PNJ_.
ML+I?73[Y8Y0M45M+U0Z7M0I'LU8GI*R'6'1+<;$6 /)/AB6P[@Q7V3*<0L@_
M2PP+_9BJ'"AT;A'@],Q=U0FG#"HSP!=\$&FQ(.X3'3$2R0G'<*R2\^"TX(<6
ME%0AY<K7PA;Q>BT _E6W=DH B9\"@XGZN0PFFA:D7K'=@E2'(3MHJAL70[FH
ME"1=UC-6&>(*:1RZ5H0QDQY$KD5I+*(GO_W47%D<OMJC?&O(%2D=HVPJL'=I
M@::<_ZJZ)E094L2\KABR4VXVJ^C%T @1\=+%NWK^[BI:YF*V[,K=0K 'N[YR
MS8JN$$YP@."@*XQ#X_TFE:24&YWR!;(LJ>\@+695S:V4*;_%G25.P$0E"#%1
M02<J44;]EB7'1U5_9GR+3.A-O9%-;-$S=;O.XU?:.)0'%5ZU:\ZQ3?P&RVTV
M6&Z9D$4 D;P* GAL7G1(XV6TB#$)B3RSS!SA@AO6A1D"F>%^I;^*-W<AAQ,8
M6CYXTZ6]/&8?2FA9W][$X&$5O') E P$PX4L%'!0]8C!N<#S&'XL'<>*"?<T
M+GG_W ]98]4MH<'C2>%DXBS[%!T'E*2L%S>>-588)[AO'*'&J4EEY#,B3?%0
MB'5 B_[H++Z9>NB)'2Q-<+K/>2*R'094&G<XZKZ>V,CAI(VL$'B(9,NX9*T-
M">Z5FR:EZK !T17(]>K,/V/:P(33?"O0>#S Z$@<0S;O>P<IP6107&$PXE8W
M2B:<ZS/GM,NQI*(NN^=T1/YO.2*!!J4%'!<OZH?]--[[78-%)DV-M&69VK('
MZ$]Z""@G*8T%I+4IC05B#836:M<(<K*(VR=^;LL%:-+#Y)_(SE&/[XTX9N_B
MGPJFZ 2(&H5B8@<FO&05K= JQ3_1+;XI>R M%U4G^,_,!HK)NVY;U,PEJ#*4
M*!8H-FQ(3##C36K=KG#HR]YAU/E?M="._?SVU8OG;U\RNAS$."2M^>S)MWXD
M\*NGW\:PH3?,-$-EJ0=;;"%SE((Y([[ ]D;T:VXIFR+--9(#%@P>A8!@-Z4#
MEH_5.617:"I7U>+:^I6E,P9O*O*I> 3F1;FM6\+>AGHKD>*RW3'; __ES/E]
MMD>_RAY]'W=P-7O!RC_/Y]O ;1[];!Y-")^2T6,A!;]5\K=SDCT[J?L8<E]Q
M*N.3Z)C-MN7Z4T#(X-*K#!(9FVB1=F(ZL%E4^MP,'37,]?0GL6(D@X2[81/(
M'XE><(GG)W^3?)3=BO:-Z!@M@6KC+G/1GM*W=C1 +8-UUN4[NCY?#B:',TGD
ME-ZV-7D_KC$+V23JXFN;:J\73Q>]G/UH#6BBGTZ/?5-!J0SK'FQT"?\FKGAT
MA:%CQB^@1CG4RX226Q"F%UA\,690B%(KQHIZ\2)]+P:7WXBOR)90+8[XB3Q0
MVZZBQUJ4Z_): JH\U.HN<(W@%@&C0\5L G-(PQ(-^8XZ7(EO<@8WE4NV&=4B
ME[KV68]B6E/$\4)T+G$M$GLC#K%U*VUTE@HI0CSS+M"CESY@O 2TMR^T<T%D
M:L^F\FPJ'V8J?WCUYLWSF=E$M80PBS"0B8E[">QC-=\A7NOG-]6:LZ*+"K;)
M1[3"KI41=QRP0)S?(H2@SXV1'5C5<?21NG2&CIYB?"/:7=0:AO2BYK+/N^&\
M&QZV&_3XM Q(.E]=CV+(TC*?4 30-FAHHXB!3XD2G'>SU_$TF;U1'AW9#9\:
M]_ Z.T6U;Z @66]2;YXK4P_3T:%ZLV+NXA102!^K/OI4' '$G-1]FAUX[>1(
M?U![;4W)IS7[!QW4%UFAFM\N.&9 &JREO!)BB!S_5%C[++45I,&>RO',/M$H
M*'VNC(<_1%WX'&]VS+M+QR8]7/S6IUSYV%;4?A$?\J;M-_5V*)K=WM%G;^J-
MM),[_MT8(E4$((!+<R4MZLZS.]N6LVUY\$G[_#F67TD) T97_?#JYY<O?A 2
M<3H+%9$UH*6W[G3'G1#:QM@L+<C@L@:U=:8TI,)>))-*O4*2CB;NR^N=;&1A
MX+ME+>EXSG=H?)76AJ9W/G?:".2\T]*+?C16EO&+FJGP?B]A">(^BI& \5%,
MY+C?QV%<5'FR6Q/8^[,DTWGS/7SSE=&I;:_;72_9-E<H"=,%NK1H]1NN],??
M=X&G])A[+T%^A4Q^N2UU:PG4@7>7? 9</G%;<3%@45.FDYD:]%0?;1*':=A0
M%^P&R0(0?5QIG_.<T6V.>44Z-QX[@&WZ$5X2)S(;PC(OKH;[H"$8XCW_Q95B
M[BN\J,XUNM\RI6MFLYDYR8RVVX=A!;!J;NNN;50R8$#29-2X*O=0.E[B0]5!
MSN4JLXZ>)6BYG.&\T;6D$"1JX:*7NYR] L5Q/*7Z&N"5).\Q<1OA@I:<\VC$
M'1Y$B[ANB%,5-D@5-M$O#6D>B,^3'A (CR&)4*?Y9DZ[^:RSYO*-CP4S*%UO
M[.:FF0YY;3^1KZ;*;Z9\29%U8=&V)-@71&A-=43 I2=SD9*] HL$)!_>Q[_@
M4"9K$=)H7RQW.$)/J2K@[GEA ?V&.W+15YI#!!_73AFGVN%8YJBK4/O!&W0^
M\. E!]_G2#&]=S?1\G'Y/CDQ@ZFBP$$7X]9Q_&>#'OJX4L> "Z8HO0].\2B
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M%LQA4P_2-.#865-O@E!UH!5Z!89[;<\HO-RY3?Z@E,IJ'"$KZ--'^QTA6[R
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M233!,T8!@X<[:9[US&?F'B4)'&1R7MZ/  T@I!6K/AJ\*T=NWON,E H[L(+
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M&\HPE,A)1\-5*]8CC)6U[VY:SGR7#"F1COD'O-QL\&Z9?-1HI=!<]-38M18
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MH8A^Z58^)$8:D:( I.(ZBC%?2]O;FCB/KQ_4/X.;GOV(/_ TJZ/]Y/KAHUO
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M^I42UUP<J\QG2V<="%K7R .&%)J0?2C27<4(IA2%B,<7?J&[[ ^?"NEVWI#
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M&C$6YT\6+1A#*<.PT-(*C(^4KK6LLUIIYL+96-*WKTW=GM*-^WZF)*(('7U
M"-"A/UFO]H.X3AFE'*NVI:4P7B63AX3H4X&:QC*SLHQX^8.70NVS[^GPD/DL
MEM@UI.N#3;]K./19X&A15UR<<FH7$#'SN'>4./:([^8<]Q02T,+;4>,_14EK
M7B)@Z':9)QC3Q)&CR[7M_"Z,Z]L:YE?[(H@7FZ]T!^4K):LDJXF(5*XK"<P'
MB5]G.L!562_C(!(24$ATF8'78BU=@+!CS/(2W=R2:'E 66:L.>BP OS/,L%
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M+75)@GF#4ZLZ0,WP4(ZD _PZP<&MI$3Z^VII?02;2^.DOU0MP359Z8#]#?0
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M^LG[3UE(NJNO@9;%D^8*%(>><P:4"$?FG^P_'2[7C#3\T#6XVGCP#L1H7Y.
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M*![!W[?=.CQ]<O&_B]DG]:>SI\7G3YX67WW]Y=%%T8E5(Z]ATM_/??P3G<?
M^W3L\\4O?G;YQ5=//W_V#;60\?7H>>F!GQ2???--\<6S9P]_X@,Q24A!;;Q%
MO,>7Q5=?/2V>??'D-[L%P\8JH%'R,$>0[;LNQ!/GLWC^:-<IY.*;GC$2;X@K
MA:[Q27U+D_;9-\^*KY]\\5M.&AN/P(?/)\3$Q;V".P;+NV_!@C7X',S)"08D
M?NM?GUY^]HTF \A;QN.(!-*$F=!PL!F(5G_J-O.C]/*>YV)74H2HB(D<@'DG
MG')*HL0U,EB*9I:(V8%]BN=V>P=UWWH^P;0]RCBI@EIV'T"DX EDJ_)PVD"
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M</$$!5=Q"!"2:?B4J-9GC+UST1&D$LI%TD75B3% $Q=!YU%P:C4:REUITC"
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MRTZU5G0*S2(Y\#^52DZI7'.JC0G!@@6U8.XV\;L,82$'3M!S2LV24ZQ4.)@
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M0W\_N3O1\@JW(7ZXJNTPV4(AYQ0\@J#RF6[C(DJZ["2^R.75<"$62R=)#7?
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M!-#PGQ;C2)H,[$CL<_?A 6?6AT&O=V)?^O*.R1'%!A0UMM1T)V[O22UQWPS
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M+=&@*60:$@I*.DDPQO>FPI-XMD_*$IIFF-;O6C^]+YP4/TPAWBX1AW/ T#1
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ME@/M59/'F3'D]2H8FAU-?^CF-:R*Q?+3>-2G*IR+&=RL/9L[=EF-_E&^2\I
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MEH6VI?^"F1+A2 8Q7VH05G8Q$<<DCMOK]\$;=--FCWL199B( +@.Q85CC[5
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MB59(A.I95KK*()LW$L::T>25$AR-,=0-O1ZY6W193^P;"9Q)?:#D@JD/,=
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MC$HD-&O%*.U88=5!J9# Z29X>"X4B_N(J=2.@LM*3V*!^S"BTD*IZ0P\ 'Q
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MGOXB12)#9=%<B)%@#-?B2:E<Y0>W9=N7+/;[9,<=T3'0C?%\PI) 0YH8K&T
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M@#VPBKMV*/X]\D)A%L_M.LI6REN4;>WR@V;5G@N@>O=<'L2USP?6,N8()9&
MLL4;FD>GY1W&&Z99!T-P>2.DS$=[- #[M.-&*;V%4]I:E=E@N]]=KT<M$\,
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M:+5%)/(.&:U^=%H\*6V<T:8@IVRE?;^M^7B+L :O D<%=J%(M\67+@3;4CG
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MC%,7_C"X+M_<O_R.GS\7_U&7U'%A$#[.*Q9I.42"H3PA$T'$'0-2S@]W3O.
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MM:S&D0B^)_W#%$46.60^ROP_OT,1$H)$D<_PM)#RMM03-WZ"3WPS",#"MWZ
M/7,)801/TJS0DT.1A=7R$.'0G['+HD0N"L@6+1J".V?80Y-HQ):_+?5\!6(;
M> 1IF?/J;$V@:PD#YD[)G,#EF%*UX,R<T^+$W[9'I^)CS!+(W.38V4\!@HP&
M#;^(QRP&:X]DATF:I$90U<"6DSR(ZN0#:)3VBS0I[-6/1=3I(NK^L8CZD,_>
ML;+ZC5=6'Y!D;K3 NEVNP+I5JG$A]I=3NA;>>2(*0%0M()X79(/0OZ[ ^GLQ
M'93QI4C!9K^1BQ0L:F<WU[3+=XSO_\P<]Y6XOG0.5'-D)8_C:#.YCH(8B)M?
MW)RC'[!X,0^H'>%&_:K6FOO7?)N0OQ7QMWPKAA\O3HRD*P?L[4#JT@!6N@#U
M]P4L7+$*.P8<;A:+QZ-W>%K@& W@V$R1;.!"<22C&X,+\1908"OA966@8.U^
M^5S"0/%B']@P]*BF\(H[Q1;G_L2@!"?*&RWJO@&5E61F&KCGG$PV-!'BTJK5
MC6XO'^*R'XQ>J=TI&G=N+(T[[ZG?YG?)-L^\W^] #?!2L,$S_OD/HO^(=?<^
MLN:=^EL1;3!7F_6^T:V_37A"I_%6%KI]<M[HU8Q6:W>0G<UT8[R96J$X8 =Q
MM"H "':[XYV3\ZY1;[>,9O-P46]%KX#FTBM@EWH?K)R9:1.1;VRO?W,#_<;W
MP2_:JURVWXI<=LF::=6-=OWMRV5KZW*YF7Z52QRDR*1?5*UO%CYT6AI\4PS$
M<? +L%I+=-^*ENBAEFC7&T:[EJY5W\@>;QAEM1Q3M0=<T!KR5*7_:P7^N-U*
M$P*A:T:SWC6:[>;:XG1HJ*\=[>Y;T17=&NJ*;K]A] MX-V\:JK:SJ'U[S:C]
M'M@:(MLE,PZI<>/<)L,<P46+:=>6(=GXX2L.9QD39",\_6 ^N2_4NR"#M0&^
M_,2&)O)R*GWC.-_1B^D0]:; 25F:))/#L1 R2X$0T2")@XCC;7QJ-?&P[)GN
MDR IP69W,\]V]#[/(1MZUEL(1"5P0R,M^4X,83ES"?B)%G,AD*MT=1TZIN\C
M>13QTD[8O_]M3I$KEW<JY-U]Y"!2=J7H\"<GP_L+Q5-&\M-XR,L&(VGPD#+7
M&]H^6_(U^5+>X\\,X9R;=+$[V,L(!:L0UVBO/&G/!:[5[4@,Y-:[1W5[)49]
MAX..?NF+W_KU9<AS.'M96@\K",[JZ:+M&!!H))N(O+@.Z*?3%+ ML8@I:F-5
M:.3VKLHPM]J)E4+OZ9,5>I8Y3R2;OQ&:[G;TZ)FHCB_-^<+T&GAE+RI6[)#$
MH6_P>=V>3)B%S94<ZH\Q9/@K+7$N!*$PWW7><<['XVW[8UP!500GR'"$_&F$
M\5LM&HG406<]T8C>>#LBJ2:]ZE](N%VV&&0)0//DO'G6[M9;C7Z:EC:)&D21
M4)+1^,.EA#2&MCIM4L'HH_GR6,DE81?O"+:HK@!?F.\P[^Q2K:R%P"!R/]M3
MH)8[,90Q4H;+=0SI# 5E*32@H: C,X7&$(25=,8%_67@KE[+5H44U);6LKTJ
MUZ2LGZH7#H@1:Z-&4&=-(ZB]CQY^Z?.KFQH5O.:JL7:%--&6Q*^S/!^T1/CX
M@57,&14A'<:).L[>%27KS&=.D<[O8$/VE:8'Y"U;A:3/YK0_AE'K#:.6I?3X
MYS5A_-HT_BD;)AG[UFE;O34M=N>Y0\8L'UW"&V&YWO"!W-$X9%_U0F5Y72Q,
MKW57BH]8%##_%H3!SU@H,E/O;NZN)/<IK(>M^!+H"M "2>[W@R5^WX Z[*ZI
M#CL[[A@?5T,LBG;PZLJC'OL.O/5 E%R4\NX;VI@YL*,A^#:-)@K*WT(P,.NU
M2+W"%V6G\3[^_H'- BX/D0J6;Y,%)J]C-WJSI/*.2+^E%D+.06:_P >F[%6+
M?LH[X$TSO)[5#DSSL/V7/IJO6=HK\E^H(0==94:\1GAP0V\XQDX7J]5TA4QM
MYORERQ('M"[ I636Y_GB4A15XKW:JASMR@LO%B8;&R<*(G-TT+ C3.9JH0AA
M.QJEDHF_X? 5UEIZI[M;O?./C*,.OM;I"(T/2XN=!5\MV%JB0)I"R\37;Z03
ML"/F\[/'GD7#YM7"GRB4O_EV74C\R3,726Y:XL*"7#\Y[S>[V2[83&3-EX@S
M=3VR>!--#-%H?.%RYE<BW5U^=L28W#)J&0GKA=D9V* !?4)N*)AZ04N\LX'I
M%%<[S54I^&A&4HD<R_0V7BG7.%;*I2KE>K5CI=PAB_^Q4NZ-5\KM=94V6AO7
M*5<;UUZS^>BU:7NDIK_&#3^XT5F2V:/P Y5:NG9]ZQP?."Q^'^G*P-YF#[7U
M]TP2?Y39[?UU61.=?B)FCEZCIBW=RFR*#_B*9-^0:=XX.88%C2,/I/<5.U3R
MCI3X/.KR@R]YH9>DFPI9;&3'/864CV(8@Q+L9A _^2PQ _YE>)#Z!I_'/NR
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MSM.5X_F0U=_66< B]T>OOK5;LEWDEMSD/,K<@YW5]^#.Y;1^(#=8-_,&V["
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MR,V!($,JM#W=/#*DW3LB0X[(D",RY(@,V0LRI%^! FFCR)#^R7E&J.'(^G$
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M"]4T9 +"N\]TN#<$Q)B@(!SL3"!AA'K,M1DZ'1SB"N/PF?C:8_1WGL #-1;
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MZL>(<E%MH]'KK7N,=LHRN\.W?G-C YDL8V$EH[N#O8^:4=N&=!19C[SX.&?
MO51.'B5B0PUA<O,>7_AL<*VH0UO4@T'X.Y)_8=&[,;2H[TOTE1P:2?S:&></
MC;\R''J\8$E2N8CVB[[B)>3G*LJR-,B("XYE((<2<;S(M2PFR-GMF\1TB,1+
M9XF(7901, HP-Y1-&F]RAFVX\?I&K[7>-!7A1-^/"C3A);&PR!A )!3Y^UTA
M,Y7D@_P>CT.NTIW')G8X 8U&'Q7,KI27_<:*U64V,S-$(B$$%V[ZY+:UY5FA
MG:H\C%#N5MT=+)&-E$L9QY%AH3P.BGJE%F4+1"OKI2:;&&>K=XQF!@U=K$^Q
M^2>%UWC[G1A\8 CRX5@0XXX/<?.2G-E78>#8%+]@LXD>>[]E]+O=%0O!;U>Y
MK1JMB\>P$["U9'WBQB^B\E)E?MY9P\9=<]DD4@/$K?3JV4AIB.*RD"KP,W(%
MGSW7_>'8TRA?@/'S'RS@6(<+YKF^FO5BWHL]Q%'>3(=GT02WF8=^#V;EZDXN
MDE['C*YC, "C?=,7]PU^.1/$%#GZH%&!9Z8B4*.)#!CU1A[Y3EXK&9PI'G))
M%!O* X 5^%%>)Y%BT)_8$&8B=0MY\"M!I8UDH=&ISX:?K-"SS/DZ'M<C\R:)
M%6C58 5ZM46$E0[/]04K*5'O27O#$!1JONY.$[_I\ZMA3-W2]84$23ZU3J,"
M*7JFVWPE1G"' XA^Z8O?^DO[E68SB[0PEG.69=?.P$RG+QPML:UJIMC@:$E)
M3'09C;W-Q9,J^7'T"#EM*'I+)IABTX?X+T"PU:.)UUJ. %>AB]F85=-JG)PW
M^T:_GHZ5*/W.\\YB60J?Q)E;\X U5QPP/G31I$)+&F=^^.03K"EPYH*[DY-!
MYLRQ@H.8J6\BFK.(2/<"I(A9G^>+JJ?P7B)\M]TQ0(Q7;68I;5NARR()Z^V,
M1PF4_2:J(CAF:^Y[&R9Y5L\(]RN430H-^RCT>//YF*75I+3^BVUQ YUR\)EW
M+F]MLN18+[EU6YFW[JOK67ZZ?&.]F[=S<H[X MZB+W4!$W1A !OJZ'T> )!L
M[ZG(@!%/< VKZP"RIJWN<@G7(GK7">]6Z,;/?T=@"')]%JXZ@J%P9B<T(;/N
MMXW=:B42:*)K@^@W(,_$5?S>PN*![7*;1K^]4O_EJ;H*S8-V85CV<^\]@\.^
M5EQW6OYUM^FLU.:ONS9VVFT9O5I&/&8GNZTZD+2YDNA^O1UMUPO<:# \-^=:
M4WH$)&XSO])]UMO:?=9NK+K/M+7NLQT+<XFKJPWV:KMA]+HK@ J[O[MV'?9[
M&+M><(JBH']QP1#=R4OW6J U%7!2.&@.GE(U0):GFZK$O7&A<9T_NYY'S([%
M,G)M]"&6=6IQ)4JYJZ;?L&D?<@B:,-@)AG3P!X8^!*&>)SJ0@S8NGH);5Q6+
MZ6*"[1]$.,:L 0?6J@W:"H*+V^!DI!WBWR)ZS= 7"6[0@]1*4;0_1%MZYOK8
M'W%QXS6U@4'.QC>K$&F7W?@.FM;+-Y[X21N]K6Q\O5DAF+?IK>^NWGJZB//W
M7TLV4"=4-\<@.*#WLEJ4Q\N%%SLC8'X<7S_6\^76\[6.]7SI>K[&L9[OP*3[
MO=7S)5D ]J8Y2O)!/S)KZ/Z)UGE&&9W*_MS&MF_;KDUL9V3"'Z\N+V[U/^\'
MWQ[?8<W<'!W"5!=++>K$A#\<V1[OAIW#RK'"W":_%PR1!;^71$1&-I!R8SA>
MPIF2MC-Z)^?!JYNVM0+Q&![0I=V-,E-_L<_O0\]TA!A08Q\"3_C,P]E*<A#]
MG@T1,#GG#[F!11G2"ES<_OWF\K3>US_<?_]\?W/Q42/9!@ULG\M0..?WS\\)
MK%JO/*.-WNKS5B9+(WPI$[6_HC?!0(<M<K%1&%^_ A-H5S"S2TV@4UO>L$HT
MAN12&]-R1*Q,=0ZH%6!'C]F3I]#C01PJW!3[IA68=ED&W7OEI33_%0T=4U.O
M+_<KN3<AC65P*-PG./ZR1QL8SRZV6YG2K36#$P\_%,<"UZ;YFT!<V)[^K]#T
MX')UT.1^8=.0^6+5XKK,&65*%QH>> S[)>AXN9[113QA_.0\B[ 98=CBJE ,
MHX&S@PM+C7E@I/*%9Z#DYJ:# 4[9MY=K:/P.7#(S#J#/V:*R"=6XC/9V%(VC
MH.?3:9 'F-WJ.-8,FOP7+1FL;IZX5<ASWWGND#'+Q]:BT71D Z1B<M=<X=;2
M64I*'\)1<';N3!8-,\>>@+D5,/JY(F$TGKD45OSTTQSY<<BGHSIM0O'->+<6
M;09RYTEKCA$AC[B=DJ));A\/X ]-[%BJ!@Y>;2=J,YA;J%U:BOA2S^\1MXC/
M7;LXN]-:4ISMR4?*V<M5A).!\Q>OH5.+%<X:7YC$TB&<R%2?L3* W6X4"6 G
M]!O9TU?1:SBV(CF_-@]=T[ZE,K&>^ARI<*BC)(Z6:VO;EU$!V.U1Z( 8WB1P
M8^ GF#XW_R>,!2B&SS9G6@+KAJB^N"[B^DM]HR*1)"]/C!1:0AO9DPFSL/VM
M ];5V'T%[>49R=H+W -\-<HS'8GD8S58,NRK.9LY\S@TH=(&[M1URZ'&6&'[
MBV@*LP8@(O]$N+3-U?Q@:EW0[Y[!9P;%LXI(HY[M0Z@@[.)/3?@5]1WX%9U,
MSI.O7V\>OUY]>WS0!]\NP73\]GCS[<^K;Q<W5P\[B=N#M2MWU3[?U1NO1$=$
M7=FR7;S_L'PK#$LP8>9$32()PBJ61!/WI-16[@Q)/3C*$RZ_07#Z#]0._*ND
ME9Y,W_:WG\S:B]#<4\.U&$_Q+@5&"7>3C:R_V!YVT-8X\R!)ADZLMJ>!R^EM
MN5"@/?RW+^83E9'@R/[']7X8RM_ ?C>'G&30?9UR,I:_N>.I#X_D3K#X%[?E
M9(LT>H7#QP,7;EZZK5TA_R1:\OG7KH>R4,PT[9R<=WO=LPR3&YP('/-" 2-/
ME"^IA8N#>ELL;KSGAA$.JM@4B:3':/:S2M>V5J"X]B@1-F1T,_;!4!AVG.WV
M+-R?\OH"AQ.E[#:V[W!OOIK3$(Y=0/CB6+7MY#+<WV(,P&O["2KIP]1]U0?@
MFY@?WY\R7ZACK/=6,Y*QGT,G]-$C=80H+5"3B47EU5<&585/2(LE:,J0A\P4
M),;<JR$($?HL%K@GCCLCN40C! %,,)%_,XK>R#W[Z]5]@_(D8($/ S7%*DO.
M9_ GB/ [@H-^3X/"$$SFZ!/;07#"E&DB0"'@\:#^3CTV@GW!,)]!_Q["CMB<
M-$3$X.CO[A0N5Q=C'"$V%J&7#,<V[!5W0T>"Q,Q#)>H2F"E^[2*82Y:N"_8[
M'K.//LU3[_SAEA@$^,X?\J[T$I2^=(5\E2^6%[MZD6#?UO\Z.5UUHV"9F-%>
M$G?ZB':.TI6^SLT6$;].SEGT7UUKTF6;;U2<=!<KP[!/4/:D$6J/^1H^X6^N
M,M&D!$Y,*VGR++5XX#-+* $R%!$Z+,SCH3Q+BR1VL?@G0L,+\26E,O!]+%'D
MD$2\%-"836 3)>:6ZQRJ>A2SRD]$E.F6DA4AE<0"MR.EYKN0!=3%:K5EJ"\4
M/+4N64OU^/:C0#B9#SN/!LF4^FZ2S%$"?RUT2ON(3DFC4YI'=$H1G,@1G/)K
M08 V$W\]= +JC<35&_R>*A^6W^9J@+_XV;&G/S[;[KMT$N/V47FTU3H/,B0B
M"=PWE LHG4/X=!C8Z-N)G/[,<\'08@$:RP$;CJ>NXS[/I?O \;&+@\BSD"NP
M/*H&EXB<7+,UD])=++I>8FYI,AR#_-5HM&)R<,XM?]2,'G@)GL4Q(M+*%7%"
M6>T3F=-$2OW$V#3Q+5R@>#O$=R/:"B1PHQU$;(0O%3C^EH?X88P^F>])HQV3
MBY@O1-N=$\2U\-^\;&<!WB'BLS K='@P'XSC,#UG?NI3]A?\149U!MQ&U\0\
M+=WRPF?5K_<#^"^_AOQP1CB141B )H"?_+2')"DZ0]I".?!U<H'H%/WS83AF
M5NB 42V\(KC$KND=D;MT]8+K\(@^<>'$(#E<)9^=E*7FR?D@\C5\\43RG\12
M1'X6,OC!.DW@Q!-+VA-SW->S=+>WO6JPK#8&&]J(\TT1GV9QFH*P.>;,!S-4
M_FT9W6E^$SW10@\>A%2C_W723(SQ])6*'/##CE7$#XC61_\,QPK/#2W4(H-I
MQK,+MD.,!MI8-= L)V2-P9,)J8N]+]CV,36*K)YAN^B F\%KBT6?>4U\<^EP
M!8GM*@!,IYX=Y!&R0*)P"2K*LPGRE%0NK9,H/0"WG'HY9U_+^@>\J#[NHGMV
MY*JD&'Q]&!\_R-C-;Z4ET"D!3J-E7- \Q6JLNNWE][[^_^99+9U$?O*TO8'!
M=E8-MG-RWCC+X .&^\3!T5TH_*WH#18@1D[O[68:S4<JN?G;DK/6.%L<EU3B
MORWM.B@^T6O\MOZA:U4X=-V3<W1W,!0B;2]3-6C0ZIGS/ @Q[:ID8G^ZKJ5_
M,9_05<<F,7>T;4.XS3Y@-7FCKE]<WX,6!4NIW?L(UL!PS*%I/'$OJ0AG+K:6
MQ+8B9F#JKV[HH+F@F];$]GW:<;3J9S.PS.A*O6?/H</?. B#L<LK_%6[#,[H
M#7BQ'WCDD++R(^9Y'.,+9B[ZOHW:'W]^N3M]='_2O^I_+%4D:V]B/7,/4[T^
MY:<7/UZHK6>G;+:AG#*A'O+9P?:ERY37H'//-V(S]T9<]QRV*YS#/IU#3+\(
ML*FIWU%JX$:_ *\51Z\_>C;VJJIZW:4$<7WA*YOU*25\/<KUM)?<9?NY C(E
MJK5QB>J4EZA>?:E$':1(E>7R*2=2#;BE=RQ26U)C[8T+7;>"T#5/SJ_!9H=;
M'05NJG^['!CZYR\#C,]\'0S@(GZV_4! ZC^($#TBS%],8JQ #F-$>!+?#)C<
M<+=3^SE:-_KPJ^LYFS#Z-R"R93%CY406W*,.BNNA:\'.Q@6R5T$@P0M2[<49
MDO&!WA.AR:A:$__Q'98>3$1*)/F\G9[XV-5WE%_E!]__^R $L 13>P4!1-*.
MQD8E4.V@GN"9V&U,<,^T/6K$FFIHL.\YQ:*IAV04^_89U<D$8RF] B7UY&+D
M';^+L6BD>P=G!X5:J;O1S1?3=C@-%VA2GW(?,ATB);M9X\M ],KB4+A#'D'G
M4 QJ!!EC:>(147I%X%=EHI8?KCO/Q; [>5Y!8,INDN0,1D]"XN8AFP5QY1+_
M<AQ-Y+.D6B"J DJ]\3$#7\,?,A,C&"+'%2^[Y$2V]")1?Z8_4@_-5/T;UH!&
MZV3&A7@CK3CH>?UJN&\L>( #Z=^Q]6KA>N#.=[***A'K'NCT3(Z-%]MR^C0_
ME3O$ 8_A-/#F^&/Q5P&;MY:M&._&(#X;51-.742@V!98FJ8]@26%J\(G .4D
M@OK"KH=8<PBJU3<=)DQ4/A@C4;"7'/Z("X\<-KR3_BW'(,K0HDX(>?2#%;>J
M?.%B#YWJ]&91PLN3!:A:E/$2A[X8+O\=H4XET,-\<>%TBUX6EAMBDZ<%?24S
M5U)$4N!2(P*@F9(B5.$H^)H&$<HG8 F3@!?CL[%>&S4:RRL[*%L<L1(^N?P*
MQ]Z9C:6PR3-MH,QQ IKOB<5 6-$G."K"PE+WBP@?K3^$3R)URE:31VT5.%+P
M@M\!A&7)2-;"\76..+XTCJ]UQ/&]@5-P!/<=P7T'!>YK5@/W-;8-[ON3N1XH
MB"@RRYM'O4N@WY05!/K=2^R6Z+FEDLRKA5_D*V8M,(< ^A+^-Y2_BT!AOFCF
M%=6(++B8&N5'/\F,(A;U3?7;&9MB7I0Y!@^YB^F &L-D*EJ2)A)P3LE:Y;I1
M.+2W#X^G6 7"O\%;'.$L(QZ3>R8KCF_]@+D^C!+6'P5%I#'/M+@,"VM08K!=
MO#8)+Y>XH&0EG"M)CQ97:\@\<MY'#+F&*-KV%$/\$#\8P<$XU$N+NV4^A=8S
MR^0,YZ56&)3["28N!2KRX)1E@ZZ?X?7/S*/%B<2DD-7<Q[[?1JO9,?J--%OK
MF7Z]5L4T7WW)K,7%C+IGBKK#B5*,[:>PE$M DMLIPY8P5&KR(\\:-1:-1KI.
MZ7._GM565$CZ-@JT-SU^N -Z':/32_< 6*C=KH+\O. '#7&^=#\I!8W"UZL$
M_ESW\<D5:/)H9>*XHV94M8/&XTAJ(:;TN[DKS:&A4>CPK2)#*VS4+P .7? D
MGS(\R958.3!Z%J\8L6JZ7&)N^<0X+STKO9(!!\T;VA)')6^X<GC< ^%TA'E#
MK) <_H^+BZNKZ^N3+( 1(L\D"A5S*WR4"V)]*D:^<EX("TT.OPQD+2^!UT_R
M!O*%E-OLCH3UAB=)9:/J$LOMRN%+NP_QH@/!@2=1H6):&6FZ4M/$3^3!/W.6
M<AG0:[7DK4X!5N!%57AD^-(7N0-;U$2]W^MG) #7$:22.>C-2'TC)?6+F[]:
MH+NU<@)=;Y41:*SI!F_>:#;;^@1N)%^ESC4=CYD6K]DQ])D#O[U[O$A]'\S0
M)ABAQ<Y&>C'*R?V&9;U;P80M)>O8_:_?-#K==(NO72K]S<A\LZK,U\O)?*.;
M*_/@T]CPS*&/8JLVX*Z+"%:S32G,*P<L;,\%:T&_1*CPA3FCHJ,/5Y<7'_4_
M7?T+HHCA5^RM2G@)MN1*$MX!;=XUNAD=WC8BX-N0XU95.6Z4DV/L1;TA.5;\
M3U3.#X,[#N7PWZK85F%=+B.VW>V*[4[U<KNJ/#?+R3/VB*LLSS629\S3./H
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MHM(5[N6WL-F$VD43D5&8+(UF9ANW*M/'QSA>M;Y]3TE"-70E:VTS)W?]>#U
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M E)\$RF].;V!3Z3W4XH%>$"I6Q>O?<M^GZV!BB3@S[$(Q"V&M6&WEGP&7)&
M)87]"7STP.X0+?C?7:#)%&Y+ON*/VF0\DR3&UKFWA;_>TU^_N_%'-_ N,")@
M3QBPH @&V&#_FGG7%,[%MZH@6(*58T-QXP9C7#<P@WLM@[XA;!*>'4VS#AFC
M'2:?-?,$'C95)/)1&.T]I95;O'+7?N>'T832^?YD%LC !&\@=;^)A,4$Y8N
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MD!.$]D$ [,D<'*\*@O5Q,JO3/SIR!H/5[@X.=[!CG.CRD$EM_=7'J^<XZ;T
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M>$]C;&>X<(J]WT7T2JR=F(H(UN%00>:]R3$1>( QG2L+"KF2@D8W+CMM%'E
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MB (,"COVYXM?'X,^]=;V(N;9;Z_K_9EBGKN #Q%EIQVL>?=CDI#@LR:^IZ"
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M>RBO4=+2RD&GT(A2F4;(WS@2ZTY2:Q3MR60"3S@U,I$U&80\AQ2#9#KRIRL
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M._JC=H"RXAA=Q$,8#-G?V2C5<#Z@G'?\O./G-?,SM@B(.R50(XI5!\S7UC2
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M.[?.,ZS@&2@]WW=<FZCMMQ#8A5UF0Q!;;&9/ &NX(&B4.1-4NN!]O6 !5R]
MP$TG.? N@%MBUAMX3+!P\4*T':TF)]8^L:!<T'G17IU[OLVN7M-"@7BONWV=
MV&%'-R]@J/4,RGT:4:]BI?X(GK2"\:25B*?I1/#=X6E7'*<1CBL4E9I +*=V
ME&_']\=GQPJ\7/M71:TW:TJ/N%BF0]>/9>&]6VM)QY\:X<^"L2H.@PJ(U1UQ
M<[>=UZ EH7S+)HS3K'>H;UEO-EEQ1[>]1G/7F:4_ T[8\LO)>OXDG.H\?[+'
M[*T9=Y+XO:FN3$$'8:HU]?CR^EXPJKFT+6PCY5^G=U<T&$6C8>=\W9+REJW
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M_/*>')(3N ;RV)]#I)NT&/*?)^35/X3_[3OFY /Y;.B/K __'U!+ P04
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M ;4<ZM?&EOL4CZ(-'H<[SES<\,^-S9]EN92%"($?(1JB"30(2*@4=.0701'
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M<6&?P,8'G\#K7^P17!</:*^#)L'>#E(MN5L"BY? -A*V ;Z<Y'* PJ9WD#9
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MF#KA\.<HQ+HOH4W<D*8]V-C1%ZM-)VY%ZI""3EQ]BW@C5@2S$L6[\%X,\5%
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MI/8EK1 ,HDU/:"1E(H:3[7RWO'FR52C ZT2A@;P4L3Y^OF.U+7GL8-@9H15
M3M,!M6;M-Q^P;CJ!+U;NIDL-8[L+G5V+7D_%)2+JDLD"7>(46DZLP20.L6CE
MB40%:(B? GPEJH.TI0Y6 M.F]5,Y>*M[6FO(RK=TCJAND7M["/*U?4,?C7HB
M"#^ S]WWX,L7JHG=WS%@<06+@W;*MMM'QP6W^_11I&#VHG!+RKFQ%<MP<V>
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M?GU:47/Z=&T$L;_@!'G2V:G/QJGK5^2+DC&G\Y3UYX:C]Y9;U%R-5G%]^1<
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MM,U>)V?E=)_BU2SIVG@JMB(-O"#LD< 8.3RD^/*+_\UWE7^SG[<EX6/:/3%
M?-($J5=(P@D44>;BW6-2H[?BP:,#9 ,)[/LYT6<)K-T S7Z%4::SB]#:5C%
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MXI?VOKG!*V[8O.MII@6(WZ'-]9ZMHD.LHL+S"I%O?WQ%;^-QG+#(G8":>O$
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M]PL(DQ;+(XCT<%=+GMW%+9](S_P+%^F?T#X\#.5X3UL/RV<=B"CK;7)[RB?
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M7W4*%'0^921(PS!%Y=@"!L 73C$=<+':.%\X:B+ >HH295I2#[@>M!(/$V\
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MICHK+8"*S8@Q@J;UR+/*OP%2E%(;N]F8/\;VY<&RDM2YPD8 UM\CC[7N#'C
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M.1+O2G]+U:)_SEAV'02ENN\E;YGH(%*6-;/98H$FIS)(BOV@K(4#+@S2F73
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MK5X@7.DMM/DDI/ JXCXE9UR7ZI(\AY(.N?O!6D<UVF<EV'J\(T3)7_0+N/J
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M3$_*3<0_J?J_=A/$"=_-F"&1"=NE8S/SD&LU8R@*NO<0V@^]8+-<N)5%XQM
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MK-^@-N[UOPF2HV7MO/V0+#%'<7X,O?7$;41R03L+X;JEL7\NRB&:%B?OD!_
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MH@ L;&A@%A8A2'Z,D5@Q_.<AU(B)3;!4T[:R!_H[X4C /T@Z\?$J[XKT5Y'
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M7+6;,M$-I#2Z7",&$DZB>'E9@RU \2FV596W%K>4QI)9"DG9BL.5W%V^1[
MR;^/S=$1S)"3@Z+$-!7>05990J3R2<-SCR"@F<>A?$P[&^.#M02G[8!#J$-3
M2^!WN*,\'V:: A/'$P%U8T" :2DJEUO!,5V=8=?V,T-ZL2(\6,=HFP&;P73_
M.[]6%=(7!-\1Z3_U+. WUU"8-D=J8+?3R_!F+*LH-_9:6LN4\Y?EP: -_X<P
M_S=H$)O2)Z/!B6VQ9JW@]J&J+ 3X][=AI!/@H)D% X<-%^&4@3-_@FSRCOR8
M-S4\S7;K)C>*]\#&YW;XI]B[?%V590'@AGG\%HPGQ-&EXI):8"G$<'#RQ&V,
M !N<0&J',:<3\5VGMR(?<BQL,ZX/M1E7C7LZ3R-DI!HXHOG\I:.K^,9=OA+B
M*\$0J95M,&"+'SY:>!0=N&RW&5>]%=&S@8)OZ>5RI8,OX2]1X]64B\#N=P*P
MC?T"&Q(OOESPIWVL)#*M162[U><*NJ&G+[15>BVL/;LL Y>BK&#70C^<SR^H
M_P9C7MY9L^<.=5^^-<H/AN\,230GA&];=R4Z Q;EO)OYEB0.)"7B=(C6FM[F
M2O>TZ&=5PI[::51\F.^=WZ[I=?+)Y5T"4RK*T#H/]VN<R4RR//HBA[BZS:H.
M$5OT%-@N"%\11K!_]F(T&=H0Z=3399GK.R=2#;S[*)NISGT5%A6F6")0LM9$
M<PX4,6.N&#L'$QK_Q)-2MV.VKHVC,2.@QUFSX1,1J<Z!D H@97EGW3(N\*9D
MJN0I+6W2B,N)[Q</3G$;5$ J8C\++ZB61I_/.X5[QP/!UD:>>F"[L25H2*'_
M9\,S7YR-F&EJ?:9M.T/B-Z^PMRQ&:FO1+M57?"K<G0?52@A38Q/++:Z>2T.=
MQ6>Q,U@SW(EH&1PG8];SZ2O GVDULUH=5'(*>J$BL$-RR#2A3;><9[ 5%2=I
M/V1G3NO)>A^+N!-QG:0J3FEB3-CKY;PY'[(:*[^L_ZB:$CBM"X@P(<DX0<PE
M!/D@2562BF77_K)CD?>CO%D&L!['GVCKYDPWFUI4Z&$N'XT@1WI#PS,V"BTL
M'HGE3)H5S4]@=3Y ;HUH80%%G1>O CVEZK '4"EN8,F /+]\UNF28=E1$F[_
M "(DN@I93?RRHJ.YE)> PS!R;"?=47XQ6QE37Q!$I&10^FC*GB2OE)'I_B._
MR(DX[^:W[0TTE;.T\$MD4ANTSO5+0#,(TZ&<:]O($<W!"VYTX 5'!ZA/:Q 7
MQP;V+_[^X=%X!GQI!=NHNQI2]0=WZ._ >^OCRQ<#CR^W).!? G9=.X=(=#28
M\&_P')E11I?L$;,AS:=,QWXM4F7[+B2KW EAF6FU^]B.R*)45U$AK-S55F:,
M"^:$Z98&D-B#.<F^\>)E;24+DK2)35A?WS 0Z/4SL##/EMG\NMUZX_4H7<!:
M&!OX9=(#%;DI ",MV7E8!("&<")MD"V;+SSC81YR%I;8(K>]RY?0"!)$L ,W
M/V+VD2027E0"&(M=/A'G,9?RVI9G,N=H/&0'[7<+M?#E6  C+3I(-T5:KBZ/
M,TH.>:]*WPPY@%9/<$MM9611_NLJ\;!&^I^N3Y^F6HL.L%)CW.8J^KGYI%%:
M-WUFO*J&H2=3OG*PX<%]T\X!V5F%WF<<4$HC>)S;UQ46L/DI_A^)Q&2T9/'2
M[_N;M?G,73[1Q9:=;+EJ#ZVFU^^TRA-8?BD_E-<TM7,N?6URL*Y3?H<Y/,5S
M)0-8/!Q]9SC<XT ?0U><4!G@NG_2,+_L:BY(E$ B?:LMJS2NN.IMG"=0S_W9
MIFG2+/;Z8^UC1L4!MANW"IAA$L<7=HXR7J'-.9$/$2S5_; QD6Y/D?8F\DCX
MMGR?I>&E[4;>0>9UJ%ET16!.<Z0CMT,BW\$J,#+G4G+*0+8:P3F9QL5WD<4,
MQ=#&>P(!8CG*G3)ZK;1BB\*KC*YI#?9Z<NT=U6]8M<OK9X8B),>#O#*ORIKY
MVYO>$W:NZ\5<P-!/\ 3@@++.4_\M$]2]P5ZRP 9N['!W!_CM9VU!)8_ [EV^
M7KWUM>)9 TB7<DQY3S\WU9[C0'_V\\_D6DF:J\7SKP\])+G63$8G_!'\2$B$
MM 43W@U/A N1!#WI^M*V6UV>H,]MNE$5X[U*@]*$U4VKM)IF'<[':B7CBWHJ
M*5**MP1C@+'9')><#V4JX1J9W:[9 3&''Q)/#9J'<;.X0Y6)MA554*CH5"#T
MN^-O3,AAZ/L%EV<7G#XL^PX1C!D4^\T/']FT J7I&H,T6/6'G O4K-(Z![ 2
MA650X(.-?<]9F;W3(6=]L(^3S[0L4L^RUY/"G+1.P@AC3Q@V-FC7#=&,/-R7
M@ZH$X@*$BE2MQEZXRHJQ'1O1"$X&4YP2T^^ASU+HA25Z'AB!$(JX'_JH&!TV
M(P$"49G#*EFTN@6%V-7EQ01\W9X</ $UW^6350]6SDSE>FT7O.0\ !Z#.HEQ
M0ZBE""I'$^B&\0&^4/..<S&/(R=FZ4Y6XG,.R')D EEDN_3CP-FL:/DFS%G>
M > L)^3FZ]$.19XL$,8!V0VOG7]-BP"=!O2O<.2^Q3\;3O[6V/AFM":XK+DI
M\Y8<RMLWK53R0\Y\VY:O)SVC_<46Z/;.ZS_W=OF"J\?O50GDC[7HSK?6C+K=
M&_=<B/TYZ)7T^QZ<$!.P[1 V/^.(0O:_8.$4Z&*RN5G97K1B3+!_L-VKD0X%
MGO90&SB((^ $/)Y-4^[4?3K1CYB+M>B]+YH1%_RJ ZOVP0U[PGVFMV1 ^BNN
ME81:/QT,_I;4&FK%AO="$N G5#94C9@S/?#]P ^*2?89.@0MR9HZT,/-LQ_N
M#I9-M7T[I"VP>,<W<\HU/'V)Y1=OF7)T_ZB; V#,;G!G:Q,ITD@FXQ$)GJBC
M,4[QG;4RHN@9+\01O&FE/VO.-;-YW(RR7ND"<EO3M2:'ASL!W46((C[ @%W"
MM,HAX-&:0- L-I$KL3KDCG3T%&)3TYC]'JZH6\@ OY%;PW?6?-HRE2,#9*/I
M)M=?E-B>?.I"KH@YVH2:J=GR7PU^C77:)&LV-S5PE\ERZZM$TR+Z;[4[9))A
M@^D+7[(=5V!%$$I908J^^]-1F[?90(EQN]>RYFU0^+V][ E6<.<SCH_GRSH"
M56""TF:.\.Q8^95J7DUL1J+A>92^&^.[?/T)[:\W S:#&\(J+.1>IAB%246N
M?C[RY8.XSRU.[AH_&\2DOX4D8,Z@@P'CV9 35T)"HF")/"^.;->T!)U):K76
M&9[W4':EWR&6/)K7/-_\8E;X8R+Z3O^ +;MO=7S+ %#N:=K19&.[0/&&XIR@
M4D:43H?\9^A!9J&"1_,;\@F!<>;HG? QB$_.JI7BFZ?R@NHY5\X&K>4;:F\7
M[NSG76?(<6 ]X,=@ 5X(ZS)A;4V>@7::#1%<F6AK:DK^-C%I5A%X/V* =B4$
M_/Z8U87KN=^,]S?M\L5E!),&,-6K[6N:>\L84WVON@U6]ZU]?6MELNP3%GAG
M6*VJ"2'&8,/<O\UV5/MC_'U3-P>U"1\ZB/TQ6W0]Z],\)\"#O7"-UF;!$6"9
M/N ), <\KWL-1^SRG0+(E)W30Q&7:V]M.;2Y8BH)@6*.NO7603M/CT72W@UW
MO;BIA=5&@=<$.>+,WSTS8Y/<0@Z8@I5&P5B'$QFS3M0T ]+,052N">=&>C,;
MK<^PI*M6+D8UTZ]^%]8R<?-1S]-0\?TOQ'UKX0GF)&_/W8J7.DYQUBDSAU"#
ME#PH_;?$C7A6AB!"XOO3<FM$,#VG?@RQF5TV0"C-X=;0V6W"LJ;\&L5'0CWY
MMZ[RH&QQ"FQLCEOX]^,\XB$4O'-"A"< #%8:IC%5!:S8.SD3<3-"&Z-Y&S7A
MK4@WGPBEKB.98> \EB)%8^Q-'MAVE\^_F8%IWO@@OLL7ODE\O3F@2IY7F+SG
MAOWR<V;5>9C,Q37V8-^U+H-M"?T[NWP;,X183WSO+I\ZUI';#& G# K)WYA?
MP6Q+ZR?8(VTV6^*8/K+0'N7MU>BDCK,H?ZX=("N>Q!,H!AB4^\0GX?SAV$1/
M,5I$ (EX;&S9;L75/<_SE7'"JUSZ3>WLI2WMSO0[<O?A:Y>WKJ,5A@TET @@
MB@F?$& Z)6*@D(=0CV*41?=3M#O;-''GK NPLT5AF#'3#/LLVS@'BZKQP*/8
M&ZS.I;KWQW1ET/3O#X(=B9?VLH,W[QS@P,2-57/U@8?,F82=PY_;(EBP<:?9
MM+XDJ&\I"FY"XUD3!FO0E]D=Q=5652M-3:'+43\"HW;YEIH'(L(NM+1L\UI+
M]R568FCP(QTG W#'#+5XB.$.?IX2PU -B.GT5..4Q[-BG9C$>-X5XI>_*I)N
M;?],Q+]I&<9WC!#/M-4W'$\^GVGZHR3I-A]IL2R[[3O"5#U;(<W\22#6/\Q"
M[.>AMZ%2[S]O/L-_*'M7B/5;^%@T^*'F)XDR\,'%4KE&T#^Y$+R6X7]L?__Y
M/^R"VDO$M5,T!SE0 %URTB1#UI6T!N,C\! (ML(L =^3.'H;2$2R<YF]Y(S;
MC&#,.(&<=H8=F2:> G=I^RF_Y5DUP9K1*0Z;[U^8>E'V$XR96W'X2N9KLV/!
MI-#\@/(<_-035"L5S(^10N%[_W5)NP02!AYW3>@0:D&K&]?I%(G"J<];$J\$
MX!O[3LH?OKCEP+-K!>2V+J$# 'QY8I!/%QG49E09(-QW*L<%;:J:/P9$*GJ=
MYY_/<FVMNUY\GM^]ZL0!$<_;BXX]?@[J0VG:GAU>=D+%UN8:!"=)QPQ57=]
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MH=P(UQAL2 $/55P7S:U6'& $I<B]'J"9=:B;O0EUZ/;X[FFL_7U%<GF\M(3
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M%_21',0%M?::P1>+]U[1.*?V7\*9!H.\P9@&[MSIQ7X6MSTY9?K6./=G*:5
MU2$Y+8-_U3R[R:E<<Z]7][OS^X)K7]3"' 8Q2\<A8S.VW<8E09E#3= ;A*0R
MF8I(RG%+R0]FVA=L.",YW78)ME;":_?2<]_O1X7Z:^2T!R[B9TB4EMZ?V,-
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M)M2;;R)&G#^WHYA_APMJ/+/[I<&27S_:EO\==:$6KU-(@TM@3X:?  0HD,/
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M$\6*)*Q$,P-;\$YA(D#G7OAU;\&EIMT)LEW3AE@F8_7E[I.%EN/#T -;E(E
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M:VJR*@M3,G\5IE'MQC+:5OP$(?]9C-V\Q+F02E&OH D:M<OZ$=S]B/37[$M
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MDSO-(+8OA'MALQ>+9_9%2Z]S0($KG=SP$H> "HP,4:MT&BZNC<L;T/]:SVL
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M]]QX\XU(?ZX#21S04!&>H3?LK/$7[*DVPA9#/9C=+=%/__?8'BT-D\A6@NZ
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MM,:+8)%6,RXV6ZIP98GC4IBXQI+*EE4DH)4.W2NGAW- )I?_O0ZB:W971;.
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M$%:QYG9=U^O>F<($9.IN9<L4Z,3CB-ER/??;-6^_7#)FW!E_1<LN9U0ZWF@
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MDXEMNC.N4A5UU\*<*]=;9=^X$_M^R\32LK;5K#2/9_ ?3[_Z)/S3IJ4C(PW
M4V6U\ C]U+1(O#E55D.X_];NP1?9(QY.WZ=GR @%,[[,$N*O9G=+_']J;QO]
M3J=+_[P=K!JM 3!Z'>@2+8'E9?XS9\?K!L*=VA&^WHV%&]?:]6-C#I]*')#
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MQB16=_F7TGG'M?$4%OXI$8P!QINXZYE=EQ.>FWUC"Z#:H4 ZA?2W)^H-=*X
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MD+L>)>38A3$[*I09F]75_GD@6NY=TY8E[^^#'A@NC8>ZPV,7K]&@T0KWI\B
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M*W]B.853?6/?><#.1:]6+&=ZB$E*I?3*?E'W.&>2IY"F)F4QPJ,@I4R<E?F
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MI,54B\)A?);#/#W&K]:PYW]69#XT7;&T\>W#7O&]:5,IIR8.)8JBI@?(P=3
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MPG%!TDSB?$8/S:/[,Q\/E0OJ\N*OI/*2P1)&Q]R#&G3<8UTV^C=24@I\"'7
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M+0B(2\3NOI47M\HR$*_:.J==F$B^+-)I'.0P&9A_3<6ZQ$DKAL@+60N@+U+
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M8JGMWT+>]_*F_/>''^T-F3JVLJ!Z*&>D\UL!1#:QPZ[46L1$M2]PT$I&(G?
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MTP9']9\^>13"JONDC&0II#9W^C).NS_@?\J2L<XO_/U'6R98R*"G.-C.>,+
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M9.G28T*.0:LR#JDZ63]YC:65SKC9[MAG"G>5,JI2"P8[T[R5]%+WG1*'[MD
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M?850(SUVZG;J>Y1.<FU84'.*&M=G^,)'*JSZ(A8^M2;)D;V1'MH/$1QWF$I
MC'=^>=;20M@"+,3G\$*=%5;2'2OGD'H_/$+[J@GW?_H) @\=;>Y_ %!+ P04
M    " #QH'Y<N#^12_OJ  !^[P  %    &5A,#(X,S$T-C Q7VEM9S(N:G!G
MI+MY/%1__#]Z[+O)OAN%5+:2)=),*2&5$@DQ266+$<E4TXRL64>$BDQ"LB=;
M(6,8)!51U)#9*MG/J7 R8]SY?'_W\;OWC_O'?=P[\Y@_YKS?C]><U_9\/9_G
MG-GXLL$$-ATY['(8$!(2 LX)WL#&!'#POV__OU[_&?G_:T-HHPM0D 1ZA--$
MA+8 P@I"(@I"&S0 "0!"8O]K _!_OH2$143%Q"4DI:1E!!N:-P'"0B(BPJ(B
M8F*BHH+56X)U0%1!3''SK@/B2B<#)+9<4;:X?;=$4M^A@:KB_A$TV'T^*EY*
M6E5-74/3<*O1MNT[+*VL;?;8VAT\Y'C8R=GER"D/S]->9[Q] B]<O!04'!(:
M?37F6BSN^HV$Q*3DE#NI:3FY]_+R"^X_>/BDM*S\:<6SRJH7C4W-+:TO7[5U
M]]!Z^_K?#+P=&?WT>6S\RU<ZB\WY_N/G]*^96>CWG[_+*ZOPO[7__!("1/ZW
MZ_^/?BD(_!(6%141E?C/+R'AV/\V*(B*;=XEKGC@I$3 %:4M%K<EE1WNEC10
MI?1WNX,JYZ,^2JL:6+(,H?]<^Q_/_M\Y%O__R;/_[=C_Y1<=D!41$B1/1 %
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MQRZ_@D62.LN8/:VI\J&D%&?N>/LO0V8F?X 8BS7]='KHUK.SS6\DEB:C38J
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MW8A:+YB8;O5?H[NG9$%,/S*+W.252+R(C2^6_/C?;8<4HC!_5S\D0:.HX(W
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M=5XSLV<C7VV+A40):S0.LP-:R.,7P F(I 5CH&2V92R=@/ 6:%K\NU')NEK
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MF^JT'$'F$CP^$%&FTF9E:UF<IOP)B)O\'[%*Z.,]'@:-3\R<A<$S?8[[LI!
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MY.;9%Z)GXX5BLL+%TD.,/CV-!IU!O:%5_O.K\'4-"#$8X>6>%8SD!HXR=)Z
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MQNJX[1I^;Z58]]%"3K%XOJQ]$GR\CP-HJJ,.PC5GR*:59%&BQ(!"RL9%W8L
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M ;X;^L4SR8% AUS[M6I2I^$:KAECB5QF.]Y##*$0)H,AO(-]QD9!'L"BF2<
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M@LW3;J;=A<>Z CARSRQ;!J6Q0(\.UZVI].RG,K/=B%4'@/[3",Z@2OJU]@X
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MG7-[BCZIG*>S?L:OHL2)9VBI:N])R%Q#V.BV:=+I3]__;RV/2^%8NA,]AM(
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MB T\%"7*R=EW!V2%L.(NN*,5P&H(L<#4;N"5+Y.TK+7=)&>J37744)MW#H%
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MT0'>5$<GQF-E%K"R(Y5KQSU&4E@G]O)P+@@>C!HCO0/RM%FZ8;@2'P.I0G9
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M//S1]HSC)=C%J5\:QR,J<6U<$5K7%PU^).F(-K!Y.3X<T[%C\T9-@R_(LL>
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M[(.V0@_$8V^=P^H#+5*0>ZDH]X]1C4W6LQS_7ZZ#<W_L_P!02P,$%     @
M\:!^7'C2ZA(8 @  E0<  !4   !E83 R.#,Q-#8P,65X,C$M,2YH=&V]56UO
MFS 0_CYI_^&$U&F3DO#29.H2@@2!-EEI$@6JJ9\F RYX QL99XGZZV<@F;HM
M6Q<I"Q\P9Y_OGN<YSC:GX9UOO7YE3CW;E2/4CQG.0M^S3+4=Y:JZ6S:=A?L
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MYW!_"W[HGH/W/94H$[@E-$U8<9B]VK2_=>8S1ZVOU?:>K:_C[U!+ P04
M" #QH'Y<\6M'""<"  #K!@  %0   &5A,#(X,S$T-C Q97@R,RTQ+FAT;;55
M78_:,!!\1^(_K'BH>A(D)*'T@#02'^&(&@)*<JKNT02'N")V9!L!_[Y.X#A:
M72M53?,0R_;L[.QX9=N+>.D[S8:]<,<S-4+YV;$7^ZYCZY=1[>K7;7NRFKU
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MP2KG>(O\GXU\C^Y7@']'[FZ$_G-R:  *?&Y_'J-5UAV!S!#ZH4\V&\,"H$_
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M1JP&/ 0![0.MW(C[<[\8$9VC.C^'R@7:N P#.=9;HW, CJT)*$2S$UN 6T@
M<(ZI[O=@)),A046FXC;3Z'%P)'<.CK=HVP\]. [SI_Q1L=!-F%3%!()#[0HA
M<GRR,Y5GBA[,%&$F7NACEJ 'JYR3#?)_-O(]NE\!_BVY70G]%^30 !3XW/X\
M1INL.P*9(?1#GU0;PP)@0,!;,977%,)D%I,BF$Z4\S$:O2CQ=KC264;WU0QA
M24L/X$)3+$'8Y%3"Z8/?*H1Z...,5B'K9DPT<"I4TBI>@LJUC\]:"9O*',L1
M3WGGM8N/Z,81/$J10GC06/)!9EIR)L*ZO!=+68,17B35:ZOR#K\-B'LB6<#
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M%U*_F8LFAT-T68SS4G^17TZ1%I?.K)3WF[C]_F%=L4#N0/9$%M&O"8R1C]A
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M_[.Y7YY=]OBCL_PK-/Y8[6]02P,$%     @ \:!^7.M^&,\=!0  LQ(  !4
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M!B8;'ED)FC5QE_[L=C9Q_-GB#NX?EMZ#<^>#OW@%&U%][T=X:'OM21L\=U)
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M"86 X#!+GJ:)&UB6X7N**7KL-D.<U("+P4W@>$8"/$$D6DD1 DX0Y6O(LR;
M4PO6C,B,9S.M/@MZ*4+F/NFT!8DV EMY0"-CU?V#;8GCZ<%=4M0WO>3]28/
MEH]XXQCR#%<(,#=_/]OJ6M)M%U/3$[)UZ'>H\H<I^OWJ#U!+ P04    " #Q
MH'Y<MZU^&A@>  !.H   %    &5A,#(X,S$T-C Q97@T+3DN:'1M[3UK<]M&
MDM]9Q?\PY\NZI"J(%D5)CA_K*EF2$]TIEDY2DLW'(3&D)@8!9@!(YO[ZZ\?,
M8 "">CAK*3&UM;%-$IA'3[^[I_OMCQ<_';_K=M[^>+AW '\+_-_;BZ.+X\-W
M;U_PW_#K"_OSV_<G![^)\XO?C@__^6R<I<5KT=^<%>)"3U4N/JIK<99-91KQ
M%Y$X5T:/G\&+\.KI?=][(Z;23'3Z6N"CFV]$H3X7&S+1$_C*Z,EE\>S=V_?O
M#C]?ZJ$NQ';OU=L7[V'5IU]COI%*"V6>O7N>#O/9FS\_R4:1S6@B_\4P*XIL
M:K]KFQKV>G!XOG]V='IQ=/)1G'P0%S\>BK/#'X[.+\[V/EX\-_D?9?;F7)P?
M[O]\=G1Q='C>[?#/AV>'!^+TY[/SG^$Y<7&"C] @_2TW3O62./S7_H]['W\X
M%'O[%_AS_]5@^RN"]O<R+_1X;K_4::QPT,W>CD[_<_"^_\PGY^+B4ADYTS#Z
M43K*S"PSLE!QM[/V/(D1U-<J>F[H7\)^4^;N"YG&[LNL-/;;=7$I<R'+XC(S
MNIB+(A,ZSTLE^CL[T>;F)OXG\DMI8,IL+$8P>2$3D1?9Z%,D1EF::UAQ.L$?
M^SN;[I5N)W@GFTZSU+WRW69O<[,O9M*(*YG 1#-E>(*(5M@VZ\RHL3)&Q7<9
M!)Z_OM2C2[$5[306 W^(6.4 :82:@(WCB< />R)7J<X,;NA*F4(/$W6?67NK
MA8A[="H_20-0'FQ&8FMS:Q< 7YIN)SQL<0T0+BZ5R-)D+D:)S.D]> [ /2H!
MWQ#V1DT A13">5::O)1I@5AXKD:%AI& '\ [.,IY]<[AY]&E3"=*[(T*PCS@
M!Q&>IYPJ6&K<ZW: 4L0X2Y+L&K%3PT\B+Z>PX[D;;PI(8#0@,_PU]2L+-] #
M>H,WW7OPSS]*@,]8PUIU*G21"P"+-@H(9S@7A"\J'2E</XX%;QL@SCU>%*'W
MF<H+0KY]1+.Q'L$'G+HB9]ST6K65B-9JZ19V;6"UGG9Q1)RH=8;W\T1>Y[6Q
MNAU\V@XVI-_=6)&E&J01'? 6 1Q'P69K^Y-X!"3D<C'H]2/X8XLF'_0&,) N
M+N'A? 9'Z$!A5\XT[M[M=@:]'?O>;OM[O,C(?=Q+4S@!V".L#DX^%1\R,P5<
MW_C?BNX+/#-E93 =/%!LT1.GB9*Y@@ED'"X)Y^]V>!Y:BYS-$C@79@'9E<[A
M1'*'- <*GD,8_:!28,6)V ^.[5A> \[!B'&L\0OX6:?PQ91^_LI,XF$8 @G]
M?::1<Z21KR^&'Y/3(1>YS))8F0:# )E"+ Y1 7E D0"I()*F2EQEA2(\4!+0
MD00$4%$2([[*)$'&4^" >3F<ZJ+@%R6_9M&,!K<3(Q=:L@I^KMN),Y%F!8CR
M*Z#-%'AM.2T30+HK6@PR0-).\Q634S_>!+/FR1DU4@@PH&6@_3G!,=97&D:,
M<U ;0'ZAC (^2'PIDR;&@6-@_Z,BPUE*DD7C$I]/U 2.&D:YDCHA7H((45S*
M J7<+,M!4X'S_QW>[7;P^&&VF66P!0HE-[4].1P9GX%)@+VG,9YI0T'IB9/&
M)DFW2S-\4$UGA X\6F05'61M?@*0WAG@GL%UY2.C9T7M5P!03*/ E_ IU^DG
M7 1N-^"3*X9A1RF1J[J"+QV:)?J/4L?$\D'@QJ!.9TGIP ;:")U=.8MN(FEX
M#AC%L(ZAS$D<?FIF)J!4J0*UJ*G4*8XLQRC49G(^M6N"IV 9:EBP>.,S3K0<
MZH2U*1)Z@%O!PCTNCM2=, \Y5+O&CPN'?9!107)6E#FNG:1T-H9A<$"[751"
M5&H?IG7-I(Z1=")4N76,^Z8?(T \I"_Z'1],0=P"*/(<B>V;Q4(2OZ<>^@\F
M@6%6M[W'L;I/VGDN,#A@GX!\WH)E-1)Y\;@TA.J2#0G+N$/)&E7F;CG#?WOC
MDS>[U )%!$9)#P0]S8 F<S(C0::D1*AC_9G8@F.V%3'1!^#L(!XLX<$$A=&T
M1#*6C,K&1$]YZ_M,%-40HZQ,T!@9)66LO-#H=I;R^:BN$425]5/Q]V@)*X"G
M:VR?7Z5-PV[3<CH$<,-(%F[H'0#N5>)T:'H8>LP9X,00QR@%44DB $;,: PQ
M-J_/3^4<.<@$%'?D;"!#TP"Z37[#O @/55KFA:?NS\_I;0PW&2-P%,IIX$1H
M=5QZC6F67?-N C9=8VQNWXG^I!)]F64QRW?:D'N)&)M3+;Q,M]S98HS[!$B(
M,*F+D!Z8AMZ@8&,PW%P3,7E?I B28.)M(<V X3+'@X!_X1ODLR' H.R"3[ 6
M8:UJP&XXN\)D22";9O9L6'YX ]&2U[=CW'B7T#F[A/8#E] C<-Y'=#?BN=>]
M% 'M B&AW@&BN;A<QNR(1!(-1HXLG!&-V'0/K]OK!X;OQ=[[XT.Q?WA\?'ZZ
MMW_T\8=_/MM\1I]/]PX.W.=[K^1:Q\4E/KKYCV<4U'A[<>9&H:V/9.*65F2S
M9S;P\?;BP#UE1]C^?O:Y6O3%P=('M[9GGY<<-BY[(]?_5KQVP/H/)Q\OPDUM
MC.54)_/7MVUK8:3G__UJ]^4K6!F.^*Y]@0^])H^<SKAFWHR"VB*>E4%>VM\#
M/X%7.LV\59&W7BU8)[#SS,Q#@4SL?DVO@^U?^17'VDQI!%V0 @]R5IEK@WX"
M$,7E,-&C2FUNBB0CP0J#[R<FRW.TRD9*Q:1NJ\] C[3"[_J;O4T!H$Q(H-#R
M9.7*1N4"1 NZ$Q)\@\3M=_VM'BA&L-C&:D^/3@]AR2F((](I[C+_UI^:GQ8P
M2K+<[E^B)6'B#?3Q@1@?@>#,25:B*0'#D2H1F"Y+K)0U5J'PB6*Y+6,-D]!/
MS9[DEM/U7NL[X](Z>9-@<!##.7R)'B3KZ":_ P"B3$%1 ;N-/+.T<6$WGI)+
MVGE %8=F '6L#H=F$KH9 !HUL_-6P*#;@LC#K2M<E@L Y0)L7%2C*$24PX$6
M>*;N#3[2ZHB;<[0?-LRSIJ_6>?8":%S8<$(L@0^(7W[=.[5.%=4\I;JR. "N
MZXZC0/LR\/ &!\:K)/\MKE5G9&ML;=(FU:@D_TEA)$$KEO/<DC:8W=-R*D#E
M,G+B5N>>NP+;?ZH8[RNTKS%(^..,9<(+DC[O_M[*Q+-*)?JOC0WQ0:LD?BU.
M 31O8) _2M0,8"ZQL>%$P\'1+VXA82BZO]42B][%[X:9 0SVW[U/))QZO[<#
M:P(\U#$LH;&U%)WPR9UVN!CHOE.$/ 3NVQ>PI9;=#0$K/VT,%> 8@&!&( F'
MWFT9&J$0[B<X@*53!G!_@8!G6#_I4$\ZU)>N2=[@'.SO5.PU T5+4]R+O"K$
M4O\BS.X)*[\YK*PT^S#R5ND9J!315T4V4>2V((F]H#!@7 [^GV]8Y4S%? Q#
M"<J-6+-Q&A^E8P\X*0M)AMH0ZL/XZW>#WLOOUR-2=F<%>X,";>L^9@5L %0U
M6KRDW 4%>AY:X9Q&T0R5HYTN0?_#+U@SMT%&2OMY(L G OPJ:R+5G!V"E2\X
M2)J0G'.5J\(ZBC2[;I>[E7I_#5Q]0#?;894DL,@C,*'J!M]#7N,AY(J0BW[X
M!<<U&F=A8  A7W&QM;WU%EG>[3#+N[]9:]W>9,*NO5]WUFG=[+K/L-:'SY[^
M-HW#N^;_U#1!$AN8>!B4![ONNVVP3<4:@+5,V&NN27C8)Q;!B@K2Z_XZ+];/
MVW DXTFB$8Q6H^(\D70>)LDY@_N;#6PN3[]9<H;=SGT/499@4$F2!PDFLR%7
M0J'=[_6W0N=$*O9@HD1L#2BSD1/4* W0JP$^M!CC\M%/U^V0-X_H9@3'YK5C
M)YDIS (0:?B99$)/ ?%A]FUPXD L^,"^#;P@S:8VG(-^B*9+Q;M/.!Q*;HX%
MR,6E<1,7U]G&7$G#9VO='4,%IT1)!&.333G69/':QYS !*A25T+5@Y4>8OMK
M=#XVS= ?TX%.V(=R9,?RN8<KAM7MZ;/72EQ*X&V#5Y2XW.:.;G*-P'WG':EM
M#&C0VWG9W]YZ]6 )RP\8KOM5&B.!LAXD"^+([^OH4;(@8 %'IR>BVO/C+./Q
M2.=7ETD$')UA@"SHO<FR3XE.@>GLVPL*0%V?%/);2>J'\\COF9&,M0QRR2-Q
M?+S/<76C9B@5TH(S)ZVNX ,P:,5ICL\[KMB(QU ^B?-Z8VQ?R,G$J(E5<_O]
MK>9UBJ9:AFQ4F9'V3G-T'&_WMC<#TK7)(1X R/Y9XA0@U^S[Y-Q&P86I !3:
ME_DE"8E@ JNGTW.4J(!*O$YIN2S+QGJ,7 6$ C(5FSS_/R7,,^@3X]I>7$Z2
M9SQVS-[T$1QHA@GT")%";\2:T^&LZ/'6 IX51G42S!&9<FX,7@VP(0PR]#E_
M7$^G*L88B$MEG^G)9#Z4HT_NKLOBFW6;F7(N^<R#!UWR;?OY$"(D<R=!W88]
MYT7@D=:-1I'=07#GYL8UNH0=T@)1DBI2$<8 =@83RNJ<Q7(=_*M%_\  225;
M70[X@5$@5:R;%I<F*R>7,.JL4&3WX=>13>%)[24:PE!D7&-M\H*SCD#7S%+/
M1RNV /.5(T6Q9WS,A_H 4].<DWURTE9:&+&/^'$Z79,!OHSZ.]O18/"]);%N
MY\X\<(!F5W#+*_3)>24<_0V5KZ'@FRNM_#+DDL,YZ\PV+: 9 $0:% 'Y4;9A
M%4"L*<9LY3663]FI39N<7L/WR6QP;Q! BL7EAKN= <>$@2GUJMJY;B0BAY9W
M&F/B'KL58=W(LC#%FV)Q195&QS*,,G@RX$>R0-&)R8G#TAZZ49F9R%3_VZ7S
M8!KX5"?26//&IM%1:+Z9T>QL\CIT6B%6F4UM -%6QK2CP!(S+-@PVESY4J.K
MS)V9%,2=T_FRDPDCZ'>VT5K@(!:')QM.NP'1#3VZ['822DND=VI7PQ:L*[ 6
MX)GP\B=MR.$KY88F"2\UF4=+QPENB%40[W86S3[*5*PAH5RT^:*VO;MD=[!L
M@/7$+JW"!?%AI+7/-@^ M^^&[7;JNZ5MKLW7T:@/^<6J2<D[!."WWH@3/K?7
MN ![W?*-^ 5OML+/WUY\/H2&@\,;<3&?P7;WC!SJT1OQ44X5P^ICAA#8JL72
MW5OXR^K%^?]J6'Z#W8$"7:*Q4) CU3'Q%B;;X.&@.+$-X#+,/'->D&=6S 2J
M@,OYF9+MR0[UG/+>6://:YE(#1[8X/:DA<"*;T@_(B5L*N<U98B=BH7.Q_;:
M0RA+K<!#O4][D0[?&=7(B_1KH^PYTH= I0I,) \_,O# M%PQ#KO$A7=W57@[
MV@$3;F=W>UFE!'NC"Z,!H8I!&KG777OBQ&+TO28?1%N;N]'+S8&P%T<]V="M
MU8;ZZG6KO,VJ6-075@P5V"3=77F35*8E^H<(%LXJ_:"&QG^[U"@MN$S"EUBB
M_CH48'8R%ZF:9 4GQ]YY-#G!V[$<G+D&$KB_6;L5[6YM12]?;M_;L]>O>?;J
M"O8M9BT%69S27D- 'U4ATZKV4XOM*VXQ?;N=![)]G6A97'#MGO2#F+_B#M8O
M"?8_;?ZN%J=H0<@[:VTMB/%U%#?2DV!=XK$5M\#(?E+<OJKB5D>MFSD^>8)N
M9?EWTMY6"_2@*+TW.@:1N[JJTDEJ<6\[:M.)0 ER2M&00>7O5GVAR[T?[>[N
MPG\O[Z.;$(K?H)S<YG*OZ2:-,Z]K)XT?F_H)U8NXIV_^:R@EW4[;0K]AK_QJ
M4>47>Y):\?=)*WG22OXC6@DC5[=S1\7D3NQ^I?422AC[F= ?D^CJE1VR*59J
M,G/Q,2O4@Z23_=W5$+Q(_H]F C8(IU%6TL5U!^=Z8JZ'<XIP%IP^72$QL"^8
M: ;CR2F.P[K(5K3%A7E8H/.K0Q#\F/2NL(8.9[4;YU[]!VDN,DWQ9FY*UV%*
M3NX--_ZRIJG\A,\@1SN 42H]Y<C. "MA'LVSR]'(E"I0/+ D#C/3 K/&"ITP
M8Y8FT:QJX,?:),*G+8=7QFE\SG2B"E\T$><2E2G>Y,:D<[MK2DH*5D6A5%?6
MH'[MJ8(LJ3A4)[!][F^6 7QYN'3P%!FM1T8'3Y'1ORQ"5RR2<D,K]DN,XZ9R
M)56!IR KIE$#JF(Y57WED3:C<HH*Q4CE7[EFSU\-VF^/WOWD"X#L>XZ*SHU>
MMW,T1HF)2C=6D4;ST(F;__-55$ZLE>>2=;A4)%/)HM#@%)IZ.<:ZS*3D)KQ6
MAD@0>3%@Q7J[3/&"-&(94K\MXR0*H\]2U  >1F5(*%5G<7_-FV?N3EF5(N4O
MH=$6W6O-I]:P<!E\*E-=<-EO;S6M.YM[<?:J,B"7=F4]I2?V_%65Y2<R51*O
M,]:+E3=J\9CP5RY16*O4TZA[3GH#UVNY5JY$7+?#I7.HB(JOGP,O-TJD^-KV
M/$P*. TTK+ JZ)5RT=HUL!/M72,N+VN'DP6[#]C*S)HWY9S+@SF(-1R9*=A=
MA+@7*G?5[E;M2@_P@%^R!-!)MO& O<!Y +B<&:XW[&JTVA@F?RU;JPE%H>)9
MY^D1U_W)$M(F=4H%@<AA030T*\(S99L\:E:MNO%Z*%.?I\Q7E<^A7O+&EKJY
M5NBZ0MYB?VWQ>;@JC*Y\3W^S7EC')_@G5!5YI/R%.5*N ^]"K!*ZFH#W7K/"
M)8\&<&OU6JX8=MYXC=*:8?G]\FF77VN\Q<<)"##4?->;_$54SX#O@G-4%:G!
MC1Z[Y!*?M0KFV-B;H NJ2^TSNJ*N9,(>T%M2<ZE4 \" TTOK]R@W[.6:11"N
MV:OOE^Q!G\Z*:J'K4?L-Y)9<UR"Q=16]K^W.K\KD)Q?!4O] TT-/WIOE;JZ
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M<*9I?7WUX!5VU2YGMLJRSJTM&[5H?!2G#DAB8M-8VJ$)EJD$PN/,]RRPI<G
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M)%I3JXV6RUJD&%H5M$2?VSPL=5M50JTE&DO4'D,G<"$>G@!$O@ W8'^R<KV
MV&- (4]>0DZ4'"CFUK1\JU<O7^SSNY1ELF8E(B!\T',HEL#"_\706#$<*X6G
M5I%'4A%5>O+ZK6DH4.48UZH*E$E[+EM):IW*Z=0Q4XL)CUZU)ICXT5)^_#"%
M'HV\=8GZ:%14[P0R/<E%TJKIR0*"E<1@Q2!*M*%6AIPR7$$;,P'\A!W/AXP'
MW(?H00^X_ A-%.7T<1\\]# 5-#+K+LR+9]\BMJMT9G/M:P20\OO,U;1K =:*
MT0K+=8%W$?;UL<7@60O,%O*L$+7X'N%6:F.MBSE=3 <S1!QQ,L&>^!>/*LR
MRR.!*G6KU$3I9)7?TZZD3IDH213!Y'BB#PE$M:ZLL^E3Y B5E=7Q@?+[Y:J-
MG]JVK3;<P9Q]<5O.C)]KHSYFI8^.N\KAK:JBLT 4!#6E\LP,YK!K*^Z;KP'<
M3F7=US;H:MM^1:-64J0T=-G(A2[SNW[U^*PT/HNV8"7CLK"HAM>8BR[FA)8>
MA-5D6@NU2*B3*?#F] +<P=LQ^TV<G$QO#TF%K%%5:U4M/9:0$[OH.3IM22V.
M8%M L 2&Y 93/157/-M0- OG?RV=@)NJ@P[UW+MNSD7Q6EE:O,S%:58[_U#O
MVZP0P@U\QMD+Y')[U5-'V(K+ZLRIS5Q@32W(3/A5]&LM.ZX';-5UE2U? 'DG
M$(9CD;G]=(H]?I\8\QRX%%H3'BY0BK]B(UIZ49 -IZ\7$2"+(XH*)S!9$2@K
M0E7',/33L8KF\_0O&NYL,Q>@BE.RZM%;U2J.HX1=D<E .Y0&T"DQAQ5U2A=>
M639=SO)=A@NC;JRPG]K4K2SF0Q?8=^R?["L-F=DCR&8SV05VH*L2MD[-<G^W
MF0L_%0I==+8=]19)W8KZLT2']4S[R$F7Q0'EM9O36K%SD:R-)%[6@9**2P*@
MXQ[!-H2.,,;&@-E(%'E9T2*>C)"\<&AQWQ >+N_X4BXDC]"3CO%0<&?'^GJ6
M6;[X;4LQ;:$!&5+'-TSSE=E'$5(OO+XI?6E:K=!5%3IB-]6*]4D*ET>!<J&]
MS2M5C$US=JM502^MO#"95*^*QFRSE\\PU$@MKZ--E:--R /,DP=N@H^+Y<$;
M14Q7QJ JM* C^'QF8+G@,]&I&%&JS'(Y8%9QW&;M^*YRL4#AT)>4T1%Y/LDO
M>\M O7SK2:J-[4#$_3SGV//94I>[PT-90KE>1]<,1/63?[*VK+"QLNLZ_F2"
M>K>3ND.??PP_I6[;%Y_95S298N);7N'3"9([_*WP%8=S;(OF%%7XO[;C>MO\
MTW:CN;W7>/E G?A"\HHH.-'AC>C54,3U5D$A>X:A" &-7U=(5AH!,!5U=J#K
MTT4SXI[XU7A1^!:##$]93?%ON@"BH1W%[T=H2B2NP$6Q)%]?"MG7/_3$P&HE
M1+!H(RT#7=(IM%^.\&R'(EL'1+8X_R/5<:5.[;FS#895^F4UPG[#JM7T+M42
MM)TJ'<?%^1^K$\PKTV"P<L>L;E;,E?IW(*K:/ZL2]A_5E?0?/80C +S?B@W&
M[O*42W?8EYQR:0VH3X#-AEWX&(5X@N4M^\9LR8X/)WQ1V+) 5.K]ED\"_HR$
M*,5L3H2=OJCG!"1:BCWDNMPDCLLRV,R.\@/^ZRG!P33N!+'F$X;6:K#3PTW&
MB%SN?2N?>]]/Y=YW<KGW)G)JHW0MQY.,C>EH;TN64VXBIZI"3ZXE,G9D<OU,
M)%L&46_81-EFUY(\-S,)UH.<6+*DLV<F!<5$<J48->A+Y%BTE#D6)A)>';P.
M1Q+[#ZW%_D,GM__0\?J2_8=N8O_!2+8]#H7E2T<NC&XB=^0@]<RM@GAA-Q<O
M-)'PBLAEXF[9-@/@Q&=3O/@O9FPLS!%QO"1-.UN'H0_(O(CZ(7!I(?EA/,"/
M?QJ$;T*]W[+9&H_\U9FB3X.,"_WC]E%7)/M>8N\H(/R4ML$$%\)5Z'L;LG\Y
M;31CQKCG=+UKAI%-P@E+(VUK;8#TI:IG:'?@8!W2*Y.B-)MXB3 AJ1WPP=P3
M% A')FR1BE$53S)]G#!!'Y-)ZRK(>H3)EUU%L_PS!]_''=8^%3F:+6>&J'A5
MYWFR2DE352X)JY;&37:3*7@%[6>6FK#N:@S;,&<JTJ'PRE3ME[+D66B1G!:I
M^;4)IM,_B_;0E:?O:[$J.I"DN@@[>,8S4AE9*XZV2MPR3YVTN+*2#1"?-EBJ
M+71., D3?LZ1QS4X$O?S5*@J)*ZVXJW,1//TK"JS5E2Y6'_CUIF-.T,V?+:3
MEI*FU95*CTUF:I&2'6MZ*TL'2'0G\A1YFF*TR/[)7)@*U%;G;2RP]9EKHAJN
MRL3*VIDZ;S3$I =\R".7-M_,>JY*J"9J55TKM(Q/E"PS3[7TB%@IS' -W&*O
MX3D;]2J:5EL?]=EDGO:4LD/"D);S/0B]1^9QMQQ'[)X#MP>0T_&.P!3YP,UM
M%UQ!VP64/EW\<^U@]^:HE#N+<0/'#Y#8B$*'!]6C/2C6%D2S>*GH0;&!%X]X
M@R/'J].D<*K3;L!3&.IK<D&&6.4B&^(&KTEY=>>MF!NQSIP0/ FGJERB2K3G
M%&N<P4Q9@1C%#%QL4CXKMT.7!/F<T(XJ=8?L_VP:.6+M\@D&$X?-.32Z>9/V
MP#P\QV(N+RI2(K54BG:<.I[_5"JQ]KQ1CEXQ)I2A;DRB0/<U]/VPFLD*49D6
MF;.8Y"E/^[KG:5_+XYK/4#/*J%"NKRZX'P#[+NLN=5GK3V%8K3UGZN!7S [Y
M<%CH*,9IQ$;37HY>OE1$9KFXE-E/3C ))8I?)3=V%%0@0MN09BOOE#DTSR+P
MK4:N&O>)BPH7YPW[\,$_=!/SGN.3MW[\\8G==#5 Q:(GNVV$F9.+V&*H$^$;
MP$91O3IXE;!/T ,WFBCTPUH&$EX&43Y\4X&]ELV8$YY=,)!(7:@*[<[.;P92
M60:Q_*Q$M><(C")^71(TTLY5UP@;R0M=R'JG3*)\?;;>94XSA ?D369#->CE
M6?+EIQI,YD9E]/*QH7JZK_*(C"Y8Z.=#)$^0=>_X;\>L)K&# >QD./=X5);&
MU19'PJ17UYO*M97PRY<H17/*2]Z?(7OTZ5%-W/&SI@ESYS*8#"#!P]!],6!+
ML!RC/)@DO4E<?CFUN;JP+C&*>611XQ "3J18\A)/X.HRXA'5H!2B@KPL6PP.
MFN2@KJ7<VE=O/VNM7XU*A;Y$M98]1%$;WH,!0T$)3Z8OF4J)*E=PPKCG0-(.
MM&7_=-3)@$H-<&,)JTP)7]WX!47<2.37.X2W97#_?23*'<Z716)%OP?$B6[4
M%O$YZ-Q"-!KSYTV9*0%&,.Q:;-IY@N8 N'U()FD&Q=0^-8N>EF2YS[(F#N9$
M#B'ZBS&_,M&/I?B+1)Z_$O<K$_U8W.\&OG@/EW6I"87^*02P"MW2"6B-6]D?
MZPIN4TU$TUFED#%%#E,%D>K;<EU^?1B_XBDZN?YL3MY7HT-A=M]X(*Z=E(?!
MI,L0JV(N73("7O3$.U.UA N+AW&LXQPQE75"I;U"].Z$D8>)L4-P4R3)EJ13
M'$Z>-B2>,0MV#I3J9(<J.FRJ5/5!RX_^$,!70IY"VX93 FW$API/_PGS^HT0
M9#E*><0YC$1VAWT"^,+?!G,SC)DB7.I,,TRY= ES4!G1PM!);DA-HV^5R%C<
M<K-Z_E@!*L4PZV,?N.%J+Q8CD].#<EBE=D*<.924R1\8CT_!4071$N5,V$=(
MXY%-6<E;H9+OIILZ26OA56?;/K==0LW-P-9H1."(,6=Y%FK#5J7L%J\UC<HR
MX*IYG+7+3W,9;SBG<:HH:C%F<&\B3*3DC&#N=.!%KA9;%6Q6ECG9F=6*?WWB
M"48;J7)#?Y$.$$Y4(L( '0/F3RDTU7Y\<15^'I&.#;Y'KP2XRM)/%F>S<LH.
M6=F2VE!T*X=+GGN?T=[%VUDG$)HTYC1QJB88L:0@*AP<?F$DY.U$]VDO+E,U
M.M-<DP*9%1!'CH69;8"JIO%([R>-5\G,\=T"X^6/F"V5\*2WC2[3Z@TUQ20(
MM1QDSQYG'0'D^7 $R=-ZE3E(B@@MF@P"(H0FB [S" RVJV2(E>>6%_-D=WB%
MY^&# W_\U%X,2^JWB1+S*^@$MFF&H0*;W T-Y2B^L:D<+8Q(4Z)F:H1ZMP;D
M<GI,G?9T(2MF$L&DQ[[6:.W98XE2IIF+U+1H"]1HRR@/5G4V+1RFE]#G%Q[0
M'C1M LDCD^K;8> Y;&&]X3E&PB\U_01Y,6 I?8G-]L,00CXWSRP")8A5 =3<
M CC/CCF35N=Y>HP5NQHBWFWJ+%^ KFP=BX($RP/_K:$?>4VQ1T8W9XJLOZ%2
M';)<F#R$('A_!)'+Q$8W9AT_5EA'AEA]JT\R?2$,H[0A12./Q]W7]C37%FD)
MOA7.8FLDSI@Z@C=%TDJ7L&<D 7DZ$&OLQD-9(\F\J_64V%5K5'271>J&#X-G
M@&*\*XE[N3OS+"2<A2N?U[L$C1 K9\S.;0:0XHAZ\>O>QDU32ISJW+&0$T+(
M\6K]QQN#Q;!DHRJ\%0HZ\5@T^OV./%BM:^[BE!5S##\9,L4&.F/A14 IOH \
M8)JDP<$\H_E1AT\^HIZ!(_4-6\P; 89@3D!1Z,TA?XK\$!G"Z P:Y?EA@O$=
M*PZC^V4O +F#/C6$#B4XI6<'"::+=_3B*YLZGFT&867P5#,4G\,.@7=W-(;V
M'5L"H\Q.0PA3HY/O5L?UKL%,N'5&$E4(3JF&8P27#S>VH8WX!,[/_!-32"L#
MJ,@-&1-$?3P=0]*RX0PZALQ^4ESJ4)!' Y<SX01"0^@H@*0B(7_9L1ET2'$I
M[U1;OCK_\?BJ*:XN,V154D&36<PG(EK5';:\RW;K\+S5)1>MUA4<(0Y7I+V0
M_A@N[X_I>"UOWO69"O>94X]\3.8M!LES6*E;S%P30UCQ2&1)CY&<]_KXP0S:
M4UBD@'D#+4, )[$H 1\:!/A0!_"108"/= "W#0+<U@%\;!#@8QW )P8!/BD!
MO%A&6A-,_.@8GAGX5=!*R3%DP2Y:I:5WNA^Q%0W9P.T3YIF9@;\0D]25ZAA)
M@I0&&16>$]CB0YQ^:0@A,EPJ8_83!C::'&(R,H.('!Z%(#[AL4=-F8W28.2N
M:70',/.;^OC&9T;J3]@C>$J0B$OWH3WVL(M'<WZ<S S*5D LG0$N&(8KQ ^_
M N)[D-#S<T,,) 4RU=UVY I/^ ET0XC(P)$?^Y3<1VT&&27HY%2Y()P 6R/C
M9F<E-L4=YP0.F1.Z? G)$&HDL)2$\ DBL3-^B?UP/]D8DDH JHA#,Z:S[OP2
MCK"/$B]7Q>=-EHMSRW..'VQQ!\PB%]$8J6Z&#&5>T"AP@8BN3*<$SX#;\?IC
M>(((];M#]A=/((ANOJ&WR!\C_O/Q39<L_G%S9@:W-DF*_+*X+X<\O&\&Q6DP
MBE0): >$W_\?[6LO%,00,DK@J4Y@AM<.)0Z-9W/!S"!0"Z5*@**!:^@A3)X'
ML7I8E0\-A V9M= 6@U)K:'01:,N9A<^F-1O-O;W]"^0%E,TY85IJRR40.'/^
M@&O/#6BO?Y2LL=?8:^Z;XX$\"DTEJI#NT&!>I$FJ<FVM:005@5-*:8R)SV_'
M.L? $,^E")*2!&8<(%;1IIS^O=VNQU,OW!;[;TZ1*7.0%DAYGFNJ]G[7:\,9
M=/&4E^D.KUL]D9IH)JUE:%43<:ZE8Q?:/L$>LMO !T=@RF]C/VX?G>)S-(/L
MFRDC<G7D<I.B/T8DO$G(#")S>%17?_&R.IY0_&:M022N %OJC(@#=/?,=(;$
MY%"++DS5Q)P]P6$&91)4LJDWII>_$)EBQ"5FG<>9BR91I@55,<DL;I!H19B?
M/#-?\9SE I/>\YP\+8E#U7X5XBEH6((2L\2[OV]O6_^YO?CR^K__Z1U^!W[K
M^]7@S5WCMX;W_V?#JU=[9Y\^^^?XT_#K;]WQS>G9W<,]_'P_^^R\P<W9Q_D;
M\L;^0A[&G^C%_5X;_$!?G4_3SF1P^N+^$GQR^IUOD_G9Q<=O9P<>*]S\_/7L
MX?SJVY=[_/WUYQ\GG\\^SW<=CWZY/T+7W^<?QP\[7[\>D,GXX'(_P"^"RR^G
M+_S;(?Q^\O#MXF[6:4ZZG[Y] [_U ?UT_.;RU;C[YF9_KW$V=1R\.SD,KJYO
MR=VI<PU^?'3<_=W;PTMR^_'K^;73WIDU.Q=WKP<G_MVGUZ\?X/[-%_OVDAS<
M?QJTIS_O[D87S?'YJX^=[Z]ZHX?VY8G=W?L67/[8/[[KSK\[I^<?S\X&YY?[
M_?[/R\YKTG=>_+2']V??!C_M_=ONY9?7MWO]V8L7G\'M\9>#4WORT^E=-AO7
MH#<;-[X=WIV_>?]?Z^CZ:GM;OD2UL1W$L[K'1#KO>$-,)N$UX\:,!2V4?#9[
MM\,HI/:8.01BL/\/4$L#!!0    ( /&@?EQDXZWC<PT  ..>   5    ;W-T
M:2TR,#(U,3(S,5]C86PN>&UL[5U;<^*X$G[?7^'->3FGMAB2,,DDJ<QN$4@R
M)"$P0.:VM;4E; &:V!(CV1#FUQ_)%V*#98R18]C-P]8RCE&WOJ_5:K5:XOR/
M)\O4)I R1/#[O8,W^WL:Q#HQ$!Z^WWOHEJK=6J.Q]\?OFO;+^:^EDG8-,:3
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MCIN&J<,!TI'J "&%P%T@*@UNTHS)ALL OO+,??I;*6Y[TNZ)<$CB;]6+-#%
MD2TV:84Z-8)%K0_$NOI%6Y*D'>0D$3AY/G['>IDAZ$[.?N]*Q^/>DKA%40E7
M7BB%4UL?MU1;'(8M7"*7T0G,B_P\07>$J1[\<1*RKJ ZD$%._XAS68<3:!*W
MQL0O7E(^Z2?)*M:L$UB+3OB)<"U/)Z6-%B_>&0RQ058U+(01LX62$Y@//ZND
M%;J<3$G02L269Y-2]OS#/<$DJE<^S,CE9 ]6&G@"F3OG>BT&->V*59>**7:\
MKV0N;%1RJ!0G*]Q2T6755,\?$BF%!U5KD2+%2FUM;<"UKTE8H/*1(I=4<$R_
MYFA)0&PYH"UMPLZ2$>3C?Z5B=LB)R:%:#L5+F>O/K@"B;BJQ:GQW/)_9&@2;
MY8I929:U0]2L &VYS",[/_?0SFU=$FV[^-DDKJN1$1$74JXX0K.5'4DP-K63
M8423Z@0@TTM7A#+3_C+_ C"DYVE?*:1O$VWIP8H0&V5>09VP6[!2A]""1E!6
MUL)=2$4ZIT9XG$MMQ+6,[@VE*N!9N]'M<A#K$9011NGB4WN!Q-?S.75IQBNC
M3_#/_ H<C(O9 Q-)MKESK>I\_9U'X=(:@C/OM_R[ILLU><S74P4MU^&80AUY
M8.#(?0.*"4F25/Q<L@$YB1"NW%Y9<\\_U'@K. >/AS7NGL2&01TQ[PR,ZIW_
MM&*++BG=C,GTZ"JI#W"GN>X(\.5\@S$'&E>$\EEN@O1%;RX)"F3?W5%OEXR'
MTIW^8+FN<RWS36J$)12\:-YH;,0BIO*(Q&MN0P5-Z9(=&QV=<(?I<TW!PH#U
M=J!Y* U;@QJ/S1>+FR2N;)WV=MF]K86;S]8[)2Y/2!)7U[0&[G*)SV>!683<
M;(O63( LU>-M/=F['42LB;//\8D2CEV;XLMIOAPEEO#1>03R$B$['</+@//9
M.544OO-%'(5<2AUZ_V_@A4/KRC>]5LG;45^Z!J#!8GE?19 2*V_AJ/M+<+@H
MLM#BD1PH7((T8%%5+<"R5.\BJ:CUB.7\R_.;7I-=CE0W8B P!S4G*995B5XS
MECOC"^)V>BI=#69 WG*9@E*7'%1*=* .T408D_J;T-84_D]TTQ*8 Y*5U#U(
M5/<JQPK8!8D3G/TF2#!S:_-[I*KS12"%7)KAB(9A+E>6K9:WK4%A M^1HW>K
M 966$BNTSGG^^*6M,T[P!O>4>K<-7W&"W DZEZ-0,BG;:HD)W"Y<,QD/GL(=
MO+",Y]Q#3HG3%<*V-'.3@:TX))6>W@T+ZXX(M7N06G78S^&N5HF<?PY9"_BI
MVYR+" $FMX9HS8FXG\B[3RU^O$F2W1F:W4VR,H.H^"*TN)'=P%Q=8+:=OHGT
MUH KI+[H/+W<;5P9;. V)>#*]@LW9S54%I:S$UV4M)V+]0S<+4$HVRS,2%<'
MCOW O#7(<\:3R]E-)YH"O^6-PHW.?0@EQ7\B6IUPC\U%=OC"BR+=+W1T77;X
M0>C--A_KQ%A,%\QO+N(?W!\MZ7"'?\D=@ZZ:_A=6OFB;*H:KA>+$U'FE+:S_
MWUH 8[,=*]8@KP"N\JM)BX,<2L37^ZFP,%^;_IX0[SWG[ Y-W!0M!U%,[/Z5
M^LKSX"N$99^*$AJ.P?&>@]:;0G,"FP3;(^5E8YLI4_ X36<0D6*R#<%7^H-)
MZRGS%0+:FY)"#2#0H? D9M[,S\%6>QXN@Q*<9]6[M5FU*#HP?!'2/;PE<^K+
M<'Y%'%HXY:X2Q59CO 3?'M:*DW,9U.#O%D^Y4.)?0+F+M3QQ]P*45P<VI%O!
M>U23?S;Y"Z@G)P-S73DI_%EBR0(KV\E);P^#R_ PO*;J3[%*A&0.HI?:FV=I
MQ,E2]\[$ :%30(W<>Y(@N?" .9G;Z.'/-0!5>FYW02[_X!T;B<CT+VR[</B0
M@/E;9SHEBO6;&W";$F/9*BA'GH.;$XLA>"Z]X R'<FJ?896F#171&O[=$N79
MN572"MU\3@E%(GL^SVKOFXXU"7&VTL/'-,E4;'4KYBJMU"USHJM)2PUGTAVB
MN<:9_AZ"NR'.0\R:N_/ G;I?EA)T<88P;R9\]\O\NF,R\*=__D=U$:=;1?/
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M\,ICB$SS$(QQK?GA+8Z'")67KK#NB'K4) 8931(&.'T:@2HY@0](:+; %:V
M]NJI!0Z0-!T82PYE_@@K#F<\^#4DWH43A\S0TI'KIJLT\P2?,P!='WH9TQ X
M0 YU8"PYE'DO+.,"F8[44L(!<]8@8)A.I2:D2EJ@8QHJ)T=V.$'G2"ENB <
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MNFIL8QCXJ*G@4;HX-&7"X:G3]4"16PEG,SZT%$LT3JIG*G9^XO>ZQ9WAMH*
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M2<AV,&X21Z'OGCN),W;6_"AR<3[^&%W[CX3'M9HH@'WSW<7R&S#= CT=9S4
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MGF]V>F2*[ I^?<_^15F_^+- K$L?T*[9N.W:DZ7_B!I*UK'OE##T9^LS!",
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MZ8$/!%A?1%(&X^$3PE32 I>@/M_7[WGMH_+-W241WCB*CCEZ3?6>"B-<2EJ
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MJDSNB\XTY9<H<)+,LW 4ZIIE#G?*"3!4EAVQX:\X@Z+P5&^[%[D(5,7+!+
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M.0Q@<''\D,%@&5>WG#,_#Y_'"(-6(.S$(2C)',\7"'/@HQ[  34$2)U5%T[
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M'!@RPFF;0<#2S3J? PY"""KJ+R=RQ.9+Z!09C$$JN_FR-/_''8XBEX4":M"
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M#P'6R0MK.^_QQWR%WPLI#B\<.)U>"/S9]<;3(S#!ZWDS;^9/.B7Y(Q8O?G3
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ME&J[H,+'F$1LQGGQX!@MH'42H<4/L[' +4G414D<.=9X7JKE^]OEU7(^N]V
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MF+GKXM@^"YYQK:(,F[/X.=E\L7+JDM*% RM<6VFZM '<K('>I#="ID$A*1?
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MQ)W RAP5?$:</W)SKIU=&JT/F*:0GHC'\N+PJ+APQW!XX5F B\O%XF9V<;T
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ML<UX,U[&69X><$Q(8Y?&Y;6RIR0*UE4<0O'0F[C,-VGX^ A3PPIN*#<NE-Y
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M+@?<JW'R(4$F$D-:_(@;XEN%23RTY<NK"3#.D/7,%V$V,K-I]IR8(-(<:6;
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M7]59V_FB%8]5)$?A]+CP:35XHXJ$O(."@=12+!2M1YM,9+6UAB&2!6.\4Y(
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M?T_4VS&HJ([^/8Y9J?!J]X%,*@GZGHQ:<TL\;W- -F"0ZRQIE\)H5FJ-PPQ
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M"E-:Y&/X%#QE-K5%#N!4F-1*'\>EX"^["04;Z*0+=:Y;SUBD$9T=[ 7K(:]
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M1LSIA0H-*^9%V^HA-K-^^SYV:#SL2AG/K@C?2E#EP.+U8!GH+:_'")^2I#+
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MI?S'A[^[EZIY!1+O$'6N]#6TI)'\@[V)E;M6B)&G?X"WJ?\6+XP8%SF>U/1
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MNV><X,+%QZ[+9?&0XZJG,O*Z1/PY@PLH^*IT)JT)W<A4,)AK9<^R9::EVW:
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M23RB;76 2'0E]&#YA@RT4B E-=:KP">95II!2JD#-!BI6"!2!BZ,WB4GQZ$
MHWA@2L*-N8,6(N[6P+?%SR<V<Z!M!Q>CC;#'. ^4^Q NRI%. AN5D*[VWMEX
MF/UJ@VVJ4.FF?3S#OF>I# :\2Q AST?EE':'QEMWVE32#;J3-V8=F#D,VKU$
M@3E?;&4=#LTK@5P3GGUB[V^BHLH3T\"0LL-2>02AV#JD+\.F]1HFK*#VX:&@
M44KY)RM;M.J;1T3Y:E72LM?&304XMA"-GH;G6:GHL(&\@W$/+JH%*%"T=)Z
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M&S'T!62JBM$B/!9WT_=R9]K?GB()LTY56:LMLXI\ U_*AH$AR@:]GDBC8K1
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MTMXTC<:^@\$;1,G1_D)</DF!P/5P5(ZYGZ3,F B[GQ+Y,DZ)/(0!WSFKV8W
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M#4KXPKW?55&).T0]#73'RKD;WM';* W)<VM%#.PAKW*/=FIV%LZ38>^<1V8
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MV?9OQ;;RAB =!SG@YA%*LCT><,DB''D>9G@Z/FL-.PG&U &FOG4^BZSZ#;#
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MP;T)H!.74RW\N=F$03K\R(CKV4!@6,@W &3UHB)CB-L^$$A@]6Z"@Y)64]]
MD">ED-G>_-:PAO.^&PC;D;#DQB4#I'JH6CM.UM3GW9A<>[*7J;4_;D-,/9_U
M*@K#C_0':.QL<>SX60L5F52N]A'Z>!7; 70')%:VLS&*0G*+ R=PL>,_H&B'
M740F@2LAJ*XQ>I@PT2&I3E3 $\)D"\>&4;Q T889[ 7]P,0!JY%&CV-F'>
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M;HT/=:9)3&(G\'"P@HZ==Y$;3$9X-W"%9+5?WZKZ]L73N%'@I=P1<W)M)36
MU2H&62%1A5B:WCU7T<Z1!5=9RV/$T#N$\@NFA2RLX% #D)DH*(74 *)L^EE
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MX'0]#$NOAM61 VM')57L*+_";BDUR*MQU/BES:B(B'PX\X4Z8#^W 3NC+*4
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M?_SOB_'#_.7+@\F!D.LH\7!<JM;!%S&5\2OV3X]T!V9_^_]02P$"% ,4
M" #QH'Y<K  _7^0% P"4BA< &@              @ $     96$P,C@S,30V
M+3$P:U]O<W1H97)A<"YH=&U02P$"% ,4    " #QH'Y<8'!T>S8@ @#^*P(
M%               @ $<!@, 96$P,C@S,30V,#%?:6UG,2YJ<&=02P$"% ,4
M    " #QH'Y<N#^12_OJ  !^[P  %               @ &$)@4 96$P,C@S
M,30V,#%?:6UG,BYJ<&=02P$"% ,4    " #QH'Y<>-+J$A@"  "5!P  %0
M            @ &Q$08 96$P,C@S,30V,#%E>#(Q+3$N:'1M4$L! A0#%
M  @ \:!^7/%K1P@G @  ZP8  !4              ( !_!,& &5A,#(X,S$T
M-C Q97@R,RTQ+FAT;5!+ 0(4 Q0    ( /&@?ERG,P41,0<  /LF   5
M          "  586!@!E83 R.#,Q-#8P,65X,S$M,2YH=&U02P$"% ,4
M" #QH'Y<.RX58S4'  "S)@  %0              @ &Z'08 96$P,C@S,30V
M,#%E>#,Q+3(N:'1M4$L! A0#%     @ \:!^7.M^&,\=!0  LQ(  !4
M         ( !(B4& &5A,#(X,S$T-C Q97@S,BTQ+FAT;5!+ 0(4 Q0    (
M /&@?EQ"3B 8&@4  ,82   5              "  7(J!@!E83 R.#,Q-#8P
M,65X,S(M,BYH=&U02P$"% ,4    " #QH'Y<MZU^&A@>  !.H   %
M        @ &_+P8 96$P,C@S,30V,#%E>#0M.2YH=&U02P$"% ,4    " #Q
MH'Y<6W[%^W88  !]#@$ $0              @ $)3@8 ;W-T:2TR,#(U,3(S
M,2YX<V102P$"% ,4    " #QH'Y<9..MXW,-  #CG@  %0
M@ &N9@8 ;W-T:2TR,#(U,3(S,5]C86PN>&UL4$L! A0#%     @ \:!^7(?B
MLC+35   IS\% !4              ( !5'0& &]S=&DM,C R-3$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( /&@?EQ;YH_2$\@  ("M"0 5              "
M 5K)!@!O<W1I+3(P,C4Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #QH'Y<<P0,
M/]=7  !9HP4 %0              @ &@D0< ;W-T:2TR,#(U,3(S,5]P<F4N
9>&UL4$L%!@     /  \ ZP,  *KI!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>ea0283146-10k_ostherap_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:osti="http://www.ostherapies.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="osti-20251231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2026-03-26</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankCheckingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankCheckingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ChaseBankSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:SVBBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:SVBBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:AyalaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:HER2AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-04-09</startDate>
            <endDate>2025-04-09</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2019-04-19</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:PatentLicenseAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:UnderwriterPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:UnderwriterPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:InducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:InducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:PrepaidCommonStockNotIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:PrepaidCommonStockNotIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:MrRomnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:MillRiverPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantsForPlacementAgentNobleCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-24</startDate>
            <endDate>2024-12-24</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-24</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BrooklineCapitalMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:CerosFinancialServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">osti:ShortTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">osti:ShortTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:GroupFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">osti:BlinkBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:AlanMussoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:AlanMussoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:ChristopherAcevedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:ChristopherAcevedoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">osti:JoacimBorgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:JohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-01-31</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-05-31</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:BlinkBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-31</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:ConsultingFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2026-01-28</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2026-01-28</startDate>
            <endDate>2026-01-28</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:LicenseFeeToUtilizeProprietaryTechnologypaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:GLPToxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:IClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:IIClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:FilingOfAnNDABLAOrMAARegistrationorTheEquivalentInAnyOtherTerritoryAroundTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">osti:RegulatoryApprovalInTheFirstOfTheUnitedStatesWithinTheEUOrWithinTheUKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeeAdvancepaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeeAdvanceOf212335MinusTheAmountAlreadyPaidPlusPTCFeeAdvanceOf31325paidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees35OnElectronicDataCaptureEDCGoLiveDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees35OnDevelopmentOfSAPTablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:StatisticsFees30OnFinalAnalysisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">osti:ServiceFeesRemainderDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-21</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-21</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:EquityLineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">osti:FairValueOfHER2AssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">osti:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MedianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">osti:SeriesASeniorConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-09</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2025-04-09</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-14</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-09</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">osti:SecurityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">osti:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">osti:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">osti:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-14</startDate>
            <endDate>2026-01-14</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:ThirdWarrantExerciseInducementAndExchangeOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-14</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-28</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">osti:PrivatelyNegotiatedWarrantExerciseInducementAndExchangeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-10</startDate>
            <endDate>2026-02-28</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>osti:Segment</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-14838">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-34">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-14839">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-14840">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-14841">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-45">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-56">001-42195</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-62">OS THERAPIES INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-72">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-77">82-5118368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-14842">115 Pullman Crossing Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-14843">Suite 103</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-14844">Grasonville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-14845">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-103">21638</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-14846">(410)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-14847">297-7793</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-142">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-146">OSTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-14848">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-14849">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-14850">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-14851">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-14852">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-14853">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-205">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-212">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-218">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-224">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-230">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-242">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="-5" id="ixv-14854" unitRef="usd">49600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-14855"
      unitRef="shares">39533227</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c0" id="ixv-14856">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-5150">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cybersecurity Governance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors has
the ultimate oversight responsibility for the risk management process and regularly reviews issues that present particular risk to us,
including those involving cybersecurity. Our board is responsible for ensuring that management has processes in place designed to identify
and assess cybersecurity risks to which we are exposed and implement processes and programs designed to manage cybersecurity risks and
mitigate and remediate cybersecurity threats and incidents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our management is responsible
for identifying, considering and assessing material cybersecurity risks on an ongoing basis, establishing processes to ensure that such
potential cybersecurity risk exposures are monitored, putting in place appropriate mitigation measures and maintaining cybersecurity programs.
In managing cybersecurity risks, we adhere to a structured framework that outlines the roles and responsibilities of management positions
and committees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Cybersecurity Risk Management and Strategy&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have implemented and maintain
various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical
computer networks, communications systems, hardware and software, and our critical data, including intellectual property, confidential
information that is proprietary, strategic or competitive in nature, and trade secrets, data we may collect about trial participants in
connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information (&#x201c;Information
Systems and Data&#x201d;). Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk
management processes. For example, the cybersecurity program works with management to prioritize our risk management processes and mitigate
cybersecurity threats that are more likely to lead to a material impact to our business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The cybersecurity program
within our company helps identify, assess and manage our cybersecurity threats and risks. Our cybersecurity program identifies and assesses
risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual
tools, internal or external audits, automated tools, subscribing to and analyzing reports and services that identify cybersecurity threats
and threat actors, conducting vulnerability assessments to identify vulnerabilities, conducting scans of the threat environment, and evaluating
threats reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures,
processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems
and Data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We use third-party service
providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example
cybersecurity software providers, managed cybersecurity service providers, and penetration testing firms.&lt;b&gt;&#160;&lt;/b&gt;We also use third-party
service providers to perform a variety of functions throughout our business, such as application providers and hosting companies. We manage
cybersecurity risks associated with our use of these providers by reviewing their security assessments and applicable reports.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are not aware of any risks
from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations, or financial condition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We face risks from cybersecurity
threats that, if realized are reasonably likely to materially affect us, including our operations, business strategy, results of operations,
or financial condition. For a description of the risks from cybersecurity threats that may materially affect us and how we may do so,
see our risk factors under &#x201c;Item 1A. Risk Factors.&#x201d;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-5157">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our board of directors has
the ultimate oversight responsibility for the risk management process and regularly reviews issues that present particular risk to us,
including those involving cybersecurity. Our board is responsible for ensuring that management has processes in place designed to identify
and assess cybersecurity risks to which we are exposed and implement processes and programs designed to manage cybersecurity risks and
mitigate and remediate cybersecurity threats and incidents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our management is responsible
for identifying, considering and assessing material cybersecurity risks on an ongoing basis, establishing processes to ensure that such
potential cybersecurity risk exposures are monitored, putting in place appropriate mitigation measures and maintaining cybersecurity programs.
In managing cybersecurity risks, we adhere to a structured framework that outlines the roles and responsibilities of management positions
and committees.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c0" id="ixv-14857">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-14858">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-5169">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-14859">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-14860">Our cybersecurity program identifies and assesses
risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual
tools, internal or external audits, automated tools, subscribing to and analyzing reports and services that identify cybersecurity threats
and threat actors, conducting vulnerability assessments to identify vulnerabilities, conducting scans of the threat environment, and evaluating
threats reported to us. Depending on the environment, we implement and maintain various technical, physical, and organizational measures,
processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems
and Data.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-5196">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We are not aware of any risks
from cybersecurity threats, including because of any previous cybersecurity incidents, that have materially affected or are reasonably
likely to materially affect us, including our business strategy, results of operations, or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-14861">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-14862">206</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-6592">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;Opinion on the Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have audited the accompanying consolidated balance
sheets of OS Therapies Incorporated and its subsidiaries (collectively, the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024,
and the related consolidated statements of operations, stockholders&#x2019; equity (deficit), and cash flows for the years then ended,
and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of
its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-14863">MaloneBailey, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-14864">Houston, Texas</dei:AuditorLocation>
    <us-gaap:Cash contextRef="c3" decimals="0" id="ixv-14865" unitRef="usd">269830</us-gaap:Cash>
    <us-gaap:Cash contextRef="c4" decimals="0" id="ixv-14866" unitRef="usd">5533527</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-14867" unitRef="usd">63082</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-14868" unitRef="usd">332912</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" id="ixv-14869" unitRef="usd">5533527</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-14870" unitRef="usd">2490</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-14871" unitRef="usd">5270</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-14872" unitRef="usd">6504132</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="0" id="ixv-14873" unitRef="usd">6506622</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="0" id="ixv-14874" unitRef="usd">5270</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-14875" unitRef="usd">6839534</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-14876" unitRef="usd">5538797</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" id="ixv-14877" unitRef="usd">9936387</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="0" id="ixv-14878" unitRef="usd">1662068</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14879" unitRef="usd">1415002</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14880" unitRef="usd">521010</us-gaap:AccruedLiabilitiesCurrent>
    <osti:AccruedPayrollAndPayrollTaxesRelatedParty contextRef="c3" decimals="0" id="ixv-14881" unitRef="usd">36792</osti:AccruedPayrollAndPayrollTaxesRelatedParty>
    <osti:AccruedPayrollAndPayrollTaxesRelatedParty contextRef="c4" decimals="0" id="ixv-14882" unitRef="usd">97257</osti:AccruedPayrollAndPayrollTaxesRelatedParty>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c3" decimals="0" id="ixv-14883" unitRef="usd">1279</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c3" decimals="0" id="ixv-14884" unitRef="usd">375000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent contextRef="c4" decimals="0" id="ixv-14885" unitRef="usd">375000</us-gaap:DividendsPayableCurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c4" decimals="0" id="ixv-14886" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14887" unitRef="usd">11764460</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14888" unitRef="usd">4627310</us-gaap:LiabilitiesCurrent>
    <osti:TEDCOGrantNonCurrent contextRef="c3" decimals="0" id="ixv-14889" unitRef="usd">100000</osti:TEDCOGrantNonCurrent>
    <osti:TEDCOGrantNonCurrent contextRef="c4" decimals="0" id="ixv-14890" unitRef="usd">100000</osti:TEDCOGrantNonCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-14891" unitRef="usd">100000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="0" id="ixv-14892" unitRef="usd">100000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-14893" unitRef="usd">11864460</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-14894" unitRef="usd">4727310</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c5"
      decimals="3"
      id="ixv-14895"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c6"
      decimals="3"
      id="ixv-14896"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c5"
      decimals="0"
      id="ixv-14897"
      unitRef="shares">2500000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c6"
      decimals="0"
      id="ixv-14898"
      unitRef="shares">2500000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-14899"
      unitRef="shares">392500</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-14900"
      unitRef="shares">392500</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c6"
      decimals="0"
      id="ixv-14901"
      unitRef="shares">1775750</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-14902"
      unitRef="shares">1775750</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="c3" decimals="0" id="ixv-14903" unitRef="usd">1070705</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="c4" decimals="0" id="ixv-14904" unitRef="usd">4078025</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c3" decimals="0" id="ixv-14905" unitRef="usd">1070705</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c4" decimals="0" id="ixv-14906" unitRef="usd">4078025</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-14907"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-14908"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-14909"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-14910"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-14911"
      unitRef="shares">37113082</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-14912"
      unitRef="shares">37113082</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-14913"
      unitRef="shares">20869908</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-14914"
      unitRef="shares">20869908</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-14915" unitRef="usd">37116</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" id="ixv-14916" unitRef="usd">20870</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-14917"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-14918"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-14919"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-14920"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-14921"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-14922"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-14923"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-14924"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-14925" unitRef="usd">61053472</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="0" id="ixv-14926" unitRef="usd">35144967</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-14927" unitRef="usd">-67186219</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-14928" unitRef="usd">-38432375</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-14929" unitRef="usd">-6095631</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-14930" unitRef="usd">-3266538</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-14931" unitRef="usd">6839534</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-14932" unitRef="usd">5538797</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-14933" unitRef="usd">16360725</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-14934" unitRef="usd">2839060</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-14935" unitRef="usd">12344976</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="0" id="ixv-14936" unitRef="usd">3974786</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-14937" unitRef="usd">-28705701</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="0" id="ixv-14938" unitRef="usd">-6813846</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="0" id="ixv-14939" unitRef="usd">249</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c7" decimals="0" id="ixv-14940" unitRef="usd">2051839</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncome contextRef="c7" decimals="0" id="ixv-14941" unitRef="usd">33997</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c0" decimals="0" id="ixv-14942" unitRef="usd">1472995</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="0" id="ixv-14943" unitRef="usd">51250</us-gaap:OtherNonoperatingExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-14944" unitRef="usd">-1424603</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-14945" unitRef="usd">-48143</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="0" id="ixv-14946" unitRef="usd">-2069092</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14947" unitRef="usd">-28753844</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-14948" unitRef="usd">-8882938</us-gaap:NetIncomeLoss>
    <osti:DeemedDividendOnSeriesAConvertiblePreferredStock contextRef="c7" decimals="0" id="ixv-14949" unitRef="usd">31250</osti:DeemedDividendOnSeriesAConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" id="ixv-14950" unitRef="usd">-28753844</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c7" decimals="0" id="ixv-14951" unitRef="usd">-8914188</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-14952"
      unitRef="shares">29253292</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-14953"
      unitRef="shares">6950100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-14954"
      unitRef="usdPershares">-0.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-14955"
      unitRef="usdPershares">-0.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-14956"
      unitRef="usdPershares">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-14957"
      unitRef="usdPershares">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-14958"
      unitRef="shares">5340000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-14959" unitRef="usd">5340</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c9"
      decimals="0"
      id="ixv-14960"
      unitRef="shares">1302082</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-14961" unitRef="usd">1302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-14962" unitRef="usd">5495330</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-14963" unitRef="usd">-29518187</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="0" id="ixv-14964" unitRef="usd">-24016215</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c13"
      decimals="0"
      id="ixv-14965"
      unitRef="shares">651041</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c13" decimals="0" id="ixv-14966" unitRef="usd">651</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c14"
      decimals="0"
      id="ixv-14967"
      unitRef="shares">-1302082</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c14" decimals="0" id="ixv-14968" unitRef="usd">-1302</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1 contextRef="c15" decimals="0" id="ixv-14969" unitRef="usd">651</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DividendsPreferredStock contextRef="c16" decimals="0" id="ixv-14970" unitRef="usd">31250</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="c7" decimals="0" id="ixv-14971" unitRef="usd">31250</us-gaap:DividendsPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c13"
      decimals="0"
      id="ixv-14972"
      unitRef="shares">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c13" decimals="0" id="ixv-14973" unitRef="usd">1600</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c15" decimals="0" id="ixv-14974" unitRef="usd">4473626</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="0" id="ixv-14975" unitRef="usd">4475226</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c13"
      decimals="0"
      id="ixv-14976"
      unitRef="shares">13153396</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c13" decimals="0" id="ixv-14977" unitRef="usd">13153</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c15" decimals="0" id="ixv-14978" unitRef="usd">24743662</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c7" decimals="0" id="ixv-14979" unitRef="usd">24756815</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c13"
      decimals="0"
      id="ixv-14980"
      unitRef="shares">411290</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock contextRef="c13" decimals="0" id="ixv-14981" unitRef="usd">411</osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock contextRef="c15" decimals="0" id="ixv-14982" unitRef="usd">-411</osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock>
    <osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor
      contextRef="c13"
      decimals="0"
      id="ixv-14983"
      unitRef="shares">320133</osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisor>
    <osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors contextRef="c13" decimals="0" id="ixv-14984" unitRef="usd">320</osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors>
    <osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors contextRef="c15" decimals="0" id="ixv-14985" unitRef="usd">-320</osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors>
    <osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors
      contextRef="c13"
      decimals="0"
      id="ixv-14986"
      unitRef="shares">32500</osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockToInvestmentAdvisors>
    <osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor contextRef="c13" decimals="0" id="ixv-14987" unitRef="usd">33</osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor>
    <osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor contextRef="c15" decimals="0" id="ixv-14988" unitRef="usd">129968</osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor>
    <osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor contextRef="c7" decimals="0" id="ixv-14989" unitRef="usd">130000</osti:StockIssuedDuringPeriodSharesToInvestmentAdvisor>
    <osti:StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors
      contextRef="c13"
      decimals="0"
      id="ixv-14990"
      unitRef="shares">-669958</osti:StockIssuedDuringPeriodSharesSurrenderOfCommonStockInvestors>
    <osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors contextRef="c13" decimals="0" id="ixv-14991" unitRef="usd">-669</osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors>
    <osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors contextRef="c15" decimals="0" id="ixv-14992" unitRef="usd">669</osti:StockIssuedDuringPeriodValueSurrenderOfCommonStockInvestors>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c15" decimals="0" id="ixv-14993" unitRef="usd">268300</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c7" decimals="0" id="ixv-14994" unitRef="usd">268300</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c13"
      decimals="0"
      id="ixv-14995"
      unitRef="shares">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c13" decimals="0" id="ixv-14996" unitRef="usd">25</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c15" decimals="0" id="ixv-14997" unitRef="usd">24975</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c7" decimals="0" id="ixv-14998" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c13"
      decimals="0"
      id="ixv-14999"
      unitRef="shares">6506</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c13" decimals="0" id="ixv-15000" unitRef="usd">7</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c15" decimals="0" id="ixv-15001" unitRef="usd">8516</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c7" decimals="0" id="ixv-15002" unitRef="usd">8523</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss contextRef="c16" decimals="0" id="ixv-15003" unitRef="usd">-8882938</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-15004" unitRef="usd">-8882938</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      decimals="0"
      id="ixv-15005"
      unitRef="shares">20869908</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-15006" unitRef="usd">20870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="0" id="ixv-15007" unitRef="usd">35144967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="0" id="ixv-15008" unitRef="usd">-38432375</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-15009" unitRef="usd">-3266538</us-gaap:StockholdersEquity>
    <osti:StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit
      contextRef="c21"
      decimals="0"
      id="ixv-15010"
      unitRef="shares">157407</osti:StockIssuedDuringPeriodSharesCommitmentSharesIssuedForEquityLineOfCredit>
    <osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit contextRef="c21" decimals="0" id="ixv-15011" unitRef="usd">157</osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit>
    <osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit contextRef="c23" decimals="0" id="ixv-15012" unitRef="usd">568078</osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit>
    <osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit contextRef="c0" decimals="0" id="ixv-15013" unitRef="usd">568235</osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit>
    <osti:StockIssuedDuringPeriodSharesCommonStockIssuedForServices
      contextRef="c21"
      decimals="0"
      id="ixv-15014"
      unitRef="shares">450000</osti:StockIssuedDuringPeriodSharesCommonStockIssuedForServices>
    <osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices contextRef="c21" decimals="0" id="ixv-15015" unitRef="usd">450</osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices>
    <osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices contextRef="c23" decimals="0" id="ixv-15016" unitRef="usd">4599054</osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices>
    <osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices contextRef="c0" decimals="0" id="ixv-15017" unitRef="usd">4599504</osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c23" decimals="0" id="ixv-15018" unitRef="usd">4265374</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-15019" unitRef="usd">4265374</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <osti:StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock
      contextRef="c21"
      decimals="0"
      id="ixv-15020"
      unitRef="shares">4939808</osti:StockIssuedDuringPeriodSharesConversionOfPreferredSharesMezzanineStockToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock contextRef="c21" decimals="0" id="ixv-15021" unitRef="usd">4939</osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock contextRef="c23" decimals="0" id="ixv-15022" unitRef="usd">3725181</osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock contextRef="c0" decimals="0" id="ixv-15023" unitRef="usd">3730120</osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock>
    <osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense
      contextRef="c21"
      decimals="0"
      id="ixv-15024"
      unitRef="shares">4774637</osti:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForPatentLicense>
    <osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense contextRef="c21" decimals="0" id="ixv-15025" unitRef="usd">4776</osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense>
    <osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense contextRef="c23" decimals="0" id="ixv-15026" unitRef="usd">6393239</osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense>
    <osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense contextRef="c0" decimals="0" id="ixv-15027" unitRef="usd">6398015</osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense>
    <osti:StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors
      contextRef="c21"
      decimals="0"
      id="ixv-15028"
      unitRef="shares">282679</osti:StockIssuedDuringPeriodSharesSaleOfCommonStockToInvestors>
    <osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors contextRef="c21" decimals="0" id="ixv-15029" unitRef="usd">282</osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors>
    <osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors contextRef="c23" decimals="0" id="ixv-15030" unitRef="usd">529878</osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors>
    <osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors contextRef="c0" decimals="0" id="ixv-15031" unitRef="usd">530160</osti:StockIssuedDuringPeriodValueSaleOfCommonStockToInvestors>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c21"
      decimals="0"
      id="ixv-15032"
      unitRef="shares">5638643</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock contextRef="c21" decimals="0" id="ixv-15033" unitRef="usd">5639</osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock contextRef="c23" decimals="0" id="ixv-15034" unitRef="usd">7138562</osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock contextRef="c0" decimals="0" id="ixv-15035" unitRef="usd">7144201</osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock>
    <osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock contextRef="c23" decimals="0" id="ixv-15036" unitRef="usd">878153</osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock>
    <osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock contextRef="c0" decimals="0" id="ixv-15037" unitRef="usd">878153</osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock>
    <osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance contextRef="c23" decimals="0" id="ixv-15038" unitRef="usd">1579870</osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance>
    <osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance contextRef="c0" decimals="0" id="ixv-15039" unitRef="usd">1579870</osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance>
    <us-gaap:NetIncomeLoss contextRef="c24" decimals="0" id="ixv-15040" unitRef="usd">-28753844</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-15041" unitRef="usd">-28753844</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c25"
      decimals="0"
      id="ixv-15042"
      unitRef="shares">37113082</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-15043" unitRef="usd">37113</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="0" id="ixv-15044" unitRef="usd">61053475</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="0" id="ixv-15045" unitRef="usd">-67186219</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-15046" unitRef="usd">-6095631</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-15047" unitRef="usd">-28753844</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="0" id="ixv-15048" unitRef="usd">-8882938</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="0" id="ixv-15049" unitRef="usd">363085</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="0" id="ixv-15050" unitRef="usd">2780</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c7" decimals="0" id="ixv-15051" unitRef="usd">1425679</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <osti:SharesIssuedForServices contextRef="c7" decimals="0" id="ixv-15052" unitRef="usd">25000</osti:SharesIssuedForServices>
    <us-gaap:OtherNoncashExpense contextRef="c7" decimals="0" id="ixv-15053" unitRef="usd">8523</us-gaap:OtherNoncashExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-15054" unitRef="usd">-1424603</us-gaap:FairValueAdjustmentOfWarrants>
    <osti:CommitmentSharesIssuedForEquityLineOfCredit contextRef="c0" decimals="0" id="ixv-15055" unitRef="usd">568235</osti:CommitmentSharesIssuedForEquityLineOfCredit>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="0" id="ixv-15056" unitRef="usd">595841</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-15057" unitRef="usd">4265957</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="0" id="ixv-15058" unitRef="usd">268300</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c0" decimals="0" id="ixv-15059" unitRef="usd">-1037631</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="0" id="ixv-15060" unitRef="usd">8274316</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="0" id="ixv-15061" unitRef="usd">-1053331</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="0" id="ixv-15062" unitRef="usd">893992</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c7" decimals="0" id="ixv-15063" unitRef="usd">358510</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c7" decimals="0" id="ixv-15064" unitRef="usd">-613605</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-15065" unitRef="usd">-59186</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c7" decimals="0" id="ixv-15066" unitRef="usd">-48423</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-15067" unitRef="usd">-14238576</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="0" id="ixv-15068" unitRef="usd">-7282295</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c0" decimals="0" id="ixv-15069" unitRef="usd">466423</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-15070" unitRef="usd">-466423</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherEquity contextRef="c0" decimals="0" id="ixv-15071" unitRef="usd">530162</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c0" decimals="0" id="ixv-15072" unitRef="usd">7858140</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c7" decimals="0" id="ixv-15073" unitRef="usd">250000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c7" decimals="0" id="ixv-15074" unitRef="usd">250000</us-gaap:RepaymentsOfShortTermDebt>
    <osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants contextRef="c0" decimals="0" id="ixv-15075" unitRef="usd">1053000</osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants>
    <osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants contextRef="c7" decimals="0" id="ixv-15076" unitRef="usd">6050000</osti:ProceedsFromSaleOfPreferredStockAndRelatedWarrants>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c7" decimals="0" id="ixv-15077" unitRef="usd">5225840</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c7" decimals="0" id="ixv-15078" unitRef="usd">1501000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-15079" unitRef="usd">9441302</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="0" id="ixv-15080" unitRef="usd">12776840</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-15081" unitRef="usd">-5263697</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="0" id="ixv-15082" unitRef="usd">5495545</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-15083" unitRef="usd">5533527</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c12" decimals="0" id="ixv-15084" unitRef="usd">38982</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-15085" unitRef="usd">269830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-15086" unitRef="usd">5533527</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NotesIssued1 contextRef="c7" decimals="0" id="ixv-15087" unitRef="usd">750500</us-gaap:NotesIssued1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 contextRef="c7" decimals="0" id="ixv-15088" unitRef="usd">31250</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:Dividends contextRef="c7" decimals="0" id="ixv-15089" unitRef="usd">1971975</us-gaap:Dividends>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c0" decimals="0" id="ixv-15090" unitRef="usd">3730121</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <osti:ConversionOfPreferredStockToCommonStock contextRef="c7" decimals="0" id="ixv-15091" unitRef="usd">1302</osti:ConversionOfPreferredStockToCommonStock>
    <osti:DeferredOfferingCostsRecordedAsAccountsPayable contextRef="c7" decimals="0" id="ixv-15092" unitRef="usd">751050</osti:DeferredOfferingCostsRecordedAsAccountsPayable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c7" decimals="0" id="ixv-15093" unitRef="usd">24757252</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <osti:ConversionOfWarrantsIntoCommonStock contextRef="c7" decimals="0" id="ixv-15094" unitRef="usd">411</osti:ConversionOfWarrantsIntoCommonStock>
    <osti:IssuanceOfCommonStockToInvestorAdvisorSettlement contextRef="c7" decimals="0" id="ixv-15095" unitRef="usd">320</osti:IssuanceOfCommonStockToInvestorAdvisorSettlement>
    <osti:ConversionOfMakewholeLiabilityToCommonStock contextRef="c7" decimals="0" id="ixv-15096" unitRef="usd">130000</osti:ConversionOfMakewholeLiabilityToCommonStock>
    <osti:ClawbackOfCommonStockForOverIssuance contextRef="c7" decimals="0" id="ixv-15097" unitRef="usd">-670</osti:ClawbackOfCommonStockForOverIssuance>
    <osti:CommonStockIssuedForPatentPurchase contextRef="c0" decimals="0" id="ixv-15098" unitRef="usd">6398015</osti:CommonStockIssuedForPatentPurchase>
    <osti:ReclassificationOfWarrantLiabilityToEquity contextRef="c0" decimals="0" id="ixv-15099" unitRef="usd">878153</osti:ReclassificationOfWarrantLiabilityToEquity>
    <osti:SharesIssuedForPrepaidServices contextRef="c0" decimals="0" id="ixv-15100" unitRef="usd">1100713</osti:SharesIssuedForPrepaidServices>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-8862">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1&#160;&#x2014;&#160;ORGANIZATION AND DESCRIPTION
OF BUSINESS, LIQUIDITY, AND RISK FACTORS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;OS Therapies Incorporated&lt;/b&gt;
(&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; the &#x201c;Company&#x201d;) is a Delaware corporation incorporated on June&#160;24,
2019. It is based in Rockville, Maryland. The Company is the successor to an LLC formed in 2018.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company intends to focus
on the identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. As of December 31,
2025, there is one ongoing clinical trial for Osteosarcoma therapy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;OS Animal Health Corp
&#x2013; Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 25, 2025, the Company
formed OS Animal Health Corp, a Delaware corporation and wholly owned subsidiary. The subsidiary had minimal activity during the year
ended December 31, 2025, consisting primarily of investor relations and audit-related expenses. During this period, the Company entered
into a license agreement with the subsidiary, pursuant to which it granted the subsidiary rights to use the HER2 Assets (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;OS Therapies UK LTD
&#x2013; Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 29, 2025, the Company
formed OS Therapies UK LTD, a United Kingdom corporation and wholly owned subsidiary. This subsidiary serves as the Company&#x2019;s research
and development arm and had substantial operating activity during 2025. The Company has transitioned its research and development activities
to this subsidiary and intends to enter into an intercompany loan agreement, which is currently pending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has prepared its
consolidated financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. Since inception, the Company has incurred significant net losses and negative cash flows from operations.
During the year ended December 31, 2025, the Company incurred a net loss of $28.8 million and used $14.2 million in cash for operating
activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, the
Company had cash and cash equivalents of $269,830. Management has evaluated whether there are conditions and events, considered in the
aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date
that these consolidated financial statements are issued. The Company&#x2019;s current cash balance is insufficient to fund operations.
During 2025, the Company incurred significant expenses, primarily related to activities in preparation for potential regulatory approvals
by the U.S. Food and Drug Administration and other regulatory authorities. The Company expects vendor and related costs associated with
these efforts to total approximately $25.0 million and continue into 2026. These factors raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s ability
to continue as a going concern is dependent upon its ability to raise additional capital to fund its research and development and future
operations. Management&#x2019;s plans to mitigate these conditions include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Equity and Debt Financing: The Company is actively
seeking additional capital through public or private equity offerings or debt financings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;However, there can be no assurance
that the Company will be successful in sequestering additional financing on favorable terms, or at all. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c0" id="ixv-15101">2019-06-24</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-15102" unitRef="usd">-28800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-5" id="ixv-15103" unitRef="usd">-14200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-15104" unitRef="usd">269830</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <osti:GoingConcernTerm contextRef="c0" id="ixv-15105">P1Y</osti:GoingConcernTerm>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c3" decimals="-5" id="ixv-15106" unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-8929">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2&#160;&#x2014;&#160;SIGNIFICANT ACCOUNTING
POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying consolidated
financial statements are presented in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;)
and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accounting and reporting
policies of the Company conform to accounting principles generally accepted in the United&#160;States of America, and the Company&#x2019;s
fiscal year end is December&#160;31.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries and majority-owned subsidiaries. The Company consolidates
all entities in which it has a controlling interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of consolidated
financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments,
which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable
under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may
differ from management&#x2019;s estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Cash consists primarily of
deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both
interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation
(FDIC) for a combined total of $250,000. In the normal course of business, the Company may have deposits that exceed the FDIC insured
limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking
relationships. As of December 31, 2025 and December 31, 2024, JPMorgan Chase Bank checking account had $233,490 and $5,216,354, respectively,
and the JPM Chase savings account had $20,269 and $20,021, respectively. As of December 31, 2025 and December 31, 2024, Silicon Valley
Bank checking account had $6,071 and $287,173, respectively, and the SVB money market account had $10,000 and $10,000, respectively. The
JPM Chase and SVB checking accounts were in excess of the FDIC limits for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Redeemable Preferred Stock and Mezzanine
Equity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s Series
A Senior Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series A Preferred Stock&#x201d;), is classified as mezzanine
equity in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 480 (&#x201c;ASC 480&#x201d;) due to its redemption features upon the occurrence of a deemed liquidation event, including (i) a merger
or consolidation or (ii) the sale, lease, transfer, or other disposition of substantially all of the Company&#x2019;s assets. Proceeds
from the issuance were allocated between the Series A Preferred Stock and the accompanying warrants to purchase shares of common stock
(the &#x201c;Series A Warrants&#x201d;) on a relative fair value basis. Of the initial $6,050,000 in proceeds, a portion was allocated to
the Series A Warrants, with the residual allocated to the Series A Preferred Stock. Similarly, of the subsequent $1,053,000 in proceeds,
a portion was allocated to the Series A Warrants, with the residual allocated to the Series A Preferred Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fixed Asset Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A capital asset is defined
as a unit of property that has an economic useful life that extends beyond 12&#160;months. Any items costing below the threshold or not
fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at
historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over five years for financial
statement purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patent Amortization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 9, 2025, in connection
with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below),
including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. These intangible assets
are amortized on a straight-line basis over their estimated useful lives, with amortization recorded quarterly. Amortization expense for
the years ended December 31, 2025 and 2024 was $360,305 and $0, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patent and License Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#x201c;HER2 Purchase Agreement&#x201d;), between the Company
and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (&#x201c;Ayala&#x201d;), the Company completed the acquisition of the &lt;i&gt;Lm&lt;/i&gt;-based
immune-oncology programs and related intellectual property assets (the &#x201c;HER2 Assets&#x201d;) from Ayala, including the assignment
by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The transaction was accounted for as an asset acquisition
in accordance with ASC 805.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the acquisition,
the Company assumed certain specified liabilities and paid an aggregate purchase price of $8,000,000, with a fair value of $6,864,438,
consisting of: (i) $400,000 to Ayala ($150,000 of which was transferred upon signing of the HER2 Purchase Agreement and the remainder
on the closing date); (ii) $100,000 to a third party on behalf of Ayala on the closing date; and (iii) $7,500,000 worth of shares of common
stock, or 4,774,637 shares based on the volume-weighted average price of the Company&#x2019;s common stock over the 30 trading days immediately
preceding the closing date of $1.5708. The fair value of the common stock issued was determined using the closing price of $1.34 per share
on April 9, 2025, resulting in a total equity value of $6,398,014 and a corresponding reduction in total purchase consideration. The fair
value of the purchase consideration is summarized below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Legal fees paid on behalf of Ayala&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Company common stock (4,774,637 shares at $1.34 per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,398,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total fair value of consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,864,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The acquired intangible assets
consist primarily of a portfolio of patents and related licenses, including patents covering &#x201c;Compositions and Methods for Evaluating
Potency of Listeria-Based Immunotherapeutics,&#x201d; which underpin the Company&#x2019;s lead programs. These patents have an effective
filing date of April 19, 2019 and an estimated remaining useful life of approximately 14 years. The assets are amortized on a straight-line
basis over their estimated useful lives. Amortization expense was $360,305 and $0 for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, expected
future amortization expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2031 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,019,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,504,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company reviews long-lived
assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability
is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising
from the assets or asset groups. &lt;span style="-sec-ix-hidden: hidden-fact-95"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96"&gt;No&lt;/span&gt;&lt;/span&gt; impairment losses on long-lived assets have been recorded for&#160;the year ended December 31, 2025
or the year ended December&#160;31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs consist
of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to
the Company&#x2019;s initial public offering and that were charged to stockholders&#x2019; equity upon the completion of such offering.
As of December 31, 2025 and 2024, the Company had &lt;span style="-sec-ix-hidden: hidden-fact-97"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;no&lt;/span&gt;&lt;/span&gt; capitalized deferred offering costs. Upon the completion of the Company&#x2019;s initial
public offering on August 2, 2024, all deferred offering costs were charged to stockholders&#x2019; deficit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development expenses
are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, and supplies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of the date of incorporation,
the Company adopted ASU&#160;2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, and all subsequent amendments to the ASU (collectively,
&#x201c;ASC&#160;606&#x201d;), which (i)&#160;creates a single framework for recognizing revenue from contracts with customers that fall
within its scope and (ii)&#160;revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, in accordance
with ASC&#160;718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees
is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation
expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be
probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized
and any previously recognized compensation expense is reversed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Short-term Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For short-term leases with
a term of 12 months or less, the Company recognizes lease expense on a straight-line basis over the lease term. The Company&#x2019;s current
lease arrangements qualify for this short-term lease exemption and are expensed as incurred. The Company did not renew its prior lease
due to landlord restrictions related to renovations of the premises and has temporarily relocated its primary office to 115 Pullman Crossing
Road, Suite #103, Grasonville, Maryland 21638. This space, which serves as the primary office of the Company&#x2019;s Chief Financial Officer,
is being provided at no cost. In May 2024, the Company entered into a month-to-month lease agreement with JLabs for general office space
in New York City, primarily for meetings and use by staff when visiting. The monthly lease payment was $750 and increased to $787.50 effective
January 1, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for income
taxes using the asset-and-liability method in accordance with ASC&#160;740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC&#160;740&#x201d;). Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &#x201c;more likely than not&#x201d;
that some portion or all of the deferred tax assets will not be realized in future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company follows the guidance
in ASC Topic&#160;740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition
of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first
step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits.
The second step involves measurement of the amount to be recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Tax positions that meet the
more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated
financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,900,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,559,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;General business credit carryover&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,045,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;R&amp;amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,214,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,501,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,214,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,501,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes loss
per share in accordance with ASC&#160;260, &lt;i&gt;Earnings per Share &lt;/i&gt;(&#x201c;ASC&#160;260&#x201d;). ASC&#160;260 requires presentation
of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the statements of operations. Basic EPS is computed by
dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock
method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect
is antidilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Below is a table listing all
preferred stock and common stock equivalents:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Common Stock Equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Series A Senior Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,401,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Underwriter/Placement Agent Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;319,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inducement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,154,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid Common Stock Not Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,441,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,512,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,317,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,792,948&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Series A Convertible Preferred
Stock issued on December 31, 2024, is not reflected in the table above as of December 31, 2024, because stockholder approval was required
for the issuance of common stock upon conversion. Stockholder approval was obtained on April 9, 2025, for the issuance of the shares of
common stock underlying the Series A Preferred Stock, which is classified as mezzanine equity, and for the Series A Warrants. Upon approval,
the conversion price of the Series A Preferred Stock and the exercise price of the Series A Warrants were automatically adjusted to $1.12
per share, based on the volume-weighted average price of the Company&#x2019;s common stock for the 10 trading days immediately preceding
April 9, 2025. This adjustment established a conversion multiplier of 3.571429 common shares per preferred share. As of December 31, 2025,
392,500 non-converted shares of Series A Preferred Stock were outstanding, which, using the conversion multiplier, are exercisable into
1,401,786 shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, a
total of 319,711 shares of common stock were underlying outstanding underwriter and placement agent warrants, consisting of 112,000 shares
issued in connection with the Company&#x2019;s initial public offering and 207,711 shares issued to placement agents in connection with
the PIPE financing in December 2024 and January 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the Company&#x2019;s two warrant exercise and inducement offerings,
held June 23 to July 10, 2025, and August 29 to September 1, 2025, warrant holders who exercised their existing warrants received new
warrants with an exercise price of $3.00 per share. In total, warrants to purchase 7,154,338 shares of common stock were exercised in
exchange for new warrants to purchase an equal number of shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrant holders who pre-funded
conversions during the August 29 to September 30, 2025 offering received an aggregate of 937,500 prepaid shares of common stock and additionally
funded 504,018 prepaid shares, resulting in a total of 1,441,518 prepaid warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company applies ASC&#160;820
&lt;i&gt;Fair Value Measurement &lt;/i&gt;(&#x201c;ASC&#160;820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition
of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an
asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market
participants on the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value hierarchy established
in ASC&#160;820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and
are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s
own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing
the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The carrying value of the
Company&#x2019;s cash, accounts payable, and accrued expenses are approximate fair value because of the short-term maturity of these financial
instruments. The redemption feature of the debt instruments is recorded at fair value (See Note&#160;3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrant liability is recorded
at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective
Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates
on behalf of management in developing model assumptions. As of December 31, 2025 and December 31, 2024, the carrying value of the warrant
liability in the aggregate was $0 and $1,971,975, respectively (See Note 8).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The valuation hierarchy is
composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1&#160;&#x2014;&#160;Assets and
liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs,
such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2&#160;&#x2014;&#160;Inputs to
the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well
as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3&#160;&#x2014;&#160;Inputs to
the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market
data exists for the assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;The
Series A Warrants issued in connection with a Securities Purchase Agreement, dated as of December 24, 2024 (the &#x201c;Purchase Agreement&#x201d;),
are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at
fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance
sheet date until exercised or reclassified, and any change in fair value is recognized in the Company&#x2019;s consolidated statements
of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation
model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available
and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has evaluated
all recently issued accounting pronouncements and plans to adopt ASU 2024-03, Disaggregated Income Statement Disclosure, in the notes
to its audited financial statements for the year ending December 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring
entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For the public business
entities, the guidance is effective for annual periods beginning after December 15, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No other recently issued accounting pronouncements are expected
to have a material impact on the Company&#x2019;s financial statements at this time.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-8935">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The accompanying consolidated
financial statements are presented in conformity with accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;)
and pursuant to the rules and regulations of U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accounting and reporting
policies of the Company conform to accounting principles generally accepted in the United&#160;States of America, and the Company&#x2019;s
fiscal year end is December&#160;31.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-8943">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries and majority-owned subsidiaries. The Company consolidates
all entities in which it has a controlling interest.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-8953">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The preparation of consolidated
financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments,
which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable
under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may
differ from management&#x2019;s estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-8963">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Cash consists primarily of
deposits with commercial banks and financial institutions. The Company maintains cash balances at various financial institutions. Both
interest and non-interest-bearing accounts with the same insured depository institution are insured by the Federal Deposit Insurance Corporation
(FDIC) for a combined total of $250,000. In the normal course of business, the Company may have deposits that exceed the FDIC insured
limit. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking
relationships. As of December 31, 2025 and December 31, 2024, JPMorgan Chase Bank checking account had $233,490 and $5,216,354, respectively,
and the JPM Chase savings account had $20,269 and $20,021, respectively. As of December 31, 2025 and December 31, 2024, Silicon Valley
Bank checking account had $6,071 and $287,173, respectively, and the SVB money market account had $10,000 and $10,000, respectively. The
JPM Chase and SVB checking accounts were in excess of the FDIC limits for the year ended December 31, 2024.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c3" decimals="0" id="ixv-15107" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:Cash contextRef="c29" decimals="0" id="ixv-15108" unitRef="usd">233490</us-gaap:Cash>
    <us-gaap:Cash contextRef="c30" decimals="0" id="ixv-15109" unitRef="usd">5216354</us-gaap:Cash>
    <us-gaap:Cash contextRef="c31" decimals="0" id="ixv-15110" unitRef="usd">20269</us-gaap:Cash>
    <us-gaap:Cash contextRef="c32" decimals="0" id="ixv-15111" unitRef="usd">20021</us-gaap:Cash>
    <us-gaap:Cash contextRef="c33" decimals="0" id="ixv-15112" unitRef="usd">6071</us-gaap:Cash>
    <us-gaap:Cash contextRef="c34" decimals="0" id="ixv-15113" unitRef="usd">287173</us-gaap:Cash>
    <us-gaap:InterestBearingDomesticDepositMoneyMarket contextRef="c3" decimals="0" id="ixv-15114" unitRef="usd">10000</us-gaap:InterestBearingDomesticDepositMoneyMarket>
    <us-gaap:InterestBearingDomesticDepositMoneyMarket contextRef="c4" decimals="0" id="ixv-15115" unitRef="usd">10000</us-gaap:InterestBearingDomesticDepositMoneyMarket>
    <osti:RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock contextRef="c0" id="ixv-8971">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Redeemable Preferred Stock and Mezzanine
Equity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s Series
A Senior Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series A Preferred Stock&#x201d;), is classified as mezzanine
equity in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 480 (&#x201c;ASC 480&#x201d;) due to its redemption features upon the occurrence of a deemed liquidation event, including (i) a merger
or consolidation or (ii) the sale, lease, transfer, or other disposition of substantially all of the Company&#x2019;s assets. Proceeds
from the issuance were allocated between the Series A Preferred Stock and the accompanying warrants to purchase shares of common stock
(the &#x201c;Series A Warrants&#x201d;) on a relative fair value basis. Of the initial $6,050,000 in proceeds, a portion was allocated to
the Series A Warrants, with the residual allocated to the Series A Preferred Stock. Similarly, of the subsequent $1,053,000 in proceeds,
a portion was allocated to the Series A Warrants, with the residual allocated to the Series A Preferred Stock.&lt;/p&gt;</osti:RedeemablePreferredStockAndMezzanineEquityPolicyTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c35"
      decimals="3"
      id="ixv-15116"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c36" decimals="0" id="ixv-15117" unitRef="usd">6050000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c37" decimals="0" id="ixv-15118" unitRef="usd">1053000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <osti:FixedAssetPolicyPolicyTextBlock contextRef="c0" id="ixv-9009">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fixed Asset Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;A capital asset is defined
as a unit of property that has an economic useful life that extends beyond 12&#160;months. Any items costing below the threshold or not
fitting the definition of a capital asset will be expensed in the consolidated financial statements. All capital assets are recorded at
historical cost as of the date acquired. Computer assets will be capitalized and Straight-Line depreciated over five years for financial
statement purposes.&lt;/p&gt;</osti:FixedAssetPolicyPolicyTextBlock>
    <osti:StraightLineDepreciatedOverPeriod contextRef="c0" id="ixv-15119">P5Y</osti:StraightLineDepreciatedOverPeriod>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c0" id="ixv-9017">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patent Amortization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 9, 2025, in connection
with the HER2 Purchase Agreement (as defined below), the Company acquired the HER2 Assets (as defined below) from Ayala (as defined below),
including the assignment by Ayala of a license agreement with the Trustees of the University of Pennsylvania. These intangible assets
are amortized on a straight-line basis over their estimated useful lives, with amortization recorded quarterly. Amortization expense for
the years ended December 31, 2025 and 2024 was $360,305 and $0, respectively.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:AdjustmentForAmortization contextRef="c0" decimals="0" id="ixv-15120" unitRef="usd">360305</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c7" decimals="0" id="ixv-15121" unitRef="usd">0</us-gaap:AdjustmentForAmortization>
    <osti:PatentLicenseAcquisitionPolicyTextBlock contextRef="c0" id="ixv-9029">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patent and License Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 9, 2025, pursuant
to the terms of an Asset Purchase Agreement, dated as of January 28, 2025 (the &#x201c;HER2 Purchase Agreement&#x201d;), between the Company
and Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) (&#x201c;Ayala&#x201d;), the Company completed the acquisition of the &lt;i&gt;Lm&lt;/i&gt;-based
immune-oncology programs and related intellectual property assets (the &#x201c;HER2 Assets&#x201d;) from Ayala, including the assignment
by Ayala of a license agreement with the Trustees of the University of Pennsylvania. The transaction was accounted for as an asset acquisition
in accordance with ASC 805.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the acquisition,
the Company assumed certain specified liabilities and paid an aggregate purchase price of $8,000,000, with a fair value of $6,864,438,
consisting of: (i) $400,000 to Ayala ($150,000 of which was transferred upon signing of the HER2 Purchase Agreement and the remainder
on the closing date); (ii) $100,000 to a third party on behalf of Ayala on the closing date; and (iii) $7,500,000 worth of shares of common
stock, or 4,774,637 shares based on the volume-weighted average price of the Company&#x2019;s common stock over the 30 trading days immediately
preceding the closing date of $1.5708. The fair value of the common stock issued was determined using the closing price of $1.34 per share
on April 9, 2025, resulting in a total equity value of $6,398,014 and a corresponding reduction in total purchase consideration. The fair
value of the purchase consideration is summarized below:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Legal fees paid on behalf of Ayala&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Company common stock (4,774,637 shares at $1.34 per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,398,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total fair value of consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,864,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The acquired intangible assets
consist primarily of a portfolio of patents and related licenses, including patents covering &#x201c;Compositions and Methods for Evaluating
Potency of Listeria-Based Immunotherapeutics,&#x201d; which underpin the Company&#x2019;s lead programs. These patents have an effective
filing date of April 19, 2019 and an estimated remaining useful life of approximately 14 years. The assets are amortized on a straight-line
basis over their estimated useful lives. Amortization expense was $360,305 and $0 for the years ended December 31, 2025 and 2024, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, expected
future amortization expense is as follows:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2031 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,019,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,504,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</osti:PatentLicenseAcquisitionPolicyTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c38" decimals="0" id="ixv-15122" unitRef="usd">8000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AssetsFairValueAdjustment contextRef="c39" decimals="0" id="ixv-15123" unitRef="usd">6864438</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c40" decimals="0" id="ixv-15124" unitRef="usd">400000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c38" decimals="0" id="ixv-15125" unitRef="usd">150000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c41" decimals="0" id="ixv-15126" unitRef="usd">100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c42" decimals="0" id="ixv-15127" unitRef="usd">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="c0"
      decimals="0"
      id="ixv-15128"
      unitRef="shares">4774637</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <osti:NumberOfTradingDays contextRef="c0" id="ixv-15129">P30D</osti:NumberOfTradingDays>
    <us-gaap:SharePrice
      contextRef="c43"
      decimals="4"
      id="ixv-15130"
      unitRef="usdPershares">1.5708</us-gaap:SharePrice>
    <osti:ClosingPricePerShare
      contextRef="c44"
      decimals="2"
      id="ixv-15131"
      unitRef="usdPershares">1.34</osti:ClosingPricePerShare>
    <osti:TotalEquityValue contextRef="c45" decimals="0" id="ixv-15132" unitRef="usd">6398014</osti:TotalEquityValue>
    <us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock contextRef="c0" id="ixv-15133">The fair
value of the purchase consideration is summarized below:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Legal fees paid on behalf of Ayala&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Company common stock (4,774,637 shares at $1.34 per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,398,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total fair value of consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,864,438&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock>
    <us-gaap:Cash contextRef="c58" decimals="0" id="ixv-15134" unitRef="usd">400000</us-gaap:Cash>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c58" decimals="0" id="ixv-15135" unitRef="usd">66424</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:CommonStockSharesIssued
      contextRef="c58"
      decimals="INF"
      id="ixv-15136"
      unitRef="shares">4774637</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c58"
      decimals="2"
      id="ixv-15137"
      unitRef="usdPershares">1.34</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c58" decimals="0" id="ixv-15138" unitRef="usd">6398014</us-gaap:CommonStockValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c58" decimals="0" id="ixv-15139" unitRef="usd">6864438</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c46" id="ixv-15140">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AdjustmentForAmortization contextRef="c0" decimals="0" id="ixv-15141" unitRef="usd">360305</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c7" decimals="0" id="ixv-15142" unitRef="usd">0</us-gaap:AdjustmentForAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c0" id="ixv-9105">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, expected
future amortization expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2030&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2031 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,019,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,504,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c3" decimals="0" id="ixv-15143" unitRef="usd">496972</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c3" decimals="0" id="ixv-15144" unitRef="usd">496972</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c3" decimals="0" id="ixv-15145" unitRef="usd">496972</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c3" decimals="0" id="ixv-15146" unitRef="usd">496972</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c3" decimals="0" id="ixv-15147" unitRef="usd">496972</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c3" decimals="0" id="ixv-15148" unitRef="usd">4019272</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-15149" unitRef="usd">6504132</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-9159">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company reviews long-lived
assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability
is measured by comparison of the book values of the assets to future net undiscounted cash flows that the assets or the asset groups are
expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which
the book value of the assets exceed their fair value, which is measured based on the estimated discounted future net cash flows arising
from the assets or asset groups. &lt;span style="-sec-ix-hidden: hidden-fact-95"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96"&gt;No&lt;/span&gt;&lt;/span&gt; impairment losses on long-lived assets have been recorded for&#160;the year ended December 31, 2025
or the year ended December&#160;31, 2024.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0" id="ixv-9171">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Deferred offering costs consist
of capitalized underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to
the Company&#x2019;s initial public offering and that were charged to stockholders&#x2019; equity upon the completion of such offering.
As of December 31, 2025 and 2024, the Company had &lt;span style="-sec-ix-hidden: hidden-fact-97"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;no&lt;/span&gt;&lt;/span&gt; capitalized deferred offering costs. Upon the completion of the Company&#x2019;s initial
public offering on August 2, 2024, all deferred offering costs were charged to stockholders&#x2019; deficit.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-9183">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Research and development expenses
are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, and supplies.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-9192">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of the date of incorporation,
the Company adopted ASU&#160;2014-09, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, and all subsequent amendments to the ASU (collectively,
&#x201c;ASC&#160;606&#x201d;), which (i)&#160;creates a single framework for recognizing revenue from contracts with customers that fall
within its scope and (ii)&#160;revises when it is appropriate to recognize a gain (loss) from the transfer of nonfinancial assets.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-9203">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, in accordance
with ASC&#160;718, employs the use of stock-based compensation. The compensation expense related to stock granted to employees and non-employees
is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur. Stock-based compensation
expense for an award with a performance condition is recognized when the achievement of such performance condition is determined to be
probable. If the outcome of such performance condition is not determined to be probable or is not met, no compensation expense is recognized
and any previously recognized compensation expense is reversed.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-9241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Short-term Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For short-term leases with
a term of 12 months or less, the Company recognizes lease expense on a straight-line basis over the lease term. The Company&#x2019;s current
lease arrangements qualify for this short-term lease exemption and are expensed as incurred. The Company did not renew its prior lease
due to landlord restrictions related to renovations of the premises and has temporarily relocated its primary office to 115 Pullman Crossing
Road, Suite #103, Grasonville, Maryland 21638. This space, which serves as the primary office of the Company&#x2019;s Chief Financial Officer,
is being provided at no cost. In May 2024, the Company entered into a month-to-month lease agreement with JLabs for general office space
in New York City, primarily for meetings and use by staff when visiting. The monthly lease payment was $750 and increased to $787.50 effective
January 1, 2025.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-15150" unitRef="usd">750</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c47" decimals="2" id="ixv-15151" unitRef="usd">787.5</us-gaap:OperatingLeasePayments>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-9249">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for income
taxes using the asset-and-liability method in accordance with ASC&#160;740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC&#160;740&#x201d;). Deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the&#160;years in which those temporary
differences are expected to be recovered or settled. The effect on the deferred tax assets and liabilities of a change in tax rate is
recognized in the period that includes the enactment date. A valuation allowance is recorded if it is &#x201c;more likely than not&#x201d;
that some portion or all of the deferred tax assets will not be realized in future periods.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company follows the guidance
in ASC Topic&#160;740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition
of tax benefits in the consolidated financial statements by providing for a two-step approach of recognition and measurement. The first
step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits.
The second step involves measurement of the amount to be recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Tax positions that meet the
more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon
ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the consolidated
financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,900,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,559,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;General business credit carryover&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,045,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;R&amp;amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,214,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,501,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,214,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,501,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-15152" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredIncomeTableTextBlock contextRef="c0" id="ixv-9264">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company will recognize
interest and penalties related to tax positions in income tax expense. As of December 31, 2025 and December&#160;31, 2024, the Company
had no unrecognized uncertain income tax positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,900,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,559,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;General business credit carryover&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,045,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,672,876&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;R&amp;amp;D credit (available for payroll tax&#160;&#160;&#160;&#160;offset)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268,568&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,214,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,501,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,214,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,501,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredIncomeTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-15153" unitRef="usd">9900522</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-15154" unitRef="usd">6559791</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="c3" decimals="0" id="ixv-15155" unitRef="usd">3045651</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="c4" decimals="0" id="ixv-15156" unitRef="usd">1672876</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="0" id="ixv-15157" unitRef="usd">268568</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="0" id="ixv-15158" unitRef="usd">268568</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="0" id="ixv-15159" unitRef="usd">13214741</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="0" id="ixv-15160" unitRef="usd">8501235</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:TaxCreditCarryforwardValuationAllowance contextRef="c3" decimals="0" id="ixv-15161" unitRef="usd">13214741</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance contextRef="c4" decimals="0" id="ixv-15162" unitRef="usd">8501235</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-9353">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company computes loss
per share in accordance with ASC&#160;260, &lt;i&gt;Earnings per Share &lt;/i&gt;(&#x201c;ASC&#160;260&#x201d;). ASC&#160;260 requires presentation
of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the statements of operations. Basic EPS is computed by
dividing the net loss available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator)
during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock
method and convertible notes payable using the if-converted method. Diluted EPS excludes all diluted potential shares if their effect
is antidilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Below is a table listing all
preferred stock and common stock equivalents:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Common Stock Equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Series A Senior Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,401,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Underwriter/Placement Agent Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;319,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inducement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,154,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid Common Stock Not Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,441,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,512,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,317,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,792,948&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Series A Convertible Preferred
Stock issued on December 31, 2024, is not reflected in the table above as of December 31, 2024, because stockholder approval was required
for the issuance of common stock upon conversion. Stockholder approval was obtained on April 9, 2025, for the issuance of the shares of
common stock underlying the Series A Preferred Stock, which is classified as mezzanine equity, and for the Series A Warrants. Upon approval,
the conversion price of the Series A Preferred Stock and the exercise price of the Series A Warrants were automatically adjusted to $1.12
per share, based on the volume-weighted average price of the Company&#x2019;s common stock for the 10 trading days immediately preceding
April 9, 2025. This adjustment established a conversion multiplier of 3.571429 common shares per preferred share. As of December 31, 2025,
392,500 non-converted shares of Series A Preferred Stock were outstanding, which, using the conversion multiplier, are exercisable into
1,401,786 shares of common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, a
total of 319,711 shares of common stock were underlying outstanding underwriter and placement agent warrants, consisting of 112,000 shares
issued in connection with the Company&#x2019;s initial public offering and 207,711 shares issued to placement agents in connection with
the PIPE financing in December 2024 and January 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the Company&#x2019;s two warrant exercise and inducement offerings,
held June 23 to July 10, 2025, and August 29 to September 1, 2025, warrant holders who exercised their existing warrants received new
warrants with an exercise price of $3.00 per share. In total, warrants to purchase 7,154,338 shares of common stock were exercised in
exchange for new warrants to purchase an equal number of shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrant holders who pre-funded
conversions during the August 29 to September 30, 2025 offering received an aggregate of 937,500 prepaid shares of common stock and additionally
funded 504,018 prepaid shares, resulting in a total of 1,441,518 prepaid warrants.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <osti:ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock contextRef="c0" id="ixv-9392">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Below is a table listing all
preferred stock and common stock equivalents:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Common Stock Equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Series A Senior Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,401,786&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Underwriter/Placement Agent Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;319,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inducement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,154,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid Common Stock Not Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,441,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,512,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,317,353&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,792,948&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</osti:ScheduleofPreferredStockandCommonStockEquivalentsTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c59"
      decimals="0"
      id="ixv-15163"
      unitRef="shares">1401786</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c61"
      decimals="0"
      id="ixv-15164"
      unitRef="shares">319711</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c62"
      decimals="0"
      id="ixv-15165"
      unitRef="shares">280448</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c63"
      decimals="0"
      id="ixv-15166"
      unitRef="shares">7154338</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c65"
      decimals="0"
      id="ixv-15167"
      unitRef="shares">1441518</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c67"
      decimals="0"
      id="ixv-15168"
      unitRef="shares">1512500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-15169"
      unitRef="shares">10317353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="0"
      id="ixv-15170"
      unitRef="shares">1792948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c48"
      decimals="2"
      id="ixv-15171"
      unitRef="usdPershares">1.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <osti:NumberOfTradingDays contextRef="c45" id="ixv-15172">P10D</osti:NumberOfTradingDays>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c49"
      decimals="6"
      id="ixv-15173"
      unitRef="shares">3.571429</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c50"
      decimals="0"
      id="ixv-15174"
      unitRef="shares">392500</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c49"
      decimals="0"
      id="ixv-15175"
      unitRef="shares">1401786</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c51"
      decimals="0"
      id="ixv-15176"
      unitRef="shares">319711</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c52"
      decimals="0"
      id="ixv-15177"
      unitRef="shares">112000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c49" decimals="0" id="ixv-15178" unitRef="usd">207711</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c3"
      decimals="2"
      id="ixv-15179"
      unitRef="usdPershares">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c53"
      decimals="0"
      id="ixv-15180"
      unitRef="shares">7154338</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <osti:PrepaidShare
      contextRef="c54"
      decimals="INF"
      id="ixv-15181"
      unitRef="shares">937500</osti:PrepaidShare>
    <osti:PrepaidShare
      contextRef="c55"
      decimals="0"
      id="ixv-15182"
      unitRef="shares">504018</osti:PrepaidShare>
    <osti:PrepaidShares
      contextRef="c56"
      decimals="0"
      id="ixv-15183"
      unitRef="shares">1441518</osti:PrepaidShares>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-9513">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company applies ASC&#160;820
&lt;i&gt;Fair Value Measurement &lt;/i&gt;(&#x201c;ASC&#160;820&#x201d;), which establishes a framework for measuring fair value and clarifies the definition
of fair value within that framework. ASC&#160;820 defines fair value as an exit price, which is the price that would be received for an
asset or paid to transfer a liability in the Company&#x2019;s principal or most advantageous market in an orderly transaction between market
participants on the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value hierarchy established
in ASC&#160;820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and
are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity&#x2019;s
own assumptions based on market data and the entity&#x2019;s judgments about the assumptions that market participants would use in pricing
the asset or liability and are to be developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The carrying value of the
Company&#x2019;s cash, accounts payable, and accrued expenses are approximate fair value because of the short-term maturity of these financial
instruments. The redemption feature of the debt instruments is recorded at fair value (See Note&#160;3).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Warrant liability is recorded
at fair value. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and market reflective
Level 1 and Level 2 inputs, the Company valued the warrant liability using Level 3 inputs, which require significant judgment and estimates
on behalf of management in developing model assumptions. As of December 31, 2025 and December 31, 2024, the carrying value of the warrant
liability in the aggregate was $0 and $1,971,975, respectively (See Note 8).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The valuation hierarchy is
composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant
to the fair value measurement. The levels within the valuation hierarchy are described below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 1&#160;&#x2014;&#160;Assets and
liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs,
such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 2&#160;&#x2014;&#160;Inputs to
the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well
as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Level 3&#160;&#x2014;&#160;Inputs to
the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market
data exists for the assets or liabilities.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c53" decimals="0" id="ixv-15184" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c57" decimals="0" id="ixv-15185" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <osti:WarrantLiabilityPolicyTextBlock contextRef="c0" id="ixv-9575">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;The
Series A Warrants issued in connection with a Securities Purchase Agreement, dated as of December 24, 2024 (the &#x201c;Purchase Agreement&#x201d;),
are recognized as a derivative liability in accordance with ASC 815. The Company recognizes the warrant instruments as a liability at
fair value and adjusts the instruments to fair value at each reporting period. The liability is subject to re-measurement at each balance
sheet date until exercised or reclassified, and any change in fair value is recognized in the Company&#x2019;s consolidated statements
of operations. The fair value of the warrants issued in connection with the Purchase Agreement were measured using a Binomial simulation
model. The determination of the fair value of the warrant liability may be subject to change as more current information becomes available
and accordingly the actual results could differ significantly. The derivative warrant liability is classified as non-current liabilities
as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.&lt;/p&gt;</osti:WarrantLiabilityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-9588">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has evaluated
all recently issued accounting pronouncements and plans to adopt ASU 2024-03, Disaggregated Income Statement Disclosure, in the notes
to its audited financial statements for the year ending December 31, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring
entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For the public business
entities, the guidance is effective for annual periods beginning after December 15, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No other recently issued accounting pronouncements are expected
to have a material impact on the Company&#x2019;s financial statements at this time.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-9606">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3&#160;&#x2014;&#160;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accrued Payroll&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the Company had payroll payable to the CEO of $36,792 and $8,871, respectively, and related payroll taxes payable of $1,279 and $88,386,
respectively. During the years ended December 31, 2025 and 2024, the Company made advances on payroll payable, and the CEO repaid amounts
previously advanced.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following summarizes activity
in respect to payroll advances to the CEO:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;191,198&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Advances during 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Repayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(414,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Advances during 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Repayments 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(134,184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the second and third
quarters of 2024, the Company issued paychecks to Paul Romness, CEO, representing the remaining balance of backpay, net of all 2024 payroll
advances. Payroll taxes related to both backpay and regular compensation were fully paid. All related-party payroll advances to Mr. Romness, previously recorded as employee advances, were
fully repaid during 2025. The balance of related-party payroll advances for Mr. Romness was $0 during 2025. All advances for 2024
were repaid in full as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Related Parties&#160;&#x2014;&#160;Convertible
Debt&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Mill River Partners LLC, an
entity affiliated with Ted Search and John Ciccio, members of the Company&#x2019;s board of directors, held convertible notes with face
amounts of $0 as of December 31, 2025, and December 31, 2024. These notes were converted into shares of the Company&#x2019;s common stock
upon the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Related Party Accounting Fees&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the Company had accounts payable of $0 and $26,765, respectively, to Shore Accountants MD Inc., an outside accounting firm that
provides payroll, bookkeeping, and tax preparation services. Shore Accountants MD Inc. is wholly owned by Christopher Acevedo, the Company&#x2019;s
Chief Financial Officer.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c68" decimals="0" id="ixv-15186" unitRef="usd">36792</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c69" decimals="0" id="ixv-15187" unitRef="usd">8871</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-15188" unitRef="usd">1279</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" id="ixv-15189" unitRef="usd">88386</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-9647">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following summarizes activity
in respect to payroll advances to the CEO:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2023&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;191,198&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Advances during 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Repayment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(414,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Advances during 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134,184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Repayments 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(134,184&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent contextRef="c12" decimals="0" id="ixv-15190" unitRef="usd">191198</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c7" decimals="0" id="ixv-15191" unitRef="usd">222875</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c7" decimals="0" id="ixv-15192" unitRef="usd">414073</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c0" decimals="0" id="ixv-15193" unitRef="usd">134184</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfOtherDebt contextRef="c0" decimals="0" id="ixv-15194" unitRef="usd">134184</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent contextRef="c70" decimals="0" id="ixv-15195" unitRef="usd">0</us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent>
    <us-gaap:ConvertibleDebt contextRef="c71" decimals="0" id="ixv-15196" unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-15197" unitRef="usd">0</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="c4" decimals="0" id="ixv-15198" unitRef="usd">26765</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-9717">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4&#160;&#x2014;&#160;CONVERTIBLE DEBT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Debt&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s convertible
notes are separated into seven groups&#160;&#x2014;&#160;A, B, C, D, E, F and BlinkBio&#160;&#x2014;&#160;per the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Conversion&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Maturity&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Collateral&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 28%"&gt;A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;None&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;80% - 87.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;E&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;F&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;BlinkBio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3/15/2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The above convertible notes
were all converted into common stock on August 2, 2024 upon consummation of the Company&#x2019;s initial public offering.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group A&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in July 2018 through
November 2021, the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;)
with certain lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;). Interest on the unpaid principal
balance accrues at a rate of 10% per annum, computed on the basis of the actual number of&#160;days elapsed and a year of 365&#160;days.
Unless earlier converted into shares of Equity Securities, the principal and accrued interest will be due and payable by the Company on
demand by the Holders at any time after the earlier of (i)&#160;the Maturity Date (as defined in each Agreement) and (ii)&#160;the closing
of the Next Equity Financing (as defined below). The stated Maturity Date was extended on October 24, 2023, under the same terms, until
October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80&#160;&#x2013;&#160;87.5% of the price paid per share for Equity Securities by the investors in the Next
Equity Financing. Equity Securities refers to Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the
next sale (or series of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less
than $3,000,000 (including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of
promissory notes) or $5,000,000, depending upon the signed agreement terms.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $3,000,000 or $5,000,000 through the sale of the Company&#x2019;s equity securities,
excluding the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without
any action on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such
qualified financing at 12.5% of the equity stock conversion price. The Company, at its option, may pay all accrued, but unpaid, interest
and other charges in cash or by the issuance of additional equity stock at a rate of the applicable conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480, &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;(&#x201c;ASC&#160;480&#x201d;), and determined the
Notes are considered share-settled debt and should be recorded as a liability. This conclusion was determined based on the debt providing
the holder with a variable number of shares at settlement with an aggregate fair value equal to the debt instrument&#x2019;s outstanding
principal. The general measurement guidance in ASC&#160;480 requires obligations that can be settled in shares with a fixed monetary value
at settlement (e.g., share-settled debt) to be carried at fair value unless other accounting guidance specifies another measurement attribute.
It has been determined that the appropriate guidance for share-settled debt is ASC&#160;835. As a result, the Notes were recorded at the
amortized cost. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued interest,
converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 263,499 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group B&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in May&#160;2020,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#x2019;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such qualified
financing at 12.5% of the equity stock conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#x2019;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 1,288,500 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group C&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in July&#160;2021,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 80% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to the Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series
of related sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000
(including the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#x2019;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such qualified
financing at 12.5% of the equity stock conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#x2019;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 986,250 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group D&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in November&#160;2022,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally the
Investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#x2019;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In connection with the Group
D Convertible Notes, the Company agreed to issue an additional 125,000 shares of common stock to the Group D Holders, prorated based on
such Holder&#x2019;s investment amount, as an inducement for their investment in the Group D Convertible Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#x2019;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 500,000 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group E&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in February 2023,
the Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#x2019;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price. In connection with the Group E Convertible Notes, the Company agreed to issue an
additional 68,750 shares of common stock to the Group E Holders, prorated based on such Holder&#x2019;s investment amount, as an inducement
for their investment in the Group E Convertible Notes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#x2019;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 262,500 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Group F&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Commencing in June 2023, the
Company entered into an unsecured Subordinated Convertible Promissory Note&#160;Agreement (the &#x201c;Agreements&#x201d;) with certain
lenders (together, the &#x201c;Holders&#x201d; or individually, the &#x201c;Holder&#x201d;), pursuant to which the Company issued a Subordinated
Convertible Promissory Note (individually the &#x201c;Note&#x201d; or together the &#x201c;Notes&#x201d;) to the Holders, principally the
investors brought in by an investment bank. Interest on the unpaid principal balance accrues at a rate of 6% per annum, computed on the
basis of the actual number of&#160;days elapsed and a year of 365&#160;days. Unless earlier converted into shares of Equity Securities,
the principal and accrued interest will be due and payable by the Company on demand by the Holders at any time after the earlier of (i)&#160;the
Maturity Date (as defined in each Agreement) and (ii)&#160;the closing of the Next Equity Financing (as defined below). The stated Maturity
Date was extended on October 24, 2023, under the same terms, until October 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Notes will automatically
convert into the type of Equity Securities issued in the Next Equity Financing upon closing. The number of shares of such Equity Securities
to be issued will be equal to the quotient obtained by dividing the outstanding principal and unpaid accrued interest due on the Note
on the date of conversion of 50% of the price paid per share for Equity Securities by the investors in the Next Equity Financing. Equity
Securities refers to Company&#x2019;s common stock or preferred stock and Next Equity Financing refers to the next sale (or series of related
sales) by the Company of its equity securities from which the Company receives gross proceeds of not less than $10,000,000 (including
the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of promissory notes).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In the event that the Company
raises aggregate additional cash proceeds of at least $10,000,000 through the sale of the Company&#x2019;s equity securities, excluding
the sales or conversions of Notes under the Agreement, the outstanding principal amount due will automatically, and without any action
on part of the holder, be converted into fully paid and non-assessable units of the Company&#x2019;s equity stock sold in such qualified
financing at 50% of the equity stock conversion price. In connection with the Group F Convertible Notes, the Company agreed to issue an
additional&#160;214,594 shares of common stock to the Group F Holders, prorated based on such Holder&#x2019;s investment amount, as an
inducement for their investment in the Group F Convertible Notes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company, at its option,
may pay all accrued, but unpaid, interest and other charges in cash or by the issuance of additional equity stock at a rate of the applicable
conversion price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company evaluated the
Notes in accordance with ASC&#160;480 and determined the Notes are considered share-settled debt and should be recorded as a liability.
This conclusion was determined based on the debt providing the holder with a variable number of shares at settlement with an aggregate
fair value equal to the debt instrument&#x2019;s outstanding principal. The general measurement guidance in ASC&#160;480 requires obligations
that can be settled in shares with a fixed monetary value at settlement (e.g., share-settled debt) to be carried at fair value unless
other accounting guidance specifies another measurement attribute. It has been determined that the appropriate guidance for share-settled
debt is ASC&#160;835. As a result, the Notes were recorded at the amortized cost. On August 2, 2024, the Company consummated its initial
public offering, and the convertible notes, including accrued interest, converted into shares of the Company&#x2019;s common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;As of December 31, 2025 and
2024, the balance of the convertible notes was $0 and $0, respectively, as the notes were converted into 773,805 shares of the Company&#x2019;s
common stock in connection with the closing of the Company&#x2019;s initial public offering on August 2, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Redemption Liability&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the redemption
liability was calculated under Level 3 of the fair value hierarchy, is determined based upon a Probability-Weighted of Expected Returns
Model (&#x201c;PWERM&#x201d;). This PWERM was determined to be the most appropriate method of estimating the value of possible redemption
or conversion outcomes over time, since the Company has not entered into a priced equity round through June 30, 2024. The fair value of
the redemption liability is calculated using the initial value of the convertible note less the debt discount rate of 12.5% in Group A,
20% in Groups B and C, and 50% in Groups D, E and F.&#160;The resulting redemption liability was amortized over the remaining life of
the notes using interest rates of 10% for Group A and 6% for Groups B&#x2013;F. Group A notes had a fixed term of three years, while Groups
B&#x2013;F had variable terms ranging from 12 months to three years. The Company retained the option to negotiate extended maturity dates
for Groups B&#x2013;F. On August 2, 2024, the Company consummated its initial public offering, and the convertible notes, including accrued
interest, converted into shares of the Company&#x2019;s common stock. The redemption liability was closed to stockholders&#x2019; equity
on such date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Fees Associated with Convertible Debt Raise&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fees associated with the
issuance of the convertible notes for Groups A, B, C and D consist of legal and investment banking fees. No related parties received any
portion of these fees. These fees are capitalized and amortized over the life of the respective convertible notes using an effective interest
rate of 10% for Group A and 6% for Groups B, C and D.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Make-whole liability&#160;&#x2014;&#160;Shares
due Noble Capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2020, the Company
entered into an advisory agreement with Noble Capital under which, in lieu of cash compensation, the Company agreed to issue 4% of its
common stock, subject to an anti-dilution clause. The make-whole liability represents shares earned due to adjustments under the anti-dilution
provision during 2020 and 2021. As of year-end 2021, the Company held an aggregate of 233,202 shares, valued at $408,413, after issuing
200,000 shares in 2020. Advisory fee expense of $152,482 was recorded in 2021 to reflect the share value earned under the anti-dilution
provision. In 2022, 70,624 shares were set aside to satisfy the anti-dilution clause, with an associated advisory fee expense of $282,496
recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On July 1, 2023, the make-whole
liability for Noble Capital was contractually nullified and unwound, and the adjustment was reflected in the Consolidated Statements of
Stockholders&#x2019; Deficit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2024, Noble Capital
and the Company settled various investment fees in dispute, as well as shares related to the anti-dilution clause that had expired. Under
the settlement, Noble Capital received 320,033 shares of common stock and $50,000 in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Make-whole liability&#160;&#x2014;&#160;Shares
Officers &amp;amp; Directors&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In January 2023, the Company
issued 350,000 shares of Class A common stock to officers, key employees, key advisors and directors, leaving 20,000 shares to be issued
to Joacim Borg, a former director, with a value of $80,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On March 1, 2023, the Company
hired Alan Musso, former CFO, and as part of his compensation, awarded him 12,500 shares of common stock at $4.00 per share, totaling
$50,000. This amount was reflected in the Company&#x2019;s make-whole stock liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upon Mr. Musso&#x2019;s resignation
on June 30, 2023, Christopher Acevedo, the current CFO, assumed the role and was awarded the balance of Mr. Musso&#x2019;s shares following
the successful completion of the Company&#x2019;s initial public offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s make-whole
share liability as of September 30, 2024 is summarized in the table below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Position&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;# Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Date&#160;Earned&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Alan Musso&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;Former CFO&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;March&#160;1,&#160;2023&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Christopher Acevedo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Current CFO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Upon IPO&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Joacim Borg&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Former&#160;Director&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;July&#160;1,&#160;2022&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;All make-whole shares due
to directors and officers were issued in October 2024. As a result, the balance of the make-whole stock liability was $0 as of December
31, 2025 and December 31, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants for Placement Agent&#160;&#x2014;&#160;Noble
Capital&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In March 2020, the Company
entered into an advisory agreement with Noble Capital, under which, in lieu of cash remuneration, it was granted a 10% warrant fee in
addition to cash compensation for debt raises from investments procured by Noble Capital. The warrants have a five-year term, with an
exercise price equal to the average price paid by the convertible debt holders in each respective debt raise round.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The warrants earned were as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;2020: 248,855 warrants, valued at $248,855&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;2021: 213,782 warrants, valued at $427,564&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;2022: 162,644 warrants, valued at $325,288&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;No warrants were earned from
2023 through December 31, 2024. Warrants issued in 2020, 2021, and 2022 were accounted for as a discount to the related convertible debt,
with the discount amortized over the life of the debt. Debt discount accretion expense for these warrants was $0 for the year ended December
31, 2025, and $49,840 for the year ended December 31, 2024. The total unamortized warrant discount was $0 as of both December 31, 2025
and December 31, 2024.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2024, Noble Capital
warrant holders exercised 116,313 warrants in a cashless transaction, and in December 2024, the remaining 294,977 warrants were exercised
in a reduced cashless transaction, resulting in the issuance of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants for Underwriter and Placement Agents&#160;&#x2014;&#160;Brookline
Capital Markets and Ceros Financial Services, Inc.&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August 2, 2024, the Company
issued a warrant to Brookline Capital Markets to purchase 112,000 shares of the Company&#x2019;s common stock pursuant to an underwriting
agreement. The warrant became exercisable 180 days after July 31, 2024, expires on July 31, 2029, and has an exercise price of $4.40 per
share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 24, 2024, in connection
with the Company&#x2019;s Purchase Agreement, Brookline earned warrants initially exercisable for 39,918 shares at $4.40 per share. These
warrants were subsequently adjusted to 156,821 shares at an exercise price of $1.12 per share, subject to further adjustment as provided
in the agreement. The warrants are exercisable for five years from April 9, 2025. As of December 31, 2025, warrants to purchase 156,821
shares remained outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Ceros, in connection with
the same Purchase Agreement, earned warrants initially exercisable for 13,951 shares at $4.40 per share, which were subsequently adjusted
to 54,807 shares at $1.12 per share, also subject to further adjustment under the agreement. These warrants are exercisable for five years
from April 9, 2025. As of December 31, 2025, 52,872 warrants remained outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Short-Term Loan &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;An investor lent the Company
$100,000 on March 7, 2024. The note is a demand note, carrying interest at 8% and was used for working capital purposes. An investor lent
the Company $150,000 on June 28, 2024. The note is a demand note, carrying interest at 8% and was also used for working capital purposes.
The Company repaid these loans, including accrued interest thereon, in August 2024.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-9727">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s convertible
notes are separated into seven groups&#160;&#x2014;&#160;A, B, C, D, E, F and BlinkBio&#160;&#x2014;&#160;per the table below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Conversion&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Maturity&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Collateral&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 28%"&gt;A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;None&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;80% - 87.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;E&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;F&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10/31/2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;BlinkBio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3/15/2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;None&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c72" decimals="2" id="ixv-15199" unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c77" id="ixv-15200">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c77" id="ixv-15201">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c73" decimals="2" id="ixv-15202" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c74" decimals="3" id="ixv-15203" unitRef="pure">0.875</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c80" decimals="2" id="ixv-15204" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c81" id="ixv-15205">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c81" id="ixv-15206">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c81" decimals="2" id="ixv-15207" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c84" decimals="2" id="ixv-15208" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c85" id="ixv-15209">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c85" id="ixv-15210">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c85" decimals="2" id="ixv-15211" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c89" decimals="2" id="ixv-15212" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c90" id="ixv-15213">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c90" id="ixv-15214">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c90" decimals="2" id="ixv-15215" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c93" decimals="2" id="ixv-15216" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c94" id="ixv-15217">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c94" id="ixv-15218">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c94" decimals="2" id="ixv-15219" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c97" decimals="2" id="ixv-15220" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c86" id="ixv-15221">2024-10-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c86" id="ixv-15222">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c86" decimals="2" id="ixv-15223" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c138"
      decimals="2"
      id="ixv-15224"
      unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c139" id="ixv-15225">2022-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCollateral contextRef="c139" id="ixv-15226">None</us-gaap:DebtInstrumentCollateral>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="c139"
      decimals="2"
      id="ixv-15227"
      unitRef="pure">1</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c72" decimals="2" id="ixv-15228" unitRef="pure">0.10</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c73" decimals="2" id="ixv-15229" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c74" decimals="3" id="ixv-15230" unitRef="pure">0.875</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c73" decimals="0" id="ixv-15231" unitRef="usd">3000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c74" decimals="0" id="ixv-15232" unitRef="usd">5000000</us-gaap:ProceedsFromConvertibleDebt>
    <osti:AggregateAdditionalCashProceeds contextRef="c75" decimals="0" id="ixv-15233" unitRef="usd">3000000</osti:AggregateAdditionalCashProceeds>
    <osti:AggregateAdditionalCashProceeds contextRef="c76" decimals="0" id="ixv-15234" unitRef="usd">5000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c77" decimals="3" id="ixv-15235" unitRef="pure">0.125</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c78" decimals="0" id="ixv-15236" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c79" decimals="0" id="ixv-15237" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c78"
      decimals="0"
      id="ixv-15238"
      unitRef="shares">263499</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c79"
      decimals="0"
      id="ixv-15239"
      unitRef="shares">263499</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c80" decimals="2" id="ixv-15240" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c81" decimals="2" id="ixv-15241" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c81" decimals="0" id="ixv-15242" unitRef="usd">10000000</us-gaap:ProceedsFromConvertibleDebt>
    <osti:AggregateAdditionalCashProceeds contextRef="c80" decimals="0" id="ixv-15243" unitRef="usd">10000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c81" decimals="3" id="ixv-15244" unitRef="pure">0.125</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c82" decimals="0" id="ixv-15245" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c83" decimals="0" id="ixv-15246" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c82"
      decimals="0"
      id="ixv-15247"
      unitRef="shares">1288500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c83"
      decimals="0"
      id="ixv-15248"
      unitRef="shares">1288500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c84" decimals="2" id="ixv-15249" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c85" decimals="2" id="ixv-15250" unitRef="pure">0.80</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c86" decimals="0" id="ixv-15251" unitRef="usd">10000000</us-gaap:ProceedsFromConvertibleDebt>
    <osti:AggregateAdditionalCashProceeds contextRef="c84" decimals="0" id="ixv-15252" unitRef="usd">10000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c85" decimals="3" id="ixv-15253" unitRef="pure">0.125</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c87" decimals="0" id="ixv-15254" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c88" decimals="0" id="ixv-15255" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c88"
      decimals="0"
      id="ixv-15256"
      unitRef="shares">986250</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c87"
      decimals="0"
      id="ixv-15257"
      unitRef="shares">986250</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c89" decimals="2" id="ixv-15258" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c90" decimals="2" id="ixv-15259" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c85" decimals="0" id="ixv-15260" unitRef="usd">10000000</us-gaap:ProceedsFromConvertibleDebt>
    <osti:AggregateAdditionalCashProceeds contextRef="c89" decimals="0" id="ixv-15261" unitRef="usd">10000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c90" decimals="2" id="ixv-15262" unitRef="pure">0.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c90"
      decimals="0"
      id="ixv-15263"
      unitRef="shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c91" decimals="0" id="ixv-15264" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c92" decimals="0" id="ixv-15265" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c91"
      decimals="0"
      id="ixv-15266"
      unitRef="shares">500000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c92"
      decimals="0"
      id="ixv-15267"
      unitRef="shares">500000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c93" decimals="2" id="ixv-15268" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c94" decimals="2" id="ixv-15269" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <osti:GrossProceeds contextRef="c90" decimals="0" id="ixv-15270" unitRef="usd">10000000</osti:GrossProceeds>
    <osti:AggregateAdditionalCashProceeds contextRef="c93" decimals="0" id="ixv-15271" unitRef="usd">10000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c94" decimals="2" id="ixv-15272" unitRef="pure">0.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c94"
      decimals="0"
      id="ixv-15273"
      unitRef="shares">68750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c95" decimals="0" id="ixv-15274" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c96" decimals="0" id="ixv-15275" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c95"
      decimals="0"
      id="ixv-15276"
      unitRef="shares">262500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c96"
      decimals="0"
      id="ixv-15277"
      unitRef="shares">262500</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="c97" decimals="2" id="ixv-15278" unitRef="pure">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtConversionConvertedInstrumentRate contextRef="c86" decimals="2" id="ixv-15279" unitRef="pure">0.50</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c94" decimals="0" id="ixv-15280" unitRef="usd">10000000</us-gaap:ProceedsFromConvertibleDebt>
    <osti:AggregateAdditionalCashProceeds contextRef="c97" decimals="0" id="ixv-15281" unitRef="usd">10000000</osti:AggregateAdditionalCashProceeds>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c86" decimals="2" id="ixv-15282" unitRef="pure">0.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c86"
      decimals="0"
      id="ixv-15283"
      unitRef="shares">214594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c98" decimals="0" id="ixv-15284" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c99" decimals="0" id="ixv-15285" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c98"
      decimals="0"
      id="ixv-15286"
      unitRef="shares">773805</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c99"
      decimals="0"
      id="ixv-15287"
      unitRef="shares">773805</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c100"
      decimals="3"
      id="ixv-15288"
      unitRef="pure">0.125</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c101"
      decimals="2"
      id="ixv-15289"
      unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c102"
      decimals="2"
      id="ixv-15290"
      unitRef="pure">0.50</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c103"
      decimals="2"
      id="ixv-15291"
      unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c104"
      decimals="2"
      id="ixv-15292"
      unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c77" decimals="2" id="ixv-15293" unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c81" decimals="2" id="ixv-15294" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c85" decimals="2" id="ixv-15295" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c90" decimals="2" id="ixv-15296" unitRef="pure">0.06</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <osti:AgreedToIssuedCashRemunerationPercentage
      contextRef="c105"
      decimals="2"
      id="ixv-15297"
      unitRef="pure">0.04</osti:AgreedToIssuedCashRemunerationPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c106"
      decimals="0"
      id="ixv-15298"
      unitRef="shares">233202</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c106" decimals="0" id="ixv-15299" unitRef="usd">408413</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c107"
      decimals="0"
      id="ixv-15300"
      unitRef="shares">200000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:NoninterestExpenseInvestmentAdvisoryFees contextRef="c106" decimals="0" id="ixv-15301" unitRef="usd">152482</us-gaap:NoninterestExpenseInvestmentAdvisoryFees>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c108"
      decimals="0"
      id="ixv-15302"
      unitRef="shares">70624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NoninterestExpenseInvestmentAdvisoryFees contextRef="c108" decimals="0" id="ixv-15303" unitRef="usd">282496</us-gaap:NoninterestExpenseInvestmentAdvisoryFees>
    <osti:CommonStockSharesAwarded
      contextRef="c0"
      decimals="0"
      id="ixv-15304"
      unitRef="shares">320033</osti:CommonStockSharesAwarded>
    <osti:CommonStockSharesAwardedInCash contextRef="c3" decimals="0" id="ixv-15305" unitRef="usd">50000</osti:CommonStockSharesAwardedInCash>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c109"
      decimals="0"
      id="ixv-15306"
      unitRef="shares">350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c110"
      decimals="0"
      id="ixv-15307"
      unitRef="shares">20000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c111" decimals="0" id="ixv-15308" unitRef="usd">80000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c112"
      decimals="0"
      id="ixv-15309"
      unitRef="shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <osti:SharesAwardedParValue
      contextRef="c112"
      decimals="2"
      id="ixv-15310"
      unitRef="usdPershares">4</osti:SharesAwardedParValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c112" decimals="0" id="ixv-15311" unitRef="usd">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <osti:ScheduleOfMakeWholeShareLiabilityTableTextBlock contextRef="c0" id="ixv-10318">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s make-whole
share liability as of September 30, 2024 is summarized in the table below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Position&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;# Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Date&#160;Earned&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: left"&gt;Alan Musso&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;Former CFO&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 11%; text-align: center"&gt;March&#160;1,&#160;2023&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Christopher Acevedo&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Current CFO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;Upon IPO&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Joacim Borg&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;Former&#160;Director&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;July&#160;1,&#160;2022&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;130,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</osti:ScheduleOfMakeWholeShareLiabilityTableTextBlock>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="c141" id="ixv-15312">Former CFO</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <osti:BusinessAcquisitionNumberofShares
      contextRef="c141"
      decimals="0"
      id="ixv-15313"
      unitRef="shares">3125</osti:BusinessAcquisitionNumberofShares>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c142" decimals="0" id="ixv-15314" unitRef="usd">12500</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 contextRef="c141" id="ixv-15315">2023-03-01</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="c143" id="ixv-15316">Current CFO</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <osti:BusinessAcquisitionNumberofShares
      contextRef="c143"
      decimals="0"
      id="ixv-15317"
      unitRef="shares">9375</osti:BusinessAcquisitionNumberofShares>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c144" decimals="0" id="ixv-15318" unitRef="usd">37500</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="c145" id="ixv-15319">Former&#160;Director</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
    <osti:BusinessAcquisitionNumberofShares
      contextRef="c145"
      decimals="0"
      id="ixv-15320"
      unitRef="shares">20000</osti:BusinessAcquisitionNumberofShares>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c146" decimals="0" id="ixv-15321" unitRef="usd">80000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 contextRef="c145" id="ixv-15322">2022-07-01</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
    <osti:BusinessAcquisitionNumberofShares
      contextRef="c147"
      decimals="0"
      id="ixv-15323"
      unitRef="shares">32500</osti:BusinessAcquisitionNumberofShares>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c148" decimals="0" id="ixv-15324" unitRef="usd">130000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c113"
      decimals="0"
      id="ixv-15325"
      unitRef="shares">0</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c114"
      decimals="0"
      id="ixv-15326"
      unitRef="shares">0</us-gaap:ExcessStockSharesIssued>
    <osti:CashRemunerationofWarrantFeePercentage
      contextRef="c105"
      decimals="2"
      id="ixv-15327"
      unitRef="pure">0.10</osti:CashRemunerationofWarrantFeePercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c115"
      decimals="0"
      id="ixv-15328"
      unitRef="shares">248855</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c115" decimals="0" id="ixv-15329" unitRef="usd">248855</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c116"
      decimals="0"
      id="ixv-15330"
      unitRef="shares">213782</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c116" decimals="0" id="ixv-15331" unitRef="usd">427564</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c117"
      decimals="0"
      id="ixv-15332"
      unitRef="shares">162644</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c117" decimals="0" id="ixv-15333" unitRef="usd">325288</us-gaap:WarrantsAndRightsOutstanding>
    <osti:DebtDiscountAccretionExpenseInWarrants contextRef="c0" decimals="0" id="ixv-15334" unitRef="usd">0</osti:DebtDiscountAccretionExpenseInWarrants>
    <osti:DebtDiscountAccretionExpenseInWarrants contextRef="c7" decimals="0" id="ixv-15335" unitRef="usd">49840</osti:DebtDiscountAccretionExpenseInWarrants>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c3" decimals="0" id="ixv-15336" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:CommonStockSharesIssued
      contextRef="c118"
      decimals="0"
      id="ixv-15337"
      unitRef="shares">116313</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c119"
      decimals="0"
      id="ixv-15338"
      unitRef="shares">294977</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c120"
      decimals="0"
      id="ixv-15339"
      unitRef="shares">112000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c121" id="ixv-15340">P180D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c121"
      decimals="2"
      id="ixv-15341"
      unitRef="usdPershares">4.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c122"
      decimals="0"
      id="ixv-15342"
      unitRef="shares">39918</us-gaap:StockIssuedDuringPeriodSharesOther>
    <osti:ExercisePrice
      contextRef="c122"
      decimals="2"
      id="ixv-15343"
      unitRef="usdPershares">4.4</osti:ExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c123"
      decimals="0"
      id="ixv-15344"
      unitRef="shares">156821</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c122"
      decimals="2"
      id="ixv-15345"
      unitRef="usdPershares">1.12</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c124" id="ixv-15346">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c125"
      decimals="0"
      id="ixv-15347"
      unitRef="shares">156821</us-gaap:ClassOfWarrantOrRightOutstanding>
    <osti:AggregateWarrantsExercisable
      contextRef="c126"
      decimals="0"
      id="ixv-15348"
      unitRef="shares">13951</osti:AggregateWarrantsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c127"
      decimals="2"
      id="ixv-15349"
      unitRef="usdPershares">4.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c127"
      decimals="0"
      id="ixv-15350"
      unitRef="shares">54807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c127"
      decimals="2"
      id="ixv-15351"
      unitRef="usdPershares">1.12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c128" id="ixv-15352">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c127"
      decimals="0"
      id="ixv-15353"
      unitRef="shares">52872</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShortTermBorrowings contextRef="c129" decimals="0" id="ixv-15354" unitRef="usd">100000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate contextRef="c3" decimals="2" id="ixv-15355" unitRef="pure">0.08</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermBorrowings contextRef="c130" decimals="0" id="ixv-15356" unitRef="usd">150000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="c131"
      decimals="2"
      id="ixv-15357"
      unitRef="pure">0.08</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <osti:TedcoGrantDisclosureTextBlock contextRef="c0" id="ixv-10501">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5&#160;&#x2014;&#160;TEDCO GRANT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May of 2021, the Company
received the first of two tranches from TEDCO&#x2019;s &lt;i&gt;Rural&#160;&amp;amp; Underserved Business Recovery from Impact of COVID-19 (RUBRIC)
Grant &lt;/i&gt;in the amount of $50,000. A second tranche of $50,000 was received in October&#160;2021 for a total reimbursable grant amount
of $100,000. The Company is obligated to report on and pay to TEDCO&#160;3% of their quarterly revenues for a five-year period following
the reward date. Income from grants and investments are not considered revenues. Royalties due to TEDCO are capped at 150% of the amount
of the award or $150,000 total. The Company has the option to eliminate the quarterly royalty obligation by making an advance payment
prior to the end of the five-year period, in which case, the Company will receive a 10% reduction of the royalty cap percentage for each
year prior to the expiration of the five-year reimbursement period that the grant is repaid in full. If the Company ceases to meet eligibility
requirements the reimbursement obligation will become due to TEDCO immediately; however, the discount for meeting the obligation will
still apply.&lt;/p&gt;</osti:TedcoGrantDisclosureTextBlock>
    <osti:NumberOfTranches
      contextRef="c149"
      decimals="0"
      id="ixv-15358"
      unitRef="pure">2</osti:NumberOfTranches>
    <us-gaap:GrantsReceivable contextRef="c149" decimals="0" id="ixv-15359" unitRef="usd">50000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable contextRef="c150" decimals="0" id="ixv-15360" unitRef="usd">50000</us-gaap:GrantsReceivable>
    <osti:ReimbursableGrantAmount contextRef="c151" decimals="0" id="ixv-15361" unitRef="usd">100000</osti:ReimbursableGrantAmount>
    <osti:PercentageOfRoyalties
      contextRef="c152"
      decimals="2"
      id="ixv-15362"
      unitRef="pure">1.50</osti:PercentageOfRoyalties>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c152" decimals="0" id="ixv-15363" unitRef="usd">150000</us-gaap:ProceedsFromRoyaltiesReceived>
    <osti:RoyaltyReductionPercentage
      contextRef="c152"
      decimals="2"
      id="ixv-15364"
      unitRef="pure">0.10</osti:RoyaltyReductionPercentage>
    <osti:ReimbursementExpirationPeriod contextRef="c152" id="ixv-15365">P5Y</osti:ReimbursementExpirationPeriod>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-10511">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6&#160;&#x2014;&#160;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employee Commitments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;There are no employee commitments
as the Company operates on an At-Will employment basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Rental Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company rents a virtual
office on a month-to-month basis at JLabs in New York, New York, a facility owned by Johnson &amp;amp; Johnson. The current monthly rent is
$787.50. Rent expense for the years ended December 31, 2025 and 2024 was $10,390 and $1,750, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;License Obligation and Manufacturing Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Advaxis (now Ayala)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In September 2018, the Company
entered into an exclusive license agreement with Advaxis, Inc., as amended, under which it acquired the rights to develop and commercialize
the Advaxis HER2 Construct, including related patents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Under the agreement, all milestone
payments were non-refundable, non-creditable and payable only once upon the achievement of the corresponding milestone. As of December
31, 2020, the first milestone was achieved and paid ($1,550,000) in January 2021. The second milestone was completed and paid ($1,375,000)
in May 2021. No milestone payments were made for the year ended December 31, 2025 or December 31, 2024. The license agreement was terminated
upon the Company&#x2019;s purchase of the HER2 Assets from Ayala on April 9, 2025, which included a payment of $400,000 and the issuance
of common stock as consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;BlinkBio&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In July&#160;2020, the Company
entered into a Licensing Agreement with BlinkBio, Inc., to utilize their proprietary technology. As of August&#160;2020, the $300,000
License fee was fully paid and recorded in license expense. These payments have been recorded in the Licensing expenses of the accompanying
statement of operations. No payments were due or made in 2024 or 2025. The Company is currently conducting early-stage research on the
licensed drug, including studies to support future toxicology evaluations. A payment schedule for future milestones is summarized below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Milestone Bearing Event&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Milestone&lt;br/&gt; Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;1.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;License Fee to utilize proprietary technology (paid)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$300,000 + $2.4 million Convertible Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; width: 3%; vertical-align: top"&gt;2.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left"&gt;Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#x201c;GLP-Tox&#x201d;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;3.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Completion of a Phase I Clinical Trial&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;4.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Completion of a Phase II Clinical Trial&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;5.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;6.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Regulatory Approval in the first of the United States, within the EU or within the UK&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company will make the
cash payments set forth in the table above by wire transfer of immediately available funds, to BlinkBio within 30&#160;days of the occurrence
of each milestone set forth with respect to the first Product to attain each such milestone, except that the first Milestone above will
apply with respect to The Company&#x2019;s first product candidate. During the Royalty Term, the Company will pay BlinkBio a royalty of
6% on Net Sales on a Product-by-Product and country-by-country basis during the Royalty Term, in a country in which no Valid Claim Covers
the manufacture, use, or sale of a Product, the royalty on Net Sales of such Product in such country will be reduced to 3%. No royalties
were due in the years ended December 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the avoidance of doubt,
each milestone payment will be payable only once, and the aggregate amount of Milestone payments payable hereunder will not exceed $22,375,000.
A Milestone may be achieved by the Company or a Commercial Sublicensee.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;George Clinical Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In June&#160;2020, the Company
entered into a Research Service Agreement, as amended, with George Clinical Inc., to use their clinical research services for the Company&#x2019;s
study: &#x201c;&lt;i&gt;An Open Label, Phase&#160;2 Study of Maintenance Therapy with OST-HER2&#160;after Resection of Recurrent Osteosarcoma&lt;/i&gt;&#x201d;.
Under the terms of the agreement, the Company was required to pay to George Clinical certain fees described in the fee schedule below.
The total budget under the agreement was approximately $2,436,928. For the years ended December 31, 2025 and 2024, the total research
and development expenses recorded in the statement of operations was $0&#160;and $86,687, respectively. The fee schedule for certain fees
and corresponding payment amounts is set forth below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;George Clinical Payment Schedule&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Payment &lt;br/&gt;
Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 3%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%"&gt;&lt;span style="font-size: 10pt"&gt;Service Fee Advance (paid)&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;49,989&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;193,671&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;35% on Electronic Data Capture (EDC) Go Live Date&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;47,740&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;35% on Development of SAP tables&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;47,740&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;30% on Final Analysis&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,920&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-size: 10pt"&gt;Service Fees&#160;&#x2013;&#160;Remainder Due&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Split monthly &lt;br/&gt;
over course &lt;br/&gt;
of study&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;George Clinical tracked and
invoiced the Company for the number of task units completed and pass-through costs were invoiced each month in arrears based on actual
costs without mark-up. The PTC Advance Fee was used to offset final pass-through fees payable. As of December 31, 2025, the balance payable
to George Clinical was $0, and the services agreement has terminated in accordance with its terms. All fees due under the agreement have
been satisfied, and no further obligations to the vendor remain.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Biolacuna Ltd&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has contracted
with Biolacuna Ltd, a global life sciences advisory firm, to assist with the following agencies requirements to register OST-HER2 and
gain approval of its use in the respective regions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;European Medicines Agency (EMA, Europe);&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Medicines Evaluation Board (MEB, Netherlands);&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Medicines and Healthcare products Regulatory Agency (MHRA,
United Kingdom); and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;U.S. Food and Drug Administration (FDA, United States).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the year ended December
31, 2025, the Company paid $11,629,063 in consulting fees, which includes refundable value-added tax (VAT) expenses. As of December 31,
2025, accounts payable related to consulting fees and VAT totaled $7,323,386.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Trustees of the University of Pennsylvania&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 9, 2025, the Company
acquired from Ayala the HER2 Assets. Pursuant to the terms of the HER2 Purchase Agreement, the amended and restated development, license
and supply agreement with Advaxis terminated. In connection with the acquisition of the HER2 Assets, the Company was assigned by Ayala
a license agreement with the Trustees of the University of Pennsylvania covering the use of HER2 construct patents. Under the terms of
the license agreement, the Company is required to pay an annual license fee to the Trustees of the University of Pennsylvania. In April
2025, the Company paid a fee of $266,317 for the year ended December 31, 2025. In addition, the Company is obligated to pay a royalty
equal to 1.5% of net sales related to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;OST-HER2-related sales;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ADXS-503-related sales;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ADXS-504-related sales; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Sales related to any new immunotherapy
drug candidates created from the &lt;i&gt;Lm&lt;/i&gt; platform during the term of such licensing agreement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;From time to time, the Company
may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any
of these claims could subject the Company to costly legal expenses and, while management generally believes that there will be adequate
insurance to cover different liabilities at such time the Company becomes a public company and commences clinical trials, the Company&#x2019;s
future insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this
were to happen, the payment of any such awards could have a material adverse effect on the results of operations and financial position.
Additionally, any such claims, whether or not successful, could damage the Company&#x2019;s reputation and business. The Company is currently
not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, could
have a material adverse effect on the Company&#x2019;s results of operations or financial position. The Company recently participated in
an arbitration hearing related to a claim brought by its former investment advisor concerning underwriter compensation for the Company&#x2019;s
initial public offering in August 2024 and any subsequent equity offerings during the following 12 months. The hearing concluded on November
7, 2025, and the arbitrators issued a ruling on January 28, 2026, awarding the former investment advisor $1,055,428 and their attorneys
$308,804.88. The Company also incurred $15,128.32 in arbitration-related fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The total amount of $1,379,361.20
has been accrued in the Company&#x2019;s financial statements as of December 31, 2025 and is recorded as Other expense, payable in 2026.
The Company does not intend to challenge the ruling. In accordance with ASC 450, the obligation is considered both probable and reasonably
estimable.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForRent contextRef="c153" decimals="2" id="ixv-15366" unitRef="usd">787.5</us-gaap:PaymentsForRent>
    <osti:RentExpense contextRef="c0" decimals="0" id="ixv-15367" unitRef="usd">10390</osti:RentExpense>
    <osti:RentExpense contextRef="c7" decimals="0" id="ixv-15368" unitRef="usd">1750</osti:RentExpense>
    <osti:MilestonePayments contextRef="c154" decimals="0" id="ixv-15369" unitRef="usd">-1550000</osti:MilestonePayments>
    <osti:MilestonePayments contextRef="c155" decimals="0" id="ixv-15370" unitRef="usd">-1375000</osti:MilestonePayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c45" decimals="0" id="ixv-15371" unitRef="usd">400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromLicenseFeesReceived contextRef="c156" decimals="0" id="ixv-15372" unitRef="usd">300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <osti:ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock contextRef="c0" id="ixv-15373">A payment schedule for future milestones is summarized below.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Milestone Bearing Event&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Milestone&lt;br/&gt; Payment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;1.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;License Fee to utilize proprietary technology (paid)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$300,000 + $2.4 million Convertible Note&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; width: 3%; vertical-align: top"&gt;2.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%; text-align: left"&gt;Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#x201c;GLP-Tox&#x201d;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;3.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Completion of a Phase I Clinical Trial&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;4.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Completion of a Phase II Clinical Trial&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;5.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;6.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;Regulatory Approval in the first of the United States, within the EU or within the UK&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</osti:ScheduleOfPaymentForFutureMilestoneEventsTableTextBlock>
    <osti:MilestoneBearingEventDescription contextRef="c161" id="ixv-15374">License Fee to utilize proprietary technology (paid)</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c162" decimals="0" id="ixv-15375" unitRef="usd">300000</osti:FutureMilestones>
    <osti:FutureMilestones
      contextRef="c163"
      decimals="-5"
      id="ixv-15376"
      unitRef="usd">2400000</osti:FutureMilestones>
    <osti:MilestoneBearingEventDescription contextRef="c164" id="ixv-15377">Commencement of a toxicology study commented pursuant to Good Laboratory Practices (per 21 CFR Part 58) such that any resulting positive data would be admissible to applicable Regulatory Authorities to support an IND (commonly referred to as &#x201c;GLP-Tox&#x201d;)</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c164" decimals="0" id="ixv-15378" unitRef="usd">375000</osti:FutureMilestones>
    <osti:MilestoneBearingEventDescription contextRef="c165" id="ixv-15379">Completion of a Phase I Clinical Trial</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c165" decimals="0" id="ixv-15380" unitRef="usd">1500000</osti:FutureMilestones>
    <osti:MilestoneBearingEventDescription contextRef="c166" id="ixv-15381">Completion of a Phase II Clinical Trial</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c166" decimals="0" id="ixv-15382" unitRef="usd">2500000</osti:FutureMilestones>
    <osti:MilestoneBearingEventDescription contextRef="c167" id="ixv-15383">Filing of an NDA, BLA or MAA registration (or the equivalent in any other territory around the world)</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c167" decimals="0" id="ixv-15384" unitRef="usd">6000000</osti:FutureMilestones>
    <osti:MilestoneBearingEventDescription contextRef="c168" id="ixv-15385">Regulatory Approval in the first of the United States, within the EU or within the UK</osti:MilestoneBearingEventDescription>
    <osti:FutureMilestones contextRef="c168" decimals="0" id="ixv-15386" unitRef="usd">12000000</osti:FutureMilestones>
    <osti:RoyaltyNetSalesPecentage contextRef="c0" decimals="2" id="ixv-15387" unitRef="pure">0.06</osti:RoyaltyNetSalesPecentage>
    <osti:RoyaltyReductionPercentage contextRef="c0" decimals="2" id="ixv-15388" unitRef="pure">0.03</osti:RoyaltyReductionPercentage>
    <osti:MilestonePayments contextRef="c0" decimals="0" id="ixv-15389" unitRef="usd">22375000</osti:MilestonePayments>
    <osti:BundgerUnderAgreement contextRef="c157" decimals="0" id="ixv-15390" unitRef="usd">2436928</osti:BundgerUnderAgreement>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-15391" unitRef="usd">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c7" decimals="0" id="ixv-15392" unitRef="usd">86687</us-gaap:OtherResearchAndDevelopmentExpense>
    <osti:ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock contextRef="c0" id="ixv-15393">The fee schedule for certain fees
and corresponding payment amounts is set forth below.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;George Clinical Payment Schedule&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Payment &lt;br/&gt;
Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 3%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 82%"&gt;&lt;span style="font-size: 10pt"&gt;Service Fee Advance (paid)&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;49,989&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;193,671&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;35% on Electronic Data Capture (EDC) Go Live Date&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;47,740&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;35% on Development of SAP tables&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;47,740&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Statistics Fees&#160;&#x2013;&#160;30% on Final Analysis&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40,920&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-size: 10pt"&gt;Service Fees&#160;&#x2013;&#160;Remainder Due&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Split monthly &lt;br/&gt;
over course &lt;br/&gt;
of study&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</osti:ScheduleOfCertainFeesAndCorrespondingPaymentTableTextBlock>
    <osti:PaymentScheduleofServiceFees contextRef="c169" id="ixv-10701">Service Fee Advance (paid)</osti:PaymentScheduleofServiceFees>
    <us-gaap:PaymentsForFees contextRef="c169" decimals="0" id="ixv-15394" unitRef="usd">49989</us-gaap:PaymentsForFees>
    <osti:PaymentScheduleofServiceFees contextRef="c170" id="ixv-10714">Service Fee Advance of $212,335 minus the amount already paid, plus PTC Fee Advance of $31,325 (paid)</osti:PaymentScheduleofServiceFees>
    <us-gaap:PaymentsForFees contextRef="c170" decimals="0" id="ixv-15395" unitRef="usd">193671</us-gaap:PaymentsForFees>
    <osti:PaymentScheduleofServiceFees contextRef="c171" id="ixv-10727">Statistics Fees&#160;&#x2013;&#160;35% on Electronic Data Capture (EDC) Go Live Date</osti:PaymentScheduleofServiceFees>
    <us-gaap:PaymentsForFees contextRef="c171" decimals="0" id="ixv-15396" unitRef="usd">47740</us-gaap:PaymentsForFees>
    <osti:PaymentScheduleofServiceFees contextRef="c172" id="ixv-10740">Statistics Fees&#160;&#x2013;&#160;35% on Development of SAP tables</osti:PaymentScheduleofServiceFees>
    <us-gaap:PaymentsForFees contextRef="c172" decimals="0" id="ixv-15397" unitRef="usd">47740</us-gaap:PaymentsForFees>
    <osti:PaymentScheduleofServiceFees contextRef="c173" id="ixv-10753">Statistics Fees&#160;&#x2013;&#160;30% on Final Analysis</osti:PaymentScheduleofServiceFees>
    <us-gaap:PaymentsForFees contextRef="c173" decimals="0" id="ixv-15398" unitRef="usd">40920</us-gaap:PaymentsForFees>
    <osti:PaymentScheduleServiceFeesRemainderDue contextRef="c174" id="ixv-10766">Service Fees&#160;&#x2013;&#160;Remainder Due</osti:PaymentScheduleServiceFeesRemainderDue>
    <osti:ServiceFeesRemainderDue contextRef="c174" id="ixv-10771">Split monthly
over course
of study</osti:ServiceFeesRemainderDue>
    <osti:OutstandingBalanceFees contextRef="c0" decimals="0" id="ixv-15399" unitRef="usd">0</osti:OutstandingBalanceFees>
    <us-gaap:PaymentsForFees contextRef="c158" decimals="0" id="ixv-15400" unitRef="usd">11629063</us-gaap:PaymentsForFees>
    <us-gaap:ValueAddedTaxReceivable contextRef="c3" decimals="0" id="ixv-15401" unitRef="usd">7323386</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:PaymentsForFees contextRef="c0" decimals="0" id="ixv-15402" unitRef="usd">266317</us-gaap:PaymentsForFees>
    <osti:PercentageOfRoyaltyPayments contextRef="c0" decimals="3" id="ixv-15403" unitRef="pure">0.015</osti:PercentageOfRoyaltyPayments>
    <us-gaap:AlternativeInvestment contextRef="c159" decimals="0" id="ixv-15404" unitRef="usd">1055428</us-gaap:AlternativeInvestment>
    <us-gaap:LegalFees contextRef="c160" decimals="2" id="ixv-15405" unitRef="usd">308804.88</us-gaap:LegalFees>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="2" id="ixv-15406" unitRef="usd">15128.32</us-gaap:ProfessionalFees>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="2" id="ixv-15407" unitRef="usd">1379361.2</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-10915">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7&#160;&#x2014;&#160;EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In 2021, the Company&#x2019;s
common stock was initially split into two classes: 50,000,000 shares of Class A common stock, $0.001 par value per share (&#x201c;Class
A Common Stock&#x201d;), and 20,000,000 shares of Class B common stock, $0.001 par value per share (&#x201c;Class B Common Stock&#x201d;).
On February 9, 2024, the Company combined the two classes under the name common stock with 50,000,000 shares authorized. On October 21,
2025, stockholders approved an increase in authorized common stock from 50,000,000 to 150,000,000 shares. As of December 31, 2025 and
2024, the Company had 37,113,082 and 20,869,908 shares of common stock outstanding, respectively. Common stock has voting rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On August&#160;2, 2024, the
Company consummated its initial public offering and sold&#160;1.6 million shares of common stock at a price of $4.00&#160;per share. Concurrent
with this consummation, all outstanding convertible notes, including accrued interest thereon, automatically converted into approximately&#160;13.2&#160;million
shares of common stock, at conversion prices ranging from $0.39&#160;per share to $2.59&#160;per share, after applying share discounts
ranging from&#160;50% to&#160;87.5% and valuation ceilings ranging from $5&#160;million to $50&#160;million, as applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
March 31, 2025, the Company issued (i) 157,407 shares of common stock in connection with its equity line of credit, (ii) 300,000 shares
of common stock to a scientific and technical advisor in exchange for scientific and technical services, which will be amortized over
a 12-month period with the remaining balance in prepaid expenses, and (iii) 20,000 shares of common stock to an advisor in exchange for
services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
June 30, 2025, the Company issued (i) 3,962,129 shares of common stock in connection with conversions of Series A Preferred Stock, (ii)
2,164,215 shares of common stock in connection with the purchase of the HER2 Assets, (iii) 2,166,381 pre-funded warrants in connection
with the purchase of the HER2 Assets, (iv) 10,000 shares of common stock to an advisor in exchange for services and (v) 2,181,257 shares
of common stock in connection with the Company&#x2019;s warrant exercise inducement and exchange offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
September 30, 2025, the Company issued (i) 977,679 shares of common stock in connection with conversions of Series A Preferred Stock,
(ii) 2,507,386 shares of common stock in connection with the Company&#x2019;s warrant exercise inducement and exchange offering and (iii)
120,000 shares of common stock to an advisor in exchange for services. Additionally, the Company received $1,050,000 in gross proceeds,
which was recorded as additional paid-in capital, from the exercise of Series A Warrants to purchase 937,500 shares of common stock, which
were issued subsequent to September 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the three months ended
December 31, 2025, the Company issued (i) 950,000 shares of common stock in connection with its warrant exercise inducement and exchange
offering related to pre-funded warrants, (ii) 2,610,422 shares of common stock upon exercise of the pre-funded warrant issued in connection
with the purchase of the HER2 Assets, and (iii) 282,679 shares of common stock sold pursuant to the Company&#x2019;s ATM program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Additionally, in three months ended December 31, 2025, the Company
received $1,426,109 in gross proceeds from the exercise of Series A Warrants to purchase 1,441,518 shares of common stock at a future
date. These proceeds were recorded as additional paid-in capital and are reflected in the Company&#x2019;s warrant register.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In 2021, the Company authorized
5,000,000 shares of Preferred Stock, of which 1,400,000 were designated as Series A Preferred Stock. A total of 1,302,082 shares of Series
A Preferred Stock were issued, which carried a 5% cumulative dividend and liquidation preference over common stock. Dividends were computed
at 5% of the principal annually and recorded monthly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span&gt;On
February 9, 2024, all outstanding Series A Preferred Stock was converted into common stock on a one-for-two basis pursuant to the filing
of the Company&#x2019;s third amended and restated certificate of incorporation. As of that date, the Company had 5,000,000 shares of authorized
Preferred Stock, with none outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Series A Preferred Stock
dividend for the year ended December 31, 2025 was $0, and for the year ended December 31, 2024 was $31,250, resulting in a total accrued
dividend payable of $375,000 as of December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Preferred Stock has the
following rights and privileges:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Voting&#160;&lt;/i&gt;&#x2014;&#160;Votes
together with the common stock on all matters on an as-converted basis. Approval of a&#160;majority of the New Preferred Stock voting
as a separate class will be required to, among other things: (i)&#160;adversely change rights of the New Preferred Stock, (ii)&#160;change
the authorized number of shares of New Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Conversion&#160;&lt;/i&gt;&#x2014;&#160;Each
share of New Preferred Stock is convertible into one share of common stock (subject to proportional adjustments for stock splits, stock
dividends and the like) at any time at the option of the holder. Conversion ratio will be subject to adjustment on a broad-based, weighted
average basis in the event of subsequent issuances at a price less than the original issue price (as adjusted) subject to customary exceptions.
The conversion into common stock occurred on February 9, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Liquidation&#160;&lt;/i&gt;&#x2014;&#160;One
times the original issue price of the New Preferred Stock plus declared but unpaid dividends on each share of New Preferred Stock (or,
if greater, the amount that the New Preferred Stock would receive on an as-converted basis) will be paid first on each share of New Preferred
Stock, and the balance of proceeds to be paid to common stock. A merger, reorganization, or similar transaction (including a sale, exclusive
license or other disposition of all or substantially all of the assets of the Company or its subsidiaries) will be treated as a liquidation,
thereby triggering payment of the liquidation preference described above. For the avoidance of doubt, the liquidation preference is intended
to provide the Investor (and its permitted assigns) with an aggregate liquidation payment of $2,500,000.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
the common stock options issued to employees and consultants for services during the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average Remaining Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,866,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,904,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,771,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;2,866,750&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3.92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the options
granted during the year ended December 31, 2025 was estimated at the date of grant using the Black-Scholes option-pricing model with the
following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Volatility (based on peer companies)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk Free Interest Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-size: 10pt"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Estimated Life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended December 31, 2025 and 2024, the Company recognized
combined share-based compensation expense of $4,265,374 and $268,300, respectively, related to these common stock options. At the Company&#x2019;s
annual meeting on October 21, 2025, stockholders approved an amendment to the Company&#x2019;s 2023 Incentive Compensation Plan, increasing
the shares of common stock authorized for issuance thereunder from 4 million to 10 million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c175"
      decimals="0"
      id="ixv-15408"
      unitRef="shares">50000000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c176"
      decimals="3"
      id="ixv-15409"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="c177"
      decimals="0"
      id="ixv-15410"
      unitRef="shares">20000000</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c178"
      decimals="3"
      id="ixv-15411"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c179"
      decimals="0"
      id="ixv-15412"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c180"
      decimals="0"
      id="ixv-15413"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c181"
      decimals="0"
      id="ixv-15414"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c43"
      decimals="0"
      id="ixv-15415"
      unitRef="shares">37113082</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c182"
      decimals="0"
      id="ixv-15416"
      unitRef="shares">20869908</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="c0" id="ixv-15417">Common stock has voting rights</us-gaap:CommonStockVotingRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c183"
      decimals="-5"
      id="ixv-15418"
      unitRef="shares">1600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c184"
      decimals="2"
      id="ixv-15419"
      unitRef="usdPershares">4</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c185"
      decimals="-5"
      id="ixv-15420"
      unitRef="shares">13200000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c186"
      decimals="2"
      id="ixv-15421"
      unitRef="usdPershares">0.39</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c186"
      decimals="2"
      id="ixv-15422"
      unitRef="usdPershares">2.59</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <osti:CommonStockConversionAfterShareDiscountsPercentage
      contextRef="c187"
      decimals="2"
      id="ixv-15423"
      unitRef="pure">0.50</osti:CommonStockConversionAfterShareDiscountsPercentage>
    <osti:CommonStockConversionAfterShareDiscountsPercentage
      contextRef="c188"
      decimals="3"
      id="ixv-15424"
      unitRef="pure">0.875</osti:CommonStockConversionAfterShareDiscountsPercentage>
    <osti:ValuationCeilingsAmount
      contextRef="c187"
      decimals="-6"
      id="ixv-15425"
      unitRef="usd">5000000</osti:ValuationCeilingsAmount>
    <osti:ValuationCeilingsAmount
      contextRef="c188"
      decimals="-6"
      id="ixv-15426"
      unitRef="usd">50000000</osti:ValuationCeilingsAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c189"
      decimals="0"
      id="ixv-15427"
      unitRef="shares">157407</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c190"
      decimals="0"
      id="ixv-15428"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c191"
      decimals="0"
      id="ixv-15429"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c192"
      decimals="0"
      id="ixv-15430"
      unitRef="shares">3962129</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c193"
      decimals="0"
      id="ixv-15431"
      unitRef="shares">2164215</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c194"
      decimals="0"
      id="ixv-15432"
      unitRef="shares">2166381</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c195"
      decimals="0"
      id="ixv-15433"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c196"
      decimals="0"
      id="ixv-15434"
      unitRef="shares">2181257</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c197"
      decimals="0"
      id="ixv-15435"
      unitRef="shares">977679</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c198"
      decimals="0"
      id="ixv-15436"
      unitRef="shares">2507386</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c199"
      decimals="0"
      id="ixv-15437"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c199" decimals="0" id="ixv-15438" unitRef="usd">1050000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c200"
      decimals="INF"
      id="ixv-15439"
      unitRef="shares">937500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c201"
      decimals="0"
      id="ixv-15440"
      unitRef="shares">950000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c202"
      decimals="0"
      id="ixv-15441"
      unitRef="shares">2610422</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c203"
      decimals="0"
      id="ixv-15442"
      unitRef="shares">282679</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <osti:GrossProceeds contextRef="c204" decimals="0" id="ixv-15443" unitRef="usd">1426109</osti:GrossProceeds>
    <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
      contextRef="c204"
      decimals="0"
      id="ixv-15444"
      unitRef="shares">1441518</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c205"
      decimals="0"
      id="ixv-15445"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <osti:PreferredStockSharesDesignated
      contextRef="c206"
      decimals="0"
      id="ixv-15446"
      unitRef="shares">1400000</osti:PreferredStockSharesDesignated>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c207"
      decimals="0"
      id="ixv-15447"
      unitRef="shares">1302082</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c208"
      decimals="2"
      id="ixv-15448"
      unitRef="pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c208"
      decimals="2"
      id="ixv-15449"
      unitRef="pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c209"
      decimals="0"
      id="ixv-15450"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c209"
      decimals="0"
      id="ixv-15451"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsPreferredStockCash contextRef="c210" decimals="0" id="ixv-15452" unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash contextRef="c211" decimals="0" id="ixv-15453" unitRef="usd">31250</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-15454" unitRef="usd">375000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c3" decimals="0" id="ixv-15455" unitRef="usd">2500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-11023">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
the common stock options issued to employees and consultants for services during the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Common Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average Remaining Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,866,750&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,904,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,771,250&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.83&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;2,866,750&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3.92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c4"
      decimals="0"
      id="ixv-15456"
      unitRef="shares">2866750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-15457"
      unitRef="usdPershares">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-11088">P4Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="0"
      id="ixv-15458"
      unitRef="shares">3904500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-15459"
      unitRef="usdPershares">1.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="c0" id="ixv-11124">P5Y</osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="0"
      id="ixv-15460"
      unitRef="shares">6771250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-15461"
      unitRef="usdPershares">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0" id="ixv-11229">P4Y5M4D</osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c3"
      decimals="0"
      id="ixv-15462"
      unitRef="shares">2866750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-15463"
      unitRef="usdPershares">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-15464">P3Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-11273">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the options
granted during the year ended December 31, 2025 was estimated at the date of grant using the Black-Scholes option-pricing model with the
following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Volatility (based on peer companies)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;112&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk Free Interest Rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-size: 10pt"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Estimated Life in years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" id="ixv-15465" unitRef="pure">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-15466" unitRef="pure">0.0355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-15467">P2Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-15468" unitRef="usd">4265374</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="0" id="ixv-15469" unitRef="usd">268300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="c212"
      decimals="-6"
      id="ixv-15470"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="c213"
      decimals="-6"
      id="ixv-15471"
      unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <us-gaap:PreferredStockTextBlock contextRef="c0" id="ixv-11331">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8&#160;&#x2014;&#160;REDEEMABLE PREFERRED
STOCK, MEZZAININE EQUITY AND WARRANT LIABILITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Securities Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On December 24, 2024, the
Company entered into the Purchase Agreement with various institutional and accredited investors. The Company completed the initial closing
on December 31, 2024 and sold an aggregate of 1,512,500 immediately separable units (the &#x201c;Units&#x201d;), each Unit consisting of
(i) one share of the Company&#x2019;s Series A Preferred Stock, and (ii) a Warrant to purchase one share of common stock, at a price per
Unit of $4.00. The Warrant has an exercise price of $4.40 per share, subject to adjustment therein, and a term of five years from the
date stockholder approval of the common stock issuances contemplated by the Purchase Agreement is obtained. The gross proceeds from the
initial closing to the Company, before deducting transaction fees and other estimated expenses, was $6,050,000. On January 14, 2025 the
Company sold and issued an additional 263,250 Units. The gross proceeds from the second closing to the Company, before deducting transaction
fees and other estimated expenses, was $1,053,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;Based
on the terms of the Series A Preferred Stock and the Company&#x2019;s Certificate of Designation, and in accordance with ASC 480, the Series
A Preferred Stock is accounted for as mezzanine equity due to the redemption feature upon a deemed liquidation event: (i) a merger or
consolidation, or (ii) the sale, lease, transfer or other disposition of substantially all the assets of the Company. $1,971,975 of the
initial cash proceeds of $6,050,000 were allocated to the Warrants and $4,078,025 of the residual proceeds were allocated to the Series
A Preferred Stock. $330,781 of the additional cash proceeds of $1,053,000 were allocated to the Warrants and $722,219 of the residual
proceeds were allocated to the Series A Preferred Stock from the January 14, 2025 settlement, with all the same terms as the first settlement
above.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;From
April 9, 2025 through December 31, 2025, Mezzanine Equity converted into 4,939,808 shares of common stock. Of the original 1,775,750 shares
of Series A Preferred Stock, 273,750 and 1,383,250 shares were converted during the three- and nine-month periods ended December 31, 2025,
respectively. As of December 31, 2025, 392,500 shares of Series A Preferred Stock remain outstanding, convertible into 1,401,786 shares
of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;Based
on the terms of the Warrants and in accordance with ASC 815, the Warrants are accounted for as a liability due to the variable exercise
price subject to adjustment. Currently, there is not an observable market for this type of derivative. Due to the lack of relevant and
market reflective Level 1 and Level 2 inputs, the Company valued the Warrant liability using Level 3 inputs, which require significant
judgment and estimates on behalf of management in developing model assumptions. The Company determined the value of the Warrant liability
using a Binomial Simulation, which takes into consideration the fair market value of the Company&#x2019;s stock, the variable nature of
the exercise price, the estimated exercise period, the volatility of its common stock, and the risk-free interest rate.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "&gt;The following assumptions
were made as of December 31, 2024 in the model: (1) a variable exercise price with a floor of $4.40 per share, (2) current common stock
price of $4.28 per share December 31, 2024, (3) discount rate of 4.38%, and (4) expected stock price volatility of 24.90%. As of December
31, 2024, the carrying value of the Warrant liability in aggregate was $1,971,975 on December 31, 2024. The following assumptions were
made as of January 14, 2025 in the model: (1) a variable exercise price with a floor of $4.40 per share, (2) current common stock price
of $4.16 per share on January 14, 2025, (3) discount rate of 4.59%, and (4) expected stock price volatility of 25.77%. As of January 14,
the carrying value of the 263,250 issued warrants was $330,781.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following assumptions
were made as of April 9, 2025 based on stockholder approval in the model for the aggregate warrants: (1) a fixed exercise price of $1.12
per share, which automatically reset and resulted in a reclassification of the warrant liability on April 9, 2025 to equity per ASC 815;
(2) then-current common stock price of $1.34 per share on April 9, 2025; (3) discount rate of 4.06%; and (4) expected stock price volatility
of 23.26%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2025, the
carrying value of the Warrant liability in aggregate was &lt;span style="-sec-ix-hidden: hidden-fact-127"&gt;$0&lt;/span&gt;. For the year ended December 31, 2025, the Company recorded a gain on the
change in fair value of the Warrant Liability in the amount of $1,424,603 and a $878,153 deduction due to reclassification to equity.
As of December 31, 2025 and December 31, 2024, the carrying value of the Warrant liability in aggregate was &lt;span style="-sec-ix-hidden: hidden-fact-128"&gt;$0&lt;/span&gt; and $1,971,975, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Series A Preferred Stock
and Warrants were issued in a basket transaction. When two or more instruments are issued in a basket transaction and some instruments
will be remeasured at fair value, the proceeds are first allocated to the instruments recorded at their fair value. Next, the residual
method is used to allocate the proceeds to the instrument(s) that are not remeasured at fair value. In this case, the Warrant is subsequently
measured at fair value, and the Series A Preferred Stock instrument is measured at initial carrying value. The Company will first allocate
the proceeds to the Warrant liability, with the residual allocated to the Series A Preferred Stock liability. The following tables reflect
the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period
from December 31, 2024 to December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash proceeds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;7,103,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fair value of Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,302,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Residual value allocated to Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,800,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unallocated cash proceeds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&#160;&lt;br/&gt; year ended&lt;br/&gt;
    December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Warrant Liability as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,971,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Additional Warrant Liability on January 14, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on the change in fair value of Warrant Liability as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;(1,122,561&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrant Liability as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,180,195&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on the change in fair value of Warrant Liability as of April 9, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(302,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stockholder approval on April 9, 2025 - warrants turn into Equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(878,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrant Liability as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PreferredStockTextBlock>
    <osti:StockIssuedDuringPeriodSharesPreferredStockSeperableUnits
      contextRef="c7"
      decimals="0"
      id="ixv-15472"
      unitRef="shares">1512500</osti:StockIssuedDuringPeriodSharesPreferredStockSeperableUnits>
    <osti:PurchaseOfCommonStock contextRef="c214" decimals="0" id="ixv-15473" unitRef="usd">1</osti:PurchaseOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c214"
      decimals="2"
      id="ixv-15474"
      unitRef="usdPershares">4</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c214"
      decimals="2"
      id="ixv-15475"
      unitRef="usdPershares">4.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c7"
      decimals="0"
      id="ixv-15476"
      unitRef="shares">6050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <osti:StockIssuedDuringPeriodSharesAdditionalUnits
      contextRef="c215"
      decimals="0"
      id="ixv-15477"
      unitRef="shares">263250</osti:StockIssuedDuringPeriodSharesAdditionalUnits>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c0" decimals="0" id="ixv-15478" unitRef="usd">1053000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c216" decimals="0" id="ixv-15479" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c217" decimals="0" id="ixv-15480" unitRef="usd">6050000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c217" decimals="0" id="ixv-15481" unitRef="usd">4078025</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c218" decimals="0" id="ixv-15482" unitRef="usd">330781</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="c215" decimals="0" id="ixv-15483" unitRef="usd">1053000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c215" decimals="0" id="ixv-15484" unitRef="usd">722219</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c219"
      decimals="0"
      id="ixv-15485"
      unitRef="shares">4939808</us-gaap:ConversionOfStockSharesConverted1>
    <osti:OriginalShares
      contextRef="c220"
      decimals="0"
      id="ixv-15486"
      unitRef="shares">1775750</osti:OriginalShares>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c221"
      decimals="0"
      id="ixv-15487"
      unitRef="shares">273750</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c222"
      decimals="0"
      id="ixv-15488"
      unitRef="shares">1383250</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c37"
      decimals="0"
      id="ixv-15489"
      unitRef="shares">392500</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c49"
      decimals="0"
      id="ixv-15490"
      unitRef="shares">1401786</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-15491"
      unitRef="usdPershares">4.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="c4"
      decimals="2"
      id="ixv-15492"
      unitRef="usdPershares">4.28</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="c7" decimals="4" id="ixv-15493" unitRef="pure">0.0438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c223"
      decimals="2"
      id="ixv-15494"
      unitRef="pure">24.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c4" decimals="0" id="ixv-15495" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c224"
      decimals="2"
      id="ixv-15496"
      unitRef="usdPershares">4.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="c224"
      decimals="2"
      id="ixv-15497"
      unitRef="usdPershares">4.16</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="c215"
      decimals="4"
      id="ixv-15498"
      unitRef="pure">0.0459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c225"
      decimals="2"
      id="ixv-15499"
      unitRef="pure">25.77</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="c215" decimals="0" id="ixv-15500" unitRef="usd">263250</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c226" decimals="0" id="ixv-15501" unitRef="usd">330781</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c227"
      decimals="2"
      id="ixv-15502"
      unitRef="pure">1.12</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c228"
      decimals="2"
      id="ixv-15503"
      unitRef="pure">1.34</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c229"
      decimals="2"
      id="ixv-15504"
      unitRef="pure">4.06</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c230"
      decimals="2"
      id="ixv-15505"
      unitRef="pure">23.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c232" decimals="0" id="ixv-15506" unitRef="usd">-1424603</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c0" decimals="0" id="ixv-15507" unitRef="usd">878153</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c4" decimals="0" id="ixv-15508" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock contextRef="c0" id="ixv-15509">The following tables reflect
the allocation of the cash proceeds and changes in Warrant Liability in the consolidated statement of operations as of and for the period
from December 31, 2024 to December 31, 2025.&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash proceeds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;7,103,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Fair value of Warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,302,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Residual value allocated to Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,800,244&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unallocated cash proceeds&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c217" decimals="0" id="ixv-15510" unitRef="usd">7103000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c217" decimals="0" id="ixv-15511" unitRef="usd">-2302756</us-gaap:FairValueAdjustmentOfWarrants>
    <osti:ResidualValueAllocatedToSeriesAPreferredStock contextRef="c217" decimals="0" id="ixv-15512" unitRef="usd">-4800244</osti:ResidualValueAllocatedToSeriesAPreferredStock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0" id="ixv-11423">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&#160;&lt;br/&gt; year ended&lt;br/&gt;
    December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Warrant Liability as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,971,975&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Additional Warrant Liability on January 14, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain on the change in fair value of Warrant Liability as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;(1,122,561&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrant Liability as of March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,180,195&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gain on the change in fair value of Warrant Liability as of April 9, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(302,042&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stockholder approval on April 9, 2025 - warrants turn into Equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(878,153&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Warrant Liability as of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c233" decimals="0" id="ixv-15513" unitRef="usd">1971975</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c234" decimals="0" id="ixv-15514" unitRef="usd">330781</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c234" decimals="0" id="ixv-15515" unitRef="usd">-1122561</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c235" decimals="0" id="ixv-15516" unitRef="usd">1180195</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c236" decimals="0" id="ixv-15517" unitRef="usd">-302042</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="c236" decimals="0" id="ixv-15518" unitRef="usd">-878153</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-11499">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 &#x2014; SEGMENT AND GEOGRAPHIC INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company operates as&#160;one&#160;operating
segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its &lt;span style="-sec-ix-hidden: hidden-fact-133"&gt;Chief Executive Officer&lt;/span&gt;, who reviews financial
information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance
and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the
rate at which the Company seeks to grow global operating margin and the allocation of budget between cost of revenues, sales and marketing,
technology and development, and general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table presents
selected financial information with respect to the Company&#x2019;s single operating segment for the years ended December&#160;31, 2025
and 2023:&lt;/p&gt;

&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;OPERATING EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,360,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,839,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;General&#160;and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,344,976&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,974,786&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,705,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,813,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;OTHER INCOME (EXPENSE)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,051,839&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Non-operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Non-operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,472,995&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,424,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;TOTAL OTHER INCOME (EXPENSE)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,143&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,069,092&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;NET LOSS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,753,844&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,882,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c0"
      decimals="0"
      id="ixv-15519"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c0"
      decimals="0"
      id="ixv-15520"
      unitRef="Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="c0" id="ixv-11504">The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer, who reviews financial
information presented on a consolidated basis. The CODM uses consolidated operating margin and net income to assess financial performance
and allocate resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0" id="ixv-11507">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following table presents
selected financial information with respect to the Company&#x2019;s single operating segment for the years ended December&#160;31, 2025
and 2023:&lt;/p&gt;

&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;OPERATING EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Research&#160;and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,360,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,839,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;General&#160;and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,344,976&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,974,786&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,705,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,813,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;OTHER INCOME (EXPENSE)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,051,839&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Non-operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Non-operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,472,995&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(51,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,424,603&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;TOTAL OTHER INCOME (EXPENSE)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(48,143&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,069,092&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;NET LOSS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,753,844&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,882,938&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c238" decimals="0" id="ixv-15521" unitRef="usd">16360725</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c239" decimals="0" id="ixv-15522" unitRef="usd">2839060</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c238" decimals="0" id="ixv-15523" unitRef="usd">12344976</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c239" decimals="0" id="ixv-15524" unitRef="usd">3974786</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c238" decimals="0" id="ixv-15525" unitRef="usd">-28705701</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c239" decimals="0" id="ixv-15526" unitRef="usd">-6813846</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c238" decimals="0" id="ixv-15527" unitRef="usd">249</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseOther contextRef="c239" decimals="0" id="ixv-15528" unitRef="usd">2051839</us-gaap:InterestExpenseOther>
    <us-gaap:OtherNonoperatingIncome contextRef="c239" decimals="0" id="ixv-15529" unitRef="usd">33997</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c238" decimals="0" id="ixv-15530" unitRef="usd">1472995</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c239" decimals="0" id="ixv-15531" unitRef="usd">51250</us-gaap:OtherNonoperatingExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c238" decimals="0" id="ixv-15532" unitRef="usd">-1424603</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:NonoperatingIncomeExpense contextRef="c238" decimals="0" id="ixv-15533" unitRef="usd">-48143</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c239" decimals="0" id="ixv-15534" unitRef="usd">-2069092</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c238" decimals="0" id="ixv-15535" unitRef="usd">-28753844</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c239" decimals="0" id="ixv-15536" unitRef="usd">-8882938</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-11674">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 10&#160;&#x2014;&#160;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Third Warrant Exercise
Inducement and Exchange Offering&#160;&lt;/i&gt;&#x2014;&#160;On January 14, 2026, the Company closed on a third warrant exercise inducement
and exchange offer (the &#x201c;Third Inducement Offering&#x201d;). The Third Inducement Offering was made to less than 10 accredited investors
that held certain existing warrants to purchase up to an aggregate of 5,382,148 shares of the Company&#x2019;s common stock having a then
current exercise price of $3.00 or $2.10 per share. Pursuant to certain inducement offer letter agreements, such holders exercised for
cash their warrants to purchase 2,499,558 shares of the Company&#x2019;s common stock at a reduced exercise price of $1.40 per share and
in exchange the Company issued to such holders new warrants to purchase up to an aggregate of 2,499,558 shares of common stock at an exercise
price of $1.40 per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of five years from such date. The gross proceeds to the Company from the Third Inducement Offering, before
deducting transaction fees and other offering expenses, were approximately $3.5 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company agreed to file
a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if not then eligible to register securities on
Form S-3) providing for the resale of the shares of common stock issued or issuable upon exercise of the new warrants issued within 30
calendar days of March 2, 2026, and to use commercially reasonable efforts to have such registration statement declared effective by the
SEC within 60 calendar days (or within 90 calendar days in case of &#x201c;full review&#x201d; by the SEC) following its initial filing
and to keep such registration statement effective at all times until the earlier of (i) the time no holder owns any new warrants or shares
of common stock issuable upon exercise thereof and (ii) the Delegend Date (as defined in the inducement offer letter agreements entered
into in connection with the Third Inducement Offering).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Privately Negotiated
Warrant Exercise Inducement and Exchange Agreements &#x2013; &lt;/i&gt;From January 10, 2026 through February 2026, the Company entered
into privately negotiated inducement offer letters, pursuant to which certain remaining holders of existing warrants exercised for
cash their warrants to purchase an aggregate of 74,108 shares of common stock at a reduced exercise price of $1.40 per share and in
exchange the Company issued new warrants to purchase up to an aggregate of 74,108 shares of common stock at an exercise price of
$1.40 per share, subject to adjustment as provided therein. Such new warrants are immediately exercisable from the date of issuance
and have a term of exercise of five years from such date. The Company received gross proceeds of approximately $103,750 from the
exercise of these warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company agreed to file a registration statement on Form S-3
(or other appropriate form, including on Form S-1, if not then eligible to register securities on Form S-3) providing for the resale of
the shares of common stock issued or issuable upon exercise of these warrants on or before March 30, 2026, and to use commercially reasonable
efforts to have such registration statement declared effective by the SEC within 60 calendar days (or within 90 calendar days in case
of &#x201c;full review&#x201d; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time no holder of these warrants owns any such warrants or shares of common stock issuable upon exercise thereof
and (ii) the Delegend Date (as defined in the privately negotiated inducement offer letters).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Bridge Financing &#x2013;
&lt;/i&gt;On March 4, 2026, pursuant to a securities purchase agreement (the &#x201c;Bridge SPA&#x201d;), the Company issued to certain accredited
investors in a private placement transaction (i) 10.0% original issue discount unsecured convertible promissory notes in an aggregate
principal amount of $2,200,000 (the &#x201c;Bridge Notes&#x201d;) and (ii) warrants to purchase up to an aggregate of 1,666,667 shares of
common stock (the &#x201c;Bridge Warrants&#x201d; and such private placement transaction, the &#x201c;Bridge Financing&#x201d;), for aggregate
gross proceeds of $2,000,000, before deducting placement agent fees and other Bridge Financing expenses. The Bridge Notes mature on March
4, 2027 and accrue interest at a rate of 4.0% per annum. The Bridge Warrants were immediately exercisable upon issuance, expire five years
from the date of issuance and have an exercise price of $1.40 per share, subject to adjustment as provided therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Bridge Notes were sold
at a 10% original issue discount, such that for each $100,000 invested by a purchaser, such purchaser received a Bridge Note in the principal
amount of $110,000. The Bridge Notes are convertible into shares of common stock under certain circumstances. If the Company completes
a &#x201c;Qualified Offering,&#x201d; defined as a registered public offering or registered direct offering resulting in at least $2.5 million
in gross proceeds from new money investments, the outstanding principal, together with all accrued and unpaid interest, will automatically
convert into the securities sold in such offering at the offering price. Additionally, prior to any such Qualified Offering or repayment
of the Bridge Notes, holders may elect to convert the Bridge Notes, in whole or in part, into shares of common stock at a conversion price
equal to 90% of the average daily volume-weighted average price of the Company&#x2019;s common stock during the 10 trading days immediately
preceding the holder&#x2019;s conversion notice, subject to adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company agreed to file
a registration statement on Form S-3 (or Form S-1 if not then eligible to register securities for Form S-3) by April 3, 2026 to register
for resale the shares of common stock issuable upon conversion of the Bridge Notes and exercise of the Bridge Warrants, and to use commercially
reasonable efforts to cause such registration statement to become effective within 60 calendar days (or 90 calendar days in the case of
a &#x201c;full review&#x201d; by the SEC) following its initial filing and to keep such registration statement effective at all times until
the earlier of (i) the time that no investor owns any Bridge Notes, Bridge Warrants or shares underlying such Bridge Notes and Bridge
Warrants or (ii) the Legend Removal Date (as defined in the Bridge SPA).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Regulatory
Meetings &#x2013; &lt;/i&gt;During early 2026, the Company continued its regulatory engagement with the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)
related to its Biologics License Application (&#x201c;BLA&#x201d;) for OST-HER2. As outlined in recent press releases, this included planned
interactions with the FDA, including a Type D meeting that was elevated to a Type B pre-BLA meeting. These activities are consistent
with the Company&#x2019;s ongoing regulatory efforts. The Company does not believe these interactions currently have a measurable impact
on its consolidated financial statements; however, the outcome of these discussions may affect future development timelines and regulatory
strategy.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c240"
      decimals="0"
      id="ixv-15537"
      unitRef="shares">5382148</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c241"
      decimals="2"
      id="ixv-15538"
      unitRef="usdPershares">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c242"
      decimals="2"
      id="ixv-15539"
      unitRef="usdPershares">2.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c240"
      decimals="0"
      id="ixv-15540"
      unitRef="shares">2499558</us-gaap:ExcessStockSharesIssued>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c243"
      decimals="2"
      id="ixv-15541"
      unitRef="usdPershares">1.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ExcessStockSharesIssued
      contextRef="c244"
      decimals="0"
      id="ixv-15542"
      unitRef="shares">2499558</us-gaap:ExcessStockSharesIssued>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c243"
      decimals="2"
      id="ixv-15543"
      unitRef="usdPershares">1.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c240" id="ixv-15544">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:OtherOwnershipInterestsOfferingCosts
      contextRef="c240"
      decimals="-5"
      id="ixv-15545"
      unitRef="usd">3500000</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c245"
      decimals="0"
      id="ixv-15546"
      unitRef="shares">74108</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c246"
      decimals="2"
      id="ixv-15547"
      unitRef="usdPershares">1.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c245"
      decimals="0"
      id="ixv-15548"
      unitRef="shares">74108</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c246"
      decimals="2"
      id="ixv-15549"
      unitRef="usdPershares">1.4</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c245" id="ixv-15550">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c246" decimals="0" id="ixv-15551" unitRef="usd">103750</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <osti:OriginalIssueDiscount
      contextRef="c247"
      decimals="3"
      id="ixv-15552"
      unitRef="pure">0.10</osti:OriginalIssueDiscount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c248" decimals="0" id="ixv-15553" unitRef="usd">2200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c247"
      decimals="0"
      id="ixv-15554"
      unitRef="shares">1666667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c247" decimals="0" id="ixv-15555" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c247"
      decimals="3"
      id="ixv-15556"
      unitRef="pure">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c248" id="ixv-15557">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="c249"
      decimals="2"
      id="ixv-15558"
      unitRef="usdPershares">1.4</us-gaap:WarrantExercisePriceDecrease>
    <osti:OriginalIssueDiscount contextRef="c0" decimals="2" id="ixv-15559" unitRef="pure">0.10</osti:OriginalIssueDiscount>
    <osti:InvestedPurchaser contextRef="c0" decimals="0" id="ixv-15560" unitRef="usd">100000</osti:InvestedPurchaser>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c0" decimals="0" id="ixv-15561" unitRef="usd">110000</us-gaap:DebtInstrumentIssuedPrincipal>
    <osti:GrossProceeds contextRef="c0" decimals="-5" id="ixv-15562" unitRef="usd">2500000</osti:GrossProceeds>
    <osti:ConversionPricePercentage contextRef="c3" decimals="2" id="ixv-15563" unitRef="pure">0.90</osti:ConversionPricePercentage>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c0" id="ixv-15564">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c0" id="ixv-15565">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c0" id="ixv-15566">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c0" id="ixv-15567">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-15568">false</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c7"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c7"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:DeemedDividendOnSeriesAConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c16"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c7"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="c13"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="c14"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="c15"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c14"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c16"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c14"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c16"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock
      contextRef="c14"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock
      contextRef="c16"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock
      contextRef="c7"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors
      contextRef="c14"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors
      contextRef="c16"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueIssuanceToInvestmentAdvisors
      contextRef="c7"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c14"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c16"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c18"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueCommitmentSharesIssuedForEquityLineOfCredit
      contextRef="c24"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices
      contextRef="c22"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueCommonStockIssuedForServices
      contextRef="c24"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c21"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c24"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock
      contextRef="c22"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfPreferredSharesMezzanineStockToCommonStock
      contextRef="c24"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense
      contextRef="c22"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueofCommonStockforPatentLicense
      contextRef="c24"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock
      contextRef="c22"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:StockIssuedDuringPeriodValueConversionOfWarrantsToCommonStock
      contextRef="c24"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock
      contextRef="c21"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock
      contextRef="c22"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassPreferredStock
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance
      contextRef="c21"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance
      contextRef="c22"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:WarrantsExercisedAndProceedsReceivedSharesPendingIssuance
      contextRef="c24"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c26"
      id="hidden-fact-56"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c26"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:SharesIssuedForServices
      contextRef="c0"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="c0"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c7"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:CommitmentSharesIssuedForEquityLineOfCredit
      contextRef="c7"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c7"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="c7"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="c7"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c7"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c7"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c7"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="c0"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="c0"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c0"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c7"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="c0"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="c0"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Dividends
      contextRef="c0"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c7"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:ConversionOfPreferredStockToCommonStock
      contextRef="c0"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:DeferredOfferingCostsRecordedAsAccountsPayable
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c0"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:ConversionOfWarrantsIntoCommonStock
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:IssuanceOfCommonStockToInvestorAdvisorSettlement
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:ConversionOfMakewholeLiabilityToCommonStock
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:ClawbackOfCommonStockForOverIssuance
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:CommonStockIssuedForPatentPurchase
      contextRef="c7"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:ReclassificationOfWarrantLiabilityToEquity
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:SharesIssuedForPrepaidServices
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c60"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c64"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c66"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c7"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCostsCurrent
      contextRef="c3"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredCostsCurrent
      contextRef="c4"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="c4"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedPayrollTaxesCurrentAndNoncurrent
      contextRef="c3"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c72"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c132"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c80"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c133"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c84"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c134"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c89"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c135"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c93"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c136"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c97"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c137"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c138"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c140"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c3"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c0"
      id="hidden-fact-116"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm contextRef="c0" id="hidden-fact-118" xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-119"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-120"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <osti:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm contextRef="c0" id="hidden-fact-121" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c3"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="c0"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <osti:UnallocatedCashProceeds
      contextRef="c217"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c237"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c231"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c3"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c239"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="c238"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="c238"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c239"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="c0" id="hidden-fact-133">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-15705">0001795091</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-15706">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-15707">FY</dei:DocumentFiscalPeriodFocus>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
